<SEC-DOCUMENT>0001144204-15-063825.txt : 20151110
<SEC-HEADER>0001144204-15-063825.hdr.sgml : 20151110
<ACCEPTANCE-DATETIME>20151109164215
ACCESSION NUMBER:		0001144204-15-063825
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		12
CONFORMED PERIOD OF REPORT:	20150930
FILED AS OF DATE:		20151109
DATE AS OF CHANGE:		20151109

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Protalix BioTherapeutics, Inc.
		CENTRAL INDEX KEY:			0001006281
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				650643773
		STATE OF INCORPORATION:			FL
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33357
		FILM NUMBER:		151216271

	BUSINESS ADDRESS:	
		STREET 1:		2 SNUNIT ST
		STREET 2:		SCIENCE PARK, POB 455
		CITY:			CARMIEL
		STATE:			L3
		ZIP:			20100
		BUSINESS PHONE:		972-4-988-9488

	MAIL ADDRESS:	
		STREET 1:		2 SNUNIT ST
		STREET 2:		SCIENCE PARK, POB 455
		CITY:			CARMIEL
		STATE:			L3
		ZIP:			20100

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ORTHODONTIX INC
		DATE OF NAME CHANGE:	19980422

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EMBASSY ACQUISITION CORP
		DATE OF NAME CHANGE:	19960124
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>v423042_10q.htm
<DESCRIPTION>10-Q
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Washington, D.C. 20549 </B></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin: 1pt 3in"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM 10-Q</B></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin: 1pt 3in"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>(Mark One) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 30.6pt"><FONT STYLE="font-family: Wingdings"><B>x</B></FONT></TD><TD><B>QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30.6pt"><B>For the quarterly period ended September 30, 2015</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>OR</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 30.6pt"><FONT STYLE="font-family: Wingdings"><B>&uml;</B></FONT></TD><TD><B>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30.6pt"><B>For the transition period from <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
to <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>001-33357 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Commission file number) </B></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin: 1pt 3in"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Exact name of registrant as specified
in its charter) </B></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin: 1pt 3in"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 50%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 50%; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-decoration: underline; text-align: center"><B><U>Florida</U></B></TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;<B>__<U>65-0643773</U>__</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(State or other jurisdiction</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>of incorporation or organization)</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(I.R.S. Employer</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Identification No.)</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P></TD></TR>
<TR>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2 Snunit Street</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Science Park</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>POB 455</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Carmiel, Israel</U></B></P></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>20100</U></B></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>(Address of principal executive offices)</B></FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>(Zip Code)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>+972-4-988-9488</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Registrant&rsquo;s telephone number,
including area code)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>N/A</U></B><BR>
<FONT STYLE="font-size: 10pt"><B>(Former name, former address and former fiscal year, if changed since last report)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Indicate by check mark whether the registrant
(1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been subject
to such filing requirements for the past 90 days.&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">x</FONT>&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Indicate by check mark whether the registrant
has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted
and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant
was required to submit and post such files). Yes <FONT STYLE="font-family: Wingdings">x</FONT>&nbsp; No&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of &ldquo;large accelerated filer&rdquo;
and &ldquo;accelerated filer&rdquo; in Rule 12b-2 of the Exchange Act.&nbsp;&nbsp;(check one):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 20%">Large accelerated filer</TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Wingdings">&#168;</FONT>&nbsp;</TD>
    <TD STYLE="width: 52%">&nbsp;</TD>
    <TD STYLE="width: 20%">Accelerated
filer</TD>
    <TD STYLE="width: 4%">&nbsp;<FONT STYLE="font-family: Wingdings">&#120;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>Non-accelerated filer</TD>
    <TD><FONT STYLE="font-family: Wingdings">&#168;</FONT>&nbsp;</TD>
    <TD>(Do not check if a smaller reporting company)</TD>
    <TD>Smaller
reporting company</TD>
    <TD><FONT STYLE="font-family: Wingdings">&#168;</FONT>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Indicate by check mark whether the registrant
is a shell company (as defined in Rule 12b-2 of the Exchange Act).&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT>&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">x</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">On November 1, 2015, approximately
99,800,397 shares of the Registrant&rsquo;s common stock, $0.001 par value, were outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">FORM 10-Q<FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">TABLE OF CONTENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 9%">&nbsp;</TD>
    <TD STYLE="width: 79%">&nbsp;</TD>
    <TD STYLE="width: 12%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><B>Page</B></P></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="#a_002"><B>PART I &ndash; FINANCIAL INFORMATION</B></A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD><A HREF="#a_001"><B>Cautionary Statement Regarding Forward-Looking Statements</B></A></TD>
    <TD STYLE="text-align: center">ii</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top">Item&nbsp;1.</TD>
    <TD STYLE="vertical-align: bottom"><A HREF="#a_003">Financial Statements</A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><A HREF="#a_006">Condensed Consolidated Balance Sheets &ndash; <BR>
As of September 30, 2015 (Unaudited) and December 31, 2014</A></P></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center">1</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><A HREF="#a_007">Condensed Consolidated Statements of Operations (Unaudited) &ndash;<BR>
For the Nine Months and the Three Months Ended September 30, 2015 and 2014</A></P></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center">2</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><A HREF="#a_008">Condensed Consolidated Statements of Changes in Capital Deficiency (Unaudited) &ndash;<BR>
For the Nine Months Ended September 30, 2015 and 2014</A></P></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center">3</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><A HREF="#a_009">Condensed Consolidated Statements of Cash Flows (Unaudited) &ndash;<BR>
For the Nine Months Ended September 30, 2015 and 2014</A></P></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center">4</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><A HREF="#a_010">Notes to Condensed Consolidated Financial Statements</A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center">6</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top">Item&nbsp;2.</TD>
    <TD STYLE="vertical-align: bottom"><A HREF="#a_011">Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations</A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center">10</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">Item 3.</TD>
    <TD STYLE="vertical-align: bottom"><A HREF="#a_012">Quantitative and Qualitative Disclosures About Market Risk</A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center">16</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top">Item&nbsp;4.</TD>
    <TD STYLE="vertical-align: bottom"><A HREF="#a_013">Controls and Procedures</A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center">17</TD></TR>
<TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="#a_014"><B>PART II &ndash; OTHER INFORMATION</B></A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">Item&nbsp;1.</TD>
    <TD STYLE="vertical-align: bottom"><A HREF="#a_015">Legal Proceedings</A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center">18</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top">Item&nbsp;1A.</TD>
    <TD STYLE="vertical-align: bottom"><A HREF="#a_016">Risk Factors</A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center">18</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">Item&nbsp;2.</TD>
    <TD STYLE="vertical-align: bottom"><A HREF="#a_017">Unregistered Sales of Equity Securities and Use of Proceeds</A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center">18</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top">Item&nbsp;3.</TD>
    <TD STYLE="vertical-align: bottom"><A HREF="#a_018">Defaults Upon Senior Securities</A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center">18</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">Item&nbsp;4.</TD>
    <TD STYLE="vertical-align: bottom"><A HREF="#a_019">Mine Safety Disclosures</A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center">18</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top">Item&nbsp;5.</TD>
    <TD STYLE="vertical-align: bottom"><A HREF="#a_020">Other Information</A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center">18</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">Item&nbsp;6.</TD>
    <TD STYLE="vertical-align: bottom"><A HREF="#a_021">Exhibits</A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center">18</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD COLSPAN="2" STYLE="vertical-align: top"><A HREF="#a_022">Signatures</A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center">20</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Except where the context otherwise requires, the terms, &ldquo;we,&rdquo;
&ldquo;us,&rdquo; &ldquo;our&rdquo; or &ldquo;the Company,&rdquo; refer to the business of Protalix BioTherapeutics, Inc. and its
consolidated subsidiaries, and &ldquo;Protalix&rdquo; or &ldquo;Protalix Ltd.&rdquo; refers to the business of Protalix Ltd., our
wholly-owned subsidiary and sole operating unit.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="a_001"></A><B>CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING
STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The statements set forth under the captions &ldquo;Business&rdquo;
and &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations&rdquo;, and other statements
included elsewhere in this Quarterly Report on Form&nbsp; 10-Q, which are not historical, constitute &ldquo;forward-looking statements&rdquo;
within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of
1934, as amended, or the Exchange Act, including statements regarding expectations, beliefs, intentions or strategies for the future.
When used in this report, the terms &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;estimate,&rdquo; &ldquo;expect,&rdquo;
&ldquo;can,&rdquo; &ldquo;continue,&rdquo; &ldquo;could,&rdquo; &ldquo;intend,&rdquo; &ldquo;may,&rdquo; &ldquo;plan,&rdquo; &ldquo;potential,&rdquo;
&ldquo;predict,&rdquo; &ldquo;project,&rdquo; &ldquo;should,&rdquo; &ldquo;will,&rdquo; &ldquo;would&rdquo; and words or phrases
of similar import, as they relate to our company or our subsidiaries or our management, are intended to identify forward-looking
statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the Private Securities Litigation
Reform Act of 1995. These forward-looking statements are only predictions and reflect our views as of the date they are made with
respect to future events and financial performance, and we undertake no obligation to update or revise, nor do we have a policy
of updating or revising, any forward-looking statement to reflect events or circumstances after the date on which the statement
is made or to reflect the occurrence of unanticipated events, except as may be required under applicable law. Forward-looking statements
are subject to many risks and uncertainties that could cause our actual results to differ materially from any future results expressed
or implied by the forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Examples of the risks and uncertainties include, but are not
limited to, the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>risks relating to the compliance by Funda&ccedil;&atilde;o Oswaldo Cruz, or Fiocruz, an arm of the Brazilian Ministry of Health,
with its purchase obligations under our supply and technology transfer agreement which may result in the termination of such agreement
which may have a material adverse effect on our company;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>risks related to the commercialization efforts for taliglucerase alfa in Brazil;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>risks related to our supply of drug product to Pfizer Inc., or Pfizer, pursuant to our amended and restated exclusive license
and supply agreement with Pfizer;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>risks related to our supply of drug product to Fiocruz pursuant to our supply arrangement with Fiocruz;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the risk that we will not be able to develop a successful sales and marketing organization for taliglucerase alfa in Brazil,
or for any other product candidate, in a timely manner, if at all;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>failure or delay in the commencement or completion of our preclinical studies and clinical trials which may be caused by several
factors, including: unforeseen safety issues; determination of dosing issues; lack of effectiveness during clinical trials; slower
than expected rates of patient recruitment; inability to monitor patients adequately during or after treatment; inability or unwillingness
of medical investigators and institutional review boards to follow our clinical protocols; or lack of sufficient funding to finance
our clinical trials;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the risk that the results of our clinical trials will not support the applicable claims of safety or efficacy, that our product
candidates will not have the desired effects or include undesirable side effects or other unexpected characteristics;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our dependence on performance by third party providers of services and supplies, including without limitation, clinical trial
services;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>risks relating to our ability to make scheduled payments of the principal of, to pay interest on or to refinance our 2018 convertible
notes, or any other indebtedness;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>risks relating to our ability to finance our research programs;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>delays in our preparation and filing of applications for regulatory approval of our other product candidates in the United
States, the European Union and elsewhere;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our expectations with respect to the potential commercial value of our product and product candidates;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the risk that products that are competitive to our product candidates may be granted orphan drug status in certain territories
and, therefore, will be subject to potential marketing and commercialization restrictions;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the impact of development of competing therapies and/or technologies by other companies;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any lack of progress of our research and development activities and our clinical activities with respect to any product candidate;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the inherent risks and uncertainties in developing the types of drug platforms and products we are developing;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>potential product liability risks, and risks of securing adequate levels of product liability and clinical trial insurance
coverage;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the possibility of infringing a third party&rsquo;s patents or other intellectual property rights;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the uncertainty of obtaining patents covering our products and processes and in successfully enforcing our intellectual property
rights against third parties;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>risks relating to changes in healthcare laws, rules and regulations in the United States or elsewhere; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the possible disruption of our operations due to terrorist activities and armed conflict, including as a result of the disruption
of the operations of regulatory authorities, our subsidiaries, our manufacturing facilities and our customers, suppliers, distributors,
collaborative partners, licensees and clinical trial sites.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Companies in the pharmaceutical and biotechnology industries
have suffered significant setbacks in advanced or late-stage clinical trials, even after obtaining promising earlier trial results
or preliminary findings for such clinical trials. Even if favorable testing data is generated from clinical trials of a drug product,
the U.S. Food and Drug Administration or foreign regulatory authorities may not accept or approve a marketing application filed
by a pharmaceutical or biotechnology company for the drug product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These forward-looking statements reflect our current views with
respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should
not place undue reliance on these forward-looking statements. These and other risks and uncertainties are detailed under the heading
<FONT STYLE="text-transform: uppercase">&ldquo;</FONT>Risk Factors<FONT STYLE="text-transform: uppercase">&rdquo;</FONT> in our
Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2014, and are described from time to time in the reports we
file with the U.S. Securities and Exchange Commission, or the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="a_002"></A><B>PART I &ndash; FINANCIAL INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="a_003"></A><B>Item&nbsp;1. Financial Statements </B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="a_006"></A><FONT STYLE="font-size: 10pt"><B>PROTALIX
BIOTHERAPEUTICS, INC. </B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>CONDENSED CONSOLIDATED BALANCE SHEETS</B></FONT><BR>
(U.S. dollars in thousands)<BR>
(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">September 30, 2015</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">December 31, 2014</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: center">ASSETS</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">CURRENT ASSETS:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 64%; font-size: 10pt; text-align: left; padding-left: 0.25in">Cash and cash equivalents&#9;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 14%; font-size: 10pt; text-align: right">34,248</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 14%; font-size: 10pt; text-align: right">54,767</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.25in">Accounts receivable - Trade&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">4,573</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,884</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.25in">Other assets&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,716</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,202</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-left: 0.25in">Inventories&#9;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">6,339</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">6,667</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.375in">Total current assets&#9;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">47,876</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">65,520</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">FUNDS IN RESPECT OF EMPLOYEE</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 0.25in">RIGHTS UPON RETIREMENT&#9;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,569</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,555</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">PROPERTY AND EQUIPMENT, NET&#9;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">9,957</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">11,282</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">DEFERRED CHARGES&#9;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">90</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">113</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.375in">Total assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">59,492</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">78,470</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">LIABILITIES NET OF CAPITAL DEFICIENCY</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">CURRENT LIABILITIES:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.125in">Accounts payable and accruals:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-left: 0.25in">Trade&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">4,057</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">3,951</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-left: 0.25in">Other&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">11,946</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">15,496</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.125in">Deferred revenues&#9;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">6,850</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">6,763</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.375in">Total current liabilities&#9;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">22,853</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">26,210</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">LONG TERM LIABILITIES:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.125in">Convertible notes&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">67,774</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">67,464</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.125in">Deferred revenues&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">35,127</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">37,232</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.125in">Liability in connection with collaboration operation&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">912</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.125in">Liability for employee rights upon retirement&#9;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,249</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,253</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.375in">Total long term liabilities&#9;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">105,150</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">107,861</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.375in">Total liabilities&#9;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">128,003</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">134,071</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>COMMITMENTS</B></P></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">CAPITAL DEFICIENCY&#9;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(68,511</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(55,601</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Total liabilities net of capital deficiency&#9;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">59,492</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">78,470</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>The accompanying notes are an integral
part of the condensed consolidated financial statements.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="a_007"></A><FONT STYLE="font-size: 10pt"><B>PROTALIX
BIOTHERAPEUTICS, INC. </B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS </B></FONT><BR>
<FONT STYLE="font-size: 10pt">(U.S. dollars in thousands, except share and per share data)</FONT><BR>
(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Nine Months Ended</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Three Months Ended</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">September 30, 2015</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">September 30, 2014</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">September 30, 2015</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">September 30, 2014</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 32%; font-size: 10pt; font-weight: bold">REVENUES&#9;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 14%; font-size: 10pt; text-align: right">12,475</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 14%; font-size: 10pt; text-align: right">11,517</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 14%; font-size: 10pt; text-align: right">4,301</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 14%; font-size: 10pt; text-align: right">2,396</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 0.125in; text-indent: -0.125in">COMPANY&rsquo;S SHARE IN COLLABORATION AGREEMENT&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">3,084</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,259</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,545</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,311</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 0.125in; text-indent: -0.125in">COST OF REVENUES&#9;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(6,785</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(7,476</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(2,346</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,798</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 0.125in; text-indent: -0.125in">GROSS PROFIT&#9;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">8,774</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">6,300</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,500</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,909</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 0.125in; text-indent: -0.125in">RESEARCH AND DEVELOPMENT EXPENSES (1)&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(18,493</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(23,280</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(5,260</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(8,052</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 0.25in">Less &ndash; grants and reimbursements&#9;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,856</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">6,146</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,207</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,947</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 0.125in; text-indent: -0.125in">RESEARCH AND DEVELOPMENT EXPENSES, NET</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(14,637</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(17,134</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(4,053</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(6,105</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 0.125in; text-indent: -0.125in">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES (2)&#9;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(6,259</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(7,289</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(2,254</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(2,012</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 0.125in; text-indent: -0.125in">OPERATING LOSS &#9;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(12,122</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(18,123</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(2,807</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(6,208</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 0.125in; text-indent: -0.125in">FINANCIAL EXPENSES</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(2,805</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(3,490</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(1,030</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(1,851</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 0.125in; text-indent: -0.125in">FINANCIAL INCOME</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">64</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">139</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-size: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: left">1</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: right"><FONT STYLE="font-size: 10pt">17</FONT></TD><TD STYLE="font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">49</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 0.125in; text-indent: -0.125in">FINANCIAL EXPENSES &ndash; NET</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(2,741</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(3,351</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,013</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,802</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 0.125in; text-indent: -0.125in">NET LOSS FOR THE PERIOD&#9;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(14,863</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(21,474</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(3,820</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(8,010</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 0.125in; text-indent: -0.125in">NET LOSS PER SHARE OF COMMON STOCK - BASIC AND DILUTED:</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.16</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.23</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.04</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.09</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 0.125in; text-indent: -0.125in">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN
    COMPUTING LOSS PER SHARE &ndash; BASIC AND DILUTED:</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">93,599,414</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">92,828,851</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">93,943,772</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">92,971,572</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 0.25in">(1) Includes share-based compensation</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">667</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">764</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">258</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">173</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 0.25in">(2) Includes share-based compensation</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">752</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(81</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">188</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(67</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -0.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -0.35pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -0.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>The accompanying
notes are an integral part of the condensed consolidated financial statements.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 6; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="a_008"></A><B>PROTALIX BIOTHERAPEUTICS, INC. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CONDENSED CONSOLIDATED STATEMENT OF CHANGES
IN CAPITAL DEFICIENCY </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(U.S. dollars in thousands, except share
data)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Additional</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Common</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Common</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">paid&ndash;in</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Accumulated</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Stock (1)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Stock</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">capital</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">deficit</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Total</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Number of shares</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Amount</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 30%; font-size: 10pt; font-weight: bold">Balance at December 31, 2013&#9;</TD><TD STYLE="width: 2%; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; font-weight: bold; text-align: right">93,551,098</TD><TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; font-weight: bold; text-align: right">94</TD><TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; font-weight: bold; text-align: right">184,345</TD><TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; font-weight: bold; text-align: right">(211,385</TD><TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="width: 2%; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; font-weight: bold; text-align: right">(26,946</TD><TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold">Changes during the nine-month period ended September 30, 2014:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Share-based compensation related to stock options&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">161</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">161</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Share-based compensation related to restricted stock award, net of forfeitures of 1,834 shares</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(1,834</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">522</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">522</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Exercise of options granted to employees (includes net exercise)&#9;&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: right">113,800</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: right"><BR><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: right">43</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: right">43</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Net loss for the period</TD><TD STYLE="font-size: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(21,474</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(21,474</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold">Balance at September 30, 2014 &#9;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">93,663,064</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">94</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">185,071</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(232,859</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(47,694</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold">Balance at December 31, 2014&#9;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">93,603,819</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">94</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">185,633</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">(241,328</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">(55,601</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold">Changes during the nine-month period ended September 30, 2015:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Share-based compensation related to stock options&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">947</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">947</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Share-based compensation related to restricted stock award, net of forfeitures of 2,501 shares</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(2,501</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">472</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">472</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">Exercise of options&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: right">550,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: right">534</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: right">534</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Net loss for the period</TD><TD STYLE="font-size: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(14,863</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(14,863</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold">Balance at September 30, 2015 &#9;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">94,151,318</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">94</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">187,586</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(256,191</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(68,511</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify"><BR>
<FONT STYLE="font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">*</TD><TD STYLE="text-align: justify">Represents amount less than thousand</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.25in; text-indent: 0in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD STYLE="text-align: justify">Common Stock, $0.001 par value; Authorized &ndash;
as of September 30, 2015 and 2014 - 150,000,000 shares.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>The accompanying notes are an integral part of the condensed
consolidated financial statements.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="a_009"></A><B>PROTALIX BIOTHERAPEUTICS, INC. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CONDENSED CONSOLIDATED STATEMENTS OF
CASH FLOWS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(U.S. dollars in thousands)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Nine Months Ended</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">September 30, 2015</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">September 30, 2014</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">CASH FLOWS FROM OPERATING ACTIVITIES:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 64%; font-size: 10pt; text-align: left; padding-left: 0.125in">Net loss&#9;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 14%; font-size: 10pt; text-align: right">(14,863</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 14%; font-size: 10pt; text-align: right">(21,474</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.25in; text-indent: -0.125in">Adjustments required to reconcile net loss to net cash <BR> used in operating activities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-left: 0.125in">Share based compensation&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,419</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">683</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-left: 0.125in">Depreciation&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,811</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,418</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.125in">Financial expenses, net (mainly exchange differences)&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">102</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">869</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.125in">Changes in accrued liability for employee rights</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.25in">upon retirement&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">16</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">149</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.125in">Loss (Gain) on amounts funded in respect of employee</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.25in">rights upon retirement&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">28</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(25</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.125in">Amortization of debt issuance costs and debt discount&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">333</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">332</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.125in">Changes in operating assets and liabilities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.25in">Decrease in deferred revenues (including non-current portion)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(2,018</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(6,172</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.25in">Increase in accounts receivable and other assets&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(3,187</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(578</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.25in">Decrease in inventories</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">328</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,127</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.25in">Decrease in accounts payable and accruals (including
    long term )&#9;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(4,396</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,736</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.125in">Net cash used in operating activities&#9;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(20,427</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(24,407</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">CASH FLOWS FROM INVESTING ACTIVITIES:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.125in">Purchase of property and equipment&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">(460</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">(617</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.125in">Investment in restricted deposit&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(93</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.25in; text-indent: -0.125in">Amounts funded in respect of employee rights upon retirement, net&#9;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(56</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(122</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.125in">Net cash used in investing activities&#9;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(516</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(832</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">CASH FLOWS FROM FINANCING ACTIVITIES:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-left: 0.125in">Exercise of options&#9;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">534</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">43</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.125in">Net cash provided by financing activities&#9;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">534</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">43</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">EFFECT OF EXCHANGE RATE CHANGES ON</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; padding-left: 0.125in">CASH&#9;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(110</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(885</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">NET DECREASE IN CASH AND</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 0.125in">CASH EQUIVALENTS&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(20,519</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(26,081</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">BALANCE OF CASH AND CASH</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; padding-left: 0.125in"><FONT STYLE="font-size: 10pt"><B>EQUIVALENTS<FONT STYLE="font-family: Times New Roman, Times, Serif"> </FONT>AT BEGINNING OF PERIOD&#9;</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">54,767</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">86,398</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">BALANCE OF CASH AND CASH</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; padding-left: 0.125in">EQUIVALENTS AT END OF PERIOD&#9;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">34,248</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">60,317</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The accompanying notes are an integral
part of the condensed consolidated financial statements.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CONDENSED CONSOLIDATED STATEMENTS OF
CASH FLOWS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(U.S. dollars in thousands)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 12.9pt 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 12.9pt 0pt 0">(Continued) - 2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 12.9pt 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Nine Months Ended</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">September 30, 2015</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">September 30, 2014</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><B>SUPPLEMENTARY
INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</B></P></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 64%; font-size: 10pt; text-align: left; padding-left: 0.25in">Purchase of property and equipment&#9;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 14%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">146</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 14%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">122</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>SUPPLEMENTARY
DISCLOSURE ON CASH FLOWS</B></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Interest paid</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,105</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,079</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 12.9pt 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 12.9pt 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 12.9pt 0pt 0; text-align: center"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>The accompanying notes are
an integral part of the condensed consolidated financial statements.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.<BR>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Unaudited)</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="a_010"></A><B>NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>a.</B></TD><TD STYLE="text-align: justify"><B>General</B></TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">Protalix BioTherapeutics, Inc. (collectively with
its subsidiaries, the &ldquo;Company&rdquo;), and its wholly-owned subsidiary, Protalix Ltd., are biopharmaceutical companies focused
on the development and commercialization of recombinant therapeutic proteins based on the Company&rsquo;s proprietary ProCellEx&reg;
protein expression system (&ldquo;ProCellEx&rdquo;). Using the ProCellEx system, the Company is developing a pipeline of proprietary recombinant therapeutic
proteins. The Company&rsquo;s initial commercial focus has been on complex therapeutic proteins, including proteins for the treatment
of genetic disorders, such as Gaucher disease and Fabry disease. The Company&rsquo;s strategy is to develop proprietary recombinant
proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications. To date,
the Company has successfully developed a treatment for Gaucher disease that has been approved for marketing in the United States,
Brazil, Israel and other markets, and the Company has number of product candidates in varying stages of the clinical development
process. In September 2009, Protalix Ltd. formed another wholly-owned subsidiary under
the laws of the Netherlands, Protalix B.V., in connection with the European Medicines Agency (&ldquo;EMA&rdquo;) application process
in the European Union. The Company&rsquo;s two subsidiaries are referred to collectively herein as the &ldquo;Subsidiaries.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">On May 1, 2012, the U.S. Food and Drug
Administration (&ldquo;FDA&rdquo;) approved for sale the Company&rsquo;s first commercial product, taliglucerase alfa for
injection, an enzyme replacement therapy (&ldquo;ERT&rdquo;) for the long-term treatment of adult patients with a confirmed
diagnosis of type 1 Gaucher disease. Subsequently, taliglucerase alfa was approved for marketing by the regulatory
authorities of other countries. Taliglucerase alfa is being marketed under the name Uplyso<SUP>TM</SUP> in Brazil and certain
other Latin American countries and Elelyso<SUP>TM</SUP> in the rest of the territories.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">Since its approval by the FDA, taliglucerase alfa
has been marketed mainly in the United States by Pfizer Inc. (&ldquo;Pfizer&rdquo;), the Company&rsquo;s commercialization partner,
as provided in the exclusive license and supply agreement by and between Protalix Ltd., the Company&rsquo;s wholly-owned subsidiary,
and Pfizer, which is referred to herein as the Pfizer Agreement. In October 2015, the Company entered into an Amended and Restated
Exclusive License and Supply Agreement (the &ldquo;Amended Pfizer Agreement&rdquo;) which amends and restates the Pfizer Agreement
in its entirety. Pursuant to the Amended Pfizer Agreement, the Company sold to Pfizer its share in the collaboration created under
the initial Pfizer Agreement for the commercialization of Elelyso in exchange for a cash payment equal to $36.0 million. As part
of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to Elelyso in
Brazil. Under the initial Pfizer Agreement, Pfizer and the Company shared revenues and expenses for the development and commercialization
of Elelyso on a 60%/40% basis globally, excluding Israel and Brazil. Under the Amended Pfizer Agreement, Pfizer is responsible
for 100% of expenses, and entitled to all of the revenues, globally for Elelyso, excluding Brazil, where the Company is responsible
for all expenses and retains all revenues. The Amended Pfizer Agreement eliminates Pfizer&rsquo;s entitlement to annual payments
of up to $12.5 million in relation to commercialization of Elelyso in Brazil. For further details please see Note 5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">On June 18, 2013, the Company entered into a Supply
and Technology Transfer Agreement (the &ldquo;Brazil Agreement&rdquo;) with Funda&ccedil;&atilde;o Oswaldo Cruz (&ldquo;Fiocruz&rdquo;),
an arm of the Brazilian Ministry of Health for taliglucerase alfa. The agreement became effective in January 2014. The technology
transfer is designed to be completed in four stages and is intended to transfer to Fiocruz the capacity and skills required for
the Brazilian government to construct its own manufacturing facility, at its sole expense, and to produce a sustainable, high-quality,
and cost-effective supply of taliglucerase alfa. The Company is not required to complete the final stage of the technology transfer
until Fiocruz purchases at least approximately $280 million worth of taliglucerase alfa.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">Fiocruz&rsquo;s purchases of Uplyso to
date have been significantly below certain agreed upon purchase milestones and, accordingly, the Company has
the right to terminate the Brazil Agreement. Notwithstanding the low purchase amounts, the Company is, at this time,
continuing to supply Uplyso to Fiocruz under the Brazil Agreement, and patients continue to be treated with Uplyso in Brazil.
Approximately 10% of adult Gaucher patients in Brazil are currently treated with Uplyso. The Company is discussing with
Fiocruz potential actions that Fiocruz may take to comply with its purchase obligations and, based on such discussions, the
Company will determine what it believes to be the course of action that is in the best interest of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.<BR>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Unaudited)</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES</B> (continued)<B>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">The Company will pay a fee equal to 5% of the
net proceeds generated in Brazil to an agent for services provided in assisting the Company complete the Brazil Agreement pursuant
to an agreement between the agent and the Company. The agreement will remain in effect with respect to the
Brazil Agreement until the termination thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">In addition to taliglucerase alfa, the Company is developing
an innovative product pipeline using its ProCellEx protein expression system. The Company&rsquo;s product pipeline currently includes,
among other candidates:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">(1) PRX-102, or alpha-GAL-A, a therapeutic protein candidate
for the treatment of Fabry disease, a rare, genetic lysosomal disorder in humans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">(2) PRX-106, the Company&rsquo;s oral antiTNF product candidate
which is being developed as an orally-delivered anti inflammatory treatment using plant cells as a natural capsule for the expressed
protein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">(3) PRX-110, a proprietary plant cell recombinant human Deoxyribonuclease
1, or DNase, under development for the treatment of cystic fibrosis, to be administered by inhalation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">(4) PRX-112, an orally administered glucocerebrosidase enzyme
for the treatment of Gaucher patients utilizing oral delivery of the recombinant GCD enzyme produced and encapsulated within carrot
cells.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">Obtaining marketing approval with respect to any
product candidate in any country is directly dependent on the Company&rsquo;s ability to implement the necessary regulatory steps
required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">Based on its current cash resources and
commitments, the Company believes it will be able to maintain its current planned development activities and the
corresponding level of expenditures for at least 12 months, although no assurance can be given that it
will not need additional funds prior to such time. If there are unexpected increases in general and administrative expenses
or research and development expenses, the Company may need to seek additional financing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>b.</B></TD><TD STYLE="text-align: justify"><B>Basis of Presentation</B></TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">The accompanying unaudited condensed consolidated
financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United
States (&ldquo;GAAP&rdquo;) for interim financial information. Accordingly, they do not include all of the information and notes
required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature)
considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results
for the interim period are not necessarily indicative of the results that may be expected for the full year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.9pt">These unaudited condensed consolidated financial
statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for
the year ended December 31, 2014, filed by the Company with the U.S. Securities and Exchange Commission (the &ldquo;Commission&rdquo;).
The comparative balance sheet at December 31, 2014 has been derived from the audited financial statements at that date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.9pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><B>c.</B></TD><TD STYLE="padding-right: 81.35pt"><B>Net loss per share</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.9pt">Basic and diluted loss per share (&ldquo;LPS&rdquo;)
are computed by dividing net loss by the weighted average number of shares of the Company&rsquo;s common stock, par value $0.001
per share (the &ldquo;Common Stock&rdquo;) outstanding for each period. Diluted LPS does not include 18,781,572 and 19,797,190
shares of Common Stock underlying outstanding options and restricted shares of Common Stock and shares issuable upon conversion
of the convertible notes (issued in September 2013) for the nine months ended September 30, 2014 and 2015, respectively, and 18,661,182
and 19,820,485 shares of Common Stock for the three months ended September 30, 2014 and 2015, respectively, because the effect
would be anti-dilutive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.9pt"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.9pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.<BR>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Unaudited)</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 2 - INVENTORIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Inventory at September 30, 2015 and December&nbsp;31,
2014 consisted of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">September 30,</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; text-align: center">(<I>U.S. dollars in thousands)</I></TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; font-size: 10pt; text-align: left">Raw materials</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 14%; font-size: 10pt; text-align: right">1,502</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 14%; font-size: 10pt; text-align: right">1,616</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Work in progress</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">132</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Finished goods</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4,837</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4,919</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Total inventory</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">6,339</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">6,667</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">During the nine months ended September 30, 2015,
the Company recorded approximately $1.6 million for write-down of inventory under cost of revenues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 3 &ndash; FAIR VALUE MEASUREMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">The Company measures fair value and discloses fair
value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale
of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.<BR>
The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure
fair value into three broad levels, which are described below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">Level 1: Quoted prices (unadjusted) in active markets
that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level
1 inputs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">Level 2: Observable prices that are based on inputs
not quoted on active markets, but corroborated by market data.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">Level 3: Unobservable inputs are used when little
or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">In determining fair value, the Company utilizes
valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible
and considers counterparty credit risk in its assessment of fair value.<BR>
The fair value of the financial instruments included in the working capital of the Company is usually identical or close to their
carrying value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The fair value of the convertible notes as of September
30, 2015 is approximately $45.5 million based on a level 2 measurement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 4 &ndash; STOCK TRANSACTIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">On March 23, 2015, the Company&rsquo;s
compensation committee approved the grant of a 10-year option to purchase 1,909,000 shares of Common Stock to its officers and
other employees with an exercise price equal to $1.72 per share under the Company&rsquo;s 2006 Employee Stock Incentive Plan, as
amended (the &ldquo;Plan&rdquo;). The options vest over a four-year period; the first 25% shares vest on the first anniversary
of the grant date and the remaining shares vest in 12 equal quarterly increments over the subsequent three-year period. Vesting
of the options granted to certain executive officers are subject to acceleration in full upon a Corporate Transaction or a Change
in Control, as those terms are defined in the Plan. The Company estimated the fair value of the options on the date of grant using
the Black-Scholes option-pricing model to be approximately $1.9 million based on the following weighted average assumptions: dividend
yield of 0% for all years; expected volatility of 61.7%; risk-free interest rates of 1.6%; and expected life of six years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.<BR>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Unaudited)</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 5 &ndash; SUBSEQUENT EVENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">On October 12, 2015, the
Company entered into the Amended Pfizer Agreement which amends and restates, in its entirety, the Pfizer Agreement. See Note
1. Pursuant to the Amended Pfizer Agreement, the Company sold its share in the collaboration with Pfizer on the
commercialization of Elelyso to Pfizer in exchange for a cash payment equal to $36.0 million. As part of the sale, the Company
agreed to transfer its rights to Elelyso in Israel to Pfizer in exchange for full rights to Elelyso in Brazil. Under the
Amended Pfizer Agreement, the Company will continue to manufacture drug substance for Pfizer, subject to certain terms and
conditions. In addition, the Company issued to Pfizer a promissory note for approximately $4.2 million, representing the
Company&rsquo;s share of accumulated losses as of the date of the Amended Pfizer Agreement. The note is to be paid in October
2020, subject to certain terms and conditions. Under the Pfizer Agreement, Pfizer and the Company shared in revenues and
expenses for the development and commercialization of Elelyso on a 60%/40% basis globally, excluding Israel and Brazil. Under
the Amended Pfizer Agreement, Pfizer is responsible for 100% of expenses, and entitled to all of the revenues, globally for
Elelyso, excluding Brazil, where the Company is responsible for all expenses and retains all revenues. The Amended Pfizer
Agreement eliminates Pfizer&rsquo;s entitlement to annual payments of up to $12.5 million in relation to commercialization of
Elelyso in Brazil.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">On October 12, 2015, the
Company also entered into a Stock Purchase Agreement with Pfizer, pursuant to which the Company issued 5,649,079 shares of
the Company&rsquo;s common stock for an aggregate purchase price equal to $10.0 million subject to certain other terms set
forth in the Stock Purchase Agreement. As part of the Stock Purchase Agreement, Pfizer has agreed to a 180-day lock-up with
respect to the purchased shares  and the Company&rsquo;s directors and executive officers have entered into 90-day lock up
agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in"><A NAME="a_011"></A>Item&nbsp;2. Management&rsquo;s
Discussion and Analysis of Financial Condition and Results of Operations</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><I>You should read the following discussion
and analysis of our financial condition and results of operations together with our financial statements and the consolidated financial
statements and the related notes included elsewhere in this Form 10-Q and in our Annual Report on Form 10-K for the year ended
December 31, 2014. Some of the information contained in this discussion and analysis, particularly with respect to our plans and
strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. You
should read &ldquo;Risk Factors&rdquo; in our Annual Report on Form 10-K for the year ended December 31, 2014 for a discussion
of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking
statements contained in the following discussion and analysis. </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are a biopharmaceutical company focused on the development
and commercialization of recombinant therapeutic proteins based on our proprietary ProCellEx<SUP>&reg;</SUP> protein expression
system, or ProCellEx. Using our ProCellEx system, we are developing a pipeline of proprietary, clinically superior versions of
recombinant therapeutic proteins that primarily target large, established pharmaceutical markets and that in most cases rely upon
known biological mechanisms of action. Our initial commercial focus has been on complex therapeutic proteins, including proteins
for the treatment of genetic disorders, such as Gaucher disease and Fabry disease. With our experience, and having successfully
developed Elelyso<SUP>TM</SUP>, our first drug product, we believe ProCellEx will enable us to develop additional proprietary recombinant
proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications. We are
now also applying the unique properties of our ProCellEx system for the oral delivery of therapeutic proteins.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On May 1, 2012, the U.S. Food and Drug Administration, or the
FDA, approved for sale our first commercial product, taliglucerase alfa for injection, an enzyme replacement therapy, or ERT, for
the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. Subsequently, taliglucerase alfa
was approved for marketing by the regulatory authorities of other countries. Taliglucerase alfa is being marketed under the name
Uplyso<SUP>TM</SUP><FONT STYLE="font-size: 10pt"> </FONT>in Brazil and certain other Latin American countries, and as Elelyso in
the rest of the territories.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Since
its approval by the FDA, taliglucerase alfa has been marketed mainly in the United States by Pfizer Inc., or Pfizer,
our commercialization partner, as provided in the exclusive license and supply agreement by and between Protalix Ltd.,
our wholly-owned subsidiary, and Pfizer, which we refer to as the Pfizer Agreement. In </FONT>October 2015, we entered into
an Amended and Restated Exclusive License and Supply Agreement, or the Amended Pfizer Agreement, which amends and restates
the Pfizer Agreement in its entirety. Pursuant to the Amended Pfizer Agreement, we sold to Pfizer our share in the
collaboration created under the initial Pfizer Agreement for the commercialization of Elelyso in exchange for a cash payment
equal to $36.0 million. As part of the sale, we agreed to transfer our rights to Elelyso in Israel to Pfizer, while gaining full rights to Elelyso in Brazil. Under the Amended Pfizer Agreement, we will continue to manufacture drug substance for Pfizer, subject
to certain terms and conditions. In addition, we issued to Pfizer a promissory note for approximately $4.2 million, representing
our share of accumulated losses as of the date of the Amended Pfizer Agreement. The note is to be paid in October 2020, subject
to certain terms and conditions. Under the initial Pfizer Agreement, Pfizer shared revenues and expenses for the development
and commercialization of Elelyso with us on a 60%/40% basis globally, excluding Israel and Brazil. Under the Amended
Pfizer Agreement, Pfizer is responsible for 100% of expenses, and entitled to all of the revenues, globally for Elelyso,
excluding Brazil, where we are responsible for all expenses and retains all revenues. The Amended Pfizer Agreement
eliminates Pfizer&rsquo;s entitlement to annual payments of up to $12.5 million in relation to commercialization of Elelyso
in Brazil.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For the first 10-year period after the execution of the Amended
Pfizer Agreement, we have agreed to sell drug substance to Pfizer for the production of Elelyso, and Pfizer maintains the right
to extend the supply period for up to two additional 30-month periods subject to certain terms and conditions. The Amended Pfizer
Agreement also includes provisions regarding cooperation for regulatory matters, supply of the drug substance to Pfizer, including
provisions addressing failure to supply, and patent enforcement, and contains customary provisions regarding termination, indemnification
and insurance requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On October 12, 2015, we also entered into a Stock Purchase
Agreement with Pfizer, pursuant to which we issued 5,649,079 shares of our common stock for an aggregate purchase price equal
to $10.0 million subject to certain other terms set forth in the Stock Purchase Agreement. As part of the Stock Purchase
Agreement, Pfizer has agreed to a 180-day lock-up with respect to the purchased shares of common stock and our directors and
executive officers have entered into 90-day lock up agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
June 18, 2013, we entered into a Supply and Technology Transfer Agreement, or the Brazil Agreement, with </FONT>Funda&ccedil;&atilde;o
Oswaldo Cruz, or Fiocruz, an arm of the Brazilian Ministry of Health<FONT STYLE="font-family: Times New Roman, Times, Serif"> for
taliglucerase alfa. The agreement became effective in January 2014. The technology transfer is designed to be completed in four
stages and is intended to transfer to Fiocruz the capacity and skills required for the Brazilian government to construct its own
manufacturing facility, at its sole expense, and to produce a sustainable, high-quality, and cost-effective supply of taliglucerase
alfa. We are not required to complete the final stage of the technology transfer until Fiocruz purchases at least approximately
$280 million worth of taliglucerase alfa.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Fiocruz&rsquo;s purchases of Uplyso to date have been significantly below certain agreed upon purchase milestones and, accordingly, we have the right to
terminate the Brazil Agreement. Notwithstanding the low purchase amounts, we are, at this time, continuing to supply Uplyso
to Fiocruz under the Brazil Agreement, and patients continue to be treated with Uplyso in Brazil. Approximately 10% of
adult Gaucher patients in Brazil are currently treated with Uplyso. We are discussing with Fiocruz potential actions that
Fiocruz may take to comply with its purchase obligations and, based on such discussions, we will determine what we believe to
be the course of action that is in the best interest of our company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We will pay a fee equal to 5% of the net proceeds
generated in Brazil to an agent for services provided in assisting us complete the Brazil Agreement pursuant to an agreement between us and the agent. The agreement will remain in effect with respect to the Brazil Agreement until the
termination thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition to taliglucerase alfa, we are developing an innovative
product pipeline using our ProCellEx protein expression system. Our product pipeline currently includes, among other candidates:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1)
PRX-102, or </FONT>alpha-GAL-A<FONT STYLE="font-family: Times New Roman, Times, Serif">, a therapeutic protein candidate for the
treatment of Fabry disease, a rare, genetic lysosomal disorder in humans, currently in an ongoing phase I/II clinical trial. We
expect to report final efficacy and safety results for the 0.2mg, 1 mg and 2mg/kg dose groups of the trial during the fourth quarter
of 2015. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2)
PRX-106, </FONT>our oral antiTNF product candidate <FONT STYLE="font-family: Times New Roman, Times, Serif">which is being developed
as </FONT>an orally-delivered anti inflammatory treatment using plant cells as a natural capsule for the expressed protein. We
<FONT STYLE="font-family: Times New Roman, Times, Serif">concluded the phase I clinical trial, which demonstrated that the drug
was safe and well tolerated, showing biological activity in the gut and inducement of regulatory T cells</FONT>. We expect to initiate
a <FONT STYLE="font-family: Times New Roman, Times, Serif">proof of concept efficacy study</FONT> by early 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(3) PRX-110, a proprietary plant cell recombinant human Deoxyribonuclease
1, or DNase, under development for the treatment of cystic fibrosis, to be administered by inhalation. We expect to initiate a
phase I clinical trial in healthy volunteers during the fourth quarter followed by proof of concept efficacy study in patients
during the first half of 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(4) PRX-112, an orally administered glucocerebrosidase enzyme
for the treatment of Gaucher patients utilizing oral delivery of the recombinant GCD enzyme produced and encapsulated within carrot
cells. PRX-112 has been the subject of successful proof of concept clinical trials, and we intend to focus our efforts on a new
formulation of the treatment during 2015 before proceeding to more advanced clinical trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Except
for the rights to commercialize taliglucerase alfa worldwide (other than Brazil), which we licensed to Pfizer, we hold the worldwide
commercialization rights to all of our proprietary development</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">candidates.
In addition, we continuously evaluate potential strategic marketing partnerships as well as collaboration programs with biotechnology
and pharmaceutical companies and academic research institutes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Critical Accounting Policies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our significant accounting policies are more fully described
in Note&nbsp;1 to our consolidated financial statements appearing in this Quarterly Report. There have not been any changes to
our significant accounting policies since the Annual Report on Form 10-K for the year ended December 31, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The discussion and analysis of our financial condition and results
of operations is based on our financial statements, which we prepared in accordance with U.S. generally accepted accounting principles.
The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of
assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well
as the reported revenues and expenses during the reporting periods. On an ongoing basis, we evaluate such estimates and judgments,
including those described in greater detail below. We base our estimates on historical experience and on various other factors
that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying
value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates
under different assumptions or conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Results of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Three months ended September 30, 2015 compared to the
three months ended September 30, 2014</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Revenues </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We recorded revenues of $4.3&nbsp;million during the three months
ended September 30, 2015, an increase of $1.9 million, or 80%, from revenues of $2.4&nbsp;million for the three months ended September
30, 2014. The increase resulted primarily from the $1.3 million of products sold in Brazil during the three months ended September
30, 2015. Revenues also represent a pro rata amortization of the $65.0&nbsp;million upfront and milestone payments of $1.1&nbsp;million
in each quarterly period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Our share in the Collaboration Agreement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We recorded revenue of $1.5 million as our share of net income
from the collaboration under the Pfizer Agreement during the three months ended September 30, 2015, an increase of $234,000 from
revenues of $1.3 million for the three months ended September 30, 2014. Our share in the collaboration agreement recorded during
the three months ended September 30, 2015 represents our 40% share of the net income generated during the period. Under the terms
and conditions of the Pfizer Agreement prior to its amendment, we record income or loss equal to 40% of the profit or loss realized
from sales of taliglucerase alfa and related expenses incurred based on reports we receive from Pfizer summarizing the results
of the collaborative activities under the Pfizer Agreement for the applicable period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Cost of Revenues</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cost of revenues was $2.3 million for the three months ended
September 30, 2015, an increase of $548,000, or 30%, from cost of revenues of $1.8 million for the three months ended September
30, 2014. The increase resulted primarily from an increase in the amount of products sold to Pfizer at cost during the three months
ended September 30, 2015. Cost of revenues is generally composed of certain fixed costs relating to our manufacturing facility,
including rent, depreciation, salary and maintenance expenses, and to a much lesser extent, the direct cost of products sold.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Research and Development Expenses, Net</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Research and development expenses were $4.1&nbsp;million for
the three months ended September 30, 2015, a decrease of $2.0 million, or 34%, from $6.1&nbsp;million for the three months ended
September 30, 2014. The decrease resulted primarily from a decrease of $1.3 million in expenses related to subcontractors and consultants
in connection with preclinical and clinical activities and $859,000 in costs related to salaries expense, partially due to the
devaluation of the New Israeli Shekel against the U.S. dollar during the three months ended on September 30, 2015. The decrease
was partially offset by a decrease in reimbursement of expenses of $522,000 in accordance with the terms and conditions of the
Pfizer Agreement during the three months ended September 30, 2015 compared to the three months ended September 30, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We expect research and development expenses
for our various development programs to continue to be our primary expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><I>Selling, General and Administrative Expenses</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Selling, general and administrative expenses
were $2.3&nbsp;million for the three months ended September 30, 2015, an increase of $242,000, from $2.0&nbsp;million for the three
months ended September 30, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><I>Financial Expenses and Income</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Financial expenses, net were $1.0 million
for the three months ended September 30, 2015 compared to financial expenses, net, of $1.8 million for the three months ended September
30, 2014. Financial expenses is composed primarily from interest expense of $776,000 for each three-month period for the 4.5% convertible
notes described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Nine months ended September 30, 2015 compared to the nine
months ended September 30, 2014</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Revenues</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We recorded revenues of $12.5&nbsp;million during the nine months
ended September 30, 2015, an increase of $1.0 million, or 8%, from revenues of $11.5&nbsp;million for the nine months ended September
30, 2014. The increase resulted primarily from an increase of $841,000 of products sold in Brazil. Revenues also represent a pro
rata amortization of the $65.0&nbsp;million upfront and milestone payments of $1.1&nbsp;million in each quarterly period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Our share in the Collaboration Agreement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We recorded revenue of $3.1 million as our share of net income
from the collaboration under the Pfizer Agreement during the nine months ended September 30, 2015, an increase of $825,000, or
37%, from revenues of $2.3 million for the nine months ended September 30, 2014. Our share in the collaboration agreement recorded
during the nine months ended September 30, 2015 represents our 40% share of the net income generated during the period. Under the
terms and conditions of the Pfizer Agreement prior to its amendment, we record income or loss equal to 40% of the profit or loss
realized from sales of taliglucerase alfa and related expenses incurred based on reports we receive from Pfizer summarizing the
results of the collaborative activities under the Pfizer Agreement for the applicable period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Cost of Revenues</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cost of revenues was $6.8 million for the nine months ended
September 30, 2015, a decrease of $691,000, or 9%, from cost of revenues of $7.5 million for the nine months ended September 30,
2014. Cost of revenues is generally composed
of certain fixed costs relating to our manufacturing facility, including rent, depreciation, salary and maintenance expenses, and
to a much lesser extent, the direct cost of products sold.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Research and Development Expenses, Net</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Research and development expenses were $14.6&nbsp;million for
the nine months ended September 30, 2015, a decrease of $2.5 million, or 15%, from $17.1&nbsp;million for the nine months ended
September 30, 2014. The decrease resulted primarily from a decrease of $2.8 million in costs related to salaries expense, mainly
due to bonuses that were paid in the nine months ended September 30, 2014 and the devaluation of the New Israeli Shekel against
the U.S. dollar during the period and a decrease of $1.1 million in expenses related to subcontractors and consultants in connection
with preclinical and clinical activities. The decrease was partially offset by a decrease in reimbursement of expenses of $2.0
million in accordance with the terms and conditions of the Pfizer Agreement during the nine months ended September 30, 2015 compared
to the nine months ended September 30, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We expect research and development expenses
for our various development programs to continue to be our primary expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><I>Selling, General and Administrative Expenses</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Selling, general and administrative expenses
were $6.3&nbsp;million for the nine months ended September 30, 2015, a decrease of $1.0 million, or 14%, from $7.3&nbsp;million
for the nine months ended September 30, 2014. The decrease resulted primarily from a decrease of $788,000 in sales and marketing
expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><I>Financial Expenses and Income</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Financial expenses net were $2.7 million for the nine months
ended September 30, 2015 compared to financial expenses of $3.4 million for the nine months ended September 30, 2014. Financial
expenses is composed primarily from interest expense of $2.3 million for each nine month period for the 4.5% convertible notes
described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Liquidity and Capital Resources</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Sources of Liquidity</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">As a result of our significant research and
development expenditures which supersedes our product sales revenue, we have not been profitable and have generated operating losses
since our inception with the exception of the quarter ended June 30, 2012 due to the $25.0 million milestone payment we received
from Pfizer in connection with FDA approval of taliglucerase alfa in that period. To date, we have funded our operations primarily
with proceeds equal to $31.3&nbsp;million from the sale of shares of convertible preferred and ordinary shares of Protalix Ltd.,
and an additional $14.1&nbsp;million in connection with the exercise of warrants issued in connection with the sale of such shares,
through December 31, 2008. In addition, on October 25, 2007, we generated gross proceeds of $50&nbsp;million in connection with
an underwritten public offering of our common stock and on each of March 23, 2011 and February 22, 2012, we generated gross proceeds
of $22.0 million and $27.2 million, respectively, in connection with underwritten public offerings of our common stock. In October
2015, we generated gross proceeds of $10 million from a private sale of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition to the foregoing, on September 18, 2013, we completed
a private placement of $69.0 million in aggregate principal amount of 4.50% convertible notes due 2018, or the Notes, including
$9.0 million aggregate principal amount of Notes related to the offering&rsquo;s initial purchaser&rsquo;s over-allotment option,
which was exercised in full.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
November 2009, Pfizer paid Protalix Ltd. $60.0 million as an upfront payment in connection with the execution of the Pfizer Agreement
and subsequently paid to Protalix Ltd. an additional $5.0 million upon Protalix Ltd.&rsquo;s meeting a certain milestone. Protalix
Ltd. also received a milestone payment of $25.0 in connection with the FDA&rsquo;s approval of taliglucerase alfa in May 2012.
</FONT>Pfizer has also paid Protalix Ltd. $8.3 million in connection with the successful achievement of certain milestones under
the Clinical Development Agreement between Pfizer and Protalix Ltd. <FONT STYLE="font-family: Times New Roman, Times, Serif">In
</FONT>October 2015, we entered into the Amended Pfizer Agreement, which amends and restates the Pfizer Agreement in its entirety.
Pursuant to the Amended Pfizer Agreement, we sold to Pfizer our share in the collaboration created under the initial Pfizer Agreement
for the commercialization of Elelyso in exchange for a cash payment equal to $36 million. Under the terms of the Amended Pfizer
Agreement, we are no longer entitled to any share from the net income from Pfizer&rsquo;s sales of Elelyso.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We believe that our existing cash and cash
equivalents will be sufficient for the foreseeable future. We have based this estimate on assumptions that are subject to change
and may prove to be wrong, and we may be required to use our available capital resources sooner than we currently expect. Because
of the numerous risks and uncertainties associated with the development and commercialization of our product candidates, we are
unable to estimate the amounts of increased capital outlays and operating expenditures associated with our current and anticipated
clinical trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Cash Flows</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Net cash used in operations was
$20.4&nbsp;million for the nine months ended September 30, 2015. The net loss for the nine months ended September 30, 2015 of
$14.8 million was further increased by a decrease of $2.0 million in deferred revenues, by an increase of $3.2 million in
accounts receivable and other assets and by a decrease of $4.4 million in accounts payable, but was partially offset
by depreciation expense of $1.8 million and $1.4 million of share based compensation. Net cash used in investing activities
for the nine months ended September 30, 2015 was $516,000 and consisted primarily of purchases of property and equipment.
Net cash provided from financing activities was $534,000 primarily from the exercise of stock options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Net cash used in operations was $24.4&nbsp;million
for the nine months ended September 30, 2014. The net loss for the nine months ended September 30, 2014 of $21.5 million was further
increased by a decrease of $6.2 million in deferred revenues, and a decrease of $1.7 million in accounts payable and accruals,
but was partially offset by depreciation expense of $2.4 million and a decrease of $1.1 million in inventories. Net cash used in
investing activities for the nine months ended September 30, 2014 was $832,000 and consisted primarily of purchases of property
and equipment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><I>Future Funding Requirements </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We expect to continue to incur significant expenditures in the
near future. We expect to continue to incur significant research and development expenses, including expenses related primarily
to the clinical trials of PRX-102 and the advancement of our other product candidates into clinical trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We believe that our existing cash and
cash equivalents will be sufficient to enable us to fund our operating expenses and capital expenditure requirements for at
least 12 months. We have based this estimate on assumptions that are subject to change and may prove to
be wrong, and we may be required to use our available capital resources sooner than we currently expect. Because of the
numerous risks and uncertainties associated with the development and commercialization of our product candidates, we are
unable to estimate the amounts of increased capital outlays and operating expenditures associated with our current and
anticipated clinical trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Our future capital requirements will depend
on many factors, including the progress and results of our clinical trials, the duration and cost of discovery and preclinical
development and laboratory testing and clinical trials for our product candidates, the timing and outcome of regulatory review
of our product candidates, our progress in commercializing taliglucerase alfa in Brazil, the costs involved in preparing, filing,
prosecuting, maintaining, defending and enforcing patent claims and other intellectual property rights, the number and development
requirements of other product candidates that we pursue and the costs of commercialization activities, including product marketing,
sales and distribution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We may need to finance our future cash needs
through corporate collaboration, licensing or similar arrangements, public or private equity offerings or debt financings. We currently
do not have any commitments for future external funding. We may need to raise additional funds more quickly if one or more of our
assumptions prove to be incorrect or if we choose to expand our product development efforts more rapidly than we presently anticipate.
We may also decide to raise additional funds even before we need them if the conditions for raising capital are favorable. Any
sale of additional equity or debt securities will likely result in dilution to our shareholders. The incurrence of indebtedness
would result in increased fixed obligations and could also result in covenants that would restrict our operations. Additional equity
or debt financing, grants or corporate collaboration and licensing arrangements may not be available on acceptable terms, if at
all. If adequate funds are not available, we may be required to delay, reduce the scope of or eliminate our research and development
programs, reduce our planned commercialization efforts or obtain funds through arrangements with collaborators or others that may
require us to relinquish rights to certain product candidates that we might otherwise seek to develop or commercialize independently.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Effects of Inflation and Currency Fluctuations </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Inflation generally affects us by increasing
our cost of labor and clinical trial costs. We do not believe that inflation has had a material effect on our results of operations
during the nine and three months ended September 30, 2015 or the nine and three months ended September 30, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Currency fluctuations could affect us through
increased or decreased acquisition costs for certain goods and services. We do not believe currency fluctuations have had a material
effect on our results of operations during the nine and three months ended September 30, 2015 or the nine and three months ended
September 30, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Off-Balance Sheet Arrangements </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We have no off-balance sheet arrangements
as of each of September 30, 2015 and September 30, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><A NAME="a_012"></A>Item&nbsp;3. Quantitative and Qualitative
Disclosures About Market Risk</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Currency Exchange Risk</B>&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">The currency of the primary economic environment
in which our operations are conducted is the U.S. dollar. We consider the currency of the primary economic environment to be the
currency in which we generate revenues and expend cash. Most of our revenues are denominated in U.S. dollars, approximately 50%
of our expenses and capital expenditures are incurred in U.S. dollars, and a significant source of our financing has been provided
in U.S. dollars. Since the dollar is the functional currency, monetary items maintained in currencies other than the dollar are
remeasured using the rate of exchange in effect at the balance sheet dates and non-monetary items are remeasured at historical
exchange rates. Revenue and expense items are remeasured at the average rate of exchange in effect during the period in which they
occur. Foreign currency translation gains or losses are recognized in the statement of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A portion of our costs, including salaries, expenses and office
expenses, are incurred in NIS. Inflation in Israel may have the effect of increasing the U.S. dollar cost of our operations in
Israel. If the U.S. dollar declines in value in relation to the NIS, it will become more expensive for us to fund our operations
in Israel. A revaluation of 1% of the NIS will affect our income before tax by less than 1%. The exchange rate of the U.S. dollar
to the NIS, based on exchange rates published by the Bank of Israel, was as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 83%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Nine months ended<BR>
September 30,</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended December 31,</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 35%; font-size: 10pt">Average rate for period</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">3.890</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">3.491</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">3.578</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Rate at period end</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">3.923</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">3.695</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">3.889</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To date, we have not engaged in hedging transactions. In the
future, we may enter into currency hedging transactions to decrease the risk of financial exposure from fluctuations in the exchange
rate of the U.S. dollar against the NIS. These measures, however, may not adequately protect us from material adverse effects due
to the impact of inflation in Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Interest Rate Risk</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Our exposure to market risk is confined to
our cash and cash equivalents. We consider all short term, highly liquid investments, which include short-term deposits with original
maturities of three months or less from the date of purchase, that are not restricted as to withdrawal or use and are readily convertible
to known amounts of cash, to be cash equivalents. The primary objective of our investment activities is to preserve principal while
maximizing the interest income we receive from our investments, without increasing risk. We invest any cash balances primarily
in bank deposits and investment grade interest-bearing instruments. We are exposed to market risks resulting from changes in interest
rates. We do not use derivative financial instruments to limit exposure to interest rate risk. Our interest gains may decline in
the future as a result of changes in the financial markets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><A NAME="a_013"></A>Item&nbsp;4. Controls and Procedures</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Evaluation of Disclosure Controls and Procedures</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">We conducted an evaluation of the effectiveness
of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report
on Form 10-Q. The controls evaluation was conducted under the supervision and with the participation of management, including our
Chief Executive Officer and Chief Financial Officer. Disclosure controls and procedures are controls and procedures designed to
reasonably assure that information required to be disclosed in our reports filed under the Exchange Act, such as this Quarterly
Report on Form 10-Q, is recorded, processed, summarized and reported within the time periods specified in the Commission&rsquo;s
rules and forms. Disclosure controls and procedures are also designed to reasonably assure that such information is accumulated
and communicated to our management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow
timely decisions regarding required disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Based on the controls evaluation, our
Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of the period covered by this Quarterly
Report on Form 10-Q, our disclosure controls and procedures were effective to provide reasonable assurance that information required
to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified by
the Commission, and that material information relating to our company and our consolidated subsidiary is made known to management,
including the Chief Executive Officer and Chief Financial Officer, particularly during the period when our periodic reports are
being prepared.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Inherent Limitations on Effectiveness of Controls</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Our management, including our Chief
Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal control
over financial reporting will prevent or detect all error and all fraud. A control system, no matter how well designed and operated,
can provide only reasonable, not absolute, assurance that the control system&rsquo;s objectives will be met. The design of a control
system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their
costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance
that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within a company
have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns
can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion
of two or more people or by management override of the controls. The design of any system of controls is based in part on certain
assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its
stated goals under all potential future conditions. Projections of any evaluation of controls effectiveness to future periods are
subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of
compliance with policies or procedures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Changes in internal controls</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">There were no changes to our internal controls over financial
reporting (as defined in Rules 13a-15f and 15d-15f under the Exchange Act) that occurred during the quarter ended September 30,
2015 that have materially affected, or that are reasonably likely to materially affect, our internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="a_014"></A><B>PART II &ndash;
OTHER INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 25.9pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in"><A NAME="a_015"></A>Item&nbsp;1. Legal Proceedings</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We are not involved in any material legal
proceedings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in"><A NAME="a_016"></A>Item&nbsp;1A. Risk Factors</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">There have been no material changes to the risk factors previously disclosed in our Annual Report on Form
10-K for the year ended December 31, 2014.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in"><A NAME="a_017"></A>Item&nbsp;2. Unregistered
Sales of Equity Securities and Use of Proceeds</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in"><FONT STYLE="font-weight: normal">Unregistered
Sales of Equity Securities</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-weight: normal">There were
no unregistered sales of equity securities during the three months ended September 30, 2015. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in"><A NAME="a_018"></A>Item&nbsp;3. Defaults
Upon Senior Securities</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-weight: normal">None.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in"><A NAME="a_019"></A>Item&nbsp;4. Mine Safety
Disclosure</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-weight: normal">Not applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in"><A NAME="a_020"></A>Item&nbsp;5. Other Information</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our 2015 Annual Meeting of Shareholders was held on November
8, 2015. Holders of 56.57% of the Company's outstanding shares of common stock entitled to vote as of the record date for the meeting
participated in person or by proxy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The matters voted upon at the meeting are set forth below including
the number of votes cast for, number of votes cast against or withheld, as applicable, the number of abstentions, the number of
broker non-votes and other applicable votes with respect to each such matter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(1)&#9;Election of Directors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 37%; padding-left: 0; padding-top: 0; padding-right: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 20%; padding-right: 0; padding-left: 0; text-align: center; padding-top: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><U>For</U></B></FONT></TD>
    <TD STYLE="width: 23%; padding-right: 0; padding-left: 0; text-align: center; padding-top: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><U>Withheld</U></B></FONT></TD>
    <TD STYLE="width: 20%; padding-right: 0; padding-left: 0; text-align: center; padding-top: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><U>Broker
    Non-Votes</U></B></FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-right: 0; padding-left: 0; padding-top: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Shlomo Yanai</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0; padding-left: 0; text-align: center; padding-top: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">32,873,863</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0; padding-left: 0; text-align: center; padding-top: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10,166,072</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0; padding-left: 0; text-align: center; padding-top: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10,139,104</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-right: 0; padding-left: 0; padding-top: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Moshe Manor</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0; padding-left: 0; text-align: center; padding-top: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">37,547,409</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0; padding-left: 0; text-align: center; padding-top: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5,560,682</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0; padding-left: 0; text-align: center; padding-top: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10,139,104</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-right: 0; padding-left: 0; padding-top: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Zeev Bronfeld</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0; padding-left: 0; text-align: center; padding-top: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">20,150,869</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0; padding-left: 0; text-align: center; padding-top: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">22,889,066</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0; padding-left: 0; text-align: center; padding-top: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10,139,104</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-right: 0; padding-left: 0; padding-top: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Amos Bar Shalev</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0; padding-left: 0; text-align: center; padding-top: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">35,991,301</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0; padding-left: 0; text-align: center; padding-top: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">7,048,634</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0; padding-left: 0; text-align: center; padding-top: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10,139,104</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-right: 0; padding-left: 0; padding-top: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Yodfat Harel Buchris</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0; padding-left: 0; text-align: center; padding-top: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">35,992,870</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0; padding-left: 0; text-align: center; padding-top: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">7,047,065</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0; padding-left: 0; text-align: center; padding-top: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10,139,104</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-right: 0; padding-left: 0; padding-top: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Roger D. Kornberg, Ph.D.</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0; padding-left: 0; text-align: center; padding-top: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">14,124,189</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0; padding-left: 0; text-align: center; padding-top: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">28,983,902</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0; padding-left: 0; text-align: center; padding-top: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10,139,104</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-right: 0; padding-left: 0; padding-top: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Aharon Schwartz, Ph.D.</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0; padding-left: 0; text-align: center; padding-top: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">29,995,219</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0; padding-left: 0; text-align: center; padding-top: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">13,044,716</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0; padding-left: 0; text-align: center; padding-top: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10,139,104</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(2)&#9;Approval, on a non-binding, advisory basis, the compensation
of the Company&rsquo;s named executive officers</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 27%; padding-right: 5.4pt; padding-left: 5.4pt; text-decoration: underline; text-align: center"><B><U>For</U></B></TD>
    <TD STYLE="width: 26%; padding-right: 5.4pt; padding-left: 5.4pt; text-decoration: underline; text-align: center"><B><U>Against</U></B></TD>
    <TD STYLE="width: 26%; padding-right: 5.4pt; padding-left: 5.4pt; text-decoration: underline; text-align: center"><B><U>Abstain</U></B></TD>
    <TD STYLE="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; text-decoration: underline; text-align: center"><B><U>Broker
    Non-Votes</U></B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">31,889,394</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">9,875,043</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">1,343,654</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">10,139,104</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(3)&#9;Ratification of the appointment of Kesselman &amp; Kesselman</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 27%; padding-right: 5.4pt; padding-left: 5.4pt; text-decoration: underline; text-align: center"><B><U>For</U></B></TD>
    <TD STYLE="width: 26%; padding-right: 5.4pt; padding-left: 5.4pt; text-decoration: underline; text-align: center"><B><U>Against</U></B></TD>
    <TD STYLE="width: 26%; padding-right: 5.4pt; padding-left: 5.4pt; text-decoration: underline; text-align: center"><B><U>Abstain</U></B></TD>
    <TD STYLE="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; text-decoration: underline; text-align: center"><B><U>Broker
    Non-Votes</U></B></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">52,062,567</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">1,040,538</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">144,090</TD>
    <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">--</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in"><A NAME="a_021"></A>Item&nbsp;6. Exhibits</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><B>&nbsp;</B></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><B>&nbsp;</B></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="7">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><B>Incorporated
        by Reference</B></P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 8%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><B>Exhibit
        Number</B></P></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 28%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><BR>
        <B>Exhibit Description</B></P></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 8%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><BR>
        <B>Form</B></P></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 10%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><B>File
        Number</B></P></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 10%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><B>Exhibit</B></P></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 12%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><B>Date</B></P></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 12%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><B>Filed
        <BR>
Herewith</B></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>3.1</TD>
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Amended and Restated Articles of Incorporation of the Company</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">S-4</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">333-48677</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">3.4</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">March 26, 1998</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>3.2</TD>
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Article of Amendment to Articles of Incorporation dated June
        9, 2006</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">8-A</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">001-33357</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">3.2</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">March 9, 2007</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>3.3</TD>
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Article of Amendment to Articles of Incorporation dated December
        13, 2006</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">8-A</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">001-33357</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">3.3</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">March 9, 2007</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>3.4</TD>
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Article of Amendment to Articles of Incorporation dated December
        26, 2006</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">8-A</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">001-33357</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">3.4</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">March 9, 2007</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>3.5</TD>
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Article of Amendment to Articles of Incorporation dated February
        26, 2007</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">8-A</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">001-33357</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">3.5</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">March 9, 2007</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>3.6</TD>
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Article of Amendment to Articles of Incorporation dated December
        17, 2014</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">10-K</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">001-33357</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">3.6</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">March 12, 2015</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>3.7</TD>
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Amended and Restated Bylaws of the Company</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">10-K</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">001-33357</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">3.7</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">March 12, 2015</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>10.1</TD>
    <TD>&nbsp;</TD>
    <TD>Amended and Restated Exclusive License and Supply Agreement dated as of October 12, 2015 between Protalix
    Ltd.     and Pfizer Inc.</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">X</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%">31.1</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 28%">Certification of Chief Executive Officer pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 8%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 10%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 10%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 12%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 12%">X</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>31.2</TD>
    <TD>&nbsp;</TD>
    <TD>Certification of Chief Financial Officer pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">X</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>32.1</TD>
    <TD>&nbsp;</TD>
    <TD>18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Certification of Chief Executive Officer </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">X</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>32.2</TD>
    <TD>&nbsp;</TD>
    <TD>18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Certification of Chief Financial Officer </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">X</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>101.INS</TD>
    <TD>&nbsp;</TD>
    <TD>XBRL INSTANCE FILE</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">X</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>101.SCH</TD>
    <TD>&nbsp;</TD>
    <TD>XBRL SHEMA FILE</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">X</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>101.CAL</TD>
    <TD>&nbsp;</TD>
    <TD>XBRL CALCULATION FILE</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">X</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>101.DEF</TD>
    <TD>&nbsp;</TD>
    <TD>XBRL DEFINITION FILE</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">X</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>101.LAB</TD>
    <TD>&nbsp;</TD>
    <TD>XBRL LABEL FILE</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">X</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>101.PRE</TD>
    <TD>&nbsp;</TD>
    <TD>XBRL PRESENTATION FILE</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">X</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="a_022"></A>SIGNATURES</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 9%">&nbsp;</TD>
    <TD STYLE="width: 91%">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 45%">PROTALIX BIOTHERAPEUTICS, INC.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Registrant)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Date: November 9, 2015</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Moshe Manor</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Moshe Manor</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">President and Chief Executive Officer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(Principal Executive Officer)</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Date: November 9, 2015</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Yossi Maimon</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Yossi Maimon</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chief Financial Officer, Treasurer and Secretary</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(Principal Financial and Accounting Officer)</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>v423042_ex10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 10.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>AMENDED AND RESTATED</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>EXCLUSIVE LICENSE AND SUPPLY AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>by and between</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PFIZER INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>and</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PROTALIX LTD. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>October 12, 2015</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 84%; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 6%; text-align: right"><B>Page</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top">Section 1.</TD>
    <TD STYLE="vertical-align: top">DEFINITIONS</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">1</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top">Section 2.</TD>
    <TD STYLE="vertical-align: top">[INTENTIONALLY OMITTED]</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">12</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top">Section 3.</TD>
    <TD STYLE="vertical-align: top">LICENSE</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">12</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">3.1</TD>
    <TD STYLE="vertical-align: top">Exclusive License</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">12</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">3.2</TD>
    <TD STYLE="vertical-align: top">Other License Provisions</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">13</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">3.4</TD>
    <TD STYLE="vertical-align: top">Sublicensing and Subcontracting</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">13</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">3.5</TD>
    <TD STYLE="vertical-align: top">Improvements</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">14</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">3.6.</TD>
    <TD STYLE="vertical-align: top">No Implied License; Brazil Activities</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">14</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top">Section 4.</TD>
    <TD STYLE="vertical-align: top">REGULATORY APPROVALS AND MARKETING</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">15</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">4.1</TD>
    <TD STYLE="vertical-align: top">Regulatory Affairs</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">15</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">4.2</TD>
    <TD STYLE="vertical-align: top">Commercialization and Pricing</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">21</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">4.3</TD>
    <TD STYLE="vertical-align: top">Protalix Trademarks</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">22</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">4.4</TD>
    <TD STYLE="vertical-align: top">Pfizer Trademarks</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">22</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">4.5</TD>
    <TD STYLE="vertical-align: top">Use of Names</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">24</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">4.6</TD>
    <TD STYLE="vertical-align: top">Access to Information</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">25</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">4.7</TD>
    <TD STYLE="vertical-align: top">Transition Assistance</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">25</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">4.8</TD>
    <TD STYLE="vertical-align: top">Records</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">26</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top">Section 5.</TD>
    <TD STYLE="vertical-align: top">MANUFACTURE AND SUPPLY.</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">26</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">5.1</TD>
    <TD STYLE="vertical-align: top">Supply Chain Committee</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">26</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">5.2</TD>
    <TD STYLE="vertical-align: top">Capacity</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">27</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">5.3</TD>
    <TD STYLE="vertical-align: top">Development Supply of Drug Substance</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">28</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">5.4</TD>
    <TD STYLE="vertical-align: top">Commercial Supply of Drug Substance</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">28</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">5.5</TD>
    <TD STYLE="vertical-align: top">Supply Term</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">28</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">5.6</TD>
    <TD STYLE="vertical-align: top">Forecasting and Ordering</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">29</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">5.7</TD>
    <TD STYLE="vertical-align: top">Pricing and Invoicing</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">30</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">5.8</TD>
    <TD STYLE="vertical-align: top">Shipping and Delivery</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">30</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">5.9</TD>
    <TD STYLE="vertical-align: top">Compliance; Quality Control Obligations</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">31</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">5.10</TD>
    <TD STYLE="vertical-align: top">Certificate of Analysis; Acceptance and Returns</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">31</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">5.11</TD>
    <TD STYLE="vertical-align: top">Product Specification and Manufacturing Changes</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">33</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in; width: 10%">5.12</TD>
    <TD STYLE="width: 84%">Change Control</TD>
    <TD STYLE="width: 6%; text-align: right">33</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">5.13</TD>
    <TD>Practices</TD>
    <TD STYLE="text-align: right">33</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">5.14</TD>
    <TD>Pest Control</TD>
    <TD STYLE="text-align: right">33</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">5.15</TD>
    <TD>Records and Audits</TD>
    <TD STYLE="text-align: right">33</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">5.16</TD>
    <TD>Quality Assurance</TD>
    <TD STYLE="text-align: right">34</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">5.17</TD>
    <TD>Technical Support</TD>
    <TD STYLE="text-align: right">34</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">5.18</TD>
    <TD>Technical Assistance; Facility Access</TD>
    <TD STYLE="text-align: right">34</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">5.19</TD>
    <TD>Other Assistance by Pfizer</TD>
    <TD STYLE="text-align: right">34</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">5.20</TD>
    <TD>Master Cell Bank</TD>
    <TD STYLE="text-align: right">35</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">5.23</TD>
    <TD>Manufacturing Transition Assistance</TD>
    <TD STYLE="text-align: right">35</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>Section 6.</TD>
    <TD>FINANCIAL PROVISIONS</TD>
    <TD STYLE="text-align: right">35</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">6.1</TD>
    <TD>Second Amendment Effective Date Payment</TD>
    <TD STYLE="text-align: right">35</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">6.2</TD>
    <TD>Deferred Payment</TD>
    <TD STYLE="text-align: right">36</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">6.3</TD>
    <TD>Payments With Respect to Commercialization in Israel</TD>
    <TD STYLE="text-align: right">36</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">6.4</TD>
    <TD>Payments With Respect to Commercialization in Brazil</TD>
    <TD STYLE="text-align: right">36</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">6.5</TD>
    <TD>Release of Payment Obligations</TD>
    <TD STYLE="text-align: right">36</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>Section 7.</TD>
    <TD>ACCOUNTING AND PROCEDURES FOR PAYMENT</TD>
    <TD STYLE="text-align: right">36</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">7.1</TD>
    <TD>Currency</TD>
    <TD STYLE="text-align: right">36</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">7.2</TD>
    <TD>Method of Payments</TD>
    <TD STYLE="text-align: right">36</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">7.3</TD>
    <TD>Tax Matters</TD>
    <TD STYLE="text-align: right">37</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>Section 8.</TD>
    <TD>PATENTS AND INFRINGEMENT</TD>
    <TD STYLE="text-align: right">38</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">8.1</TD>
    <TD>Filing and Prosecution</TD>
    <TD STYLE="text-align: right">38</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">8.2</TD>
    <TD>Correspondence</TD>
    <TD STYLE="text-align: right">38</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">8.3</TD>
    <TD>Maintenance</TD>
    <TD STYLE="text-align: right">39</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">8.4</TD>
    <TD>Notices and Encumbrances</TD>
    <TD STYLE="text-align: right">39</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">8.5</TD>
    <TD>Patent Term Extensions</TD>
    <TD STYLE="text-align: right">40</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">8.6</TD>
    <TD>Third Party Infringement</TD>
    <TD STYLE="text-align: right">40</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">8.7</TD>
    <TD>Paragraph IV Notices</TD>
    <TD STYLE="text-align: right">41</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">8.8</TD>
    <TD>Other Actions by a Third Party</TD>
    <TD STYLE="text-align: right">41</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">8.9</TD>
    <TD>Compensation to Inventors</TD>
    <TD STYLE="text-align: right">42</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">8.10</TD>
    <TD>Patent Marking</TD>
    <TD STYLE="text-align: right">42</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">8.11</TD>
    <TD>In-Licensed Patents</TD>
    <TD STYLE="text-align: right">42</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; width: 10%">Section 9.</TD>
    <TD STYLE="vertical-align: top; width: 84%">CONFIDENTIALITY; PUBLICATION</TD>
    <TD STYLE="vertical-align: bottom; width: 6%; text-align: right">42</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">9.1</TD>
    <TD STYLE="vertical-align: top">Confidential Information</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">42</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">9.2</TD>
    <TD STYLE="vertical-align: top">Permitted Disclosure of Confidential Information</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">42</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">9.3</TD>
    <TD STYLE="vertical-align: top">Publication</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">44</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">9.4</TD>
    <TD STYLE="vertical-align: top">Publicity</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">44</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">9.5</TD>
    <TD STYLE="vertical-align: top">Filing, Registration or Notification of the Agreement</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">45</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top">Section 10.</TD>
    <TD STYLE="vertical-align: top">REPRESENTATIONS, WARRANTIES AND COVENANTS</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">46</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">10.1</TD>
    <TD STYLE="vertical-align: top">Protalix Representations, Warranties and Covenants</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">46</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">10.2</TD>
    <TD STYLE="vertical-align: top">Manufacturing Representations, Warranties and Covenants</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">50</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">10.3</TD>
    <TD STYLE="vertical-align: top">Environmental Representations, Warranties and Covenants</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">52</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">10.4</TD>
    <TD STYLE="vertical-align: top">Pfizer Representations, Warranties and Covenants</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">53</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">10.5</TD>
    <TD STYLE="vertical-align: top">Disclaimer of Warranty</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">54</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top">Section 11.</TD>
    <TD STYLE="vertical-align: top">ADDITIONAL COVENANTS</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">54</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">11.1</TD>
    <TD STYLE="vertical-align: top">Restrictions on Transfers and Liens</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">54</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">11.2</TD>
    <TD STYLE="vertical-align: top">Third Party Licenses and Agreements</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">55</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">11.3</TD>
    <TD STYLE="vertical-align: top">Compliance with Laws</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">55</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">11.4</TD>
    <TD STYLE="vertical-align: top">Coordination outside the Territory</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">55</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">11.5</TD>
    <TD STYLE="vertical-align: top">Protalix Non-Compete</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">55</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">11.6</TD>
    <TD STYLE="vertical-align: top">Limitation on Non-Compete Restrictions</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">55</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top">Section 12.</TD>
    <TD STYLE="vertical-align: top">[Reserved.]</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">55</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top">Section 13.</TD>
    <TD STYLE="vertical-align: top">TERM</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">55</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top">Section 14.</TD>
    <TD STYLE="vertical-align: top">TERMINATION</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">56</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">14.1</TD>
    <TD STYLE="vertical-align: top">Pfizer Termination Right for Convenience</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">56</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">14.2</TD>
    <TD STYLE="vertical-align: top">Pfizer Termination Right for Breach</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">56</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">14.3</TD>
    <TD STYLE="vertical-align: top">Protalix Right of Termination</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">56</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">14.4</TD>
    <TD STYLE="vertical-align: top">Continuing and Accrued Obligations and Surviving Provisions</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">56</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">14.5</TD>
    <TD STYLE="vertical-align: top">Effects of Termination or Expiration</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">57</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">14.6</TD>
    <TD STYLE="vertical-align: top">Bankruptcy</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">57</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top">Section 15.</TD>
    <TD STYLE="vertical-align: top">INDEMNIFICATION AND INSURANCE</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">58</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">15.1</TD>
    <TD STYLE="vertical-align: top">Indemnification</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">58</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">15.2</TD>
    <TD STYLE="vertical-align: top">Losses</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">59</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in; width: 10%">15.3</TD>
    <TD STYLE="vertical-align: top; width: 84%">Defense Procedures; Procedures for Third Party Claims</TD>
    <TD STYLE="vertical-align: bottom; width: 6%; text-align: right">60</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">15.4</TD>
    <TD STYLE="vertical-align: top">Disclaimer of Liability for Consequential Damages</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">60</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">15.5</TD>
    <TD STYLE="vertical-align: top">Sole Remedy</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">61</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">15.6</TD>
    <TD STYLE="vertical-align: top">Insurance Requirements</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">61</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top">Section 16.</TD>
    <TD STYLE="vertical-align: top">[RESERVED.]</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">63</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top">Section 17.</TD>
    <TD STYLE="vertical-align: top">GOVERNING&nbsp;&nbsp;LAW AND JURISDICTION</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">63</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">17.1</TD>
    <TD STYLE="vertical-align: top">Governing Law</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">63</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">17.2</TD>
    <TD STYLE="vertical-align: top">Jurisdiction</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">64</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top">Section 18.</TD>
    <TD STYLE="vertical-align: top">MISCELLANEOUS</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">64</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">18.1</TD>
    <TD STYLE="vertical-align: top">Force Majeure</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">64</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">18.2</TD>
    <TD STYLE="vertical-align: top">Severability</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">64</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">18.3</TD>
    <TD STYLE="vertical-align: top">Waivers</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">64</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">18.4</TD>
    <TD STYLE="vertical-align: top">Entire Agreements; Amendments</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">65</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">18.5</TD>
    <TD STYLE="vertical-align: top">Survival</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">65</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">18.6</TD>
    <TD STYLE="vertical-align: top">Assignment; Binding Effect</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">65</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">18.7</TD>
    <TD STYLE="vertical-align: top">Divestiture</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">66</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">18.8</TD>
    <TD STYLE="vertical-align: top">Independent Contractor</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">66</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">18.9</TD>
    <TD STYLE="vertical-align: top">Notices</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">66</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">18.10</TD>
    <TD STYLE="vertical-align: top">Third Party Beneficiaries</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">67</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">18.11</TD>
    <TD STYLE="vertical-align: top">Binding Effect</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">67</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">18.12</TD>
    <TD STYLE="vertical-align: top">Performance by Affiliates</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">67</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">18.13</TD>
    <TD STYLE="vertical-align: top">Corporate Integrity Agreement</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">68</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">18.14</TD>
    <TD STYLE="vertical-align: top">Counterparts</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">68</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">18.15</TD>
    <TD STYLE="vertical-align: top">Headings</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">68</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.33in">18.16</TD>
    <TD STYLE="vertical-align: top">Equitable Remedies</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">68</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 63pt; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><U>EXHIBITS</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>EXHIBIT A &ndash; AMINO ACID SEQUENCE FOR DRUG SUBSTANCE</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>EXHIBIT B &ndash; PROTALIX PATENT RIGHTS</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>EXHIBIT C &ndash; THIRD PARTY LICENSES</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>EXHIBIT D &ndash; BRAZIL <FONT STYLE="text-transform: uppercase">Uplyso Trademarks</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="text-transform: uppercase">EXHIBIT E </FONT>&ndash;<FONT STYLE="text-transform: uppercase"> IMPORTATION AUTHORIZATION</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->v<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT>&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="text-transform: uppercase">EXHIBIT F </FONT>&ndash; <FONT STYLE="text-transform: uppercase">TRANSITION PLAN </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="text-transform: uppercase">Exhibit g </FONT>&ndash;<FONT STYLE="text-transform: uppercase"> PERSISTENT FAILURE
TO SUPPLY promissory note</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>EXHIBIT H &ndash; PROTALIX PAYMENT PROMISSORY NOTE</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>EXHIBIT I &ndash; PRESS RELEASE</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>EXHIBIT J &ndash; [***] LETTER AGREEMENT <FONT STYLE="font-variant: small-caps">COMPLIANCE CERTIFICATE</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="text-transform: uppercase">EXHIBIT K &ndash; cOMPLIANCE CERTIFICATE</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="text-transform: uppercase">exhibit l &ndash; Audit Completion CertificatION</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><U>APPENDICES</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Appendix 4.1(g) &ndash; Regulatory Approvals for the Licensed Product
in the Field in the Territory</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Appendix 7.2(a) &ndash; Protalix Account Information</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Appendix 7.2(b) &ndash; Pfizer Account Information</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Appendix 10.1(t) &ndash; Pfizer&rsquo;s Anti-Bribery and Anti-Corruption
Principles</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->vi<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">AMENDED AND RESTATED EXCLUSIVE
LICENSE AND SUPPLY AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">This Amended and Restated Exclusive License
and Supply Agreement (this &ldquo;<U>Agreement</U>&rdquo;) dated as of October 12, 2015 (the &ldquo;<U>Second Amendment Effective
Date</U>&rdquo;) between Protalix Ltd., a limited liability company incorporated under the laws of Israel with offices located
at 2 Snunit Street, Science Park, P.O.B. 455, Carmiel 20100, Israel (&ldquo;<U>Protalix</U>&rdquo;), and Pfizer Inc., a Delaware
corporation with offices located at 235 East 42nd Street, New York, New York, 10017, U.S.A. (&ldquo;<U>Pfizer</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">WHEREAS, Protalix and Pfizer are parties to
that certain Exclusive License and Supply Agreement (the &ldquo;<U>Original Agreement</U>&rdquo;) dated November 30, 2009, pursuant
to which Protalix provided Pfizer with an exclusive license in all countries of the world other than Israel to certain patents,
patent applications, technology, know how and scientific and technical information relating to an enzyme replacement therapy for
the treatment of Gaucher Disease;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">WHEREAS, Protalix and Pfizer amended the Original
Agreement pursuant to the Amendment to the Exclusive License and Supply Agreement (the &ldquo;<U>First Amendment</U>&rdquo; and,
the Original Agreement as amended by the First Amendment, the &ldquo;<U>Amended Agreement</U>&rdquo;) dated June 18, 2013 (the
&ldquo;<U>Amendment Effective Date</U>&rdquo;) pursuant to which the parties amended the territory and other terms with respect
to Brazil; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">WHEREAS, Protalix and Pfizer wish to further
amend and also restate in its entirety the Amended Agreement (including, for the avoidance of doubt, the First Amendment) to modify
the territory and make such other changes as set forth herein, with the effect that the Original Agreement and First Amendment
shall be superseded hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">NOW, THEREFORE, in consideration of the mutual
covenants and agreements provided<U> </U>herein, Protalix and Pfizer hereby agree that the Amended Agreement is hereby amended
and restated in its entirety to read as follows:</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-transform: uppercase; text-indent: -1in"><FONT STYLE="text-transform: none">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-transform: uppercase; text-indent: -1in"><FONT STYLE="text-transform: none">Section
1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>DEFINITIONS</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">For purposes of this Agreement, the following
definitions shall be applicable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Affiliate</U>&rdquo;
means any entity directly or indirectly controlled by, controlling, or under common control with, a party to this Agreement, but
only for so long as such control shall continue. For purposes of this definition, &ldquo;control&rdquo; (including, with correlative
meanings, &ldquo;controlled by&rdquo;, &ldquo;controlling&rdquo; and &ldquo;under common control with&rdquo;) means (a) possession,
direct or indirect, of the power to direct or cause direction of the management or policies of an entity (whether through ownership
of securities or other ownership interests, by contract or otherwise), or (b) beneficial ownership of at least 50% of the voting
securities or other ownership interest (whether directly or pursuant to any option, warrant or other similar arrangement) or other
comparable equity interests of an entity, it being understood and agreed that for purposes of clause (a), neither ownership of
voting securities or other ownership interests of an entity nor membership or representation on (if less than half of the members
of) an entity&rsquo;s board of directors shall, by themselves, be presumed to constitute the power to direct or cause direction
of the management or policies of such entity. With respect to the grant of license rights by Protalix to Pfizer under <U>Section
3</U>, &ldquo;Affiliate&rdquo; shall exclude any Third Party that becomes an Affiliate due to such Third Party&rsquo;s acquisition
of Protalix.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Allocation
Percentage</U>&rdquo; shall have the meaning assigned to it in <U>Section 5.2(c)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Amended
Agreement</U>&rdquo; shall have the meaning assigned to it in the Recitals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Amendment
Effective Date</U>&rdquo; shall have the meaning assigned to it in the Recitals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Brazil
Activities</U>&rdquo; shall have the meaning assigned to it in <U>Section 3.6(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Brazil
Uplyso Trademark</U>&rdquo; means the trademark &ldquo;UPLYSO&trade;&rdquo; registered in Brazil, as set forth in <U>Exhibit D</U>,
as such <U>Exhibit D</U> may be updated by mutual agreement of the parties within thirty (30) days following the Second Amendment
Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Business
Associates</U>&rdquo; shall have the meaning assigned to it in <U>Appendix 10.1(t)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Business
Day</U>&rdquo; means a day other than a Saturday, Sunday, or bank or other public holiday in New York, New York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Capacity
Cap</U>&rdquo; shall have the meaning assigned to it in <U>Section 5.2(c)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Capacity
Expansion Project</U>&rdquo; shall have the meaning assigned to it in <U>Section 5.2(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Change
of Control</U>&rdquo; means any transaction or series of related transactions that would occasion: (a) any share exchange, re-capitalization,
business combination, consolidation, merger, or other transaction or series of transactions resulting in the exchange of the outstanding
shares of a party, unless the stockholders of a party that exist immediately prior to the closing date of such transaction (or
series of related transactions) hold, after the closing date, more than fifty percent (50%) of the voting securities or other similar
interest of the surviving entity in such transaction computed on a fully diluted basis; (b) a sale, lease, or other transfer of
all or substantially all of the stock or assets of a party; (c) any tender offer or exchange offer for fifty percent (50%) or more
of the outstanding voting securities or other similar interest of a party or the filing of a registration statement under the United
States Securities Act of 1933, as amended, in connection therewith; or (d) any Person or group acting in concert having acquired
beneficial ownership or the right to acquire beneficial ownership of fifty percent (50%) or more of the outstanding voting securities
or similar interest of a party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Commercialization</U>&rdquo;
means, with respect to a product or compound (including any Compound, Licensed Product, Drug Substance or Competing Product), any
activities directed to and including marketing, promoting, distributing, offering for sale and selling such product or compound,
importing such product or compound (to the extent applicable) and conducting [***]. When used as a verb, &ldquo;<U>Commercialize</U>&rdquo;
means to engage in Commercialization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Commercially
Reasonable Efforts</U>&rdquo; means, with respect to the efforts to be expended by a party with respect to the objective that is
the subject of such efforts, reasonable, good faith efforts and resources to accomplish such objective that such party would normally
use to accomplish a similar objective under similar circumstances, it being understood and agreed that with respect to the Development
or Commercialization of the Licensed Product in the Territory by Pfizer, such efforts shall be similar to those efforts and resources
consistent with the usual practice of Pfizer in pursuing the Development or Commercialization of drug products owned by it or to
which it otherwise has rights that are of similar market potential as a Licensed Product in the Territory, taking into account
all relevant factors, including the orphan drug status (if any) of the Licensed Product and other regulatory matters, safety and
efficacy matters, product labeling or anticipated labeling, pricing, present and future market potential, past performance of the
Licensed Product, past performance of Pfizer&rsquo;s own drug products that are of similar market potential (taking into account
that the Licensed Product is intended for the treatment of a rare disease), financial return [***], medical and clinical considerations,
present and future regulatory environment and competitive market conditions, all as measured by the facts and circumstances at
the time such efforts are due. It is anticipated that the level of effort constituting Commercially Reasonable Efforts may change
over time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Competing
Product</U>&rdquo; means [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Compliance
Questionnaire</U>&rdquo; shall have the meaning assigned to it in <U>Section 10.1(s)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Compound</U>&rdquo;
means (a) prGCD and (b) any analogs, derivatives and variants thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Confidential
Information</U>&rdquo; means the Protalix Confidential Information or the Pfizer Confidential Information, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.19&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Control</U>&rdquo;
or &ldquo;<U>Controlled</U>&rdquo; means, with respect to any compound, material, information, or intellectual property right,
that a party owns or has a license to use, commercialize, manufacture, market, distribute or sell, and has the ability to grant
to the other party access and/or a license or a sublicense (as applicable under this Agreement) to such compound, material, information,
or intellectual property right as provided<U> </U>for herein without violating (a) the terms of any agreement or other arrangements
with any Third Party existing before or after the Second Amendment Effective Date or (b) any law or governmental regulation applicable
to such license or sublicense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.20&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Country</U>&rdquo;
means any generally recognized sovereign entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.21&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Court</U>&rdquo;
shall have the meaning assigned to it in <U>Section 17.2</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.22&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Development</U>&rdquo;
or &ldquo;<U>Develop</U>&rdquo; means conducting pre-clinical studies and clinical trials, collecting, validating and analyzing
pre-clinical and clinical trial data, preparing and submitting regulatory filings, obtaining Regulatory Approvals, and regulatory
affairs related to the foregoing. When used as a verb, &ldquo;Develop&rdquo; means to engage in Development. For clarity, Development
does not include Phase 4 Trials or any of the foregoing in connection therewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.23&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Divestiture</U>&rdquo;
shall have the meaning assigned to it in <U>Section 18.7</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.24&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Drug
Substance</U>&rdquo; means the Compound component of a pharmaceutical drug product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.25&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Early
Access Program</U>&rdquo; means any program to provide patients with the Licensed Product prior to Regulatory Approval and prior
to Launch in any Country in the Territory. Early Access Programs include treatment INDs / protocols in the United States, named
patient programs in the EU and compassionate use programs in other Countries in the Territory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.26&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Effective
Date</U>&rdquo; means the date of the Original Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.27&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>EMEA</U>&rdquo;
means the European Agency for the Evaluation of Medicinal Products or any successor agency thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.28&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Environmental
Laws</U>&rdquo; means all applicable Laws relating to (a) safety (including occupational health and safety); conservation, preservation
or protection of human health, drinking water, natural resources, biota and the environment; (b) the generation, use, storage,
handling, treatment, transportation or disposal of Hazardous Materials or Waste, (c) Releases and threatened Releases of Hazardous
Materials, or (d) chemical classification and labeling.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.29&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Environmental
Permits</U>&rdquo; shall have the meaning assigned to it in <U>Section 10.3(a)(ii)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.30&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>European
Union</U>&rdquo; or &ldquo;<U>EU</U>&rdquo; means the Countries that are members of the European Union as of the Effective Date
or that become members of the European Union thereafter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.31&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Expansion
Costs</U>&rdquo; shall have the meaning assigned to in <U>Section 5.2(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.32&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Facility</U>&rdquo;
means, as applicable, a party&rsquo;s Manufacturing facility and such other facilities used by such party (or its Affiliates) in
the Manufacture or storage of (a) Drug Substance, (b) Licensed Product or (c) materials utilized in the Manufacture of Drug Substance
or Licensed Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.33&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;Failure
to Supply&rdquo; shall have the meaning assigned to it in Section 5.21(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.34&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>FCPA</U>&rdquo;
shall have the meaning assigned to it in <U>Appendix 10.1(t)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.35&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>FDA</U>&rdquo;
means the United States Food and Drug Administration or any successor agency thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.36&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>FDCA</U>&rdquo;
means the U.S. Federal Food, Drug and Cosmetic Act, as amended, and the regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.37&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Field</U>&rdquo;
means enzyme replacement therapy for the treatment of Gaucher Disease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.38&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Fill/Finish</U>&rdquo;
means (a) formulating the Licensed Product using Drug Substance and other excipients, (b) filling the Licensed Product into vials,
(c) lyophilization of the Drug Substance for incorporation into the Licensed Product, and (d) testing, including ongoing stability
testing, and release of the Licensed Product. For the avoidance of doubt, Fill/Finish shall not include any activities included
in the definition of Labeling and Packaging.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.39&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Fiocruz</U>&rdquo;
means Funda&ccedil;&atilde;o Oswaldo Cruz, an agency of the Brazilian Ministry of Health organized under the Laws of Brazil.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.40&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>First
Amendment</U>&rdquo; shall have the meaning assigned to it in the Recitals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.41&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Force
Majeure Event</U>&rdquo; shall have the meaning assigned to it in <U>Section 18.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.42&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Forecast</U>&rdquo;
shall have the meaning assigned to it in <U>Section 5.6(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.43&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>FTE
Rate</U>&rdquo; means [***] per full time equivalent person engaged in scientific, regulatory, process development, manufacturing
or other similar work, consisting of [***] hours per year of such qualified work.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.44&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>GAAP</U>&rdquo;
means United States generally accepted accounting principles consistently applied.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.45&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Good
Manufacturing Practices</U>&rdquo; or &ldquo;<U>GMP</U>&rdquo; means all applicable Good Manufacturing Practices including, (i)
the applicable part of quality assurance to ensure that products are consistently produced and controlled in accordance with the
quality standards appropriate for their intended use, as defined in European Commission Directive 2003/94/EC laying down the principals
and guidelines of good manufacturing practice, (ii) the principles detailed in the U.S. Current Good Manufacturing Practices, 21
C.F.R. Sections 210, 211, 601 and 610, (iii) the Rules Governing Medicinal Products in the European Community, Volume IV Good Manufacturing
Practice for Medicinal Products, (iv) the principles detailed in the ICH Q7A guidelines, and (v) the equivalent Laws in any relevant
Country, each as may be amended and applicable from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.46&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Government
Official</U>&rdquo; shall have the meaning assigned to it in <U>Section 10.1(r)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.47&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Governmental
Authority</U>&rdquo; means any court, agency, department, authority or other instrumentality of any national, state, county, city
or other political subdivision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.48&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Hazardous
Materials</U>&rdquo; means any and all materials (including substances, chemicals compounds, mixtures, products, byproducts, biologic
agents, living or genetically modified materials, wastes, pollutants and contaminants), that are (a) (i) listed, classified, characterized
or regulated pursuant to Environmental Laws; (ii) identified or classified as &ldquo;hazardous&rdquo;, &ldquo;dangerous&rdquo;,
&ldquo;toxic&rdquo;, &ldquo;pollutant&rdquo;, &ldquo;contaminant&rdquo;, &ldquo;waste&rdquo;, &ldquo;irritant&rdquo;, &ldquo;corrosive&rdquo;,
&ldquo;flammable&rdquo;, &ldquo;radioactive&rdquo;, &ldquo;reactive&rdquo;, &ldquo;carcinogenic&rdquo;, &ldquo;mutagenic&rdquo;,
&ldquo;bioaccumulative&rdquo;, or &ldquo;persistent&rdquo; in the environment; or (iii) in quantity or concentration capable of
causing harm or injury to human health, natural resources or the environment, if Released or resulting in human exposure; or (b)
petroleum products and their derivatives, asbestos-containing material, lead-based paint, polychlorinated biphenyls, urea formaldehyde,
or viral, bacterial or fungal material.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.49&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Improvement
Notice</U>&rdquo; shall have the meaning assigned to in <U>Section 3.5</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.50&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Increased
Capacity Cap</U>&rdquo; shall have the meaning assigned to it in <U>Section 5.2(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.51&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>IND</U>&rdquo;
means an investigational new drug application filed with the FDA in accordance with the FDCA with respect to a drug product or
an analogous application or filing with any Regulatory Authority outside of the United States (including any supra-national agency
such as the European Union) for the purpose of commencing clinical development of a drug product in such jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.52&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Indemnified
Party</U>&rdquo; shall have the meaning assigned to it in <U>Section 15.3(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.53&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Indemnifying
Party</U>&rdquo; shall have the meaning assigned to it in <U>Section 15.3(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.54&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Initial
Forecast</U>&rdquo; shall have the meaning assigned to it in <U>Section 5.6(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.55&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Inventories</U>&rdquo;
shall have the meaning assigned to it in <U>Section 4.2(c)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.56&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Israel
Grant</U>&rdquo; shall have the meaning assigned to it in <U>Section 10.1(i)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.57&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>IU</U>&rdquo;
shall have the meaning assigned to it in <U>Section 5.7(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.58&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Labeling
and Packaging</U>&rdquo; means the final product labeling and packaging of the Licensed Product (whether in commercial or clinical
packaging presentation), including materials to be inserted such as patient inserts, patient medication guides, professional inserts
and any other written, printed or graphic materials accompanying the Licensed Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.59&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Launch</U>&rdquo;
means the first shipment of a Licensed Product in commercial quantities for commercial sale by Pfizer, its Affiliates or its Sublicensees
to a Third Party in a Country in the Territory after receipt by Pfizer of the first Regulatory Approval (and, in any Country in
which Price Approval is necessary or relevant for a majority of the population to obtain access to drug products, Price Approval)
for such Licensed Product in such Country.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.60&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Laws</U>&rdquo;
means all laws, statutes, rules, regulations, codes, administrative or judicial orders, judgments, decrees, injunctions and/or
ordinances of any Governmental Authority, and common law or other legal requirements of any kind, whether currently in existence
or hereafter promulgated, enacted, adopted or amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.61&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Licensed
Product</U>&rdquo; means any finished dosage form of a drug product that contains Drug Substance (excluding any Oral Formulation)
and either: (a) the manufacture, sale, offer for sale, importation, or use of such drug product (i) would, absent the license granted
by Protalix to Pfizer herein, infringe at least one Valid Claim of a Protalix Patent Right, or (ii) embodies, incorporates or uses
Protalix Technology; or (b) such drug product is supplied by Protalix to Pfizer under this Agreement (or is manufactured using
Drug Substance supplied by Protalix to Pfizer under this Agreement) or is manufactured by Pfizer or a Third Party (or is manufactured
using Drug Substance manufactured by Pfizer or a Third Party).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.62&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Long
Range Forecast</U>&rdquo; shall have the meaning assigned to it in <U>Section 5.6(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.63&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Losses</U>&rdquo;
shall have the meaning assigned to it in <U>Section 15.2</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.64&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Manufacture</U>&rdquo;
or &ldquo;<U>Manufacturing</U>&rdquo; means all activities related to the manufacturing of the Drug Substance or Licensed Product,
and/or any ingredient thereof, including manufacturing for clinical use or commercial sale, in-process and finished product testing,
Fill/Finish, Labeling and Packaging, release of product, quality assurance activities related to manufacturing and release of product
and ongoing stability tests and regulatory activities related to any of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.65&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Manufacturing
Certificate of Analysis</U>&rdquo; shall have the meaning assigned to it in <U>Section 5.10(a)(i)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.66&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Manufacturing
Transition Plan</U>&rdquo; shall have the meaning assigned to it in <U>Section 5.23</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.67&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;Minimum Delivery Requirements&rdquo;
shall have the meaning assigned to it in <U>Section 5.21(a)</U>.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.68&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Minimum
Shelf Life</U>&rdquo; shall have the meaning assigned to it in <U>Section 5.8(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.69&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>NDA</U>&rdquo;
means a New Drug Application filed with the FDA in accordance with the FDCA with respect to a drug product or an analogous application
or filing with any Regulatory Authority outside of the United States (including any supra-national agency such as the European
Union) for the purpose of obtaining approval to market and sell a drug product in such jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.70&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&ldquo;<U>Notice of Non-Conformance</U>&rdquo; shall have the meaning assigned to it in <U>Section 5.10(a)(ii)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.71&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Oral
Formulation</U>&rdquo; means an oral formulation of a drug product for the treatment of Gaucher Disease which contains any Compound
as the active pharmaceutical ingredient.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.72&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Original
Agreement</U>&rdquo; shall have the meaning assigned to it in the Recitals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.73&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Outside
of the Scope Product</U>&rdquo; shall have the meaning assigned to it in <U>Section 8.2</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.74&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Patent
Application</U>&rdquo; means any application for a Patent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.75&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Patent Challenge</U>&rdquo;
has the meaning assigned to it in <U>Section 3.7(a)</U>.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.76&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Patent
Rights</U>&rdquo; means Patents and Patent Applications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.77&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Patents</U>&rdquo;
means issued patents, whether domestic or foreign, including all continuations, continuations-in-part, divisions, provisionals
and renewals, and letters of patent granted with respect to any of the foregoing, patents of addition, supplementary protection
certificates, registration or confirmation patents and all reissues, re-examination and extensions thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.78&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;Persistent
Failure to Supply&rdquo; shall have the meaning assigned to it in Section 5.21(b).</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.79&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Person</U>&rdquo;
means an individual, corporation, partnership, company, joint venture, unincorporated organization, limited liability company or
partnership, sole proprietorship, association, bank, trust company or trust, whether or not legal entities, or any Governmental
Authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.80&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Pfizer
Confidential Information</U>&rdquo; means all information relating to the Compound or Licensed Product, as well as any other information
regarding the business and operations of Pfizer, that is or has been disclosed (whether orally or in writing) by Pfizer to Protalix
or its Affiliates to the extent that such information is not: (a) as of the date of disclosure known to Protalix or its Affiliates;
or (b) disclosed in published literature, or otherwise generally known to the public through no breach by or Protalix; of this
Agreement or (c) obtained by Protalix or its Affiliates from a Third Party free from any obligation of confidentiality to Pfizer;
or (d) independently developed by Protalix or its Affiliates without use of the Pfizer Confidential Information; or (e) in the
good faith judgment of Protalix, after consultation with legal counsel, is required to be disclosed under Law; <U>provided</U>&nbsp;that,
in the case of (e), Protalix provides Pfizer prior notice (to the extent practicable) of such disclosure and agrees to cooperate,
at the request and sole expense of Pfizer, with Pfizer&rsquo;s efforts to preserve the confidentiality of such information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.81&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Pfizer
Improvements</U>&rdquo; has the meaning assigned to it in <U>Section 3.6(d)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.82&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Pfizer
Payment</U>&rdquo; has the meaning assigned to it in <U>Section 6.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.83&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Phase
4 Trial</U>&rdquo; means a clinical trial for the Licensed Product that is initiated in a Country after receipt of Regulatory Approval
for the Licensed Product in such Country and is principally intended to support the marketing and Commercialization of the Licensed
Product, including investigator initiated trials and clinical experience trials. &ldquo;<U>prGCD</U>&rdquo; means a plant cell
expressed recombinant human Glucocerebrosidase enzyme having the sequence set forth in <U>Exhibit A</U> to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.84&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Presentation</U>&rdquo;
means [***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.85&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Price</U>&rdquo;
means the price Pfizer pays to Protalix per IU of Drug Substance manufactured for and shipped to Pfizer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.86&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Price
Approval</U>&rdquo; means, in any Country where a Governmental Authority authorizes reimbursement for, or approves or determines
pricing for, drug products, receipt (or, if required to make such authorization, approval or determination effective, publication)
of such reimbursement authorization or pricing approval or determination (as the case may be).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.87&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Product
Mark</U>&rdquo; shall have the meaning assigned to in <U>Section 4.4(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.88&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Product
Specifications</U>&rdquo; means those Manufacturing, performance, quality - control release, and Fill/Finish specifications for
Drug Substance or Licensed Product in the Territory, which are initially as set forth in the applicable Regulatory Approval for
a Licensed Product, as such specifications may be amended from time to time pursuant to the terms of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.89&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Proposed Transaction</U>&rdquo;
shall have the meaning assigned to it in <U>Section 11.7</U>.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.90&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Protalix
Confidential Information</U>&rdquo; [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.91&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Protalix
Improvement</U>&rdquo; means any necessary or useful improvement, change, or modification to the Drug Substance, Licensed Product
or Protalix Technology which may be developed, created, or acquired by Protalix after the Effective Date and before termination
of this Agreement, including new or improved methods of Manufacturing, means of delivery (other than an Oral Formulation), dosage,
formulation (other than an Oral Formulation), and analysis. To the extent an improvement, change or modification to prGCD also
constitutes an analog, derivative or variant of prGCD, such improvement, change or modification shall be deemed to be a Compound
and not a Protalix Improvement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.92&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Protalix
Patent Rights</U>&rdquo; [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.93&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Protalix
Payment</U>&rdquo; has the meaning assigned to it in <U>Section 6.2</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.94&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Protalix
System Patent Rights</U>&rdquo; means Protalix Patent Rights that relate primarily to the System.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.95&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Protalix
Technology</U>&rdquo; means any Technology owned or otherwise Controlled by Protalix or any of its Affiliates as of the Second
Amendment Effective Date or at any time during the Term that is necessary or useful for the Development, Manufacture, use or Commercialization
of Compound, Drug Substance or a drug product that contains Drug Substance, including the System.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.96&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Protalix Withholding Tax
Action</U>&rdquo; has the meaning assigned to in <U>Section 7.3(c)(iii)</U>.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.97&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Purchase
Order</U>&rdquo; shall have the meaning assigned to it in <U>Section 5.6(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.98&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Quality
Agreement</U>&rdquo; means the Quality Agreement entered into between Protalix and Pfizer, dated January 4, 2011, with respect
to the Drug Substance being Manufactured by Protalix [***] in the Territory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.99&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Redacted
Agreement</U>&rdquo; shall have the meaning assigned to it in <U>Section 9.5</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.100&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Regulatory Approval</U>&rdquo;
means any and all approvals, with respect to any Country, or authorizations (other than Price Approvals) of a Regulatory Authority,
that are necessary for the commercial Manufacture, distribution, use, marketing or sale of a drug product in such Country.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.101&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Regulatory Authority</U>&rdquo;
means, in respect of a particular Country or jurisdiction, the Governmental Authority having responsibility for granting Regulatory
Approvals in such Country or jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.102&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Regulatory Exclusivity</U>&rdquo;
means any rights or protections which are recognized, afforded or granted by a Regulatory Authority in any Country or region of
the Territory, in association with the Regulatory Approval of a Licensed Product, providing such Licensed Product: (a) a period
of marketing exclusivity, during which the Regulatory Authority recognizing, affording or granting such marketing exclusivity will
refrain from either reviewing or approving a marketing authorization application or similar regulatory submission, submitted by
a party other than Pfizer, its Affiliates or Sublicensees seeking to market a drug product in which the Drug Substance is the primary
ingredient, or during which such an application or submission may be reviewed or approved by a Regulatory Authority, but the product
may not be placed on the market or (b) a period of data exclusivity, during which a party, other than Pfizer, its Affiliates or
Sublicensees, seeking to market a drug product in which the Drug Substance is the primary ingredient, is precluded from either
referencing or relying upon a Licensed Product&rsquo;s clinical dossier or relying on previous findings of safety or effectiveness
with respect to a Licensed Product to support the submission, review or approval of a marketing authorization application or similar
regulatory submission before the applicable Regulatory Authority. Regulatory Exclusivity shall include rights conferred in the
United States pursuant to the Hatch-Waxman Act or the FDA Modernization Act of 1997 or in the European Union/European Economic
Area pursuant to Section 10.1 of Directive 2001/EC/83 or section 14.11 of Regulation (EC) No. 726/2004.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.103&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Release</U>&rdquo; means
any release, spill, emission, leaking, pumping, injection, deposit, disposal, discharge, dispersal, leaching or migration into
the indoor or outdoor environment, including the uncontrolled presence or the movement of Hazardous Materials through the ambient
air, soil, subsurface water, groundwater, wetlands, lands or subsurface strata.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.104&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Released Obligations</U>&rdquo;
has the meaning assigned to it in <U>Section 6.5</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.105&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Resulting Companies</U>&rdquo;
shall have the meaning assigned to it in <U>Section 18.7(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.106&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Second Amendment Effective
Date</U>&rdquo; shall have the meaning assigned to it in the Recitals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.107&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Sublicense</U>&rdquo; means
the grant by Pfizer of a sublicense under, or an agreement of Pfizer not to assert, any of the rights licensed by Protalix to Pfizer
pursuant to <U>Section 3.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.108&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Sublicensee</U>&rdquo; means
a Third Party to whom Pfizer has granted a Sublicense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.109&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Supply Term</U>&rdquo; shall
have the meaning assigned to it in <U>Section 5.5</U><B>.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.110&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>System</U>&rdquo; means Protalix&rsquo;s
proprietary protein expression system, ProCellEx&trade;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.111&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Technology</U>&rdquo; means
proprietary materials, technology, data, results and non-public technical, scientific and clinical information, in any tangible
or intangible form, including know-how, expertise, trade secrets, practices, techniques, methods, processes, developments, specifications,
formulations, formulae, including any intellectual property rights embodying any of the foregoing, but excluding any Patent Rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.112&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Technology Transfer Agreement</U>&rdquo;
means the Technology Transfer and Supply Agreement between Protalix and Fiocruz, dated June 18, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.113&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Term</U>&rdquo; shall have
the meaning assigned to it in <U>Section 13</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.114&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Territory</U>&rdquo; means
the entire world, excluding Brazil.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.115&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Third Party</U>&rdquo; means
any Person other than Pfizer, Protalix, or any of their respective Affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.116&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Third Party Claim</U>&rdquo;
shall have the meaning assigned to it in <U>Section 15.3</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.117&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Third Party License</U>&rdquo;
means each license agreement between Protalix and a Third Party set forth on <U>Exhibit C</U> pursuant to which or from which Protalix
licenses Protalix Patent Rights or Protalix Technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.118&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Transition Manager</U>&rdquo;
shall have the meaning assigned to it in <U>Section 4.7(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.119&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Transition Period</U>&rdquo;
shall have the meaning assigned to it in <U>Section 4.7(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.120&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Transition Plan</U>&rdquo;
shall have the meaning assigned to it in <U>Section 4.7(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.121&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Transition Team</U>&rdquo;
shall have the meaning assigned to it in <U>Section 4.7(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.122&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Unmatured Note</U>&rdquo;
shall have the meaning assigned to it in <U>Section 5.21(b)(i)</U>.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.123&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Uplyso
Trademarks</U>&rdquo; means the trademark &ldquo;UPLYSO&trade;&rdquo; in certain countries in the world.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.124&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Valid Claim</U>&rdquo; means
(a) a claim of an issued and unexpired Patent (including the term of any patent term extension, supplemental protection certificate,
renewal or other extension) which has not been held unpatentable, invalid or unenforceable in a final decision of a court or other
Governmental Authority of competent jurisdiction from which no appeal may be or has been taken, and which has not been admitted
to be invalid or unenforceable through reissue, re-examination or disclaimer; or (b) a claim of a Patent Application, which claim
has been pending less than five (5) years from the original priority date of such claim in a given jurisdiction, unless or until
such claim thereafter issues as a claim of an issued Patent (from and after which time the same shall be deemed a Valid Claim subject
to paragraph (a) above).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.125&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***] means [***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.126&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***]<U> License Agreement</U>&rdquo;
means that License Agreement by and between Protalix and [***]effective as of [***], as amended from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.127&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Waste</U>&rdquo; means all
wastes which arise from the Manufacture, handling or storage of Drug Substance hereunder, or which is otherwise produced through
the implementation of this Agreement, including Hazardous Materials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.128&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Work Plan</U>&rdquo; shall
have the meaning assigned to it in <U>Section 5.2(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.129&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><U>Construction</U>. Except where expressly
stated otherwise in this Agreement, the following rules of interpretation apply to this Agreement: (a) &ldquo;include&rdquo;, &ldquo;includes&rdquo;
and &ldquo;including&rdquo; are not limiting and mean include, includes and including, without limitation; (b) definitions contained
in this Agreement are applicable to the singular as well as the plural forms of such terms; (c) references to an agreement, statute
or instrument mean such agreement, statute or instrument as from time to time amended, modified or supplemented; (d) references
to a Person are also to its permitted successors and assigns; (e) references to an &ldquo;Article&rdquo;, &ldquo;Section&rdquo;,
&ldquo;Exhibit&rdquo; or &ldquo;Schedule&rdquo; refer to an Article or Section of, or any Exhibit or Schedule to, this Agreement
unless otherwise indicated; (f) the word &ldquo;will&rdquo; shall be construed to have the same meaning and effect as the word
&ldquo;shall&rdquo;; and (g) the word &ldquo;any&rdquo; shall mean &ldquo;any and all&rdquo; unless otherwise indicated by context.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-transform: uppercase; text-indent: -1in"><FONT STYLE="text-transform: none">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-transform: uppercase; text-indent: -1in"><FONT STYLE="text-transform: none">Section
2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>[INTENTIONALLY OMITTED]</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-transform: uppercase; text-indent: -1in"><FONT STYLE="text-transform: none">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-transform: uppercase; text-indent: -1in"><FONT STYLE="text-transform: none">Section
3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>LICENSE</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">3.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Exclusive
License</U>. Subject to the terms of this Agreement, including <U>Section 3.2</U>, Protalix hereby grants to Pfizer and Pfizer
hereby accepts an exclusive (even as to Protalix and its Affiliates, except as set forth in <U>Section 3.2</U>), irrevocable, perpetual,
fully-paid (upon Pfizer&rsquo;s payment of the Pfizer Payment pursuant to <U>Section 6.1</U> of the Agreement), royalty-free license
in the Territory and within the Field, including the right to Sublicense (subject to <U>Section 3.4</U>):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;under
the Protalix Patent Rights to (i) use, sell, offer for sale, supply, cause to be supplied, and import the Licensed Product, (ii)
conduct the Fill/Finish activities and Labeling and Packaging activities, (iii) engage in Development activities with respect to
the Licensed Product, and (iv) make and have made the Drug Substance solely for incorporation in the Licensed Product; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
use Protalix Technology and Protalix Confidential Information in connection with (i) the conduct of the Fill/Finish activities
and Labeling and Packaging activities, (ii) preparing and submitting regulatory filings and communicating with Regulatory Authorities
with respect to the Licensed Product, (iii) the use, sale, offer for sale, supply and importation of the Licensed Product, (iv)
Development activities with respect to the Licensed Product, and (v) making and having made the Drug Substance solely for incorporation
in the Licensed Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">3.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Other
License Provisions</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
licenses granted to Pfizer pursuant to <U>Section 3.1</U> shall be co-exclusive with Protalix only to the extent it is necessary
for Protalix to perform its obligations under this Agreement. During the Term, and without limiting the scope of the licenses granted
to Pfizer pursuant to <U>Section 3.1</U>, neither Protalix nor any of its Affiliates shall (i) directly or indirectly, alone or
in collaboration with any Third Party, Commercialize the Compound (other than the Oral Formulation), a drug product containing
the [***]. The parties expressly acknowledge and agree that the exclusivity grant in favor of Pfizer in <U>Section 3.1</U> shall
not be construed as limiting Protalix&rsquo;s right to Develop, Manufacture or Commercialize [***]. Notwithstanding anything to
the contrary herein, Protalix may conduct or have conducted Manufacturing activities and engage in or have engaged in Development
activities in Israel at any time in connection with its sale, offer for sale, supply or importation of the Licensed Product outside
the Territory; <U>provided however</U>, that Protalix shall not be permitted to conduct clinical studies of the [***] within Israel
without the prior written consent of Pfizer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
purposes of clarity, and without limiting the licenses granted under <U>Section 3.1</U>, Pfizer acknowledges that in the event
Protalix does not have exclusive rights to Protalix Patent Rights licensed by Protalix from Third Parties [***] vis &agrave; vis
the Third Party licensor, Pfizer&rsquo;s rights to such Protalix Patent Rights under the sublicenses granted under <U>Section 3.1</U>
would not be exclusive vis &agrave; vis the Third Party licensor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">3.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">3.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Sublicensing
and Subcontracting</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pfizer
may grant Sublicenses subject to the terms and conditions set forth in this <U>Section 3.4</U>. Any Sublicense obligations required
by the Third Party License to be included in a sublicense shall be deemed to be included in this Agreement as obligations of Pfizer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
Sublicense granted by Pfizer pursuant to <U>Section 3.4(a)</U> shall be subject and subordinate to the terms and conditions of
this Agreement and shall contain terms and conditions consistent with those in this Agreement, and shall not in any way diminish,
reduce or eliminate any of Pfizer&rsquo;s obligations under this Agreement. Without limiting the foregoing, each Sublicense agreement
with Sublicensees shall contain the following provisions: (i) a requirement that such Sublicensee comply with the confidentiality
and non-use provisions of <U>Section 9</U> with respect to both parties&rsquo; Confidential Information, (ii) a requirement to
comply with all other applicable terms of this Agreement, and (iii) a provision prohibiting such Sublicensee from further sublicensing
unless such further sublicense complies with the terms of this <U>Section 3.4</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Right
to Subcontract</U>. Each party may, subject to <U>Section 9</U> and <U>Section 3.4(d)</U>, subcontract its obligations under this
Agreement to an Affiliate or Third Party as it would in the normal course of its business without the prior written consent of
the other party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Liability
for Affiliates, Sublicensees and Subcontractors</U>. Each party shall ensure that each of its Affiliates, sublicensees and subcontractors
accepts and complies with all of the applicable terms and conditions of this Agreement as if such Affiliates or sublicensees or
subcontractors were parties to this Agreement and each party shall remain fully responsible for its Affiliates&rsquo; and sublicensees&rsquo;
and subcontractors&rsquo; performance under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">3.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Improvements</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
the Term, Protalix shall give written notice (an &ldquo;<U>Improvement Notice</U>&rdquo;) to Pfizer within thirty (30) days of
any actual or constructive reduction to practice of any Protalix Improvement. The Improvement Notice shall set forth the nature
and details of the Protalix Improvement and any data obtained or generated by Protalix. Where such Protalix Improvements are to
an invention, Protalix shall state in the Improvement Notice whether it intends to prepare and file patent applications related
thereto. For the avoidance of doubt, the Improvement Notice and its contents shall be deemed Protalix Confidential Information
and subject to the confidentiality provisions set forth in <U>Section 9</U> hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
Protalix Improvement shall be deemed to be included within the Protalix Technology licensed to Pfizer pursuant to <U>Section 3.1</U>
of this Agreement, without the payment of any additional fees, including milestones or royalties. Any Patent Application directed
to a Protalix Improvement shall be considered to be a Protalix Patent Right licensed pursuant to <U>Section 3.1</U> of this Agreement,
without the payment of any additional fees, including milestones or royalties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">3.6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Implied License; Brazil Activities</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
for the licenses and other rights granted to Pfizer herein, all right, title and interest in and to the Protalix Patent Rights,
Protalix Technology, Protalix Confidential Information and Protalix Improvements shall remain solely with Protalix and its Third
Party licensors, as applicable. Except as expressly provided<U> </U>in this <U>Section 3</U> or elsewhere in this Agreement, neither
party will be deemed by this Agreement to have been granted any license or other rights to the other party&rsquo;s intellectual
property rights, either expressly or by implication, estoppel or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
anything to the contrary in this Agreement, for the avoidance of doubt, Protalix shall have the (i) sole authority and exclusive
right to determine all operating plans and strategies for the Drug Substance and Licensed Product outside the Territory and the
exclusive right to research, Develop or Commercialize the Drug Substance or Licensed Product outside the Territory and to Manufacture
(including Fill/Finish) the Drug Substance or Licensed Product for sale outside the Territory, and (ii) right to enter into, and
perform any of its obligations under, any agreements (including the Technology Transfer Agreement), including sublicenses, relating
to Protalix&rsquo;s rights in clause (i) of this sentence (collectively, the &ldquo;<U>Brazil Activities</U>&rdquo;), without obtaining
any additional consents from Pfizer with respect thereto or having Pfizer participate therein. For the avoidance of doubt, as used
in this <U>Section 3.6(b)</U>, the term &ldquo;Commercialize&rdquo; includes the activities referred to in <U>Section 1.13</U>
with respect to both Drug Substance and Licensed Product. Without limiting the foregoing, Protalix shall have the right to engage
Third Parties to perform Fill/Finish activities for, and/or supply Licensed Product to, Protalix for sale of such Licensed Product
outside the Territory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pfizer
acknowledges and agrees that Protalix is permitted to sublicense to Fiocruz (or any other sublicensee of Protalix in Brazil) the
Brazil Uplyso Trademark and any other Product Marks required by applicable Laws to be included on the labeling and packaging of
the finished packaged product for use in the Brazil Activities as they exist on the labeling and packaging of finished packaged
product at the time such finished packaged product is supplied to Fiocruz (or such sublicensee), and subject to the quality control
provisions set forth in the Technology Transfer Agreement (or equivalent provisions in another agreement with the applicable sublicensee),
which shall be at least as protective as those set forth in <U>Section 4.4(d)</U>. For the avoidance of doubt, the rights granted
pursuant to this <U>Section 3.6(c)</U> do not include grants to use the name or trade name of Pfizer (other than the right to sublicense
such right to Fiocruz (or any other sublicensee of Protalix in Brazil) to the extent such right is granted to Protalix pursuant
to <U>Section 4.5</U> or required to be made pursuant to <U>Section 4.4(d)(iv)(B)</U>). Any such right to use such name or trade
name shall be governed by <U>Section 4.5</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pfizer
acknowledges and agrees that Protalix is permitted to sublicense to Fiocruz any drug product manufacturing-related enhancements
that are specifically directed to, or new presentations of, the Licensed Product developed or otherwise owned by Pfizer or its
Affiliates (&ldquo;<U>Pfizer Improvements</U>&rdquo;), pursuant to the Technology Transfer Agreement (or another agreement with
the applicable sublicensee); <U>provided</U> that the Pfizer Improvements are used solely for the Licensed Product by Protalix
and Fiocruz (or the applicable sublicensee). Pfizer agrees to consider in good faith any reasonable requests for technical support
to transfer technical manufacturing information relating solely to the Pfizer Improvement in connection with such sublicense. Such
requests for technical support shall be limited to [***] person hours and should additional technical support be required, Protalix
shall provide to Pfizer a written request for such additional technical support. Protalix shall reimburse Pfizer for all actual
Pfizer costs associated with such technical support, including out-of pocket expenses and documented employee time at the FTE Rate.
For the avoidance of doubt, Pfizer shall be under no obligations to provide any technical support pursuant to this <U>Section 3.6(d)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40.5pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;3.7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***]</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-transform: uppercase; text-indent: -1in"><FONT STYLE="text-transform: none">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-transform: uppercase; text-indent: -1in"><FONT STYLE="text-transform: none">Section
4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>REGULATORY APPROVALS AND MARKETING</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">4.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Regulatory
Affairs</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Regulatory
Affairs in the Territory other than Israel</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Copies
of Regulatory Filings</U>. The parties acknowledge that Protalix has provided to Pfizer complete copies of all regulatory filings
in the Territory (other than Israel) relating to the Licensed Product, including INDs, filings with the FDA or other Regulatory
Authorities, supplements or amendments thereto, all written correspondence with the FDA or other Regulatory Authorities regarding
such regulatory filings, and all existing written minutes of meetings and memoranda of conversations between Protalix (including,
to the extent practicable, Protalix&rsquo;s investigators) and the FDA or other Regulatory Authorities in Protalix&rsquo;s possession
(or in the possession of any of Protalix&rsquo;s agents and subcontractors, such as contract research organizations used by Protalix),
to the extent Protalix had the right to access and provide to Pfizer such materials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Transfer
of Regulatory Filings</U>. The parties acknowledge that Protalix assigned and transferred to Pfizer (i) Protalix&rsquo;s entire
right, title and interest in and to the Regulatory Approvals for the Licensed Product in the Field in the Territory (other than
Israel) and (ii) Protalix&rsquo;s entire right, title and interest in and to any other regulatory filings in the Territory (other
than Israel) with respect to the Drug Substance as incorporated into the Licensed Product (and for the avoidance of doubt, excluding
any such regulatory filings with respect to the Drug Substance as a part of any Oral Formulation), or the Licensed Product, and
any related data.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Regulatory
Filings</U>. During the Term, and with respect to Israel, following the transfer of ownership of regulatory filings relating to
the Drug Substance as incorporated into the Licensed Product (and for the avoidance of doubt, excluding any regulatory filings
with respect to the Drug Substance as part of any Oral Formulation), or the Licensed Product in Israel, all regulatory filings
with the FDA or other Regulatory Authorities pertaining to the Drug Substance as incorporated into the Licensed Product (and for
the avoidance of doubt, excluding any such regulatory filings with respect to the Drug Substance as part of any Oral Formulation),
or Licensed Product in the Territory shall be made in the name of Pfizer or its Affiliates in accordance with <U>Section 4.1(g)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Regulatory
Affairs in Israel</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Transfer
of Regulatory Filings</U>. Within the timeframe set forth by the Transition Team and to the extent permitted by applicable Law,
(A) Protalix shall assign and transfer to Pfizer, Protalix&rsquo;s entire right, title and interest in and to all regulatory filings
and Regulatory Approvals in Israel with respect to the Drug Substance or Licensed Product in the Field (and for the avoidance of
doubt, excluding any such regulatory filings or Regulatory Approvals with respect to the Drug Substance as a part of any Oral Formulation),
and any related data, pursuant to instruments to such effect in form and substance reasonably satisfactory to Pfizer, and shall
perform all other actions reasonably requested by Pfizer to effect and confirm such assignment and transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Copies
of Regulatory Filings</U>. Protalix shall provide to Pfizer, at Pfizer&rsquo;s expense, complete copies of any regulatory filings
in Israel relating to the Licensed Product, including INDs, NDAs, filings with the Regulatory Authorities, supplements or amendments
thereto, all written correspondence with Regulatory Authorities regarding such regulatory filings, and all existing written minutes
of meetings and memoranda of conversations between Protalix (including, to the extent practicable, Protalix&rsquo;s investigators)
and Regulatory Authorities in Protalix&rsquo;s possession (or in the possession of any of Protalix&rsquo;s agents and subcontractors,
such as contract research organizations used by Protalix), to the extent Protalix has the right to access and provide to Pfizer
such materials. To the extent available, Protalix shall provide such copies to Pfizer in electronic form.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Regulatory
Affairs in Brazil</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Transfer
of Regulatory Filings</U>. Within the timeframe set forth by the Transition Team and to the extent permitted by applicable Laws,
Pfizer shall assign and transfer to Protalix Pfizer&rsquo;s entire right, title and interest in and to all regulatory filings and
Regulatory Approvals in Brazil with respect to the Drug Substance or Licensed Product, and any related data, pursuant to instruments
to such effect in form and substance reasonably satisfactory to Protalix, and shall perform all other actions reasonably requested
by Protalix to effect and confirm such assignment and transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Copies
of Regulatory Filings</U>. To the extent not already provided by Pfizer, Pfizer shall provide to Protalix, at Protalix&rsquo;s
expense, complete copies of any regulatory filings in Brazil relating to the Licensed Product, including INDs, NDAs, filings with
the Regulatory Authorities, supplements or amendments thereto, all written correspondence with Regulatory Authorities regarding
such regulatory filings, and all existing written minutes of meetings and memoranda of conversations between Pfizer (including,
to the extent practicable, Pfizer&rsquo;s investigators) and Regulatory Authorities in Pfizer&rsquo;s possession (or in the possession
of any of Pfizer&rsquo;s agents and subcontractors, such as contract research organizations used by Pfizer), to the extent Pfizer
has the right to access and provide to Protalix such materials. To the extent available, Pfizer shall provide such copies to Protalix
in electronic form.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Cooperation</U>.
The parties shall cooperate through the Transition Team to ensure that [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Rights
of Reference and Access to Data</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
the manufacturer and supplier of Drug Substance, Protalix shall provide to Pfizer original copies of any Certificate of Pharmaceutical
Product (&ldquo;<U>CPP</U>&rdquo;) issued to Protalix as necessary to support Pfizer&rsquo;s regulatory filings for the Licensed
Product in the Field in the Territory. Protalix shall use Commercially Reasonable Efforts to apply for and obtain such CPP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Assignment
of Contracts</U>. Upon Pfizer&rsquo;s reasonable request and to the extent legally permissible, Protalix shall assign to Pfizer
any contract Protalix has entered into with a Third Party that solely relates to the Development of the Licensed Product in the
Territory, to the extent Pfizer requests such contract to be assigned and such contract is assignable. Protalix shall provide copies
all such contracts to Pfizer&rsquo;s Transition Manager.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Responsibility</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pfizer
shall have the sole authority and exclusive right to determine all regulatory plans and strategies for the Licensed Product in
the Field in the Territory. Without limiting the foregoing, subject to <U>Section 4.1(b)(i)</U>, Pfizer (or, in any Country in
the Territory, one or more of its Affiliates or Sublicensees) will own and be responsible for preparing, seeking, submitting and
maintaining all regulatory filings and Regulatory Approvals for the Licensed Product in Field in the Territory, including preparing
all reports necessary as part of a regulatory filing or Regulatory Approval. Protalix shall provide (A) such assistance as Pfizer
or its Affiliates or Sublicensees reasonably requires to obtain and maintain Regulatory Approvals for the Licensed Product in the
Field in the Territory, (B) provide Pfizer with all reasonable assistance and cooperation to take all actions reasonably requested
by Pfizer that are necessary to enable Pfizer to comply with any Law applicable to the Licensed Product and (C) provide reasonable
assistance to enable Pfizer to obtain or maintain Regulatory Approvals for the Licensed Product in the Field in any Country in
the Territory, including by providing CMC, facility, bioanalytical and clinical information and data that Pfizer is required to
provide to Regulatory Authorities (to the extent such data is in Protalix&rsquo;s possession and Control). Pfizer or its Affiliates
or Sublicensees shall have the sole right to apply for and secure exclusivity rights that may be available under the Law of Countries
in the Territory, including any Regulatory Exclusivity. Protalix shall use Commercially Reasonable Efforts to cooperate with Pfizer
and its Affiliates and Sublicensees, and to take such reasonable actions to assist Pfizer and its Affiliates and Sublicensees,
in obtaining such exclusivity rights in each Country, as Pfizer may reasonably request from time to time. Such requested cooperation
and assistance referred to in this <U>Section 4.1(g)(i)</U> (including as referenced in the foregoing sentence and the foregoing
subclauses (A), (B) and (C)) shall be provided at [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Once
Protalix or its designee Fiocruz (or another applicable sublicensee) has successfully received Regulatory Approval for the Licensed
Product in Brazil, Protalix shall have the sole authority and exclusive right to determine all regulatory plans and strategies
for the Licensed Product in Brazil. Subject to the foregoing, Protalix or its designee Fiocruz (or another applicable sublicensee)
shall have the sole authority and exclusive right to determine all regulatory plans and strategies for the Licensed Product outside
the Territory, including the right to file a marketing authorization application in Brazil. Without limiting the foregoing, subject
to <U>Section 4.1(c)(i)</U>, Protalix (or Fiocruz or such other sublicensee) will own and be responsible for preparing, seeking,
submitting and maintaining its marketing application and all regulatory filings and Regulatory Approvals for the Licensed Product
outside the Territory, including preparing all reports necessary as part of a regulatory filing or Regulatory Approval. Pfizer
shall provide such assistance as Protalix reasonably requires to obtain Regulatory Approvals for the Presentation of the Licensed
Product Commercialized as of the Second Amendment Effective Date in Brazil. Until Protalix or its designee Fiocruz (or such other
applicable sublicensee) has successfully received Regulatory Approval for the Licensed Product in Brazil (and the corresponding
marketing authorization held by Pfizer or its Affiliate in Brazil has been cancelled), Protalix and its designee Fiocruz (or such
other applicable sublicensee) shall have express and irrevocable authorization and approval for Protalix and its designee Fiocruz
(or such other applicable sublicensee) to import the Licensed Product and Drug Substance into Brazil under Pfizer&rsquo;s or its
Affiliates&rsquo; Regulatory Approvals with Regulatory Authorities in Brazil, as allowed under applicable Law, which express authorization
and approval is set forth in writing on Exhibit E. Pfizer or its relevant Affiliate shall issue one or more of such authorizations
as reasonably required by Protalix or its designee Fiocruz (or such other applicable sublicensee). Protalix, Fiocruz, or such other
sublicensee shall have the sole right to apply for and secure exclusivity rights that may be available in Brazil, including any
Regulatory Exclusivity. Pfizer shall use Commercially Reasonable Efforts to cooperate with Protalix, Fiocruz or such other sublicensee
and to take such reasonable actions to assist Protalix, Fiocruz or such other sublicensee in obtaining such exclusivity rights
in Brazil, as Protalix may reasonably request from time to time. Such requested cooperation and assistance shall be provided [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Pharmacovigilance</U>.
After the Second Amendment Effective Date and prior to[***], the safety units of each of the parties shall meet and agree upon
an amendment to the written pharmacovigilance agreement that defines Pfizer&rsquo;s pharmacovigilance responsibilities for the
Licensed Product in the Territory and Protalix&rsquo;s pharmacovigilance responsibilities for the Licensed Product outside the
Territory and the process for exchanging adverse event reports and other safety information relating to a Licensed Product that
will permit each party to comply with applicable Laws and requirements of Regulatory Authorities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Communications
with Regulatory Authorities in the Territory</U>. For so long as[***]:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Protalix
shall provide Pfizer notice of all meetings, conferences, and discussions (including meeting of experts convened by any Regulatory
Authority in Israel concerning any topic relevant to the Licensed Product) scheduled with any Regulatory Authority in Israel concerning
any regulatory matters relating to the Licensed Product promptly after the scheduling of such meeting, conference, or discussion
(to the extent Protalix is made aware of them in advance). Pfizer or its designee (or such other applicable sublicensee) shall
be entitled to have one or more representatives present at all such meetings unless prohibited by applicable Law or unless reasonably
impracticable under the circumstances. Pfizer or its designee (or such other applicable sublicensee) and Protalix shall use all
reasonable efforts to agree in advance on the scheduling of such meetings, conferences and discussions and on the objectives to
be accomplished at such meetings, conferences and discussions and the agenda for the meetings, conferences and discussions with
such Regulatory Authority; <U>provided</U> that [***];</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Protalix
shall provide Pfizer or its designee (or such other applicable sublicensee) with copies, which copies may be in draft form, of
all material submissions to any Regulatory Authority in Israel relating to the Licensed Product, to be provided sufficiently in
advance of such planned submission to such Regulatory Authority in order to allow Pfizer or its designee (or such other applicable
sublicensee) to provide comments regarding such submission, which comments shall be considered by Protalix in good faith with respect
to such submission; <U>provided</U> that [***];</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1.5in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Protalix
shall provide to Pfizer, as soon as reasonably practicable but in no event more than three (3) Business Days after its receipt,
copies of any material documents or other material correspondence received from any Regulatory Authority pertaining to the Licensed
Product; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1.5in">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Protalix
shall reasonably cooperate with Pfizer or its designee regarding (1) filings and communications with any Regulatory Authority,
(2) patient advocacy and support, and (3) pharmacovigilance activities, in each case, in Israel with respect to the Drug Substance
or the Licensed Product; <U>provided</U> that [***]. For purposes of clarification, Protalix is not obligated to pursue additional
indications and/or submissions in Israel other than required modifications due to those related to safety under the current, Protalix
marketing authorization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Communications
with Regulatory Authorities Outside the Territory</U>. Until any marketing authorization application for Licensed Product submitted
by Protalix or its designee Fiocruz (or such other applicable sublicensee) is approved by the National Sanitary Surveillance Agency
of the Brazilian Government (or any successor or replacement agency that has the authority to grant the necessary Regulatory Approvals)
and any other required Regulatory Approval is obtained by Protalix or its designee Fiocruz (or such other applicable sublicensee),
and with respect to any Pfizer or Pfizer Affiliate Regulatory Approvals and regulatory filings (including marketing authorizations)
in Brazil and related data:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pfizer
shall provide Protalix notice of all meetings, conferences, and discussions (including meeting of experts convened by any Regulatory
Authority in Brazil concerning any topic relevant to the Licensed Product) scheduled with any Regulatory Authority in Brazil concerning
any regulatory matters relating to the Licensed Product promptly after the scheduling of such meeting, conference, or discussion
(to the extent Pfizer is made aware of them in advance). Protalix or its designee Fiocruz (or such other applicable sublicensee)
shall be entitled to have one or more representatives present at all such meetings unless prohibited by applicable Law or unless
reasonably impracticable under the circumstances. Protalix or its designee Fiocruz (or such other applicable sublicensee) and Pfizer
shall use all reasonable efforts to agree in advance on the scheduling of such meetings, conferences and discussions and on the
objectives to be accomplished at such meetings, conferences and discussions and the agenda for the meetings, conferences and discussions
with such Regulatory Authority; <U>provided</U> that [***];</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pfizer
shall provide Protalix or its designee Fiocruz (or such other applicable sublicensee) with copies, which copies may be in draft
form, of all material submissions to any Regulatory Authority in Brazil relating to the Licensed Product, to be provided sufficiently
in advance of such planned submission to such Regulatory Authority in order to allow Protalix or its designee Fiocruz (or such
other applicable sublicensee) to provide comments regarding such submission, which comments shall be considered by Pfizer in good
faith with respect to such submission; <U>provided</U> that [***];</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pfizer
and Protalix (or Protalix&rsquo;s designee Fiocruz (or such other applicable sublicensee)) shall provide to the other, as soon
as reasonably practicable but in no event more than three (3) Business Days after its receipt, copies of any material documents
or other material correspondence received from any Regulatory Authority in Brazil; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pfizer
shall reasonably cooperate with Protalix and its Affiliates or its designee Fiocruz (or such other applicable sublicensee) regarding
(1) filings and communications with any Regulatory Authority, (2) patient advocacy and support, and (3) pharmacovigilance activities,
in each case, in Brazil with respect to the Drug Substance or the Licensed Product; <U>provided</U> that [***]. For purposes of
clarification, Pfizer is not obligated to pursue additional indications and/or submissions in Brazil other than required modifications
due to those related to safety under the current, Pfizer marketing authorization.<B> </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>[Reserved]</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Recalls
or Other Corrective Action</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pfizer
shall promptly notify Protalix of any material actions to be taken by Pfizer in the Territory with respect to any recall or market
withdrawal or other corrective action related to the Licensed Product prior to such action, if reasonably practicable under the
circumstances, to permit Protalix a reasonable opportunity to consult with Pfizer with respect thereto. [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Protalix
shall promptly notify Pfizer of any material actions to be taken by Protalix outside the Territory with respect to any recall or
market withdrawal or other corrective action related to the Licensed Product prior to such action, if reasonably practicable under
the circumstances, to permit Pfizer a reasonable opportunity to consult with Protalix with respect thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">4.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Commercialization
and Pricing</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pfizer
shall have the sole authority and exclusive right to Commercialize, and shall be responsible for paying all costs and expenses
(except as otherwise expressly set forth in this Agreement) associated with the Commercialization of, the Licensed Product in the
Field in the Territory, including marketing, promoting, selling, distributing and [***] for the Licensed Product and obtaining
any necessary Price Approvals. Protalix hereby agrees to refrain from selling Licensed Product outside the Territory to any Person
if Protalix has knowledge or reason to believe that such Licensed Product is intended for transshipment or delivery by such Person
in the Territory. Pfizer hereby agrees to refrain from selling the Licensed Product in the Territory to any Person if Pfizer has
knowledge or reason to believe that such Licensed Product is intended for transshipment or delivery by such Person outside the
Territory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
anything to the contrary in <U>Section 4.2(a)</U>, Protalix shall continue to Commercialize the Licensed Product in the Field in
Israel following the Second Amendment Effective Date until such time that Pfizer has received the necessary Regulatory Approvals
for Pfizer to commence Commercialization of the Licensed Product in the Field in Israel, but in no event extending longer than
[***] after the Second Amendment Effective Date (the &ldquo;<U>Israel Transition Period</U>&rdquo;), and during the Israel Transition
Period, (i) Protalix shall not materially alter its usual activities and practices with respect to inventory levels (including
samples) of the Licensed Product maintained at the wholesale, pharmacy or institutional levels in Israel, without the consent of
the Transition Team, (ii) Protalix shall not take any non-routine action that deviates from the ordinary course of business with
respect to the Commercialization of the Licensed Product in the Field in Israel without consulting with the Transition Team, and
(iii) Protalix shall inform the Transition Team of any allegations, inquiries, or investigations of violations of Protalix&rsquo;s
policies or Laws related to commercialization of the Licensed Product in Israel. Pfizer shall provide Protalix written notice immediately
upon becoming aware that Pfizer has received the necessary Regulatory Approvals for Pfizer to commence Commercialization of the
Licensed Product in the Field in Israel. Pfizer shall consider in good faith whether to continue to participate in any[***] at
the end of the Israel Transition Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Following
the Second Amendment Effective Date, Pfizer shall purchase all remaining finished goods inventories of Licensed Product relating
to Israel [***]. Such shipment shall be accompanied by a Manufacturing Certificate of Analysis and shall be subject to <U>Sections
5.10(a)</U> through <U>(d)</U>, and such invoice shall be payable to Protalix within forty-five (45) days of receipt of the invoice.
Any disputes with respect to such invoice shall be escalated to the Transition Team for resolution. If the Transition Team is unable
to resolve such dispute, then such dispute shall be escalated to the Supply Chain Committee to resolve pursuant to <U>Section 5.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">4.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Protalix
Trademarks</U>. Protalix hereby grants to Pfizer a license to use any trademarks (including Protalix&rsquo;s name or trade names)
Controlled by Protalix solely for the purposes of selling, and solely to the extent reasonably necessary to sell, the Inventories
in Israel pursuant to <U>Section 4.2(c)</U>, subject to quality control provisions substantially equivalent to those set forth
in <U>Section 4.4(d)</U>, which shall apply mutatis mutandis hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">4.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Pfizer
Trademarks</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Assignment</U>.
The parties acknowledge that Protalix transferred and assigned to Pfizer all of its worldwide rights, title and interest to the
Uplyso Trademarks, including any goodwill associated with such Uplyso Trademarks. Pfizer shall be responsible for paying all costs
and expenses associated with recording the trademark assignment instrument with the appropriate governmental authorities throughout
the world.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Choice
of Trademarks</U>. Pfizer may choose, in its sole discretion, to use the Uplyso Trademarks or any other trademarks to Commercialize
the Licensed Product in the Field in the Territory and Pfizer shall own all such trademarks (collectively, the &ldquo;<U>Product
Marks</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>License
to Protalix</U>. Pfizer hereby grants to Protalix an exclusive license, free of charge, to use the Brazil Uplyso Trademark and
any other Product Marks required by applicable Laws to be included on the labeling and packaging of the finished packaged product
outside the Territory solely in connection with the packaging, sale, marketing, promotion, advertising, disposition and distribution
of the Licensed Product in the Field outside the Territory. Pfizer acknowledges and agrees that Protalix is permitted to sublicense
to Fiocruz (or any other sublicensee of Protalix in Brazil) the Brazil Uplyso Trademark and any other Product Marks required by
applicable Laws to be included on the labeling and packaging of the finished packaged product outside the Territory as set forth
in <U>Section 3.6(c)</U>. For the avoidance of doubt, the rights granted pursuant to this <U>Section 4.4(c)</U> do not include
grants to use the name or trade name of Pfizer (other than to the extent such right is granted to Protalix pursuant to <U>Section
4.5</U> or required to be made pursuant to <U>Section 4.4(d)(iv)(B)</U>). Any such right to use such name or trade name shall be
governed by <U>Section 4.5</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Quality
Control</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
quality of the Licensed Product sold by Protalix outside the Territory under or in connection with the Brazil Uplyso Trademark
(and any Product Marks licensed to Protalix pursuant to <U>Section 3.6(c) </U>and <U>Section 4.4(c)</U>) must be of a sufficiently
high quality to be generally comparable to the quality of the Licensed Product sold by Pfizer in the Territory under or in connection
with the Product Marks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Protalix
shall comply with all applicable Laws pertaining to the proper use and designation of the Brazil Uplyso Trademark (and any Product
Marks licensed to Protalix pursuant to <U>Section 3.6(c)</U> and <U>Section 4.4(c)</U>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Protalix
agrees to use the Brazil Uplyso Trademark (and any Product Marks licensed to Protalix pursuant to <U>Section 3.6(c)</U> and <U>Section
4.4(c)</U>) only in the form and manner and with appropriate legends as prescribed from time to time by Pfizer.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additionally,
Protalix shall:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: 1in">(A)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;display
the proper form of trademark notice associated with the Brazil Uplyso Trademark (and any Product Marks licensed to Protalix pursuant
to <U>Section 3.6(c)</U> and <U>Section 4.4(c)</U>);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: 1in">(B)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;on
any item which bears the Brazil Uplyso Trademark (and any Product Marks licensed to Protalix pursuant to <U>Section 3.6(c)</U>
and <U>Section 4.4(c)</U>), include where practicable a statement identifying Pfizer or its Affiliate, as applicable, as the owner
of the Brazil Uplyso Trademark or Product Mark and where possible indicating that Protalix or its Affiliate, as applicable, is
an authorized user of the Brazil Uplyso Trademark or Product Mark;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: 1in">(C)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;not
use any Product Mark as a corporate name, business name, or trade name;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: 1in">(D)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;not
use any Product Mark in a manner that would reasonably be expected to materially impair the validity, reputation, or distinctiveness
of any Product Mark; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: 1in">(E)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;not
use any Product Mark in a manner that would reasonably be expected to materially impair the reputation of Pfizer or any of its
Affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Prosecution
and Maintenance of Product Marks</U>. Pfizer shall have the sole right, but not the obligation, through counsel of its choosing,
to prosecute and maintain the Product Marks in the Territory and the first right, but not the obligation, through counsel of its
choosing, to prosecute and maintain the Product Marks outside the Territory. In the event Pfizer elects not to prosecute or maintain
the Brazil Uplyso Trademark outside the Territory, Pfizer shall provide reasonable prior written notice to Protalix of its intention
not to prosecute or maintain any such Product Mark outside the Territory, and Protalix shall have the right to prosecute or maintain
the Brazil Uplyso Trademark on behalf of Pfizer. All costs and expenses incurred by Pfizer in the filing, prosecution and maintenance
of Product Marks in the Territory shall be [***]. All costs and expenses incurred by either party in the filing, prosecution and
maintenance of Product Marks (in the case of Pfizer) or the Brazil Uplyso Trademark outside the Territory as provided in this <U>Section
4.4(e)</U> shall be [***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Enforcement
of Product Marks</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pfizer
will promptly notify Protalix in the event of any actual, potential or suspected infringement of the Brazil Uplyso Trademark by
any Third Party and Protalix will promptly notify Pfizer in the event of any actual, potential or suspected infringement of the
Brazil Uplyso Trademark or a Product Mark by any Third Party. Pfizer shall have the sole right, but not the obligation, to institute
litigation or take other remedial measures in connection with Third Party infringement of Product Marks in the Territory and the
first right, but not the obligation, to institute litigation or take other remedial measures in connection with Third Party infringement
of Product Marks outside the Territory. If Pfizer fails to initiate litigation or take other remedial measures against a Third
Party who is infringing the Brazil Uplyso Trademark outside the Territory within ninety (90) days after becoming aware of the basis
for such litigation or action, then Protalix may, in its discretion, provide Pfizer with written notice of Protalix&rsquo;s intent
to initiate a suit or take other appropriate action. If Protalix provides such notice and Pfizer fails to initiate litigation or
take such other appropriate action within thirty (30) days after receipt of such notice from Protalix, then Protalix shall have
the right to initiate litigation or take other appropriate action that it believes is reasonably required to protect its right
to use the Brazil Uplyso Trademark outside the Territory. Upon request of Protalix, Pfizer agrees to timely join as party-plaintiff
in any such litigation, and in any event to cooperate with Protalix in connection with such infringement action. All costs and
expenses incurred by Pfizer in enforcing the Product Marks in the Territory shall be borne by Pfizer and any recoveries resulting
from such litigation or other appropriate action, in pursuing such litigation or other appropriate action, shall be retained by
Pfizer. All costs and expenses incurred by Protalix in enforcing the Brazil Uplyso Trademark outside the Territory shall be [***]
and Protalix shall reimburse Pfizer for any and all costs or expenses incurred by Pfizer in connection with such enforcement by
Protalix outside the Territory. Protalix shall retain all recoveries received by Protalix as a result of its enforcement of the
Brazil Uplyso Trademark outside the Territory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">4.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Use
of Names</U>. No right, expressed or implied, is granted by this Agreement to a party to use in any manner the name or any other
trade name of the other party or its Affiliates in connection with this Agreement. Notwithstanding the foregoing, Protalix shall
have the right to use the Pfizer corporate name, subject to Pfizer&rsquo;s trademark usage guidelines provided to Protalix from
time to time, including at least sixty (60) days prior to the date of Protalix&rsquo;s first use of the Pfizer corporate name,
on package inserts, packaging or trade packaging associated with the Licensed Product outside the Territory solely as required
by applicable Laws outside the Territory. Protalix will submit for Pfizer&rsquo;s approval (which approval shall not be unreasonably
withheld or delayed) a sample of each such proposed use of the Pfizer corporate name within sixty (60) days before the first use
permitted pursuant to this <U>Section 4.5</U>. Notwithstanding anything to the contrary in this <U>Section 4.5</U>, Pfizer shall
have the right to use the name of Protalix or its Affiliates or any other trade name of Protalix pursuant to and in accordance
with <U>Section 4.3</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">4.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Access
to Information</U>. At Pfizer&rsquo;s reasonable request during the Term, Protalix shall provide Pfizer, its designated Affiliate
or its agents and representatives with reasonable access [***], during regular business hours to (a) information concerning the
Drug Substance, Licensed Product, Protalix Patent Rights and/or Protalix Technology that may be reasonably necessary for Pfizer
to seek Regulatory Approval for Licensed Product, Manufacture (including performing Fill/Finish activities on) the Drug Substance
or the Licensed Product or Commercialize the Licensed Product, in each case, in the Field in the Territory and (b) Protalix-designated
employees who possess the information described in clause (a) of this <U>Section 4.6</U>, in each case, solely for the purpose
of enabling Pfizer to exercise the licenses granted to Pfizer hereunder. Such requested cooperation and assistance shall be provided
at no cost to Pfizer, except that [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">4.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Transition
Assistance</U>. During the Transition Period, each party shall use Commercially Reasonable Efforts to cooperate with the other
party and to take such reasonable actions to assist the other party, as the other party may reasonably request, (i) to ensure the
smooth transition of the Commercialization of the Drug Substance or Licensed Product from Protalix to Pfizer (or a Third Party
designated by Pfizer) in Israel and from Pfizer to Protalix (or a Third Party designated by Protalix) in Brazil, and (ii) to ensure
the continuity of patient care in Brazil and Israel. Except as set forth in this Agreement, the parties shall no longer have any
obligations under the Agreement to Commercialize or Develop the Licensed Product, conduct any pre-clinical or clinical studies
or participate in any committees with the other party other than the Supply Chain Committee and the Transition Team.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Transition
Team</U>. Within five (5) days following the Second Amendment Effective Date, Pfizer and Protalix shall each appoint a person (each
a &ldquo;<U>Transition Manager</U>&rdquo; and together, the &ldquo;<U>Transition Team</U>&rdquo;) to facilitate a smooth transition
of the Commercialization of the Drug Substance or Licensed Product from Protalix to Pfizer (or a Third Party designated by Pfizer)
in Israel and from Pfizer to Protalix (or a Third Party designated by Protalix) in Brazil, and to implement the Transition Plan
(as defined below). Each party shall notify the other party in writing of the identity and contact information for their respective
Transition Manager, which shall be the primary contact for each party with respect to the transition and the Transition Plan and
all activities thereunder. For [***] following the Second Amendment Effective Date (the &ldquo;<U>Transition Period</U>&rdquo;),
the Transition Managers shall meet (in person, by teleconference, video-conference or other reasonable means, in each case as mutually
agreed upon by the Transition Managers) as reasonably necessary, but not less frequently than a weekly basis, as mutually agreed
upon by the Transition Managers to facilitate the implementation of the Transition Plan. In the event that the Transition Plan
has not been implemented within [***] following the Second Amendment Effective Date, the parties shall mutually agree in good faith
on a new Transition Period, and following such agreement the term Transition Period shall refer to such new period as so agreed
upon by the parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Transition
Plan</U>. In connection with the transition of Israel and Brazil, during the Transition Period, the parties shall use Commercially
Reasonable Efforts to accomplish all of the transition activities described in <U>Exhibit F</U> to effect a reasonably smooth and
orderly transition (the &ldquo;<U>Transition Plan</U>&rdquo;). Pfizer and Protalix will commence delivery of the items specified
in the Transition Plan as soon as reasonably practicable and shall use Commercially Reasonable Efforts to meet the timelines specified
in the Transition Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">4.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Records</U>.
Each party will maintain accurate records and books relating to its activities in relation to the Development of the Drug Substance
and the Licensed Product, including any activities conducted under the Development plans between the parties pursuant to the Amended
Agreement.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-transform: uppercase; text-indent: -1in"><FONT STYLE="text-transform: none">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-transform: uppercase; text-indent: -1in"><FONT STYLE="text-transform: none">Section
5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>MANUFACTURE AND SUPPLY.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">5.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Supply
Chain Committee</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Formation
and Membership</U>. The parties shall continue to maintain a Supply Chain Committee (the &ldquo;<U>Supply Chain Committee</U>&rdquo;)
during the Supply Term. The Supply Chain Committee shall consist of representatives appointed by each party. The Supply Chain Committee
will provide a forum for the discussion of matters related to the Manufacture of and supply chain for the Drug Substance and Licensed
Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Meetings</U>.
During the Supply Term, the Supply Chain Committee shall meet monthly or as otherwise determined by the parties (each such meeting,
a &ldquo;<U>Supply Chain Committee Meeting</U>&rdquo;). Upon the request of the Supply Chain Committee, each party will provide
written materials relating to its Manufacturing and related activities in advance of a Supply Chain Committee Meeting. All Supply
Chain Committee Meetings may be conducted in person, by videoconference or by teleconference at such times and such Pfizer or Protalix
locations as shall be determined by the Supply Chain Committee. In-person meetings of the Supply Chain Committee will alternate
between appropriate offices of each party. The parties shall each bear all expenses of their respective representatives relating
to their participation on the Supply Chain Committee. The members of the Supply Chain Committee also may convene or be polled or
consulted from time to time by means of telecommunications, video conferences, electronic mail or correspondence, as deemed necessary
or appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Responsibilities</U>.
The Supply Chain Committee will have the following roles and responsibilities:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Discuss
each party&rsquo;s requirements for Drug Substance and Licensed Product for Development activities in accordance with <U>Section
5.3</U>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Act
as a forum pursuant to which the parties may discuss Manufacturing issues, and any issues that may affect patient access to the
Licensed Product in the Territory;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1.5in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Be
informed of requests for and results of regulatory inspections related to Drug Substance and Licensed Product and review steps
to be taken by Protalix to address any deficiencies noted;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1.5in">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Monitor
logistical strategies, Protalix&rsquo;s capacity for Manufacturing Drug Substance and inventory levels for Drug Substance and Licensed
Product for consistency with the Forecasts and Long Range Forecasts and address any Failure to Supply and Persistent Failure to
Supply;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1.5in">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Be
informed of and discuss proposed changes in Manufacturing sites, testing sites, and responsibilities in the supply chain for Drug
Substance and Licensed Product;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1.5in">(vi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Be
informed of and address any quality-related issues concerning the Drug Substance and Licensed Product including non-conformance;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1.5in">(vii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Provide
updates on the Supply Chain Committee&rsquo;s activities and achievements to the parties, as applicable, no less frequently than
once each quarter after the Second Amendment Effective Date; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1.5in">(viii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Such
other roles and responsibilities provided<U> </U>for in this Agreement or as may be assigned to the Supply Chain Committee in writing
by mutual agreement of the parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Decision-Making</U>.
Except for a decision to create a Technical Subcommittee as described in <U>Section 5.1(e)</U>, the Supply Chain Committee will
have no decision-making authority, but instead will act in an advisory capacity to the parties, unless otherwise agreed by the
parties in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Technical
Subcommittee</U>. The Supply Chain Committee may, from time to time, create a subcommittee (a &ldquo;<U>Technical Subcommittee</U>&rdquo;)
to advise the Supply Chain Committee and the parties on and analyze any technical issues relating to Manufacturing Drug Substance
or Licensed Product, including issues relating to quality or process, identified by either party or by the Supply Chain Committee.
Any Technical Subcommittee shall consist of representatives from each party with the appropriate technical expertise to analyze
and provide advice with respect to any such technical issues, and such representatives may or may not also be representatives on
the Supply Chain Committee. Each Technical Subcommittee will continue to operate until resolution of the identified problem, as
determined by the Supply Chain Committee. If the Supply Chain Committee is unable to reach agreement with respect to the issue
identified by the Supply Chain Committee, Pfizer&rsquo;s Vice President of Global External Supply and Protalix&rsquo;s Chief Operating
Officer<FONT STYLE="color: #1F497D"> </FONT>will meet promptly to attempt to resolve the dispute by good faith negotiations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">5.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Capacity</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Protalix
shall [***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***]
Along with such request, Pfizer shall [*** ]If Protalix determines [***] Protalix shall [***] Pfizer and Protalix shall agree [***]
Pfizer shall [***] Notwithstanding the foregoing, in no case shall Protalix [***] Pfizer shall [***] Protalix shall [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Protalix
shall dedicate at least [***] of its Drug Substance Manufacturing capacity in order to Manufacture Drug Substance for Pfizer&rsquo;s
clinical and commercial use in the Field in the Territory and may dedicate all remaining capacity to Manufacture Drug Substance
for Protalix&rsquo;s clinical and commercial use in the Field outside the Territory (such allocation between the Territory and
outside the Territory, the &ldquo;<U>Allocation Percentage</U>&rdquo;). Subject to the Current Capacity Cap or, after achieving
the Increased Capacity Goal, the Increased Capacity Cap (collectively, the &ldquo;<U>Capacity Cap</U>&rdquo;), subject to the Allocation
Percentage, and subject to and in accordance with the terms of this <U>Section 5</U> and the Quality Agreement, Protalix shall
supply all quantities of the Drug Substance ordered by Pfizer under this Agreement for clinical and commercial use in the Field
in the Territory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the event either party reasonably believes that capacity for the Manufacture of Drug Substance in excess of the Increased Capacity
Cap is necessary to meet projected future clinical and commercial need for Licensed Product in the Territory, the parties shall
discuss such matter in good faith, including the funding of any capital expenditures necessary to increase such Manufacturing capacity
beyond the Increased Capacity Cap.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">5.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Development
Supply of Drug Substance</U>. Subject to the Capacity Cap and the Allocation Percentage, Protalix shall Manufacture and supply
Pfizer&rsquo;s requirements of the Drug Substance for incorporation into Licensed Product for Development activities to be performed
by Pfizer in the Field in the Territory, which supply shall be subject to and in accordance with the terms of this <U>Section 5</U>.
For the avoidance of doubt, in no event shall Protalix be obligated to Manufacture or supply quantities of Drug Substance in excess
of the Capacity Cap unless otherwise agreed by the parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">5.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Commercial
Supply of Drug Substance</U>. Subject to the Capacity Cap and the Allocation Percentage, Protalix shall Manufacture and supply
Pfizer&rsquo;s requirements of the Drug Substance for incorporation into Licensed Product and commercial sale in the Field in the
Territory pursuant to this Agreement, which supply shall be subject to and in accordance with the terms of this <U>Section 5</U>
and the Quality Agreement. For the avoidance of doubt, in no event shall Protalix be obligated to Manufacture or supply quantities
of Drug Substance in excess of the Capacity Cap unless otherwise agreed by the parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">5.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Supply
Term</U>. The terms of this <U>Section 5</U> shall be effective as of the Second Amendment Effective Date and, unless this Agreement
is earlier terminated pursuant to <U>Section 14</U>, shall remain in effect only until terminated in accordance with this <U>Section
5</U> (the &ldquo;<U>Supply Term</U>&rdquo;).&nbsp; The initial term for the supply of Drug Substance under this <U>Section 5</U>
shall be for ten (10) years after the Second Amendment Effective Date (the &ldquo;<U>Initial Supply Term</U>&rdquo;).&nbsp; If
Protalix determines not to extend the supply of Drug Substance to Pfizer hereunder beyond such Initial Supply Term, Protalix shall
have the right to provide written notice of termination of the Supply Term, at least three (3) years prior to the effective date
of termination of the Supply Term set forth in such notice (which shall in no event be prior to the end of the Initial Supply Term)
(the &ldquo;<U>Supply Termination Notice</U>&rdquo;); <U>provided</U> that notwithstanding the timely issuance of a Supply Termination
Notice by Protalix in accordance with the foregoing sentence Pfizer shall have the right to extend the Supply Term for up to two
additional periods of thirty (30) months each (each, a &ldquo;<U>Renewal Supply Term</U>&rdquo;) by providing to Protalix a written
extension notice at least one (1) year prior to the end of the Initial Supply Term or the first Renewal Supply Term, as applicable
(with the first Renewal Supply Term commencing at the end of the Initial Supply Term and the second Renewal Supply Term commencing
at the end of the first Renewal Supply Term).&nbsp; For the avoidance of doubt, (i) in the event Pfizer does not provide a written
extension notice at least one (1) year prior to the end of the Initial Supply Term in accordance with the foregoing sentence, the
Supply Term shall terminate upon the stated effective date of termination in the Supply Termination Notice, (ii) in the event Pfizer
provides a written extension notice for the first Renewal Supply Term in accordance with the foregoing sentence, but does not provide
a written extension notice for the second Renewal Supply Term at least one (1) year prior to the end of the first Renewal Supply
Term in accordance with the foregoing sentence, the Supply Term shall terminate upon the end of the first Renewal Supply Term,
and (iii) in the event Pfizer provides a written extension notice for the first and second Renewal Supply Terms in accordance with
the foregoing sentence, the Supply Term shall terminate fifteen (15) years after the Second Amendment Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">5.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Forecasting
and Ordering</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Forecasts;
Purchase Orders</U>. [***], Pfizer shall deliver to Protalix Pfizer&rsquo;s quarterly projection of the quantities of Drug Substance
that Pfizer anticipates ordering from Protalix pursuant to this Agreement for the four (4) calendar quarters commencing with the
first quarter that includes the first requested delivery date (the &ldquo;<U>Initial Forecast</U>&rdquo;), together with a firm
purchase order (a &ldquo;<U>Purchase Order</U>&rdquo;) for Drug Substance for the first calendar quarter covered by such Initial
Forecast. The quantities of Drug Substance specified for the following quarter of such Initial Forecast shall be binding as provided
in this <U>Section 5.6</U> and the remaining two (2) quarters of such Initial Forecast shall be non-binding. Thereafter, ninety
(90) days prior to the first business day of each subsequent calendar quarter during the Term, Pfizer shall deliver to Protalix
a rolling four (4) calendar quarter forecast updating the prior forecast (together with the Initial Forecast, each a &ldquo;<U>Forecast</U>&rdquo;),
together with a Purchase Order for the first calendar quarter of such Forecast. The quantities of Drug Substance specified for
the following quarter of such Forecast shall be binding as provided in this <U>Section 5.6</U> and the remaining two (2) quarters
of such Forecast shall be non-binding. Unless agreed separately between the parties, each Purchase Order shall specify no more
than three (3) delivery dates for the Drug Substance in each calendar quarter. Purchase Orders shall be in writing, and no verbal
communications or e-mail shall be construed to mean a commitment to purchase or sell. Each Purchase Order delivered by Pfizer to
Protalix pursuant to this <U>Section 5.6(a)</U> shall be binding on Protalix to the extent provided by <U>Section 5.6(c)</U>. Protalix
shall confirm receipt of any [***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Long
Range Capacity Planning</U>. Concurrent with the Initial Forecast, for the purposes of discussion and planning of Manufacturing
capacity, Pfizer shall provide a non-binding forecast of its projected Drug Substance needs for the eight (8) calendar quarters
following that specified in the Initial Forecast as described in <U>Section 5.6(a)</U> (a &ldquo;<U>Long Range Forecast</U>&rdquo;).
Each Long Range Forecast shall be deemed to be revised by any subsequent Forecast. In the event Protalix anticipates that it will
be unable to supply the quantities of Drug Substance reflected in a Long Range Forecast, Protalix shall promptly notify Pfizer
and the Supply Chain Committee shall work to remedy the shortfall in accordance with and subject to the terms of this <U>Section
5</U> in an effort to assure that the necessary capacity exists. Unless otherwise agreed to by the parties during the Term, the
Long Range Forecast shall be updated by Pfizer annually by July 1 of each calendar year during the Term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Maximum
Quantities</U>. Unless otherwise agreed in writing by Protalix, in no event shall Protalix be obligated to deliver quantities of
Drug Substance [***] The foregoing limitation shall be in addition to the Capacity Cap. Protalix shall, however, use Commercially
Reasonable Efforts, but will be under no obligation, to supply Drug Substance [***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Minimum
Quantities</U>. If the quantities of Drug Substance specified in a Purchase Order for a quarter are less than [***] of the quantities
specified by Pfizer for the same period in the Forecast delivered [***], then, at the election of Pfizer set forth in a notice
which Pfizer shall deliver to Protalix within [***], (i) Protalix shall, [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Receipt
and Acceptance. Subject to <U>Sections 5.6(c)</U> and <U>5.6(d)</U>, Pfizer shall purchase all Drug Substance ordered and specified
in a Purchase Order. Purchase Orders may be delivered electronically or by other means to such location as Protalix shall designate.
Nothing in any such Purchase Order or written acceptance shall supersede the terms and conditions of this Agreement or the Quality
Agreement. All Purchase Orders, confirmations of receipt of Purchase Orders and other notices contemplated under this <U>Section
5.6(e)</U> shall be sent to the attention of such persons as each party may identify to the other in writing from time to time
in accordance with <U>Section 18.9</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">5.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Pricing
and Invoicing</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Supply
Delivery Price</U>. [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Invoices</U>.
Following the release of the Drug Substance subject to the Purchase Order hereunder and the submission to Pfizer of the Manufacturing
Certificate of Acceptance and the Certificate of Compliance (as defined in the Quality Agreement) relating to such released Drug
Substance, each delivery of Drug Substance under a Purchase Order hereunder shall be accompanied by an invoice. Protalix shall
invoice Drug Substance at [***] Protalix shall include the following information, where applicable, on all invoices: the type,
description, and quantity of the product delivered; the date of shipment; the prices; any applicable taxes, transportation charges
or other charges provided for in the applicable Purchase Order; and the applicable Purchase Order number. [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Taxes</U>.
All sales and use taxes which Protalix is required by law to collect from Pfizer with respect to the Manufacture and supply of
Drug Substance to Pfizer shall be separately stated in Protalix&rsquo;s invoice and shall be paid by Pfizer to Protalix unless
Pfizer provides an exemption to Protalix. Protalix shall be solely responsible for the timely payment of all such taxes to the
applicable taxing authority, and Protalix shall pay (without reimbursement by Pfizer), and shall hold Pfizer harmless against,
any penalties, interest or additional taxes that may be levied or assessed as a result of the failure or delay of Protalix to pay
any such taxes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">5.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Shipping
and Delivery</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Storage</U>.
Protalix shall maintain dedicated freezer storage (i.e., freezers that is used only to store Drug Substance manufactured for Pfizer)
for Drug Substance manufactured but not yet delivered to Pfizer pursuant to a Purchase Order. Such dedicated freezers shall be
maintained in compliance with cGMP requirements and shall be stored in a secure area to prevent unauthorized access and/or manipulation.
Procedures shall be in place for reporting and neutralizing unauthorized entry into such dedicated freezers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Delivery</U>.
Subject to <U>Section 5.5</U>, Protalix shall deliver (or have delivered) to Pfizer in accordance with this <U>Section 5.8</U>
the quantities of the Drug Substance specified for a given delivery date in each Purchase Order with, in the case of Drug Substance,
no less than: [***] Such decision by the Supply Chain Committee shall be intended to ensure sufficient supply of Drug Substance
meeting the requirements of the applicable Regulatory Authorities and Regulatory Approvals throughout the Territory. If the Supply
Chain Committee determines to increase the Minimum Shelf Life, then the Minimum Shelf Life shall be increased by [***] of such
approved increase in shelf life. All dates for delivery of Drug Substance are [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Delivery
Terms</U>. The Drug Substance shall be supplied to Pfizer [***]. The Drug Substance shall be shipped [***]. Pfizer shall be responsible
for[***] For the avoidance of doubt, title and risk of loss shall not transfer to Pfizer until the Drug Substance is delivered
to Pfizer or its designee in accordance with this <U>Section 5.8(c)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Retention</U>.
Unless the parties agree otherwise, Protalix shall maintain analytical samples of each batch of Drug Substance in storage for a
time period based upon Protalix&rsquo;s sample retention policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">5.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Compliance;
Quality Control Obligations</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
parties shall determine if the Quality Agreement needs to be updated, and if necessary, shall update the Quality Agreement within
sixty (60) days following the Second Amendment Effective Date. The Quality Agreement shall set forth the parties&rsquo; compliance
obligations with respect to the Drug Substance Manufactured by Protalix for clinical and commercial requirements in the Territory.
To the extent there are any inconsistencies or conflicts between this Agreement and the Quality Agreement with respect to quality
issues, the terms and conditions of the Quality Agreement shall control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">5.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Certificate
of Analysis; Acceptance and Returns</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Manufacturing
Certificate of Analysis; Notice of Non-Conformance</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Following
Manufacture</U>. Following the release of the Drug Substance subject to an applicable Purchase Order by Protalix and before issuing
an invoice for such Drug Substance pursuant to <U>Section 5.7(b)</U>, Protalix shall supply to Pfizer the applicable batch number
for the Drug Substance, and such other information as the parties may set forth in the Quality Agreement with respect to the Manufacture
(a &ldquo;<U>Manufacturing Certificate of Analysis</U>&rdquo;) for such Drug Substance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Following
Delivery</U>. Pfizer shall (within the time period specified in <U>Section 5.10(b)</U>) inspect, or cause to have inspected, each
shipment of the Drug Substance for any damage, defect or shortage and give Protalix written notice of any such damaged, defective
or short shipment (a &ldquo;<U>Notice of Non-Conformance</U>&rdquo;) within the time periods specified in <U>Sections 5.10(a)(iii)</U>
and <U>5.10(b)</U>, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Latent
defects shall be communicated to Protalix, together with appropriate detail, within fifteen (15) Business Days of the date on which
such latent defect was first discovered by Pfizer or was notified to Pfizer by the relevant party discovering the defect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Rejection</U>.
Pfizer shall have [***] following its receipt of each shipment of the Drug Substance to inspect such shipment. If Pfizer determines
that any shipment of the Drug Substance does not conform to the Product Specifications (or is otherwise a short shipment), it shall
promptly notify Protalix within [***] following such determination in compliance with the procedures set forth in the Quality Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Disputes</U>.
If Pfizer delivers a Notice of Non-Conformance in respect of all or any part of a shipment of the Drug Substance, and Protalix
does not agree with Pfizer&rsquo;s determination that such shipment fails to meet the Product Specifications (or is otherwise a
short shipment), the parties shall in good faith attempt to resolve such dispute at the Supply Chain Committee. Protalix and Pfizer
shall have thirty (30) days, unless otherwise agreed in writing by the parties, from the date of Protalix&rsquo;s receipt of a
Notice of Non-Conformance to resolve such dispute regarding whether all or any part of such shipment was Manufactured in conformance
with the Product Specifications (or was otherwise a short shipment). If the dispute regarding whether all or any part of a shipment
rejected by Pfizer was Manufactured in conformance with the Product Specifications (or was otherwise a short shipment) is not resolved
in such thirty (30) day period, then [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Destruction</U>.
In the event any shipment of Drug Substance is rejected pursuant to this <U>Section 5.10</U> as a result of any act or omission
of Protalix, then Pfizer shall, at the direction of Protalix, either (x) destroy such rejected Drug Substance or Licensed Product
at Protalix&rsquo;s expense (in accordance with applicable Law) or (y) return such rejected Drug Substance or Licensed Product
to Protalix, at a location designated by Protalix and at Protalix&rsquo;s expense; <U>provided</U>&nbsp;that if Protalix requests
the return of such rejected Drug Substance or Licensed Product, Protalix shall not use such Drug Substance or Licensed Product
for any purpose, shall destroy such rejected Drug Substance or Licensed Product and certify to Pfizer that it has destroyed such
rejected Drug Substance or Licensed Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Refund,
Replacement of Non-Conforming Product</U>. Pfizer may return to Protalix at Protalix&rsquo;s expense any Drug Substance rejected
pursuant to this <U>Section 5.10</U> as a result of any act or omission of Protalix, its Affiliates or their respective agents,
vendors, suppliers or subcontractors. In addition to any other rights or remedies of Pfizer hereunder, Protalix shall at Pfizer&rsquo;s
sole discretion (i) replace any Drug Substance rejected by Pfizer, at no additional cost to Pfizer, as soon as reasonably practicable
on an expedited basis; or (ii) provide a credit or refund to Pfizer for the full amount invoiced to and paid by Pfizer for such
Drug Substance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Shortages</U>.
In the event that the materials and/or Manufacturing capacity required by Protalix to Manufacture and to deliver to Pfizer the
Drug Substance required as specified in Purchase Orders are in short supply, Protalix shall notify Pfizer of such shortage and
the Supply Chain Committee shall promptly meet to discuss the shortage. Protalix shall provide to the Supply Chain Committee a
written plan of action stating in reasonable detail the proposed measures to address such shortage and the date such shortage is
expected to end. Protalix shall use its Commercially Reasonable Efforts to minimize the duration of any shortage, including using
all capacity at its Facility to Manufacture Drug Substance (including stopping the manufacture of all other products at the Facility
for sales by Protalix or Third Parties). During any such shortage, Protalix shall allocate the materials and resources used in
the supply of the Drug Substance such that Pfizer receives [***] of the Drug Substance for the Territory and Protalix receives
[***] of the Drug Substance for outside the Territory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 38; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">5.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Product
Specification and Manufacturing Changes</U>. Product Specification and Manufacturing changes, including those resulting from a
request received by a party from a Governmental Authority, shall be dealt with pursuant to the Quality Agreement; <U>provided</U>
that all applicable Regulatory Approvals shall be prepared and filed by the parties in accordance with the provisions of <U>Section
4</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">5.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Change
Control</U>. Protalix shall not make any changes to its process, raw materials, supply sources, manufacturing locations or facilities
(including Drug Substance storage facilities and equipment) used to make Drug Substance for Pfizer under this agreement, including
any such changes that may require Pfizer to provide notification to Regulatory Authorities, except to the extent permitted under
the Quality Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">5.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Practices</U>.
Protalix shall comply with current Good Manufacturing Practices (cGMP) as it applies to receipt, storage, handling and control
of materials and the Drug Substance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">5.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Pest
Control</U>. Protalix shall manufacture and store Drug Substance, and shall store all ingredients, raw materials and components
used to manufacture Drug Substance, in a clean, dry area, free from insects and rodents, in a manner to prevent entry of foreign
materials and contamination of Drug Substance. Protalix&rsquo;s pest control measures shall include adequate cleaning of the facility,
control of food and drink, protection of Drug Substance from the environment, monitoring of flying and crawling pests, and logs
detailing findings and actions taken. Protalix&rsquo;s pest control program shall be described in a written procedure subject to
review and approval of Pfizer. Failure of Protalix to comply with this <U>Section 5.14</U> shall be deemed a material breach of
this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">5.15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Records
and Audits</U>. Protalix shall maintain complete and accurate records of all matters relating to the Manufacturing of Drug Substance
that enable Protalix to demonstrate compliance with its obligations under this Agreement, including Protalix&rsquo;s compliance
with applicable Laws, in accordance with the terms of the Quality Agreement. As used in this <U>Section 5.15</U>, records include
all books, documents, and other data specified in the Quality Agreement regardless of type or form. Protalix shall maintain such
records for the period of time set forth in the Quality Agreement. Pfizer or its representatives may (at Pfizer&rsquo;s sole cost
and expense), subject to the confidentiality provisions in <U>Section 9</U>, audit such records of Protalix in accordance with
the terms of the Quality Agreement at any time during the Supply Term and for the [***] period following the expiration or termination
of (x) the Supply Term or (y) the last Purchase Order in effect, whichever occurs later, during normal business hours and upon
reasonable advance written notice to Protalix. Protalix shall make such records readily available for such audit, and Pfizer or
its representatives may copy any and all such records in connection with any such audit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 39; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">5.16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Quality
Assurance</U>. Protalix shall have a formal quality assurance program and appropriate written quality control procedures covering
its operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">5.17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Technical
Support</U>. Protalix shall provide means for Pfizer to contact Protalix&rsquo;s service representative twenty-four (24) hours
a day, seven (7) days a week during the Supply Term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">5.18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Technical
Assistance; Facility Access</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: 1.5in">(A)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pfizer
shall have the right to provide technical assistance and advice to Protalix on an ongoing basis, including in-person at Protalix&rsquo;s
Facility;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: 1.5in">(B)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pfizer
may physically inspect Protalix&rsquo;s Facility, including being present during Manufacturing operations, quality control, quality
assurance, pack out and shipping;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: 1.5in">(C)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Protalix
shall provide Pfizer with reasonable ongoing access to its Facility and all relevant Manufacturing records and personnel (wherever
located) of Protalix and will use Commercially Reasonable Efforts to facilitate access to any Third Party suppliers of materials
for the Drug Substance; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: 1.5in">(D)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Protalix
shall reasonably cooperate with Pfizer and its representatives in connection with the activities described above and, upon mutual
agreement of the parties as to any deficiencies, Protalix shall use its Commercially Reasonable Efforts to promptly correct any
such deficiencies if and to the extent mutually agreed by the parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">Pfizer and its representatives shall carry out
the activities described in this <U>Section 5.18</U> during Protalix&rsquo;s regular business hours at times reasonably agreed
upon by Pfizer and Protalix, with as minimal disruption to Protalix&rsquo;s operations as reasonably practicable [***]. Such requested
cooperation and assistance pursuant to <U>Sections 5.18(C)</U> and <U>5.18(D)</U>, shall be provided [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">5.19&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Other
Assistance by Pfizer</U>. Protalix acknowledges that Pfizer has expertise with respect to manufacturing and pharmaceutical sciences
and is able to provide assistance to Protalix in the following areas: (a) registering with the FDA and EMEA a manufacturing technology
for commercial supply of Drug Substance, including the preparation of a complete, approvable chemistry, manufacturing, and controls
section of an NDA and other regulatory filings packages, (b) the regulatory review process, (c) addressing regulatory review feedback
or post-approval requirements by any Regulatory Authority, (d) bioprocess, analytical or formulation development, (e) validation,
(f) characterization and stability studies, (g) preparing for and supporting pre-approval inspections; and (h) preparing Protalix&rsquo;s
Facility to make it suitable for Regulatory Approval, including finalizing any required changes to the facility or equipment train,
IQ/OQ/PQ, and equipment cleaning and cleaning validation (collectively, the &ldquo;<U>Advisory Services</U>&rdquo;). At any time
during the Term, Pfizer shall have the right to provide Advisory Services to Protalix and upon reasonable advance written notice
from Pfizer, Protalix shall reasonably consider in good faith the recommendations of Pfizer with respect to such Advisory Services.
Pfizer shall be responsible for and bear [***] of the costs and expenses it incurs in providing Advisory Services to Protalix.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 40; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">5.20&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Master
Cell Bank</U>. During the Term, Protalix shall, as the supplier of Drug Substance, maintain half of the master cell bank relating
to the Drug Substance in a location selected by Protalix and the other half of the master cell bank relating to the Drug Substance
at a different location selected by Protalix and approved by Pfizer (such approval not to be unreasonably withheld or delayed),
which may include the Facility where Pfizer performs Fill/Finish activities (<U>provided</U>&nbsp;that Pfizer obtains all required
approvals from the applicable Regulatory Authority necessary to store the master cell bank in such Facility).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">5.21&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">5.22&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">5.23&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Manufacturing
Transition Assistance</U>. Upon Pfizer&rsquo;s request, in order to ensure continuity of supply of the Drug Substance following
expiration or termination of this Agreement or Pfizer&rsquo;s election to exercise its right to Manufacture or have a Third Party
Manufacture the Drug Substance, Protalix shall provide reasonable assistance to Pfizer in arranging for the Manufacture of the
Drug Substance by Pfizer or by an alternative supplier chosen by Pfizer, including providing technical consulting services to Pfizer
or such alternative supplier and transferring know-how and other information relating to the Manufacture of the Drug Substance
to Pfizer or such alternative supplier. [***] Protalix shall provide such assistance in accordance with a written transition plan
(the &ldquo;<U>Manufacturing Transition Plan</U>&rdquo;) that details the actions and timelines for transitioning the Manufacture
of the Drug Substance to Pfizer or such alternative supplier in a timely and efficient manner without material risk or disruption
to either Protalix or Pfizer and no later than the end of the Term (if in connection with the expiration or termination of the
Agreement) or no later than the time agreed to by the parties (if in connection with Pfizer&rsquo;s exercise of its right to Manufacture
or have a Third Party Manufacture the Drug Substance). Protalix shall provide the proposed Manufacturing Transition Plan to Pfizer
for Pfizer&rsquo;s written approval, which shall not be unreasonably withheld, within [***] following Pfizer&rsquo;s request. In
addition, upon Pfizer&rsquo;s request, Protalix shall use Commercially Reasonable Efforts to cause the counterparty to any contract
relating to the Manufacture of the Drug Substance (a) to consent to the partial assignment to Pfizer or such alternative supplier
of those rights necessary for such manufacture by Pfizer or such alternative supplier or (b) to otherwise reasonably cooperate
with Pfizer in Pfizer&rsquo;s efforts to establish a new contractual relationship with such counterparty on substantially the same
terms as the terms of its contract with Protalix.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-transform: uppercase; text-indent: -1in"><FONT STYLE="text-transform: none">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-transform: uppercase; text-indent: -1in"><FONT STYLE="text-transform: none">Section
6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>FINANCIAL PROVISIONS</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">6.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Second
Amendment Effective Date Payment</U>. Within thirty (30) days following the Second Amendment Effective Date, Pfizer shall pay to
Protalix the amount of thirty-six million dollars (US $36,000,000) (the &ldquo;<U>Pfizer Payment</U>&rdquo;) in accordance with
<U>Section 7.2(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 41; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">6.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Deferred
Payment</U>. Within thirty (30) days of the fifth (5<SUP>th</SUP>) anniversary of the Second Amendment Effective Date, Protalix
shall pay to Pfizer the non-refundable, non-creditable amount of four million three hundred thousand seven hundred sixteen dollars
and forty-six cents (US $4,300,716.46) (the &ldquo;<U>Protalix Payment</U>&rdquo;) in accordance with <U>Section 7.2(b)</U> and
as set forth in the promissory note delivered by Protalix to Pfizer. Protalix shall have delivered a promissory note in the form
of <U>Exhibit H</U> on the Second Amendment Effective Date (the &ldquo;<U>Promissory Note</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">6.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Payments
With Respect to Commercialization in Israel</U>. During the Israel Transition Period, [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">6.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Payments
With Respect to Commercialization in Brazil</U>. Until such time that Protalix has provided written notice to Pfizer permitting
Pfizer to cancel its Brazilian marketing authorization with respect to the Licensed Product, [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">6.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Release
of Payment Obligations</U>. Upon (i) the payment by Pfizer to Protalix of the Pfizer Payment, Pfizer shall be deemed to have fully
satisfied and discharged, and Protalix hereby fully and forever releases Pfizer and its Affiliates from, all payment obligations
under Section 6 of the Amended Agreement that have accrued as of the Second Amendment Effective Date, including milestone payments
and profit sharing payments, and (ii) the later to occur of (A) the delivery of the promissory note for the Protalix Payment by
Protalix to Pfizer as required under <U>Section 6.2</U> and (B) Protalix providing Pfizer with written notice permitting Pfizer
to cancel its Brazilian marketing authorization with respect to the Licensed Product, Protalix shall be deemed to have fully satisfied
and discharged, and Pfizer hereby fully and forever releases Protalix and its Affiliates from, all payment obligations under Section
2 of the First Amendment (which, for the avoidance of doubt, shall no longer be in effect as of the Second Amendment Effective
Date) and Section 6 of the Amended Agreement that have accrued as of the Second Amendment Effective Date (except to the extent
such payments under Section 2 of the First Amendment are payable pursuant to <U>Section 6.4</U> of this Agreement) (collectively,
the &ldquo;<U>Released Obligations</U>&rdquo;), other than payment of the Protalix Payment in accordance herewith. In addition,
the Released Obligations include all associated reporting obligations, reconciliation payments and procedures and payments in respect
of reimbursable expenses that may have accrued under Section 7 of the Amended Agreement. In connection with the foregoing release,
each party hereby waives any and all rights to inspect or audit the books and records of the other party and its Affiliates and
sublicensees relating to the Released Obligations and to seek any adjustment or modification of any amounts paid or payable in
connection with any such audit or inspection.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-transform: uppercase; text-indent: -1in"><FONT STYLE="text-transform: none">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-transform: uppercase; text-indent: -1in"><FONT STYLE="text-transform: none">Section
7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>ACCOUNTING AND PROCEDURES FOR PAYMENT</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">7.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Currency</U>.
All payments to be made hereunder by one party to the other party shall be computed and paid in United States dollars.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">7.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Method
of Payments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
payment to be made hereunder by Pfizer to Protalix shall be made by electronic transfer in immediately available funds via either
a bank wire transfer, an ACH (automated clearing house) mechanism, or any other means of electronic funds transfer, at Protalix&rsquo;s
election, to the account designated on <U>Appendix 7.2(a)</U>. With respect to any payment invoiced by Protalix to Pfizer, Protalix
may designate a different bank account on such invoice. With respect to any other payment, Protalix may designate a different bank
account at least forty-five (45) days before such payment is due.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 42; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
payment to be made hereunder by Protalix to Pfizer shall be made by electronic transfer in immediately available funds via either
a bank wire transfer, an ACH (automated clearing house) mechanism, or any other means of electronic funds transfer, at Pfizer&rsquo;s
election, to the account designated on <U>Appendix 7.2(b)</U>, or to such other bank account as Pfizer shall designate in a notice
at least fifteen (15) Business Days before the payment is due.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">7.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Tax
Matters</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>VAT</U>.
It is understood and agreed between the parties that any payments made by Pfizer under this Agreement are inclusive of any value
added or similar tax imposed upon such payments. It is understood and agreed between the parties that any payments made by Protalix
to Pfizer under this Agreement are exclusive of any value added or similar tax (VAT), which shall be added thereon as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Tax
Cooperation</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject
to <U>Section 7.3(c)</U> to the extent Pfizer is required to deduct and withhold taxes on any payments to Protalix, Pfizer shall
pay the amounts of such taxes to the proper Governmental Authority in a timely manner and promptly transmit to Protalix an official
tax certificate or other evidence of such withholding sufficient to enable Protalix to claim credits for such payments of taxes.
&nbsp;Protalix shall provide to Pfizer any tax forms that may be reasonably necessary in order for Pfizer not to withhold tax or
to withhold tax at a reduced rate under an applicable bilateral income tax treaty. &nbsp;Protalix shall use reasonable efforts
to provide any such tax forms to Pfizer at least thirty (30) days prior to the due date for any payments for which Protalix desires
that Pfizer apply a reduced withholding rate. &nbsp;Each party shall provide the other with reasonable assistance to enable the
recovery, as permitted by law, of withholding taxes, VAT, or similar obligations resulting from payments made under this Agreement,
such recovery to be for the benefit of the party bearing such withholding tax or VAT. Each party further agrees to provide reasonable
cooperation to the other party, at the other party&rsquo;s expense, in connection with any official or unofficial tax audit or
contest relating to payments made by Pfizer to Protalix under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject
to <U>Section 7.3(c)</U>, to the extent Protalix is required to deduct and withhold taxes on any payments to Pfizer, Protalix shall
pay the amounts of such taxes to the proper Governmental Authority in a timely manner and promptly transmit to Pfizer an official
tax certificate or other evidence of such withholding sufficient to enable Pfizer to claim credits for such payments of taxes.
Pfizer shall provide to Protalix any tax forms that may be reasonably necessary in order for Protalix not to withhold tax or to
withhold tax at a reduced rate under an applicable bilateral income tax treaty. Pfizer shall use reasonable efforts to provide
any such tax forms to Protalix at least thirty (30) days prior to the due date for any payments for which Pfizer desires that Protalix
apply a reduced withholding rate. Each party shall provide the other with reasonable assistance to enable the recovery, as permitted
by Law, of withholding taxes, or similar obligations resulting from payments made under this Agreement, such recovery to be for
the benefit of the party bearing such withholding tax. Each party further agrees to provide reasonable cooperation to the other
party, at the other party&rsquo;s expense, in connection with any official or unofficial tax audit or contest relating to payments
made by Protalix to Pfizer under this Agreement.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 43; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***]</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-transform: uppercase; text-indent: -1in"><FONT STYLE="text-transform: none">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-transform: uppercase; text-indent: -1in"><FONT STYLE="text-transform: none">Section
8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>PATENTS AND INFRINGEMENT</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">8.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Filing
and Prosecution</U>. Protalix shall have the exclusive right, subject to <U>Sections 8.2</U> through <U>8.5</U>, to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;file
Patent Applications on any invention included in the Protalix Patent Rights;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;take
all reasonable steps to prosecute all pending and new Patent Applications included within the Protalix Patent Rights;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;respond
to oppositions, interferences, nullity actions, re-examinations, revocation actions and similar proceedings filed by Third Parties
against the grant of Patents for such Patent Applications; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;maintain
in force any patents in the Territory included within the Protalix Patent Rights by duly filing all necessary papers and paying
any fees required by the relevant patent laws and regulations of the particular Country in which the patent was granted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***]
shall be responsible for bearing [***] of the expenses and costs incurred by [***] in connection with the exercise of its rights
under this <U>Section 8.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">8.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Correspondence</U>.
[***] will keep [***] fully-informed of the status of the [***] Patent Rights to the extent the Protalix Patent Rights [***], and
will provide [***] with copies of all substantive documentation submitted to, or received from, the patent offices in connection
therewith. With respect to any substantive submissions that [***] is required to or otherwise intends to submit to a patent office
regarding such Protalix Patent Rights, [***] shall use Commercially Reasonable Efforts to provide a draft of such submission to
[***] at least thirty (30) days prior to the deadline or intended filing date, whichever is earlier, for submission of such documentation.
[***] shall have the right to review and comment upon any such submission by [***] to a patent office that could affect the scope
of coverage or validity of any claim of the Protalix Patent Rights to the extent covering the Compound or Licensed Product, or
the Development, Manufacture, or Commercialization of [***], and will provide such comments, if any, no later than ten (10) days
prior to the applicable deadline or intended filing date. Notwithstanding the foregoing, when such substantive documentation submitted
to or received from the patent offices is solely related to [***], [***] shall have the right, but no obligation, to fully inform
[***] of the status of these Protalix Patent Rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 44; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
[***] written request, <U>provided </U>that [***] submits such written request reasonably in advance of any relevant filing deadline
or intended filing date, [***] will file Patent Applications directed to the rights licensed to [***] under this Agreement [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;With
respect to Protalix Patent Rights that are [***][***] shall consider in good faith all comments provided<U> </U>by [***] with respect
to a Protalix Patent Right to the extent relating to [***], and incorporate all such comments that [***] deems reasonable and appropriate.
If [***] disagrees with any such comment provided<U> </U>by [***] after giving such comments due consideration, [***] shall provide
[***] with an explanation of the basis for such disagreement. If a failure to incorporate [***]&rsquo;s comment would reasonably
be expected to impair the Licensed Product in the Field in the Territory, [***] shall have final-decision making authority with
respect to filings and prosecution of such Protalix Patent Rights (other than the Protalix System Patent Rights). [***] shall have
final-decision making authority with respect to filings and prosecution of Protalix Patent Rights relating solely to an [***] and
with respect to filings and prosecution of Protalix Patent Rights that [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
the foregoing, [***]&rsquo;s obligation to keep [***] informed of the status of the Protalix System Patent Rights will be limited
to situations where changes to the status of the Protalix System Patent Rights would reasonably be expected to impair the Licensed
Product in the Field in the Territory. With respect to the Protalix System Patent Rights, [***] shall reasonably consider all comments
provided<U> </U>by [***], but [***] shall have final-decision making authority with respect to filings and prosecution of the Protalix
System Patent Rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">8.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Maintenance</U>.
Protalix will maintain for the full life thereof all Patent Rights under the Protalix Patent Rights where the abandonment for non-payment
would [***]. Protalix will notify Pfizer of any decision (a) not to file applications for, or (b) not to enter the national phase
for a PCT patent application (or not to validate a patent in a particular Country) for, or (c) to cease prosecution and/or maintenance
of, or (d) not to pursue, or (e) to cease to pay the expenses of prosecution or maintenance of, any Protalix Patent Rights in any
Country in the Territory. Protalix will provide such notice upon the earlier of (i) its decision with respect to any of the foregoing,
or (ii) ninety (90) days prior to any filing or payment due date, or any other due date that requires action, in connection with
such Protalix Patent Rights. In such event, Pfizer shall have the right to make the filing, or to continue the prosecution and
maintenance of such Patent Rights (other than Protalix System Patent Rights) in its own name and at its sole expense, and such
Patent Rights shall be assigned to Pfizer and shall no longer be part of the Protalix Patent Rights. Notwithstanding the foregoing,
Protalix shall have no obligation to provide such notice where the subject Protalix Patent Rights are directed solely to an [***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">8.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notices
and Encumbrances</U>. Protalix agrees that it will, and will cause its Affiliates to, (a) execute and file those notices and other
filings as Pfizer shall request be made, from time to time with the United States Patent and Trademark Office (or any successor
agency) or any analogous patent office in the Territory with respect to the rights granted under this Agreement and, (b) maintain
(subject to <U>Section 8.3</U>) at all times during the Term sole ownership of the Patents and Patent Applications under the Protalix
Patent Rights (other than Protalix Patent Rights directed solely to [***]), free and clear of any and all mortgages, liens, pledges,
security interests, charges or encumbrances. Protalix shall also keep the Protalix Technology (other than Protalix Technology directed
solely to or solely embodied in [***]), free and clear of any and all mortgages, liens, pledges, security interests, charges or
encumbrances during the Term. For the sake of clarity, encumbrances as contemplated in this <U>Section 8.4</U> specifically exclude
licenses to Protalix Patent Rights and Protalix Technology, wherein such licenses are [***] [***] [***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 45; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">8.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Patent
Term Extensions</U>. Pfizer shall have the first right, but not the obligation, to seek, in Protalix&rsquo;s name if so required,
patent term extensions, and supplemental protection certificates and the like available under Law, including 35 U.S.C. &sect; 156
and applicable foreign counterparts, in any Country in the Territory in relation to the Protalix Patent Rights covering the Compound
(other than Protalix Patent Rights directed solely to the Compound [***]) or Licensed Products. In the event that Pfizer decides
not to seek such patent term extension or supplemental patent protection in any Country in the Territory, Protalix shall have the
right to seek such patent term extension or supplemental patent protection in any such Country. Protalix and Pfizer shall cooperate
in connection with all such activities, and Pfizer, its agents and attorneys will give due consideration to all suggestions and
comments of Protalix regarding any such activities, but in the event of a disagreement between the parties, as it relates to the
Compound ([***]) or Licensed Product, Pfizer will have the final decision-making authority. Any costs incurred by Pfizer in connection
with this <U>Section 8.5</U> shall be borne [***]. Any costs incurred by Protalix in connection with this <U>Section 8.5</U> shall
be borne [***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">8.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Third
Party Infringement</U>. Each party will promptly notify the other in the event of any actual, potential or suspected infringement
of a Patent under the Protalix Patent Rights by any Third Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Infringement
of Protalix Patent Rights in the Field</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pfizer
shall have the sole right, but not the obligation, to institute litigation or take other remedial measures in connection with Third
Party infringement of the Protalix Patent Rights occurring in the Field within the Territory (other than Protalix Patent Rights
directly solely to [***]), where such Third Party infringement would reasonably be expected [***]. In order to establish standing,
Protalix, upon request of Pfizer, agrees to timely commence or to join in any such litigation, at [***] and in any event to cooperate
with Pfizer at [***]. Any costs and expenses incurred by Pfizer with respect to any such litigation or remedial measures shall
be [***] and any recoveries resulting from such litigation or measures relating to a claim of a Third Party infringement in pursuing
such claim, will be [***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Protalix
shall have the sole right, but not the obligation, to institute litigation or take other remedial measures in connection with Third
Party infringement of any Protalix Patent Rights occurring [***] and with respect to Third Party infringement of any Protalix Patent
Rights directed solely to [***] and any such litigation or remedial measures shall be [***]. Protalix shall retain [***] received
by Protalix as a result of its enforcement of Protalix Patent Rights under this <U>Section 8.6(a)(ii)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 46; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Infringement
of Protalix Patent Rights </U>[***]<U>.</U> Protalix shall have the sole right, but not the obligation, to institute litigation
or take other remedial measures in connection with Third Party infringement occurring [***] and any such litigation or remedial
measures shall be [***]. Protalix shall either (i) provide Pfizer with prior written notice of Protalix&rsquo;s intent to initiate
a suit, take other appropriate action, or to not file suit or seek other redress or (ii) convene a meeting of the parties to discuss
what would be in the parties&rsquo; best interest with respect to the Third Party infringement occurring [***]. Protalix shall
retain [***] received by Protalix as a result of its enforcement of Protalix Patent Rights under this <U>Section 8.6(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">8.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Paragraph
IV Notices</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
either party receives a notice under 21 U.S.C. &sect;355(b)(2)(A)(iv) or 355(j)(2)(A)(vii)(IV) directed to a Compound ([***]) or
Licensed Product, concerning any Protalix Patent Right (&ldquo;<U>Paragraph IV Notice</U>&rdquo;), then it shall provide a copy
of such notice to the other party promptly and in any event no later than two (2) Business Days after its receipt thereof. Pfizer
shall have the exclusive right, but not the obligation, to initiate patent infringement litigation based on a Paragraph IV Notice
directed to a Compound ([***]) or Licensed Product, concerning a Protalix Patent Right, and any expenses incurred by Pfizer with
respect to such infringement litigation shall be [***]. Upon request of Pfizer, Protalix agrees to timely join as party&minus;plaintiff
in any such litigation, and in any event to cooperate with Pfizer in connection with such infringement action, including timely
filing such action in Protalix&rsquo;s name if required. Pfizer shall promptly notify Protalix of its intention not to initiate
patent infringement litigation based on such Paragraph IV Notice. The amount of any recovery from any such infringement suit with
respect to activities in the Field in the Territory will be [***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Protalix
and Pfizer are aware of currently proposed legislation in the United States that may create or affect the regulatory pathway for
a follow-on biologic product to the Licensed Product. [***] To the extent required to establish standing, and possibly to comply
with heretofore unknown regulations accompanying this regulatory pathway, [***], shall reasonably cooperate with [***] in any litigation
or administrative action at [***] expense and shall commence or join in any such litigation or administrative action at [***] request
and expense. The amount of any recovery from any such proceedings shall first be used to pay reasonable costs, including attorneys&rsquo;
fees and the remaining amount of the recovery will be [***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">8.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Other
Actions by a Third Party</U>. Each party shall promptly notify the other in the event of any (a) claims by a Third Party of alleged
patent infringement by Pfizer or Protalix or any of their respective Affiliates with respect to [***] of a Compound ([***]) or
Licensed Product or (b) legal or administrative action by any Third Party involving a Protalix Patent Right (other than Protalix
Patent Rights directed solely to [***]) of which it becomes aware, including any nullity, revocation, reexamination or compulsory
license proceeding. Pfizer shall have the first right, but no obligation, to defend against any such action involving such Protalix
Patent Right in the Territory when the alleged patent infringement would reasonably be expected to [***], and any such defense
shall be [***]. Protalix, upon request of Pfizer, agrees to join in any such action [***] and in any event to cooperate with Pfizer
[***] If Pfizer fails to defend Protalix against any such action involving a Protalix Patent Right, then Protalix shall have the
right to defend such action, and any such defense shall be[***]. Pfizer, upon request of Protalix, shall reasonably cooperate with
Protalix in any such action [***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 47; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">8.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Compensation
to Inventors</U>. [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">8.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Patent
Marking</U>. Each party shall comply with the patent marking statutes in each Country in which a Licensed Product in the Field
is made, offered for sale, sold or imported by such party, its Affiliates and sublicensees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">8.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>In-Licensed
Patents</U>. With respect to this <U>Section 8</U>, &ldquo;Protalix&nbsp;Patent Rights&rdquo; shall include Patent Rights that
are Controlled by Protalix or any of its Affiliates pursuant to a Third Party License (<I>i.e.,</I> such Patent Rights are not
owned by Protalix or any of its Affiliates) only if [***]</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-transform: uppercase; text-indent: -1in"><FONT STYLE="text-transform: none">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-transform: uppercase; text-indent: -1in"><FONT STYLE="text-transform: none">Section
9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>CONFIDENTIALITY; PUBLICATION</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">9.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Confidential
Information</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pfizer
and Protalix each agree that during the Term and for five (5) years after the Term, it will keep confidential, and will cause its
Affiliates to keep confidential, all of the other party&rsquo;s Confidential Information that is disclosed to it, or to any of
its Affiliates. Pfizer and Protalix each agree to take such action, and to cause its Affiliates to take such action, to preserve
the confidentiality of Protalix Confidential Information and Pfizer Confidential Information, respectively, as it would customarily
take to preserve the confidentiality of its own similar types of confidential information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
of Pfizer, Protalix and their respective Affiliates agree (i) to use Protalix Confidential Information and Pfizer Confidential
Information, respectively, only as expressly permitted in this Agreement and (ii) not to disclose Protalix Confidential Information
and Pfizer Confidential Information, respectively, to any Third Parties under any circumstance without the prior consent of the
other party, except as expressly permitted in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">9.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Permitted
Disclosure of Confidential Information</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Disclosure
of Protalix Confidential Information</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
anything to the contrary in this <U>Section 9</U>, Pfizer may disclose Protalix Confidential Information: (A) to Governmental Authorities
(x) to the extent desirable to obtain or maintain Regulatory Approvals for the Compound or Licensed Product within the Territory,
and (y) in order to respond to inquiries, requests or investigations relating to this Agreement; (B) to Sublicensees, outside consultants,
contractors, advisory boards, managed care organizations, and non-clinical and clinical investigators, in each case to the extent
desirable to Develop, register or Commercialize the Compound or Licensed Product; <U>provided </U>that Pfizer shall obtain the
same confidentiality obligations and degree of care from such Third Parties as it obtains with respect to its own similar types
of confidential information; <U>provided further</U> that no Protalix Confidential Information consisting of non-public information
relating to Protalix&rsquo;s manufacturing know-how may be disclosed (and, notwithstanding anything to the contrary herein, Protalix
shall not have any obligation under this Agreement to disclose any such manufacturing know-how) to any Sublicensee that is a direct
competitor of Protalix in the field of plant cell expressed biologics manufacturing, except to the extent such disclosure is necessary
for Pfizer to identify and establish an alternative source of supply of Drug Substance pursuant to <U>Section 5.21(d)</U>; (C)
in connection with filing or prosecuting Patent Rights or trademark rights as permitted by this Agreement; (D) in connection with
prosecuting or defending litigation as permitted by this Agreement; (E) in connection with or included in scientific presentations
and publications relating to the Compound or Licensed Product, including abstracts, posters, journal articles and the like, and
posting results of and other information about clinical trials to clinicaltrials.gov or PhRMA websites; and (F) to the extent necessary
or desirable in order to enforce its rights under this Agreement.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 48; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
Pfizer is required or requested to disclose Protalix Confidential Information (x) as required by Law or legal proceedings or (y)
as required to be contained in Pfizer&rsquo;s financial statements prepared in accordance with GAAP, as applied on a consistent
basis, Pfizer shall (1) with respect to disclosures described in clause (x), use Commercially Reasonable Efforts to obtain confidential
treatment of financial and trade secret information, and (2) with respect to disclosures described in clauses (x) and (y), if reasonably
practicable under the circumstances, give Protalix sufficient advance notice of the text so that Protalix will have the opportunity
to seek, at its own cost, an appropriate protective order or other remedy or waive compliance with the provisions of this Agreement.
If Protalix seeks a protective order, Pfizer will cooperate. If Protalix fails to obtain a protective order or waive compliance
with the relevant portions of this Agreement, Pfizer will disclose only that portion of information concerning the Compound or
Licensed Product which its legal counsel determines it is required to disclose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Disclosure
of Pfizer Confidential Information</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
anything to the contrary in this <U>Section 9</U>, Protalix may disclose Pfizer Confidential Information to: (x) Governmental Authorities
in order to respond to inquiries, requests or investigations relating to this Agreement or to comply with applicable Laws and (y)
to the extent necessary or desirable in order to enforce its rights under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
Protalix is required or requested to disclose Pfizer Confidential Information (x) as required by Law or legal proceedings or in
connection with <U>Section 9.2(b)(i) </U>above or (y) as required to be contained in Protalix financial statements prepared in
accordance with GAAP, as applied on a consistent basis, Protalix shall (1) with respect to disclosures described in clause (x),
use Commercially Reasonable Efforts to obtain confidential treatment of financial and trade secret information, and (2) with respect
to disclosures described in clauses (x) and (y), if reasonably practicable under the circumstances, give Pfizer sufficient advance
notice of the text so that Pfizer will have the opportunity to seek, at its own cost, an appropriate protective order or other
remedy or waive compliance with the provisions of this Agreement. If Pfizer seeks a protective order, Protalix will cooperate.
If Pfizer fails to obtain a protective order or waive compliance with the relevant portions of this Agreement, Protalix will disclose
only that portion of information concerning the Compound or Licensed Product which its legal counsel determines it is required
to disclose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 49; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
Protalix desires to disclose Pfizer Confidential Information that (x) has been announced previously in accordance with <U>Section
9.4</U> (Publicity), or (y) has been announced previously by Pfizer, such disclosure is permitted so long as (1) it is consistent
with such previously announced statement and (2) Pfizer is permitted a review and comment period of no fewer than sixty (60) days
prior to the planned disclosure to redact any Pfizer Confidential Information and ensure the disclosure is within the scope of
previous disclosures as set forth in this <U>Section 9.2(b)(iii)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">9.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Publication</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject
to <U>Section 9.3(d)</U>, neither Pfizer nor any of its Affiliates or their respective employees, consultants, contractors and
agents shall publish or present any information, including the results of any preclinical or clinical studies, with respect to
the Compound or Licensed Product unless Pfizer has used Commercially Reasonable Efforts to provide Protalix with thirty (30) days&rsquo;
notice prior to any such publication or presentation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject
to <U>Section 9.3(c)</U> and <U>Section 9.3(d)</U>, neither Protalix nor any of its Affiliates or their respective employees, consultants,
contractors, licensees and agents shall publish or present any information, including the results of any preclinical or clinical
studies, with respect to the Compound ([***]) or Licensed Product without the prior written approval of Pfizer ([***]), except
as may be required by Law or legal proceedings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Section
9.3(a)</U> does not prohibit: (i) Protalix and its Affiliates (and their respective employees, consultants, contractors, licensees
and agents) from publishing or presenting information relating to the development or use of the System that does not contain information
with respect to the Compound (other than the Oral Formulation) or Licensed Product; (ii) Protalix and its Affiliates (and their
respective employees, consultants, contractors, licensees and agents) from publishing or presenting information relating to the
Oral Formulation; or (iii) Protalix and its Affiliates (and their respective employees, consultants, contractors, licensees and
agents) from publishing or presenting information that has been either previously published or presented by Protalix in accordance
with <U>Section 9.3(a)</U> or by Pfizer. Protalix will use Commercially Reasonable Efforts to provide Pfizer a copy of any such
proposed publication or presentation described in clauses (i) or (ii) of this <U>Section 9.3(c)</U> at least thirty (30) days prior
to any such publication or presentation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Nothing
in this <U>Section 9.3</U> shall be construed to (a) limit the rights of either party&rsquo;s Third Party clinical investigators
to publish the results of their studies or (b) prevent either party from complying with applicable Law with respect to the disclosure
of clinical study data and results or of any other material matter or information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">9.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Publicity</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
public announcement of the execution of this Agreement is set forth on <U>Exhibit I</U> attached hereto and shall be promptly disseminated
as a press release following the execution of this Agreement by Protalix.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 50; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
as set forth in <U>Sections 9.3</U>, <U>9.4(a)</U> or <U>9.4(c) </U>or with respect to any activities or contemplated activities
by Protalix outside of the Territory, Protalix shall not make (and shall cause its Affiliates not to make) any public statement
(written or oral), including in analyst meetings, concerning the terms of, or events related to, this Agreement or concerning the
Licensed Product in the Territory without the prior written approval of Pfizer (which may be withheld in its sole and final discretion)
except where such statement: (i) is required by Law or legal proceedings (or to respond to a specific request of the securities
exchange upon which Protalix&rsquo;s securities are listed); (ii) is required to be contained in Protalix financial statements
prepared in accordance with GAAP; (iii) has been announced previously in accordance with this <U>Section 9.4</U>; or (iv) has been
announced previously by Pfizer; so long as, in the case of (iii) or (iv), such public statement is consistent with such previously
announced statement. In the case of any public statement (written or oral) that is required by Law or legal proceedings, Protalix
shall (and shall cause its Affiliates to) (x) use Commercially Reasonable Efforts to obtain confidential treatment of financial
and trade secret information (except in connection with press releases) and (y) if reasonably practicable under the circumstances,
give Pfizer sufficient advance notice of the text so that Pfizer will have the opportunity to comment upon the statement, and give
due consideration to any specific reasonable comments of Pfizer on such text timely received from Pfizer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Section
9.4(b)</U> does not prohibit Protalix from making public announcements that any of the following has commenced or has been completed:
any [***]; <U>provided</U> that such public announcement complies with all applicable Laws. Protalix will provide Pfizer a copy
of any such proposed public announcement at least ten (10) Business Days prior to such announcement so that Pfizer will have the
opportunity to comment upon the announcement, and give due consideration to any specific reasonable comments of Pfizer on such
text timely received from Pfizer. For the avoidance of doubt, this <U>Section 9.4(c)</U> shall be subject to <U>Section 9.3(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">9.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Filing,
Registration or Notification of the Agreement</U>. If a party determines that it is required by Law to publicly file, register
or notify this Agreement with a Governmental Authority, such party shall provide to the other party a redacted version of this
Agreement indicating the sections of the Agreement to be redacted in such filing and both parties shall agree in good faith upon
a final redacted version of the Agreement for such filing (the &ldquo;<U>Redacted Agreement</U>&rdquo;). The disclosing party shall
(a) initially file the Redacted Agreement, (b) request, and use Commercially Reasonable Efforts to obtain, confidential treatment
of all terms redacted from this Agreement, as reflected in the Redacted Agreement, for a period of at least ten (10) years, (c)
permit the other party to review and approve such request for confidential treatment and any subsequent correspondence with respect
thereto at least five (5) Business Days prior to its submission to such Governmental Authority, (d) promptly deliver to the other
party any written correspondence received by it or its representatives from such Governmental Authority with respect to such confidential
treatment request and promptly advise the other party of any other communications between it or its representatives with such Governmental
Authority with respect to such confidential treatment request, (e) upon the written request of the other party, request an appropriate
extension of the term of the confidential treatment period for this Agreement, the Original Agreement and the First Amendment,
and (vi) if such Governmental Authority requests any changes to the redactions set forth in the Redacted Agreement, use Commercially
Reasonable Efforts to support the redactions in the Redacted Agreement as originally filed and shall not agree to any changes to
the Redacted Agreement without first discussing such changes with the other party and taking the other party&rsquo;s comments into
consideration when deciding whether to agree to such changes. Each party shall be responsible for its own legal and other external
costs in connection with any such filing, registration or notification. Notwithstanding the foregoing or anything to the contrary
herein, Pfizer acknowledges and agrees that Protalix BioTherapeutics, Inc. shall have the right to describe (and, as reasonably
necessary, include) this Agreement in its U.S. Securities and Exchange Commission (&ldquo;<U>SEC</U>&rdquo;) filings; <U>provided</U>,
<U>however</U>, that Protalix shall give Pfizer sufficient advance notice of the text describing this Agreement in its filings
with the SEC so that Pfizer will have the opportunity to comment upon such description, and Protalix shall give due consideration
to any specific reasonable comments of Pfizer on such description timely received from Pfizer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 51; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>





<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-transform: uppercase; text-indent: -1in"><FONT STYLE="text-transform: none">Section
10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>REPRESENTATIONS, WARRANTIES AND COVENANTS</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">10.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Protalix
Representations, Warranties and Covenants</U></FONT>. Protalix hereby represents and warrants as of the Second Amendment Effective
Date (unless otherwise indicated) and covenants to Pfizer as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Protalix
has the corporate power and authority to execute and deliver this Agreement and to perform its obligations hereunder, and the
execution, delivery and performance of this Agreement by Protalix have been duly and validly authorized and approved by proper
corporate action on the part of Protalix, and Protalix has taken all other action required by Law, its certificate of incorporation,
by-laws or other organizational documents or any agreement to which it is a party or to which it may be subject, required to authorize
such execution, delivery and performance. Assuming due authorization, execution and delivery on the part of Pfizer, this Agreement
constitutes a legal, valid and binding obligation of Protalix, enforceable against Protalix in accordance with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
execution and delivery of this Agreement by Protalix and the performance by Protalix contemplated hereunder does not and will
not violate any Laws (as in effect on the Second Amendment Effective Date), except for such violations that would not have an
adverse effect on the ability of Protalix to perform its obligations under this Agreement, or any order of any court or Governmental
Authority in effect on the Second Amendment Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
the knowledge of Protalix, the Protalix Patent Rights owned by Protalix or its Affiliates are valid and enforceable and no Third
Party (i) is infringing any such Protalix Patent Rights or (ii) has challenged the validity or enforceability of the Protalix
Patent Rights owned by Protalix or its Affiliates (including by way of example through the institution or written threat of institution
of interference, nullity or similar invalidity proceedings before the United States Patent and Trademark Office or any analogous
foreign entity).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
the knowledge of Protalix, neither (i) the Manufacture, use or Development (including the use or provision of Licensed Product
in Early Access Programs) by Protalix (or its Affiliates) of the Drug Substance or Licensed Product on or prior to the Second
Amendment Effective Date has infringed nor (ii) the Manufacture, use, Development, sale, offer for sale, supply or importation
by Protalix or Pfizer (or their respective Affiliates) of the Drug Substance or Licensed Product (as currently constituted) on
or prior to the Second Amendment Effective Date or as contemplated by this Agreement has infringed or would infringe any issued
Patent of any Third Party that exists on the Second Amendment Effective Date or, if and when issued, any valid claim within any
Third Party Patent Application published before the Second Amendment Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 52; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Exhibit
B</U> contains a complete and correct list as of the Second Amendment Effective Date of all Patents and Patent Applications owned
by or otherwise Controlled by Protalix (and indicating which entity owns or Controls each Patent and Patent Application and which
are owned and which are Controlled) covering the Compound, any Licensed Product and the System.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Protalix
is the sole and exclusive owner of all the Protalix Patent Rights and Protalix Technology (other than Patent Rights licensed to
Protalix as described in <U>Exhibit B</U>), free of any lien, encumbrance, charge, security interest, mortgage or other similar
restriction, and no Person (including any Affiliate of Protalix) has any right, interest or claim in or to, and neither Protalix
nor any of its Affiliates has entered into any agreement granting any right, interest or claim in or to any Protalix Patent Rights
owned by Protalix or its Affiliates or Protalix Technology to any Third Party, including any academic organization or agency.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Protalix
has complied in all material respects with all applicable Laws, including any disclosure requirements, in connection with the
filing, prosecution and maintenance of the Protalix Patent Rights (other than Patent Rights licensed to Protalix) in the Territory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prior
to the Second Amendment Effective Date, to the extent such activities have been conducted by Protalix, its Affiliates or Third
Parties acting on behalf of Protalix, the Compound, Drug Substance and Licensed Product have been Developed, Manufactured, stored,
labeled, distributed and tested by Protalix and its Affiliates and, to the knowledge of Protalix, by any Third Parties acting
on behalf of Protalix, in compliance in all material respects with all applicable Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other
than Patent Rights licensed to Protalix as described in <U>Exhibit B</U>, none of the rights of Protalix or its Affiliates under
the Protalix Patent Rights were developed with federal funding from the United States government or any other Governmental Authority,
other than grants received by Protalix from the Office of the Chief Scientist of the Israeli Ministry of Industry, Trade and Labor
(the &ldquo;<U>Israel Grant</U>&rdquo;), a copy of which Protalix has provided to Pfizer prior to the Second Amendment Effective
Date. No obligations, restrictions or covenants have been imposed upon Protalix or its licensees, the Drug Substance or the Licensed
Product in connection with the Israel Grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Protalix
has obtained assignments from the inventors of all inventorship rights relating to the Protalix Patent Rights (other than Patent
Rights licensed to Protalix), and all such assignments of inventorship rights covering the Protalix Patent Rights (other than
Patent Rights licensed to Protalix) are valid and enforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 53; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
Third Party License as heretofore delivered by Protalix to Pfizer represents the complete agreement and understanding between
the Third Party licensor(s) under such Third Party License and Protalix relating to the Protalix Patent Rights and Protalix Technology
which are the subject of such Third Party License. No Third Party License has been modified, supplemented or amended, other than
by amendments thereto provided<U> </U>to Pfizer prior to the Second Amendment Effective Date. Except for the Third Party Licenses
listed on <U>Exhibit C</U>, there are no agreements to which Protalix or any of its Affiliates is a party pursuant to which Protalix
or any of its Affiliates has a license, or an option to obtain a license, or holds an immunity from suit, with respect to patents
which (i) are pending, applied for, granted or registered, and (ii) but for Protalix&rsquo;s rights under such agreements, could
be asserted by Third Parties to be infringed by the Manufacture, distribution, use, marketing or sale of the Drug Substance or
Licensed Product. Each Third Party License is in full force and effect, all payments to date required to be made thereunder by
Protalix have been made, and Protalix is in compliance in all respects with its respective obligations thereunder. [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Protalix
has previously delivered to Pfizer all of its material agreements with any Third Parties regarding the Development, supply and
Manufacture of all goods and services relating to the Drug Substance and Licensed Product to the extent requested by Pfizer, none
of which have been modified, supplemented or amended in any material respect, other than by amendments thereto provided<U> </U>to
Pfizer prior to the Second Amendment Effective Date. Each such agreement is in full force and effect, all payments to date required
to be made thereunder by Protalix have been made, and Protalix is in compliance in all respects with its respective obligations
thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Protalix
has heretofore disclosed to Pfizer all material scientific and technical information and all material information relating to
safety and efficacy known to it or its Affiliates with respect to the Drug Substance and Licensed Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Protalix
has heretofore disclosed to Pfizer all material correspondence and contact information between Protalix and the FDA and any other
Governmental Authorities regarding the Drug Substance or Licensed Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(o)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither
the execution and delivery of this Agreement nor the performance hereof by Protalix requires Protalix to obtain any permits, authorizations
or consents from any Governmental Authority or from any other Person, and such execution, delivery and performance will not result
in the breach of or give rise to any right of termination, rescission, renegotiation or acceleration under, or trigger any other
rights under, any agreement or contract to which Protalix is a party or to which it may be subject that relates to the Protalix
Patent Rights, Protalix Technology, Drug Substance or Licensed Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(p)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
is no action, claim, demand, suit, proceeding, arbitration, grievance, citation, summons, subpoena, inquiry or investigation of
any nature, civil, criminal, regulatory or otherwise, in law or in equity, pending or, to the knowledge of Protalix, threatened
against Protalix, any of its Affiliates or any Third Party, in each case in connection with the Protalix Patent Rights owned by
Protalix, Protalix Technology owned by Protalix, the Drug Substance, the Licensed Product, the System, Protalix&rsquo;s business
practices relating to the Drug Substance or the Licensed Product, Protalix&rsquo;s compliance with the Foreign Corrupt Practices
Act of 1977, as amended and the U.K. Bribery Act, or relating to the transactions contemplated by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 54; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(q)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
the knowledge of Protalix, information provided by Protalix in response to any of Pfizer&rsquo;s due diligence requests prior
to the Second Amendment Effective Date was in all material respects complete, truthful and accurate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(r)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Protalix
and, to Protalix&rsquo;s knowledge, any agent or subcontractor of Protalix engaged in activities related to this Agreement has
not and will not directly or indirectly offer or pay, or authorize such offer or payment, of any money or anything of value or
improperly seek to influence any Government Official or any other person in order to gain an improper advantage, and has not accepted,
and will not accept in the future such payment in connection with this Agreement. For purposes of this <U>Section 10.1</U>, a
&ldquo;<U>Government Official</U>&rdquo; is defined as and includes: (i) any elected or appointed government official (e.g., a
member of a ministry of health); (ii) any employee or person acting for or on behalf of a Government Official, agency, or enterprise
performing a governmental function; (iii) any political party, officer, employee, or person acting for or on behalf of a political
party or candidate for public office; (iv) an employee or person acting for or on behalf of a public international organization;
or (v) any person otherwise categorized as a Government Official under local Law where &ldquo;Government&rdquo; includes all levels
and subdivisions of non-U.S. governments (i.e., local, regional, or national and administrative, legislative, or executive).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(s)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
the knowledge of Protalix, all information provided by Protalix or its Affiliate to Pfizer during pre-contractual due diligence,
including the information provided in the compliance questionnaire (the &ldquo;<U>Compliance Questionnaire</U>&rdquo;), is in
all material respects complete, truthful and accurate. Further, Protalix undertakes to promptly update this representation and
warranty if (during the Term) Protalix, or any of its employees, or individuals, or subcontractors who will be primarily responsible
for performing under this Agreement, or a relative of such an employee or individual or subcontractor, becomes a Government Official
or, if a government or Government Official becomes an owner of five percent (5%) or more of Protalix.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(t)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Protalix
will comply in all material respects with Pfizer&rsquo;s Anti-Bribery and Anti-Corruption Principles set forth on <U>Appendix
10.1(t)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(u)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Protalix
will complete and submit to Pfizer an executed copy of the compliance certification attached hereto as <U>Exhibit K</U> on the
Second Amendment Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(w)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Protalix
has implemented, and will maintain, a system of internal accounting controls designed to ensure the making and keeping of fair
and accurate books, records, and accounts with respect to Protalix&rsquo;s business or any services provided under the Agreement,
as and to the extent required under <U>Section 4.8</U> and <U>Section 5.15</U> hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(x)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Protalix
undertakes to promptly inform Pfizer if it becomes aware of any compliance issues related to any allegations of improper payments
to healthcare professionals or Government Officials that have not been previously reported and related to any discussions, notices
or changes with respect to any investigation by Governmental Authorities or Regulatory Authorities or prosecution involving allegations
of corruption or serious criminal misconduct involving its business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 55; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(y)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Protalix
will, subject to and in accordance with <U>Section 5.15</U> hereof, permit, during the Supply Term and for [***] after final payment
has been made under the Agreement, Pfizer&rsquo;s internal and external auditors access to any relevant books, documents, papers,
and records of Protalix involving transactions related to the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(z)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;With
respect to the Commercialization of the Licensed Product in Israel, since January 1, 2015, Protalix has not (i) materially altered
its activities and practices with respect to inventory levels of the Licensed Product maintained at the wholesale, pharmacy or
institutional levels, including its practices with respect to product samples, or (ii) sold, transferred or given any supplies
or samples of the Licensed Product to any Third Party in or for use in Israel, in each case, except in the ordinary course of
business that is consistent with past practice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(aa)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">10.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Manufacturing
Representations, Warranties and Covenants</U></FONT>. Each party hereby represents and warrants as of the Second Amendment Effective
Date (unless otherwise stated) and covenants to the other party as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
Drug Substance and Licensed Product Manufactured and supplied hereunder by, or under authority of, such party shall be Manufactured
and supplied such that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
Facility and all equipment, tooling and molds utilized in the Manufacture and supply of Drug Substance and Licensed Product hereunder
by such party shall, during the Term, be maintained in good operating condition and shall be maintained and operated in accordance
with all applicable Laws. The Manufacturing and storage operations, procedures and processes utilized by such party in Manufacture
and supply of Drug Substance and Licensed Product hereunder (including any Facility) shall be in full compliance with all applicable
Laws, including GMP and health and safety Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Such
party shall perform all of its Manufacturing and supply obligations under this Agreement in full compliance with all applicable
Laws. Such party shall hold during the Term all licenses, permits and similar authorizations required by any Governmental Authority
for such party to perform its Manufacturing and supply obligations under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Drug Substance and Licensed Product, as applicable, furnished by such party [***]:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shall
be Manufactured, packaged, labeled, handled, stored and shipped in accordance with, shall be of the quality specified in, and
shall conform to, the Product Specifications;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shall
be Manufactured, packaged, labeled, handled, stored and shipped in compliance with all applicable Laws including GMP, and in accordance
with the Quality Agreement (with respect to Drug Substance and/or Licensed Product furnished by Protalix to Pfizer under this
Agreement) and any other quality assurance requirements provided in writing to such party by the other party, and this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 56; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shall
not contain any material that has not been used, handled or stored in accordance with the Product Specifications, all applicable
Laws, the Quality Agreement (with respect to Drug Substance and/or Licensed Product furnished by Protalix to Pfizer under this
Agreement) and any other quality assurance requirements of the other party or the supplier of such material, and this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shall
not contain any material that would cause the Drug Substance or Licensed Product to be adulterated or misbranded within the meaning
of any Laws;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shall
be free from defects in material and workmanship; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">(vi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shall,
at the time delivered, have a remaining shelf-life as specified in the Quality Agreement (with respect to Drug Substance and/or
Licensed Product furnished by Protalix to Pfizer under this Agreement) and <U>Section 5.8(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Such
party does not currently employ and will not employ during the Term, and such party does not use as a subcontractor and will not
use during the Term, and such party&rsquo;s subcontractors do not currently employ and will not employ or engage during the Term,
any Person that has been debarred or is subject to debarment or has otherwise been disqualified or suspended from performing scientific
or clinical investigations or otherwise subjected to any restrictions or sanctions by the FDA or any other Governmental Authority
or Regulatory Authority or professional body with respect to the performance of scientific or clinical investigations; any other
Person who by virtue of any Laws is or may be disqualified, restricted or prevented in any way from performing the services to
be <U>provided</U>&nbsp;under this Agreement; or any Person convicted of a criminal offense in relation to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
respect of a company, partnership or association, the development or approval, including the process for development or approval
of an abbreviated drug application;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
respect of an individual:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 1in">(A)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
development or approval of any drug product or otherwise relating to the regulation of any drug product; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 1in">(B)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;bribery,
payment of illegal gratuities, fraud, perjury, false statement, racketeering, blackmail, extortion, falsification or destruction
of records or interference with, obstruction of an investigation into a prosecution of any criminal offense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 57; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
the foregoing in this <U>Section 10.2</U>, Pfizer shall not be responsible for any failure to conform to the representations and
warranties under <U>Sections 10.2(a)</U> and <U>10.2(b)</U>, and shall have no liability to Protalix with respect thereto to the
extent that Pfizer&rsquo;s failure to conform to such representations and warranties is as a result of an act or omission of Protalix,
Protalix&rsquo;s Affiliates or their respective agents, consultants or contractors in respect of the Manufacture of Drug Substance.
Notwithstanding the foregoing in this <U>Section 10.2</U>, Protalix shall not be responsible for any failure to conform to the
representations and warranties under <U>Sections 10.2(a)</U> and <U>10.2(b)</U>, and shall have no liability to Pfizer with respect
thereto to the extent that Protalix&rsquo;s failure to conform to such representations and warranties is as a result of an act
or omission of Pfizer, Pfizer&rsquo;s Affiliates or their respective agents, consultants or contractors in respect of their Fill/Finish
activities or supply of Licensed Product to Protalix for Commercialization in Israel or in respect of the Drug Substance after
acceptance by Pfizer of the Drug Substance supplied to Pfizer, such as a failure to properly store the Drug Substance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">10.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Environmental
Representations, Warranties and Covenants</U></FONT>. Each party hereby represents and warrants as of the Second Amendment Effective
Date (unless otherwise indicated) and covenants to the other party as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Compliance
With Environmental Laws</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
the knowledge of such party, there is no pending or threatened governmental enforcement action or private claim against such party
pursuant to applicable Environmental Law, no Release or threatened Release of Hazardous Materials, nor any other existing environmental
conditions, events or circumstances that are reasonably likely to limit, impede or otherwise jeopardize such party&rsquo;s ability
to meet its Manufacturing obligations under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Such
party shall perform all of the Manufacturing services to be <U>provided</U>&nbsp;by it hereunder in compliance with all Environmental
Laws and all licenses, registrations, notifications, certificates, approvals, authorizations or permits required under applicable
Environmental Laws (&ldquo;<U>Environmental Permits</U>&rdquo;), except where such non-compliance would not be reasonably likely
to limit, impede or otherwise jeopardize such party&rsquo;s ability to meet its Manufacturing obligations under this Agreement.
Such party shall abate any condition or practice, regardless of whether such condition or practice constitutes non-compliance
with Environmental Laws, with respect to its usage, handling, storage or disposal of Hazardous Materials, that would be reasonably
likely to limit, impede or otherwise jeopardize such party&rsquo;s ability to fulfill its Manufacturing obligations under this
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notice
to Other Party</U>. Such party shall provide the other party with reasonably prompt notice in the event of any significant event,
occurrence or circumstance, including any governmental or private action in connection with such party&rsquo;s compliance with
applicable Environmental Laws or with respect to such party&rsquo;s usage, handling, storage or disposal of Hazardous Materials,
which would be reasonably likely to limit, impede or otherwise jeopardize such party&rsquo;s ability to fulfill its Manufacturing
obligations under this Agreement. These could include, but are not limited to: (i) material revocation or modification of any
of such party&rsquo;s Environmental Permits, (ii) any action by Governmental Authorities that may reasonably lead to the material
revocation or modification of such party&rsquo;s Environmental Permits, (iii) any Third Party claim against the management or
ownership of any Facility pursuant to applicable Environmental Law that could reasonably and materially impact such party&rsquo;s
obligations under this Agreement, (iv) any fire, explosion, significant accident (one causing serious injury or fatality), or
catastrophic Release of Hazardous Materials, (v) any significant non-compliance with Environmental Laws, and (vi) any environmental
condition or operating practice that may reasonably be believed to present a significant threat to human health, safety or the
environment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 58; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Equipment</U>.
Such party shall be solely responsible for the safe operation and maintenance of all equipment used to fulfill its Manufacturing
obligations under this Agreement, and all associated employee training, regardless of whether the equipment is owned by such party,
the other party or a Third Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Environmental,
Health and Safety Reviews</U>. Each party shall permit the other party reasonable access to conduct periodic reviews during regular
business hours of the environmental and health and safety practices and performance of the Facility(ies) where such party&rsquo;s
performance is occurring. In connection with such audit or evaluation, such party shall assist in the other party&rsquo;s completion
of an Environmental Health &amp; Safety survey of such party or the scheduling of an Environmental Health &amp; Safety audit of
any Facility, as applicable. Such party will provide copies of all Environmental Permits to the other party upon request in connection
with such review. The other party shall share its findings with such party as soon as practicable and such party shall correct,
at no expense to the other party, such deficiencies in its environmental and health and safety management practices that materially
jeopardize its ability to fulfill its Manufacturing obligations under this Agreement. Such party acknowledges that such reviews
and evaluations conducted by the other party are for the benefit of the other party only; they are not a substitute for such party&rsquo;s
own environmental and health and safety management obligations under this Agreement and accordingly, such party may not rely upon
them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">10.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Pfizer
Representations, Warranties and Covenants</U></FONT>. Pfizer hereby represents and warrants as of the Second Amendment Effective
Date (unless otherwise indicated) and covenants to Protalix as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pfizer
has the corporate power and authority to execute and deliver this Agreement and to perform its obligations hereunder, and the
execution, delivery and performance of this Agreement by Pfizer have been duly and validly authorized and approved by proper corporate
action on the part of Pfizer, and Pfizer has taken all other action required by Law, its certificate of incorporation or by-laws,
or any agreement to which it is a party or to which it may be subject, required to authorize such execution, delivery and performance.
Assuming due authorization, execution and delivery on the part of Protalix, this Agreement constitutes a legal, valid and binding
obligation of Pfizer, enforceable against Pfizer in accordance with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
execution and delivery of this Agreement by Pfizer and the performance by Pfizer contemplated hereunder does not and will not
violate any Laws, except for such violations that would not have an adverse effect on the ability of Pfizer to perform its obligation
under this Agreement, or any order of any court or Governmental Authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 59; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither
the execution and delivery of this Agreement nor the performance hereof by Pfizer requires Pfizer to obtain any permits, authorizations
or consents from any Governmental Authority (other than any Regulatory Approvals relating to the Manufacture, use, importation
or sale of the Compound or Licensed Product) or from any other Person, and such execution, delivery and performance will not result
in the breach of or give rise to any right of termination under any agreement or contract to which Pfizer is a party or to which
it may be subject, except for those breaches or rights that would not adversely affect the ability of Pfizer to perform its obligations
under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
is no action, claim, demand, suit, proceeding, arbitration, grievance, citation, summons, subpoena, inquiry or investigation of
any nature, civil, criminal, regulatory or otherwise, in law or in equity, pending or, to the knowledge of Pfizer, threatened
against Pfizer or any of its Affiliates or any Third Party relating to the transactions contemplated by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">10.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Disclaimer
of Warranty</U></FONT>. EXCEPT AS OTHERWISE EXPRESSLY STATED IN THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATION OR WARRANTY
OF ANY KIND WITH RESPECT TO THE COMPOUND, DRUG SUBSTANCE, ANY LICENSED PRODUCT, PROTALIX IMPROVEMENT, PROTALIX PATENT RIGHTS,
PROTALIX TECHNOLOGY OR CONFIDENTIAL INFORMATION. EXCEPT AS OTHERWISE EXPRESSLY STATED IN THIS AGREEMENT, EACH PARTY EXPRESSLY
DISCLAIMS ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-transform: uppercase; text-indent: -1in"><FONT STYLE="text-transform: none">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-transform: uppercase; text-indent: -1in"><FONT STYLE="text-transform: none">Section
11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>ADDITIONAL COVENANTS</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">11.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Restrictions
on Transfers and Liens</U></FONT>. Protalix shall not (and shall cause its Affiliates not to) sell, assign or otherwise transfer
to any Person any Protalix Patent Rights or any Protalix Technology (or agree to do any of the foregoing), except to the extent
permitted by, and in compliance with, <U>Section 18.6</U> (including, for the avoidance of doubt, to any permitted assignee of
the Agreement permitted by and in compliance with <U>Section 18.6</U>). In addition, Protalix hereby covenants and agrees that
Protalix shall not incur or permit to exist (and shall cause each of its Affiliates not to incur or permit to exist), with respect
to any Protalix Patent Rights owned by Protalix and/or Protalix Technology owned by Protalix, any lien, encumbrance, charge, security
interest, mortgage, liability, grant of license to Third Parties in the Field in the Territory or other restriction (including
in connection with any indebtedness). For purposes of clarity, this <U>Section 11.1</U> is not intended to prohibit Protalix from
(i) licensing to an Affiliate of Protalix or a Third Party rights under any Protalix Patent Rights or any Protalix Technology
to the extent such rights have not been licensed to Pfizer pursuant to this Agreement and to the extent such license by Protalix
does not otherwise conflict with the terms of this Agreement, or (ii) otherwise entering into any collaboration, license, assignment
or other commercial agreement with a Third Party with respect to the Protalix Patents or Protalix Technology in relation to any
products (excluding the Licensed Product) outside of the Field.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 60; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">11.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Third
Party Licenses and Agreements</U></FONT>. Protalix (a) shall not execute or otherwise permit, and shall cause its Affiliates to
refrain from executing or otherwise permitting, any amendment, modification or waiver to any of the Third Party Licenses without
the prior written consent of Pfizer, (b) shall not make any election or exercise any right or option (or omit to take any action)
which would, and shall cause its Affiliates to refrain from making any election or exercising any right or option (or omitting
to take any action) which would, terminate or relinquish in whole or in part any right under a Third Party License, (c) shall
comply, and shall cause its Affiliates to comply in all respects, with all of its, and its Affiliates&rsquo;, obligations under
the Third Party Licenses, (d) shall take, and shall cause its Affiliates to take, such actions as shall be necessary to keep in
full force and effect the Third Party Licenses, and (e) shall give prompt notice to Pfizer, together with a detailed summary of
outstanding issues if Pfizer so requests, of any notice received from the Third Party, of any actual or alleged defaults, breaches,
violations, proposed amendments or proposed modifications of, or any proposed waivers under, any of the Third Party Licenses by
any of the parties thereto. Protalix shall not assign or otherwise transfer any Third Party License or any of its rights or obligations
thereunder to any Person (or agree to do any of the foregoing) except to the extent permitted by, and in compliance with, <U>Section
18.6</U>. This <U>Section 11.2</U> shall apply to the [***] to the same extent it applies to a Third Party License.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">11.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Compliance
with Laws</U></FONT>. Each of Protalix and Pfizer shall conduct, and shall use reasonable efforts to cause its Affiliates to conduct,
all its activities contemplated under this Agreement in accordance with all applicable Laws of the Country in which such activities
are conducted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">11.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Coordination
outside the Territory</U></FONT>. Protalix and its Affiliates shall not, unless required by applicable Law, (a) conduct, or consent
to or support any activities by a Third Party, with respect to the Licensed Product in the Field outside the Territory (including
investigator-initiated research) if, in the good faith and reasonable judgment of Protalix, such activities would reasonably be
expected to adversely impact the market for the Licensed Product in the Field in the Territory in any material respect, or (b)
make any revisions to the labeling for the Licensed Product in the Field outside the Territory without first discussing such activities
with Pfizer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">11.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Protalix
Non-Compete</U></FONT>. From the Second Amendment Effective Date until the earlier of (a) the effective date of termination of
this Agreement or (b) the [***] anniversary of the Second Amendment Effective Date, neither Protalix nor any of its Affiliates
shall, directly or indirectly, alone or in collaboration with any Third Party, Commercialize in any Country in the Territory any
Competing Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">11.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Limitation
on Non-Compete Restrictions</U></FONT>. Notwithstanding anything to the contrary herein, neither Protalix nor any of its Affiliates
will be deemed to be in breach of the restrictions set forth in <U>Section 11.5</U>, if Protalix or any of its Affiliates undergoes
[***] (and such Commercialization shall not be deemed to be a breach of <U>Section 11.5</U>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">11.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">11.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">11.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***]</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-transform: uppercase; text-indent: -1in"><FONT STYLE="text-transform: none">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-transform: uppercase; text-indent: -1in"><FONT STYLE="text-transform: none">Section
12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>[Reserved.]</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-transform: uppercase; text-indent: -1in"><FONT STYLE="text-transform: none">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-transform: uppercase; text-indent: -1in"><FONT STYLE="text-transform: none">Section
13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>TERM</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This Agreement shall be effective as of
the Second Amendment Effective Date and shall remain in effect until the later of (i) the end of the term of the last to expire
of the Protalix Patent Rights and (ii) the expiration of the Supply Term, unless earlier terminated pursuant to <U>Section 14
</U>(the &ldquo;<U>Term</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 61; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: none">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-transform: uppercase; text-indent: -1in"><FONT STYLE="text-transform: none">Section
14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>TERMINATION</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">14.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Pfizer
Termination Right for Convenience</U></FONT>. At any time and for any reason, Pfizer shall have the right, at Pfizer&rsquo;s sole
discretion, to terminate this Agreement in its entirety, or with respect to a particular Country or Countries within the Territory,
such termination to be effective upon thirty (30) days prior written notice to Protalix.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">14.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Pfizer
Termination Right for Breach</U></FONT>. If Protalix materially breaches or materially defaults in the performance or observance
of any of its obligations under this Agreement related to the Manufacture of the Drug Substance (including a Failure to Supply)
or a violation of any applicable anti-corruption law, and such breach or default is not cured within ninety (90) days after Pfizer
provides Protalix with written notice specifying such breach or default, then, in addition to all other remedies available at
law or in equity, Pfizer shall have the right to terminate this Agreement by providing Protalix written notice within ten (10)
days following the expiration of such ninety (90)-day period (such termination to be effective upon receipt of such notice). For
the avoidance of doubt, and notwithstanding the foregoing, a breach of <U>Section 10.1(r)</U> shall be considered a material breach
for purposes of this <U>Section 14.2</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">14.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Protalix
Right of Termination</U>. Protalix shall have no right to terminate this Agreement for any reason other than as set forth in this
<U>Section 14.3</U>. If Pfizer materially breaches or materially defaults in the performance or observance of any of its obligations
under this Agreement, and such breach or default is not cured within ninety (90) days after Protalix provides Pfizer with written
notice specifying such breach or default, then Protalix shall have the right to terminate this Agreement by providing Protalix
written notice within ten (10) days following the expiration of such ninety (90)-day period (such termination to be effective upon
receipt). For purposes of this <U>Section 14.3</U>, material breaches or material defaults in the performance or observance of
any of Pfizer&rsquo;s obligations under this Agreement (for which a termination right may be triggered if such breach is not cured
as set forth above) shall be limited to: (i) Pfizer&rsquo;s failure to pay the Price for the Drug Substance in accordance with
the terms of this Agreement and such failure to pay is not being disputed in good faith; and (ii) Pfizer&rsquo;s breach of <U>Section
3.7</U>.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">14.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Continuing
and Accrued Obligations and Surviving Provisions</U></FONT>. Termination of this Agreement for any reason (i) shall be without
prejudice to and shall not impair or limit in any manner (A) Protalix&rsquo;s right to receive any payment from Pfizer that accrued
in accordance with this Agreement prior to the effective date of such termination, including for any Drug Substance ordered by
Pfizer pursuant to this Agreement prior to the effective date of such termination, whether or not the due date for such payment
is after such effective date of termination, (B) Pfizer&rsquo;s right to receive the Protalix Payment from Protalix, which such
payment to be made in accordance with <U>Section 14.5(b)</U>, and any payment from Protalix that accrued pursuant to this Agreement
prior to the effective date of such termination (subject to the last two sentences of Section 5.21(b)(i)) and (C) any remedies
that either party may have and (ii) shall not release a party hereto from any indebtedness, liability, payment or other obligation
incurred hereunder (including liability for breach of this Agreement) by such party prior to the effective date of termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 62; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">14.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Effects
of Termination or Expiration</U></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>License
Grants</U>. The licenses granted to Pfizer under <U>Section 3.1</U> shall be perpetual and irrevocable such that the expiration
or termination of this Agreement for any reason shall not affect or limit any of the rights granted thereunder. Upon the effective
date of termination of this Agreement in accordance with this <U>Section 14</U>, except as otherwise provided in <U>Section 14.4</U>,
this <U>Section 14.5</U>, and <U>Section 18.4</U>, all other licenses and rights provided for herein, and all obligations of the
parties hereunder, shall terminate and this Agreement shall cease to be of further force or effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Deferred
Payment</U>. If the Agreement is terminated by Pfizer pursuant to <U>Section 14.1</U> or by Protalix pursuant to <U>Section 14.3
</U>before Protalix has made the Protalix Payment, Protalix shall pay to Pfizer the Protalix Payment in accordance with <U>Section
6.2</U>. If the Agreement is terminated by Pfizer pursuant to <U>Section 14.2</U>, Protalix shall pay to Pfizer the Protalix Payment
within thirty (30) days following the effective date of termination of this Agreement as provided in the Promissory Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Confidential
Information</U>. Following any termination of this Agreement, each of Pfizer and Protalix shall, upon request of the other party,
return or destroy all Protalix Confidential Information and Pfizer Confidential Information, respectively, disclosed to it pursuant
to this Agreement, including all copies and extracts of documents, as promptly as practicable following receipt of such request,
except (i) that one (1) copy may be kept for the purpose of complying with continuing obligations under this Agreement and (ii)
to the extent and for so long as necessary to perform its obligations or exercise its rights under this <U>Section 14.5</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">14.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Bankruptcy</U></FONT>.
All rights and licenses granted under or pursuant to this Agreement by Protalix are, and shall otherwise be deemed to be, for
purposes of Section 365(n) of the U.S. Bankruptcy Code, licenses of rights to &ldquo;intellectual property&rdquo; as defined under
Section 101 of the U.S. Bankruptcy Code. The parties agree that Pfizer, as the licensee of intellectual property under this Agreement,
shall retain and may fully exercise all of its rights and elections under the U.S. Bankruptcy Code. Without limiting the foregoing,
Section 365(n) shall apply to any case commenced under Chapter 15 of the U.S. Bankruptcy Code and, if the foreign representative
in such a case rejects or repudiates rights of licenses granted under or pursuant to this Agreement, Pfizer shall be entitled
to make the election and exercise the rights described in Section 365(n). The parties further agree that, in the event of a rejection
of this Agreement by Protalix in any bankruptcy proceeding by or against Protalix under the U.S. Bankruptcy Code or rejection
or repudiation by a foreign representative in a foreign bankruptcy proceeding, (a) Pfizer shall be entitled to a complete duplicate
of (or complete access to, as appropriate) any such intellectual property and all embodiments of such intellectual property, which,
if not already in the possession of the licensee, shall be promptly delivered to it upon Pfizer&rsquo;s written request therefor,
and (b) Protalix shall not interfere with Pfizer&rsquo;s rights to intellectual property and all embodiments of intellectual property,
and shall assist and not interfere with Pfizer in obtaining intellectual property and all embodiments of intellectual property
from another entity. The term &ldquo;embodiments&rdquo; of intellectual property includes all tangible, intangible, electronic
or other embodiments of rights and licenses hereunder, including all compounds and products embodying intellectual property, Licensed
Products, regulatory filings, clinical studies and related rights, and Technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 63; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-transform: uppercase; text-indent: -1in"><FONT STYLE="text-transform: none">Section
15.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>INDEMNIFICATION AND INSURANCE</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">15.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Indemnification</U></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Protalix
will indemnify, defend and hold Pfizer and Pfizer&rsquo;s Affiliates, and their respective directors, officers and employees harmless
from and against all Third Party Claims (defined in <U>Section 15.3</U> below) and associated Losses, in each case to the extent
arising out of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
breach of any covenant, warranty or representation made by Protalix under this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
negligence, recklessness, or willful misconduct of, or violation of law by, Protalix or any of its Affiliates;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any
acts or omissions of Protalix or any of its Affiliates, agents, consultants or contractors (A) in connection with the research,
Development, Manufacture or Commercialization of the Drug Substance or Licensed Product prior to the Effective Date, (B) in connection
with the research, Development, Manufacture (including Fill/Finish) or Commercialization of the Drug Substance or Licensed Products
in Brazil following the Amendment Effective Date, (C) in connection with the research, Development, Manufacture (including Fill/Finish)
or Commercialization of the Drug Substance or Licensed Product prior to the Second Amendment Effective Date and during the Israel
Transition Period or (D) in connection with the Manufacture of the Drug Substance for supply to Pfizer pursuant to<FONT STYLE="color: #1F497D">
</FONT><U>Section 5</U>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A)
any claim made by an [***] against Pfizer for any consideration allegedly owed to an [***] in connection with Commercialization
of the Licensed Product in Brazil, or the Technology Transfer Agreement, or (B) any inquiry, investigation, litigation or proceeding
by a governmental authority or Third Party regarding any ATME Person in connection with the Commercialization of the Licensed
Product in Brazil by Protalix, the Technology Transfer Agreement, or any other actions of an ATME Person on behalf of Protalix;
or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any
and all claims asserted by [***] against any Pfizer Indemnified Party with respect to the Drug Substance, the Licensed Product
[***], including any claims of infringement or misappropriation or for royalties, milestone payments, license fees or other payments
due thereunder, in relation to Pfizer&rsquo;s exercise (in accordance with this Agreement) of the license granted hereunder to
Pfizer under the Protalix Patent Rights licensed by Protalix from VTIP [***]; provided however, Protalix shall not indemnify,
defend and hold Pfizer harmless to extent any such claim asserted by [***] relates to [***] intellectual property that has not
been licensed to Protalix under the [***]. For the avoidance of doubt, (a) in no event shall Pfizer be responsible for any royalties,
milestone payments, license fees or other payments payable to VTIP under the [***], and (b) Protalix shall be solely responsible
to [***] for any amounts owed to [***] under the [***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 64; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Protalix shall be obligated to so indemnify, defend and hold
Pfizer harmless only to the extent that such Losses (i) do not arise from the negligence, recklessness or willful misconduct of
Pfizer and (ii) are not Losses as to which Protalix is entitled to indemnification pursuant to <U>Section 15.1(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pfizer
will indemnify, defend and hold Protalix, its Affiliates, and their respective directors, officers and employees harmless from
and against all Third Party Claims and associated Losses, to the extent arising out of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
breach of any covenant, warranty or representation made by Pfizer under this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
negligence, recklessness, or willful misconduct of, or violation of law by, Pfizer or any of its Affiliates; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A)
any acts or omissions of Pfizer or any of its Affiliates, agents, consultants or contractors in connection with the research,
Development, Manufacture (including Fill/Finish) or Commercialization of the Drug Substance or Licensed Product in the Field inside
the Territory (other than Israel or Brazil) after the Effective Date, (B) any acts or omissions of Pfizer or any of its Affiliates,
agents consultants or contractors in connection with the research, Development, Manufacture (including Fill/Finish) or Commercialization
of the Drug Substance or Licensed Product in the Field in Brazil prior to the Amendment Effective Date, or (C) any acts or omissions
of Pfizer or any of its Affiliates, agents, consultants or contractors in connection with the research, Development, Manufacture
(including Fill/Finish) or Commercialization of the Drug Substance or Licensed Product in the Field in Israel after the Israel
Transition Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pfizer shall be obligated to so indemnify, defend and hold
Protalix harmless only to the extent that such Losses (i) do not arise from the negligence, recklessness or willful misconduct
of Protalix and (ii) are not Losses as to which Pfizer is entitled to indemnification pursuant to <U>Section 15.1(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">15.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Losses</U></FONT>.
For purposes of this Agreement, &ldquo;<U>Losses</U>&rdquo; means any and all damages (including all incidental, consequential,
statutory and treble damages), awards, deficiencies, settlement amounts, defaults, assessments, fines, dues, penalties, costs,
fees, liabilities, obligations, taxes, liens, losses and expenses incurred by or awarded to Third Parties with respect to a Third
Party Claim by reason of any judgment, order, decree, stipulation or injunction, or any settlement entered into, and all other
documented costs and expenses incurred in investigating, preparing or defending any Third Party Claim litigation or proceeding,
commenced or threatened, or in complying with any judgments, orders, decrees, stipulations and injunctions (including court costs,
interest and reasonable fees of attorneys, accountants and other experts).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 65; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">15.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Defense
Procedures; Procedures for Third Party Claims</U></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
purposes of this Agreement, &ldquo;<U>Third Party Claim</U>&rdquo; means a claim asserted by a Third Party (in no event to include
any Affiliate of either party) against a party or any of its Affiliates, or any of their respective directors, officers and employees.
In the event a Third Party Claim is asserted with respect to any matter for which a party or any of its Affiliates, or any of
their respective directors, officers and employees (the &ldquo;<U>Indemnified Party</U>&rdquo;) is entitled to indemnification
hereunder, then the Indemnified Party shall promptly notify in writing the party obligated to indemnify the Indemnified Party
(the &ldquo;<U>Indemnifying Party</U>&rdquo;) thereof; <U>provided</U>, <U>however</U>, that no delay on the part of the Indemnified
Party in notifying the Indemnifying Party shall relieve the Indemnifying Party from any obligation hereunder unless (and then
only to the extent that) the Indemnifying Party is prejudiced thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Indemnifying Party shall assume direction and control of the defense, litigation, settlement, appeal or other disposition of the
Third Party Claim (including the right to settle the claim solely for monetary consideration) with counsel selected by the Indemnifying
Party and reasonably acceptable to the Indemnified Party. The Indemnified Party shall have the right to join in (including the
right to conduct discovery, interview and examine witnesses and participate in all settlement conferences), but not control, at
its own expense, the defense of any Third Party Claim that the Indemnifying Party is defending as <U>provided</U>&nbsp;in this
Agreement. Notwithstanding anything to the contrary contained herein, an Indemnified Party shall be entitled to assume the defense
of any Third Party Claim with respect to the Indemnified Party, upon written notice to the Indemnifying Party, in which case the
Indemnifying Party shall be relieved of liability under <U>Section 15.1</U>, as applicable, solely for such Third Party Claim
and related Losses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither
party will enter into any settlement of any suit involving Licensed Products that materially affects the other party&rsquo;s rights
or obligations with respect to the Licensed Product without the other party&rsquo;s prior written consent. Without limiting the
foregoing, the Indemnifying Party shall not, without the written consent of the Indemnified Party (which consent shall not be
unreasonably withheld), effect any settlement of any pending or threatened litigation in which the Indemnified Party has sought
indemnification hereunder by the Indemnifying Party, unless such settlement involves solely monetary damages and includes an unconditional
release of the Indemnified Party from all liability on claims that are the subject matter of such litigation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">15.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Disclaimer
of Liability for Consequential Damages</U>. IN NO EVENT SHALL EITHER PARTY OR ANY OF ITS RESPECTIVE AFFILIATES BE LIABLE UNDER
THIS AGREEMENT FOR SPECIAL, INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES, WHETHER IN CONTRACT, WARRANTY, TORT, NEGLIGENCE, STRICT
LIABILITY OR OTHERWISE, INCLUDING LOSS OF PROFITS OR REVENUE, SUFFERED BY PFIZER, PROTALIX OR ANY OF THEIR RESPECTIVE AFFILIATES,
EXCEPT TO THE EXTENT THE DAMAGES RESULT FROM A PARTY&rsquo;S WILLFUL MISCONDUCT OR INTENTIONAL BREACH OF ITS OBLIGATIONS UNDER
THIS AGREEMENT AND EXCEPT FOR ANY PERSISTENT FAILURE TO SUPPLY PAYMENTS AS EXPRESSLY PROVIDED IN <U>SECTION 5.21</U>. THE FOREGOING
SENTENCE SHALL NOT LIMIT THE OBLIGATIONS OF EITHER PARTY TO INDEMNIFY THE OTHER PARTY FROM AND AGAINST THIRD PARTY CLAIMS UNDER
<FONT STYLE="text-transform: uppercase"><U>Section 15</U></FONT> OR LIABILITIES RESULTING FROM A BREACH OF THE CONFIDENTIALITY
OBLIGATIONS UNDER <FONT STYLE="text-transform: uppercase"><U>Section </U></FONT><U>9</U> ABOVE AND PROVIDED<U> </U>THAT THIS <U>SECTION
15.4</U> SHALL NOT RELIEVE EITHER PARTY FROM ITS PAYMENT OBLIGATIONS UNDER THIS AGREEMENT.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 66; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">15.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Sole
Remedy</U></FONT>. EXCEPT AS EXPRESSLY PROVIDED<U> </U>IN THIS AGREEMENT AND EXCEPT FOR ANY EQUITABLE REMEDIES THAT MAY BE AVAILABLE
TO A PARTY, INDEMNIFICATION PURSUANT TO <FONT STYLE="text-transform: uppercase"><U>Section 15</U> </FONT>SHALL BE THE SOLE AND
EXCLUSIVE REMEDY (WHETHER BASED ON CONTRACT, TORT OR ANY OTHER LEGAL THEORY) AVAILABLE TO PROTALIX OR PFIZER FOR THE MATTERS COVERED
THEREIN.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">15.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Insurance
Requirements</U></FONT>. As of the Second Amendment Effective Date, Protalix shall provide and maintain such insurance coverage,
in minimum types and amounts as described in <U>subsection (b)</U> below. As of the Second Amendment Effective Date, Pfizer shall
self insure or provide and maintain such insurance coverage, in minimum types and amounts as described in <U>subsection (d)</U>
below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Protalix
Insurance Generally</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
and all deductibles for Protalix&rsquo;s insurance policies (the &ldquo;<U>Protalix Insurance Policies</U>&rdquo;) shall be assumed
by, for the account of, and at Protalix&rsquo;s sole risk. All deductibles and self-insured retention amounts shall be assumed
by Protalix.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Such
Protalix Insurance Policies shall be primary and non-contributing with respect to any other similar insurance policies available
to Pfizer or its Affiliates. Except for employers&rsquo; liability and property insurance policies, Protalix will add Pfizer and
its Affiliates on all such Protalix Insurance Policies as additional insureds with respect to liability incurred by Pfizer or
its Affiliates arising from any acts or omissions of Protalix, and Protalix will require that the property insurance policy included
in the Protalix Insurance Policies include a waiver of subrogation in favor of Pfizer and its Affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prior
to the Second Amendment Effective Date, Protalix has provided Pfizer with original certificates and additional insurance endorsements
evidencing the specified insurance coverage, and at each renewal thereof or expiration of any one coverage, whichever occurs first,
Protalix shall furnish to Pfizer original certificates and additional insurance endorsements evidencing the specified insurance
coverage. Such certificates shall provide that not less than thirty (30) days prior written notice of any policy cancellation
or detrimental change shall be given to Pfizer. The certificate(s) of insurance shall be signed by a person authorized by the
insurer(s) to bind coverage on its (their) behalf. Protalix shall provide, pay for, and maintain in effect, the Protalix Insurance
Policies with a minimum &ldquo;A-&rdquo; A.M. Bests rating or S&amp;P minimum of BBB or their substantial equivalent (in the case
of such policies in Israel, to the extent such ratings or substantial equivalents are available).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 67; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Protalix
Insurance Requirements</U>. The insurance required under <U>subsection (a)</U> shall be written for not less than any limits of
liability specified herein or as required by law, whichever is greater; Protalix has the right to provide the total limits required
by any combination of primary and excess/umbrella coverage; said Protalix insurance to include, without limitation, the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Insurance
for liability applicable with respect to persons performing the work hereunder and employer&rsquo;s liability insurance covering
all claims by or in respect to the employees of Protalix and all subcontractors, providing:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Employer&rsquo;s
liability insurance with a limit of the greater of the equivalent of [***] for each occurrence and in the aggregate in the Protalix
Insurance Policies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Commercial
General/Public Liability insurance with the following limits and forms/endorsements:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 1in">(A)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
occurrence and in the aggregate: [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 1in">(B)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Clinical
Trials Coverage or Products &amp; Completed Operations Aggregate once products are marketed: $[***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 1in">(C)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pfizer
and its Affiliates as additional insureds with respect to any legal liability of Pfizer or its Affiliates, arising out of Protalix&rsquo;s
performance hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If Protalix has care, custody or control of Pfizer property
or inventory, Protalix shall be responsible for any loss or damage to it, and provide all risk property coverage included within
the Protalix Insurance Policies at full replacement cost for same.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Pfizer
Insurance Generally</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
and all deductibles for Pfizer&rsquo;s insurance policies (the &ldquo;<U>Pfizer Insurance Policies</U>&rdquo;) shall be assumed
by, for the account of, and at Pfizer&rsquo;s sole risk.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
the extent of its negligence, such Pfizer Insurance Policies shall be primary and non-contributing with respect to any other similar
insurance policies available to Protalix or its Affiliates. Except for workers compensation/employers&rsquo; liability, Pfizer
will add Protalix and its Affiliates, as additional insureds, and Pfizer will require that the Pfizer Insurance Policies provide
a waiver of subrogation in favor of Protalix and its Affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prior
to the Second Amendment Effective Date of the Agreement and, at Protalix&rsquo;s request, at each renewal thereof or expiration
of any one coverage, whichever occurs first, Pfizer shall furnish to Protalix original certificates evidencing the specified insurance
coverage. Such certificates shall provide that not less than thirty (30) days prior written notice of any policy cancellation
or detrimental change shall be given to Protalix. The certificate(s) of insurance shall be signed by a person authorized by the
insurer(s) to bind coverage on its (their) behalf. Pfizer<B> </B>shall provide, pay for, and maintain in effect the Pfizer Insurance
Policies with minimum &ldquo;A-&rdquo; A.M. Bests rated insurance carriers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 68; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Pfizer
Insurance Requirements</U>. The insurance required under <U>subsection (c)</U> shall be written for not less than any limits of
liability specified herein or as required by law, whichever is greater; Pfizer has the right to provide the total limits required
by any combination of self insurance, primary and excess/umbrella coverage; said Pfizer Insurance to include, without limitation,
the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Insurance
for liability under the workers&rsquo; compensation or occupational disease laws of any state or other jurisdiction in which Pfizer
performs activities pursuant to this Agreement (or be a qualified self-insurer in those states and jurisdictions) or otherwise
applicable with respect to persons performing hereunder and employer&rsquo;s liability insurance covering all claims by or in
respect to the employees of Pfizer, providing:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in">Employer&rsquo;s liability insurance with a limit of
[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Commercial
General Liability insurance with the following limits and forms/endorsements:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 1in">(A)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
occurrence: [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 1in">(B)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Products
&amp; Completed Operations Aggregate: [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 1in">(C)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Protalix
and its Affiliates as additional insureds with respect to any legal liability of Protalix or its Affiliates, arising out of Pfizer&rsquo;s
performance hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Umbrella
(Excess) Liability Coverage (follow form) in an amount not less than [***] per occurrence.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-transform: uppercase; text-indent: -1in"><FONT STYLE="text-transform: none">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-transform: uppercase; text-indent: -1in"><FONT STYLE="text-transform: none">Section
16.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>[RESERVED.]</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-transform: uppercase; text-indent: -1in"><FONT STYLE="text-transform: none">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-transform: uppercase; text-indent: -1in"><FONT STYLE="text-transform: none">Section
17.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>GOVERNING LAW AND JURISDICTION</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">17.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Governing
Law</U></FONT>. This Agreement shall be governed by and construed in accordance with the substantive laws of the State of New
York, without regard to conflicts of law rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 69; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">17.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Jurisdiction</U></FONT>.
In the event of any controversy, claim or counterclaim arising out of or relating to this Agreement, the parties shall first attempt
to resolve such controversy or claim through good faith negotiations for a period of not less than thirty (30) days following
notification of such controversy or claim to the other party. If such controversy or claim cannot be resolved by means of such
negotiations during such period, then such controversy or claim shall be resolved by the United States District Court for the
Southern District of New York or, in the event federal subject matter jurisdiction is lacking, a New York State court sitting
in New York, New York (the &ldquo;<U>Court</U>&rdquo;). Each party (a) irrevocably submits to the exclusive jurisdiction of the
Court for purposes of any action, suit or other proceeding relating to or arising out of this Agreement and (b) agrees not to
raise any objection at any time to the laying or maintaining of the venue of any such action, suit or proceeding in the Court,
irrevocably waives any claim that such action, suit or other proceeding has been brought in an inconvenient forum and further
irrevocably waives the right to object, with respect to such action, suit or other proceeding, that the Court does not have any
jurisdiction over such party. The provisions of the U.N. Convention on Contracts for the International Sale of Goods shall not
apply to this Agreement. Protalix hereby irrevocably designates, appoints and empowers CT Corporation System, 111 Eighth Avenue,
New York, NY&nbsp; 10011, as its true and lawful agent and attorney-in-fact in its name, place and stead to receive and accept
on its behalf service of process in any action, suit or proceeding in the Court with respect to any matters as to which it has
submitted to jurisdiction as set forth in the immediately preceding sentence.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-transform: uppercase; text-indent: -1in"><FONT STYLE="text-transform: none">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-transform: uppercase; text-indent: -1in"><FONT STYLE="text-transform: none">Section
18.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>MISCELLANEOUS</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">18.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Force
Majeure</U></FONT>. Neither party hereto shall be liable to the other party for any losses or damages attributable to a default
under or breach of this Agreement that is the result of war (whether declared or undeclared), acts of God, revolution, acts of
terror, fire, earthquake, flood, pestilence, riot, enactment or change of Law (following the Second Amendment Effective Date),
accident(s), labor trouble, shortage of or inability to obtain material equipment or transport or any other cause beyond the reasonable
control of such party (each, a &ldquo;<U>Force Majeure Event</U>&rdquo;); <U>provided</U>&nbsp;that if such a cause occurs, then
the party affected will promptly notify the other party of the nature and likely result and duration (if known) of such cause
and use its Commercially Reasonable Efforts to avoid or remove such causes of nonperformance as soon as is reasonably practicable.
Upon termination of the Force Majeure Event, the performance of any suspended obligation or duty shall promptly recommence. If
the event lasts for a period of longer than one (1) month, the parties shall meet and work diligently to implement appropriate
remedial measures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">18.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Severability</U></FONT>.
If and solely to the extent that any provision of this Agreement shall be invalid or unenforceable, or shall render this entire
Agreement to be unenforceable or invalid, such offending provision shall be of no effect and shall not affect the enforceability
or validity of the remainder of this Agreement or any of its provisions; <U>provided,</U>&nbsp;<U>however</U>, the parties shall
use their respective reasonable efforts to mutually agree to replace the invalid provisions in a manner that best accomplishes
the original intentions of the parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">18.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Waivers</U></FONT>.
Any term or condition of this Agreement may be waived at any time by the party that is entitled to the benefit thereof, but no
such waiver shall be effective unless set forth in a written instrument duly executed by or on behalf of the party waiving such
term or condition. Neither the waiver by any party of any term or condition of this Agreement nor the failure on the part of any
party, in one or more instances, to enforce any of the provisions of this Agreement or to exercise any right or privilege, shall
be deemed or construed to be a waiver of such term or condition for any similar instance in the future or of any subsequent breach
hereof. All rights, remedies, undertakings, obligations and agreements contained in this Agreement shall be cumulative and none
of them shall be a limitation of any other remedy, right, undertaking, obligation or agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 70; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">18.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Entire
Agreements; Amendments</U></FONT>. This Agreement, together with the Quality Agreement(s), sets forth the entire agreement and
understanding between the parties as to the subject matter hereof and supersedes all agreements or understandings, verbal or written,
made between Protalix and Pfizer before the Second Amendment Effective Date with respect to the subject matter hereof, including
the Confidential Disclosure Agreement between the parties, dated June 11, 2009 and the Amended Agreement, except as otherwise
provided in <U>Section 6.4</U>. <B><I> </I></B>All Confidential Information disclosed by either party to the other party prior
to the Second Amendment Effective Date will be deemed to have been disclosed pursuant to this Agreement. None of the terms of
this Agreement shall be amended, supplemented or modified except in writing signed by the parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">18.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Survival</U>.
The provisions of <U>Section 3.1</U> (Exclusive License), <U>Section 3.3</U> (Non-Assertion of Rights), <U>Section 3.4</U> (Sublicensing
and Subcontracting), <U>Section 3.6(a)</U> (No Implied License; Brazil Activities), <U>Section 4.1(f)</U> (Assignment of Contracts),
<U>Section 4.1(g)(i)</U> (Responsibility), <U>Section 4.1(l)</U> (Recalls or Other Corrective Action), <U>Section 4.2(a)</U> (Commercialization
and Pricing), <U>Section 4.4</U> (Pfizer Trademarks), <U>Section 4.5</U> (Use of Names), <U>Section 5.15</U> (Records and Audits),
<U>Section 5.21(f)</U> (Damages), <U>Section 5.23</U> (Manufacturing Transition Assistance), <U>Section 6.2</U> (Deferred Payment),
<U>Section 8</U> (Patents and Infringement), <U>Sections 9.1</U> and <U>9.2</U> (Confidentiality), <U>Section 9.3</U> (Publication),
<U>Section 9.4</U> (Publicity), <U>Section 10.5</U> (Disclaimer of Warranty), <U>Section 11.1</U> (Restrictions on Transfers and
Liens), <U>Section 11.2</U> (Third Party Licenses and Agreements), <U>Section 11.4</U> (Coordinating outside the Territory), <U>Section
14.4</U> (Continuing and Accrued Obligations and Surviving Provisions), <U>Section 14.5</U> (Effect of Termination or Expiration),
<U>Section 14.6</U> (Bankruptcy), <U>Section 15</U> (Indemnification) other than Section 15.6 (Insurance Requirements), <U>Section
17</U> (Governing Law and Jurisdiction) and this <U>Section 18</U> (Miscellaneous), as well as (x) any other Sections or defined
terms referred to in such Sections or necessary to give them effect and (y) any other provision that by its terms expressly survives
termination of this Agreement, shall survive termination of this Agreement and remain in force until discharged in full. Furthermore,
any other provisions required to interpret and enforce the parties&rsquo; rights and obligations or to wind up their outstanding
obligations under this Agreement shall survive to the extent required.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">18.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Assignment;
Binding Effect</U></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither
this Agreement nor any rights or obligations of either party to this Agreement may be assigned or otherwise transferred by either
party without the consent of the other party; <U>provided,</U>&nbsp;<U>however</U>, either party may, without such consent, assign
this Agreement, in whole or in part: (i) to any of its respective Affiliates, <U>provided</U>&nbsp;that such assigning party
shall remain jointly and severally liable with such Affiliate in respect of all obligations so assigned; (ii) to a Third Party
where a party or its Affiliate is required, or makes a good faith determination based on advice of counsel, to divest a Licensed
Product in order to comply with Law or the order of any Governmental Authority as a result of a merger or acquisition; or (iii)
to a Third Party successor to all or substantially all of the assets of such party whether by merger, sale of stock, all or substantially
all of a party&rsquo;s assets or other similar transaction, so long as such Third Party agrees in writing to be bound by the terms
of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 71; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
purported assignment in violation of this <U>Section 18.6</U> shall be void. Any permitted assignee shall assume all obligations
of its assignor under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pfizer
may assume this Agreement in any proceeding under the U.S. Bankruptcy Code upon satisfaction of the conditions set forth in U.S.
Bankruptcy Code Section 365(b)(1).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">18.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Divestiture</U></FONT>.
For the avoidance of doubt, nothing in this <U>Section 18.7</U> shall prevent Pfizer from assigning its rights and obligations
under this Agreement pursuant to <U>Section 18.6</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
anything to the contrary contained in this Agreement, to the extent related to or arising in connection with a divestiture (whether
by sale, spin-off, or similar transaction) by Pfizer of all or any portion of a Pfizer business or business unit (a &ldquo;<U>Divestiture</U>&rdquo;),
Pfizer may, without prior written notice to or consent of Protalix, without any penalty, and at no additional cost to Pfizer or
to any affiliate of Pfizer or to the company or the group of companies resulting from such Divestiture (collectively, such companies,
the &ldquo;<U>Resulting Companies</U>&rdquo;): (1) assign its rights and obligations under this Agreement, in whole or in part
to one or more of the Resulting Companies, or (2) split and assign, in whole or in part, its rights and obligations under this
Agreement to one or more of the Resulting Companies so as to retain the benefits of this Agreement for both Pfizer and the applicable
Resulting Companies following such Divestiture; <U>provided</U> that [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;From
and after any partial assignment or split the rights and obligations of Pfizer hereunder shall be divided between Pfizer and the
Resulting Companies to whom such rights and obligations are transferred as specified by Pfizer, such that all such rights and
obligations related to the business of the applicable Resulting Companies shall be enforceable only by and against the applicable
Resulting Companies, and all other such rights and obligations shall be enforceable only by and against Pfizer.&nbsp; Protalix
will, [***], work cooperatively with Pfizer and the applicable Resulting Companies to ensure a smooth and orderly transition,
including, to the extent requested by Pfizer, entering into separate agreements with Pfizer and the applicable Resulting Companies
on substantially the same terms and conditions (as adjusted to take into account the nature of the separate contracts while maintaining
the economic, business and other purposes of the Agreement).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">18.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Independent
Contractor</U></FONT>. The relationship between Protalix and Pfizer is that of independent contractors. Protalix and Pfizer are
not joint venturers, partners, principal and agent, employer and employee, and have no other relationship other than independent
contracting parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">18.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Notices</U></FONT>.
Each communication and document made or delivered by one party to another under this Agreement shall be made in the English language.
All notices, consents, approvals, requests or other communications required hereunder given by one party to the other hereunder
shall be in writing and made by registered or certified air mail, express overnight courier or delivered personally to the following
addresses of the respective parties:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 72; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 20%">If to Protalix:</TD>
    <TD STYLE="width: 80%">Protalix Ltd.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>2 Snunit Street</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Science Park</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>P.O.B. 455</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Carmiel 20100, Israel</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Attention: &nbsp;Chief Executive Officer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>If to Pfizer:</TD>
    <TD>Pfizer Inc.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">235 East 42<SUP>nd</SUP> Street</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">New York, New York, 10017-5755</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>U.S.A.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Attention: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;President of the Global Innovative Products Business Unit</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>with a copy to:</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Pfizer Inc.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">235 East 42<SUP>nd</SUP> Street</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">New York, New York, 10017-5755</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>U.S.A.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Attention: &nbsp;&nbsp;&nbsp;&nbsp;Chief Counsel, Global Innovative Products Business Unit</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Pfizer Inc.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">235 East 42<SUP>nd</SUP> Street</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">New York, New York, 10017-5755</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>U.S.A.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Attention: &nbsp;&nbsp;&nbsp;&nbsp;Senior Vice President, Business Development</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Notices hereunder shall be deemed to be effective (a) upon
receipt if personally delivered, (b) on the tenth (10th) Business Day following the date of mailing if sent by registered or certified
air mail and (c) on the second (2nd) Business Day following the date of delivery to the overnight courier if sent by overnight
courier. A party may change its address listed above by sending notice to the other party in accordance with this <U>Section 18.9</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">18.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Third
Party Beneficiaries</U></FONT>. None of the provisions of this Agreement shall be for the benefit of or enforceable by any Third
Party, including any creditor of either party. No Third Party shall obtain any right under any provision of this Agreement or
shall by reason of any such provision make any claim in respect of any debt, liability or obligation (or otherwise) against either
party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">18.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Binding
Effect</U></FONT>. This Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective heirs,
successors and permitted assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">18.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Performance
by Affiliates</U></FONT>. To the extent that this Agreement imposes obligations on Affiliates of a party, such party agrees to
cause its Affiliates to perform such obligations. Pfizer may use one or more of its Affiliates to exercise its rights or perform
its obligations and duties hereunder, <U>provided</U>&nbsp;that Pfizer shall remain liable hereunder for the prompt payment and
performance of all of its obligations hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 73; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">18.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Corporate
Integrity Agreement</U></FONT>. Protalix acknowledges that (a) Pfizer develops and promotes its products in compliance with the
statutes, regulations and written directives of Medicare, Medicaid and all other federal health care programs (as defined in 42
U.S.C. &sect; 1320a-7b(f)) and with the statutes, regulations, and written directives of the Food and Drug Administration, and
(b) Pfizer shall not be obligated to take any action pursuant to this Agreement that it believes, in its sole discretion, constitutes
a violation of any of Pfizer&rsquo;s obligations set forth in <U>subsection (a)</U> above or such Corporate Integrity Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">18.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Counterparts</U></FONT>.
This Agreement may be executed in any counterparts, each of which, when executed, shall be deemed to be an original and which
together shall constitute one and the same document.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">18.15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Headings</U></FONT>.
Headings in this Agreement are included herein for ease of reference only and shall have no legal effect. References to the parties,
Sections, Schedules, and Exhibits are to the parties, Sections, Schedules and Exhibits to and of this Agreement unless otherwise
specified.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">18.16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Equitable
Remedies</U></FONT>. The parties agree that irreparable damage may occur in the event that any of the provisions of this Agreement
were not performed in accordance with their specific terms or were otherwise breached.&nbsp; It is accordingly agreed that, without
limitation of other remedies which may be available to a party for breach of this Agreement by the other party, the parties shall
be entitled to seek an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and
provisions of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 74; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">IN WITNESS WHEREOF the parties hereto have
caused this Agreement to be executed by their duly authorized officers upon the date set out below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">Protalix Ltd.</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">Pfizer Inc.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Name:&nbsp;</TD>
    <TD>Moshe Manor</TD>
    <TD>&nbsp;</TD>
    <TD>Name:&nbsp;</TD>
    <TD>Michael Goettler</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Title:</TD>
    <TD>President and Chief Executive Officer</TD>
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>Global Commercial Officer, Senior Vice President</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 75 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">Protalix Biotherapeutics, Inc.</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 45%">&nbsp;</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Name:</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Title:</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Date:</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 76; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>v423042_ex31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 31.1 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CERTIFICATION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Moshe Manor, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.5pt">1.</TD><TD>I have reviewed this quarterly report on Form 10-Q of Protalix BioTherapeutics, Inc.;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">2.</TD><TD>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with
respect to the period covered by this report;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">3.</TD><TD>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in
all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
presented in this report;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">4.</TD><TD>The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls
and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined
in Exchange Act Rules 13a-15(f) and 15d-15(f)<FONT STYLE="font-weight: normal">) </FONT>for the registrant and have:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD>Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known
to us by others within those entities, particularly during the period in which this report is being prepared;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed
under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with generally accepted accounting principles;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD>Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on
such evaluation; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD>Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during
the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report)
that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial
reporting; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">5.</TD><TD>The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control
over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors
(or persons performing the equivalent functions):</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.45pt"></TD><TD STYLE="width: 24.5pt">a)</TD><TD>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting
which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial
information; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.45pt"></TD><TD STYLE="width: 24.5pt">b)</TD><TD>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">Date: November 9, 2015</TD></TR>
<TR>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Moshe Manor</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page --></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">Moshe Manor</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">President and Chief Executive
Officer&nbsp;</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>





</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>v423042_ex31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 31.2 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CERTIFICATION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Yossi Maimon, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.5pt">1.</TD><TD>I have reviewed this quarterly report on Form 10-Q of Protalix BioTherapeutics, Inc.;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">2.</TD><TD>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with
respect to the period covered by this report;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">3.</TD><TD>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in
all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
presented in this report;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">4.</TD><TD>The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls
and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined
in Exchange Act Rules 13a-15(f) and 15d-15(f)<FONT STYLE="font-weight: normal">) </FONT>for the registrant and have:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD>Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known
to us by others within those entities, particularly during the period in which this report is being prepared;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed
under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with generally accepted accounting principles;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD>Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on
such evaluation; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD>Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during
the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report)
that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial
reporting; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">5.</TD><TD>The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control
over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors
(or persons performing the equivalent functions):</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.45pt"></TD><TD STYLE="width: 24.5pt">a)</TD><TD>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting
which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial
information; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.45pt"></TD><TD STYLE="width: 24.5pt">b)</TD><TD>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">Date: &nbsp;November 9, 2015</TD></TR>
<TR>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Yossi Maimon</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page --></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">Yossi Maimon</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">Chief Financial Officer,
Treasurer&nbsp;</P></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>v423042_ex32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 32.1 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><U>CERTIFICATION </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the quarterly report of Protalix BioTherapeutics,
Inc. (the &ldquo;Company&rdquo;) on Form 10-Q for the period ended September 30, 2015 as filed with the Securities and Exchange
Commission (the &ldquo;Report&rdquo;), I, Moshe Manor, President and Chief Executive Officer of the Company, hereby certify as
of the date hereof, solely for purposes of Title 18, Chapter 63, Section&nbsp;1350 of the United States Code, that to my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">(1) the Report fully complies with the requirements
of Section&nbsp;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">(2) the information contained in the Report fairly
presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods
indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-indent: -12.25pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This Certificate is being furnished to the Securities and Exchange
Commission as an exhibit to the Report.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-indent: -12.25pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-indent: -12.25pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">Date: November 9, 2015</TD></TR>
<TR>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Moshe Manor</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page --></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">Moshe Manor</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">President and Chief Executive
Officer&nbsp;</P></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>v423042_ex32-2.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 32.2 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>CERTIFICATION </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the quarterly report of Protalix BioTherapeutics,
Inc. (the &ldquo;Company&rdquo;) on Form 10-Q for the period ended September 30, 2015 as filed with the Securities and Exchange
Commission (the &ldquo;Report&rdquo;), I, Yossi Maimon, Vice President and Chief Financial Officer of the Company, hereby certify
as of the date hereof, solely for the purposes of Title 18, Chapter 63, Section&nbsp;1350 of the United States Code, that to  my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">(1) the Report fully complies with the requirements
of Section&nbsp;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">(2) the information contained in the Report fairly
presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods
indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-indent: -12.25pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This Certificate is being furnished to the Securities and Exchange
Commission as an exhibit to the Report.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-indent: -12.25pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-indent: -12.25pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">Date: November 9, 2015</TD></TR>
<TR>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Yossi Maimon</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page --></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">Yossi Maimon</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">Vice President and Chief
Financial Officer&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.1in">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>7
<FILENAME>plx-20150930.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--Created by The Vintage Group, Powered by IRIS Carbon-->
<xbrli:xbrl xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2015-01-31" xmlns:plx="http://www.protalix.com/20150930">
  <link:schemaRef xlink:type="simple" xlink:href="plx-20150930.xsd" />
  <xbrli:context id="D2015-01-01_To_2015-09-30">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2015-09-30">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014-12-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014-01-01_To_2014-09-30">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-01-01_To_2015-09-30_ResearchAndDevelopmentExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014-01-01_To_2014-09-30_ResearchAndDevelopmentExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-01-01_To_2015-09-30_SellingGeneralAndAdministrativeExpensesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014-01-01_To_2014-09-30_SellingGeneralAndAdministrativeExpensesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013-12-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014-09-30">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013-12-31_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013-12-31_AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013-12-31_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014-01-01_To_2014-09-30_AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014-01-01_To_2014-09-30_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014-01-01_To_2014-09-30_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014-09-30_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014-09-30_AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014-09-30_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014-12-31_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014-12-31_AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014-12-31_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-01-01_To_2015-09-30_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-01-01_To_2015-09-30_AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-01-01_To_2015-09-30_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2015-09-30_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2015-09-30_AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2015-09-30_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-01-01_To_2015-09-30_SubsidiariesMember_BrazilAgreementMember_FiocruzMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">us-gaap:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:BrazilAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">plx:FiocruzMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013-06-18_SubsidiariesMember_BrazilAgreementMember_FiocruzMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">us-gaap:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:BrazilAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">plx:FiocruzMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-06-18</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2015-09-30_ProtalixBioTherapeuticsIncorporationMember_PfizerAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">plx:ProtalixBioTherapeuticsIncorporationMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:PfizerAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2015-09-30_PfizerIncorporationMember_PfizerAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">plx:PfizerIncorporationMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:PfizerAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014-07-01_To_2014-09-30">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-07-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-07-01_To_2015-09-30">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-07-01</xbrli:startDate>
      <xbrli:endDate>2015-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-07-01_To_2015-09-30_ResearchAndDevelopmentExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-07-01</xbrli:startDate>
      <xbrli:endDate>2015-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014-07-01_To_2014-09-30_ResearchAndDevelopmentExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-07-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-07-01_To_2015-09-30_SellingGeneralAndAdministrativeExpensesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-07-01</xbrli:startDate>
      <xbrli:endDate>2015-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014-07-01_To_2014-09-30_SellingGeneralAndAdministrativeExpensesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-07-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2015-03-23_EmployeeStockOptionMember_EmployeeStockIncentivePlan2006Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-03-23</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-03-01_To_2015-03-23_EmployeeStockOptionMember_EmployeeStockIncentivePlan2006Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-03-01</xbrli:startDate>
      <xbrli:endDate>2015-03-23</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-03-01_To_2015-03-23_EmployeeStockOptionMember_ShareBasedCompensationAwardTrancheOneMember_EmployeeStockIncentivePlan2006Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-03-01</xbrli:startDate>
      <xbrli:endDate>2015-03-23</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-03-01_To_2015-03-23_EmployeeStockOptionMember_ShareBasedCompensationAwardTrancheTwoMember_EmployeeStockIncentivePlan2006Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-03-01</xbrli:startDate>
      <xbrli:endDate>2015-03-23</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2015-11-01">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-11-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2015-10-31_SubsequentEventMember_AmendedPfizerAgreementMember_BR_ProtalixBioTherapeuticsIncorporationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:AmendedPfizerAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">plx:ProtalixBioTherapeuticsIncorporationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2015-10-31_AmendedPfizerAgreementMember_PfizerIncorporationMember_SubsequentEventMember_ExcludingBrazilMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:AmendedPfizerAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">plx:PfizerIncorporationMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">plx:ExcludingBrazilMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-10-01_To_2015-10-31_SubsequentEventMember_AmendedPfizerAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:AmendedPfizerAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-10-01</xbrli:startDate>
      <xbrli:endDate>2015-10-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2015-10-31_ProtalixBioTherapeuticsIncorporationMember_SubsequentEventMember_AmendedPfizerAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">plx:ProtalixBioTherapeuticsIncorporationMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:AmendedPfizerAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-10-01_To_2015-10-31_SubsequentEventMember_PfizerIncorporationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">plx:PfizerIncorporationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-10-01</xbrli:startDate>
      <xbrli:endDate>2015-10-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-10-01_To_2015-10-31_SubsequentEventMember_ExecutiveOfficerMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ExecutiveOfficerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-10-01</xbrli:startDate>
      <xbrli:endDate>2015-10-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-10-01_To_2015-10-31_SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-10-01</xbrli:startDate>
      <xbrli:endDate>2015-10-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2015-10-31_AmendedPfizerAgreementMember_October2015PromissoryNoteToPfizerMember_SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:AmendedPfizerAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:October2015PromissoryNoteToPfizerMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-10-01_To_2015-10-31_AmendedPfizerAgreementMember_October2015PromissoryNoteToPfizerMember_SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:AmendedPfizerAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:October2015PromissoryNoteToPfizerMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-10-01</xbrli:startDate>
      <xbrli:endDate>2015-10-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:unit id="USD">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="USDPerShare">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <xbrli:unit id="Shares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="Pure">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="Item">
    <xbrli:measure>plx:item</xbrli:measure>
  </xbrli:unit>
  <us-gaap:InventoryNet id="Tag1" contextRef="I2014-12-31" unitRef="USD" decimals="-3">6667000</us-gaap:InventoryNet>
  <us-gaap:AssetsCurrent id="Tag2" contextRef="I2015-09-30" unitRef="USD" decimals="-3">47876000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent id="Tag3" contextRef="I2014-12-31" unitRef="USD" decimals="-3">65520000</us-gaap:AssetsCurrent>
  <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent id="Tag4" contextRef="I2015-09-30" unitRef="USD" decimals="-3">1569000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
  <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent id="Tag5" contextRef="I2014-12-31" unitRef="USD" decimals="-3">1555000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
  <us-gaap:PropertyPlantAndEquipmentNet id="Tag6" contextRef="I2015-09-30" unitRef="USD" decimals="-3">9957000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet id="Tag7" contextRef="I2014-12-31" unitRef="USD" decimals="-3">11282000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:DeferredCosts id="Tag8" contextRef="I2015-09-30" unitRef="USD" decimals="-3">90000</us-gaap:DeferredCosts>
  <us-gaap:DeferredCosts id="Tag9" contextRef="I2014-12-31" unitRef="USD" decimals="-3">113000</us-gaap:DeferredCosts>
  <us-gaap:Assets id="Tag10" contextRef="I2015-09-30" unitRef="USD" decimals="-3">59492000</us-gaap:Assets>
  <us-gaap:Assets id="Tag11" contextRef="I2014-12-31" unitRef="USD" decimals="-3">78470000</us-gaap:Assets>
  <us-gaap:CommitmentsAndContingencies id="Tag12" contextRef="I2015-09-30" unitRef="USD" xsi:nil="true" />
  <us-gaap:CommitmentsAndContingencies id="Tag13" contextRef="I2014-12-31" unitRef="USD" xsi:nil="true" />
  <us-gaap:AccountsPayableTradeCurrent id="Tag14" contextRef="I2015-09-30" unitRef="USD" decimals="-3">4057000</us-gaap:AccountsPayableTradeCurrent>
  <us-gaap:AccountsPayableTradeCurrent id="Tag15" contextRef="I2014-12-31" unitRef="USD" decimals="-3">3951000</us-gaap:AccountsPayableTradeCurrent>
  <us-gaap:AccountsPayableOtherCurrent id="Tag16" contextRef="I2015-09-30" unitRef="USD" decimals="-3">11946000</us-gaap:AccountsPayableOtherCurrent>
  <us-gaap:AccountsPayableOtherCurrent id="Tag17" contextRef="I2014-12-31" unitRef="USD" decimals="-3">15496000</us-gaap:AccountsPayableOtherCurrent>
  <us-gaap:DeferredRevenueCurrent id="Tag18" contextRef="I2015-09-30" unitRef="USD" decimals="-3">6850000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueCurrent id="Tag19" contextRef="I2014-12-31" unitRef="USD" decimals="-3">6763000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:LiabilitiesCurrent id="Tag20" contextRef="I2015-09-30" unitRef="USD" decimals="-3">22853000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent id="Tag21" contextRef="I2014-12-31" unitRef="USD" decimals="-3">26210000</us-gaap:LiabilitiesCurrent>
  <us-gaap:ConvertibleDebtNoncurrent id="Tag22" contextRef="I2015-09-30" unitRef="USD" decimals="-3">67774000</us-gaap:ConvertibleDebtNoncurrent>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="Tag23" contextRef="I2015-09-30" unitRef="USD" decimals="-3">34248000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:ConvertibleDebtNoncurrent id="Tag24" contextRef="I2014-12-31" unitRef="USD" decimals="-3">67464000</us-gaap:ConvertibleDebtNoncurrent>
  <us-gaap:DeferredRevenueNoncurrent id="Tag25" contextRef="I2015-09-30" unitRef="USD" decimals="-3">35127000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:DeferredRevenueNoncurrent id="Tag26" contextRef="I2014-12-31" unitRef="USD" decimals="-3">37232000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:LongTermDebtNoncurrent id="Tag27" contextRef="I2014-12-31" unitRef="USD" decimals="-3">912000</us-gaap:LongTermDebtNoncurrent>
  <us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent id="Tag28" contextRef="I2015-09-30" unitRef="USD" decimals="-3">2249000</us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent>
  <us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent id="Tag29" contextRef="I2014-12-31" unitRef="USD" decimals="-3">2253000</us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent>
  <us-gaap:LiabilitiesNoncurrent id="Tag30" contextRef="I2015-09-30" unitRef="USD" decimals="-3">105150000</us-gaap:LiabilitiesNoncurrent>
  <us-gaap:LiabilitiesNoncurrent id="Tag31" contextRef="I2014-12-31" unitRef="USD" decimals="-3">107861000</us-gaap:LiabilitiesNoncurrent>
  <us-gaap:Liabilities id="Tag32" contextRef="I2015-09-30" unitRef="USD" decimals="-3">128003000</us-gaap:Liabilities>
  <us-gaap:Liabilities id="Tag33" contextRef="I2014-12-31" unitRef="USD" decimals="-3">134071000</us-gaap:Liabilities>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="Tag34" contextRef="I2014-12-31" unitRef="USD" decimals="-3">54767000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:StockholdersEquity id="Tag35" contextRef="I2015-09-30" unitRef="USD" decimals="-3">-68511000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="Tag36" contextRef="I2014-12-31" unitRef="USD" decimals="-3">-55601000</us-gaap:StockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="Tag37" contextRef="I2015-09-30" unitRef="USD" decimals="-3">59492000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="Tag38" contextRef="I2014-12-31" unitRef="USD" decimals="-3">78470000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:AccountsReceivableNetCurrent id="Tag39" contextRef="I2015-09-30" unitRef="USD" decimals="-3">4573000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AccountsReceivableNetCurrent id="Tag40" contextRef="I2014-12-31" unitRef="USD" decimals="-3">1884000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:OtherAssetsCurrent id="Tag41" contextRef="I2015-09-30" unitRef="USD" decimals="-3">2716000</us-gaap:OtherAssetsCurrent>
  <us-gaap:OtherAssetsCurrent id="Tag42" contextRef="I2014-12-31" unitRef="USD" decimals="-3">2202000</us-gaap:OtherAssetsCurrent>
  <us-gaap:InventoryNet id="Tag43" contextRef="I2015-09-30" unitRef="USD" decimals="-3">6339000</us-gaap:InventoryNet>
  <us-gaap:NetIncomeLoss id="Tag44" contextRef="D2015-01-01_To_2015-09-30" unitRef="USD" decimals="-3">-14863000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="Tag45" contextRef="D2014-01-01_To_2014-09-30" unitRef="USD" decimals="-3">-21474000</us-gaap:NetIncomeLoss>
  <us-gaap:ShareBasedCompensation id="Tag46" contextRef="D2015-01-01_To_2015-09-30" unitRef="USD" decimals="-3">1419000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation id="Tag47" contextRef="D2014-01-01_To_2014-09-30" unitRef="USD" decimals="-3">683000</us-gaap:ShareBasedCompensation>
  <us-gaap:Depreciation id="Tag48" contextRef="D2015-01-01_To_2015-09-30" unitRef="USD" decimals="-3">1811000</us-gaap:Depreciation>
  <us-gaap:Depreciation id="Tag49" contextRef="D2014-01-01_To_2014-09-30" unitRef="USD" decimals="-3">2418000</us-gaap:Depreciation>
  <us-gaap:ForeignCurrencyTransactionGainLossUnrealized id="Tag50" contextRef="D2015-01-01_To_2015-09-30" unitRef="USD" decimals="-3">-102000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
  <us-gaap:ForeignCurrencyTransactionGainLossUnrealized id="Tag51" contextRef="D2014-01-01_To_2014-09-30" unitRef="USD" decimals="-3">-869000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
  <us-gaap:PensionAndOtherPostretirementBenefitExpense id="Tag52" contextRef="D2015-01-01_To_2015-09-30" unitRef="USD" decimals="-3">16000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
  <us-gaap:PensionAndOtherPostretirementBenefitExpense id="Tag53" contextRef="D2014-01-01_To_2014-09-30" unitRef="USD" decimals="-3">149000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
  <plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement id="Tag54" contextRef="D2015-01-01_To_2015-09-30" unitRef="USD" decimals="-3">-28000</plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement>
  <plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement id="Tag55" contextRef="D2014-01-01_To_2014-09-30" unitRef="USD" decimals="-3">25000</plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement>
  <us-gaap:AmortizationOfFinancingCosts id="Tag56" contextRef="D2015-01-01_To_2015-09-30" unitRef="USD" decimals="-3">333000</us-gaap:AmortizationOfFinancingCosts>
  <us-gaap:AmortizationOfFinancingCosts id="Tag57" contextRef="D2014-01-01_To_2014-09-30" unitRef="USD" decimals="-3">332000</us-gaap:AmortizationOfFinancingCosts>
  <us-gaap:IncreaseDecreaseInDeferredRevenue id="Tag58" contextRef="D2015-01-01_To_2015-09-30" unitRef="USD" decimals="-3">-2018000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInDeferredRevenue id="Tag59" contextRef="D2014-01-01_To_2014-09-30" unitRef="USD" decimals="-3">-6172000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInAccountsReceivable id="Tag60" contextRef="D2015-01-01_To_2015-09-30" unitRef="USD" decimals="-3">3187000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInAccountsReceivable id="Tag61" contextRef="D2014-01-01_To_2014-09-30" unitRef="USD" decimals="-3">578000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInInventories id="Tag62" contextRef="D2015-01-01_To_2015-09-30" unitRef="USD" decimals="-3">-328000</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:IncreaseDecreaseInInventories id="Tag63" contextRef="D2014-01-01_To_2014-09-30" unitRef="USD" decimals="-3">-1127000</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities id="Tag64" contextRef="D2015-01-01_To_2015-09-30" unitRef="USD" decimals="-3">-4396000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities id="Tag65" contextRef="D2014-01-01_To_2014-09-30" unitRef="USD" decimals="-3">-1736000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations id="Tag66" contextRef="D2015-01-01_To_2015-09-30" unitRef="USD" decimals="-3">-20427000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations id="Tag67" contextRef="D2014-01-01_To_2014-09-30" unitRef="USD" decimals="-3">-24407000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="Tag68" contextRef="D2015-01-01_To_2015-09-30" unitRef="USD" decimals="-3">460000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="Tag69" contextRef="D2014-01-01_To_2014-09-30" unitRef="USD" decimals="-3">617000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:IncreaseDecreaseInRestrictedCash id="Tag70" contextRef="D2014-01-01_To_2014-09-30" unitRef="USD" decimals="-3">93000</us-gaap:IncreaseDecreaseInRestrictedCash>
  <us-gaap:PaymentsForProceedsFromOtherInvestingActivities id="Tag71" contextRef="D2014-01-01_To_2014-09-30" unitRef="USD" decimals="-3">122000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations id="Tag72" contextRef="D2015-01-01_To_2015-09-30" unitRef="USD" decimals="-3">-516000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations id="Tag73" contextRef="D2014-01-01_To_2014-09-30" unitRef="USD" decimals="-3">-832000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:ProceedsFromStockOptionsExercised id="Tag74" contextRef="D2015-01-01_To_2015-09-30" unitRef="USD" decimals="-3">534000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockOptionsExercised id="Tag75" contextRef="D2014-01-01_To_2014-09-30" unitRef="USD" decimals="-3">43000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations id="Tag76" contextRef="D2015-01-01_To_2015-09-30" unitRef="USD" decimals="-3">534000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations id="Tag77" contextRef="D2014-01-01_To_2014-09-30" unitRef="USD" decimals="-3">43000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents id="Tag78" contextRef="D2015-01-01_To_2015-09-30" unitRef="USD" decimals="-3">-110000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents id="Tag79" contextRef="D2014-01-01_To_2014-09-30" unitRef="USD" decimals="-3">-885000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease id="Tag80" contextRef="D2015-01-01_To_2015-09-30" unitRef="USD" decimals="-3">-20519000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease id="Tag81" contextRef="D2014-01-01_To_2014-09-30" unitRef="USD" decimals="-3">-26081000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="Tag82" contextRef="I2013-12-31" unitRef="USD" decimals="-3">86398000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="Tag83" contextRef="I2014-09-30" unitRef="USD" decimals="-3">60317000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment id="Tag84" contextRef="D2015-01-01_To_2015-09-30" unitRef="USD" decimals="-3">146000</plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment>
  <plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment id="Tag85" contextRef="D2014-01-01_To_2014-09-30" unitRef="USD" decimals="-3">122000</plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment>
  <us-gaap:InterestPaidNet id="Tag86" contextRef="D2015-01-01_To_2015-09-30" unitRef="USD" decimals="-3">3105000</us-gaap:InterestPaidNet>
  <us-gaap:InterestPaidNet id="Tag87" contextRef="D2014-01-01_To_2014-09-30" unitRef="USD" decimals="-3">3079000</us-gaap:InterestPaidNet>
  <us-gaap:IncreaseDecreaseInRestrictedCash id="Tag88" contextRef="D2015-01-01_To_2015-09-30" unitRef="USD" xsi:nil="true" />
  <us-gaap:PaymentsForProceedsFromOtherInvestingActivities id="Tag89" contextRef="D2015-01-01_To_2015-09-30" unitRef="USD" decimals="-3">56000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
  <us-gaap:StockholdersEquity id="Tag90" contextRef="I2013-12-31_CommonStockMember" unitRef="USD" decimals="-3">94000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="Tag91" contextRef="I2013-12-31_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">184345000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="Tag92" contextRef="I2013-12-31_RetainedEarningsMember" unitRef="USD" decimals="-3">-211385000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="Tag93" contextRef="I2013-12-31" unitRef="USD" decimals="-3">-26946000</us-gaap:StockholdersEquity>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="Tag94" contextRef="D2014-01-01_To_2014-09-30_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">161000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="Tag95" contextRef="D2014-01-01_To_2014-09-30" unitRef="USD" decimals="-3">161000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures id="Tag96" contextRef="D2014-01-01_To_2014-09-30_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">522000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
  <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures id="Tag97" contextRef="D2014-01-01_To_2014-09-30" unitRef="USD" decimals="-3">522000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="Tag98" contextRef="D2014-01-01_To_2014-09-30_CommonStockMember" unitRef="Shares" decimals="INF">113800</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="Tag99" contextRef="D2014-01-01_To_2014-09-30_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">43000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="Tag100" contextRef="D2014-01-01_To_2014-09-30" unitRef="USD" decimals="-3">43000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:NetIncomeLoss id="Tag101" contextRef="D2014-01-01_To_2014-09-30_RetainedEarningsMember" unitRef="USD" decimals="-3">-21474000</us-gaap:NetIncomeLoss>
  <us-gaap:SharesOutstanding id="Tag102" contextRef="I2014-09-30_CommonStockMember" unitRef="Shares" decimals="INF">93663064</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="Tag103" contextRef="I2014-09-30_CommonStockMember" unitRef="USD" decimals="-3">94000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="Tag104" contextRef="I2014-09-30_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">185071000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="Tag105" contextRef="I2014-09-30_RetainedEarningsMember" unitRef="USD" decimals="-3">-232859000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="Tag106" contextRef="I2014-09-30" unitRef="USD" decimals="-3">-47694000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding id="Tag107" contextRef="I2014-12-31_CommonStockMember" unitRef="Shares" decimals="INF">93603819</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="Tag108" contextRef="I2014-12-31_CommonStockMember" unitRef="USD" decimals="-3">94000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="Tag109" contextRef="I2014-12-31_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">185633000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="Tag110" contextRef="I2014-12-31_RetainedEarningsMember" unitRef="USD" decimals="-3">-241328000</us-gaap:StockholdersEquity>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="Tag111" contextRef="D2015-01-01_To_2015-09-30_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">947000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="Tag112" contextRef="D2015-01-01_To_2015-09-30" unitRef="USD" decimals="-3">947000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited id="Tag113" contextRef="D2015-01-01_To_2015-09-30" unitRef="Shares" decimals="INF">2501</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited>
  <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares id="Tag114" contextRef="D2015-01-01_To_2015-09-30_CommonStockMember" unitRef="Shares" decimals="INF">-2501</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares>
  <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures id="Tag115" contextRef="D2015-01-01_To_2015-09-30_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">472000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
  <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures id="Tag116" contextRef="D2015-01-01_To_2015-09-30" unitRef="USD" decimals="-3">472000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
  <us-gaap:NetIncomeLoss id="Tag117" contextRef="D2015-01-01_To_2015-09-30_RetainedEarningsMember" unitRef="USD" decimals="-3">-14863000</us-gaap:NetIncomeLoss>
  <us-gaap:SharesOutstanding id="Tag118" contextRef="I2015-09-30_CommonStockMember" unitRef="Shares" decimals="INF">94151318</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="Tag119" contextRef="I2015-09-30_CommonStockMember" unitRef="USD" decimals="-3">94000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="Tag120" contextRef="I2015-09-30_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">187586000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="Tag121" contextRef="I2015-09-30_RetainedEarningsMember" unitRef="USD" decimals="-3">-256191000</us-gaap:StockholdersEquity>
  <us-gaap:CommonStockParOrStatedValuePerShare id="Tag122" contextRef="I2015-09-30" unitRef="USDPerShare" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized id="Tag123" contextRef="I2015-09-30" unitRef="Shares" decimals="INF">150000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="Tag124" contextRef="D2014-01-01_To_2014-09-30_CommonStockMember" unitRef="USD" xsi:nil="true" />
  <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures id="Tag125" contextRef="D2014-01-01_To_2014-09-30_CommonStockMember" unitRef="USD" xsi:nil="true" />
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="Tag126" contextRef="D2014-01-01_To_2014-09-30_CommonStockMember" unitRef="USD" xsi:nil="true" />
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="Tag127" contextRef="D2014-01-01_To_2014-09-30_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
  <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures id="Tag128" contextRef="D2014-01-01_To_2014-09-30_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="Tag129" contextRef="D2014-01-01_To_2014-09-30_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="Tag130" contextRef="D2015-01-01_To_2015-09-30_CommonStockMember" unitRef="USD" xsi:nil="true" />
  <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures id="Tag131" contextRef="D2015-01-01_To_2015-09-30_CommonStockMember" unitRef="USD" xsi:nil="true" />
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="Tag132" contextRef="D2015-01-01_To_2015-09-30_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
  <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures id="Tag133" contextRef="D2015-01-01_To_2015-09-30_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
  <us-gaap:NetIncomeLoss id="Tag134" contextRef="D2014-01-01_To_2014-09-30_CommonStockMember" unitRef="USD" xsi:nil="true" />
  <us-gaap:NetIncomeLoss id="Tag135" contextRef="D2014-01-01_To_2014-09-30_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
  <us-gaap:NetIncomeLoss id="Tag136" contextRef="D2015-01-01_To_2015-09-30_CommonStockMember" unitRef="USD" xsi:nil="true" />
  <us-gaap:NetIncomeLoss id="Tag137" contextRef="D2015-01-01_To_2015-09-30_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
  <us-gaap:SharesOutstanding id="Tag138" contextRef="I2013-12-31_CommonStockMember" unitRef="Shares" decimals="INF">93551098</us-gaap:SharesOutstanding>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="Tag139" contextRef="D2015-01-01_To_2015-09-30_CommonStockMember" unitRef="Shares" decimals="INF">550000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="Tag140" contextRef="D2015-01-01_To_2015-09-30_CommonStockMember" unitRef="USD" xsi:nil="true" />
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="Tag141" contextRef="D2015-01-01_To_2015-09-30_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">534000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="Tag142" contextRef="D2015-01-01_To_2015-09-30" unitRef="USD" decimals="-3">534000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="Tag143" contextRef="D2015-01-01_To_2015-09-30_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
  <us-gaap:CommonStockParOrStatedValuePerShare id="Tag144" contextRef="I2014-09-30" unitRef="USDPerShare" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized id="Tag145" contextRef="I2014-09-30" unitRef="Shares" decimals="INF">150000000</us-gaap:CommonStockSharesAuthorized>
  <plx:RevenuesOtherThanCompanyShareInCollaborationAgreement id="Tag146" contextRef="D2015-01-01_To_2015-09-30" unitRef="USD" decimals="-3">12475000</plx:RevenuesOtherThanCompanyShareInCollaborationAgreement>
  <plx:RevenuesOtherThanCompanyShareInCollaborationAgreement id="Tag147" contextRef="D2014-01-01_To_2014-09-30" unitRef="USD" decimals="-3">11517000</plx:RevenuesOtherThanCompanyShareInCollaborationAgreement>
  <plx:CompanyShareInCollaborationAgreement id="Tag148" contextRef="D2015-01-01_To_2015-09-30" unitRef="USD" decimals="-3">3084000</plx:CompanyShareInCollaborationAgreement>
  <plx:CompanyShareInCollaborationAgreement id="Tag149" contextRef="D2014-01-01_To_2014-09-30" unitRef="USD" decimals="-3">2259000</plx:CompanyShareInCollaborationAgreement>
  <us-gaap:CostOfRevenue id="Tag150" contextRef="D2015-01-01_To_2015-09-30" unitRef="USD" decimals="-3">6785000</us-gaap:CostOfRevenue>
  <us-gaap:CostOfRevenue id="Tag151" contextRef="D2014-01-01_To_2014-09-30" unitRef="USD" decimals="-3">7476000</us-gaap:CostOfRevenue>
  <us-gaap:GrossProfit id="Tag152" contextRef="D2015-01-01_To_2015-09-30" unitRef="USD" decimals="-3">8774000</us-gaap:GrossProfit>
  <us-gaap:GrossProfit id="Tag153" contextRef="D2014-01-01_To_2014-09-30" unitRef="USD" decimals="-3">6300000</us-gaap:GrossProfit>
  <us-gaap:ResearchAndDevelopmentExpense id="Tag154" contextRef="D2015-01-01_To_2015-09-30" unitRef="USD" decimals="-3">18493000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="Tag155" contextRef="D2014-01-01_To_2014-09-30" unitRef="USD" decimals="-3">23280000</us-gaap:ResearchAndDevelopmentExpense>
  <plx:GrantsAndReimbursementsReceivedOrReceivable id="Tag156" contextRef="D2015-01-01_To_2015-09-30" unitRef="USD" decimals="-3">3856000</plx:GrantsAndReimbursementsReceivedOrReceivable>
  <plx:GrantsAndReimbursementsReceivedOrReceivable id="Tag157" contextRef="D2014-01-01_To_2014-09-30" unitRef="USD" decimals="-3">6146000</plx:GrantsAndReimbursementsReceivedOrReceivable>
  <plx:ResearchDevelopmentAndEngineeringExpenseNet id="Tag158" contextRef="D2015-01-01_To_2015-09-30" unitRef="USD" decimals="-3">14637000</plx:ResearchDevelopmentAndEngineeringExpenseNet>
  <plx:ResearchDevelopmentAndEngineeringExpenseNet id="Tag159" contextRef="D2014-01-01_To_2014-09-30" unitRef="USD" decimals="-3">17134000</plx:ResearchDevelopmentAndEngineeringExpenseNet>
  <us-gaap:SellingGeneralAndAdministrativeExpense id="Tag160" contextRef="D2015-01-01_To_2015-09-30" unitRef="USD" decimals="-3">6259000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:SellingGeneralAndAdministrativeExpense id="Tag161" contextRef="D2014-01-01_To_2014-09-30" unitRef="USD" decimals="-3">7289000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:OperatingIncomeLoss id="Tag162" contextRef="D2015-01-01_To_2015-09-30" unitRef="USD" decimals="-3">-12122000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="Tag163" contextRef="D2014-01-01_To_2014-09-30" unitRef="USD" decimals="-3">-18123000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OtherNonoperatingExpense id="Tag164" contextRef="D2015-01-01_To_2015-09-30" unitRef="USD" decimals="-3">2805000</us-gaap:OtherNonoperatingExpense>
  <us-gaap:OtherNonoperatingExpense id="Tag165" contextRef="D2014-01-01_To_2014-09-30" unitRef="USD" decimals="-3">3490000</us-gaap:OtherNonoperatingExpense>
  <us-gaap:OtherNonoperatingIncome id="Tag166" contextRef="D2015-01-01_To_2015-09-30" unitRef="USD" decimals="-3">64000</us-gaap:OtherNonoperatingIncome>
  <us-gaap:OtherNonoperatingIncome id="Tag167" contextRef="D2014-01-01_To_2014-09-30" unitRef="USD" decimals="-3">139000</us-gaap:OtherNonoperatingIncome>
  <us-gaap:NonoperatingIncomeExpense id="Tag168" contextRef="D2015-01-01_To_2015-09-30" unitRef="USD" decimals="-3">-2741000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense id="Tag169" contextRef="D2014-01-01_To_2014-09-30" unitRef="USD" decimals="-3">-3351000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:EarningsPerShareBasicAndDiluted id="Tag170" contextRef="D2015-01-01_To_2015-09-30" unitRef="USDPerShare" decimals="2">-0.16</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="Tag171" contextRef="D2014-01-01_To_2014-09-30" unitRef="USDPerShare" decimals="2">-0.23</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="Tag172" contextRef="D2015-01-01_To_2015-09-30" unitRef="Shares" decimals="0">93599414</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="Tag173" contextRef="D2014-01-01_To_2014-09-30" unitRef="Shares" decimals="0">92828851</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Tag174" contextRef="D2015-01-01_To_2015-09-30_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="-3">667000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Tag175" contextRef="D2014-01-01_To_2014-09-30_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="-3">764000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Tag176" contextRef="D2015-01-01_To_2015-09-30_SellingGeneralAndAdministrativeExpensesMember" unitRef="USD" decimals="-3">752000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Tag177" contextRef="D2014-01-01_To_2014-09-30_SellingGeneralAndAdministrativeExpensesMember" unitRef="USD" decimals="-3">-81000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:GrossProfit id="Tag178" contextRef="D2014-07-01_To_2014-09-30" unitRef="USD" decimals="-3">1909000</us-gaap:GrossProfit>
  <us-gaap:ResearchAndDevelopmentExpense id="Tag179" contextRef="D2015-07-01_To_2015-09-30" unitRef="USD" decimals="-3">5260000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="Tag180" contextRef="D2014-07-01_To_2014-09-30" unitRef="USD" decimals="-3">8052000</us-gaap:ResearchAndDevelopmentExpense>
  <plx:GrantsAndReimbursementsReceivedOrReceivable id="Tag181" contextRef="D2015-07-01_To_2015-09-30" unitRef="USD" decimals="-3">1207000</plx:GrantsAndReimbursementsReceivedOrReceivable>
  <plx:GrantsAndReimbursementsReceivedOrReceivable id="Tag182" contextRef="D2014-07-01_To_2014-09-30" unitRef="USD" decimals="-3">1947000</plx:GrantsAndReimbursementsReceivedOrReceivable>
  <plx:ResearchDevelopmentAndEngineeringExpenseNet id="Tag183" contextRef="D2015-07-01_To_2015-09-30" unitRef="USD" decimals="-3">4053000</plx:ResearchDevelopmentAndEngineeringExpenseNet>
  <plx:ResearchDevelopmentAndEngineeringExpenseNet id="Tag184" contextRef="D2014-07-01_To_2014-09-30" unitRef="USD" decimals="-3">6105000</plx:ResearchDevelopmentAndEngineeringExpenseNet>
  <us-gaap:SellingGeneralAndAdministrativeExpense id="Tag185" contextRef="D2015-07-01_To_2015-09-30" unitRef="USD" decimals="-3">2254000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:SellingGeneralAndAdministrativeExpense id="Tag186" contextRef="D2014-07-01_To_2014-09-30" unitRef="USD" decimals="-3">2012000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:OperatingIncomeLoss id="Tag187" contextRef="D2015-07-01_To_2015-09-30" unitRef="USD" decimals="-3">-2807000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="Tag188" contextRef="D2014-07-01_To_2014-09-30" unitRef="USD" decimals="-3">-6208000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OtherNonoperatingExpense id="Tag189" contextRef="D2015-07-01_To_2015-09-30" unitRef="USD" decimals="-3">1030000</us-gaap:OtherNonoperatingExpense>
  <us-gaap:OtherNonoperatingExpense id="Tag190" contextRef="D2014-07-01_To_2014-09-30" unitRef="USD" decimals="-3">1851000</us-gaap:OtherNonoperatingExpense>
  <us-gaap:OtherNonoperatingIncome id="Tag191" contextRef="D2015-07-01_To_2015-09-30" unitRef="USD" decimals="-3">17000</us-gaap:OtherNonoperatingIncome>
  <us-gaap:OtherNonoperatingIncome id="Tag192" contextRef="D2014-07-01_To_2014-09-30" unitRef="USD" decimals="-3">49000</us-gaap:OtherNonoperatingIncome>
  <us-gaap:NonoperatingIncomeExpense id="Tag193" contextRef="D2015-07-01_To_2015-09-30" unitRef="USD" decimals="-3">-1013000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense id="Tag194" contextRef="D2014-07-01_To_2014-09-30" unitRef="USD" decimals="-3">-1802000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NetIncomeLoss id="Tag195" contextRef="D2015-07-01_To_2015-09-30" unitRef="USD" decimals="-3">-3820000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="Tag196" contextRef="D2014-07-01_To_2014-09-30" unitRef="USD" decimals="-3">-8010000</us-gaap:NetIncomeLoss>
  <us-gaap:EarningsPerShareBasicAndDiluted id="Tag197" contextRef="D2015-07-01_To_2015-09-30" unitRef="USDPerShare" decimals="2">-0.04</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="Tag198" contextRef="D2014-07-01_To_2014-09-30" unitRef="USDPerShare" decimals="2">-0.09</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="Tag199" contextRef="D2015-07-01_To_2015-09-30" unitRef="Shares" decimals="0">93943772</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="Tag200" contextRef="D2014-07-01_To_2014-09-30" unitRef="Shares" decimals="0">92971572</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Tag201" contextRef="D2015-07-01_To_2015-09-30_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="-3">258000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Tag202" contextRef="D2014-07-01_To_2014-09-30_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="-3">173000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Tag203" contextRef="D2015-07-01_To_2015-09-30_SellingGeneralAndAdministrativeExpensesMember" unitRef="USD" decimals="-3">188000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Tag204" contextRef="D2014-07-01_To_2014-09-30_SellingGeneralAndAdministrativeExpensesMember" unitRef="USD" decimals="-3">-67000</us-gaap:AllocatedShareBasedCompensationExpense>
  <plx:RevenuesOtherThanCompanyShareInCollaborationAgreement id="Tag205" contextRef="D2015-07-01_To_2015-09-30" unitRef="USD" decimals="-3">4301000</plx:RevenuesOtherThanCompanyShareInCollaborationAgreement>
  <plx:RevenuesOtherThanCompanyShareInCollaborationAgreement id="Tag206" contextRef="D2014-07-01_To_2014-09-30" unitRef="USD" decimals="-3">2396000</plx:RevenuesOtherThanCompanyShareInCollaborationAgreement>
  <plx:CompanyShareInCollaborationAgreement id="Tag207" contextRef="D2015-07-01_To_2015-09-30" unitRef="USD" decimals="-3">1545000</plx:CompanyShareInCollaborationAgreement>
  <plx:CompanyShareInCollaborationAgreement id="Tag208" contextRef="D2014-07-01_To_2014-09-30" unitRef="USD" decimals="-3">1311000</plx:CompanyShareInCollaborationAgreement>
  <us-gaap:CostOfRevenue id="Tag209" contextRef="D2015-07-01_To_2015-09-30" unitRef="USD" decimals="-3">2346000</us-gaap:CostOfRevenue>
  <us-gaap:CostOfRevenue id="Tag210" contextRef="D2014-07-01_To_2014-09-30" unitRef="USD" decimals="-3">1798000</us-gaap:CostOfRevenue>
  <us-gaap:GrossProfit id="Tag211" contextRef="D2015-07-01_To_2015-09-30" unitRef="USD" decimals="-3">3500000</us-gaap:GrossProfit>
  <dei:EntityFilerCategory id="Tag212" contextRef="D2015-01-01_To_2015-09-30">Accelerated Filer</dei:EntityFilerCategory>
  <dei:DocumentFiscalPeriodFocus id="Tag213" contextRef="D2015-01-01_To_2015-09-30">Q3</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentFiscalYearFocus id="Tag214" contextRef="D2015-01-01_To_2015-09-30">2015</dei:DocumentFiscalYearFocus>
  <dei:EntityCentralIndexKey id="Tag215" contextRef="D2015-01-01_To_2015-09-30">0001006281</dei:EntityCentralIndexKey>
  <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock id="Tag216" contextRef="D2015-01-01_To_2015-09-30">&lt;div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"&gt;
&lt;p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px;"&gt;&lt;b&gt;NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES&lt;/b&gt;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman', Times, serif; letter-spacing: normal; orphans: auto; text-indent: 0px; text-transform: none; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; margin-top: 0px; margin-bottom: 0px;"&gt;

&lt;tr style="vertical-align: top; text-align: justify;"&gt;
&lt;td style="width: 0.5in;"&gt;&lt;/td&gt;
&lt;td style="width: 0.25in; text-align: left;"&gt;&lt;b&gt;a.&lt;/b&gt;&lt;/td&gt;
&lt;td style="text-align: justify;"&gt;&lt;b&gt;General&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin-top: 0pt; margin-bottom: 0pt; font-stretch: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;"&gt;&lt;font style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 13.3333px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: inline !important; float: none;"&gt;Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &amp;#147;Company&amp;#148;), and its wholly-owned subsidiary, Protalix Ltd., are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company's proprietary ProCellEx&amp;#174; protein expression system (&amp;#147;ProCellEx&amp;#148;). Using the ProCellEx system, the Company is developing a pipeline of proprietary recombinant therapeutic proteins. The Company's initial commercial focus has been on complex therapeutic proteins, including proteins for the treatment of genetic disorders, such as Gaucher disease and Fabry disease. The Company's strategy is to develop proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications. To date, the Company has successfully developed a treatment for Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets, and the Company has number of product candidates in varying stages of the clinical development process. In September 2009, Protalix Ltd. formed another wholly-owned subsidiary under the laws of the Netherlands, Protalix B.V., in connection with the European Medicines Agency (&amp;#147;EMA&amp;#148;) application process in the European Union. The Company's two subsidiaries are referred to collectively herein as the &amp;#147;Subsidiaries.&amp;#148;&lt;/font&gt;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;"&gt;On May 1, 2012, the U.S. Food and Drug Administration (&amp;#147;FDA&amp;#148;) approved for sale the Company's first commercial product, taliglucerase alfa for injection, an enzyme replacement therapy (&amp;#147;ERT&amp;#148;) for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. Subsequently, taliglucerase alfa was approved for marketing by the regulatory authorities of other countries. Taliglucerase alfa is being marketed under the name Uplyso&lt;sup&gt;TM&lt;/sup&gt; in Brazil and certain other Latin American countries and&amp;#160;Elelyso&lt;sup&gt;TM&lt;/sup&gt; in the rest of the territories.&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;"&gt;Since its approval by the FDA, taliglucerase alfa has been marketed mainly in the United States by Pfizer Inc. (&amp;#147;Pfizer&amp;#148;), the Company's commercialization partner, as provided in the exclusive license and supply agreement by and between Protalix Ltd., the Company's wholly-owned subsidiary, and Pfizer, which is referred to herein as the Pfizer Agreement. In October 2015, the Company entered into an Amended and Restated Exclusive License and Supply Agreement (the &amp;#147;Amended Pfizer Agreement&amp;#148;) which amends and restates the Pfizer Agreement in its entirety. Pursuant to the Amended Pfizer Agreement, the Company sold to Pfizer its share in the collaboration created under the initial Pfizer Agreement for the commercialization of Elelyso in exchange for a cash payment equal to $&lt;font&gt;36.0&lt;/font&gt; million. &lt;font style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 13.3333px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: inline !important; float: none;"&gt;As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to Elelyso in Brazil. Under the initial Pfizer Agreement, Pfizer and the Company shared revenues and expenses for the development and commercialization of Elelyso on a&amp;#160;&lt;/font&gt;&lt;font&gt;60&lt;/font&gt;%/&lt;font&gt;40&lt;/font&gt;% basis globally, excluding Israel and Brazil. Under the Amended Pfizer Agreement, Pfizer is responsible for &lt;font&gt;100&lt;/font&gt;% of expenses, and entitled to all of the revenues, globally for Elelyso, excluding Brazil, where the Company is responsible for all expenses and retains all revenues. The Amended Pfizer Agreement eliminates Pfizer's entitlement to annual payments of up to $&lt;font&gt;12.5&lt;/font&gt; million in relation to commercialization of Elelyso in Brazil.&amp;#160;&lt;font style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 13.3333px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: inline !important; float: none;"&gt;For further details please see Note 5.&lt;/font&gt;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;"&gt;On June 18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &amp;#147;Brazil Agreement&amp;#148;) with Funda&amp;#231;&amp;#227;o Oswaldo Cruz (&amp;#147;Fiocruz&amp;#148;), an arm of the Brazilian Ministry of Health for taliglucerase alfa. The agreement became effective in January 2014. The technology transfer is designed to be completed in &lt;font&gt;four&lt;/font&gt; stages and is intended to transfer to Fiocruz the capacity and skills required for the Brazilian government to construct its own manufacturing facility, at its sole expense, and to produce a sustainable, high-quality, and cost-effective supply of taliglucerase alfa. The Company is not required to complete the final stage of the technology transfer until Fiocruz purchases at least approximately $&lt;font&gt;280&lt;/font&gt; million worth of taliglucerase alfa.&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;"&gt;&lt;font style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 13.3333px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: inline !important; float: none;"&gt;Fiocruz's purchases of Uplyso to date have been significantly below certain agreed upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the low purchase amounts, the Company is, at this time, continuing to supply Uplyso to Fiocruz under the Brazil Agreement, and patients continue to be treated with Uplyso in Brazil. Approximately&lt;/font&gt;&amp;#160;&lt;font&gt;10&lt;/font&gt;% of adult Gaucher patients in Brazil are currently treated with Uplyso. The Company is discussing with Fiocruz potential actions that Fiocruz may take to comply with its purchase obligations and, based on such discussions, the Company will determine what it believes to be the course of action that is in the best interest of the Company.&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;"&gt;The Company will pay a fee equal to &lt;font&gt;5&lt;/font&gt;%&amp;#160;&lt;font style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 13.3333px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: inline !important; float: none;"&gt;of the net proceeds generated in Brazil to an agent for services provided in assisting the Company complete the Brazil Agreement pursuant to an agreement between the agent and the Company. The agreement will remain in effect with respect to the Brazil Agreement until the termination thereof.&lt;/font&gt;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;"&gt;In addition to taliglucerase alfa, the Company is developing an innovative product pipeline using its ProCellEx protein expression system. The Company's product pipeline currently includes, among other candidates:&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;"&gt;(1) PRX-102, or alpha-GAL-A, a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder in humans.&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;"&gt;(2) PRX-106, the Company's oral antiTNF product candidate which is being developed as an orally-delivered anti inflammatory treatment using plant cells as a natural capsule for the expressed protein.&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;"&gt;(3) PRX-110, a proprietary plant cell recombinant human Deoxyribonuclease 1, or DNase, under development for the treatment of cystic fibrosis, to be administered by inhalation.&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;"&gt;(4) PRX-112, an orally administered glucocerebrosidase enzyme for the treatment of Gaucher patients utilizing oral delivery of the recombinant GCD enzyme produced and encapsulated within carrot cells.&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;"&gt;Obtaining marketing approval with respect to any product candidate in any country is directly dependent on the Company's ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;"&gt;Based on its current cash resources and commitments, the Company believes it will be able to maintain its current planned development activities and the corresponding level of expenditures for &lt;font style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 13.3333px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: inline !important; float: none;"&gt;at least 12 months&lt;/font&gt;, although &lt;font&gt;no&lt;/font&gt; assurance can be given that it will not need additional funds prior to such time. If there are unexpected increases in general and administrative expenses or research and development expenses, the Company may need to seek additional financing.&lt;/p&gt;
&lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;div&gt;
&lt;div class="CursorPointer"&gt;
&lt;table cellpadding="0" cellspacing="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 0px; width: 100%;"&gt;

&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 0.5in;"&gt;&lt;/td&gt;
&lt;td style="width: 0.25in; font-family: 'times new roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;b&gt;b.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;b&gt;Basis of Presentation&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (&amp;#147;GAAP&amp;#148;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December 31, 2014, filed by the Company with the U.S. Securities and Exchange Commission &lt;font style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 13.3333330154419px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: inline !important; float: none;"&gt;(the &amp;#147;Commission&amp;#148;)&lt;/font&gt;. The comparative balance sheet at December 31, 2014 has been derived from the audited financial statements at that date.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;div&gt;
&lt;div class="CursorPointer"&gt;
&lt;table cellpadding="0" cellspacing="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 0px; width: 100%;"&gt;

&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 0.5in;"&gt;&lt;/td&gt;
&lt;td style="width: 0.25in; font-family: 'times new roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;b&gt;c.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;b&gt;Net loss per share&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Basic and diluted loss per share (&amp;#147;LPS&amp;#148;) are computed by dividing net loss by the weighted average number of shares of the Company's common stock, par value $&lt;font&gt;0.001&lt;/font&gt; per share (the &amp;#147;Common Stock&amp;#148;) outstanding for each period. Diluted LPS does not include &lt;font&gt;18,781,572&lt;/font&gt;&amp;#160;and &lt;font&gt;19,797,190&lt;/font&gt; shares of Common Stock underlying outstanding options and restricted shares of Common Stock and shares issuable upon conversion of the convertible notes (issued in September 2013) for the nine months ended September 30, 2014 and 2015, respectively, and &lt;font&gt;18,661,182&lt;/font&gt; and &lt;font&gt;19,820,485&lt;/font&gt; shares of Common Stock for the three months ended September 30, 2014 and 2015, respectively, because the effect would be anti-dilutive.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;
&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
  <us-gaap:BasisOfAccountingPolicyPolicyTextBlock id="Tag217" contextRef="D2015-01-01_To_2015-09-30">&lt;div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"&gt;
&lt;div class="CursorPointer"&gt;
&lt;table cellpadding="0" cellspacing="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 0px; width: 100%;"&gt;

&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 0.5in;"&gt;&lt;/td&gt;
&lt;td style="width: 0.25in; font-family: 'times new roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;b&gt;b.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;b&gt;Basis of Presentation&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (&amp;#147;GAAP&amp;#148;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December 31, 2014, filed by the Company with the U.S. Securities and Exchange Commission &lt;font style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 13.3333330154419px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: inline !important; float: none;"&gt;(the &amp;#147;Commission&amp;#148;)&lt;/font&gt;. The comparative balance sheet at December 31, 2014 has been derived from the audited financial statements at that date.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
  <dei:EntityCommonStockSharesOutstanding id="Tag218" contextRef="I2015-11-01" unitRef="Shares" decimals="INF">99800397</dei:EntityCommonStockSharesOutstanding>
  <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares id="Tag219" contextRef="D2014-01-01_To_2014-09-30_CommonStockMember" unitRef="Shares" decimals="0">-1834</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares>
  <us-gaap:EarningsPerSharePolicyTextBlock id="Tag220" contextRef="D2015-01-01_To_2015-09-30">&lt;div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"&gt;
&lt;div class="CursorPointer"&gt;
&lt;table cellpadding="0" cellspacing="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 0px; width: 100%;"&gt;

&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 0.5in;"&gt;&lt;/td&gt;
&lt;td style="width: 0.25in; font-family: 'times new roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;b&gt;c.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;b&gt;Net loss per share&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Basic and diluted loss per share (&amp;#147;LPS&amp;#148;) are computed by dividing net loss by the weighted average number of shares of the Company's common stock, par value $&lt;font&gt;0.001&lt;/font&gt; per share (the &amp;#147;Common Stock&amp;#148;) outstanding for each period. Diluted LPS does not include &lt;font&gt;18,781,572&lt;/font&gt;&amp;#160;and &lt;font&gt;19,797,190&lt;/font&gt; shares of Common Stock underlying outstanding options and restricted shares of Common Stock and shares issuable upon conversion of the convertible notes (issued in September 2013) for the nine months ended September 30, 2014 and 2015, respectively, and &lt;font&gt;18,661,182&lt;/font&gt; and &lt;font&gt;19,820,485&lt;/font&gt; shares of Common Stock for the three months ended September 30, 2014 and 2015, respectively, because the effect would be anti-dilutive.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Tag221" contextRef="D2014-01-01_To_2014-09-30" unitRef="Shares" decimals="INF">18781572</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Tag222" contextRef="D2015-01-01_To_2015-09-30" unitRef="Shares" decimals="INF">19797190</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Tag223" contextRef="D2014-07-01_To_2014-09-30" unitRef="Shares" decimals="INF">18661182</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Tag224" contextRef="D2015-07-01_To_2015-09-30" unitRef="Shares" decimals="INF">19820485</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:InventoryRawMaterialsNetOfReserves id="Tag225" contextRef="I2015-09-30" unitRef="USD" decimals="-3">1502000</us-gaap:InventoryRawMaterialsNetOfReserves>
  <us-gaap:InventoryRawMaterialsNetOfReserves id="Tag226" contextRef="I2014-12-31" unitRef="USD" decimals="-3">1616000</us-gaap:InventoryRawMaterialsNetOfReserves>
  <us-gaap:InventoryWorkInProcessNetOfReserves id="Tag227" contextRef="I2014-12-31" unitRef="USD" decimals="-3">132000</us-gaap:InventoryWorkInProcessNetOfReserves>
  <us-gaap:InventoryFinishedGoodsNetOfReserves id="Tag228" contextRef="I2015-09-30" unitRef="USD" decimals="-3">4837000</us-gaap:InventoryFinishedGoodsNetOfReserves>
  <us-gaap:InventoryFinishedGoodsNetOfReserves id="Tag229" contextRef="I2014-12-31" unitRef="USD" decimals="-3">4919000</us-gaap:InventoryFinishedGoodsNetOfReserves>
  <us-gaap:InventoryWriteDown id="Tag230" contextRef="D2015-01-01_To_2015-09-30" unitRef="USD" decimals="-5">1600000</us-gaap:InventoryWriteDown>
  <us-gaap:InventoryDisclosureTextBlock id="Tag231" contextRef="D2015-01-01_To_2015-09-30">&lt;div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-family: 'times new roman', times; font-size: 10pt;"&gt;&lt;b&gt;NOTE 2 - INVENTORIES&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in;"&gt;&lt;font style="font-family: 'times new roman', times; font-size: 10pt;"&gt;Inventory at September 30, 2015 and December 31, 2014 consisted of the following:&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in;"&gt;&lt;font style="font-family: 'times new roman', times; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;div&gt;
&lt;div style="display: block; margin-left: 0.7in;"&gt;
&lt;div class="CursorPointer"&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 85%; /* margin-left: 0.7in;"&gt;

&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; border-bottom: Black 0.75pt solid;"&gt;&lt;strong&gt;&lt;font style="font-family: 'times new roman', times; font-size: 10pt;"&gt; September 30, &lt;/font&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;strong&gt;&lt;font style="font-family: 'times new roman', times; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/strong&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap" colspan="2"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; border-bottom: Black 0.75pt solid;"&gt;&lt;strong&gt;&lt;font style="font-family: 'times new roman', times; font-size: 10pt;"&gt; December 31, &lt;/font&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; padding: 0px; width: 20px;" nowrap="nowrap" colspan="5"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; border-bottom: Black 0.75pt solid;"&gt;&lt;strong&gt;&lt;font style="font-family: 'times new roman', times; font-size: 10pt;"&gt; 2015 &lt;/font&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;strong&gt;&lt;font style="font-family: 'times new roman', times; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/strong&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap" colspan="2"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; border-bottom: Black 0.75pt solid;"&gt;&lt;strong&gt;&lt;font style="font-family: 'times new roman', times; font-size: 10pt;"&gt; 2014 &lt;/font&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; padding: 0px; width: 20px;" nowrap="nowrap" colspan="5"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="text-align: center; padding: 0px;" colspan="6" nowrap="nowrap"&gt;&lt;font style="font-family: 'times new roman', times; font-size: 10pt;"&gt;(&lt;i&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; width: 74%;"&gt;&lt;font style="font-family: 'times new roman', times; font-size: 10pt;"&gt;Raw materials&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; width: 1%;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 1%;"&gt;&lt;font style="font-family: 'times new roman', times; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt;"&gt;1,502&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"&gt;&lt;font style="font-family: 'times new roman', times; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"&gt;&lt;font style="font-family: 'times new roman', times; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 1%;"&gt;&lt;font style="font-family: 'times new roman', times; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"&gt;&lt;font style="font-family: 'times new roman', times; font-size: 10pt;"&gt;&lt;font&gt;1,616&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"&gt;&lt;font style="font-family: 'times new roman', times; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-family: 'times new roman', times; font-size: 10pt;"&gt;Work&amp;#160;in&amp;#160;progress&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-family: 'times new roman', times; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-family: 'times new roman', times; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-family: 'times new roman', times; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-family: 'times new roman', times; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-family: 'times new roman', times; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-family: 'times new roman', times; font-size: 10pt;"&gt;&lt;font&gt;132&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-family: 'times new roman', times; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-family: 'times new roman', times; font-size: 10pt;"&gt;Finished goods&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-family: 'times new roman', times; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-family: 'times new roman', times; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt;"&gt;4,837&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-family: 'times new roman', times; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-family: 'times new roman', times; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-family: 'times new roman', times; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-family: 'times new roman', times; font-size: 10pt;"&gt;&lt;font&gt;4,919&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-family: 'times new roman', times; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-family: 'times new roman', times; font-size: 10pt;"&gt;Total inventory&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-family: 'times new roman', times; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-family: 'times new roman', times; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt;"&gt;6,339&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-family: 'times new roman', times; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-family: 'times new roman', times; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-family: 'times new roman', times; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-family: 'times new roman', times; font-size: 10pt;"&gt;&lt;font&gt;6,667&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-family: 'times new roman', times; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.9pt;"&gt;&lt;font style="font-family: 'times new roman', times; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in;"&gt;&lt;font style="font-family: 'times new roman', times; font-size: 10pt;"&gt;During the nine months ended September 30, 2015, the Company recorded approximately $&lt;font&gt;&lt;strong&gt;&lt;font style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 13.3333px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: inline !important; float: none;"&gt;1.6&lt;/font&gt;&lt;/strong&gt;&lt;/font&gt;&amp;#160;million for write-down of inventory under cost of revenues.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
  <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited id="Tag232" contextRef="D2014-01-01_To_2014-09-30" unitRef="Shares" decimals="INF">1834</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited>
  <us-gaap:ScheduleOfInventoryCurrentTableTextBlock id="Tag233" contextRef="D2015-01-01_To_2015-09-30">&lt;div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"&gt;
&lt;div style="display: block; margin-left: 0.7in;"&gt;
&lt;div class="CursorPointer"&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 85%; /* margin-left: 0.7in;"&gt;

&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; border-bottom: Black 0.75pt solid;"&gt;&lt;strong&gt;&lt;font style="font-family: 'times new roman', times; font-size: 10pt;"&gt; September 30, &lt;/font&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;strong&gt;&lt;font style="font-family: 'times new roman', times; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/strong&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap" colspan="2"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; border-bottom: Black 0.75pt solid;"&gt;&lt;strong&gt;&lt;font style="font-family: 'times new roman', times; font-size: 10pt;"&gt; December 31, &lt;/font&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; padding: 0px; width: 20px;" nowrap="nowrap" colspan="5"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; border-bottom: Black 0.75pt solid;"&gt;&lt;strong&gt;&lt;font style="font-family: 'times new roman', times; font-size: 10pt;"&gt; 2015 &lt;/font&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;strong&gt;&lt;font style="font-family: 'times new roman', times; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/strong&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap" colspan="2"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; border-bottom: Black 0.75pt solid;"&gt;&lt;strong&gt;&lt;font style="font-family: 'times new roman', times; font-size: 10pt;"&gt; 2014 &lt;/font&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; padding: 0px; width: 20px;" nowrap="nowrap" colspan="5"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="text-align: center; padding: 0px;" colspan="6" nowrap="nowrap"&gt;&lt;font style="font-family: 'times new roman', times; font-size: 10pt;"&gt;(&lt;i&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; width: 74%;"&gt;&lt;font style="font-family: 'times new roman', times; font-size: 10pt;"&gt;Raw materials&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; width: 1%;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 1%;"&gt;&lt;font style="font-family: 'times new roman', times; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt;"&gt;1,502&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"&gt;&lt;font style="font-family: 'times new roman', times; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"&gt;&lt;font style="font-family: 'times new roman', times; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 1%;"&gt;&lt;font style="font-family: 'times new roman', times; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"&gt;&lt;font style="font-family: 'times new roman', times; font-size: 10pt;"&gt;&lt;font&gt;1,616&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"&gt;&lt;font style="font-family: 'times new roman', times; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-family: 'times new roman', times; font-size: 10pt;"&gt;Work&amp;#160;in&amp;#160;progress&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-family: 'times new roman', times; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-family: 'times new roman', times; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-family: 'times new roman', times; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-family: 'times new roman', times; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-family: 'times new roman', times; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-family: 'times new roman', times; font-size: 10pt;"&gt;&lt;font&gt;132&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-family: 'times new roman', times; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-family: 'times new roman', times; font-size: 10pt;"&gt;Finished goods&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-family: 'times new roman', times; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-family: 'times new roman', times; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt;"&gt;4,837&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-family: 'times new roman', times; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-family: 'times new roman', times; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-family: 'times new roman', times; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-family: 'times new roman', times; font-size: 10pt;"&gt;&lt;font&gt;4,919&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-family: 'times new roman', times; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-family: 'times new roman', times; font-size: 10pt;"&gt;Total inventory&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-family: 'times new roman', times; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-family: 'times new roman', times; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt;"&gt;6,339&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-family: 'times new roman', times; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-family: 'times new roman', times; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-family: 'times new roman', times; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-family: 'times new roman', times; font-size: 10pt;"&gt;&lt;font&gt;6,667&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-family: 'times new roman', times; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
  <us-gaap:ConvertibleDebtFairValueDisclosures id="Tag234" contextRef="I2015-09-30" unitRef="USD" decimals="-5">45500000</us-gaap:ConvertibleDebtFairValueDisclosures>
  <us-gaap:FairValueDisclosuresTextBlock id="Tag235" contextRef="D2015-01-01_To_2015-09-30">&lt;div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;b&gt;NOTE 3 &amp;#150; FAIR VALUE MEASUREMENT&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;The fair value of the financial instruments included in the working capital of the Company is usually identical or close to their carrying value.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;The fair value of the convertible notes as of September 30, 2015 is approximately $&lt;font&gt;45.5&lt;/font&gt;&amp;#160;million based on a level 2 measurement.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
  <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue id="Tag236" contextRef="I2015-03-23_EmployeeStockOptionMember_EmployeeStockIncentivePlan2006Member" unitRef="USD" decimals="-5">1900000</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate id="Tag237" contextRef="D2015-03-01_To_2015-03-23_EmployeeStockOptionMember_EmployeeStockIncentivePlan2006Member" unitRef="Pure" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate id="Tag238" contextRef="D2015-03-01_To_2015-03-23_EmployeeStockOptionMember_EmployeeStockIncentivePlan2006Member" unitRef="Pure" decimals="3">0.617</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate id="Tag239" contextRef="D2015-03-01_To_2015-03-23_EmployeeStockOptionMember_EmployeeStockIncentivePlan2006Member" unitRef="Pure" decimals="3">0.016</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="Tag240" contextRef="D2015-03-01_To_2015-03-23_EmployeeStockOptionMember_EmployeeStockIncentivePlan2006Member">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock id="Tag241" contextRef="D2015-01-01_To_2015-09-30">&lt;div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-family: 'times new roman', times; font-size: 10pt;"&gt;&lt;b&gt;NOTE 4 &amp;#150; STOCK TRANSACTIONS&lt;/b&gt;&lt;/font&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0in;"&gt;&lt;font style="font-family: 'times new roman', times; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0in;"&gt;&lt;font style="font-family: 'times new roman', times; font-size: 10pt;"&gt;On March 23, 2015, the Company's compensation committee approved the grant of a &lt;font&gt;10&lt;/font&gt;-year option to purchase &lt;font&gt;1,909,000&lt;/font&gt; shares of Common Stock to its officers and other employees with an exercise price equal to $&lt;font&gt;1.72&lt;/font&gt; per share under the Company's 2006 Employee Stock Incentive Plan, as amended (the &amp;#147;Plan&amp;#148;). The options vest over a &lt;font&gt;four&lt;/font&gt;-year period; the first &lt;font&gt;25&lt;/font&gt;% shares vest on the first anniversary of the grant date and the remaining shares vest in &lt;font&gt;12&lt;/font&gt; equal quarterly increments over the subsequent &lt;font&gt;three&lt;/font&gt;-year period. Vesting of the options granted to certain executive officers are subject to acceleration in full upon a Corporate Transaction or a Change in Control, as those terms are defined in the Plan. The Company estimated the fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately $&lt;font&gt;1.9&lt;/font&gt; million based on the following weighted average assumptions: dividend yield of &lt;font&gt;0&lt;/font&gt;% for all years; expected volatility of &lt;font&gt;61.7&lt;/font&gt;%; risk-free interest rates of &lt;font&gt;1.6&lt;/font&gt;%; and expected life of &lt;font&gt;six&lt;/font&gt; years.&lt;/font&gt;&lt;/p&gt; &lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod id="Tag242" contextRef="D2015-03-01_To_2015-03-23_EmployeeStockOptionMember_EmployeeStockIncentivePlan2006Member">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod id="Tag243" contextRef="D2015-03-01_To_2015-03-23_EmployeeStockOptionMember_EmployeeStockIncentivePlan2006Member" unitRef="Shares" decimals="INF">1909000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice id="Tag244" contextRef="D2015-03-01_To_2015-03-23_EmployeeStockOptionMember_EmployeeStockIncentivePlan2006Member" unitRef="USDPerShare" decimals="2">1.72</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 id="Tag245" contextRef="D2015-03-01_To_2015-03-23_EmployeeStockOptionMember_EmployeeStockIncentivePlan2006Member">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage id="Tag246" contextRef="D2015-03-01_To_2015-03-23_EmployeeStockOptionMember_ShareBasedCompensationAwardTrancheOneMember_EmployeeStockIncentivePlan2006Member" unitRef="Pure" decimals="2">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
  <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod id="Tag247" contextRef="D2015-03-01_To_2015-03-23_EmployeeStockOptionMember_ShareBasedCompensationAwardTrancheTwoMember_EmployeeStockIncentivePlan2006Member" unitRef="Item" decimals="INF">12</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 id="Tag248" contextRef="D2015-03-01_To_2015-03-23_EmployeeStockOptionMember_ShareBasedCompensationAwardTrancheTwoMember_EmployeeStockIncentivePlan2006Member">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <dei:AmendmentFlag id="Tag249" contextRef="D2015-01-01_To_2015-09-30">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate id="Tag250" contextRef="D2015-01-01_To_2015-09-30">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentPeriodEndDate id="Tag251" contextRef="D2015-01-01_To_2015-09-30">2015-09-30</dei:DocumentPeriodEndDate>
  <dei:TradingSymbol id="Tag252" contextRef="D2015-01-01_To_2015-09-30">PLX</dei:TradingSymbol>
  <dei:EntityRegistrantName id="Tag253" contextRef="D2015-01-01_To_2015-09-30">PROTALIX BIOTHERAPEUTICS, INC.	</dei:EntityRegistrantName>
  <dei:DocumentType id="Tag254" contextRef="D2015-01-01_To_2015-09-30">10-Q</dei:DocumentType>
  <plx:LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfitsEliminationAmount id="Tag255" contextRef="I2015-10-31_ProtalixBioTherapeuticsIncorporationMember_SubsequentEventMember_AmendedPfizerAgreementMember" unitRef="USD" decimals="-5">12500000</plx:LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfitsEliminationAmount>
  <plx:PurchaseAmountToBeSatisfiedToReceiveEntitledRights id="Tag256" contextRef="I2013-06-18_SubsidiariesMember_BrazilAgreementMember_FiocruzMember" unitRef="USD" decimals="-6">280000000</plx:PurchaseAmountToBeSatisfiedToReceiveEntitledRights>
  <plx:CollaborativeArrangementRevenuesExpensesSharingPercentage id="Tag257" contextRef="I2015-09-30_PfizerIncorporationMember_PfizerAgreementMember" unitRef="Pure" decimals="2">0.60</plx:CollaborativeArrangementRevenuesExpensesSharingPercentage>
  <plx:CollaborativeArrangementRevenuesExpensesSharingPercentage id="Tag258" contextRef="I2015-09-30_ProtalixBioTherapeuticsIncorporationMember_PfizerAgreementMember" unitRef="Pure" decimals="2">0.40</plx:CollaborativeArrangementRevenuesExpensesSharingPercentage>
  <plx:PercentageOfAdultGaucherPatientsTreatedWithUplyso id="Tag259" contextRef="D2015-01-01_To_2015-09-30_SubsidiariesMember_BrazilAgreementMember_FiocruzMember" unitRef="Pure" decimals="2">0.10</plx:PercentageOfAdultGaucherPatientsTreatedWithUplyso>
  <us-gaap:SubsequentEventsTextBlock id="Tag260" contextRef="D2015-01-01_To_2015-09-30">&lt;div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"&gt;
&lt;p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px;"&gt;&lt;b&gt;NOTE 5 &amp;#150; SUBSEQUENT EVENTS&lt;/b&gt;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0in; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 0.5in;"&gt;On October 12, 2015, the Company entered into the Amended Pfizer Agreement which amends and restates, in its entirety, the Pfizer Agreement. See Note 1. Pursuant to the Amended Pfizer Agreement, the Company sold its share in the collaboration with Pfizer on the commercialization of Elelyso to Pfizer in exchange for a cash payment equal to $&lt;font&gt;36.0&lt;/font&gt; million. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer in exchange for full rights to Elelyso in Brazil. Under the Amended Pfizer Agreement, the Company will continue to manufacture drug substance for Pfizer, subject to certain terms and conditions. In addition, the Company issued to Pfizer a promissory note for approximately $&lt;font&gt;4.2&lt;/font&gt; million, representing the Company's share of accumulated losses as of the date of the Amended Pfizer Agreement.&amp;#160;The note is to be paid in October 2020, subject to certain terms and conditions. Under the Pfizer Agreement, Pfizer and the Company shared in revenues and expenses for the development and commercialization of Elelyso on a 60%/40% basis globally, excluding Israel and Brazil. Under the Amended Pfizer Agreement, Pfizer is responsible for 100% of expenses, and entitled to all of the revenues, globally for Elelyso, excluding Brazil, where the Company is responsible for all expenses and retains all revenues. The Amended Pfizer Agreement eliminates Pfizer's entitlement to annual payments of up to $12.5 million in relation to commercialization of Elelyso in Brazil.&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0in; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 0.5in;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0in; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 0.5in;"&gt;On October 12, 2015, the Company also entered into a Stock Purchase Agreement with Pfizer, pursuant to which the Company issued &lt;font&gt;5,649,079&lt;/font&gt; shares of the Company's common stock for an aggregate purchase price equal to $&lt;font&gt;10.0&lt;/font&gt;&amp;#160;million subject to certain other terms set forth in the Stock Purchase Agreement. As part of the Stock Purchase Agreement, Pfizer has agreed to a &lt;font&gt;180&lt;/font&gt;-day lock-up with respect to the purchased shares and the Company's directors and executive officers have entered into &lt;font&gt;90&lt;/font&gt;-day lock up agreements.&lt;/p&gt;
&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="Tag261" contextRef="D2015-10-01_To_2015-10-31_SubsequentEventMember" unitRef="Shares" decimals="INF">5649079</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="Tag262" contextRef="D2015-10-01_To_2015-10-31_SubsequentEventMember" unitRef="USD" decimals="-5">10000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <plx:NatureOfOperationsPolicyTextBlock id="Tag263" contextRef="D2015-01-01_To_2015-09-30">&lt;div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"&gt;
&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman', Times, serif; letter-spacing: normal; orphans: auto; text-indent: 0px; text-transform: none; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; margin-top: 0px; margin-bottom: 0px;"&gt;

&lt;tr style="vertical-align: top; text-align: justify;"&gt;
&lt;td style="width: 0.5in;"&gt;&lt;/td&gt;
&lt;td style="width: 0.25in; text-align: left;"&gt;&lt;b&gt;a.&lt;/b&gt;&lt;/td&gt;
&lt;td style="text-align: justify;"&gt;&lt;b&gt;General&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin-top: 0pt; margin-bottom: 0pt; font-stretch: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;"&gt;&lt;font style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 13.3333px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: inline !important; float: none;"&gt;Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &amp;#147;Company&amp;#148;), and its wholly-owned subsidiary, Protalix Ltd., are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company's proprietary ProCellEx&amp;#174; protein expression system (&amp;#147;ProCellEx&amp;#148;). Using the ProCellEx system, the Company is developing a pipeline of proprietary recombinant therapeutic proteins. The Company's initial commercial focus has been on complex therapeutic proteins, including proteins for the treatment of genetic disorders, such as Gaucher disease and Fabry disease. The Company's strategy is to develop proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications. To date, the Company has successfully developed a treatment for Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets, and the Company has number of product candidates in varying stages of the clinical development process. In September 2009, Protalix Ltd. formed another wholly-owned subsidiary under the laws of the Netherlands, Protalix B.V., in connection with the European Medicines Agency (&amp;#147;EMA&amp;#148;) application process in the European Union. The Company's two subsidiaries are referred to collectively herein as the &amp;#147;Subsidiaries.&amp;#148;&lt;/font&gt;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;"&gt;On May 1, 2012, the U.S. Food and Drug Administration (&amp;#147;FDA&amp;#148;) approved for sale the Company's first commercial product, taliglucerase alfa for injection, an enzyme replacement therapy (&amp;#147;ERT&amp;#148;) for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. Subsequently, taliglucerase alfa was approved for marketing by the regulatory authorities of other countries. Taliglucerase alfa is being marketed under the name Uplyso&lt;sup&gt;TM&lt;/sup&gt; in Brazil and certain other Latin American countries and&amp;#160;Elelyso&lt;sup&gt;TM&lt;/sup&gt; in the rest of the territories.&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;"&gt;Since its approval by the FDA, taliglucerase alfa has been marketed mainly in the United States by Pfizer Inc. (&amp;#147;Pfizer&amp;#148;), the Company's commercialization partner, as provided in the exclusive license and supply agreement by and between Protalix Ltd., the Company's wholly-owned subsidiary, and Pfizer, which is referred to herein as the Pfizer Agreement. In October 2015, the Company entered into an Amended and Restated Exclusive License and Supply Agreement (the &amp;#147;Amended Pfizer Agreement&amp;#148;) which amends and restates the Pfizer Agreement in its entirety. Pursuant to the Amended Pfizer Agreement, the Company sold to Pfizer its share in the collaboration created under the initial Pfizer Agreement for the commercialization of Elelyso in exchange for a cash payment equal to $&lt;font&gt;36.0&lt;/font&gt; million. &lt;font style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 13.3333px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: inline !important; float: none;"&gt;As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to Elelyso in Brazil. Under the initial Pfizer Agreement, Pfizer and the Company shared revenues and expenses for the development and commercialization of Elelyso on a&amp;#160;&lt;/font&gt;&lt;font&gt;60&lt;/font&gt;%/&lt;font&gt;40&lt;/font&gt;% basis globally, excluding Israel and Brazil. Under the Amended Pfizer Agreement, Pfizer is responsible for &lt;font&gt;100&lt;/font&gt;% of expenses, and entitled to all of the revenues, globally for Elelyso, excluding Brazil, where the Company is responsible for all expenses and retains all revenues. The Amended Pfizer Agreement eliminates Pfizer's entitlement to annual payments of up to $&lt;font&gt;12.5&lt;/font&gt; million in relation to commercialization of Elelyso in Brazil.&amp;#160;&lt;font style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 13.3333px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: inline !important; float: none;"&gt;For further details please see Note 5.&lt;/font&gt;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;"&gt;On June 18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &amp;#147;Brazil Agreement&amp;#148;) with Funda&amp;#231;&amp;#227;o Oswaldo Cruz (&amp;#147;Fiocruz&amp;#148;), an arm of the Brazilian Ministry of Health for taliglucerase alfa. The agreement became effective in January 2014. The technology transfer is designed to be completed in &lt;font&gt;four&lt;/font&gt; stages and is intended to transfer to Fiocruz the capacity and skills required for the Brazilian government to construct its own manufacturing facility, at its sole expense, and to produce a sustainable, high-quality, and cost-effective supply of taliglucerase alfa. The Company is not required to complete the final stage of the technology transfer until Fiocruz purchases at least approximately $&lt;font&gt;280&lt;/font&gt; million worth of taliglucerase alfa.&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;"&gt;&lt;font style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 13.3333px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: inline !important; float: none;"&gt;Fiocruz's purchases of Uplyso to date have been significantly below certain agreed upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the low purchase amounts, the Company is, at this time, continuing to supply Uplyso to Fiocruz under the Brazil Agreement, and patients continue to be treated with Uplyso in Brazil. Approximately&lt;/font&gt;&amp;#160;&lt;font&gt;10&lt;/font&gt;% of adult Gaucher patients in Brazil are currently treated with Uplyso. The Company is discussing with Fiocruz potential actions that Fiocruz may take to comply with its purchase obligations and, based on such discussions, the Company will determine what it believes to be the course of action that is in the best interest of the Company.&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;"&gt;The Company will pay a fee equal to &lt;font&gt;5&lt;/font&gt;%&amp;#160;&lt;font style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 13.3333px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: inline !important; float: none;"&gt;of the net proceeds generated in Brazil to an agent for services provided in assisting the Company complete the Brazil Agreement pursuant to an agreement between the agent and the Company. The agreement will remain in effect with respect to the Brazil Agreement until the termination thereof.&lt;/font&gt;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;"&gt;In addition to taliglucerase alfa, the Company is developing an innovative product pipeline using its ProCellEx protein expression system. The Company's product pipeline currently includes, among other candidates:&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;"&gt;(1) PRX-102, or alpha-GAL-A, a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder in humans.&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;"&gt;(2) PRX-106, the Company's oral antiTNF product candidate which is being developed as an orally-delivered anti inflammatory treatment using plant cells as a natural capsule for the expressed protein.&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;"&gt;(3) PRX-110, a proprietary plant cell recombinant human Deoxyribonuclease 1, or DNase, under development for the treatment of cystic fibrosis, to be administered by inhalation.&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;"&gt;(4) PRX-112, an orally administered glucocerebrosidase enzyme for the treatment of Gaucher patients utilizing oral delivery of the recombinant GCD enzyme produced and encapsulated within carrot cells.&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;"&gt;Obtaining marketing approval with respect to any product candidate in any country is directly dependent on the Company's ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;"&gt;Based on its current cash resources and commitments, the Company believes it will be able to maintain its current planned development activities and the corresponding level of expenditures for &lt;font style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 13.3333px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: inline !important; float: none;"&gt;at least 12 months&lt;/font&gt;, although &lt;font&gt;no&lt;/font&gt; assurance can be given that it will not need additional funds prior to such time. If there are unexpected increases in general and administrative expenses or research and development expenses, the Company may need to seek additional financing.&lt;/p&gt;
&lt;/div&gt;</plx:NatureOfOperationsPolicyTextBlock>
  <plx:ProceedsFromSaleOfShareInCollaboration id="Tag264" contextRef="D2015-10-01_To_2015-10-31_SubsequentEventMember_AmendedPfizerAgreementMember" unitRef="USD" decimals="-5">36000000</plx:ProceedsFromSaleOfShareInCollaboration>
  <plx:CollaborativeArrangementRevenuesExpensesSharingPercentage id="Tag265" contextRef="I2015-10-31_AmendedPfizerAgreementMember_PfizerIncorporationMember_SubsequentEventMember_ExcludingBrazilMember" unitRef="Pure" decimals="2">1.00</plx:CollaborativeArrangementRevenuesExpensesSharingPercentage>
  <plx:CollaborativeArrangementRevenuesExpensesSharingPercentage id="Tag266" contextRef="I2015-10-31_SubsequentEventMember_AmendedPfizerAgreementMember_BR_ProtalixBioTherapeuticsIncorporationMember" unitRef="Pure" decimals="2">1.00</plx:CollaborativeArrangementRevenuesExpensesSharingPercentage>
  <plx:AgentFeePercentageOfNetProceeds id="Tag267" contextRef="D2015-01-01_To_2015-09-30_SubsidiariesMember_BrazilAgreementMember_FiocruzMember" unitRef="Pure" decimals="2">0.05</plx:AgentFeePercentageOfNetProceeds>
  <plx:StockPurchaseAgreementLockUpPeriod id="Tag268" contextRef="D2015-10-01_To_2015-10-31_SubsequentEventMember_PfizerIncorporationMember">P180D</plx:StockPurchaseAgreementLockUpPeriod>
  <plx:StockPurchaseAgreementLockUpPeriod id="Tag269" contextRef="D2015-10-01_To_2015-10-31_SubsequentEventMember_ExecutiveOfficerMember">P90D</plx:StockPurchaseAgreementLockUpPeriod>
  <us-gaap:DebtInstrumentFaceAmount id="Tag270" contextRef="I2015-10-31_AmendedPfizerAgreementMember_October2015PromissoryNoteToPfizerMember_SubsequentEventMember" unitRef="USD" decimals="-5">4200000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentMaturityDate id="Tag271" contextRef="D2015-10-01_To_2015-10-31_AmendedPfizerAgreementMember_October2015PromissoryNoteToPfizerMember_SubsequentEventMember">2020-10-31</us-gaap:DebtInstrumentMaturityDate>
  <link:footnoteLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:label="value1" xlink:href="#Tag126" />
    <link:loc xlink:type="locator" xlink:label="value1" xlink:href="#Tag140" />
    <link:footnote xlink:type="resource" xml:lang="en-US" xlink:label="footnote1" xlink:role="http://www.xbrl.org/2003/role/footnote">




Represents amount less than thousand




</link:footnote>
    <link:footnoteArc xlink:type="arc" xlink:from="value1" xlink:to="footnote1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1" />
  </link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>plx-20150930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--Created by The Vintage Group, Powered by IRIS Carbon-->
<xsd:schema xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:plx="http://www.protalix.com/20150930" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2015-01-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.protalix.com/20150930">
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20150930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20150930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20150930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20150930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://www.protalix.com/role/plx-daei" id="plx-daei">
        <link:definition>001 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-ccbs" id="plx-ccbs">
        <link:definition>002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-ccsoo" id="plx-ccsoo">
        <link:definition>003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-ccsoop" id="plx-ccsoop">
        <link:definition>004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-ccsocicd" id="plx-ccsocicd">
        <link:definition>005 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN CAPITAL DEFICIENCY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-ccsocicdp" id="plx-ccsocicdp">
        <link:definition>006 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN CAPITAL DEFICIENCY (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-ccsocf" id="plx-ccsocf">
        <link:definition>007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-sap" id="plx-sap">
        <link:definition>101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-i" id="plx-i">
        <link:definition>102 - Disclosure - INVENTORIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-fvm1" id="plx-fvm1">
        <link:definition>103 - Disclosure - FAIR VALUE MEASUREMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-st" id="plx-st">
        <link:definition>104 - Disclosure - STOCK TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-sapp1" id="plx-sapp1">
        <link:definition>201 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policy)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-sapt" id="plx-sapt">
        <link:definition>301 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-it" id="plx-it">
        <link:definition>302 - Disclosure - INVENTORIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-lasa" id="plx-lasa">
        <link:definition>8000 - Disclosure - LICENSE AND SUPPLY AGREEMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-pae" id="plx-pae">
        <link:definition>8010 - Disclosure - PROPERTY AND EQUIPMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-lferur" id="plx-lferur">
        <link:definition>8020 - Disclosure - LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-c" id="plx-c">
        <link:definition>8030 - Disclosure - COMMITMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-sc" id="plx-sc">
        <link:definition>8040 - Disclosure - SHARE CAPITAL</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-cn1" id="plx-cn1">
        <link:definition>8050 - Disclosure - CONVERTIBLE NOTE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-toi" id="plx-toi">
        <link:definition>8060 - Disclosure - TAXES ON INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-sfsi" id="plx-sfsi">
        <link:definition>8070 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-rpt" id="plx-rpt">
        <link:definition>8080 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-paet" id="plx-paet">
        <link:definition>8090 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-sct" id="plx-sct">
        <link:definition>8100 - Disclosure - SHARE CAPITAL (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-cnt1" id="plx-cnt1">
        <link:definition>8110 - Disclosure - CONVERTIBLE NOTES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-toit" id="plx-toit">
        <link:definition>8120 - Disclosure - TAXES ON INCOME (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-sfsit" id="plx-sfsit">
        <link:definition>8130 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-rptt" id="plx-rptt">
        <link:definition>8140 - Disclosure - RELATED PARTY TRANSACTIONS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-lasad" id="plx-lasad">
        <link:definition>8150 - Disclosure - LICENSE AND SUPPLY AGREEMENT (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-paed" id="plx-paed">
        <link:definition>8160 - Disclosure - PROPERTY AND EQUIPMENT (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-lferurd" id="plx-lferurd">
        <link:definition>8170 - Disclosure - LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-cd" id="plx-cd">
        <link:definition>8180 - Disclosure - COMMITMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-scnd" id="plx-scnd">
        <link:definition>8190 - Disclosure - SHARE CAPITAL (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-scsooarsgted" id="plx-scsooarsgted">
        <link:definition>8200 - Disclosure - SHARE CAPITAL (Summary of Option and Restricted Stock Granted to Employees) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-scfvaoogd" id="plx-scfvaoogd">
        <link:definition>8210 - Disclosure - SHARE CAPITAL (Fair Value Assumptions of Options Granted) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-scogted" id="plx-scogted">
        <link:definition>8220 - Disclosure - SHARE CAPITAL (Options Granted to Employees) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-scrsgted" id="plx-scrsgted">
        <link:definition>8230 - Disclosure - SHARE CAPITAL (Restricted Stock Granted to Employees) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-scoarsgtcdaospd" id="plx-scoarsgtcdaospd">
        <link:definition>8240 - Disclosure - SHARE CAPITAL (Options and Restricted Stocks Granted to Consultants, Directors and Other Service Providers) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-scsooarsd" id="plx-scsooarsd">
        <link:definition>8250 - Disclosure - SHARE CAPITAL (Summary of Outstanding and Restricted Stocks) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-scsbcead" id="plx-scsbcead">
        <link:definition>8260 - Disclosure - SHARE CAPITAL (Share Based Compensation Expense Allocation) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-cnnd1" id="plx-cnnd1">
        <link:definition>8270 - Disclosure - CONVERTIBLE NOTES (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-cnsoierd1" id="plx-cnsoierd1">
        <link:definition>8280 - Disclosure - CONVERTIBLE NOTES (Schedule of Interest Expense Recognized) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-toind" id="plx-toind">
        <link:definition>8290 - Disclosure - TAXES ON INCOME (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-toiditd" id="plx-toiditd">
        <link:definition>8300 - Disclosure - TAXES ON INCOME (Deferred Income Taxes) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-toiotyd" id="plx-toiotyd">
        <link:definition>8310 - Disclosure - TAXES ON INCOME (Open Tax Years) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-sfsoa" id="plx-sfsoa">
        <link:definition>8320 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Other Assets) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-sfsiapaaod" id="plx-sfsiapaaod">
        <link:definition>8330 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals, Other) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-sfsird" id="plx-sfsird">
        <link:definition>8340 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Revenues) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-rptd" id="plx-rptd">
        <link:definition>8350 - Disclosure - RELATED PARTY TRANSACTIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-ccbsp" id="plx-ccbsp">
        <link:definition>8360 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-sapd" id="plx-sapd">
        <link:definition>40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-sapulopaed" id="plx-sapulopaed">
        <link:definition>40102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Useful Lives of Property and Equipment) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-id" id="plx-id">
        <link:definition>40201 - Disclosure - INVENTORIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-fvmd1" id="plx-fvmd1">
        <link:definition>40301 - Disclosure - FAIR VALUE MEASUREMENT (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-std" id="plx-std">
        <link:definition>40401 - Disclosure - STOCK TRANSACTIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-sed" id="plx-sed">
        <link:definition>8400 - Disclosure - SUBSEQUENT EVENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/Disclosure-SUBSEQUENTEVENTS" id="Disclosure-SUBSEQUENTEVENTS">
        <link:definition>105 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/Disclosure-SUBSEQUENTEVENTSDetails" id="Disclosure-SUBSEQUENTEVENTSDetails">
        <link:definition>40501 - Disclosure - SUBSEQUENT EVENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2006/ref" schemaLocation="http://www.xbrl.org/2006/ref-2006-02-27.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/XLink" schemaLocation="http://www.xbrl.org/2003/xl-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2013-01-31" schemaLocation="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2015-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd" />
  <xsd:element name="NatureOfOperationsPolicyTextBlock" id="plx_NatureOfOperationsPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="CompanyShareInCollaborationAgreement" id="plx_CompanyShareInCollaborationAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="GrantsAndReimbursementsReceivedOrReceivable" id="plx_GrantsAndReimbursementsReceivedOrReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="ResearchDevelopmentAndEngineeringExpenseNet" id="plx_ResearchDevelopmentAndEngineeringExpenseNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="ScheduleOfUsefulLifeTableTextBlock" id="plx_ScheduleOfUsefulLifeTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="LaboratoryEquipmentMember" id="plx_LaboratoryEquipmentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="MilestonePayment" id="plx_MilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="ScenarioTwoMember" id="plx_ScenarioTwoMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="UponFDAApprovalMember" id="plx_UponFDAApprovalMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="CollaborativeArrangementRevenuesExpensesSharingPercentage" id="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xsd:element name="EligablePaymentReceivableUponAchievement" id="plx_EligablePaymentReceivableUponAchievement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="ProtalixBioTherapeuticsIncorporationMember" id="plx_ProtalixBioTherapeuticsIncorporationMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="PfizerIncorporationMember" id="plx_PfizerIncorporationMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="SupplyCommitmentPerYear" id="plx_SupplyCommitmentPerYear" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="PurchaseAmountToBeSatisfiedToReceiveEntitledRights" id="plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" id="plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="NumberOfSubsidiaries" id="plx_NumberOfSubsidiaries" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="RevenueRecognizedOverDesignatedPeriod" id="plx_RevenueRecognizedOverDesignatedPeriod" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="RevenueRecognizedPeriod" id="plx_RevenueRecognizedPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="CollaborativeAndLicenseArrangementDisclosureTextBlock" id="plx_CollaborativeAndLicenseArrangementDisclosureTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="CollaborationOperationMember" id="plx_CollaborationOperationMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" id="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" id="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="FurnitureAndComputerEquipmentMember" id="plx_FurnitureAndComputerEquipmentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="EquipmentUnderConstructionMember" id="plx_EquipmentUnderConstructionMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="CompensationToTheNon-executiveDirectorsMember" id="plx_CompensationToTheNon-executiveDirectorsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="EmployeeSeveranceObligationPayment" id="plx_EmployeeSeveranceObligationPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod" id="plx_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="ExpectedDefintedBenefitContributionDuringPeriod" id="plx_ExpectedDefintedBenefitContributionDuringPeriod" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="AgreementMaintenanceFee" id="plx_AgreementMaintenanceFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="AmortizationOfDebtIssuanceCosts" id="plx_AmortizationOfDebtIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="AnnualIncreaseToMaintenanceFee" id="plx_AnnualIncreaseToMaintenanceFee" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xsd:element name="CashlessExerciseOfStockOptions" id="plx_CashlessExerciseOfStockOptions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="CollaborativeAndLicenseArrangementDisclosure" id="plx_CollaborativeAndLicenseArrangementDisclosure" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="CollaborativeAndLicenseArrangementTable" id="plx_CollaborativeAndLicenseArrangementTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="CommitmentAmount" id="plx_CommitmentAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="CommitmentsAndContingenciesAxis" id="plx_CommitmentsAndContingenciesAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="CommitmentsAndContingenciesDomain" id="plx_CommitmentsAndContingenciesDomain" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="CommitmentsAndContingenciesLineItems" id="plx_CommitmentsAndContingenciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="CommitmentsAndContingenciesTable" id="plx_CommitmentsAndContingenciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="ConsiderationForLicense" id="plx_ConsiderationForLicense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="DebtInstrumentConvertibleBaseValueForConversionRate" id="plx_DebtInstrumentConvertibleBaseValueForConversionRate" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="DebtInstrumentConvertibleConversionShareNumber" id="plx_DebtInstrumentConvertibleConversionShareNumber" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xsd:element name="DocumentAndEntityInformationAbstract" id="plx_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="EffectiveAdjustedIncomeTaxRateThereafter" id="plx_EffectiveAdjustedIncomeTaxRateThereafter" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xsd:element name="EffectiveAdjustedIncomeTaxRateYearFive" id="plx_EffectiveAdjustedIncomeTaxRateYearFive" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xsd:element name="EffectiveAdjustedIncomeTaxRateYearFour" id="plx_EffectiveAdjustedIncomeTaxRateYearFour" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xsd:element name="EffectiveAdjustedIncomeTaxRateYearOne" id="plx_EffectiveAdjustedIncomeTaxRateYearOne" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xsd:element name="EffectiveAdjustedIncomeTaxRateYearThree" id="plx_EffectiveAdjustedIncomeTaxRateYearThree" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xsd:element name="EffectiveAdjustedIncomeTaxRateYearTwo" id="plx_EffectiveAdjustedIncomeTaxRateYearTwo" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xsd:element name="EmployeesMember" id="plx_EmployeesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="FivePointZeroMember" id="plx_FivePointZeroMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="ForfeitureRate" id="plx_ForfeitureRate" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xsd:element name="FundingArrangementsMember" id="plx_FundingArrangementsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" id="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="GrantYearTwoThousandTwelveMember" id="plx_GrantYearTwoThousandTwelveMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="GrantYearTwoThousandTwelveSecondMember" id="plx_GrantYearTwoThousandTwelveSecondMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="IncomeTaxDisclosureLineItems" id="plx_IncomeTaxDisclosureLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="IncomeTaxDisclosureTable" id="plx_IncomeTaxDisclosureTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="IncreaseInLiabilitiesForPropertyPlantAndEquipment" id="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="LiabilitiesAccruedFromLicensingAgreement" id="plx_LiabilitiesAccruedFromLicensingAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="ManagementAndConsultingFeesToChairmanOfBoardMember" id="plx_ManagementAndConsultingFeesToChairmanOfBoardMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="MaximumAggregatePaymentsOfRoyaltiesToGrantReceived" id="plx_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xsd:element name="MilestonePaymentsMember" id="plx_MilestonePaymentsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="MonthlyRentLeaseExpense" id="plx_MonthlyRentLeaseExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="NinePointSixSixMember" id="plx_NinePointSixSixMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="OCSMember" id="plx_OCSMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="OfficersAndCertainEmployeesMember" id="plx_OfficersAndCertainEmployeesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="OfficersAndDirectorsInPrivateTransactionMember" id="plx_OfficersAndDirectorsInPrivateTransactionMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="OneSixPointSevenMember" id="plx_OneSixPointSevenMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="OptionsAndRestrictedStockGrantedToEmployeesMember" id="plx_OptionsAndRestrictedStockGrantedToEmployeesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="OptionsAndRestrictedStockMember" id="plx_OptionsAndRestrictedStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" id="plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="ProbableAggregateMilestonePaymentMember" id="plx_ProbableAggregateMilestonePaymentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="ProceedsFromIssuanceOfCommonStockNetOfExpenses" id="plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="ProductsManufacturedOutsideOfIsraelMember" id="plx_ProductsManufacturedOutsideOfIsraelMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="ResearchAndLicenseAgreementsMember" id="plx_ResearchAndLicenseAgreementsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="RestrictedAmountMember" id="plx_RestrictedAmountMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="RoyaltiesOnSaleOfProducts" id="plx_RoyaltiesOnSaleOfProducts" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="ScenarioOneMember" id="plx_ScenarioOneMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="ScheduleOfOpenTaxYearsTableTextBlock" id="plx_ScheduleOfOpenTaxYearsTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock" id="plx_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="SevenPointFiveFiveMember" id="plx_SevenPointFiveFiveMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" id="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" id="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod" id="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="SignificantAccountingPoliciesLineItems" id="plx_SignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="SignificantAccountingPoliciesTable" id="plx_SignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="SixPointEightOneZeroMember" id="plx_SixPointEightOneZeroMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="SixPointNineMember" id="plx_SixPointNineMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="StockOptionsAndRestrictedSharesMember" id="plx_StockOptionsAndRestrictedSharesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="SupplementalInformationAbstract" id="plx_SupplementalInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="SupplementalInformationRevenueAxis" id="plx_SupplementalInformationRevenueAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="SupplementalOfferingAndStockIssuanceCosts" id="plx_SupplementalOfferingAndStockIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="SupplementaryBalanceSheetsInformationTableTextBlock" id="plx_SupplementaryBalanceSheetsInformationTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="SupplementaryIncomeStatementInformationTableTextBlock" id="plx_SupplementaryIncomeStatementInformationTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="TaxBurdenDistributionLawMember" id="plx_TaxBurdenDistributionLawMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal" id="plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="TaxYearThereafterMember" id="plx_TaxYearThereafterMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="TaxYearTwoThousandNineMember" id="plx_TaxYearTwoThousandNineMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="ThreePointZeroTwoZeroMember" id="plx_ThreePointZeroTwoZeroMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="TwoPointSixFiveMember" id="plx_TwoPointSixFiveMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="TwoPointThreeFiveZeroMember" id="plx_TwoPointThreeFiveZeroMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="UponNearTermClinicalDevelopmentMilestonesMember" id="plx_UponNearTermClinicalDevelopmentMilestonesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="VehicleLeaseAndMaintenanceAgreementsMember" id="plx_VehicleLeaseAndMaintenanceAgreementsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="WithholdingTaxRateOnForeignIncome" id="plx_WithholdingTaxRateOnForeignIncome" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xsd:element name="YissumAgreementMember" id="plx_YissumAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="ZeroPointNineSevenTwoMember" id="plx_ZeroPointNineSevenTwoMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="ZeroPointOneTwoZeroMember" id="plx_ZeroPointOneTwoZeroMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="ZeroPointThreeNineNineMember" id="plx_ZeroPointThreeNineNineMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="ZeroPointZeroZeroOneMember" id="plx_ZeroPointZeroZeroOneMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="PresidentAndChiefExecutiveOfficerMember" id="plx_PresidentAndChiefExecutiveOfficerMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" id="plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="TwoPointThreeSevenZeroMember" id="plx_TwoPointThreeSevenZeroMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="ThreePointThreeSevenZeroMember" id="plx_ThreePointThreeSevenZeroMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="GrantYearTwoThousandFourteenMember" id="plx_GrantYearTwoThousandFourteenMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="AccruedLiabilityInConnectionWithCollaborationOperationCurrent" id="plx_AccruedLiabilityInConnectionWithCollaborationOperationCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="AccountsPayablePropertyAndEquipmentSuppliersCurrent" id="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="OtherAssetsInstitutionsCurrent" id="plx_OtherAssetsInstitutionsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="OtherAssetsSundryCurrent" id="plx_OtherAssetsSundryCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="CollaborativeArrangementMilestonePaymentAmount" id="plx_CollaborativeArrangementMilestonePaymentAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption" id="plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="RightToTerminateAgreementRevenueThreshold" id="plx_RightToTerminateAgreementRevenueThreshold" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="PfizerAgreementMember" id="plx_PfizerAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="BrazilAgreementMember" id="plx_BrazilAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="FiocruzMember" id="plx_FiocruzMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="PurchaseOrderReceived" id="plx_PurchaseOrderReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="PercentageOfAdultGaucherPatientsTreatedWithUplyso" id="plx_PercentageOfAdultGaucherPatientsTreatedWithUplyso" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="EmployeeStockIncentivePlan2006Member" id="plx_EmployeeStockIncentivePlan2006Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="AmendedPfizerAgreementMember" id="plx_AmendedPfizerAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="ProceedsFromSaleOfShareInCollaboration" id="plx_ProceedsFromSaleOfShareInCollaboration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="ExcludingBrazilMember" id="plx_ExcludingBrazilMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfitsEliminationAmount" id="plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfitsEliminationAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="AgentFeePercentageOfNetProceeds" id="plx_AgentFeePercentageOfNetProceeds" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="StockPurchaseAgreementLockUpPeriod" id="plx_StockPurchaseAgreementLockUpPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="RevenuesOtherThanCompanyShareInCollaborationAgreement" id="plx_RevenuesOtherThanCompanyShareInCollaborationAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="October2015PromissoryNoteToPfizerMember" id="plx_October2015PromissoryNoteToPfizerMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>plx-20150930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--Created by The Vintage Group, Powered by IRIS Carbon-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.protalix.com/role/plx-ccbs" xlink:type="simple" xlink:href="plx-20150930.xsd#plx-ccbs" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-ccsocf" xlink:type="simple" xlink:href="plx-20150930.xsd#plx-ccsocf" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-paed" xlink:type="simple" xlink:href="plx-20150930.xsd#plx-paed" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-cnsoierd1" xlink:type="simple" xlink:href="plx-20150930.xsd#plx-cnsoierd1" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-toiditd" xlink:type="simple" xlink:href="plx-20150930.xsd#plx-toiditd" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-id" xlink:type="simple" xlink:href="plx-20150930.xsd#plx-id" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-ccsoo" xlink:type="simple" xlink:href="plx-20150930.xsd#plx-ccsoo" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-ccbs">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:title="us-gaap_Assets" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:title="us-gaap_AssetsCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" xlink:title="Calculation : us-gaap_Assets to us-gaap_AssetsCurrent" order="1" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:title="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:title="Calculation : us-gaap_AssetsCurrent to us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:title="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent" xlink:title="us-gaap_AccountsPayableTradeCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent" xlink:title="Calculation : us-gaap_LiabilitiesCurrent to us-gaap_AccountsPayableTradeCurrent" order="1" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:title="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:title="us-gaap_StockholdersEquity" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" xlink:title="Calculation : us-gaap_LiabilitiesAndStockholdersEquity to us-gaap_StockholdersEquity" order="1" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:title="us-gaap_LiabilitiesNoncurrent" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent" xlink:title="us-gaap_DeferredRevenueNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent" xlink:title="Calculation : us-gaap_LiabilitiesNoncurrent to us-gaap_DeferredRevenueNoncurrent" order="1" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:title="us-gaap_Liabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesNoncurrent" xlink:title="Calculation : us-gaap_Liabilities to us-gaap_LiabilitiesNoncurrent" order="1" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredCosts" xlink:label="us-gaap_DeferredCosts" xlink:title="us-gaap_DeferredCosts" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DeferredCosts" xlink:title="Calculation : us-gaap_Assets to us-gaap_DeferredCosts" order="2" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:title="us-gaap_InventoryNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InventoryNet" xlink:title="Calculation : us-gaap_AssetsCurrent to us-gaap_InventoryNet" order="2" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:title="us-gaap_AccountsPayableOtherCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent" xlink:title="Calculation : us-gaap_LiabilitiesCurrent to us-gaap_AccountsPayableOtherCurrent" order="2" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="us-gaap_ConvertibleDebtNoncurrent" xlink:title="us-gaap_ConvertibleDebtNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_ConvertibleDebtNoncurrent" xlink:title="Calculation : us-gaap_LiabilitiesNoncurrent to us-gaap_ConvertibleDebtNoncurrent" order="2" weight="1" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" xlink:title="Calculation : us-gaap_Liabilities to us-gaap_LiabilitiesCurrent" order="2" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:title="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:title="Calculation : us-gaap_Assets to us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" order="3" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:title="us-gaap_AccountsReceivableNetCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" xlink:title="Calculation : us-gaap_AssetsCurrent to us-gaap_AccountsReceivableNetCurrent" order="3" weight="1" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" xlink:title="Calculation : us-gaap_LiabilitiesAndStockholdersEquity to us-gaap_Liabilities" order="3" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" xlink:title="us-gaap_LongTermDebtNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent" xlink:title="Calculation : us-gaap_LiabilitiesNoncurrent to us-gaap_LongTermDebtNoncurrent" order="3" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:title="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:title="Calculation : us-gaap_Assets to us-gaap_PropertyPlantAndEquipmentNet" order="4" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:title="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:title="Calculation : us-gaap_LiabilitiesNoncurrent to us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" order="4" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:title="us-gaap_DeferredRevenueCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRevenueCurrent" xlink:title="Calculation : us-gaap_LiabilitiesCurrent to us-gaap_DeferredRevenueCurrent" order="13" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" xlink:title="us-gaap_OtherAssetsCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" xlink:title="Calculation : us-gaap_AssetsCurrent to us-gaap_OtherAssetsCurrent" order="13" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-ccsocf">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:title="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:title="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:title="Calculation : us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease to us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" order="1" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:title="us-gaap_NetIncomeLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetIncomeLoss" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to us-gaap_NetIncomeLoss" order="1" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:title="Calculation : us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease to us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" order="2" weight="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:title="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" order="2" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:title="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:title="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations to us-gaap_PaymentsForProceedsFromOtherInvestingActivities" order="2" weight="-1" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:title="Calculation : us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease to us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" order="3" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:title="us-gaap_AmortizationOfFinancingCosts" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_AmortizationOfFinancingCosts" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to us-gaap_AmortizationOfFinancingCosts" order="3" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:title="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations to us-gaap_ProceedsFromStockOptionsExercised" order="3" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:title="us-gaap_IncreaseDecreaseInRestrictedCash" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations to us-gaap_IncreaseDecreaseInRestrictedCash" order="3" weight="-1" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:title="Calculation : us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease to us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="4" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:title="us-gaap_ShareBasedCompensation" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_ShareBasedCompensation" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to us-gaap_ShareBasedCompensation" order="4" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations to us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="4" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:title="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to us-gaap_ForeignCurrencyTransactionGainLossUnrealized" order="6" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:title="us-gaap_PensionAndOtherPostretirementBenefitExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to us-gaap_PensionAndOtherPostretirementBenefitExpense" order="7" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:title="us-gaap_IncreaseDecreaseInDeferredRevenue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to us-gaap_IncreaseDecreaseInDeferredRevenue" order="9" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:title="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to us-gaap_IncreaseDecreaseInAccountsReceivable" order="10" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:title="us-gaap_IncreaseDecreaseInInventories" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInInventories" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to us-gaap_IncreaseDecreaseInInventories" order="11" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="12" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:title="us-gaap_Depreciation" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_Depreciation" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to us-gaap_Depreciation" order="22" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-paed">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:title="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="Calculation : us-gaap_PropertyPlantAndEquipmentNet to us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:title="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:title="Calculation : us-gaap_PropertyPlantAndEquipmentNet to us-gaap_PropertyPlantAndEquipmentGross" order="2" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-cnsoierd1">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xlink:title="us-gaap_InterestExpense" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization" xlink:title="us-gaap_InterestExpenseDebtExcludingAmortization" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization" xlink:title="Calculation : us-gaap_InterestExpense to us-gaap_InterestExpenseDebtExcludingAmortization" order="1" weight="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_AmortizationOfDebtIssuanceCosts" xlink:label="plx_AmortizationOfDebtIssuanceCosts" xlink:title="plx_AmortizationOfDebtIssuanceCosts" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InterestExpense" xlink:to="plx_AmortizationOfDebtIssuanceCosts" xlink:title="Calculation : us-gaap_InterestExpense to plx_AmortizationOfDebtIssuanceCosts" order="2" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-toiditd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:title="us-gaap_DeferredTaxAssetsNet" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:title="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:title="Calculation : us-gaap_DeferredTaxAssetsNet to us-gaap_DeferredTaxAssetsValuationAllowance" order="1" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:title="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:title="Calculation : us-gaap_DeferredTaxAssetsNet to us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="2" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:title="us-gaap_DeferredTaxAssetsDeferredIncome" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:title="Calculation : us-gaap_DeferredTaxAssetsNet to us-gaap_DeferredTaxAssetsDeferredIncome" order="3" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments" xlink:title="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments" xlink:title="Calculation : us-gaap_DeferredTaxAssetsNet to us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments" order="4" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:title="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:title="Calculation : us-gaap_DeferredTaxAssetsNet to us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" order="5" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:title="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:title="Calculation : us-gaap_DeferredTaxAssetsNet to us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" order="6" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:title="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:title="Calculation : us-gaap_DeferredTaxAssetsNet to us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="7" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-id">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:title="us-gaap_InventoryNet" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:title="us-gaap_InventoryRawMaterialsNetOfReserves" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:title="Calculation : us-gaap_InventoryNet to us-gaap_InventoryRawMaterialsNetOfReserves" order="1" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:title="us-gaap_InventoryWorkInProcessNetOfReserves" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:title="Calculation : us-gaap_InventoryNet to us-gaap_InventoryWorkInProcessNetOfReserves" order="2" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:title="us-gaap_InventoryFinishedGoodsNetOfReserves" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:title="Calculation : us-gaap_InventoryNet to us-gaap_InventoryFinishedGoodsNetOfReserves" order="3" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-ccsoo">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:title="us-gaap_NetIncomeLoss" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:title="us-gaap_OperatingIncomeLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" xlink:title="Calculation : us-gaap_NetIncomeLoss to us-gaap_OperatingIncomeLoss" order="14" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" xlink:title="us-gaap_GrossProfit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_GrossProfit" xlink:title="Calculation : us-gaap_OperatingIncomeLoss to us-gaap_GrossProfit" order="23" weight="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_RevenuesOtherThanCompanyShareInCollaborationAgreement" xlink:label="plx_RevenuesOtherThanCompanyShareInCollaborationAgreement" xlink:title="plx_RevenuesOtherThanCompanyShareInCollaborationAgreement" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="plx_RevenuesOtherThanCompanyShareInCollaborationAgreement" xlink:title="Calculation : us-gaap_GrossProfit to plx_RevenuesOtherThanCompanyShareInCollaborationAgreement" order="1" weight="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_CompanyShareInCollaborationAgreement" xlink:label="plx_CompanyShareInCollaborationAgreement" xlink:title="plx_CompanyShareInCollaborationAgreement" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="plx_CompanyShareInCollaborationAgreement" xlink:title="Calculation : us-gaap_GrossProfit to plx_CompanyShareInCollaborationAgreement" order="2" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" xlink:title="us-gaap_CostOfRevenue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_CostOfRevenue" xlink:title="Calculation : us-gaap_GrossProfit to us-gaap_CostOfRevenue" order="3" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:label="plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:title="plx_ResearchDevelopmentAndEngineeringExpenseNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:title="Calculation : us-gaap_OperatingIncomeLoss to plx_ResearchDevelopmentAndEngineeringExpenseNet" order="33" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:title="us-gaap_ResearchAndDevelopmentExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:title="Calculation : plx_ResearchDevelopmentAndEngineeringExpenseNet to us-gaap_ResearchAndDevelopmentExpense" order="12" weight="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_GrantsAndReimbursementsReceivedOrReceivable" xlink:label="plx_GrantsAndReimbursementsReceivedOrReceivable" xlink:title="plx_GrantsAndReimbursementsReceivedOrReceivable" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:to="plx_GrantsAndReimbursementsReceivedOrReceivable" xlink:title="Calculation : plx_ResearchDevelopmentAndEngineeringExpenseNet to plx_GrantsAndReimbursementsReceivedOrReceivable" order="22" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:title="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:title="Calculation : us-gaap_OperatingIncomeLoss to us-gaap_SellingGeneralAndAdministrativeExpense" order="43" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:title="us-gaap_NonoperatingIncomeExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" xlink:title="Calculation : us-gaap_NetIncomeLoss to us-gaap_NonoperatingIncomeExpense" order="24" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" xlink:title="us-gaap_OtherNonoperatingExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingExpense" xlink:title="Calculation : us-gaap_NonoperatingIncomeExpense to us-gaap_OtherNonoperatingExpense" order="10" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" xlink:title="us-gaap_OtherNonoperatingIncome" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncome" xlink:title="Calculation : us-gaap_NonoperatingIncomeExpense to us-gaap_OtherNonoperatingIncome" order="20" weight="1" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>plx-20150930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--Created by The Vintage Group, Powered by IRIS Carbon-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-ccsoop" xlink:type="simple" xlink:href="plx-20150930.xsd#plx-ccsoop" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-ccsocicd" xlink:type="simple" xlink:href="plx-20150930.xsd#plx-ccsocicd" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-ccsocicdp" xlink:type="simple" xlink:href="plx-20150930.xsd#plx-ccsocicdp" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-lasad" xlink:type="simple" xlink:href="plx-20150930.xsd#plx-lasad" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-paed" xlink:type="simple" xlink:href="plx-20150930.xsd#plx-paed" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-cd" xlink:type="simple" xlink:href="plx-20150930.xsd#plx-cd" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-scnd" xlink:type="simple" xlink:href="plx-20150930.xsd#plx-scnd" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-scsooarsgted" xlink:type="simple" xlink:href="plx-20150930.xsd#plx-scsooarsgted" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-scogted" xlink:type="simple" xlink:href="plx-20150930.xsd#plx-scogted" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-scrsgted" xlink:type="simple" xlink:href="plx-20150930.xsd#plx-scrsgted" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-scoarsgtcdaospd" xlink:type="simple" xlink:href="plx-20150930.xsd#plx-scoarsgtcdaospd" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-scsooarsd" xlink:type="simple" xlink:href="plx-20150930.xsd#plx-scsooarsd" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-scsbcead" xlink:type="simple" xlink:href="plx-20150930.xsd#plx-scsbcead" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-toind" xlink:type="simple" xlink:href="plx-20150930.xsd#plx-toind" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-toiotyd" xlink:type="simple" xlink:href="plx-20150930.xsd#plx-toiotyd" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-rptd" xlink:type="simple" xlink:href="plx-20150930.xsd#plx-rptd" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-sapulopaed" xlink:type="simple" xlink:href="plx-20150930.xsd#plx-sapulopaed" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-std" xlink:type="simple" xlink:href="plx-20150930.xsd#plx-std" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-sapd" xlink:type="simple" xlink:href="plx-20150930.xsd#plx-sapd" />
  <link:roleRef roleURI="http://www.protalix.com/role/Disclosure-SUBSEQUENTEVENTSDetails" xlink:type="simple" xlink:href="plx-20150930.xsd#Disclosure-SUBSEQUENTEVENTSDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-ccsoop">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="Definition : us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:title="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:title="us-gaap_IncomeStatementLocationDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:title="Definition : us-gaap_IncomeStatementLocationAxis to us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:title="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:title="Definition : us-gaap_IncomeStatementLocationDomain to us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:title="Definition : us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:title="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:title="Definition : us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:title="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:title="Definition : us-gaap_IncomeStatementLocationDomain to us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="2" xbrldt:closed="false" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-ccsocicd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:title="us-gaap_StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:title="us-gaap_StatementTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:title="Definition : us-gaap_StatementLineItems to us-gaap_StatementTable" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:title="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:title="us-gaap_EquityComponentDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:title="Definition : us-gaap_StatementEquityComponentsAxis to us-gaap_EquityComponentDomain" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:title="us-gaap_CommonStockMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" xlink:title="Definition : us-gaap_EquityComponentDomain to us-gaap_CommonStockMember" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:title="Definition : us-gaap_StatementTable to us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1" xlink:title="us-gaap_EquityComponentDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_1" xlink:title="Definition : us-gaap_StatementEquityComponentsAxis to us-gaap_EquityComponentDomain" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:title="us-gaap_AdditionalPaidInCapitalMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:title="Definition : us-gaap_EquityComponentDomain to us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:title="us-gaap_RetainedEarningsMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" xlink:title="Definition : us-gaap_EquityComponentDomain to us-gaap_RetainedEarningsMember" xlink:type="arc" order="3" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:title="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:title="Definition : us-gaap_StatementLineItems to us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="4" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:title="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:title="Definition : us-gaap_StatementLineItems to us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="4.5" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="Definition : us-gaap_StatementLineItems to us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="7" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="Definition : us-gaap_StatementLineItems to us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="7.5" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:title="us-gaap_NetIncomeLoss" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:title="Definition : us-gaap_StatementLineItems to us-gaap_NetIncomeLoss" xlink:type="arc" order="8" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:title="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:title="Definition : us-gaap_StatementLineItems to plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:type="arc" order="8.94" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xlink:title="us-gaap_SharesOutstanding" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" xlink:title="Definition : us-gaap_StatementLineItems to us-gaap_SharesOutstanding" xlink:type="arc" order="9.94286" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:title="us-gaap_StockholdersEquity" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" xlink:title="Definition : us-gaap_StatementLineItems to us-gaap_StockholdersEquity" xlink:type="arc" order="9.94287" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="Definition : us-gaap_StatementLineItems to us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="9.94311" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:title="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:title="Definition : us-gaap_StatementLineItems to plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:type="arc" order="9.94463" xbrldt:closed="false" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-ccsocicdp">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:title="us-gaap_StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:title="us-gaap_StatementTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:title="Definition : us-gaap_StatementLineItems to us-gaap_StatementTable" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:title="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:title="Definition : us-gaap_StatementLineItems to us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:title="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:title="Definition : us-gaap_StatementLineItems to us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="3" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:title="us-gaap_CommonStockSharesAuthorized" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:title="Definition : us-gaap_StatementLineItems to us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="4" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="Definition : us-gaap_StatementLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="5" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:title="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:title="Definition : us-gaap_StatementLineItems to us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" order="6" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:title="us-gaap_AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="Definition : us-gaap_AwardTypeAxis to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="10" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:title="us-gaap_RestrictedStockMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to us-gaap_RestrictedStockMember" xlink:type="arc" order="10" xbrldt:closed="false" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:title="Definition : us-gaap_StatementTable to us-gaap_AwardTypeAxis" xlink:type="arc" order="10" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:title="Definition : us-gaap_AwardTypeAxis to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" xbrldt:closed="false" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-lasad">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:title="us-gaap_StatementScenarioAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:title="us-gaap_ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:title="Definition : us-gaap_StatementScenarioAxis to us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember" xlink:title="plx_ProtalixBioTherapeuticsIncorporationMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_ProtalixBioTherapeuticsIncorporationMember" xlink:title="Definition : us-gaap_ArrangementsAndNonarrangementTransactionsMember to plx_ProtalixBioTherapeuticsIncorporationMember" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ScenarioTwoMember" xlink:label="plx_ScenarioTwoMember" xlink:title="plx_ScenarioTwoMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="plx_ScenarioTwoMember" xlink:title="Definition : us-gaap_ScenarioUnspecifiedDomain to plx_ScenarioTwoMember" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_CollaborativeAndLicenseArrangementTable" xlink:label="plx_CollaborativeAndLicenseArrangementTable" xlink:title="plx_CollaborativeAndLicenseArrangementTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="plx_CollaborativeAndLicenseArrangementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:title="Definition : plx_CollaborativeAndLicenseArrangementTable to us-gaap_StatementScenarioAxis" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:title="us-gaap_TypeOfArrangementAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:title="Definition : us-gaap_TypeOfArrangementAxis to us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_CollaborationOperationMember" xlink:label="plx_CollaborationOperationMember" xlink:title="plx_CollaborationOperationMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_CollaborationOperationMember" xlink:title="Definition : us-gaap_ArrangementsAndNonarrangementTransactionsMember to plx_CollaborationOperationMember" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ScenarioOneMember" xlink:label="plx_ScenarioOneMember" xlink:title="plx_ScenarioOneMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="plx_ScenarioOneMember" xlink:title="Definition : us-gaap_ScenarioUnspecifiedDomain to plx_ScenarioOneMember" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="plx_SignificantAccountingPoliciesLineItems" xlink:title="plx_SignificantAccountingPoliciesLineItems" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_MilestonePayment" xlink:label="plx_MilestonePayment" xlink:title="plx_MilestonePayment" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_MilestonePayment" xlink:title="Definition : plx_SignificantAccountingPoliciesLineItems to plx_MilestonePayment" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="plx_CollaborativeAndLicenseArrangementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:title="Definition : plx_CollaborativeAndLicenseArrangementTable to us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="2.5" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_UponFDAApprovalMember" xlink:label="plx_UponFDAApprovalMember" xlink:title="plx_UponFDAApprovalMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="plx_UponFDAApprovalMember" xlink:title="Definition : us-gaap_ScenarioUnspecifiedDomain to plx_UponFDAApprovalMember" xlink:type="arc" order="3" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_UponNearTermClinicalDevelopmentMilestonesMember" xlink:label="plx_UponNearTermClinicalDevelopmentMilestonesMember" xlink:title="plx_UponNearTermClinicalDevelopmentMilestonesMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="plx_UponNearTermClinicalDevelopmentMilestonesMember" xlink:title="Definition : us-gaap_ScenarioUnspecifiedDomain to plx_UponNearTermClinicalDevelopmentMilestonesMember" xlink:type="arc" order="4" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:title="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:title="Definition : plx_SignificantAccountingPoliciesLineItems to us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" order="4" xbrldt:closed="false" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_CollaborativeAndLicenseArrangementTable" xlink:title="Definition : plx_SignificantAccountingPoliciesLineItems to plx_CollaborativeAndLicenseArrangementTable" xlink:type="arc" order="5" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_LiabilitiesAccruedFromLicensingAgreement" xlink:label="plx_LiabilitiesAccruedFromLicensingAgreement" xlink:title="plx_LiabilitiesAccruedFromLicensingAgreement" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_LiabilitiesAccruedFromLicensingAgreement" xlink:title="Definition : plx_SignificantAccountingPoliciesLineItems to plx_LiabilitiesAccruedFromLicensingAgreement" xlink:type="arc" order="6" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_RevenueRecognizedOverDesignatedPeriod" xlink:label="plx_RevenueRecognizedOverDesignatedPeriod" xlink:title="plx_RevenueRecognizedOverDesignatedPeriod" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_RevenueRecognizedOverDesignatedPeriod" xlink:title="Definition : plx_SignificantAccountingPoliciesLineItems to plx_RevenueRecognizedOverDesignatedPeriod" xlink:type="arc" order="7" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_RevenueRecognizedPeriod" xlink:label="plx_RevenueRecognizedPeriod" xlink:title="plx_RevenueRecognizedPeriod" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_RevenueRecognizedPeriod" xlink:title="Definition : plx_SignificantAccountingPoliciesLineItems to plx_RevenueRecognizedPeriod" xlink:type="arc" order="8" xbrldt:closed="false" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-paed">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:title="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="Definition : us-gaap_PropertyPlantAndEquipmentLineItems to us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_LaboratoryEquipmentMember" xlink:label="plx_LaboratoryEquipmentMember" xlink:title="plx_LaboratoryEquipmentMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="plx_LaboratoryEquipmentMember" xlink:title="Definition : us-gaap_PropertyPlantAndEquipmentTypeDomain to plx_LaboratoryEquipmentMember" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:title="Definition : us-gaap_ScheduleOfPropertyPlantAndEquipmentTable to us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:title="Definition : us-gaap_PropertyPlantAndEquipmentByTypeAxis to us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_FurnitureAndComputerEquipmentMember" xlink:label="plx_FurnitureAndComputerEquipmentMember" xlink:title="plx_FurnitureAndComputerEquipmentMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="plx_FurnitureAndComputerEquipmentMember" xlink:title="Definition : us-gaap_PropertyPlantAndEquipmentTypeDomain to plx_FurnitureAndComputerEquipmentMember" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:title="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:title="Definition : us-gaap_PropertyPlantAndEquipmentLineItems to us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:title="us-gaap_LeaseholdImprovementsMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" xlink:title="Definition : us-gaap_PropertyPlantAndEquipmentTypeDomain to us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="3" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="Definition : us-gaap_PropertyPlantAndEquipmentLineItems to us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="3" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_EquipmentUnderConstructionMember" xlink:label="plx_EquipmentUnderConstructionMember" xlink:title="plx_EquipmentUnderConstructionMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="plx_EquipmentUnderConstructionMember" xlink:title="Definition : us-gaap_PropertyPlantAndEquipmentTypeDomain to plx_EquipmentUnderConstructionMember" xlink:type="arc" order="4" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges" xlink:title="us-gaap_AssetImpairmentCharges" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AssetImpairmentCharges" xlink:title="Definition : us-gaap_PropertyPlantAndEquipmentLineItems to us-gaap_AssetImpairmentCharges" xlink:type="arc" order="6" xbrldt:closed="false" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-cd">
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_CommitmentsAndContingenciesLineItems" xlink:label="plx_CommitmentsAndContingenciesLineItems" xlink:title="plx_CommitmentsAndContingenciesLineItems" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_CommitmentsAndContingenciesTable" xlink:label="plx_CommitmentsAndContingenciesTable" xlink:title="plx_CommitmentsAndContingenciesTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="plx_CommitmentsAndContingenciesTable" xlink:title="Definition : plx_CommitmentsAndContingenciesLineItems to plx_CommitmentsAndContingenciesTable" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_CommitmentsAndContingenciesAxis" xlink:label="plx_CommitmentsAndContingenciesAxis" xlink:title="plx_CommitmentsAndContingenciesAxis" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_CommitmentsAndContingenciesDomain" xlink:label="plx_CommitmentsAndContingenciesDomain" xlink:title="plx_CommitmentsAndContingenciesDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="plx_CommitmentsAndContingenciesAxis" xlink:to="plx_CommitmentsAndContingenciesDomain" xlink:title="Definition : plx_CommitmentsAndContingenciesAxis to plx_CommitmentsAndContingenciesDomain" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:title="us-gaap_RangeMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:title="us-gaap_MinimumMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" xlink:title="Definition : us-gaap_RangeMember to us-gaap_MinimumMember" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_OCSMember" xlink:label="plx_OCSMember" xlink:title="plx_OCSMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_CommitmentsAndContingenciesDomain" xlink:to="plx_OCSMember" xlink:title="Definition : plx_CommitmentsAndContingenciesDomain to plx_OCSMember" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:title="us-gaap_RangeAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="plx_CommitmentsAndContingenciesTable" xlink:to="us-gaap_RangeAxis" xlink:title="Definition : plx_CommitmentsAndContingenciesTable to us-gaap_RangeAxis" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:title="Definition : us-gaap_RangeAxis to us-gaap_RangeMember" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_CommitmentsAndContingenciesDomain" xlink:label="plx_CommitmentsAndContingenciesDomain_1" xlink:title="plx_CommitmentsAndContingenciesDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="plx_CommitmentsAndContingenciesAxis" xlink:to="plx_CommitmentsAndContingenciesDomain_1" xlink:title="Definition : plx_CommitmentsAndContingenciesAxis to plx_CommitmentsAndContingenciesDomain" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:title="us-gaap_MaximumMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" xlink:title="Definition : us-gaap_RangeMember to us-gaap_MaximumMember" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ProductsManufacturedOutsideOfIsraelMember" xlink:label="plx_ProductsManufacturedOutsideOfIsraelMember" xlink:title="plx_ProductsManufacturedOutsideOfIsraelMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_CommitmentsAndContingenciesDomain" xlink:to="plx_ProductsManufacturedOutsideOfIsraelMember" xlink:title="Definition : plx_CommitmentsAndContingenciesDomain to plx_ProductsManufacturedOutsideOfIsraelMember" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_AnnualIncreaseToMaintenanceFee" xlink:label="plx_AnnualIncreaseToMaintenanceFee" xlink:title="plx_AnnualIncreaseToMaintenanceFee" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="plx_AnnualIncreaseToMaintenanceFee" xlink:title="Definition : plx_CommitmentsAndContingenciesLineItems to plx_AnnualIncreaseToMaintenanceFee" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="plx_CommitmentsAndContingenciesTable" xlink:to="plx_CommitmentsAndContingenciesAxis" xlink:title="Definition : plx_CommitmentsAndContingenciesTable to plx_CommitmentsAndContingenciesAxis" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_FundingArrangementsMember" xlink:label="plx_FundingArrangementsMember" xlink:title="plx_FundingArrangementsMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_CommitmentsAndContingenciesDomain" xlink:to="plx_FundingArrangementsMember" xlink:title="Definition : plx_CommitmentsAndContingenciesDomain to plx_FundingArrangementsMember" xlink:type="arc" order="3" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_RoyaltiesOnSaleOfProducts" xlink:label="plx_RoyaltiesOnSaleOfProducts" xlink:title="plx_RoyaltiesOnSaleOfProducts" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="plx_RoyaltiesOnSaleOfProducts" xlink:title="Definition : plx_CommitmentsAndContingenciesLineItems to plx_RoyaltiesOnSaleOfProducts" xlink:type="arc" order="3" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ResearchAndLicenseAgreementsMember" xlink:label="plx_ResearchAndLicenseAgreementsMember" xlink:title="plx_ResearchAndLicenseAgreementsMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_CommitmentsAndContingenciesDomain" xlink:to="plx_ResearchAndLicenseAgreementsMember" xlink:title="Definition : plx_CommitmentsAndContingenciesDomain to plx_ResearchAndLicenseAgreementsMember" xlink:type="arc" order="4" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_AgreementMaintenanceFee" xlink:label="plx_AgreementMaintenanceFee" xlink:title="plx_AgreementMaintenanceFee" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="plx_AgreementMaintenanceFee" xlink:title="Definition : plx_CommitmentsAndContingenciesLineItems to plx_AgreementMaintenanceFee" xlink:type="arc" order="4" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ProbableAggregateMilestonePaymentMember" xlink:label="plx_ProbableAggregateMilestonePaymentMember" xlink:title="plx_ProbableAggregateMilestonePaymentMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_CommitmentsAndContingenciesDomain" xlink:to="plx_ProbableAggregateMilestonePaymentMember" xlink:title="Definition : plx_CommitmentsAndContingenciesDomain to plx_ProbableAggregateMilestonePaymentMember" xlink:type="arc" order="5" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ConsiderationForLicense" xlink:label="plx_ConsiderationForLicense" xlink:title="plx_ConsiderationForLicense" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="plx_ConsiderationForLicense" xlink:title="Definition : plx_CommitmentsAndContingenciesLineItems to plx_ConsiderationForLicense" xlink:type="arc" order="5" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_MilestonePaymentsMember" xlink:label="plx_MilestonePaymentsMember" xlink:title="plx_MilestonePaymentsMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_CommitmentsAndContingenciesDomain" xlink:to="plx_MilestonePaymentsMember" xlink:title="Definition : plx_CommitmentsAndContingenciesDomain to plx_MilestonePaymentsMember" xlink:type="arc" order="6" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived" xlink:label="plx_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived" xlink:title="plx_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="plx_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived" xlink:title="Definition : plx_CommitmentsAndContingenciesLineItems to plx_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived" xlink:type="arc" order="6" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_VehicleLeaseAndMaintenanceAgreementsMember" xlink:label="plx_VehicleLeaseAndMaintenanceAgreementsMember" xlink:title="plx_VehicleLeaseAndMaintenanceAgreementsMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_CommitmentsAndContingenciesDomain" xlink:to="plx_VehicleLeaseAndMaintenanceAgreementsMember" xlink:title="Definition : plx_CommitmentsAndContingenciesDomain to plx_VehicleLeaseAndMaintenanceAgreementsMember" xlink:type="arc" order="7" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" xlink:title="us-gaap_RoyaltyExpense" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_RoyaltyExpense" xlink:title="Definition : plx_CommitmentsAndContingenciesLineItems to us-gaap_RoyaltyExpense" xlink:type="arc" order="7" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseAgreementsMember" xlink:label="us-gaap_LeaseAgreementsMember" xlink:title="us-gaap_LeaseAgreementsMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_CommitmentsAndContingenciesDomain" xlink:to="us-gaap_LeaseAgreementsMember" xlink:title="Definition : plx_CommitmentsAndContingenciesDomain to us-gaap_LeaseAgreementsMember" xlink:type="arc" order="8" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:title="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:title="Definition : plx_CommitmentsAndContingenciesLineItems to us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:type="arc" order="8" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_CommitmentAmount" xlink:label="plx_CommitmentAmount" xlink:title="plx_CommitmentAmount" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="plx_CommitmentAmount" xlink:title="Definition : plx_CommitmentsAndContingenciesLineItems to plx_CommitmentAmount" xlink:type="arc" order="9" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_YissumAgreementMember" xlink:label="plx_YissumAgreementMember" xlink:title="plx_YissumAgreementMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_CommitmentsAndContingenciesDomain" xlink:to="plx_YissumAgreementMember" xlink:title="Definition : plx_CommitmentsAndContingenciesDomain to plx_YissumAgreementMember" xlink:type="arc" order="10" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_MonthlyRentLeaseExpense" xlink:label="plx_MonthlyRentLeaseExpense" xlink:title="plx_MonthlyRentLeaseExpense" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="plx_MonthlyRentLeaseExpense" xlink:title="Definition : plx_CommitmentsAndContingenciesLineItems to plx_MonthlyRentLeaseExpense" xlink:type="arc" order="10" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit" xlink:title="us-gaap_SecurityDeposit" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_SecurityDeposit" xlink:title="Definition : plx_CommitmentsAndContingenciesLineItems to us-gaap_SecurityDeposit" xlink:type="arc" order="11" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet" xlink:title="us-gaap_OperatingLeasesRentExpenseNet" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeasesRentExpenseNet" xlink:title="Definition : plx_CommitmentsAndContingenciesLineItems to us-gaap_OperatingLeasesRentExpenseNet" xlink:type="arc" order="12" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:title="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:title="Definition : plx_CommitmentsAndContingenciesLineItems to us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="arc" order="13" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:title="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:title="Definition : plx_CommitmentsAndContingenciesLineItems to us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="arc" order="14" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:title="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:title="Definition : plx_CommitmentsAndContingenciesLineItems to us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="arc" order="15" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:title="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:title="Definition : plx_CommitmentsAndContingenciesLineItems to us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="arc" order="16" xbrldt:closed="false" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-scnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:title="us-gaap_AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="Definition : us-gaap_AwardTypeAxis to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:title="us-gaap_RestrictedStockMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to us-gaap_RestrictedStockMember" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ExecutiveOfficerMember" xlink:label="us-gaap_ExecutiveOfficerMember" xlink:title="us-gaap_ExecutiveOfficerMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="us-gaap_ExecutiveOfficerMember" xlink:title="Definition : us-gaap_TitleOfIndividualWithRelationshipToEntityDomain to us-gaap_ExecutiveOfficerMember" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_OfficersAndCertainEmployeesMember" xlink:label="plx_OfficersAndCertainEmployeesMember" xlink:title="plx_OfficersAndCertainEmployeesMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="plx_OfficersAndCertainEmployeesMember" xlink:title="Definition : us-gaap_TitleOfIndividualWithRelationshipToEntityDomain to plx_OfficersAndCertainEmployeesMember" xlink:type="arc" order="1.25" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:title="us-gaap_TitleOfIndividualAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="Definition : us-gaap_TitleOfIndividualAxis to us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:title="us-gaap_SaleOfStockPricePerShare" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_EmployeesMember" xlink:label="plx_EmployeesMember" xlink:title="plx_EmployeesMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="plx_EmployeesMember" xlink:title="Definition : us-gaap_TitleOfIndividualWithRelationshipToEntityDomain to plx_EmployeesMember" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:title="us-gaap_EmployeeStockOptionMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" xlink:title="Definition : us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to us-gaap_AwardTypeAxis" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:title="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="3" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_OfficersAndDirectorsInPrivateTransactionMember" xlink:label="plx_OfficersAndDirectorsInPrivateTransactionMember" xlink:title="plx_OfficersAndDirectorsInPrivateTransactionMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="plx_OfficersAndDirectorsInPrivateTransactionMember" xlink:title="Definition : us-gaap_TitleOfIndividualWithRelationshipToEntityDomain to plx_OfficersAndDirectorsInPrivateTransactionMember" xlink:type="arc" order="3" xbrldt:closed="false" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:title="Definition : us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to us-gaap_TitleOfIndividualAxis" xlink:type="arc" order="3.5" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="4" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_PresidentAndChiefExecutiveOfficerMember" xlink:label="plx_PresidentAndChiefExecutiveOfficerMember" xlink:title="plx_PresidentAndChiefExecutiveOfficerMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="plx_PresidentAndChiefExecutiveOfficerMember" xlink:title="Definition : us-gaap_TitleOfIndividualWithRelationshipToEntityDomain to plx_PresidentAndChiefExecutiveOfficerMember" xlink:type="arc" order="4" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="5" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="6" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc" order="7" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" xlink:title="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" xlink:type="arc" order="8" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:title="us-gaap_VestingAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:title="us-gaap_VestingDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:title="Definition : us-gaap_VestingAxis to us-gaap_VestingDomain" xlink:type="arc" order="10" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:title="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:title="Definition : us-gaap_VestingDomain to us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="10" xbrldt:closed="false" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="11" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:title="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" order="13" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:title="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="14" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BoardOfDirectorsChairmanMember" xlink:label="us-gaap_BoardOfDirectorsChairmanMember" xlink:title="us-gaap_BoardOfDirectorsChairmanMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="us-gaap_BoardOfDirectorsChairmanMember" xlink:title="Definition : us-gaap_TitleOfIndividualWithRelationshipToEntityDomain to us-gaap_BoardOfDirectorsChairmanMember" xlink:type="arc" order="14" xbrldt:closed="false" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" xlink:title="Definition : us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to us-gaap_VestingAxis" xlink:type="arc" order="14" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:title="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="15" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_1" xlink:title="us-gaap_VestingDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain_1" xlink:title="Definition : us-gaap_VestingAxis to us-gaap_VestingDomain" xlink:type="arc" order="20" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:title="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:title="Definition : us-gaap_VestingDomain to us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" order="20" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="36" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="46" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:title="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" order="56" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption" xlink:label="plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption" xlink:title="plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption" xlink:type="arc" order="116" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:title="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="126" xbrldt:closed="false" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-scsooarsgted">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:title="us-gaap_PlanNameAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:title="us-gaap_PlanNameDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:title="Definition : us-gaap_PlanNameAxis to us-gaap_PlanNameDomain" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_EmployeesMember" xlink:label="plx_EmployeesMember" xlink:title="plx_EmployeesMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="plx_EmployeesMember" xlink:title="Definition : us-gaap_TitleOfIndividualWithRelationshipToEntityDomain to plx_EmployeesMember" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" xlink:title="Definition : us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to us-gaap_PlanNameAxis" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:title="us-gaap_TitleOfIndividualAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="Definition : us-gaap_TitleOfIndividualAxis to us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_1" xlink:title="us-gaap_PlanNameDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_1" xlink:title="Definition : us-gaap_PlanNameAxis to us-gaap_PlanNameDomain" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:title="Definition : us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to us-gaap_TitleOfIndividualAxis" xlink:type="arc" order="2.5" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_GrantYearTwoThousandTwelveMember" xlink:label="plx_GrantYearTwoThousandTwelveMember" xlink:title="plx_GrantYearTwoThousandTwelveMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="plx_GrantYearTwoThousandTwelveMember" xlink:title="Definition : us-gaap_PlanNameDomain to plx_GrantYearTwoThousandTwelveMember" xlink:type="arc" order="3" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="arc" order="3" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_GrantYearTwoThousandTwelveSecondMember" xlink:label="plx_GrantYearTwoThousandTwelveSecondMember" xlink:title="plx_GrantYearTwoThousandTwelveSecondMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="plx_GrantYearTwoThousandTwelveSecondMember" xlink:title="Definition : us-gaap_PlanNameDomain to plx_GrantYearTwoThousandTwelveSecondMember" xlink:type="arc" order="4" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="5" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_GrantYearTwoThousandFourteenMember" xlink:label="plx_GrantYearTwoThousandFourteenMember" xlink:title="plx_GrantYearTwoThousandFourteenMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="plx_GrantYearTwoThousandFourteenMember" xlink:title="Definition : us-gaap_PlanNameDomain to plx_GrantYearTwoThousandFourteenMember" xlink:type="arc" order="5" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:title="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:type="arc" order="6" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" xlink:title="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" xlink:type="arc" order="7" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="17" xbrldt:closed="false" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-scogted">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_OptionsAndRestrictedStockGrantedToEmployeesMember" xlink:label="plx_OptionsAndRestrictedStockGrantedToEmployeesMember" xlink:title="plx_OptionsAndRestrictedStockGrantedToEmployeesMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="plx_OptionsAndRestrictedStockGrantedToEmployeesMember" xlink:title="Definition : us-gaap_TitleOfIndividualWithRelationshipToEntityDomain to plx_OptionsAndRestrictedStockGrantedToEmployeesMember" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:title="us-gaap_TitleOfIndividualAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:title="Definition : us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to us-gaap_TitleOfIndividualAxis" xlink:type="arc" order="1.5" xbrldt:closed="false" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="Definition : us-gaap_TitleOfIndividualAxis to us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="3" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="3" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="3" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="4" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="4" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="4" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="5" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="5" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="6" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="6" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:title="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="15" xbrldt:closed="false" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-scrsgted">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:title="us-gaap_RestrictedStockMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to us-gaap_RestrictedStockMember" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:title="us-gaap_AwardTypeAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" xlink:title="Definition : us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to us-gaap_AwardTypeAxis" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="2" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="Definition : us-gaap_AwardTypeAxis to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:title="us-gaap_TitleOfIndividualAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="Definition : us-gaap_TitleOfIndividualAxis to us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_EmployeesMember" xlink:label="plx_EmployeesMember" xlink:title="plx_EmployeesMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="plx_EmployeesMember" xlink:title="Definition : us-gaap_TitleOfIndividualWithRelationshipToEntityDomain to plx_EmployeesMember" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="2.5" xbrldt:closed="false" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:title="Definition : us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to us-gaap_TitleOfIndividualAxis" xlink:type="arc" order="2.5" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="3" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="4" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="5" xbrldt:closed="false" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-scoarsgtcdaospd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" xlink:label="plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" xlink:title="plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" xlink:title="Definition : us-gaap_TitleOfIndividualWithRelationshipToEntityDomain to plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1.5" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1.5" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:title="us-gaap_TitleOfIndividualAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:title="Definition : us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to us-gaap_TitleOfIndividualAxis" xlink:type="arc" order="1.5" xbrldt:closed="false" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="Definition : us-gaap_TitleOfIndividualAxis to us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" xlink:label="plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" xlink:title="plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" xlink:title="Definition : us-gaap_TitleOfIndividualWithRelationshipToEntityDomain to plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="3" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="3" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="3" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="4" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="4" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="4" xbrldt:closed="false" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-scsooarsd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:title="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:title="Definition : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems to us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:title="Definition : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis to us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_OptionsAndRestrictedStockMember" xlink:label="plx_OptionsAndRestrictedStockMember" xlink:title="plx_OptionsAndRestrictedStockMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="plx_OptionsAndRestrictedStockMember" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to plx_OptionsAndRestrictedStockMember" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ZeroPointZeroZeroOneMember" xlink:label="plx_ZeroPointZeroZeroOneMember" xlink:title="plx_ZeroPointZeroZeroOneMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="plx_ZeroPointZeroZeroOneMember" xlink:title="Definition : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to plx_ZeroPointZeroZeroOneMember" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:title="Definition : us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable to us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:title="us-gaap_AwardTypeAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_AwardTypeAxis" xlink:title="Definition : us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable to us-gaap_AwardTypeAxis" xlink:type="arc" order="1.5" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" xlink:title="Definition : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis to us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="Definition : us-gaap_AwardTypeAxis to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:title="Definition : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems to us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:title="us-gaap_RestrictedStockMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to us-gaap_RestrictedStockMember" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ZeroPointOneTwoZeroMember" xlink:label="plx_ZeroPointOneTwoZeroMember" xlink:title="plx_ZeroPointOneTwoZeroMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="plx_ZeroPointOneTwoZeroMember" xlink:title="Definition : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to plx_ZeroPointOneTwoZeroMember" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:title="Definition : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems to us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="arc" order="3" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ZeroPointThreeNineNineMember" xlink:label="plx_ZeroPointThreeNineNineMember" xlink:title="plx_ZeroPointThreeNineNineMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="plx_ZeroPointThreeNineNineMember" xlink:title="Definition : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to plx_ZeroPointThreeNineNineMember" xlink:type="arc" order="3" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:title="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:title="Definition : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems to us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="4" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ZeroPointNineSevenTwoMember" xlink:label="plx_ZeroPointNineSevenTwoMember" xlink:title="plx_ZeroPointNineSevenTwoMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="plx_ZeroPointNineSevenTwoMember" xlink:title="Definition : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to plx_ZeroPointNineSevenTwoMember" xlink:type="arc" order="4" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:title="Definition : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems to us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="arc" order="5" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_TwoPointThreeFiveZeroMember" xlink:label="plx_TwoPointThreeFiveZeroMember" xlink:title="plx_TwoPointThreeFiveZeroMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="plx_TwoPointThreeFiveZeroMember" xlink:title="Definition : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to plx_TwoPointThreeFiveZeroMember" xlink:type="arc" order="5" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_TwoPointThreeSevenZeroMember" xlink:label="plx_TwoPointThreeSevenZeroMember" xlink:title="plx_TwoPointThreeSevenZeroMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="plx_TwoPointThreeSevenZeroMember" xlink:title="Definition : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to plx_TwoPointThreeSevenZeroMember" xlink:type="arc" order="5.5" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_TwoPointSixFiveMember" xlink:label="plx_TwoPointSixFiveMember" xlink:title="plx_TwoPointSixFiveMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="plx_TwoPointSixFiveMember" xlink:title="Definition : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to plx_TwoPointSixFiveMember" xlink:type="arc" order="6" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:title="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:title="Definition : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems to us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="6" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ThreePointZeroTwoZeroMember" xlink:label="plx_ThreePointZeroTwoZeroMember" xlink:title="plx_ThreePointZeroTwoZeroMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="plx_ThreePointZeroTwoZeroMember" xlink:title="Definition : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to plx_ThreePointZeroTwoZeroMember" xlink:type="arc" order="7" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:title="Definition : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="7" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ThreePointThreeSevenZeroMember" xlink:label="plx_ThreePointThreeSevenZeroMember" xlink:title="plx_ThreePointThreeSevenZeroMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="plx_ThreePointThreeSevenZeroMember" xlink:title="Definition : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to plx_ThreePointThreeSevenZeroMember" xlink:type="arc" order="7.5" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_FivePointZeroMember" xlink:label="plx_FivePointZeroMember" xlink:title="plx_FivePointZeroMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="plx_FivePointZeroMember" xlink:title="Definition : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to plx_FivePointZeroMember" xlink:type="arc" order="8" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:title="Definition : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" order="8" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_SixPointEightOneZeroMember" xlink:label="plx_SixPointEightOneZeroMember" xlink:title="plx_SixPointEightOneZeroMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="plx_SixPointEightOneZeroMember" xlink:title="Definition : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to plx_SixPointEightOneZeroMember" xlink:type="arc" order="9" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_SixPointNineMember" xlink:label="plx_SixPointNineMember" xlink:title="plx_SixPointNineMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="plx_SixPointNineMember" xlink:title="Definition : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to plx_SixPointNineMember" xlink:type="arc" order="10" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_SevenPointFiveFiveMember" xlink:label="plx_SevenPointFiveFiveMember" xlink:title="plx_SevenPointFiveFiveMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="plx_SevenPointFiveFiveMember" xlink:title="Definition : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to plx_SevenPointFiveFiveMember" xlink:type="arc" order="11" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_NinePointSixSixMember" xlink:label="plx_NinePointSixSixMember" xlink:title="plx_NinePointSixSixMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="plx_NinePointSixSixMember" xlink:title="Definition : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to plx_NinePointSixSixMember" xlink:type="arc" order="12" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_OneSixPointSevenMember" xlink:label="plx_OneSixPointSevenMember" xlink:title="plx_OneSixPointSevenMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="plx_OneSixPointSevenMember" xlink:title="Definition : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to plx_OneSixPointSevenMember" xlink:type="arc" order="13" xbrldt:closed="false" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-scsbcead">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="Definition : us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:title="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:title="us-gaap_IncomeStatementLocationDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:title="Definition : us-gaap_IncomeStatementLocationAxis to us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember" xlink:title="us-gaap_CostOfSalesMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_CostOfSalesMember" xlink:title="Definition : us-gaap_IncomeStatementLocationDomain to us-gaap_CostOfSalesMember" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:title="Definition : us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1.5" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_1" xlink:title="us-gaap_IncomeStatementLocationDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_1" xlink:title="Definition : us-gaap_IncomeStatementLocationAxis to us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:title="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:title="Definition : us-gaap_IncomeStatementLocationDomain to us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:title="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:title="Definition : us-gaap_IncomeStatementLocationDomain to us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="3" xbrldt:closed="false" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-toind">
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_IncomeTaxDisclosureLineItems" xlink:label="plx_IncomeTaxDisclosureLineItems" xlink:title="plx_IncomeTaxDisclosureLineItems" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_IncomeTaxDisclosureTable" xlink:label="plx_IncomeTaxDisclosureTable" xlink:title="plx_IncomeTaxDisclosureTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="plx_IncomeTaxDisclosureLineItems" xlink:to="plx_IncomeTaxDisclosureTable" xlink:title="Definition : plx_IncomeTaxDisclosureLineItems to plx_IncomeTaxDisclosureTable" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:title="us-gaap_IncomeTaxAuthorityAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:title="us-gaap_IncomeTaxAuthorityDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:title="Definition : us-gaap_IncomeTaxAuthorityAxis to us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:title="dei_EntityDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsidiariesMember" xlink:label="us-gaap_SubsidiariesMember" xlink:title="us-gaap_SubsidiariesMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="us-gaap_SubsidiariesMember" xlink:title="Definition : dei_EntityDomain to us-gaap_SubsidiariesMember" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_TaxYearThereafterMember" xlink:label="plx_TaxYearThereafterMember" xlink:title="plx_TaxYearThereafterMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="plx_TaxYearThereafterMember" xlink:title="Definition : us-gaap_IncomeTaxAuthorityDomain to plx_TaxYearThereafterMember" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:title="us-gaap_RangeMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:title="us-gaap_MinimumMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" xlink:title="Definition : us-gaap_RangeMember to us-gaap_MinimumMember" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:title="us-gaap_RangeAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="plx_IncomeTaxDisclosureTable" xlink:to="us-gaap_RangeAxis" xlink:title="Definition : plx_IncomeTaxDisclosureTable to us-gaap_RangeAxis" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:title="dei_LegalEntityAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="plx_IncomeTaxDisclosureTable" xlink:to="dei_LegalEntityAxis" xlink:title="Definition : plx_IncomeTaxDisclosureTable to dei_LegalEntityAxis" xlink:type="arc" order="1.5" xbrldt:closed="false" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:title="Definition : dei_LegalEntityAxis to dei_EntityDomain" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:title="Definition : us-gaap_RangeAxis to us-gaap_RangeMember" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_1" xlink:title="us-gaap_IncomeTaxAuthorityDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_1" xlink:title="Definition : us-gaap_IncomeTaxAuthorityAxis to us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_TaxYearTwoThousandNineMember" xlink:label="plx_TaxYearTwoThousandNineMember" xlink:title="plx_TaxYearTwoThousandNineMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="plx_TaxYearTwoThousandNineMember" xlink:title="Definition : us-gaap_IncomeTaxAuthorityDomain to plx_TaxYearTwoThousandNineMember" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:title="us-gaap_MaximumMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" xlink:title="Definition : us-gaap_RangeMember to us-gaap_MaximumMember" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:title="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:title="Definition : plx_IncomeTaxDisclosureLineItems to us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="plx_IncomeTaxDisclosureTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:title="Definition : plx_IncomeTaxDisclosureTable to us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="2.75" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_TaxBurdenDistributionLawMember" xlink:label="plx_TaxBurdenDistributionLawMember" xlink:title="plx_TaxBurdenDistributionLawMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="plx_TaxBurdenDistributionLawMember" xlink:title="Definition : us-gaap_IncomeTaxAuthorityDomain to plx_TaxBurdenDistributionLawMember" xlink:type="arc" order="3" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_EffectiveAdjustedIncomeTaxRateYearOne" xlink:label="plx_EffectiveAdjustedIncomeTaxRateYearOne" xlink:title="plx_EffectiveAdjustedIncomeTaxRateYearOne" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_IncomeTaxDisclosureLineItems" xlink:to="plx_EffectiveAdjustedIncomeTaxRateYearOne" xlink:title="Definition : plx_IncomeTaxDisclosureLineItems to plx_EffectiveAdjustedIncomeTaxRateYearOne" xlink:type="arc" order="3" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_RestrictedAmountMember" xlink:label="plx_RestrictedAmountMember" xlink:title="plx_RestrictedAmountMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="plx_RestrictedAmountMember" xlink:title="Definition : us-gaap_IncomeTaxAuthorityDomain to plx_RestrictedAmountMember" xlink:type="arc" order="4" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_EffectiveAdjustedIncomeTaxRateYearFour" xlink:label="plx_EffectiveAdjustedIncomeTaxRateYearFour" xlink:title="plx_EffectiveAdjustedIncomeTaxRateYearFour" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_IncomeTaxDisclosureLineItems" xlink:to="plx_EffectiveAdjustedIncomeTaxRateYearFour" xlink:title="Definition : plx_IncomeTaxDisclosureLineItems to plx_EffectiveAdjustedIncomeTaxRateYearFour" xlink:type="arc" order="4" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_EffectiveAdjustedIncomeTaxRateYearTwo" xlink:label="plx_EffectiveAdjustedIncomeTaxRateYearTwo" xlink:title="plx_EffectiveAdjustedIncomeTaxRateYearTwo" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_IncomeTaxDisclosureLineItems" xlink:to="plx_EffectiveAdjustedIncomeTaxRateYearTwo" xlink:title="Definition : plx_IncomeTaxDisclosureLineItems to plx_EffectiveAdjustedIncomeTaxRateYearTwo" xlink:type="arc" order="5" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_EffectiveAdjustedIncomeTaxRateYearThree" xlink:label="plx_EffectiveAdjustedIncomeTaxRateYearThree" xlink:title="plx_EffectiveAdjustedIncomeTaxRateYearThree" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_IncomeTaxDisclosureLineItems" xlink:to="plx_EffectiveAdjustedIncomeTaxRateYearThree" xlink:title="Definition : plx_IncomeTaxDisclosureLineItems to plx_EffectiveAdjustedIncomeTaxRateYearThree" xlink:type="arc" order="6" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_EffectiveAdjustedIncomeTaxRateYearFive" xlink:label="plx_EffectiveAdjustedIncomeTaxRateYearFive" xlink:title="plx_EffectiveAdjustedIncomeTaxRateYearFive" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_IncomeTaxDisclosureLineItems" xlink:to="plx_EffectiveAdjustedIncomeTaxRateYearFive" xlink:title="Definition : plx_IncomeTaxDisclosureLineItems to plx_EffectiveAdjustedIncomeTaxRateYearFive" xlink:type="arc" order="7" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_EffectiveAdjustedIncomeTaxRateThereafter" xlink:label="plx_EffectiveAdjustedIncomeTaxRateThereafter" xlink:title="plx_EffectiveAdjustedIncomeTaxRateThereafter" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_IncomeTaxDisclosureLineItems" xlink:to="plx_EffectiveAdjustedIncomeTaxRateThereafter" xlink:title="Definition : plx_IncomeTaxDisclosureLineItems to plx_EffectiveAdjustedIncomeTaxRateThereafter" xlink:type="arc" order="8" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_WithholdingTaxRateOnForeignIncome" xlink:label="plx_WithholdingTaxRateOnForeignIncome" xlink:title="plx_WithholdingTaxRateOnForeignIncome" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_IncomeTaxDisclosureLineItems" xlink:to="plx_WithholdingTaxRateOnForeignIncome" xlink:title="Definition : plx_IncomeTaxDisclosureLineItems to plx_WithholdingTaxRateOnForeignIncome" xlink:type="arc" order="9" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:title="us-gaap_OperatingLossCarryforwards" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" xlink:title="Definition : plx_IncomeTaxDisclosureLineItems to us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="10" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal" xlink:label="plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal" xlink:title="plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_IncomeTaxDisclosureLineItems" xlink:to="plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal" xlink:title="Definition : plx_IncomeTaxDisclosureLineItems to plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal" xlink:type="arc" order="11" xbrldt:closed="false" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-toiotyd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="us-gaap_IncomeTaxContingencyLineItems" xlink:title="us-gaap_IncomeTaxContingencyLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="us-gaap_IncomeTaxContingencyTable" xlink:title="us-gaap_IncomeTaxContingencyTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxContingencyTable" xlink:title="Definition : us-gaap_IncomeTaxContingencyLineItems to us-gaap_IncomeTaxContingencyTable" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:title="us-gaap_IncomeTaxAuthorityDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd#country_IL" xlink:label="country_IL" xlink:title="country_IL" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="country_IL" xlink:title="Definition : us-gaap_IncomeTaxAuthorityDomain to country_IL" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:title="us-gaap_RangeMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:title="us-gaap_MinimumMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" xlink:title="Definition : us-gaap_RangeMember to us-gaap_MinimumMember" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:title="us-gaap_IncomeTaxAuthorityAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:title="Definition : us-gaap_IncomeTaxContingencyTable to us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:title="us-gaap_RangeAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_RangeAxis" xlink:title="Definition : us-gaap_IncomeTaxContingencyTable to us-gaap_RangeAxis" xlink:type="arc" order="1.5" xbrldt:closed="false" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:title="Definition : us-gaap_IncomeTaxAuthorityAxis to us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:title="Definition : us-gaap_RangeAxis to us-gaap_RangeMember" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd#country_US" xlink:label="country_US" xlink:title="country_US" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="country_US" xlink:title="Definition : us-gaap_IncomeTaxAuthorityDomain to country_US" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear" xlink:title="us-gaap_OpenTaxYear" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_OpenTaxYear" xlink:title="Definition : us-gaap_IncomeTaxContingencyLineItems to us-gaap_OpenTaxYear" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:title="us-gaap_MaximumMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" xlink:title="Definition : us-gaap_RangeMember to us-gaap_MaximumMember" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd#country_NL" xlink:label="country_NL" xlink:title="country_NL" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="country_NL" xlink:title="Definition : us-gaap_IncomeTaxAuthorityDomain to country_NL" xlink:type="arc" order="3" xbrldt:closed="false" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-rptd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:title="us-gaap_RelatedPartyTransactionLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:title="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:title="Definition : us-gaap_RelatedPartyTransactionLineItems to us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:title="us-gaap_RelatedPartyDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" xlink:title="Definition : us-gaap_RelatedPartyTransactionsByRelatedPartyAxis to us-gaap_RelatedPartyDomain" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ManagementAndConsultingFeesToChairmanOfBoardMember" xlink:label="plx_ManagementAndConsultingFeesToChairmanOfBoardMember" xlink:title="plx_ManagementAndConsultingFeesToChairmanOfBoardMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="plx_ManagementAndConsultingFeesToChairmanOfBoardMember" xlink:title="Definition : us-gaap_RelatedPartyDomain to plx_ManagementAndConsultingFeesToChairmanOfBoardMember" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="Definition : us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_1" xlink:title="us-gaap_RelatedPartyDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_1" xlink:title="Definition : us-gaap_RelatedPartyTransactionsByRelatedPartyAxis to us-gaap_RelatedPartyDomain" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:title="us-gaap_RelatedPartyTransactionAmountsOfTransaction" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:title="Definition : us-gaap_RelatedPartyTransactionLineItems to us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_CompensationToTheNon-executiveDirectorsMember" xlink:label="plx_CompensationToTheNon-executiveDirectorsMember" xlink:title="plx_CompensationToTheNon-executiveDirectorsMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="plx_CompensationToTheNon-executiveDirectorsMember" xlink:title="Definition : us-gaap_RelatedPartyDomain to plx_CompensationToTheNon-executiveDirectorsMember" xlink:type="arc" order="2" xbrldt:closed="false" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-sapulopaed">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:title="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="Definition : us-gaap_PropertyPlantAndEquipmentLineItems to us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:title="Definition : us-gaap_PropertyPlantAndEquipmentByTypeAxis to us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:title="us-gaap_RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:title="us-gaap_RangeMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:title="Definition : us-gaap_RangeAxis to us-gaap_RangeMember" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_LaboratoryEquipmentMember" xlink:label="plx_LaboratoryEquipmentMember" xlink:title="plx_LaboratoryEquipmentMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="plx_LaboratoryEquipmentMember" xlink:title="Definition : us-gaap_PropertyPlantAndEquipmentTypeDomain to plx_LaboratoryEquipmentMember" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:title="us-gaap_MinimumMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" xlink:title="Definition : us-gaap_RangeMember to us-gaap_MinimumMember" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:title="Definition : us-gaap_ScheduleOfPropertyPlantAndEquipmentTable to us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:title="us-gaap_FurnitureAndFixturesMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:title="Definition : us-gaap_PropertyPlantAndEquipmentTypeDomain to us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1.5" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:title="Definition : us-gaap_PropertyPlantAndEquipmentByTypeAxis to us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember_1" xlink:title="us-gaap_RangeMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember_1" xlink:title="Definition : us-gaap_RangeAxis to us-gaap_RangeMember" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:title="us-gaap_ComputerEquipmentMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" xlink:title="Definition : us-gaap_PropertyPlantAndEquipmentTypeDomain to us-gaap_ComputerEquipmentMember" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:title="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:title="Definition : us-gaap_PropertyPlantAndEquipmentLineItems to us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:title="us-gaap_MaximumMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" xlink:title="Definition : us-gaap_RangeMember to us-gaap_MaximumMember" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_RangeAxis" xlink:title="Definition : us-gaap_ScheduleOfPropertyPlantAndEquipmentTable to us-gaap_RangeAxis" xlink:type="arc" order="2" xbrldt:closed="false" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-std">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" xlink:title="us-gaap_ClassOfStockLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" xlink:title="us-gaap_ScheduleOfStockByClassTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" xlink:title="Definition : us-gaap_ClassOfStockLineItems to us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="0.1" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:title="us-gaap_TitleOfIndividualAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:title="Definition : us-gaap_ScheduleOfStockByClassTable to us-gaap_TitleOfIndividualAxis" xlink:type="arc" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="Definition : us-gaap_TitleOfIndividualAxis to us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_OfficersAndCertainEmployeesMember" xlink:label="plx_OfficersAndCertainEmployeesMember" xlink:title="plx_OfficersAndCertainEmployeesMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="plx_OfficersAndCertainEmployeesMember" xlink:title="Definition : us-gaap_TitleOfIndividualWithRelationshipToEntityDomain to plx_OfficersAndCertainEmployeesMember" xlink:type="arc" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:title="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:title="Definition : us-gaap_TitleOfIndividualAxis to us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:title="us-gaap_VestingAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_VestingAxis" xlink:title="Definition : us-gaap_ScheduleOfStockByClassTable to us-gaap_VestingAxis" xlink:type="arc" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:title="us-gaap_VestingDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:title="Definition : us-gaap_VestingAxis to us-gaap_VestingDomain" xlink:type="arc" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:title="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:title="Definition : us-gaap_VestingDomain to us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:title="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:title="Definition : us-gaap_VestingDomain to us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_1" xlink:title="us-gaap_VestingDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain_1" xlink:title="Definition : us-gaap_VestingAxis to us-gaap_VestingDomain" xlink:type="arc" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:title="us-gaap_AwardTypeAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" xlink:title="Definition : us-gaap_ScheduleOfStockByClassTable to us-gaap_AwardTypeAxis" xlink:type="arc" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="Definition : us-gaap_AwardTypeAxis to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:title="us-gaap_EmployeeStockOptionMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:title="Definition : us-gaap_AwardTypeAxis to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:title="us-gaap_PlanNameAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" xlink:title="Definition : us-gaap_ScheduleOfStockByClassTable to us-gaap_PlanNameAxis" xlink:type="arc" order="4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:title="us-gaap_PlanNameDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:title="Definition : us-gaap_PlanNameAxis to us-gaap_PlanNameDomain" xlink:type="arc" order="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_EmployeeStockIncentivePlan2006Member" xlink:label="plx_EmployeeStockIncentivePlan2006Member" xlink:title="plx_EmployeeStockIncentivePlan2006Member" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="plx_EmployeeStockIncentivePlan2006Member" xlink:title="Definition : us-gaap_PlanNameDomain to plx_EmployeeStockIncentivePlan2006Member" xlink:type="arc" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_1" xlink:title="us-gaap_PlanNameDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_1" xlink:title="Definition : us-gaap_PlanNameAxis to us-gaap_PlanNameDomain" xlink:type="arc" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:title="Definition : us-gaap_ClassOfStockLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:title="Definition : us-gaap_ClassOfStockLineItems to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="Definition : us-gaap_ClassOfStockLineItems to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:title="Definition : us-gaap_ClassOfStockLineItems to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="4" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod" xlink:title="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod" xlink:title="Definition : us-gaap_ClassOfStockLineItems to plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod" xlink:type="arc" order="5" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="Definition : us-gaap_ClassOfStockLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="6" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:title="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:title="Definition : us-gaap_ClassOfStockLineItems to plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:type="arc" order="7" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="Definition : us-gaap_ClassOfStockLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="8" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="Definition : us-gaap_ClassOfStockLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="9" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="Definition : us-gaap_ClassOfStockLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="Definition : us-gaap_ClassOfStockLineItems to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="11" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-sapd">
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="plx_SignificantAccountingPoliciesLineItems" xlink:title="plx_SignificantAccountingPoliciesLineItems" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_NumberOfSubsidiaries" xlink:label="plx_NumberOfSubsidiaries" xlink:title="plx_NumberOfSubsidiaries" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_NumberOfSubsidiaries" xlink:title="Definition : plx_SignificantAccountingPoliciesLineItems to plx_NumberOfSubsidiaries" xlink:type="arc" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:label="us-gaap_ProceedsFromCollaborators" xlink:title="us-gaap_ProceedsFromCollaborators" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ProceedsFromCollaborators" xlink:title="Definition : plx_SignificantAccountingPoliciesLineItems to us-gaap_ProceedsFromCollaborators" xlink:type="arc" order="2" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_CollaborativeArrangementMilestonePaymentAmount" xlink:label="plx_CollaborativeArrangementMilestonePaymentAmount" xlink:title="plx_CollaborativeArrangementMilestonePaymentAmount" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_CollaborativeArrangementMilestonePaymentAmount" xlink:title="Definition : plx_SignificantAccountingPoliciesLineItems to plx_CollaborativeArrangementMilestonePaymentAmount" xlink:type="arc" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet" xlink:title="us-gaap_SalesRevenueGoodsNet" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_SalesRevenueGoodsNet" xlink:title="Definition : plx_SignificantAccountingPoliciesLineItems to us-gaap_SalesRevenueGoodsNet" xlink:type="arc" order="4" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_SupplyCommitmentPerYear" xlink:label="plx_SupplyCommitmentPerYear" xlink:title="plx_SupplyCommitmentPerYear" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_SupplyCommitmentPerYear" xlink:title="Definition : plx_SignificantAccountingPoliciesLineItems to plx_SupplyCommitmentPerYear" xlink:type="arc" order="5" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_PurchaseOrderReceived" xlink:label="plx_PurchaseOrderReceived" xlink:title="plx_PurchaseOrderReceived" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_PurchaseOrderReceived" xlink:title="Definition : plx_SignificantAccountingPoliciesLineItems to plx_PurchaseOrderReceived" xlink:type="arc" order="6" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" xlink:label="plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" xlink:title="plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" xlink:title="Definition : plx_SignificantAccountingPoliciesLineItems to plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" xlink:type="arc" order="7" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights" xlink:label="plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights" xlink:title="plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights" xlink:title="Definition : plx_SignificantAccountingPoliciesLineItems to plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights" xlink:type="arc" order="8" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_RightToTerminateAgreementRevenueThreshold" xlink:label="plx_RightToTerminateAgreementRevenueThreshold" xlink:title="plx_RightToTerminateAgreementRevenueThreshold" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_RightToTerminateAgreementRevenueThreshold" xlink:title="Definition : plx_SignificantAccountingPoliciesLineItems to plx_RightToTerminateAgreementRevenueThreshold" xlink:type="arc" order="9" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_PercentageOfAdultGaucherPatientsTreatedWithUplyso" xlink:label="plx_PercentageOfAdultGaucherPatientsTreatedWithUplyso" xlink:title="plx_PercentageOfAdultGaucherPatientsTreatedWithUplyso" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_PercentageOfAdultGaucherPatientsTreatedWithUplyso" xlink:title="Definition : plx_SignificantAccountingPoliciesLineItems to plx_PercentageOfAdultGaucherPatientsTreatedWithUplyso" xlink:type="arc" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:title="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:title="Definition : plx_SignificantAccountingPoliciesLineItems to us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="11" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="Definition : plx_SignificantAccountingPoliciesLineItems to us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="12" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_EligablePaymentReceivableUponAchievement" xlink:label="plx_EligablePaymentReceivableUponAchievement" xlink:title="plx_EligablePaymentReceivableUponAchievement" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_EligablePaymentReceivableUponAchievement" xlink:title="Definition : plx_SignificantAccountingPoliciesLineItems to plx_EligablePaymentReceivableUponAchievement" xlink:type="arc" order="13" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ProceedsFromSaleOfShareInCollaboration" xlink:label="plx_ProceedsFromSaleOfShareInCollaboration" xlink:title="plx_ProceedsFromSaleOfShareInCollaboration" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_ProceedsFromSaleOfShareInCollaboration" xlink:title="Definition : plx_SignificantAccountingPoliciesLineItems to plx_ProceedsFromSaleOfShareInCollaboration" xlink:type="arc" order="14" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:title="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:title="Definition : plx_SignificantAccountingPoliciesLineItems to plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:type="arc" order="15" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfitsEliminationAmount" xlink:label="plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfitsEliminationAmount" xlink:title="plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfitsEliminationAmount" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfitsEliminationAmount" xlink:title="Definition : plx_SignificantAccountingPoliciesLineItems to plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfitsEliminationAmount" xlink:type="arc" order="16" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_AgentFeePercentageOfNetProceeds" xlink:label="plx_AgentFeePercentageOfNetProceeds" xlink:title="plx_AgentFeePercentageOfNetProceeds" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_AgentFeePercentageOfNetProceeds" xlink:title="Definition : plx_SignificantAccountingPoliciesLineItems to plx_AgentFeePercentageOfNetProceeds" xlink:type="arc" order="17" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="plx_SignificantAccountingPoliciesTable" xlink:title="plx_SignificantAccountingPoliciesTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_SignificantAccountingPoliciesTable" xlink:title="Definition : plx_SignificantAccountingPoliciesLineItems to plx_SignificantAccountingPoliciesTable" xlink:type="arc" order="18" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:title="us-gaap_SubsequentEventTypeAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:title="Definition : plx_SignificantAccountingPoliciesTable to us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:title="us-gaap_SubsequentEventTypeDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:title="Definition : us-gaap_SubsequentEventTypeAxis to us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:title="us-gaap_SubsequentEventMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:title="Definition : us-gaap_SubsequentEventTypeDomain to us-gaap_SubsequentEventMember" xlink:type="arc" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_1" xlink:title="us-gaap_SubsequentEventTypeDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_1" xlink:title="Definition : us-gaap_SubsequentEventTypeAxis to us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:title="us-gaap_TypeOfArrangementAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:title="Definition : plx_SignificantAccountingPoliciesTable to us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:title="Definition : us-gaap_TypeOfArrangementAxis to us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_BrazilAgreementMember" xlink:label="plx_BrazilAgreementMember" xlink:title="plx_BrazilAgreementMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_BrazilAgreementMember" xlink:title="Definition : us-gaap_ArrangementsAndNonarrangementTransactionsMember to plx_BrazilAgreementMember" xlink:type="arc" order="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_PfizerAgreementMember" xlink:label="plx_PfizerAgreementMember" xlink:title="plx_PfizerAgreementMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_PfizerAgreementMember" xlink:title="Definition : us-gaap_ArrangementsAndNonarrangementTransactionsMember to plx_PfizerAgreementMember" xlink:type="arc" order="2" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_AmendedPfizerAgreementMember" xlink:label="plx_AmendedPfizerAgreementMember" xlink:title="plx_AmendedPfizerAgreementMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_AmendedPfizerAgreementMember" xlink:title="Definition : us-gaap_ArrangementsAndNonarrangementTransactionsMember to plx_AmendedPfizerAgreementMember" xlink:type="arc" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:title="Definition : us-gaap_TypeOfArrangementAxis to us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:title="dei_LegalEntityAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="dei_LegalEntityAxis" xlink:title="Definition : plx_SignificantAccountingPoliciesTable to dei_LegalEntityAxis" xlink:type="arc" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:title="dei_EntityDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:title="Definition : dei_LegalEntityAxis to dei_EntityDomain" xlink:type="arc" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsidiariesMember" xlink:label="us-gaap_SubsidiariesMember" xlink:title="us-gaap_SubsidiariesMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="us-gaap_SubsidiariesMember" xlink:title="Definition : dei_EntityDomain to us-gaap_SubsidiariesMember" xlink:type="arc" order="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember" xlink:title="plx_ProtalixBioTherapeuticsIncorporationMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="plx_ProtalixBioTherapeuticsIncorporationMember" xlink:title="Definition : dei_EntityDomain to plx_ProtalixBioTherapeuticsIncorporationMember" xlink:type="arc" order="21" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_1" xlink:title="dei_EntityDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_1" xlink:title="Definition : dei_LegalEntityAxis to dei_EntityDomain" xlink:type="arc" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:title="us-gaap_CounterpartyNameAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:title="Definition : plx_SignificantAccountingPoliciesTable to us-gaap_CounterpartyNameAxis" xlink:type="arc" order="4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:title="us-gaap_RepurchaseAgreementCounterpartyNameDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:title="Definition : us-gaap_CounterpartyNameAxis to us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_PfizerIncorporationMember" xlink:label="plx_PfizerIncorporationMember" xlink:title="plx_PfizerIncorporationMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="plx_PfizerIncorporationMember" xlink:title="Definition : us-gaap_RepurchaseAgreementCounterpartyNameDomain to plx_PfizerIncorporationMember" xlink:type="arc" order="10" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_FiocruzMember" xlink:label="plx_FiocruzMember" xlink:title="plx_FiocruzMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="plx_FiocruzMember" xlink:title="Definition : us-gaap_RepurchaseAgreementCounterpartyNameDomain to plx_FiocruzMember" xlink:type="arc" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain_1" xlink:title="us-gaap_RepurchaseAgreementCounterpartyNameDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain_1" xlink:title="Definition : us-gaap_CounterpartyNameAxis to us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="us-gaap_StatementGeographicalAxis" xlink:title="us-gaap_StatementGeographicalAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_StatementGeographicalAxis" xlink:title="Definition : plx_SignificantAccountingPoliciesTable to us-gaap_StatementGeographicalAxis" xlink:type="arc" order="5" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="us-gaap_SegmentGeographicalDomain" xlink:title="us-gaap_SegmentGeographicalDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_SegmentGeographicalDomain" xlink:title="Definition : us-gaap_StatementGeographicalAxis to us-gaap_SegmentGeographicalDomain" xlink:type="arc" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd#country_BR" xlink:label="country_BR" xlink:title="country_BR" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentGeographicalDomain" xlink:to="country_BR" xlink:title="Definition : us-gaap_SegmentGeographicalDomain to country_BR" xlink:type="arc" order="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ExcludingBrazilMember" xlink:label="plx_ExcludingBrazilMember" xlink:title="plx_ExcludingBrazilMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentGeographicalDomain" xlink:to="plx_ExcludingBrazilMember" xlink:title="Definition : us-gaap_SegmentGeographicalDomain to plx_ExcludingBrazilMember" xlink:type="arc" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="us-gaap_SegmentGeographicalDomain_1" xlink:title="us-gaap_SegmentGeographicalDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_SegmentGeographicalDomain_1" xlink:title="Definition : us-gaap_StatementGeographicalAxis to us-gaap_SegmentGeographicalDomain" xlink:type="arc" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:title="us-gaap_StatementScenarioAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:title="Definition : plx_SignificantAccountingPoliciesTable to us-gaap_StatementScenarioAxis" xlink:type="arc" order="6" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:title="us-gaap_ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:title="Definition : us-gaap_StatementScenarioAxis to us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc" order="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ScenarioOneMember" xlink:label="plx_ScenarioOneMember" xlink:title="plx_ScenarioOneMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="plx_ScenarioOneMember" xlink:title="Definition : us-gaap_ScenarioUnspecifiedDomain to plx_ScenarioOneMember" xlink:type="arc" order="2" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_UponFDAApprovalMember" xlink:label="plx_UponFDAApprovalMember" xlink:title="plx_UponFDAApprovalMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="plx_UponFDAApprovalMember" xlink:title="Definition : us-gaap_ScenarioUnspecifiedDomain to plx_UponFDAApprovalMember" xlink:type="arc" order="3" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_UponNearTermClinicalDevelopmentMilestonesMember" xlink:label="plx_UponNearTermClinicalDevelopmentMilestonesMember" xlink:title="plx_UponNearTermClinicalDevelopmentMilestonesMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="plx_UponNearTermClinicalDevelopmentMilestonesMember" xlink:title="Definition : us-gaap_ScenarioUnspecifiedDomain to plx_UponNearTermClinicalDevelopmentMilestonesMember" xlink:type="arc" order="4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain_1" xlink:title="us-gaap_ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain_1" xlink:title="Definition : us-gaap_StatementScenarioAxis to us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="Definition : plx_SignificantAccountingPoliciesTable to us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="7" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:title="Definition : us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_StockOptionsAndRestrictedSharesMember" xlink:label="plx_StockOptionsAndRestrictedSharesMember" xlink:title="plx_StockOptionsAndRestrictedSharesMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="plx_StockOptionsAndRestrictedSharesMember" xlink:title="Definition : us-gaap_AntidilutiveSecuritiesNameDomain to plx_StockOptionsAndRestrictedSharesMember" xlink:type="arc" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:title="Definition : us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="2" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/Disclosure-SUBSEQUENTEVENTSDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" xlink:title="us-gaap_SubsequentEventLineItems" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ProceedsFromSaleOfShareInCollaboration" xlink:label="plx_ProceedsFromSaleOfShareInCollaboration" xlink:title="plx_ProceedsFromSaleOfShareInCollaboration" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="plx_ProceedsFromSaleOfShareInCollaboration" xlink:title="Definition : us-gaap_SubsequentEventLineItems to plx_ProceedsFromSaleOfShareInCollaboration" xlink:type="arc" order="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:title="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:title="Definition : us-gaap_SubsequentEventLineItems to plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:type="arc" order="2" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" xlink:label="plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" xlink:title="plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" xlink:title="Definition : us-gaap_SubsequentEventLineItems to plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" xlink:type="arc" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:title="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:title="Definition : us-gaap_SubsequentEventLineItems to us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:title="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:title="Definition : us-gaap_SubsequentEventLineItems to us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="5" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfitsEliminationAmount" xlink:label="plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfitsEliminationAmount" xlink:title="plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfitsEliminationAmount" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfitsEliminationAmount" xlink:title="Definition : us-gaap_SubsequentEventLineItems to plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfitsEliminationAmount" xlink:type="arc" order="6" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_StockPurchaseAgreementLockUpPeriod" xlink:label="plx_StockPurchaseAgreementLockUpPeriod" xlink:title="plx_StockPurchaseAgreementLockUpPeriod" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="plx_StockPurchaseAgreementLockUpPeriod" xlink:title="Definition : us-gaap_SubsequentEventLineItems to plx_StockPurchaseAgreementLockUpPeriod" xlink:type="arc" order="7" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:title="us-gaap_DebtInstrumentMaturityDate" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" xlink:title="Definition : us-gaap_SubsequentEventLineItems to us-gaap_DebtInstrumentMaturityDate" xlink:type="arc" order="8" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:title="us-gaap_DebtInstrumentFaceAmount" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" xlink:title="Definition : us-gaap_SubsequentEventLineItems to us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="9" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" xlink:title="us-gaap_SubsequentEventTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" xlink:title="Definition : us-gaap_SubsequentEventLineItems to us-gaap_SubsequentEventTable" xlink:type="arc" order="10" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:title="us-gaap_SubsequentEventTypeAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:title="Definition : us-gaap_SubsequentEventTable to us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:title="us-gaap_SubsequentEventTypeDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:title="Definition : us-gaap_SubsequentEventTypeAxis to us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:title="us-gaap_SubsequentEventMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:title="Definition : us-gaap_SubsequentEventTypeDomain to us-gaap_SubsequentEventMember" xlink:type="arc" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_1" xlink:title="us-gaap_SubsequentEventTypeDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_1" xlink:title="Definition : us-gaap_SubsequentEventTypeAxis to us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:title="us-gaap_TypeOfArrangementAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:title="Definition : us-gaap_SubsequentEventTable to us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:title="Definition : us-gaap_TypeOfArrangementAxis to us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_BrazilAgreementMember" xlink:label="plx_BrazilAgreementMember" xlink:title="plx_BrazilAgreementMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_BrazilAgreementMember" xlink:title="Definition : us-gaap_ArrangementsAndNonarrangementTransactionsMember to plx_BrazilAgreementMember" xlink:type="arc" order="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_PfizerAgreementMember" xlink:label="plx_PfizerAgreementMember" xlink:title="plx_PfizerAgreementMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_PfizerAgreementMember" xlink:title="Definition : us-gaap_ArrangementsAndNonarrangementTransactionsMember to plx_PfizerAgreementMember" xlink:type="arc" order="2" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_AmendedPfizerAgreementMember" xlink:label="plx_AmendedPfizerAgreementMember" xlink:title="plx_AmendedPfizerAgreementMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_AmendedPfizerAgreementMember" xlink:title="Definition : us-gaap_ArrangementsAndNonarrangementTransactionsMember to plx_AmendedPfizerAgreementMember" xlink:type="arc" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:title="Definition : us-gaap_TypeOfArrangementAxis to us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:title="us-gaap_DebtInstrumentAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:title="Definition : us-gaap_SubsequentEventTable to us-gaap_DebtInstrumentAxis" xlink:type="arc" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:title="us-gaap_DebtInstrumentNameDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:title="Definition : us-gaap_DebtInstrumentAxis to us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_October2015PromissoryNoteToPfizerMember" xlink:label="plx_October2015PromissoryNoteToPfizerMember" xlink:title="plx_October2015PromissoryNoteToPfizerMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_October2015PromissoryNoteToPfizerMember" xlink:title="Definition : us-gaap_DebtInstrumentNameDomain to plx_October2015PromissoryNoteToPfizerMember" xlink:type="arc" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_1" xlink:title="us-gaap_DebtInstrumentNameDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_1" xlink:title="Definition : us-gaap_DebtInstrumentAxis to us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:title="dei_LegalEntityAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="dei_LegalEntityAxis" xlink:title="Definition : us-gaap_SubsequentEventTable to dei_LegalEntityAxis" xlink:type="arc" order="4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:title="dei_EntityDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:title="Definition : dei_LegalEntityAxis to dei_EntityDomain" xlink:type="arc" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsidiariesMember" xlink:label="us-gaap_SubsidiariesMember" xlink:title="us-gaap_SubsidiariesMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="us-gaap_SubsidiariesMember" xlink:title="Definition : dei_EntityDomain to us-gaap_SubsidiariesMember" xlink:type="arc" order="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember" xlink:title="plx_ProtalixBioTherapeuticsIncorporationMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="plx_ProtalixBioTherapeuticsIncorporationMember" xlink:title="Definition : dei_EntityDomain to plx_ProtalixBioTherapeuticsIncorporationMember" xlink:type="arc" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_1" xlink:title="dei_EntityDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_1" xlink:title="Definition : dei_LegalEntityAxis to dei_EntityDomain" xlink:type="arc" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:title="us-gaap_CounterpartyNameAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:title="Definition : us-gaap_SubsequentEventTable to us-gaap_CounterpartyNameAxis" xlink:type="arc" order="5" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:title="us-gaap_RepurchaseAgreementCounterpartyNameDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:title="Definition : us-gaap_CounterpartyNameAxis to us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_PfizerIncorporationMember" xlink:label="plx_PfizerIncorporationMember" xlink:title="plx_PfizerIncorporationMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="plx_PfizerIncorporationMember" xlink:title="Definition : us-gaap_RepurchaseAgreementCounterpartyNameDomain to plx_PfizerIncorporationMember" xlink:type="arc" order="10" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_FiocruzMember" xlink:label="plx_FiocruzMember" xlink:title="plx_FiocruzMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="plx_FiocruzMember" xlink:title="Definition : us-gaap_RepurchaseAgreementCounterpartyNameDomain to plx_FiocruzMember" xlink:type="arc" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain_1" xlink:title="us-gaap_RepurchaseAgreementCounterpartyNameDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain_1" xlink:title="Definition : us-gaap_CounterpartyNameAxis to us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:title="us-gaap_TitleOfIndividualAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:title="Definition : us-gaap_SubsequentEventTable to us-gaap_TitleOfIndividualAxis" xlink:type="arc" order="6" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="Definition : us-gaap_TitleOfIndividualAxis to us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ExecutiveOfficerMember" xlink:label="us-gaap_ExecutiveOfficerMember" xlink:title="us-gaap_ExecutiveOfficerMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="us-gaap_ExecutiveOfficerMember" xlink:title="Definition : us-gaap_TitleOfIndividualWithRelationshipToEntityDomain to us-gaap_ExecutiveOfficerMember" xlink:type="arc" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:title="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:title="Definition : us-gaap_TitleOfIndividualAxis to us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="us-gaap_StatementGeographicalAxis" xlink:title="us-gaap_StatementGeographicalAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_StatementGeographicalAxis" xlink:title="Definition : us-gaap_SubsequentEventTable to us-gaap_StatementGeographicalAxis" xlink:type="arc" order="7" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="us-gaap_SegmentGeographicalDomain" xlink:title="us-gaap_SegmentGeographicalDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_SegmentGeographicalDomain" xlink:title="Definition : us-gaap_StatementGeographicalAxis to us-gaap_SegmentGeographicalDomain" xlink:type="arc" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd#country_BR" xlink:label="country_BR" xlink:title="country_BR" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentGeographicalDomain" xlink:to="country_BR" xlink:title="Definition : us-gaap_SegmentGeographicalDomain to country_BR" xlink:type="arc" order="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ExcludingBrazilMember" xlink:label="plx_ExcludingBrazilMember" xlink:title="plx_ExcludingBrazilMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentGeographicalDomain" xlink:to="plx_ExcludingBrazilMember" xlink:title="Definition : us-gaap_SegmentGeographicalDomain to plx_ExcludingBrazilMember" xlink:type="arc" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="us-gaap_SegmentGeographicalDomain_1" xlink:title="us-gaap_SegmentGeographicalDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_SegmentGeographicalDomain_1" xlink:title="Definition : us-gaap_StatementGeographicalAxis to us-gaap_SegmentGeographicalDomain" xlink:type="arc" order="2" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>plx-20150930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--Created by The Vintage Group, Powered by IRIS Carbon-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_NatureOfOperationsPolicyTextBlock" xlink:label="plx_NatureOfOperationsPolicyTextBlock" xlink:title="plx_NatureOfOperationsPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_plx_NatureOfOperationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_NatureOfOperationsPolicyTextBlock" xml:lang="en-US" id="label_plx_NatureOfOperationsPolicyTextBlock">Nature Of Operations [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_NatureOfOperationsPolicyTextBlock" xlink:to="label_plx_NatureOfOperationsPolicyTextBlock" xlink:title="Label : plx_NatureOfOperationsPolicyTextBlock to label_plx_NatureOfOperationsPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_plx_NatureOfOperationsPolicyTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_NatureOfOperationsPolicyTextBlock_1" xml:lang="en-US" id="label_plx_NatureOfOperationsPolicyTextBlock_1">General</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_NatureOfOperationsPolicyTextBlock" xlink:to="label_plx_NatureOfOperationsPolicyTextBlock_1" xlink:title="Label : plx_NatureOfOperationsPolicyTextBlock to label_plx_NatureOfOperationsPolicyTextBlock_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_NatureOfOperationsPolicyTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_NatureOfOperationsPolicyTextBlock_2" xml:lang="en-US" id="label_plx_NatureOfOperationsPolicyTextBlock_2">Nature Of Operations Policy</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_NatureOfOperationsPolicyTextBlock" xlink:to="label_plx_NatureOfOperationsPolicyTextBlock_2" xlink:title="Label : plx_NatureOfOperationsPolicyTextBlock to label_plx_NatureOfOperationsPolicyTextBlock_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_CompanyShareInCollaborationAgreement" xlink:label="plx_CompanyShareInCollaborationAgreement" xlink:title="plx_CompanyShareInCollaborationAgreement" />
    <link:label xlink:type="resource" xlink:label="label_plx_CompanyShareInCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_CompanyShareInCollaborationAgreement" xml:lang="en-US" id="label_plx_CompanyShareInCollaborationAgreement">Company''s Share In Collaboration Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CompanyShareInCollaborationAgreement" xlink:to="label_plx_CompanyShareInCollaborationAgreement" xlink:title="Label : plx_CompanyShareInCollaborationAgreement to label_plx_CompanyShareInCollaborationAgreement" />
    <link:label xlink:type="resource" xlink:label="label_plx_CompanyShareInCollaborationAgreement_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_CompanyShareInCollaborationAgreement_1" xml:lang="en-US" id="label_plx_CompanyShareInCollaborationAgreement_1">The Company''s share in collaboration agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CompanyShareInCollaborationAgreement" xlink:to="label_plx_CompanyShareInCollaborationAgreement_1" xlink:title="Label : plx_CompanyShareInCollaborationAgreement to label_plx_CompanyShareInCollaborationAgreement_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_CompanyShareInCollaborationAgreement_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_CompanyShareInCollaborationAgreement_2" xml:lang="en-US" id="label_plx_CompanyShareInCollaborationAgreement_2">COMPANY'S SHARE IN COLLABORATION AGREEMENT</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CompanyShareInCollaborationAgreement" xlink:to="label_plx_CompanyShareInCollaborationAgreement_2" xlink:title="Label : plx_CompanyShareInCollaborationAgreement to label_plx_CompanyShareInCollaborationAgreement_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_GrantsAndReimbursementsReceivedOrReceivable" xlink:label="plx_GrantsAndReimbursementsReceivedOrReceivable" xlink:title="plx_GrantsAndReimbursementsReceivedOrReceivable" />
    <link:label xlink:type="resource" xlink:label="label_plx_GrantsAndReimbursementsReceivedOrReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_GrantsAndReimbursementsReceivedOrReceivable" xml:lang="en-US" id="label_plx_GrantsAndReimbursementsReceivedOrReceivable">Grants And Reimbursements Received Or Receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_GrantsAndReimbursementsReceivedOrReceivable" xlink:to="label_plx_GrantsAndReimbursementsReceivedOrReceivable" xlink:title="Label : plx_GrantsAndReimbursementsReceivedOrReceivable to label_plx_GrantsAndReimbursementsReceivedOrReceivable" />
    <link:label xlink:type="resource" xlink:label="label_plx_GrantsAndReimbursementsReceivedOrReceivable_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_GrantsAndReimbursementsReceivedOrReceivable_1" xml:lang="en-US" id="label_plx_GrantsAndReimbursementsReceivedOrReceivable_1">Grants and reimbursements received or receivable from governmental institutions and collaboration partners for research and development expenses incurred.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_GrantsAndReimbursementsReceivedOrReceivable" xlink:to="label_plx_GrantsAndReimbursementsReceivedOrReceivable_1" xlink:title="Label : plx_GrantsAndReimbursementsReceivedOrReceivable to label_plx_GrantsAndReimbursementsReceivedOrReceivable_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_GrantsAndReimbursementsReceivedOrReceivable_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_GrantsAndReimbursementsReceivedOrReceivable_2" xml:lang="en-US" id="label_plx_GrantsAndReimbursementsReceivedOrReceivable_2">Less - grants and reimbursements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_GrantsAndReimbursementsReceivedOrReceivable" xlink:to="label_plx_GrantsAndReimbursementsReceivedOrReceivable_2" xlink:title="Label : plx_GrantsAndReimbursementsReceivedOrReceivable to label_plx_GrantsAndReimbursementsReceivedOrReceivable_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:label="plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:title="plx_ResearchDevelopmentAndEngineeringExpenseNet" />
    <link:label xlink:type="resource" xlink:label="label_plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_ResearchDevelopmentAndEngineeringExpenseNet" xml:lang="en-US" id="label_plx_ResearchDevelopmentAndEngineeringExpenseNet">Research Development And Engineering Expense Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:to="label_plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:title="Label : plx_ResearchDevelopmentAndEngineeringExpenseNet to label_plx_ResearchDevelopmentAndEngineeringExpenseNet" />
    <link:label xlink:type="resource" xlink:label="label_plx_ResearchDevelopmentAndEngineeringExpenseNet_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_ResearchDevelopmentAndEngineeringExpenseNet_1" xml:lang="en-US" id="label_plx_ResearchDevelopmentAndEngineeringExpenseNet_1">Research and development expenses, net.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:to="label_plx_ResearchDevelopmentAndEngineeringExpenseNet_1" xlink:title="Label : plx_ResearchDevelopmentAndEngineeringExpenseNet to label_plx_ResearchDevelopmentAndEngineeringExpenseNet_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_ResearchDevelopmentAndEngineeringExpenseNet_2" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:title="label_plx_ResearchDevelopmentAndEngineeringExpenseNet_2" xml:lang="en-US" id="label_plx_ResearchDevelopmentAndEngineeringExpenseNet_2">RESEARCH AND DEVELOPMENT EXPENSES, NET</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:to="label_plx_ResearchDevelopmentAndEngineeringExpenseNet_2" xlink:title="Label : plx_ResearchDevelopmentAndEngineeringExpenseNet to label_plx_ResearchDevelopmentAndEngineeringExpenseNet_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ScheduleOfUsefulLifeTableTextBlock" xlink:label="plx_ScheduleOfUsefulLifeTableTextBlock" xlink:title="plx_ScheduleOfUsefulLifeTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_plx_ScheduleOfUsefulLifeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_ScheduleOfUsefulLifeTableTextBlock" xml:lang="en-US" id="label_plx_ScheduleOfUsefulLifeTableTextBlock">Schedule Of Useful Life [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ScheduleOfUsefulLifeTableTextBlock" xlink:to="label_plx_ScheduleOfUsefulLifeTableTextBlock" xlink:title="Label : plx_ScheduleOfUsefulLifeTableTextBlock to label_plx_ScheduleOfUsefulLifeTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_plx_ScheduleOfUsefulLifeTableTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_ScheduleOfUsefulLifeTableTextBlock_1" xml:lang="en-US" id="label_plx_ScheduleOfUsefulLifeTableTextBlock_1">Schedule Of Useful Life Table Text Block</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ScheduleOfUsefulLifeTableTextBlock" xlink:to="label_plx_ScheduleOfUsefulLifeTableTextBlock_1" xlink:title="Label : plx_ScheduleOfUsefulLifeTableTextBlock to label_plx_ScheduleOfUsefulLifeTableTextBlock_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_ScheduleOfUsefulLifeTableTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_ScheduleOfUsefulLifeTableTextBlock_2" xml:lang="en-US" id="label_plx_ScheduleOfUsefulLifeTableTextBlock_2">Schedule of Useful Life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ScheduleOfUsefulLifeTableTextBlock" xlink:to="label_plx_ScheduleOfUsefulLifeTableTextBlock_2" xlink:title="Label : plx_ScheduleOfUsefulLifeTableTextBlock to label_plx_ScheduleOfUsefulLifeTableTextBlock_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_LaboratoryEquipmentMember" xlink:label="plx_LaboratoryEquipmentMember" xlink:title="plx_LaboratoryEquipmentMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_LaboratoryEquipmentMember" xml:lang="en-US" id="label_plx_LaboratoryEquipmentMember">Laboratory Equipment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_LaboratoryEquipmentMember" xlink:to="label_plx_LaboratoryEquipmentMember" xlink:title="Label : plx_LaboratoryEquipmentMember to label_plx_LaboratoryEquipmentMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_LaboratoryEquipmentMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_LaboratoryEquipmentMember_1" xml:lang="en-US" id="label_plx_LaboratoryEquipmentMember_1">Laboratory Equipment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_LaboratoryEquipmentMember" xlink:to="label_plx_LaboratoryEquipmentMember_1" xlink:title="Label : plx_LaboratoryEquipmentMember to label_plx_LaboratoryEquipmentMember_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_MilestonePayment" xlink:label="plx_MilestonePayment" xlink:title="plx_MilestonePayment" />
    <link:label xlink:type="resource" xlink:label="label_plx_MilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_MilestonePayment" xml:lang="en-US" id="label_plx_MilestonePayment">Milestone Payment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_MilestonePayment" xlink:to="label_plx_MilestonePayment" xlink:title="Label : plx_MilestonePayment to label_plx_MilestonePayment" />
    <link:label xlink:type="resource" xlink:label="label_plx_MilestonePayment_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_MilestonePayment_1" xml:lang="en-US" id="label_plx_MilestonePayment_1">Milestone payment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_MilestonePayment" xlink:to="label_plx_MilestonePayment_1" xlink:title="Label : plx_MilestonePayment to label_plx_MilestonePayment_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_MilestonePayment_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_MilestonePayment_2" xml:lang="en-US" id="label_plx_MilestonePayment_2">Milestone payment received</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_MilestonePayment" xlink:to="label_plx_MilestonePayment_2" xlink:title="Label : plx_MilestonePayment to label_plx_MilestonePayment_2" />
    <link:label xlink:type="resource" xlink:label="label_plx_MilestonePayment_3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_plx_MilestonePayment_3" xml:lang="en-US" id="label_plx_MilestonePayment_3">Milestone payment (see Note 2)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_MilestonePayment" xlink:to="label_plx_MilestonePayment_3" xlink:title="Label : plx_MilestonePayment to label_plx_MilestonePayment_3" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ScenarioTwoMember" xlink:label="plx_ScenarioTwoMember" xlink:title="plx_ScenarioTwoMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_ScenarioTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_ScenarioTwoMember" xml:lang="en-US" id="label_plx_ScenarioTwoMember">Scenario Two [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ScenarioTwoMember" xlink:to="label_plx_ScenarioTwoMember" xlink:title="Label : plx_ScenarioTwoMember to label_plx_ScenarioTwoMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_ScenarioTwoMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_ScenarioTwoMember_1" xml:lang="en-US" id="label_plx_ScenarioTwoMember_1">Scenario Two [Member].</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ScenarioTwoMember" xlink:to="label_plx_ScenarioTwoMember_1" xlink:title="Label : plx_ScenarioTwoMember to label_plx_ScenarioTwoMember_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_ScenarioTwoMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_ScenarioTwoMember_2" xml:lang="en-US" id="label_plx_ScenarioTwoMember_2">Upon Filing of Pediatric Investigation Plan to EMA [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ScenarioTwoMember" xlink:to="label_plx_ScenarioTwoMember_2" xlink:title="Label : plx_ScenarioTwoMember to label_plx_ScenarioTwoMember_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_UponFDAApprovalMember" xlink:label="plx_UponFDAApprovalMember" xlink:title="plx_UponFDAApprovalMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_UponFDAApprovalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_UponFDAApprovalMember" xml:lang="en-US" id="label_plx_UponFDAApprovalMember">Upon FDAApproval [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_UponFDAApprovalMember" xlink:to="label_plx_UponFDAApprovalMember" xlink:title="Label : plx_UponFDAApprovalMember to label_plx_UponFDAApprovalMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_UponFDAApprovalMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_UponFDAApprovalMember_1" xml:lang="en-US" id="label_plx_UponFDAApprovalMember_1">Upon FDA approval Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_UponFDAApprovalMember" xlink:to="label_plx_UponFDAApprovalMember_1" xlink:title="Label : plx_UponFDAApprovalMember to label_plx_UponFDAApprovalMember_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:title="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" />
    <link:label xlink:type="resource" xlink:label="label_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xml:lang="en-US" id="label_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage">Collaborative Arrangement Revenues and Expenses Sharing Percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:to="label_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:title="Label : plx_CollaborativeArrangementRevenuesExpensesSharingPercentage to label_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" />
    <link:label xlink:type="resource" xlink:label="label_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_1" xml:lang="en-US" id="label_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_1">Collaborative arrangement revenues and expense sharing percentage.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:to="label_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_1" xlink:title="Label : plx_CollaborativeArrangementRevenuesExpensesSharingPercentage to label_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_2" xml:lang="en-US" id="label_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_2">Agreement, future revenues and expenses sharing percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:to="label_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_2" xlink:title="Label : plx_CollaborativeArrangementRevenuesExpensesSharingPercentage to label_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_EligablePaymentReceivableUponAchievement" xlink:label="plx_EligablePaymentReceivableUponAchievement" xlink:title="plx_EligablePaymentReceivableUponAchievement" />
    <link:label xlink:type="resource" xlink:label="label_plx_EligablePaymentReceivableUponAchievement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_EligablePaymentReceivableUponAchievement" xml:lang="en-US" id="label_plx_EligablePaymentReceivableUponAchievement">Eligable Payment Receivable Upon Achievement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EligablePaymentReceivableUponAchievement" xlink:to="label_plx_EligablePaymentReceivableUponAchievement" xlink:title="Label : plx_EligablePaymentReceivableUponAchievement to label_plx_EligablePaymentReceivableUponAchievement" />
    <link:label xlink:type="resource" xlink:label="label_plx_EligablePaymentReceivableUponAchievement_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_EligablePaymentReceivableUponAchievement_1" xml:lang="en-US" id="label_plx_EligablePaymentReceivableUponAchievement_1">Eligable Payment Receivable Upon Achievement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EligablePaymentReceivableUponAchievement" xlink:to="label_plx_EligablePaymentReceivableUponAchievement_1" xlink:title="Label : plx_EligablePaymentReceivableUponAchievement to label_plx_EligablePaymentReceivableUponAchievement_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_EligablePaymentReceivableUponAchievement_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_EligablePaymentReceivableUponAchievement_2" xml:lang="en-US" id="label_plx_EligablePaymentReceivableUponAchievement_2">Eligable payment receivable upon achievement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EligablePaymentReceivableUponAchievement" xlink:to="label_plx_EligablePaymentReceivableUponAchievement_2" xlink:title="Label : plx_EligablePaymentReceivableUponAchievement to label_plx_EligablePaymentReceivableUponAchievement_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:title="dei_AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="label_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_dei_AmendmentFlag" xml:lang="en-US" id="label_dei_AmendmentFlag">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="label_dei_AmendmentFlag" xlink:title="Label : dei_AmendmentFlag to label_dei_AmendmentFlag" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember" xlink:title="plx_ProtalixBioTherapeuticsIncorporationMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_ProtalixBioTherapeuticsIncorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_ProtalixBioTherapeuticsIncorporationMember" xml:lang="en-US" id="label_plx_ProtalixBioTherapeuticsIncorporationMember">Protalix Bio Therapeutics Incorporation [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProtalixBioTherapeuticsIncorporationMember" xlink:to="label_plx_ProtalixBioTherapeuticsIncorporationMember" xlink:title="Label : plx_ProtalixBioTherapeuticsIncorporationMember to label_plx_ProtalixBioTherapeuticsIncorporationMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_ProtalixBioTherapeuticsIncorporationMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_ProtalixBioTherapeuticsIncorporationMember_1" xml:lang="en-US" id="label_plx_ProtalixBioTherapeuticsIncorporationMember_1">Protalix Bio Therapeutics Incorporation [Member].</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProtalixBioTherapeuticsIncorporationMember" xlink:to="label_plx_ProtalixBioTherapeuticsIncorporationMember_1" xlink:title="Label : plx_ProtalixBioTherapeuticsIncorporationMember to label_plx_ProtalixBioTherapeuticsIncorporationMember_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_ProtalixBioTherapeuticsIncorporationMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_ProtalixBioTherapeuticsIncorporationMember_2" xml:lang="en-US" id="label_plx_ProtalixBioTherapeuticsIncorporationMember_2">Protalix Bio Therapeutics Inc. [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProtalixBioTherapeuticsIncorporationMember" xlink:to="label_plx_ProtalixBioTherapeuticsIncorporationMember_2" xlink:title="Label : plx_ProtalixBioTherapeuticsIncorporationMember to label_plx_ProtalixBioTherapeuticsIncorporationMember_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_PfizerIncorporationMember" xlink:label="plx_PfizerIncorporationMember" xlink:title="plx_PfizerIncorporationMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_PfizerIncorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_PfizerIncorporationMember" xml:lang="en-US" id="label_plx_PfizerIncorporationMember">Pfizer Incorporation [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PfizerIncorporationMember" xlink:to="label_plx_PfizerIncorporationMember" xlink:title="Label : plx_PfizerIncorporationMember to label_plx_PfizerIncorporationMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_PfizerIncorporationMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_PfizerIncorporationMember_1" xml:lang="en-US" id="label_plx_PfizerIncorporationMember_1">Pfizer Incorporation [Member].</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PfizerIncorporationMember" xlink:to="label_plx_PfizerIncorporationMember_1" xlink:title="Label : plx_PfizerIncorporationMember to label_plx_PfizerIncorporationMember_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_PfizerIncorporationMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_PfizerIncorporationMember_2" xml:lang="en-US" id="label_plx_PfizerIncorporationMember_2">Pfizer Incorporation [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PfizerIncorporationMember" xlink:to="label_plx_PfizerIncorporationMember_2" xlink:title="Label : plx_PfizerIncorporationMember to label_plx_PfizerIncorporationMember_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_SupplyCommitmentPerYear" xlink:label="plx_SupplyCommitmentPerYear" xlink:title="plx_SupplyCommitmentPerYear" />
    <link:label xlink:type="resource" xlink:label="label_plx_SupplyCommitmentPerYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_SupplyCommitmentPerYear" xml:lang="en-US" id="label_plx_SupplyCommitmentPerYear">Supply Commitment Per Year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SupplyCommitmentPerYear" xlink:to="label_plx_SupplyCommitmentPerYear" xlink:title="Label : plx_SupplyCommitmentPerYear to label_plx_SupplyCommitmentPerYear" />
    <link:label xlink:type="resource" xlink:label="label_plx_SupplyCommitmentPerYear_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_SupplyCommitmentPerYear_1" xml:lang="en-US" id="label_plx_SupplyCommitmentPerYear_1">The floor purchase amount that one or more customers of the entity must satisfy per calendar year to comply with the terms of disclosed arrangements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SupplyCommitmentPerYear" xlink:to="label_plx_SupplyCommitmentPerYear_1" xlink:title="Label : plx_SupplyCommitmentPerYear to label_plx_SupplyCommitmentPerYear_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_SupplyCommitmentPerYear_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_SupplyCommitmentPerYear_2" xml:lang="en-US" id="label_plx_SupplyCommitmentPerYear_2">Supply commitment per year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SupplyCommitmentPerYear" xlink:to="label_plx_SupplyCommitmentPerYear_2" xlink:title="Label : plx_SupplyCommitmentPerYear to label_plx_SupplyCommitmentPerYear_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights" xlink:label="plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights" xlink:title="plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights" />
    <link:label xlink:type="resource" xlink:label="label_plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights" xml:lang="en-US" id="label_plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights">Purchase Amount To Be Satisfied To Receive Entitled Rights</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights" xlink:to="label_plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights" xlink:title="Label : plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights to label_plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights" />
    <link:label xlink:type="resource" xlink:label="label_plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights_1" xml:lang="en-US" id="label_plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights_1">The floor purchase amount that one or more customers of the entity must satisfy in order to be entitled to certain rights under the terms of disclosed arrangements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights" xlink:to="label_plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights_1" xlink:title="Label : plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights to label_plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights_2" xml:lang="en-US" id="label_plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights_2">Supply commitment for entitled rights to be received</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights" xlink:to="label_plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights_2" xlink:title="Label : plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights to label_plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" xlink:label="plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" xlink:title="plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" />
    <link:label xlink:type="resource" xlink:label="label_plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" xml:lang="en-US" id="label_plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits">License And Supply Agreement Potential Future Payment Based On Net Profits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" xlink:to="label_plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" xlink:title="Label : plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits to label_plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" />
    <link:label xlink:type="resource" xlink:label="label_plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits_1" xml:lang="en-US" id="label_plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits_1">License And Supply Agreement Potential Future Payment Based On Net Profits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" xlink:to="label_plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits_1" xlink:title="Label : plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits to label_plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits_2" xml:lang="en-US" id="label_plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits_2">License and supply agreement potential future payment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" xlink:to="label_plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits_2" xlink:title="Label : plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits to label_plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_NumberOfSubsidiaries" xlink:label="plx_NumberOfSubsidiaries" xlink:title="plx_NumberOfSubsidiaries" />
    <link:label xlink:type="resource" xlink:label="label_plx_NumberOfSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_NumberOfSubsidiaries" xml:lang="en-US" id="label_plx_NumberOfSubsidiaries">Number Of Subsidiaries</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_NumberOfSubsidiaries" xlink:to="label_plx_NumberOfSubsidiaries" xlink:title="Label : plx_NumberOfSubsidiaries to label_plx_NumberOfSubsidiaries" />
    <link:label xlink:type="resource" xlink:label="label_plx_NumberOfSubsidiaries_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_NumberOfSubsidiaries_1" xml:lang="en-US" id="label_plx_NumberOfSubsidiaries_1">Number of subsidiaries.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_NumberOfSubsidiaries" xlink:to="label_plx_NumberOfSubsidiaries_1" xlink:title="Label : plx_NumberOfSubsidiaries to label_plx_NumberOfSubsidiaries_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_NumberOfSubsidiaries_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_NumberOfSubsidiaries_2" xml:lang="en-US" id="label_plx_NumberOfSubsidiaries_2">Number of Subsidiaries</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_NumberOfSubsidiaries" xlink:to="label_plx_NumberOfSubsidiaries_2" xlink:title="Label : plx_NumberOfSubsidiaries to label_plx_NumberOfSubsidiaries_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_RevenueRecognizedOverDesignatedPeriod" xlink:label="plx_RevenueRecognizedOverDesignatedPeriod" xlink:title="plx_RevenueRecognizedOverDesignatedPeriod" />
    <link:label xlink:type="resource" xlink:label="label_plx_RevenueRecognizedOverDesignatedPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_RevenueRecognizedOverDesignatedPeriod" xml:lang="en-US" id="label_plx_RevenueRecognizedOverDesignatedPeriod">Revenue Recognized Over Designated Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_RevenueRecognizedOverDesignatedPeriod" xlink:to="label_plx_RevenueRecognizedOverDesignatedPeriod" xlink:title="Label : plx_RevenueRecognizedOverDesignatedPeriod to label_plx_RevenueRecognizedOverDesignatedPeriod" />
    <link:label xlink:type="resource" xlink:label="label_plx_RevenueRecognizedOverDesignatedPeriod_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_RevenueRecognizedOverDesignatedPeriod_1" xml:lang="en-US" id="label_plx_RevenueRecognizedOverDesignatedPeriod_1">Revenue recognized over designated period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_RevenueRecognizedOverDesignatedPeriod" xlink:to="label_plx_RevenueRecognizedOverDesignatedPeriod_1" xlink:title="Label : plx_RevenueRecognizedOverDesignatedPeriod to label_plx_RevenueRecognizedOverDesignatedPeriod_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_RevenueRecognizedOverDesignatedPeriod_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_RevenueRecognizedOverDesignatedPeriod_2" xml:lang="en-US" id="label_plx_RevenueRecognizedOverDesignatedPeriod_2">Revenue recognized over designated period of relationship</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_RevenueRecognizedOverDesignatedPeriod" xlink:to="label_plx_RevenueRecognizedOverDesignatedPeriod_2" xlink:title="Label : plx_RevenueRecognizedOverDesignatedPeriod to label_plx_RevenueRecognizedOverDesignatedPeriod_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_RevenueRecognizedPeriod" xlink:label="plx_RevenueRecognizedPeriod" xlink:title="plx_RevenueRecognizedPeriod" />
    <link:label xlink:type="resource" xlink:label="label_plx_RevenueRecognizedPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_RevenueRecognizedPeriod" xml:lang="en-US" id="label_plx_RevenueRecognizedPeriod">Revenue Recognized Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_RevenueRecognizedPeriod" xlink:to="label_plx_RevenueRecognizedPeriod" xlink:title="Label : plx_RevenueRecognizedPeriod to label_plx_RevenueRecognizedPeriod" />
    <link:label xlink:type="resource" xlink:label="label_plx_RevenueRecognizedPeriod_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_RevenueRecognizedPeriod_1" xml:lang="en-US" id="label_plx_RevenueRecognizedPeriod_1">Revenue Recognized Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_RevenueRecognizedPeriod" xlink:to="label_plx_RevenueRecognizedPeriod_1" xlink:title="Label : plx_RevenueRecognizedPeriod to label_plx_RevenueRecognizedPeriod_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_RevenueRecognizedPeriod_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_RevenueRecognizedPeriod_2" xml:lang="en-US" id="label_plx_RevenueRecognizedPeriod_2">Revenue recognition period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_RevenueRecognizedPeriod" xlink:to="label_plx_RevenueRecognizedPeriod_2" xlink:title="Label : plx_RevenueRecognizedPeriod to label_plx_RevenueRecognizedPeriod_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_CollaborativeAndLicenseArrangementDisclosureTextBlock" xlink:label="plx_CollaborativeAndLicenseArrangementDisclosureTextBlock" xlink:title="plx_CollaborativeAndLicenseArrangementDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_plx_CollaborativeAndLicenseArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_CollaborativeAndLicenseArrangementDisclosureTextBlock" xml:lang="en-US" id="label_plx_CollaborativeAndLicenseArrangementDisclosureTextBlock">Collaborative and License Arrangement Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CollaborativeAndLicenseArrangementDisclosureTextBlock" xlink:to="label_plx_CollaborativeAndLicenseArrangementDisclosureTextBlock" xlink:title="Label : plx_CollaborativeAndLicenseArrangementDisclosureTextBlock to label_plx_CollaborativeAndLicenseArrangementDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_plx_CollaborativeAndLicenseArrangementDisclosureTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_CollaborativeAndLicenseArrangementDisclosureTextBlock_1" xml:lang="en-US" id="label_plx_CollaborativeAndLicenseArrangementDisclosureTextBlock_1">Collaborative And License Arrangement Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CollaborativeAndLicenseArrangementDisclosureTextBlock" xlink:to="label_plx_CollaborativeAndLicenseArrangementDisclosureTextBlock_1" xlink:title="Label : plx_CollaborativeAndLicenseArrangementDisclosureTextBlock to label_plx_CollaborativeAndLicenseArrangementDisclosureTextBlock_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_CollaborativeAndLicenseArrangementDisclosureTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_CollaborativeAndLicenseArrangementDisclosureTextBlock_2" xml:lang="en-US" id="label_plx_CollaborativeAndLicenseArrangementDisclosureTextBlock_2">LICENSE AND SUPPLY AGREEMENT</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CollaborativeAndLicenseArrangementDisclosureTextBlock" xlink:to="label_plx_CollaborativeAndLicenseArrangementDisclosureTextBlock_2" xlink:title="Label : plx_CollaborativeAndLicenseArrangementDisclosureTextBlock to label_plx_CollaborativeAndLicenseArrangementDisclosureTextBlock_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_CollaborationOperationMember" xlink:label="plx_CollaborationOperationMember" xlink:title="plx_CollaborationOperationMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_CollaborationOperationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_CollaborationOperationMember" xml:lang="en-US" id="label_plx_CollaborationOperationMember">Collaboration Operation [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CollaborationOperationMember" xlink:to="label_plx_CollaborationOperationMember" xlink:title="Label : plx_CollaborationOperationMember to label_plx_CollaborationOperationMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_CollaborationOperationMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_CollaborationOperationMember_1" xml:lang="en-US" id="label_plx_CollaborationOperationMember_1">Collaboration Operation Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CollaborationOperationMember" xlink:to="label_plx_CollaborationOperationMember_1" xlink:title="Label : plx_CollaborationOperationMember to label_plx_CollaborationOperationMember_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:title="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" />
    <link:label xlink:type="resource" xlink:label="label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xml:lang="en-US" id="label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares">Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:to="label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:title="Label : plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares to label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" />
    <link:label xlink:type="resource" xlink:label="label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_1" xml:lang="en-US" id="label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_1">Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:to="label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_1" xlink:title="Label : plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares to label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_2" xml:lang="en-US" id="label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_2">Share-based compensation related to restricted stock award, net of forfeitures, shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:to="label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_2" xlink:title="Label : plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares to label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:title="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" />
    <link:label xlink:type="resource" xlink:label="label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xml:lang="en-US" id="label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures">Share Based Compensation Restricted Stock Awards Net Of Forfeitures</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:to="label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:title="Label : plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures to label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" />
    <link:label xlink:type="resource" xlink:label="label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_1" xml:lang="en-US" id="label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_1">Amount of recognized equity-based compensation during the period for restricted stock awards.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:to="label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_1" xlink:title="Label : plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures to label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_2" xml:lang="en-US" id="label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_2">Share-based compensation related to restricted stock award, net of forfeitures</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:to="label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_2" xlink:title="Label : plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures to label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_FurnitureAndComputerEquipmentMember" xlink:label="plx_FurnitureAndComputerEquipmentMember" xlink:title="plx_FurnitureAndComputerEquipmentMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_FurnitureAndComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_FurnitureAndComputerEquipmentMember" xml:lang="en-US" id="label_plx_FurnitureAndComputerEquipmentMember">Furniture And Computer Equipment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_FurnitureAndComputerEquipmentMember" xlink:to="label_plx_FurnitureAndComputerEquipmentMember" xlink:title="Label : plx_FurnitureAndComputerEquipmentMember to label_plx_FurnitureAndComputerEquipmentMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_FurnitureAndComputerEquipmentMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_FurnitureAndComputerEquipmentMember_1" xml:lang="en-US" id="label_plx_FurnitureAndComputerEquipmentMember_1">Furniture And Computer Equipment Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_FurnitureAndComputerEquipmentMember" xlink:to="label_plx_FurnitureAndComputerEquipmentMember_1" xlink:title="Label : plx_FurnitureAndComputerEquipmentMember to label_plx_FurnitureAndComputerEquipmentMember_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_EquipmentUnderConstructionMember" xlink:label="plx_EquipmentUnderConstructionMember" xlink:title="plx_EquipmentUnderConstructionMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_EquipmentUnderConstructionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_EquipmentUnderConstructionMember" xml:lang="en-US" id="label_plx_EquipmentUnderConstructionMember">Equipment Under Construction [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EquipmentUnderConstructionMember" xlink:to="label_plx_EquipmentUnderConstructionMember" xlink:title="Label : plx_EquipmentUnderConstructionMember to label_plx_EquipmentUnderConstructionMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_EquipmentUnderConstructionMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_EquipmentUnderConstructionMember_1" xml:lang="en-US" id="label_plx_EquipmentUnderConstructionMember_1">Equipment Under Construction [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EquipmentUnderConstructionMember" xlink:to="label_plx_EquipmentUnderConstructionMember_1" xlink:title="Label : plx_EquipmentUnderConstructionMember to label_plx_EquipmentUnderConstructionMember_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_CompensationToTheNon-executiveDirectorsMember" xlink:label="plx_CompensationToTheNon-executiveDirectorsMember" xlink:title="plx_CompensationToTheNon-executiveDirectorsMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_CompensationToTheNon-executiveDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_CompensationToTheNon-executiveDirectorsMember" xml:lang="en-US" id="label_plx_CompensationToTheNon-executiveDirectorsMember">Compensation To The Non -executiveDirectors [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CompensationToTheNon-executiveDirectorsMember" xlink:to="label_plx_CompensationToTheNon-executiveDirectorsMember" xlink:title="Label : plx_CompensationToTheNon-executiveDirectorsMember to label_plx_CompensationToTheNon-executiveDirectorsMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_CompensationToTheNon-executiveDirectorsMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_CompensationToTheNon-executiveDirectorsMember_1" xml:lang="en-US" id="label_plx_CompensationToTheNon-executiveDirectorsMember_1">Compensation To The Non-executive Directors Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CompensationToTheNon-executiveDirectorsMember" xlink:to="label_plx_CompensationToTheNon-executiveDirectorsMember_1" xlink:title="Label : plx_CompensationToTheNon-executiveDirectorsMember to label_plx_CompensationToTheNon-executiveDirectorsMember_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_EmployeeSeveranceObligationPayment" xlink:label="plx_EmployeeSeveranceObligationPayment" xlink:title="plx_EmployeeSeveranceObligationPayment" />
    <link:label xlink:type="resource" xlink:label="label_plx_EmployeeSeveranceObligationPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_EmployeeSeveranceObligationPayment" xml:lang="en-US" id="label_plx_EmployeeSeveranceObligationPayment">Employee Severance Obligation Payment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EmployeeSeveranceObligationPayment" xlink:to="label_plx_EmployeeSeveranceObligationPayment" xlink:title="Label : plx_EmployeeSeveranceObligationPayment to label_plx_EmployeeSeveranceObligationPayment" />
    <link:label xlink:type="resource" xlink:label="label_plx_EmployeeSeveranceObligationPayment_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_EmployeeSeveranceObligationPayment_1" xml:lang="en-US" id="label_plx_EmployeeSeveranceObligationPayment_1">Employee severance obligation payment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EmployeeSeveranceObligationPayment" xlink:to="label_plx_EmployeeSeveranceObligationPayment_1" xlink:title="Label : plx_EmployeeSeveranceObligationPayment to label_plx_EmployeeSeveranceObligationPayment_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_EmployeeSeveranceObligationPayment_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_EmployeeSeveranceObligationPayment_2" xml:lang="en-US" id="label_plx_EmployeeSeveranceObligationPayment_2">Employee severance obligation payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EmployeeSeveranceObligationPayment" xlink:to="label_plx_EmployeeSeveranceObligationPayment_2" xlink:title="Label : plx_EmployeeSeveranceObligationPayment to label_plx_EmployeeSeveranceObligationPayment_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:title="dei_CurrentFiscalYearEndDate" />
    <link:label xlink:type="resource" xlink:label="label_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_dei_CurrentFiscalYearEndDate" xml:lang="en-US" id="label_dei_CurrentFiscalYearEndDate">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="label_dei_CurrentFiscalYearEndDate" xlink:title="Label : dei_CurrentFiscalYearEndDate to label_dei_CurrentFiscalYearEndDate" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod" xlink:label="plx_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod" xlink:title="plx_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod" />
    <link:label xlink:type="resource" xlink:label="label_plx_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod" xml:lang="en-US" id="label_plx_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod">Expected Severance Liabilities Payments For Future Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod" xlink:to="label_plx_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod" xlink:title="Label : plx_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod to label_plx_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod" />
    <link:label xlink:type="resource" xlink:label="label_plx_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod_1" xml:lang="en-US" id="label_plx_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod_1">Expected severance liabilities payments for future period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod" xlink:to="label_plx_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod_1" xlink:title="Label : plx_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod to label_plx_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod_2" xml:lang="en-US" id="label_plx_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod_2">Expected severance liabilities payments for fiscal year end 2015</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod" xlink:to="label_plx_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod_2" xlink:title="Label : plx_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod to label_plx_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ExpectedDefintedBenefitContributionDuringPeriod" xlink:label="plx_ExpectedDefintedBenefitContributionDuringPeriod" xlink:title="plx_ExpectedDefintedBenefitContributionDuringPeriod" />
    <link:label xlink:type="resource" xlink:label="label_plx_ExpectedDefintedBenefitContributionDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_ExpectedDefintedBenefitContributionDuringPeriod" xml:lang="en-US" id="label_plx_ExpectedDefintedBenefitContributionDuringPeriod">Expected Definted Benefit Contribution During Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ExpectedDefintedBenefitContributionDuringPeriod" xlink:to="label_plx_ExpectedDefintedBenefitContributionDuringPeriod" xlink:title="Label : plx_ExpectedDefintedBenefitContributionDuringPeriod to label_plx_ExpectedDefintedBenefitContributionDuringPeriod" />
    <link:label xlink:type="resource" xlink:label="label_plx_ExpectedDefintedBenefitContributionDuringPeriod_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_ExpectedDefintedBenefitContributionDuringPeriod_1" xml:lang="en-US" id="label_plx_ExpectedDefintedBenefitContributionDuringPeriod_1">Expected Definted Benefit Contribution During Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ExpectedDefintedBenefitContributionDuringPeriod" xlink:to="label_plx_ExpectedDefintedBenefitContributionDuringPeriod_1" xlink:title="Label : plx_ExpectedDefintedBenefitContributionDuringPeriod to label_plx_ExpectedDefintedBenefitContributionDuringPeriod_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_ExpectedDefintedBenefitContributionDuringPeriod_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_ExpectedDefintedBenefitContributionDuringPeriod_2" xml:lang="en-US" id="label_plx_ExpectedDefintedBenefitContributionDuringPeriod_2">Expected contribution to one or more Contribution Plans</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ExpectedDefintedBenefitContributionDuringPeriod" xlink:to="label_plx_ExpectedDefintedBenefitContributionDuringPeriod_2" xlink:title="Label : plx_ExpectedDefintedBenefitContributionDuringPeriod to label_plx_ExpectedDefintedBenefitContributionDuringPeriod_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_AgreementMaintenanceFee" xlink:label="plx_AgreementMaintenanceFee" xlink:title="plx_AgreementMaintenanceFee" />
    <link:label xlink:type="resource" xlink:label="label_plx_AgreementMaintenanceFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_AgreementMaintenanceFee" xml:lang="en-US" id="label_plx_AgreementMaintenanceFee">Agreement Maintenance Fee</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AgreementMaintenanceFee" xlink:to="label_plx_AgreementMaintenanceFee" xlink:title="Label : plx_AgreementMaintenanceFee to label_plx_AgreementMaintenanceFee" />
    <link:label xlink:type="resource" xlink:label="label_plx_AgreementMaintenanceFee_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_AgreementMaintenanceFee_1" xml:lang="en-US" id="label_plx_AgreementMaintenanceFee_1">Agreement maintenance fee</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AgreementMaintenanceFee" xlink:to="label_plx_AgreementMaintenanceFee_1" xlink:title="Label : plx_AgreementMaintenanceFee to label_plx_AgreementMaintenanceFee_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_AgreementMaintenanceFee_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_AgreementMaintenanceFee_2" xml:lang="en-US" id="label_plx_AgreementMaintenanceFee_2">Agreement maintenance fee</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AgreementMaintenanceFee" xlink:to="label_plx_AgreementMaintenanceFee_2" xlink:title="Label : plx_AgreementMaintenanceFee to label_plx_AgreementMaintenanceFee_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_AmortizationOfDebtIssuanceCosts" xlink:label="plx_AmortizationOfDebtIssuanceCosts" xlink:title="plx_AmortizationOfDebtIssuanceCosts" />
    <link:label xlink:type="resource" xlink:label="label_plx_AmortizationOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_AmortizationOfDebtIssuanceCosts" xml:lang="en-US" id="label_plx_AmortizationOfDebtIssuanceCosts">Amortization Of Debt Issuance Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AmortizationOfDebtIssuanceCosts" xlink:to="label_plx_AmortizationOfDebtIssuanceCosts" xlink:title="Label : plx_AmortizationOfDebtIssuanceCosts to label_plx_AmortizationOfDebtIssuanceCosts" />
    <link:label xlink:type="resource" xlink:label="label_plx_AmortizationOfDebtIssuanceCosts_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_AmortizationOfDebtIssuanceCosts_1" xml:lang="en-US" id="label_plx_AmortizationOfDebtIssuanceCosts_1">Amount of noncash expense included in interest expense to issue debt and obtain financing associated with the related debt instruments. Alternate captions include noncash interest expense.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AmortizationOfDebtIssuanceCosts" xlink:to="label_plx_AmortizationOfDebtIssuanceCosts_1" xlink:title="Label : plx_AmortizationOfDebtIssuanceCosts to label_plx_AmortizationOfDebtIssuanceCosts_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_AmortizationOfDebtIssuanceCosts_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_AmortizationOfDebtIssuanceCosts_2" xml:lang="en-US" id="label_plx_AmortizationOfDebtIssuanceCosts_2">Amortization of debt issuance costs and debt discount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AmortizationOfDebtIssuanceCosts" xlink:to="label_plx_AmortizationOfDebtIssuanceCosts_2" xlink:title="Label : plx_AmortizationOfDebtIssuanceCosts to label_plx_AmortizationOfDebtIssuanceCosts_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_AnnualIncreaseToMaintenanceFee" xlink:label="plx_AnnualIncreaseToMaintenanceFee" xlink:title="plx_AnnualIncreaseToMaintenanceFee" />
    <link:label xlink:type="resource" xlink:label="label_plx_AnnualIncreaseToMaintenanceFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_AnnualIncreaseToMaintenanceFee" xml:lang="en-US" id="label_plx_AnnualIncreaseToMaintenanceFee">Annual Increase To Maintenance Fee</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AnnualIncreaseToMaintenanceFee" xlink:to="label_plx_AnnualIncreaseToMaintenanceFee" xlink:title="Label : plx_AnnualIncreaseToMaintenanceFee to label_plx_AnnualIncreaseToMaintenanceFee" />
    <link:label xlink:type="resource" xlink:label="label_plx_AnnualIncreaseToMaintenanceFee_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_AnnualIncreaseToMaintenanceFee_1" xml:lang="en-US" id="label_plx_AnnualIncreaseToMaintenanceFee_1">Annual increase to maintenance fee.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AnnualIncreaseToMaintenanceFee" xlink:to="label_plx_AnnualIncreaseToMaintenanceFee_1" xlink:title="Label : plx_AnnualIncreaseToMaintenanceFee to label_plx_AnnualIncreaseToMaintenanceFee_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_AnnualIncreaseToMaintenanceFee_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_AnnualIncreaseToMaintenanceFee_2" xml:lang="en-US" id="label_plx_AnnualIncreaseToMaintenanceFee_2">Annual increase to maintenance fee</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AnnualIncreaseToMaintenanceFee" xlink:to="label_plx_AnnualIncreaseToMaintenanceFee_2" xlink:title="Label : plx_AnnualIncreaseToMaintenanceFee to label_plx_AnnualIncreaseToMaintenanceFee_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd#country_BR" xlink:label="country_BR" xlink:title="country_BR" />
    <link:label xlink:type="resource" xlink:label="label_country_BR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_country_BR" xml:lang="en-US" id="label_country_BR">BRAZIL</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_BR" xlink:to="label_country_BR" xlink:title="Label : country_BR to label_country_BR" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_CashlessExerciseOfStockOptions" xlink:label="plx_CashlessExerciseOfStockOptions" xlink:title="plx_CashlessExerciseOfStockOptions" />
    <link:label xlink:type="resource" xlink:label="label_plx_CashlessExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_CashlessExerciseOfStockOptions" xml:lang="en-US" id="label_plx_CashlessExerciseOfStockOptions">Cashless Exercise Of Stock Options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CashlessExerciseOfStockOptions" xlink:to="label_plx_CashlessExerciseOfStockOptions" xlink:title="Label : plx_CashlessExerciseOfStockOptions to label_plx_CashlessExerciseOfStockOptions" />
    <link:label xlink:type="resource" xlink:label="label_plx_CashlessExerciseOfStockOptions_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_CashlessExerciseOfStockOptions_1" xml:lang="en-US" id="label_plx_CashlessExerciseOfStockOptions_1">Cashless exercise of stock options.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CashlessExerciseOfStockOptions" xlink:to="label_plx_CashlessExerciseOfStockOptions_1" xlink:title="Label : plx_CashlessExerciseOfStockOptions to label_plx_CashlessExerciseOfStockOptions_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_CashlessExerciseOfStockOptions_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_CashlessExerciseOfStockOptions_2" xml:lang="en-US" id="label_plx_CashlessExerciseOfStockOptions_2">Exercise of options granted to employees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CashlessExerciseOfStockOptions" xlink:to="label_plx_CashlessExerciseOfStockOptions_2" xlink:title="Label : plx_CashlessExerciseOfStockOptions to label_plx_CashlessExerciseOfStockOptions_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_CollaborativeAndLicenseArrangementDisclosure" xlink:label="plx_CollaborativeAndLicenseArrangementDisclosure" xlink:title="plx_CollaborativeAndLicenseArrangementDisclosure" />
    <link:label xlink:type="resource" xlink:label="label_plx_CollaborativeAndLicenseArrangementDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_CollaborativeAndLicenseArrangementDisclosure" xml:lang="en-US" id="label_plx_CollaborativeAndLicenseArrangementDisclosure">LICENSE AND SUPPLY AGREEMENT [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CollaborativeAndLicenseArrangementDisclosure" xlink:to="label_plx_CollaborativeAndLicenseArrangementDisclosure" xlink:title="Label : plx_CollaborativeAndLicenseArrangementDisclosure to label_plx_CollaborativeAndLicenseArrangementDisclosure" />
    <link:label xlink:type="resource" xlink:label="label_plx_CollaborativeAndLicenseArrangementDisclosure_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_CollaborativeAndLicenseArrangementDisclosure_1" xml:lang="en-US" id="label_plx_CollaborativeAndLicenseArrangementDisclosure_1">LICENSE AND SUPPLY AGREEMENT [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CollaborativeAndLicenseArrangementDisclosure" xlink:to="label_plx_CollaborativeAndLicenseArrangementDisclosure_1" xlink:title="Label : plx_CollaborativeAndLicenseArrangementDisclosure to label_plx_CollaborativeAndLicenseArrangementDisclosure_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_CollaborativeAndLicenseArrangementTable" xlink:label="plx_CollaborativeAndLicenseArrangementTable" xlink:title="plx_CollaborativeAndLicenseArrangementTable" />
    <link:label xlink:type="resource" xlink:label="label_plx_CollaborativeAndLicenseArrangementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_CollaborativeAndLicenseArrangementTable" xml:lang="en-US" id="label_plx_CollaborativeAndLicenseArrangementTable">Collaborative And License Arrangement [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CollaborativeAndLicenseArrangementTable" xlink:to="label_plx_CollaborativeAndLicenseArrangementTable" xlink:title="Label : plx_CollaborativeAndLicenseArrangementTable to label_plx_CollaborativeAndLicenseArrangementTable" />
    <link:label xlink:type="resource" xlink:label="label_plx_CollaborativeAndLicenseArrangementTable_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_CollaborativeAndLicenseArrangementTable_1" xml:lang="en-US" id="label_plx_CollaborativeAndLicenseArrangementTable_1">Collaborative And License Arrangement Table</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CollaborativeAndLicenseArrangementTable" xlink:to="label_plx_CollaborativeAndLicenseArrangementTable_1" xlink:title="Label : plx_CollaborativeAndLicenseArrangementTable to label_plx_CollaborativeAndLicenseArrangementTable_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_CommitmentAmount" xlink:label="plx_CommitmentAmount" xlink:title="plx_CommitmentAmount" />
    <link:label xlink:type="resource" xlink:label="label_plx_CommitmentAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_CommitmentAmount" xml:lang="en-US" id="label_plx_CommitmentAmount">Commitment Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CommitmentAmount" xlink:to="label_plx_CommitmentAmount" xlink:title="Label : plx_CommitmentAmount to label_plx_CommitmentAmount" />
    <link:label xlink:type="resource" xlink:label="label_plx_CommitmentAmount_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_CommitmentAmount_1" xml:lang="en-US" id="label_plx_CommitmentAmount_1">Commitment amount.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CommitmentAmount" xlink:to="label_plx_CommitmentAmount_1" xlink:title="Label : plx_CommitmentAmount to label_plx_CommitmentAmount_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_CommitmentAmount_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_CommitmentAmount_2" xml:lang="en-US" id="label_plx_CommitmentAmount_2">Subcontracting commitment amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CommitmentAmount" xlink:to="label_plx_CommitmentAmount_2" xlink:title="Label : plx_CommitmentAmount to label_plx_CommitmentAmount_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_CommitmentsAndContingenciesAxis" xlink:label="plx_CommitmentsAndContingenciesAxis" xlink:title="plx_CommitmentsAndContingenciesAxis" />
    <link:label xlink:type="resource" xlink:label="label_plx_CommitmentsAndContingenciesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_CommitmentsAndContingenciesAxis" xml:lang="en-US" id="label_plx_CommitmentsAndContingenciesAxis">Commitments And Contingencies [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CommitmentsAndContingenciesAxis" xlink:to="label_plx_CommitmentsAndContingenciesAxis" xlink:title="Label : plx_CommitmentsAndContingenciesAxis to label_plx_CommitmentsAndContingenciesAxis" />
    <link:label xlink:type="resource" xlink:label="label_plx_CommitmentsAndContingenciesAxis_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_CommitmentsAndContingenciesAxis_1" xml:lang="en-US" id="label_plx_CommitmentsAndContingenciesAxis_1">Commitments And Contingencies Axis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CommitmentsAndContingenciesAxis" xlink:to="label_plx_CommitmentsAndContingenciesAxis_1" xlink:title="Label : plx_CommitmentsAndContingenciesAxis to label_plx_CommitmentsAndContingenciesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_CommitmentsAndContingenciesDomain" xlink:label="plx_CommitmentsAndContingenciesDomain" xlink:title="plx_CommitmentsAndContingenciesDomain" />
    <link:label xlink:type="resource" xlink:label="label_plx_CommitmentsAndContingenciesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_CommitmentsAndContingenciesDomain" xml:lang="en-US" id="label_plx_CommitmentsAndContingenciesDomain">Commitments And Contingencies [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CommitmentsAndContingenciesDomain" xlink:to="label_plx_CommitmentsAndContingenciesDomain" xlink:title="Label : plx_CommitmentsAndContingenciesDomain to label_plx_CommitmentsAndContingenciesDomain" />
    <link:label xlink:type="resource" xlink:label="label_plx_CommitmentsAndContingenciesDomain_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_CommitmentsAndContingenciesDomain_1" xml:lang="en-US" id="label_plx_CommitmentsAndContingenciesDomain_1">Commitments And Contingencies [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CommitmentsAndContingenciesDomain" xlink:to="label_plx_CommitmentsAndContingenciesDomain_1" xlink:title="Label : plx_CommitmentsAndContingenciesDomain to label_plx_CommitmentsAndContingenciesDomain_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:title="dei_DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="label_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_dei_DocumentPeriodEndDate" xml:lang="en-US" id="label_dei_DocumentPeriodEndDate">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="label_dei_DocumentPeriodEndDate" xlink:title="Label : dei_DocumentPeriodEndDate to label_dei_DocumentPeriodEndDate" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_CommitmentsAndContingenciesLineItems" xlink:label="plx_CommitmentsAndContingenciesLineItems" xlink:title="plx_CommitmentsAndContingenciesLineItems" />
    <link:label xlink:type="resource" xlink:label="label_plx_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_CommitmentsAndContingenciesLineItems" xml:lang="en-US" id="label_plx_CommitmentsAndContingenciesLineItems">Commitments And Contingencies [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="label_plx_CommitmentsAndContingenciesLineItems" xlink:title="Label : plx_CommitmentsAndContingenciesLineItems to label_plx_CommitmentsAndContingenciesLineItems" />
    <link:label xlink:type="resource" xlink:label="label_plx_CommitmentsAndContingenciesLineItems_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_CommitmentsAndContingenciesLineItems_1" xml:lang="en-US" id="label_plx_CommitmentsAndContingenciesLineItems_1">Commitments And Contingencies [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="label_plx_CommitmentsAndContingenciesLineItems_1" xlink:title="Label : plx_CommitmentsAndContingenciesLineItems to label_plx_CommitmentsAndContingenciesLineItems_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_CommitmentsAndContingenciesTable" xlink:label="plx_CommitmentsAndContingenciesTable" xlink:title="plx_CommitmentsAndContingenciesTable" />
    <link:label xlink:type="resource" xlink:label="label_plx_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_CommitmentsAndContingenciesTable" xml:lang="en-US" id="label_plx_CommitmentsAndContingenciesTable">Commitments And Contingencies [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CommitmentsAndContingenciesTable" xlink:to="label_plx_CommitmentsAndContingenciesTable" xlink:title="Label : plx_CommitmentsAndContingenciesTable to label_plx_CommitmentsAndContingenciesTable" />
    <link:label xlink:type="resource" xlink:label="label_plx_CommitmentsAndContingenciesTable_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_CommitmentsAndContingenciesTable_1" xml:lang="en-US" id="label_plx_CommitmentsAndContingenciesTable_1">Commitments And Contingencies Table</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CommitmentsAndContingenciesTable" xlink:to="label_plx_CommitmentsAndContingenciesTable_1" xlink:title="Label : plx_CommitmentsAndContingenciesTable to label_plx_CommitmentsAndContingenciesTable_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ConsiderationForLicense" xlink:label="plx_ConsiderationForLicense" xlink:title="plx_ConsiderationForLicense" />
    <link:label xlink:type="resource" xlink:label="label_plx_ConsiderationForLicense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_ConsiderationForLicense" xml:lang="en-US" id="label_plx_ConsiderationForLicense">Consideration For License</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ConsiderationForLicense" xlink:to="label_plx_ConsiderationForLicense" xlink:title="Label : plx_ConsiderationForLicense to label_plx_ConsiderationForLicense" />
    <link:label xlink:type="resource" xlink:label="label_plx_ConsiderationForLicense_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_ConsiderationForLicense_1" xml:lang="en-US" id="label_plx_ConsiderationForLicense_1">Consideration for license.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ConsiderationForLicense" xlink:to="label_plx_ConsiderationForLicense_1" xlink:title="Label : plx_ConsiderationForLicense to label_plx_ConsiderationForLicense_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_ConsiderationForLicense_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_ConsiderationForLicense_2" xml:lang="en-US" id="label_plx_ConsiderationForLicense_2">Consideration for license</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ConsiderationForLicense" xlink:to="label_plx_ConsiderationForLicense_2" xlink:title="Label : plx_ConsiderationForLicense to label_plx_ConsiderationForLicense_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_DebtInstrumentConvertibleBaseValueForConversionRate" xlink:label="plx_DebtInstrumentConvertibleBaseValueForConversionRate" xlink:title="plx_DebtInstrumentConvertibleBaseValueForConversionRate" />
    <link:label xlink:type="resource" xlink:label="label_plx_DebtInstrumentConvertibleBaseValueForConversionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_DebtInstrumentConvertibleBaseValueForConversionRate" xml:lang="en-US" id="label_plx_DebtInstrumentConvertibleBaseValueForConversionRate">Debt Instrument Convertible Base Value For Conversion Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_DebtInstrumentConvertibleBaseValueForConversionRate" xlink:to="label_plx_DebtInstrumentConvertibleBaseValueForConversionRate" xlink:title="Label : plx_DebtInstrumentConvertibleBaseValueForConversionRate to label_plx_DebtInstrumentConvertibleBaseValueForConversionRate" />
    <link:label xlink:type="resource" xlink:label="label_plx_DebtInstrumentConvertibleBaseValueForConversionRate_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_DebtInstrumentConvertibleBaseValueForConversionRate_1" xml:lang="en-US" id="label_plx_DebtInstrumentConvertibleBaseValueForConversionRate_1">Debt Instrument Convertible Base Value For Conversion Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_DebtInstrumentConvertibleBaseValueForConversionRate" xlink:to="label_plx_DebtInstrumentConvertibleBaseValueForConversionRate_1" xlink:title="Label : plx_DebtInstrumentConvertibleBaseValueForConversionRate to label_plx_DebtInstrumentConvertibleBaseValueForConversionRate_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_DebtInstrumentConvertibleBaseValueForConversionRate_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_DebtInstrumentConvertibleBaseValueForConversionRate_2" xml:lang="en-US" id="label_plx_DebtInstrumentConvertibleBaseValueForConversionRate_2">Base value for conversion rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_DebtInstrumentConvertibleBaseValueForConversionRate" xlink:to="label_plx_DebtInstrumentConvertibleBaseValueForConversionRate_2" xlink:title="Label : plx_DebtInstrumentConvertibleBaseValueForConversionRate to label_plx_DebtInstrumentConvertibleBaseValueForConversionRate_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_DebtInstrumentConvertibleConversionShareNumber" xlink:label="plx_DebtInstrumentConvertibleConversionShareNumber" xlink:title="plx_DebtInstrumentConvertibleConversionShareNumber" />
    <link:label xlink:type="resource" xlink:label="label_plx_DebtInstrumentConvertibleConversionShareNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_DebtInstrumentConvertibleConversionShareNumber" xml:lang="en-US" id="label_plx_DebtInstrumentConvertibleConversionShareNumber">Debt Instrument Convertible Conversion Share Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_DebtInstrumentConvertibleConversionShareNumber" xlink:to="label_plx_DebtInstrumentConvertibleConversionShareNumber" xlink:title="Label : plx_DebtInstrumentConvertibleConversionShareNumber to label_plx_DebtInstrumentConvertibleConversionShareNumber" />
    <link:label xlink:type="resource" xlink:label="label_plx_DebtInstrumentConvertibleConversionShareNumber_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_DebtInstrumentConvertibleConversionShareNumber_1" xml:lang="en-US" id="label_plx_DebtInstrumentConvertibleConversionShareNumber_1">Debt Instrument Convertible Conversion Share Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_DebtInstrumentConvertibleConversionShareNumber" xlink:to="label_plx_DebtInstrumentConvertibleConversionShareNumber_1" xlink:title="Label : plx_DebtInstrumentConvertibleConversionShareNumber to label_plx_DebtInstrumentConvertibleConversionShareNumber_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_DebtInstrumentConvertibleConversionShareNumber_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_DebtInstrumentConvertibleConversionShareNumber_2" xml:lang="en-US" id="label_plx_DebtInstrumentConvertibleConversionShareNumber_2">Number of shares for basis conversion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_DebtInstrumentConvertibleConversionShareNumber" xlink:to="label_plx_DebtInstrumentConvertibleConversionShareNumber_2" xlink:title="Label : plx_DebtInstrumentConvertibleConversionShareNumber to label_plx_DebtInstrumentConvertibleConversionShareNumber_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:title="us-gaap_AwardTypeAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AwardTypeAxis" xml:lang="en-US" id="label_us-gaap_AwardTypeAxis">Award Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="label_us-gaap_AwardTypeAxis" xlink:title="Label : us-gaap_AwardTypeAxis to label_us-gaap_AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_DocumentAndEntityInformationAbstract" xlink:label="plx_DocumentAndEntityInformationAbstract" xlink:title="plx_DocumentAndEntityInformationAbstract" />
    <link:label xlink:type="resource" xlink:label="label_plx_DocumentAndEntityInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_DocumentAndEntityInformationAbstract" xml:lang="en-US" id="label_plx_DocumentAndEntityInformationAbstract">Document And Entity Information [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="label_plx_DocumentAndEntityInformationAbstract" xlink:title="Label : plx_DocumentAndEntityInformationAbstract to label_plx_DocumentAndEntityInformationAbstract" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_EffectiveAdjustedIncomeTaxRateThereafter" xlink:label="plx_EffectiveAdjustedIncomeTaxRateThereafter" xlink:title="plx_EffectiveAdjustedIncomeTaxRateThereafter" />
    <link:label xlink:type="resource" xlink:label="label_plx_EffectiveAdjustedIncomeTaxRateThereafter" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_EffectiveAdjustedIncomeTaxRateThereafter" xml:lang="en-US" id="label_plx_EffectiveAdjustedIncomeTaxRateThereafter">Effective Adjusted Income Tax Rate Thereafter</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EffectiveAdjustedIncomeTaxRateThereafter" xlink:to="label_plx_EffectiveAdjustedIncomeTaxRateThereafter" xlink:title="Label : plx_EffectiveAdjustedIncomeTaxRateThereafter to label_plx_EffectiveAdjustedIncomeTaxRateThereafter" />
    <link:label xlink:type="resource" xlink:label="label_plx_EffectiveAdjustedIncomeTaxRateThereafter_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_EffectiveAdjustedIncomeTaxRateThereafter_1" xml:lang="en-US" id="label_plx_EffectiveAdjustedIncomeTaxRateThereafter_1">Effective Adjusted Income Tax Rate Thereafter</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EffectiveAdjustedIncomeTaxRateThereafter" xlink:to="label_plx_EffectiveAdjustedIncomeTaxRateThereafter_1" xlink:title="Label : plx_EffectiveAdjustedIncomeTaxRateThereafter to label_plx_EffectiveAdjustedIncomeTaxRateThereafter_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_EffectiveAdjustedIncomeTaxRateThereafter_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_EffectiveAdjustedIncomeTaxRateThereafter_2" xml:lang="en-US" id="label_plx_EffectiveAdjustedIncomeTaxRateThereafter_2">Additional tax rate, 2014 and thereafter</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EffectiveAdjustedIncomeTaxRateThereafter" xlink:to="label_plx_EffectiveAdjustedIncomeTaxRateThereafter_2" xlink:title="Label : plx_EffectiveAdjustedIncomeTaxRateThereafter to label_plx_EffectiveAdjustedIncomeTaxRateThereafter_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_EffectiveAdjustedIncomeTaxRateYearFive" xlink:label="plx_EffectiveAdjustedIncomeTaxRateYearFive" xlink:title="plx_EffectiveAdjustedIncomeTaxRateYearFive" />
    <link:label xlink:type="resource" xlink:label="label_plx_EffectiveAdjustedIncomeTaxRateYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_EffectiveAdjustedIncomeTaxRateYearFive" xml:lang="en-US" id="label_plx_EffectiveAdjustedIncomeTaxRateYearFive">Effective Adjusted Income Tax Rate Year Five</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EffectiveAdjustedIncomeTaxRateYearFive" xlink:to="label_plx_EffectiveAdjustedIncomeTaxRateYearFive" xlink:title="Label : plx_EffectiveAdjustedIncomeTaxRateYearFive to label_plx_EffectiveAdjustedIncomeTaxRateYearFive" />
    <link:label xlink:type="resource" xlink:label="label_plx_EffectiveAdjustedIncomeTaxRateYearFive_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_EffectiveAdjustedIncomeTaxRateYearFive_1" xml:lang="en-US" id="label_plx_EffectiveAdjustedIncomeTaxRateYearFive_1">Effective Adjusted Income Tax Rate Year Five</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EffectiveAdjustedIncomeTaxRateYearFive" xlink:to="label_plx_EffectiveAdjustedIncomeTaxRateYearFive_1" xlink:title="Label : plx_EffectiveAdjustedIncomeTaxRateYearFive to label_plx_EffectiveAdjustedIncomeTaxRateYearFive_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_EffectiveAdjustedIncomeTaxRateYearFive_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_EffectiveAdjustedIncomeTaxRateYearFive_2" xml:lang="en-US" id="label_plx_EffectiveAdjustedIncomeTaxRateYearFive_2">Additional gradual decrease in tax rate, 2015</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EffectiveAdjustedIncomeTaxRateYearFive" xlink:to="label_plx_EffectiveAdjustedIncomeTaxRateYearFive_2" xlink:title="Label : plx_EffectiveAdjustedIncomeTaxRateYearFive to label_plx_EffectiveAdjustedIncomeTaxRateYearFive_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_EffectiveAdjustedIncomeTaxRateYearFour" xlink:label="plx_EffectiveAdjustedIncomeTaxRateYearFour" xlink:title="plx_EffectiveAdjustedIncomeTaxRateYearFour" />
    <link:label xlink:type="resource" xlink:label="label_plx_EffectiveAdjustedIncomeTaxRateYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_EffectiveAdjustedIncomeTaxRateYearFour" xml:lang="en-US" id="label_plx_EffectiveAdjustedIncomeTaxRateYearFour">Effective Adjusted Income Tax Rate Year Four</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EffectiveAdjustedIncomeTaxRateYearFour" xlink:to="label_plx_EffectiveAdjustedIncomeTaxRateYearFour" xlink:title="Label : plx_EffectiveAdjustedIncomeTaxRateYearFour to label_plx_EffectiveAdjustedIncomeTaxRateYearFour" />
    <link:label xlink:type="resource" xlink:label="label_plx_EffectiveAdjustedIncomeTaxRateYearFour_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_EffectiveAdjustedIncomeTaxRateYearFour_1" xml:lang="en-US" id="label_plx_EffectiveAdjustedIncomeTaxRateYearFour_1">Additional gradual decrease in tax rate, 2015</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EffectiveAdjustedIncomeTaxRateYearFour" xlink:to="label_plx_EffectiveAdjustedIncomeTaxRateYearFour_1" xlink:title="Label : plx_EffectiveAdjustedIncomeTaxRateYearFour to label_plx_EffectiveAdjustedIncomeTaxRateYearFour_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_EffectiveAdjustedIncomeTaxRateYearFour_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_EffectiveAdjustedIncomeTaxRateYearFour_2" xml:lang="en-US" id="label_plx_EffectiveAdjustedIncomeTaxRateYearFour_2">Additional gradual decrease in tax rate, 2014</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EffectiveAdjustedIncomeTaxRateYearFour" xlink:to="label_plx_EffectiveAdjustedIncomeTaxRateYearFour_2" xlink:title="Label : plx_EffectiveAdjustedIncomeTaxRateYearFour to label_plx_EffectiveAdjustedIncomeTaxRateYearFour_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:title="dei_EntityDomain" />
    <link:label xlink:type="resource" xlink:label="label_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_dei_EntityDomain" xml:lang="en-US" id="label_dei_EntityDomain">Entity [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="label_dei_EntityDomain" xlink:title="Label : dei_EntityDomain to label_dei_EntityDomain" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_EffectiveAdjustedIncomeTaxRateYearOne" xlink:label="plx_EffectiveAdjustedIncomeTaxRateYearOne" xlink:title="plx_EffectiveAdjustedIncomeTaxRateYearOne" />
    <link:label xlink:type="resource" xlink:label="label_plx_EffectiveAdjustedIncomeTaxRateYearOne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_EffectiveAdjustedIncomeTaxRateYearOne" xml:lang="en-US" id="label_plx_EffectiveAdjustedIncomeTaxRateYearOne">Effective Adjusted Income Tax Rate Year One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EffectiveAdjustedIncomeTaxRateYearOne" xlink:to="label_plx_EffectiveAdjustedIncomeTaxRateYearOne" xlink:title="Label : plx_EffectiveAdjustedIncomeTaxRateYearOne to label_plx_EffectiveAdjustedIncomeTaxRateYearOne" />
    <link:label xlink:type="resource" xlink:label="label_plx_EffectiveAdjustedIncomeTaxRateYearOne_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_EffectiveAdjustedIncomeTaxRateYearOne_1" xml:lang="en-US" id="label_plx_EffectiveAdjustedIncomeTaxRateYearOne_1">Effective Adjusted Income Tax Rate Year One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EffectiveAdjustedIncomeTaxRateYearOne" xlink:to="label_plx_EffectiveAdjustedIncomeTaxRateYearOne_1" xlink:title="Label : plx_EffectiveAdjustedIncomeTaxRateYearOne to label_plx_EffectiveAdjustedIncomeTaxRateYearOne_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_EffectiveAdjustedIncomeTaxRateYearOne_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_EffectiveAdjustedIncomeTaxRateYearOne_2" xml:lang="en-US" id="label_plx_EffectiveAdjustedIncomeTaxRateYearOne_2">Additional tax rate, 2012</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EffectiveAdjustedIncomeTaxRateYearOne" xlink:to="label_plx_EffectiveAdjustedIncomeTaxRateYearOne_2" xlink:title="Label : plx_EffectiveAdjustedIncomeTaxRateYearOne to label_plx_EffectiveAdjustedIncomeTaxRateYearOne_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_EffectiveAdjustedIncomeTaxRateYearThree" xlink:label="plx_EffectiveAdjustedIncomeTaxRateYearThree" xlink:title="plx_EffectiveAdjustedIncomeTaxRateYearThree" />
    <link:label xlink:type="resource" xlink:label="label_plx_EffectiveAdjustedIncomeTaxRateYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_EffectiveAdjustedIncomeTaxRateYearThree" xml:lang="en-US" id="label_plx_EffectiveAdjustedIncomeTaxRateYearThree">Effective Adjusted Income Tax Rate Year Three</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EffectiveAdjustedIncomeTaxRateYearThree" xlink:to="label_plx_EffectiveAdjustedIncomeTaxRateYearThree" xlink:title="Label : plx_EffectiveAdjustedIncomeTaxRateYearThree to label_plx_EffectiveAdjustedIncomeTaxRateYearThree" />
    <link:label xlink:type="resource" xlink:label="label_plx_EffectiveAdjustedIncomeTaxRateYearThree_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_EffectiveAdjustedIncomeTaxRateYearThree_1" xml:lang="en-US" id="label_plx_EffectiveAdjustedIncomeTaxRateYearThree_1">Effective Adjusted Income Tax Rate Year Three</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EffectiveAdjustedIncomeTaxRateYearThree" xlink:to="label_plx_EffectiveAdjustedIncomeTaxRateYearThree_1" xlink:title="Label : plx_EffectiveAdjustedIncomeTaxRateYearThree to label_plx_EffectiveAdjustedIncomeTaxRateYearThree_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_EffectiveAdjustedIncomeTaxRateYearThree_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_EffectiveAdjustedIncomeTaxRateYearThree_2" xml:lang="en-US" id="label_plx_EffectiveAdjustedIncomeTaxRateYearThree_2">Additional gradual decrease in tax rate, 2013</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EffectiveAdjustedIncomeTaxRateYearThree" xlink:to="label_plx_EffectiveAdjustedIncomeTaxRateYearThree_2" xlink:title="Label : plx_EffectiveAdjustedIncomeTaxRateYearThree to label_plx_EffectiveAdjustedIncomeTaxRateYearThree_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_EffectiveAdjustedIncomeTaxRateYearTwo" xlink:label="plx_EffectiveAdjustedIncomeTaxRateYearTwo" xlink:title="plx_EffectiveAdjustedIncomeTaxRateYearTwo" />
    <link:label xlink:type="resource" xlink:label="label_plx_EffectiveAdjustedIncomeTaxRateYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_EffectiveAdjustedIncomeTaxRateYearTwo" xml:lang="en-US" id="label_plx_EffectiveAdjustedIncomeTaxRateYearTwo">Effective Adjusted Income Tax Rate Year Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EffectiveAdjustedIncomeTaxRateYearTwo" xlink:to="label_plx_EffectiveAdjustedIncomeTaxRateYearTwo" xlink:title="Label : plx_EffectiveAdjustedIncomeTaxRateYearTwo to label_plx_EffectiveAdjustedIncomeTaxRateYearTwo" />
    <link:label xlink:type="resource" xlink:label="label_plx_EffectiveAdjustedIncomeTaxRateYearTwo_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_EffectiveAdjustedIncomeTaxRateYearTwo_1" xml:lang="en-US" id="label_plx_EffectiveAdjustedIncomeTaxRateYearTwo_1">Effective Adjusted Income Tax Rate Year Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EffectiveAdjustedIncomeTaxRateYearTwo" xlink:to="label_plx_EffectiveAdjustedIncomeTaxRateYearTwo_1" xlink:title="Label : plx_EffectiveAdjustedIncomeTaxRateYearTwo to label_plx_EffectiveAdjustedIncomeTaxRateYearTwo_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_EffectiveAdjustedIncomeTaxRateYearTwo_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_EffectiveAdjustedIncomeTaxRateYearTwo_2" xml:lang="en-US" id="label_plx_EffectiveAdjustedIncomeTaxRateYearTwo_2">Additional tax rate, 2013</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EffectiveAdjustedIncomeTaxRateYearTwo" xlink:to="label_plx_EffectiveAdjustedIncomeTaxRateYearTwo_2" xlink:title="Label : plx_EffectiveAdjustedIncomeTaxRateYearTwo to label_plx_EffectiveAdjustedIncomeTaxRateYearTwo_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_EmployeesMember" xlink:label="plx_EmployeesMember" xlink:title="plx_EmployeesMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_EmployeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_EmployeesMember" xml:lang="en-US" id="label_plx_EmployeesMember">Employees [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EmployeesMember" xlink:to="label_plx_EmployeesMember" xlink:title="Label : plx_EmployeesMember to label_plx_EmployeesMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_EmployeesMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_EmployeesMember_1" xml:lang="en-US" id="label_plx_EmployeesMember_1">Employees [Member].</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EmployeesMember" xlink:to="label_plx_EmployeesMember_1" xlink:title="Label : plx_EmployeesMember to label_plx_EmployeesMember_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_FivePointZeroMember" xlink:label="plx_FivePointZeroMember" xlink:title="plx_FivePointZeroMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_FivePointZeroMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_FivePointZeroMember" xml:lang="en-US" id="label_plx_FivePointZeroMember">Five Point Zero [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_FivePointZeroMember" xlink:to="label_plx_FivePointZeroMember" xlink:title="Label : plx_FivePointZeroMember to label_plx_FivePointZeroMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_FivePointZeroMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_FivePointZeroMember_1" xml:lang="en-US" id="label_plx_FivePointZeroMember_1">Five Point Zero Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_FivePointZeroMember" xlink:to="label_plx_FivePointZeroMember_1" xlink:title="Label : plx_FivePointZeroMember to label_plx_FivePointZeroMember_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_FivePointZeroMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_FivePointZeroMember_2" xml:lang="en-US" id="label_plx_FivePointZeroMember_2">5.000 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_FivePointZeroMember" xlink:to="label_plx_FivePointZeroMember_2" xlink:title="Label : plx_FivePointZeroMember to label_plx_FivePointZeroMember_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ForfeitureRate" xlink:label="plx_ForfeitureRate" xlink:title="plx_ForfeitureRate" />
    <link:label xlink:type="resource" xlink:label="label_plx_ForfeitureRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_ForfeitureRate" xml:lang="en-US" id="label_plx_ForfeitureRate">Forfeiture Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ForfeitureRate" xlink:to="label_plx_ForfeitureRate" xlink:title="Label : plx_ForfeitureRate to label_plx_ForfeitureRate" />
    <link:label xlink:type="resource" xlink:label="label_plx_ForfeitureRate_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_ForfeitureRate_1" xml:lang="en-US" id="label_plx_ForfeitureRate_1">Forfeiture rate.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ForfeitureRate" xlink:to="label_plx_ForfeitureRate_1" xlink:title="Label : plx_ForfeitureRate to label_plx_ForfeitureRate_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_ForfeitureRate_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_ForfeitureRate_2" xml:lang="en-US" id="label_plx_ForfeitureRate_2">Forfeiture rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ForfeitureRate" xlink:to="label_plx_ForfeitureRate_2" xlink:title="Label : plx_ForfeitureRate to label_plx_ForfeitureRate_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_FundingArrangementsMember" xlink:label="plx_FundingArrangementsMember" xlink:title="plx_FundingArrangementsMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_FundingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_FundingArrangementsMember" xml:lang="en-US" id="label_plx_FundingArrangementsMember">Funding Arrangements [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_FundingArrangementsMember" xlink:to="label_plx_FundingArrangementsMember" xlink:title="Label : plx_FundingArrangementsMember to label_plx_FundingArrangementsMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_FundingArrangementsMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_FundingArrangementsMember_1" xml:lang="en-US" id="label_plx_FundingArrangementsMember_1">Funding Arrangements Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_FundingArrangementsMember" xlink:to="label_plx_FundingArrangementsMember_1" xlink:title="Label : plx_FundingArrangementsMember to label_plx_FundingArrangementsMember_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:title="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" />
    <link:label xlink:type="resource" xlink:label="label_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xml:lang="en-US" id="label_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement">Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:to="label_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:title="Label : plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement to label_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" />
    <link:label xlink:type="resource" xlink:label="label_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_1" xml:lang="en-US" id="label_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_1">Gain (loss) on amounts funded in respect of employee rights upon retirement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:to="label_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_1" xlink:title="Label : plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement to label_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_2" xml:lang="en-US" id="label_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_2">Loss (Gain) on amounts funded in respect of employee rights upon retirement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:to="label_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_2" xlink:title="Label : plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement to label_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_GrantYearTwoThousandTwelveMember" xlink:label="plx_GrantYearTwoThousandTwelveMember" xlink:title="plx_GrantYearTwoThousandTwelveMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_GrantYearTwoThousandTwelveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_GrantYearTwoThousandTwelveMember" xml:lang="en-US" id="label_plx_GrantYearTwoThousandTwelveMember">Grant Year Two Thousand Twelve [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_GrantYearTwoThousandTwelveMember" xlink:to="label_plx_GrantYearTwoThousandTwelveMember" xlink:title="Label : plx_GrantYearTwoThousandTwelveMember to label_plx_GrantYearTwoThousandTwelveMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_GrantYearTwoThousandTwelveMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_GrantYearTwoThousandTwelveMember_1" xml:lang="en-US" id="label_plx_GrantYearTwoThousandTwelveMember_1">Grant Year Two Thousand Twelve Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_GrantYearTwoThousandTwelveMember" xlink:to="label_plx_GrantYearTwoThousandTwelveMember_1" xlink:title="Label : plx_GrantYearTwoThousandTwelveMember to label_plx_GrantYearTwoThousandTwelveMember_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_GrantYearTwoThousandTwelveMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_GrantYearTwoThousandTwelveMember_2" xml:lang="en-US" id="label_plx_GrantYearTwoThousandTwelveMember_2">2012 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_GrantYearTwoThousandTwelveMember" xlink:to="label_plx_GrantYearTwoThousandTwelveMember_2" xlink:title="Label : plx_GrantYearTwoThousandTwelveMember to label_plx_GrantYearTwoThousandTwelveMember_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_GrantYearTwoThousandTwelveSecondMember" xlink:label="plx_GrantYearTwoThousandTwelveSecondMember" xlink:title="plx_GrantYearTwoThousandTwelveSecondMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_GrantYearTwoThousandTwelveSecondMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_GrantYearTwoThousandTwelveSecondMember" xml:lang="en-US" id="label_plx_GrantYearTwoThousandTwelveSecondMember">Grant Year Two Thousand Twelve Second [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_GrantYearTwoThousandTwelveSecondMember" xlink:to="label_plx_GrantYearTwoThousandTwelveSecondMember" xlink:title="Label : plx_GrantYearTwoThousandTwelveSecondMember to label_plx_GrantYearTwoThousandTwelveSecondMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_GrantYearTwoThousandTwelveSecondMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_GrantYearTwoThousandTwelveSecondMember_1" xml:lang="en-US" id="label_plx_GrantYearTwoThousandTwelveSecondMember_1">Grant Year Two Thousand Twelve Second [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_GrantYearTwoThousandTwelveSecondMember" xlink:to="label_plx_GrantYearTwoThousandTwelveSecondMember_1" xlink:title="Label : plx_GrantYearTwoThousandTwelveSecondMember to label_plx_GrantYearTwoThousandTwelveSecondMember_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_GrantYearTwoThousandTwelveSecondMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_GrantYearTwoThousandTwelveSecondMember_2" xml:lang="en-US" id="label_plx_GrantYearTwoThousandTwelveSecondMember_2">2012 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_GrantYearTwoThousandTwelveSecondMember" xlink:to="label_plx_GrantYearTwoThousandTwelveSecondMember_2" xlink:title="Label : plx_GrantYearTwoThousandTwelveSecondMember to label_plx_GrantYearTwoThousandTwelveSecondMember_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_IncomeTaxDisclosureLineItems" xlink:label="plx_IncomeTaxDisclosureLineItems" xlink:title="plx_IncomeTaxDisclosureLineItems" />
    <link:label xlink:type="resource" xlink:label="label_plx_IncomeTaxDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_IncomeTaxDisclosureLineItems" xml:lang="en-US" id="label_plx_IncomeTaxDisclosureLineItems">Income Tax Disclosure [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_IncomeTaxDisclosureLineItems" xlink:to="label_plx_IncomeTaxDisclosureLineItems" xlink:title="Label : plx_IncomeTaxDisclosureLineItems to label_plx_IncomeTaxDisclosureLineItems" />
    <link:label xlink:type="resource" xlink:label="label_plx_IncomeTaxDisclosureLineItems_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_IncomeTaxDisclosureLineItems_1" xml:lang="en-US" id="label_plx_IncomeTaxDisclosureLineItems_1">Income Tax Disclosure Line Items</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_IncomeTaxDisclosureLineItems" xlink:to="label_plx_IncomeTaxDisclosureLineItems_1" xlink:title="Label : plx_IncomeTaxDisclosureLineItems to label_plx_IncomeTaxDisclosureLineItems_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_IncomeTaxDisclosureTable" xlink:label="plx_IncomeTaxDisclosureTable" xlink:title="plx_IncomeTaxDisclosureTable" />
    <link:label xlink:type="resource" xlink:label="label_plx_IncomeTaxDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_IncomeTaxDisclosureTable" xml:lang="en-US" id="label_plx_IncomeTaxDisclosureTable">Income Tax Disclosure [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_IncomeTaxDisclosureTable" xlink:to="label_plx_IncomeTaxDisclosureTable" xlink:title="Label : plx_IncomeTaxDisclosureTable to label_plx_IncomeTaxDisclosureTable" />
    <link:label xlink:type="resource" xlink:label="label_plx_IncomeTaxDisclosureTable_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_IncomeTaxDisclosureTable_1" xml:lang="en-US" id="label_plx_IncomeTaxDisclosureTable_1">Income Tax Disclosure Table</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_IncomeTaxDisclosureTable" xlink:to="label_plx_IncomeTaxDisclosureTable_1" xlink:title="Label : plx_IncomeTaxDisclosureTable to label_plx_IncomeTaxDisclosureTable_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:label="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:title="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="label_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xml:lang="en-US" id="label_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment">Increase In Liabilities For Property Plant And Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:to="label_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:title="Label : plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment to label_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="label_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_1" xml:lang="en-US" id="label_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_1">Increase in liabilities for property, plant and equipment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:to="label_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_1" xlink:title="Label : plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment to label_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_2" xml:lang="en-US" id="label_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_2">Purchase of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:to="label_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_2" xlink:title="Label : plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment to label_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_LiabilitiesAccruedFromLicensingAgreement" xlink:label="plx_LiabilitiesAccruedFromLicensingAgreement" xlink:title="plx_LiabilitiesAccruedFromLicensingAgreement" />
    <link:label xlink:type="resource" xlink:label="label_plx_LiabilitiesAccruedFromLicensingAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_LiabilitiesAccruedFromLicensingAgreement" xml:lang="en-US" id="label_plx_LiabilitiesAccruedFromLicensingAgreement">Liabilities Accrued From Licensing Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_LiabilitiesAccruedFromLicensingAgreement" xlink:to="label_plx_LiabilitiesAccruedFromLicensingAgreement" xlink:title="Label : plx_LiabilitiesAccruedFromLicensingAgreement to label_plx_LiabilitiesAccruedFromLicensingAgreement" />
    <link:label xlink:type="resource" xlink:label="label_plx_LiabilitiesAccruedFromLicensingAgreement_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_LiabilitiesAccruedFromLicensingAgreement_1" xml:lang="en-US" id="label_plx_LiabilitiesAccruedFromLicensingAgreement_1">Liabilities accrued from licensing agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_LiabilitiesAccruedFromLicensingAgreement" xlink:to="label_plx_LiabilitiesAccruedFromLicensingAgreement_1" xlink:title="Label : plx_LiabilitiesAccruedFromLicensingAgreement to label_plx_LiabilitiesAccruedFromLicensingAgreement_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_LiabilitiesAccruedFromLicensingAgreement_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_LiabilitiesAccruedFromLicensingAgreement_2" xml:lang="en-US" id="label_plx_LiabilitiesAccruedFromLicensingAgreement_2">Accrued long term liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_LiabilitiesAccruedFromLicensingAgreement" xlink:to="label_plx_LiabilitiesAccruedFromLicensingAgreement_2" xlink:title="Label : plx_LiabilitiesAccruedFromLicensingAgreement to label_plx_LiabilitiesAccruedFromLicensingAgreement_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ManagementAndConsultingFeesToChairmanOfBoardMember" xlink:label="plx_ManagementAndConsultingFeesToChairmanOfBoardMember" xlink:title="plx_ManagementAndConsultingFeesToChairmanOfBoardMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_ManagementAndConsultingFeesToChairmanOfBoardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_ManagementAndConsultingFeesToChairmanOfBoardMember" xml:lang="en-US" id="label_plx_ManagementAndConsultingFeesToChairmanOfBoardMember">Management And Consulting Fees To Chairman Of Board [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ManagementAndConsultingFeesToChairmanOfBoardMember" xlink:to="label_plx_ManagementAndConsultingFeesToChairmanOfBoardMember" xlink:title="Label : plx_ManagementAndConsultingFeesToChairmanOfBoardMember to label_plx_ManagementAndConsultingFeesToChairmanOfBoardMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_ManagementAndConsultingFeesToChairmanOfBoardMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_ManagementAndConsultingFeesToChairmanOfBoardMember_1" xml:lang="en-US" id="label_plx_ManagementAndConsultingFeesToChairmanOfBoardMember_1">Management And Consulting Fees To Chairman Of Board [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ManagementAndConsultingFeesToChairmanOfBoardMember" xlink:to="label_plx_ManagementAndConsultingFeesToChairmanOfBoardMember_1" xlink:title="Label : plx_ManagementAndConsultingFeesToChairmanOfBoardMember to label_plx_ManagementAndConsultingFeesToChairmanOfBoardMember_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived" xlink:label="plx_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived" xlink:title="plx_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived" />
    <link:label xlink:type="resource" xlink:label="label_plx_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived" xml:lang="en-US" id="label_plx_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived">Maximum Aggregate Payments Of Royalties To Grant Received</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived" xlink:to="label_plx_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived" xlink:title="Label : plx_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived to label_plx_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived" />
    <link:label xlink:type="resource" xlink:label="label_plx_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived_1" xml:lang="en-US" id="label_plx_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived_1">Percetnage aggregate royalties should not exceed grant amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived" xlink:to="label_plx_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived_1" xlink:title="Label : plx_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived to label_plx_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived_2" xml:lang="en-US" id="label_plx_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived_2">Percentage amount the aggregate amount of royalties that should not exceed grant received</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived" xlink:to="label_plx_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived_2" xlink:title="Label : plx_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived to label_plx_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_MilestonePaymentsMember" xlink:label="plx_MilestonePaymentsMember" xlink:title="plx_MilestonePaymentsMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_MilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_MilestonePaymentsMember" xml:lang="en-US" id="label_plx_MilestonePaymentsMember">Milestone Payments [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_MilestonePaymentsMember" xlink:to="label_plx_MilestonePaymentsMember" xlink:title="Label : plx_MilestonePaymentsMember to label_plx_MilestonePaymentsMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_MilestonePaymentsMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_MilestonePaymentsMember_1" xml:lang="en-US" id="label_plx_MilestonePaymentsMember_1">Milestone Payments Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_MilestonePaymentsMember" xlink:to="label_plx_MilestonePaymentsMember_1" xlink:title="Label : plx_MilestonePaymentsMember to label_plx_MilestonePaymentsMember_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_MonthlyRentLeaseExpense" xlink:label="plx_MonthlyRentLeaseExpense" xlink:title="plx_MonthlyRentLeaseExpense" />
    <link:label xlink:type="resource" xlink:label="label_plx_MonthlyRentLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_MonthlyRentLeaseExpense" xml:lang="en-US" id="label_plx_MonthlyRentLeaseExpense">Monthly Rent Lease Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_MonthlyRentLeaseExpense" xlink:to="label_plx_MonthlyRentLeaseExpense" xlink:title="Label : plx_MonthlyRentLeaseExpense to label_plx_MonthlyRentLeaseExpense" />
    <link:label xlink:type="resource" xlink:label="label_plx_MonthlyRentLeaseExpense_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_MonthlyRentLeaseExpense_1" xml:lang="en-US" id="label_plx_MonthlyRentLeaseExpense_1">Monthly rent/lease expense.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_MonthlyRentLeaseExpense" xlink:to="label_plx_MonthlyRentLeaseExpense_1" xlink:title="Label : plx_MonthlyRentLeaseExpense to label_plx_MonthlyRentLeaseExpense_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_MonthlyRentLeaseExpense_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_MonthlyRentLeaseExpense_2" xml:lang="en-US" id="label_plx_MonthlyRentLeaseExpense_2">Monthly rent/lease expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_MonthlyRentLeaseExpense" xlink:to="label_plx_MonthlyRentLeaseExpense_2" xlink:title="Label : plx_MonthlyRentLeaseExpense to label_plx_MonthlyRentLeaseExpense_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_NinePointSixSixMember" xlink:label="plx_NinePointSixSixMember" xlink:title="plx_NinePointSixSixMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_NinePointSixSixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_NinePointSixSixMember" xml:lang="en-US" id="label_plx_NinePointSixSixMember">Nine Point Six Six [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_NinePointSixSixMember" xlink:to="label_plx_NinePointSixSixMember" xlink:title="Label : plx_NinePointSixSixMember to label_plx_NinePointSixSixMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_NinePointSixSixMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_NinePointSixSixMember_1" xml:lang="en-US" id="label_plx_NinePointSixSixMember_1">Nine Point Six Six [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_NinePointSixSixMember" xlink:to="label_plx_NinePointSixSixMember_1" xlink:title="Label : plx_NinePointSixSixMember to label_plx_NinePointSixSixMember_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_NinePointSixSixMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_NinePointSixSixMember_2" xml:lang="en-US" id="label_plx_NinePointSixSixMember_2">9.660 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_NinePointSixSixMember" xlink:to="label_plx_NinePointSixSixMember_2" xlink:title="Label : plx_NinePointSixSixMember to label_plx_NinePointSixSixMember_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_OCSMember" xlink:label="plx_OCSMember" xlink:title="plx_OCSMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_OCSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_OCSMember" xml:lang="en-US" id="label_plx_OCSMember">OCS [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OCSMember" xlink:to="label_plx_OCSMember" xlink:title="Label : plx_OCSMember to label_plx_OCSMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_OCSMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_OCSMember_1" xml:lang="en-US" id="label_plx_OCSMember_1">OCS Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OCSMember" xlink:to="label_plx_OCSMember_1" xlink:title="Label : plx_OCSMember to label_plx_OCSMember_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_OfficersAndCertainEmployeesMember" xlink:label="plx_OfficersAndCertainEmployeesMember" xlink:title="plx_OfficersAndCertainEmployeesMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_OfficersAndCertainEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_OfficersAndCertainEmployeesMember" xml:lang="en-US" id="label_plx_OfficersAndCertainEmployeesMember">Officers And Certain Employees [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OfficersAndCertainEmployeesMember" xlink:to="label_plx_OfficersAndCertainEmployeesMember" xlink:title="Label : plx_OfficersAndCertainEmployeesMember to label_plx_OfficersAndCertainEmployeesMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_OfficersAndCertainEmployeesMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_OfficersAndCertainEmployeesMember_1" xml:lang="en-US" id="label_plx_OfficersAndCertainEmployeesMember_1">Officers And Certain Employees Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OfficersAndCertainEmployeesMember" xlink:to="label_plx_OfficersAndCertainEmployeesMember_1" xlink:title="Label : plx_OfficersAndCertainEmployeesMember to label_plx_OfficersAndCertainEmployeesMember_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_OfficersAndDirectorsInPrivateTransactionMember" xlink:label="plx_OfficersAndDirectorsInPrivateTransactionMember" xlink:title="plx_OfficersAndDirectorsInPrivateTransactionMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_OfficersAndDirectorsInPrivateTransactionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_OfficersAndDirectorsInPrivateTransactionMember" xml:lang="en-US" id="label_plx_OfficersAndDirectorsInPrivateTransactionMember">Officers And Directors In Private Transaction [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OfficersAndDirectorsInPrivateTransactionMember" xlink:to="label_plx_OfficersAndDirectorsInPrivateTransactionMember" xlink:title="Label : plx_OfficersAndDirectorsInPrivateTransactionMember to label_plx_OfficersAndDirectorsInPrivateTransactionMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_OfficersAndDirectorsInPrivateTransactionMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_OfficersAndDirectorsInPrivateTransactionMember_1" xml:lang="en-US" id="label_plx_OfficersAndDirectorsInPrivateTransactionMember_1">Officers And Directors In Private Transaction [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OfficersAndDirectorsInPrivateTransactionMember" xlink:to="label_plx_OfficersAndDirectorsInPrivateTransactionMember_1" xlink:title="Label : plx_OfficersAndDirectorsInPrivateTransactionMember to label_plx_OfficersAndDirectorsInPrivateTransactionMember_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_OneSixPointSevenMember" xlink:label="plx_OneSixPointSevenMember" xlink:title="plx_OneSixPointSevenMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_OneSixPointSevenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_OneSixPointSevenMember" xml:lang="en-US" id="label_plx_OneSixPointSevenMember">One Six Point Seven [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OneSixPointSevenMember" xlink:to="label_plx_OneSixPointSevenMember" xlink:title="Label : plx_OneSixPointSevenMember to label_plx_OneSixPointSevenMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_OneSixPointSevenMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_OneSixPointSevenMember_1" xml:lang="en-US" id="label_plx_OneSixPointSevenMember_1">One Six Point Seven Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OneSixPointSevenMember" xlink:to="label_plx_OneSixPointSevenMember_1" xlink:title="Label : plx_OneSixPointSevenMember to label_plx_OneSixPointSevenMember_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_OneSixPointSevenMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_OneSixPointSevenMember_2" xml:lang="en-US" id="label_plx_OneSixPointSevenMember_2">16.700 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OneSixPointSevenMember" xlink:to="label_plx_OneSixPointSevenMember_2" xlink:title="Label : plx_OneSixPointSevenMember to label_plx_OneSixPointSevenMember_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_OptionsAndRestrictedStockGrantedToEmployeesMember" xlink:label="plx_OptionsAndRestrictedStockGrantedToEmployeesMember" xlink:title="plx_OptionsAndRestrictedStockGrantedToEmployeesMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_OptionsAndRestrictedStockGrantedToEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_OptionsAndRestrictedStockGrantedToEmployeesMember" xml:lang="en-US" id="label_plx_OptionsAndRestrictedStockGrantedToEmployeesMember">Options And Restricted Stock Granted To Employees [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OptionsAndRestrictedStockGrantedToEmployeesMember" xlink:to="label_plx_OptionsAndRestrictedStockGrantedToEmployeesMember" xlink:title="Label : plx_OptionsAndRestrictedStockGrantedToEmployeesMember to label_plx_OptionsAndRestrictedStockGrantedToEmployeesMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_OptionsAndRestrictedStockGrantedToEmployeesMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_OptionsAndRestrictedStockGrantedToEmployeesMember_1" xml:lang="en-US" id="label_plx_OptionsAndRestrictedStockGrantedToEmployeesMember_1">Options And Restricted Stock Granted To Employees Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OptionsAndRestrictedStockGrantedToEmployeesMember" xlink:to="label_plx_OptionsAndRestrictedStockGrantedToEmployeesMember_1" xlink:title="Label : plx_OptionsAndRestrictedStockGrantedToEmployeesMember to label_plx_OptionsAndRestrictedStockGrantedToEmployeesMember_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xml:lang="en-US" id="label_us-gaap_ArrangementsAndNonarrangementTransactionsMember">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="label_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:title="Label : us-gaap_ArrangementsAndNonarrangementTransactionsMember to label_us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_OptionsAndRestrictedStockMember" xlink:label="plx_OptionsAndRestrictedStockMember" xlink:title="plx_OptionsAndRestrictedStockMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_OptionsAndRestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_OptionsAndRestrictedStockMember" xml:lang="en-US" id="label_plx_OptionsAndRestrictedStockMember">Options And Restricted Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OptionsAndRestrictedStockMember" xlink:to="label_plx_OptionsAndRestrictedStockMember" xlink:title="Label : plx_OptionsAndRestrictedStockMember to label_plx_OptionsAndRestrictedStockMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_OptionsAndRestrictedStockMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_OptionsAndRestrictedStockMember_1" xml:lang="en-US" id="label_plx_OptionsAndRestrictedStockMember_1">Options And Restricted Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OptionsAndRestrictedStockMember" xlink:to="label_plx_OptionsAndRestrictedStockMember_1" xlink:title="Label : plx_OptionsAndRestrictedStockMember to label_plx_OptionsAndRestrictedStockMember_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" xlink:label="plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" xlink:title="plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" xml:lang="en-US" id="label_plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember">Options Granted To Consultants Directors And Other Service Providers [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" xlink:to="label_plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" xlink:title="Label : plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember to label_plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember_1" xml:lang="en-US" id="label_plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember_1">Options Granted To Consultants, Directors And Other Service Providers Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" xlink:to="label_plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember_1" xlink:title="Label : plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember to label_plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ProbableAggregateMilestonePaymentMember" xlink:label="plx_ProbableAggregateMilestonePaymentMember" xlink:title="plx_ProbableAggregateMilestonePaymentMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_ProbableAggregateMilestonePaymentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_ProbableAggregateMilestonePaymentMember" xml:lang="en-US" id="label_plx_ProbableAggregateMilestonePaymentMember">Probable Aggregate Milestone Payment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProbableAggregateMilestonePaymentMember" xlink:to="label_plx_ProbableAggregateMilestonePaymentMember" xlink:title="Label : plx_ProbableAggregateMilestonePaymentMember to label_plx_ProbableAggregateMilestonePaymentMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_ProbableAggregateMilestonePaymentMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_ProbableAggregateMilestonePaymentMember_1" xml:lang="en-US" id="label_plx_ProbableAggregateMilestonePaymentMember_1">Probable Aggregate Milestone Payment Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProbableAggregateMilestonePaymentMember" xlink:to="label_plx_ProbableAggregateMilestonePaymentMember_1" xlink:title="Label : plx_ProbableAggregateMilestonePaymentMember to label_plx_ProbableAggregateMilestonePaymentMember_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses" xlink:label="plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses" xlink:title="plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses" />
    <link:label xlink:type="resource" xlink:label="label_plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses" xml:lang="en-US" id="label_plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses">Proceeds From Issuance Of Common Stock Net Of Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses" xlink:to="label_plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses" xlink:title="Label : plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses to label_plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses" />
    <link:label xlink:type="resource" xlink:label="label_plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses_1" xml:lang="en-US" id="label_plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses_1">Proceeds from issuance of common stock net of expenses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses" xlink:to="label_plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses_1" xlink:title="Label : plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses to label_plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses_2" xml:lang="en-US" id="label_plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses_2">Issuance of shares, net of issuance cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses" xlink:to="label_plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses_2" xlink:title="Label : plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses to label_plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ProductsManufacturedOutsideOfIsraelMember" xlink:label="plx_ProductsManufacturedOutsideOfIsraelMember" xlink:title="plx_ProductsManufacturedOutsideOfIsraelMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_ProductsManufacturedOutsideOfIsraelMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_ProductsManufacturedOutsideOfIsraelMember" xml:lang="en-US" id="label_plx_ProductsManufacturedOutsideOfIsraelMember">Products Manufactured Outside Of Israel [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProductsManufacturedOutsideOfIsraelMember" xlink:to="label_plx_ProductsManufacturedOutsideOfIsraelMember" xlink:title="Label : plx_ProductsManufacturedOutsideOfIsraelMember to label_plx_ProductsManufacturedOutsideOfIsraelMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_ProductsManufacturedOutsideOfIsraelMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_ProductsManufacturedOutsideOfIsraelMember_1" xml:lang="en-US" id="label_plx_ProductsManufacturedOutsideOfIsraelMember_1">Products Manufactured Outside Of Israel Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProductsManufacturedOutsideOfIsraelMember" xlink:to="label_plx_ProductsManufacturedOutsideOfIsraelMember_1" xlink:title="Label : plx_ProductsManufacturedOutsideOfIsraelMember to label_plx_ProductsManufacturedOutsideOfIsraelMember_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ResearchAndLicenseAgreementsMember" xlink:label="plx_ResearchAndLicenseAgreementsMember" xlink:title="plx_ResearchAndLicenseAgreementsMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_ResearchAndLicenseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_ResearchAndLicenseAgreementsMember" xml:lang="en-US" id="label_plx_ResearchAndLicenseAgreementsMember">Research And License Agreements [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ResearchAndLicenseAgreementsMember" xlink:to="label_plx_ResearchAndLicenseAgreementsMember" xlink:title="Label : plx_ResearchAndLicenseAgreementsMember to label_plx_ResearchAndLicenseAgreementsMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_ResearchAndLicenseAgreementsMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_ResearchAndLicenseAgreementsMember_1" xml:lang="en-US" id="label_plx_ResearchAndLicenseAgreementsMember_1">Research And License Agreements Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ResearchAndLicenseAgreementsMember" xlink:to="label_plx_ResearchAndLicenseAgreementsMember_1" xlink:title="Label : plx_ResearchAndLicenseAgreementsMember to label_plx_ResearchAndLicenseAgreementsMember_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_RestrictedAmountMember" xlink:label="plx_RestrictedAmountMember" xlink:title="plx_RestrictedAmountMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_RestrictedAmountMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_RestrictedAmountMember" xml:lang="en-US" id="label_plx_RestrictedAmountMember">Restricted Amount [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_RestrictedAmountMember" xlink:to="label_plx_RestrictedAmountMember" xlink:title="Label : plx_RestrictedAmountMember to label_plx_RestrictedAmountMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_RestrictedAmountMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_RestrictedAmountMember_1" xml:lang="en-US" id="label_plx_RestrictedAmountMember_1">Restricted Amount Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_RestrictedAmountMember" xlink:to="label_plx_RestrictedAmountMember_1" xlink:title="Label : plx_RestrictedAmountMember to label_plx_RestrictedAmountMember_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_RoyaltiesOnSaleOfProducts" xlink:label="plx_RoyaltiesOnSaleOfProducts" xlink:title="plx_RoyaltiesOnSaleOfProducts" />
    <link:label xlink:type="resource" xlink:label="label_plx_RoyaltiesOnSaleOfProducts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_RoyaltiesOnSaleOfProducts" xml:lang="en-US" id="label_plx_RoyaltiesOnSaleOfProducts">Royalties On Sale Of Products</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_RoyaltiesOnSaleOfProducts" xlink:to="label_plx_RoyaltiesOnSaleOfProducts" xlink:title="Label : plx_RoyaltiesOnSaleOfProducts to label_plx_RoyaltiesOnSaleOfProducts" />
    <link:label xlink:type="resource" xlink:label="label_plx_RoyaltiesOnSaleOfProducts_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_RoyaltiesOnSaleOfProducts_1" xml:lang="en-US" id="label_plx_RoyaltiesOnSaleOfProducts_1">Percentage of royalties based on sale of products developed from projects funded.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_RoyaltiesOnSaleOfProducts" xlink:to="label_plx_RoyaltiesOnSaleOfProducts_1" xlink:title="Label : plx_RoyaltiesOnSaleOfProducts to label_plx_RoyaltiesOnSaleOfProducts_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_RoyaltiesOnSaleOfProducts_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_RoyaltiesOnSaleOfProducts_2" xml:lang="en-US" id="label_plx_RoyaltiesOnSaleOfProducts_2">Royalties based on sale of products developed from funded projects, percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_RoyaltiesOnSaleOfProducts" xlink:to="label_plx_RoyaltiesOnSaleOfProducts_2" xlink:title="Label : plx_RoyaltiesOnSaleOfProducts to label_plx_RoyaltiesOnSaleOfProducts_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:title="dei_TradingSymbol" />
    <link:label xlink:type="resource" xlink:label="label_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_dei_TradingSymbol" xml:lang="en-US" id="label_dei_TradingSymbol">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="label_dei_TradingSymbol" xlink:title="Label : dei_TradingSymbol to label_dei_TradingSymbol" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ScenarioOneMember" xlink:label="plx_ScenarioOneMember" xlink:title="plx_ScenarioOneMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_ScenarioOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_ScenarioOneMember" xml:lang="en-US" id="label_plx_ScenarioOneMember">Scenario One [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ScenarioOneMember" xlink:to="label_plx_ScenarioOneMember" xlink:title="Label : plx_ScenarioOneMember to label_plx_ScenarioOneMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_ScenarioOneMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_ScenarioOneMember_1" xml:lang="en-US" id="label_plx_ScenarioOneMember_1">Scenario One [Member].</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ScenarioOneMember" xlink:to="label_plx_ScenarioOneMember_1" xlink:title="Label : plx_ScenarioOneMember to label_plx_ScenarioOneMember_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_ScenarioOneMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_ScenarioOneMember_2" xml:lang="en-US" id="label_plx_ScenarioOneMember_2">Upon each FDA and European Medicine Agency approval [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ScenarioOneMember" xlink:to="label_plx_ScenarioOneMember_2" xlink:title="Label : plx_ScenarioOneMember to label_plx_ScenarioOneMember_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ScheduleOfOpenTaxYearsTableTextBlock" xlink:label="plx_ScheduleOfOpenTaxYearsTableTextBlock" xlink:title="plx_ScheduleOfOpenTaxYearsTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_plx_ScheduleOfOpenTaxYearsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_ScheduleOfOpenTaxYearsTableTextBlock" xml:lang="en-US" id="label_plx_ScheduleOfOpenTaxYearsTableTextBlock">Schedule Of Open Tax Years [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ScheduleOfOpenTaxYearsTableTextBlock" xlink:to="label_plx_ScheduleOfOpenTaxYearsTableTextBlock" xlink:title="Label : plx_ScheduleOfOpenTaxYearsTableTextBlock to label_plx_ScheduleOfOpenTaxYearsTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_plx_ScheduleOfOpenTaxYearsTableTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_ScheduleOfOpenTaxYearsTableTextBlock_1" xml:lang="en-US" id="label_plx_ScheduleOfOpenTaxYearsTableTextBlock_1">Schedule Of Open Tax Years Table Text Block</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ScheduleOfOpenTaxYearsTableTextBlock" xlink:to="label_plx_ScheduleOfOpenTaxYearsTableTextBlock_1" xlink:title="Label : plx_ScheduleOfOpenTaxYearsTableTextBlock to label_plx_ScheduleOfOpenTaxYearsTableTextBlock_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_ScheduleOfOpenTaxYearsTableTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_ScheduleOfOpenTaxYearsTableTextBlock_2" xml:lang="en-US" id="label_plx_ScheduleOfOpenTaxYearsTableTextBlock_2">Schedule of Open Tax Years</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ScheduleOfOpenTaxYearsTableTextBlock" xlink:to="label_plx_ScheduleOfOpenTaxYearsTableTextBlock_2" xlink:title="Label : plx_ScheduleOfOpenTaxYearsTableTextBlock to label_plx_ScheduleOfOpenTaxYearsTableTextBlock_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock" xlink:label="plx_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock" xlink:title="plx_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_plx_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock" xml:lang="en-US" id="label_plx_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock">Schedule Of Options And Restricted Stocks Granted [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock" xlink:to="label_plx_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock" xlink:title="Label : plx_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock to label_plx_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_plx_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock_1" xml:lang="en-US" id="label_plx_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock_1">Schedule of Options and Restricted Stocks Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock" xlink:to="label_plx_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock_1" xlink:title="Label : plx_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock to label_plx_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_SevenPointFiveFiveMember" xlink:label="plx_SevenPointFiveFiveMember" xlink:title="plx_SevenPointFiveFiveMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_SevenPointFiveFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_SevenPointFiveFiveMember" xml:lang="en-US" id="label_plx_SevenPointFiveFiveMember">Seven Point Five Five [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SevenPointFiveFiveMember" xlink:to="label_plx_SevenPointFiveFiveMember" xlink:title="Label : plx_SevenPointFiveFiveMember to label_plx_SevenPointFiveFiveMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_SevenPointFiveFiveMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_SevenPointFiveFiveMember_1" xml:lang="en-US" id="label_plx_SevenPointFiveFiveMember_1">Seven Point Five Five Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SevenPointFiveFiveMember" xlink:to="label_plx_SevenPointFiveFiveMember_1" xlink:title="Label : plx_SevenPointFiveFiveMember to label_plx_SevenPointFiveFiveMember_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_SevenPointFiveFiveMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_SevenPointFiveFiveMember_2" xml:lang="en-US" id="label_plx_SevenPointFiveFiveMember_2">7.550 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SevenPointFiveFiveMember" xlink:to="label_plx_SevenPointFiveFiveMember_2" xlink:title="Label : plx_SevenPointFiveFiveMember to label_plx_SevenPointFiveFiveMember_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:title="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" />
    <link:label xlink:type="resource" xlink:label="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xml:lang="en-US" id="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue">Share Based Compensation Arrangement By Share Based Payment Award Grant Date Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:to="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:title="Label : plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue to label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" />
    <link:label xlink:type="resource" xlink:label="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_1" xml:lang="en-US" id="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_1">Share based compensation arrangement by share based payment award grant date fair value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:to="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_1" xlink:title="Label : plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue to label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_2" xml:lang="en-US" id="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_2">Fair value of at grant date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:to="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_2" xlink:title="Label : plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue to label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_2" />
    <link:label xlink:type="resource" xlink:label="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_3" xml:lang="en-US" id="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_3">Fair value of option on the date of grant</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:to="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_3" xlink:title="Label : plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue to label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_3" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" xlink:title="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" />
    <link:label xlink:type="resource" xlink:label="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" xml:lang="en-US" id="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm">Share based compensation arrangement by share based payment award granted contractual term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" xlink:to="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" xlink:title="Label : plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm to label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" />
    <link:label xlink:type="resource" xlink:label="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm_1" xml:lang="en-US" id="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm_1">Shares of common stock issued, lock up period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" xlink:to="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm_1" xlink:title="Label : plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm to label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm_2" xml:lang="en-US" id="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm_2">Share Based Compensation Arrangement By Share Based Payment Award Granted Contractual Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" xlink:to="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm_2" xlink:title="Label : plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm to label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm_2" />
    <link:label xlink:type="resource" xlink:label="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm_3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm_3" xml:lang="en-US" id="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm_3">Expiration period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" xlink:to="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm_3" xlink:title="Label : plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm to label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm_3" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod" xlink:title="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod" />
    <link:label xlink:type="resource" xlink:label="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod" xml:lang="en-US" id="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod">Share Based Compensation Arrangement By Share Based Payment Award Number Of Installments For Vesting Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod" xlink:to="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod" xlink:title="Label : plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod to label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod" />
    <link:label xlink:type="resource" xlink:label="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod_1" xml:lang="en-US" id="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod_1">Share based compensation arrangement by share based payment award number of installments for vesting period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod" xlink:to="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod_1" xlink:title="Label : plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod to label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod_2" xml:lang="en-US" id="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod_2">Number of installments for vesting of stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod" xlink:to="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod_2" xlink:title="Label : plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod to label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="plx_SignificantAccountingPoliciesLineItems" xlink:title="plx_SignificantAccountingPoliciesLineItems" />
    <link:label xlink:type="resource" xlink:label="label_plx_SignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_SignificantAccountingPoliciesLineItems" xml:lang="en-US" id="label_plx_SignificantAccountingPoliciesLineItems">Significant Accounting Policies [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="label_plx_SignificantAccountingPoliciesLineItems" xlink:title="Label : plx_SignificantAccountingPoliciesLineItems to label_plx_SignificantAccountingPoliciesLineItems" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="plx_SignificantAccountingPoliciesTable" xlink:title="plx_SignificantAccountingPoliciesTable" />
    <link:label xlink:type="resource" xlink:label="label_plx_SignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_SignificantAccountingPoliciesTable" xml:lang="en-US" id="label_plx_SignificantAccountingPoliciesTable">Significant Accounting Policies [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="label_plx_SignificantAccountingPoliciesTable" xlink:title="Label : plx_SignificantAccountingPoliciesTable to label_plx_SignificantAccountingPoliciesTable" />
    <link:label xlink:type="resource" xlink:label="label_plx_SignificantAccountingPoliciesTable_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_SignificantAccountingPoliciesTable_1" xml:lang="en-US" id="label_plx_SignificantAccountingPoliciesTable_1">Significant Accounting Policies [Table].</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="label_plx_SignificantAccountingPoliciesTable_1" xlink:title="Label : plx_SignificantAccountingPoliciesTable to label_plx_SignificantAccountingPoliciesTable_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_SixPointEightOneZeroMember" xlink:label="plx_SixPointEightOneZeroMember" xlink:title="plx_SixPointEightOneZeroMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_SixPointEightOneZeroMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_SixPointEightOneZeroMember" xml:lang="en-US" id="label_plx_SixPointEightOneZeroMember">Six Point Eight One Zero [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SixPointEightOneZeroMember" xlink:to="label_plx_SixPointEightOneZeroMember" xlink:title="Label : plx_SixPointEightOneZeroMember to label_plx_SixPointEightOneZeroMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_SixPointEightOneZeroMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_SixPointEightOneZeroMember_1" xml:lang="en-US" id="label_plx_SixPointEightOneZeroMember_1">Six Point Eight One Zero Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SixPointEightOneZeroMember" xlink:to="label_plx_SixPointEightOneZeroMember_1" xlink:title="Label : plx_SixPointEightOneZeroMember to label_plx_SixPointEightOneZeroMember_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_SixPointEightOneZeroMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_SixPointEightOneZeroMember_2" xml:lang="en-US" id="label_plx_SixPointEightOneZeroMember_2">6.810 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SixPointEightOneZeroMember" xlink:to="label_plx_SixPointEightOneZeroMember_2" xlink:title="Label : plx_SixPointEightOneZeroMember to label_plx_SixPointEightOneZeroMember_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_SixPointNineMember" xlink:label="plx_SixPointNineMember" xlink:title="plx_SixPointNineMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_SixPointNineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_SixPointNineMember" xml:lang="en-US" id="label_plx_SixPointNineMember">Six Point Nine [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SixPointNineMember" xlink:to="label_plx_SixPointNineMember" xlink:title="Label : plx_SixPointNineMember to label_plx_SixPointNineMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_SixPointNineMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_SixPointNineMember_1" xml:lang="en-US" id="label_plx_SixPointNineMember_1">Six Point Nine Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SixPointNineMember" xlink:to="label_plx_SixPointNineMember_1" xlink:title="Label : plx_SixPointNineMember to label_plx_SixPointNineMember_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_SixPointNineMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_SixPointNineMember_2" xml:lang="en-US" id="label_plx_SixPointNineMember_2">6.900 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SixPointNineMember" xlink:to="label_plx_SixPointNineMember_2" xlink:title="Label : plx_SixPointNineMember to label_plx_SixPointNineMember_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_StockOptionsAndRestrictedSharesMember" xlink:label="plx_StockOptionsAndRestrictedSharesMember" xlink:title="plx_StockOptionsAndRestrictedSharesMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_StockOptionsAndRestrictedSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_StockOptionsAndRestrictedSharesMember" xml:lang="en-US" id="label_plx_StockOptionsAndRestrictedSharesMember">Stock Options And Restricted Shares [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_StockOptionsAndRestrictedSharesMember" xlink:to="label_plx_StockOptionsAndRestrictedSharesMember" xlink:title="Label : plx_StockOptionsAndRestrictedSharesMember to label_plx_StockOptionsAndRestrictedSharesMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_StockOptionsAndRestrictedSharesMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_StockOptionsAndRestrictedSharesMember_1" xml:lang="en-US" id="label_plx_StockOptionsAndRestrictedSharesMember_1">Stock Options And Restricted Shares [Member].</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_StockOptionsAndRestrictedSharesMember" xlink:to="label_plx_StockOptionsAndRestrictedSharesMember_1" xlink:title="Label : plx_StockOptionsAndRestrictedSharesMember to label_plx_StockOptionsAndRestrictedSharesMember_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_StockOptionsAndRestrictedSharesMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_StockOptionsAndRestrictedSharesMember_2" xml:lang="en-US" id="label_plx_StockOptionsAndRestrictedSharesMember_2">Options and Restricted Shares [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_StockOptionsAndRestrictedSharesMember" xlink:to="label_plx_StockOptionsAndRestrictedSharesMember_2" xlink:title="Label : plx_StockOptionsAndRestrictedSharesMember to label_plx_StockOptionsAndRestrictedSharesMember_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:title="dei_EntityWellKnownSeasonedIssuer" />
    <link:label xlink:type="resource" xlink:label="label_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_dei_EntityWellKnownSeasonedIssuer" xml:lang="en-US" id="label_dei_EntityWellKnownSeasonedIssuer">Entity Well Known Seasoned Issuer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="label_dei_EntityWellKnownSeasonedIssuer" xlink:title="Label : dei_EntityWellKnownSeasonedIssuer to label_dei_EntityWellKnownSeasonedIssuer" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_SupplementalInformationAbstract" xlink:label="plx_SupplementalInformationAbstract" xlink:title="plx_SupplementalInformationAbstract" />
    <link:label xlink:type="resource" xlink:label="label_plx_SupplementalInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_SupplementalInformationAbstract" xml:lang="en-US" id="label_plx_SupplementalInformationAbstract">SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SupplementalInformationAbstract" xlink:to="label_plx_SupplementalInformationAbstract" xlink:title="Label : plx_SupplementalInformationAbstract to label_plx_SupplementalInformationAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:title="dei_EntityVoluntaryFilers" />
    <link:label xlink:type="resource" xlink:label="label_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_dei_EntityVoluntaryFilers" xml:lang="en-US" id="label_dei_EntityVoluntaryFilers">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="label_dei_EntityVoluntaryFilers" xlink:title="Label : dei_EntityVoluntaryFilers to label_dei_EntityVoluntaryFilers" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_SupplementalInformationRevenueAxis" xlink:label="plx_SupplementalInformationRevenueAxis" xlink:title="plx_SupplementalInformationRevenueAxis" />
    <link:label xlink:type="resource" xlink:label="label_plx_SupplementalInformationRevenueAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_SupplementalInformationRevenueAxis" xml:lang="en-US" id="label_plx_SupplementalInformationRevenueAxis">Supplemental Information Revenue [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SupplementalInformationRevenueAxis" xlink:to="label_plx_SupplementalInformationRevenueAxis" xlink:title="Label : plx_SupplementalInformationRevenueAxis to label_plx_SupplementalInformationRevenueAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:title="dei_EntityCurrentReportingStatus" />
    <link:label xlink:type="resource" xlink:label="label_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_dei_EntityCurrentReportingStatus" xml:lang="en-US" id="label_dei_EntityCurrentReportingStatus">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="label_dei_EntityCurrentReportingStatus" xlink:title="Label : dei_EntityCurrentReportingStatus to label_dei_EntityCurrentReportingStatus" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:title="dei_EntityFilerCategory" />
    <link:label xlink:type="resource" xlink:label="label_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_dei_EntityFilerCategory" xml:lang="en-US" id="label_dei_EntityFilerCategory">Entity Filer Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="label_dei_EntityFilerCategory" xlink:title="Label : dei_EntityFilerCategory to label_dei_EntityFilerCategory" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_SupplementalOfferingAndStockIssuanceCosts" xlink:label="plx_SupplementalOfferingAndStockIssuanceCosts" xlink:title="plx_SupplementalOfferingAndStockIssuanceCosts" />
    <link:label xlink:type="resource" xlink:label="label_plx_SupplementalOfferingAndStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_SupplementalOfferingAndStockIssuanceCosts" xml:lang="en-US" id="label_plx_SupplementalOfferingAndStockIssuanceCosts">Supplemental Offering And Stock Issuance Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SupplementalOfferingAndStockIssuanceCosts" xlink:to="label_plx_SupplementalOfferingAndStockIssuanceCosts" xlink:title="Label : plx_SupplementalOfferingAndStockIssuanceCosts to label_plx_SupplementalOfferingAndStockIssuanceCosts" />
    <link:label xlink:type="resource" xlink:label="label_plx_SupplementalOfferingAndStockIssuanceCosts_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_SupplementalOfferingAndStockIssuanceCosts_1" xml:lang="en-US" id="label_plx_SupplementalOfferingAndStockIssuanceCosts_1">Supplemental offering and stock issuance costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SupplementalOfferingAndStockIssuanceCosts" xlink:to="label_plx_SupplementalOfferingAndStockIssuanceCosts_1" xlink:title="Label : plx_SupplementalOfferingAndStockIssuanceCosts to label_plx_SupplementalOfferingAndStockIssuanceCosts_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_SupplementalOfferingAndStockIssuanceCosts_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_SupplementalOfferingAndStockIssuanceCosts_2" xml:lang="en-US" id="label_plx_SupplementalOfferingAndStockIssuanceCosts_2">Issuance cost not yet paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SupplementalOfferingAndStockIssuanceCosts" xlink:to="label_plx_SupplementalOfferingAndStockIssuanceCosts_2" xlink:title="Label : plx_SupplementalOfferingAndStockIssuanceCosts to label_plx_SupplementalOfferingAndStockIssuanceCosts_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xlink:title="dei_EntityPublicFloat" />
    <link:label xlink:type="resource" xlink:label="label_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_dei_EntityPublicFloat" xml:lang="en-US" id="label_dei_EntityPublicFloat">Entity Public Float</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="label_dei_EntityPublicFloat" xlink:title="Label : dei_EntityPublicFloat to label_dei_EntityPublicFloat" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_SupplementaryBalanceSheetsInformationTableTextBlock" xlink:label="plx_SupplementaryBalanceSheetsInformationTableTextBlock" xlink:title="plx_SupplementaryBalanceSheetsInformationTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_plx_SupplementaryBalanceSheetsInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_SupplementaryBalanceSheetsInformationTableTextBlock" xml:lang="en-US" id="label_plx_SupplementaryBalanceSheetsInformationTableTextBlock">Supplementary Balance Sheets Information [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SupplementaryBalanceSheetsInformationTableTextBlock" xlink:to="label_plx_SupplementaryBalanceSheetsInformationTableTextBlock" xlink:title="Label : plx_SupplementaryBalanceSheetsInformationTableTextBlock to label_plx_SupplementaryBalanceSheetsInformationTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_plx_SupplementaryBalanceSheetsInformationTableTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_SupplementaryBalanceSheetsInformationTableTextBlock_1" xml:lang="en-US" id="label_plx_SupplementaryBalanceSheetsInformationTableTextBlock_1">Supplementary Balance Sheets Information Table Text Block</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SupplementaryBalanceSheetsInformationTableTextBlock" xlink:to="label_plx_SupplementaryBalanceSheetsInformationTableTextBlock_1" xlink:title="Label : plx_SupplementaryBalanceSheetsInformationTableTextBlock to label_plx_SupplementaryBalanceSheetsInformationTableTextBlock_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_SupplementaryBalanceSheetsInformationTableTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_SupplementaryBalanceSheetsInformationTableTextBlock_2" xml:lang="en-US" id="label_plx_SupplementaryBalanceSheetsInformationTableTextBlock_2">Supplemental Information, Balance Sheets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SupplementaryBalanceSheetsInformationTableTextBlock" xlink:to="label_plx_SupplementaryBalanceSheetsInformationTableTextBlock_2" xlink:title="Label : plx_SupplementaryBalanceSheetsInformationTableTextBlock to label_plx_SupplementaryBalanceSheetsInformationTableTextBlock_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:title="dei_EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="label_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_dei_EntityRegistrantName" xml:lang="en-US" id="label_dei_EntityRegistrantName">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="label_dei_EntityRegistrantName" xlink:title="Label : dei_EntityRegistrantName to label_dei_EntityRegistrantName" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_SupplementaryIncomeStatementInformationTableTextBlock" xlink:label="plx_SupplementaryIncomeStatementInformationTableTextBlock" xlink:title="plx_SupplementaryIncomeStatementInformationTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_plx_SupplementaryIncomeStatementInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_SupplementaryIncomeStatementInformationTableTextBlock" xml:lang="en-US" id="label_plx_SupplementaryIncomeStatementInformationTableTextBlock">Supplementary Income Statement Information [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SupplementaryIncomeStatementInformationTableTextBlock" xlink:to="label_plx_SupplementaryIncomeStatementInformationTableTextBlock" xlink:title="Label : plx_SupplementaryIncomeStatementInformationTableTextBlock to label_plx_SupplementaryIncomeStatementInformationTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_plx_SupplementaryIncomeStatementInformationTableTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_SupplementaryIncomeStatementInformationTableTextBlock_1" xml:lang="en-US" id="label_plx_SupplementaryIncomeStatementInformationTableTextBlock_1">Supplementary Income Statement Information [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SupplementaryIncomeStatementInformationTableTextBlock" xlink:to="label_plx_SupplementaryIncomeStatementInformationTableTextBlock_1" xlink:title="Label : plx_SupplementaryIncomeStatementInformationTableTextBlock to label_plx_SupplementaryIncomeStatementInformationTableTextBlock_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_SupplementaryIncomeStatementInformationTableTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_SupplementaryIncomeStatementInformationTableTextBlock_2" xml:lang="en-US" id="label_plx_SupplementaryIncomeStatementInformationTableTextBlock_2">Supplemental Information, Income Statement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SupplementaryIncomeStatementInformationTableTextBlock" xlink:to="label_plx_SupplementaryIncomeStatementInformationTableTextBlock_2" xlink:title="Label : plx_SupplementaryIncomeStatementInformationTableTextBlock to label_plx_SupplementaryIncomeStatementInformationTableTextBlock_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:title="dei_EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="label_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_dei_EntityCentralIndexKey" xml:lang="en-US" id="label_dei_EntityCentralIndexKey">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="label_dei_EntityCentralIndexKey" xlink:title="Label : dei_EntityCentralIndexKey to label_dei_EntityCentralIndexKey" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_TaxBurdenDistributionLawMember" xlink:label="plx_TaxBurdenDistributionLawMember" xlink:title="plx_TaxBurdenDistributionLawMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_TaxBurdenDistributionLawMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_TaxBurdenDistributionLawMember" xml:lang="en-US" id="label_plx_TaxBurdenDistributionLawMember">Tax Burden Distribution Law [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_TaxBurdenDistributionLawMember" xlink:to="label_plx_TaxBurdenDistributionLawMember" xlink:title="Label : plx_TaxBurdenDistributionLawMember to label_plx_TaxBurdenDistributionLawMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_TaxBurdenDistributionLawMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_TaxBurdenDistributionLawMember_1" xml:lang="en-US" id="label_plx_TaxBurdenDistributionLawMember_1">Tax Burden Distribution Law Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_TaxBurdenDistributionLawMember" xlink:to="label_plx_TaxBurdenDistributionLawMember_1" xlink:title="Label : plx_TaxBurdenDistributionLawMember to label_plx_TaxBurdenDistributionLawMember_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal" xlink:label="plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal" xlink:title="plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal" />
    <link:label xlink:type="resource" xlink:label="label_plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal" xml:lang="en-US" id="label_plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal">Tax Rate Assumption Related To Deferred Tax Difference Reversal</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal" xlink:to="label_plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal" xlink:title="Label : plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal to label_plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal" />
    <link:label xlink:type="resource" xlink:label="label_plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal_1" xml:lang="en-US" id="label_plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal_1">Deferred taxes are computed using the tax rates expected to be in effect when those differences reverse.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal" xlink:to="label_plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal_1" xlink:title="Label : plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal to label_plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal_2" xml:lang="en-US" id="label_plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal_2">Tax rates expected to be in effect when deferred tax asset differences reverse</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal" xlink:to="label_plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal_2" xlink:title="Label : plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal to label_plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_TaxYearThereafterMember" xlink:label="plx_TaxYearThereafterMember" xlink:title="plx_TaxYearThereafterMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_TaxYearThereafterMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_TaxYearThereafterMember" xml:lang="en-US" id="label_plx_TaxYearThereafterMember">Tax Year Thereafter [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_TaxYearThereafterMember" xlink:to="label_plx_TaxYearThereafterMember" xlink:title="Label : plx_TaxYearThereafterMember to label_plx_TaxYearThereafterMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_TaxYearThereafterMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_TaxYearThereafterMember_1" xml:lang="en-US" id="label_plx_TaxYearThereafterMember_1">Law for Amending the Israel Income Tax Ordinance, Tax Thereafter [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_TaxYearThereafterMember" xlink:to="label_plx_TaxYearThereafterMember_1" xlink:title="Label : plx_TaxYearThereafterMember to label_plx_TaxYearThereafterMember_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_TaxYearTwoThousandNineMember" xlink:label="plx_TaxYearTwoThousandNineMember" xlink:title="plx_TaxYearTwoThousandNineMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_TaxYearTwoThousandNineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_TaxYearTwoThousandNineMember" xml:lang="en-US" id="label_plx_TaxYearTwoThousandNineMember">Tax Year Two Thousand Nine [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_TaxYearTwoThousandNineMember" xlink:to="label_plx_TaxYearTwoThousandNineMember" xlink:title="Label : plx_TaxYearTwoThousandNineMember to label_plx_TaxYearTwoThousandNineMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_TaxYearTwoThousandNineMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_TaxYearTwoThousandNineMember_1" xml:lang="en-US" id="label_plx_TaxYearTwoThousandNineMember_1">Law for Amending the Israel Income Tax Ordinance - 2009, Tax year [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_TaxYearTwoThousandNineMember" xlink:to="label_plx_TaxYearTwoThousandNineMember_1" xlink:title="Label : plx_TaxYearTwoThousandNineMember to label_plx_TaxYearTwoThousandNineMember_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:title="dei_EntityCommonStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="label_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US" id="label_dei_EntityCommonStockSharesOutstanding">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="label_dei_EntityCommonStockSharesOutstanding" xlink:title="Label : dei_EntityCommonStockSharesOutstanding to label_dei_EntityCommonStockSharesOutstanding" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ThreePointZeroTwoZeroMember" xlink:label="plx_ThreePointZeroTwoZeroMember" xlink:title="plx_ThreePointZeroTwoZeroMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_ThreePointZeroTwoZeroMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_ThreePointZeroTwoZeroMember" xml:lang="en-US" id="label_plx_ThreePointZeroTwoZeroMember">Three Point Zero Two Zero Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ThreePointZeroTwoZeroMember" xlink:to="label_plx_ThreePointZeroTwoZeroMember" xlink:title="Label : plx_ThreePointZeroTwoZeroMember to label_plx_ThreePointZeroTwoZeroMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_ThreePointZeroTwoZeroMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_ThreePointZeroTwoZeroMember_1" xml:lang="en-US" id="label_plx_ThreePointZeroTwoZeroMember_1">3.020 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ThreePointZeroTwoZeroMember" xlink:to="label_plx_ThreePointZeroTwoZeroMember_1" xlink:title="Label : plx_ThreePointZeroTwoZeroMember to label_plx_ThreePointZeroTwoZeroMember_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_ThreePointZeroTwoZeroMember_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_ThreePointZeroTwoZeroMember_2" xml:lang="en-US" id="label_plx_ThreePointZeroTwoZeroMember_2">Three Point Zero Two Zero [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ThreePointZeroTwoZeroMember" xlink:to="label_plx_ThreePointZeroTwoZeroMember_2" xlink:title="Label : plx_ThreePointZeroTwoZeroMember to label_plx_ThreePointZeroTwoZeroMember_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_TwoPointSixFiveMember" xlink:label="plx_TwoPointSixFiveMember" xlink:title="plx_TwoPointSixFiveMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_TwoPointSixFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_TwoPointSixFiveMember" xml:lang="en-US" id="label_plx_TwoPointSixFiveMember">Two Point Six Five [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_TwoPointSixFiveMember" xlink:to="label_plx_TwoPointSixFiveMember" xlink:title="Label : plx_TwoPointSixFiveMember to label_plx_TwoPointSixFiveMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_TwoPointSixFiveMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_TwoPointSixFiveMember_1" xml:lang="en-US" id="label_plx_TwoPointSixFiveMember_1">Two Point Six Five [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_TwoPointSixFiveMember" xlink:to="label_plx_TwoPointSixFiveMember_1" xlink:title="Label : plx_TwoPointSixFiveMember to label_plx_TwoPointSixFiveMember_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_TwoPointSixFiveMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_TwoPointSixFiveMember_2" xml:lang="en-US" id="label_plx_TwoPointSixFiveMember_2">2.650 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_TwoPointSixFiveMember" xlink:to="label_plx_TwoPointSixFiveMember_2" xlink:title="Label : plx_TwoPointSixFiveMember to label_plx_TwoPointSixFiveMember_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_TwoPointThreeFiveZeroMember" xlink:label="plx_TwoPointThreeFiveZeroMember" xlink:title="plx_TwoPointThreeFiveZeroMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_TwoPointThreeFiveZeroMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_TwoPointThreeFiveZeroMember" xml:lang="en-US" id="label_plx_TwoPointThreeFiveZeroMember">Two Point Three Five Zero [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_TwoPointThreeFiveZeroMember" xlink:to="label_plx_TwoPointThreeFiveZeroMember" xlink:title="Label : plx_TwoPointThreeFiveZeroMember to label_plx_TwoPointThreeFiveZeroMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_TwoPointThreeFiveZeroMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_TwoPointThreeFiveZeroMember_1" xml:lang="en-US" id="label_plx_TwoPointThreeFiveZeroMember_1">Two Point Three Five Zero [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_TwoPointThreeFiveZeroMember" xlink:to="label_plx_TwoPointThreeFiveZeroMember_1" xlink:title="Label : plx_TwoPointThreeFiveZeroMember to label_plx_TwoPointThreeFiveZeroMember_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_TwoPointThreeFiveZeroMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_TwoPointThreeFiveZeroMember_2" xml:lang="en-US" id="label_plx_TwoPointThreeFiveZeroMember_2">2.350 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_TwoPointThreeFiveZeroMember" xlink:to="label_plx_TwoPointThreeFiveZeroMember_2" xlink:title="Label : plx_TwoPointThreeFiveZeroMember to label_plx_TwoPointThreeFiveZeroMember_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_UponNearTermClinicalDevelopmentMilestonesMember" xlink:label="plx_UponNearTermClinicalDevelopmentMilestonesMember" xlink:title="plx_UponNearTermClinicalDevelopmentMilestonesMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_UponNearTermClinicalDevelopmentMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_UponNearTermClinicalDevelopmentMilestonesMember" xml:lang="en-US" id="label_plx_UponNearTermClinicalDevelopmentMilestonesMember">Upon Near Term Clinical Development Milestones [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_UponNearTermClinicalDevelopmentMilestonesMember" xlink:to="label_plx_UponNearTermClinicalDevelopmentMilestonesMember" xlink:title="Label : plx_UponNearTermClinicalDevelopmentMilestonesMember to label_plx_UponNearTermClinicalDevelopmentMilestonesMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_UponNearTermClinicalDevelopmentMilestonesMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_UponNearTermClinicalDevelopmentMilestonesMember_1" xml:lang="en-US" id="label_plx_UponNearTermClinicalDevelopmentMilestonesMember_1">Upon Near Term Clinical Development Milestones Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_UponNearTermClinicalDevelopmentMilestonesMember" xlink:to="label_plx_UponNearTermClinicalDevelopmentMilestonesMember_1" xlink:title="Label : plx_UponNearTermClinicalDevelopmentMilestonesMember to label_plx_UponNearTermClinicalDevelopmentMilestonesMember_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_VehicleLeaseAndMaintenanceAgreementsMember" xlink:label="plx_VehicleLeaseAndMaintenanceAgreementsMember" xlink:title="plx_VehicleLeaseAndMaintenanceAgreementsMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_VehicleLeaseAndMaintenanceAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_VehicleLeaseAndMaintenanceAgreementsMember" xml:lang="en-US" id="label_plx_VehicleLeaseAndMaintenanceAgreementsMember">Vehicle Lease And Maintenance Agreements [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_VehicleLeaseAndMaintenanceAgreementsMember" xlink:to="label_plx_VehicleLeaseAndMaintenanceAgreementsMember" xlink:title="Label : plx_VehicleLeaseAndMaintenanceAgreementsMember to label_plx_VehicleLeaseAndMaintenanceAgreementsMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_VehicleLeaseAndMaintenanceAgreementsMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_VehicleLeaseAndMaintenanceAgreementsMember_1" xml:lang="en-US" id="label_plx_VehicleLeaseAndMaintenanceAgreementsMember_1">Vehicle Lease and Maintenance Agreements Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_VehicleLeaseAndMaintenanceAgreementsMember" xlink:to="label_plx_VehicleLeaseAndMaintenanceAgreementsMember_1" xlink:title="Label : plx_VehicleLeaseAndMaintenanceAgreementsMember to label_plx_VehicleLeaseAndMaintenanceAgreementsMember_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_WithholdingTaxRateOnForeignIncome" xlink:label="plx_WithholdingTaxRateOnForeignIncome" xlink:title="plx_WithholdingTaxRateOnForeignIncome" />
    <link:label xlink:type="resource" xlink:label="label_plx_WithholdingTaxRateOnForeignIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_WithholdingTaxRateOnForeignIncome" xml:lang="en-US" id="label_plx_WithholdingTaxRateOnForeignIncome">Withholding Tax Rate On Foreign Income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_WithholdingTaxRateOnForeignIncome" xlink:to="label_plx_WithholdingTaxRateOnForeignIncome" xlink:title="Label : plx_WithholdingTaxRateOnForeignIncome to label_plx_WithholdingTaxRateOnForeignIncome" />
    <link:label xlink:type="resource" xlink:label="label_plx_WithholdingTaxRateOnForeignIncome_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_WithholdingTaxRateOnForeignIncome_1" xml:lang="en-US" id="label_plx_WithholdingTaxRateOnForeignIncome_1">Withholding Tax Rate On Foreign Income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_WithholdingTaxRateOnForeignIncome" xlink:to="label_plx_WithholdingTaxRateOnForeignIncome_1" xlink:title="Label : plx_WithholdingTaxRateOnForeignIncome to label_plx_WithholdingTaxRateOnForeignIncome_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_WithholdingTaxRateOnForeignIncome_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_WithholdingTaxRateOnForeignIncome_2" xml:lang="en-US" id="label_plx_WithholdingTaxRateOnForeignIncome_2">Withholding tax on the U.S. revenue source portion of the payments made to the Company for its share of Pfizer's net profits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_WithholdingTaxRateOnForeignIncome" xlink:to="label_plx_WithholdingTaxRateOnForeignIncome_2" xlink:title="Label : plx_WithholdingTaxRateOnForeignIncome to label_plx_WithholdingTaxRateOnForeignIncome_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd#country_IL" xlink:label="country_IL" xlink:title="country_IL" />
    <link:label xlink:type="resource" xlink:label="label_country_IL" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_country_IL" xml:lang="en-US" id="label_country_IL">ISRAEL [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_IL" xlink:to="label_country_IL" xlink:title="Label : country_IL to label_country_IL" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_YissumAgreementMember" xlink:label="plx_YissumAgreementMember" xlink:title="plx_YissumAgreementMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_YissumAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_YissumAgreementMember" xml:lang="en-US" id="label_plx_YissumAgreementMember">Yissum Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_YissumAgreementMember" xlink:to="label_plx_YissumAgreementMember" xlink:title="Label : plx_YissumAgreementMember to label_plx_YissumAgreementMember" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ZeroPointNineSevenTwoMember" xlink:label="plx_ZeroPointNineSevenTwoMember" xlink:title="plx_ZeroPointNineSevenTwoMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_ZeroPointNineSevenTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_ZeroPointNineSevenTwoMember" xml:lang="en-US" id="label_plx_ZeroPointNineSevenTwoMember">Zero Point Nine Seven Two [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ZeroPointNineSevenTwoMember" xlink:to="label_plx_ZeroPointNineSevenTwoMember" xlink:title="Label : plx_ZeroPointNineSevenTwoMember to label_plx_ZeroPointNineSevenTwoMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_ZeroPointNineSevenTwoMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_ZeroPointNineSevenTwoMember_1" xml:lang="en-US" id="label_plx_ZeroPointNineSevenTwoMember_1">Zero Point Nine Seven Two [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ZeroPointNineSevenTwoMember" xlink:to="label_plx_ZeroPointNineSevenTwoMember_1" xlink:title="Label : plx_ZeroPointNineSevenTwoMember to label_plx_ZeroPointNineSevenTwoMember_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_ZeroPointNineSevenTwoMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_ZeroPointNineSevenTwoMember_2" xml:lang="en-US" id="label_plx_ZeroPointNineSevenTwoMember_2">0.972 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ZeroPointNineSevenTwoMember" xlink:to="label_plx_ZeroPointNineSevenTwoMember_2" xlink:title="Label : plx_ZeroPointNineSevenTwoMember to label_plx_ZeroPointNineSevenTwoMember_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ZeroPointOneTwoZeroMember" xlink:label="plx_ZeroPointOneTwoZeroMember" xlink:title="plx_ZeroPointOneTwoZeroMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_ZeroPointOneTwoZeroMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_ZeroPointOneTwoZeroMember" xml:lang="en-US" id="label_plx_ZeroPointOneTwoZeroMember">Zero Point One Two Zero [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ZeroPointOneTwoZeroMember" xlink:to="label_plx_ZeroPointOneTwoZeroMember" xlink:title="Label : plx_ZeroPointOneTwoZeroMember to label_plx_ZeroPointOneTwoZeroMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_ZeroPointOneTwoZeroMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_ZeroPointOneTwoZeroMember_1" xml:lang="en-US" id="label_plx_ZeroPointOneTwoZeroMember_1">Zero Point One Two Zero Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ZeroPointOneTwoZeroMember" xlink:to="label_plx_ZeroPointOneTwoZeroMember_1" xlink:title="Label : plx_ZeroPointOneTwoZeroMember to label_plx_ZeroPointOneTwoZeroMember_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_ZeroPointOneTwoZeroMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_ZeroPointOneTwoZeroMember_2" xml:lang="en-US" id="label_plx_ZeroPointOneTwoZeroMember_2">0.120 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ZeroPointOneTwoZeroMember" xlink:to="label_plx_ZeroPointOneTwoZeroMember_2" xlink:title="Label : plx_ZeroPointOneTwoZeroMember to label_plx_ZeroPointOneTwoZeroMember_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ZeroPointThreeNineNineMember" xlink:label="plx_ZeroPointThreeNineNineMember" xlink:title="plx_ZeroPointThreeNineNineMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_ZeroPointThreeNineNineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_ZeroPointThreeNineNineMember" xml:lang="en-US" id="label_plx_ZeroPointThreeNineNineMember">Zero Point Three Nine Nine [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ZeroPointThreeNineNineMember" xlink:to="label_plx_ZeroPointThreeNineNineMember" xlink:title="Label : plx_ZeroPointThreeNineNineMember to label_plx_ZeroPointThreeNineNineMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_ZeroPointThreeNineNineMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_ZeroPointThreeNineNineMember_1" xml:lang="en-US" id="label_plx_ZeroPointThreeNineNineMember_1">Zero Point Three Nine Nine [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ZeroPointThreeNineNineMember" xlink:to="label_plx_ZeroPointThreeNineNineMember_1" xlink:title="Label : plx_ZeroPointThreeNineNineMember to label_plx_ZeroPointThreeNineNineMember_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_ZeroPointThreeNineNineMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_ZeroPointThreeNineNineMember_2" xml:lang="en-US" id="label_plx_ZeroPointThreeNineNineMember_2">0.399 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ZeroPointThreeNineNineMember" xlink:to="label_plx_ZeroPointThreeNineNineMember_2" xlink:title="Label : plx_ZeroPointThreeNineNineMember to label_plx_ZeroPointThreeNineNineMember_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ZeroPointZeroZeroOneMember" xlink:label="plx_ZeroPointZeroZeroOneMember" xlink:title="plx_ZeroPointZeroZeroOneMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_ZeroPointZeroZeroOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_ZeroPointZeroZeroOneMember" xml:lang="en-US" id="label_plx_ZeroPointZeroZeroOneMember">Zero Point Zero Zero One [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ZeroPointZeroZeroOneMember" xlink:to="label_plx_ZeroPointZeroZeroOneMember" xlink:title="Label : plx_ZeroPointZeroZeroOneMember to label_plx_ZeroPointZeroZeroOneMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_ZeroPointZeroZeroOneMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_ZeroPointZeroZeroOneMember_1" xml:lang="en-US" id="label_plx_ZeroPointZeroZeroOneMember_1">Zero Point Zero Zero One [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ZeroPointZeroZeroOneMember" xlink:to="label_plx_ZeroPointZeroZeroOneMember_1" xlink:title="Label : plx_ZeroPointZeroZeroOneMember to label_plx_ZeroPointZeroZeroOneMember_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_ZeroPointZeroZeroOneMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_ZeroPointZeroZeroOneMember_2" xml:lang="en-US" id="label_plx_ZeroPointZeroZeroOneMember_2">0.001 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ZeroPointZeroZeroOneMember" xlink:to="label_plx_ZeroPointZeroZeroOneMember_2" xlink:title="Label : plx_ZeroPointZeroZeroOneMember to label_plx_ZeroPointZeroZeroOneMember_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_PresidentAndChiefExecutiveOfficerMember" xlink:label="plx_PresidentAndChiefExecutiveOfficerMember" xlink:title="plx_PresidentAndChiefExecutiveOfficerMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_PresidentAndChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_PresidentAndChiefExecutiveOfficerMember" xml:lang="en-US" id="label_plx_PresidentAndChiefExecutiveOfficerMember">President and Chief Executive Officer [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PresidentAndChiefExecutiveOfficerMember" xlink:to="label_plx_PresidentAndChiefExecutiveOfficerMember" xlink:title="Label : plx_PresidentAndChiefExecutiveOfficerMember to label_plx_PresidentAndChiefExecutiveOfficerMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_PresidentAndChiefExecutiveOfficerMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_PresidentAndChiefExecutiveOfficerMember_1" xml:lang="en-US" id="label_plx_PresidentAndChiefExecutiveOfficerMember_1">President and Chief Executive Officer [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PresidentAndChiefExecutiveOfficerMember" xlink:to="label_plx_PresidentAndChiefExecutiveOfficerMember_1" xlink:title="Label : plx_PresidentAndChiefExecutiveOfficerMember to label_plx_PresidentAndChiefExecutiveOfficerMember_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_PresidentAndChiefExecutiveOfficerMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_PresidentAndChiefExecutiveOfficerMember_2" xml:lang="en-US" id="label_plx_PresidentAndChiefExecutiveOfficerMember_2">First or second ranking officer of the entity that may be appointed by the board of directors and Highest ranking executive officer, who has ultimate managerial responsibility for the entity and who reports to the board of directors. In addition, the chief executive officer (CEO) may also be the chairman of the board or president.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PresidentAndChiefExecutiveOfficerMember" xlink:to="label_plx_PresidentAndChiefExecutiveOfficerMember_2" xlink:title="Label : plx_PresidentAndChiefExecutiveOfficerMember to label_plx_PresidentAndChiefExecutiveOfficerMember_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" xlink:label="plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" xlink:title="plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" xml:lang="en-US" id="label_plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember">Options and Restricted Stocks Granted to Consultants Directors and Other Service Providers [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" xlink:to="label_plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" xlink:title="Label : plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember to label_plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember_1" xml:lang="en-US" id="label_plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember_1">Options and Restricted Stocks Granted To Consultants Directors And Other Service Providers [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" xlink:to="label_plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember_1" xlink:title="Label : plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember to label_plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember_2" xml:lang="en-US" id="label_plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember_2">Options and Restricted Stocks Granted To Consultants Directors And Other Service Providers [Member].</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" xlink:to="label_plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember_2" xlink:title="Label : plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember to label_plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_TwoPointThreeSevenZeroMember" xlink:label="plx_TwoPointThreeSevenZeroMember" xlink:title="plx_TwoPointThreeSevenZeroMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_TwoPointThreeSevenZeroMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_TwoPointThreeSevenZeroMember" xml:lang="en-US" id="label_plx_TwoPointThreeSevenZeroMember">Two Point Three Seven Zero [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_TwoPointThreeSevenZeroMember" xlink:to="label_plx_TwoPointThreeSevenZeroMember" xlink:title="Label : plx_TwoPointThreeSevenZeroMember to label_plx_TwoPointThreeSevenZeroMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_TwoPointThreeSevenZeroMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_TwoPointThreeSevenZeroMember_1" xml:lang="en-US" id="label_plx_TwoPointThreeSevenZeroMember_1">2.370 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_TwoPointThreeSevenZeroMember" xlink:to="label_plx_TwoPointThreeSevenZeroMember_1" xlink:title="Label : plx_TwoPointThreeSevenZeroMember to label_plx_TwoPointThreeSevenZeroMember_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_TwoPointThreeSevenZeroMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_TwoPointThreeSevenZeroMember_2" xml:lang="en-US" id="label_plx_TwoPointThreeSevenZeroMember_2">Two Point Three Seven Zero [Member].</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_TwoPointThreeSevenZeroMember" xlink:to="label_plx_TwoPointThreeSevenZeroMember_2" xlink:title="Label : plx_TwoPointThreeSevenZeroMember to label_plx_TwoPointThreeSevenZeroMember_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ThreePointThreeSevenZeroMember" xlink:label="plx_ThreePointThreeSevenZeroMember" xlink:title="plx_ThreePointThreeSevenZeroMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_ThreePointThreeSevenZeroMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_ThreePointThreeSevenZeroMember" xml:lang="en-US" id="label_plx_ThreePointThreeSevenZeroMember">Three Point Three Seven Zero [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ThreePointThreeSevenZeroMember" xlink:to="label_plx_ThreePointThreeSevenZeroMember" xlink:title="Label : plx_ThreePointThreeSevenZeroMember to label_plx_ThreePointThreeSevenZeroMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_ThreePointThreeSevenZeroMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_ThreePointThreeSevenZeroMember_1" xml:lang="en-US" id="label_plx_ThreePointThreeSevenZeroMember_1">3.370 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ThreePointThreeSevenZeroMember" xlink:to="label_plx_ThreePointThreeSevenZeroMember_1" xlink:title="Label : plx_ThreePointThreeSevenZeroMember to label_plx_ThreePointThreeSevenZeroMember_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_ThreePointThreeSevenZeroMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_ThreePointThreeSevenZeroMember_2" xml:lang="en-US" id="label_plx_ThreePointThreeSevenZeroMember_2">Three Point Three Seven Zero [Member].</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ThreePointThreeSevenZeroMember" xlink:to="label_plx_ThreePointThreeSevenZeroMember_2" xlink:title="Label : plx_ThreePointThreeSevenZeroMember to label_plx_ThreePointThreeSevenZeroMember_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_GrantYearTwoThousandFourteenMember" xlink:label="plx_GrantYearTwoThousandFourteenMember" xlink:title="plx_GrantYearTwoThousandFourteenMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_GrantYearTwoThousandFourteenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_GrantYearTwoThousandFourteenMember" xml:lang="en-US" id="label_plx_GrantYearTwoThousandFourteenMember">Grant Year Two Thousand Fourteen [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_GrantYearTwoThousandFourteenMember" xlink:to="label_plx_GrantYearTwoThousandFourteenMember" xlink:title="Label : plx_GrantYearTwoThousandFourteenMember to label_plx_GrantYearTwoThousandFourteenMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_GrantYearTwoThousandFourteenMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_GrantYearTwoThousandFourteenMember_1" xml:lang="en-US" id="label_plx_GrantYearTwoThousandFourteenMember_1">2014 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_GrantYearTwoThousandFourteenMember" xlink:to="label_plx_GrantYearTwoThousandFourteenMember_1" xlink:title="Label : plx_GrantYearTwoThousandFourteenMember to label_plx_GrantYearTwoThousandFourteenMember_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_GrantYearTwoThousandFourteenMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_GrantYearTwoThousandFourteenMember_2" xml:lang="en-US" id="label_plx_GrantYearTwoThousandFourteenMember_2">Represents information pertaining to grant year 2014.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_GrantYearTwoThousandFourteenMember" xlink:to="label_plx_GrantYearTwoThousandFourteenMember_2" xlink:title="Label : plx_GrantYearTwoThousandFourteenMember to label_plx_GrantYearTwoThousandFourteenMember_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_AccruedLiabilityInConnectionWithCollaborationOperationCurrent" xlink:label="plx_AccruedLiabilityInConnectionWithCollaborationOperationCurrent" xlink:title="plx_AccruedLiabilityInConnectionWithCollaborationOperationCurrent" />
    <link:label xlink:type="resource" xlink:label="label_plx_AccruedLiabilityInConnectionWithCollaborationOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_AccruedLiabilityInConnectionWithCollaborationOperationCurrent" xml:lang="en-US" id="label_plx_AccruedLiabilityInConnectionWithCollaborationOperationCurrent">Accrued Liability, In Connection With Collaboration Operation, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AccruedLiabilityInConnectionWithCollaborationOperationCurrent" xlink:to="label_plx_AccruedLiabilityInConnectionWithCollaborationOperationCurrent" xlink:title="Label : plx_AccruedLiabilityInConnectionWithCollaborationOperationCurrent to label_plx_AccruedLiabilityInConnectionWithCollaborationOperationCurrent" />
    <link:label xlink:type="resource" xlink:label="label_plx_AccruedLiabilityInConnectionWithCollaborationOperationCurrent_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_AccruedLiabilityInConnectionWithCollaborationOperationCurrent_1" xml:lang="en-US" id="label_plx_AccruedLiabilityInConnectionWithCollaborationOperationCurrent_1">Liability in connection with collaboration operation - current portion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AccruedLiabilityInConnectionWithCollaborationOperationCurrent" xlink:to="label_plx_AccruedLiabilityInConnectionWithCollaborationOperationCurrent_1" xlink:title="Label : plx_AccruedLiabilityInConnectionWithCollaborationOperationCurrent to label_plx_AccruedLiabilityInConnectionWithCollaborationOperationCurrent_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_AccruedLiabilityInConnectionWithCollaborationOperationCurrent_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_AccruedLiabilityInConnectionWithCollaborationOperationCurrent_2" xml:lang="en-US" id="label_plx_AccruedLiabilityInConnectionWithCollaborationOperationCurrent_2">Carrying value as of the balance sheet date of obligations incurred through that date and payable arising in connection with collaboration operation (due within one year or within the normal operating cycle if longer).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AccruedLiabilityInConnectionWithCollaborationOperationCurrent" xlink:to="label_plx_AccruedLiabilityInConnectionWithCollaborationOperationCurrent_2" xlink:title="Label : plx_AccruedLiabilityInConnectionWithCollaborationOperationCurrent to label_plx_AccruedLiabilityInConnectionWithCollaborationOperationCurrent_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:title="dei_DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="label_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_dei_DocumentFiscalYearFocus" xml:lang="en-US" id="label_dei_DocumentFiscalYearFocus">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="label_dei_DocumentFiscalYearFocus" xlink:title="Label : dei_DocumentFiscalYearFocus to label_dei_DocumentFiscalYearFocus" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" xlink:label="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" xlink:title="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" />
    <link:label xlink:type="resource" xlink:label="label_plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" xml:lang="en-US" id="label_plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent">Accounts Payable, Property And Equipment Suppliers, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" xlink:to="label_plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" xlink:title="Label : plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent to label_plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" />
    <link:label xlink:type="resource" xlink:label="label_plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_1" xml:lang="en-US" id="label_plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_1">Property and equipment suppliers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" xlink:to="label_plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_1" xlink:title="Label : plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent to label_plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_2" xml:lang="en-US" id="label_plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_2">Carrying value as of the balance sheet date of obligations incurred and payable to property and equipment suppliers. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" xlink:to="label_plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_2" xlink:title="Label : plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent to label_plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:title="dei_DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="label_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_dei_DocumentFiscalPeriodFocus" xml:lang="en-US" id="label_dei_DocumentFiscalPeriodFocus">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="label_dei_DocumentFiscalPeriodFocus" xlink:title="Label : dei_DocumentFiscalPeriodFocus to label_dei_DocumentFiscalPeriodFocus" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_OtherAssetsInstitutionsCurrent" xlink:label="plx_OtherAssetsInstitutionsCurrent" xlink:title="plx_OtherAssetsInstitutionsCurrent" />
    <link:label xlink:type="resource" xlink:label="label_plx_OtherAssetsInstitutionsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_OtherAssetsInstitutionsCurrent" xml:lang="en-US" id="label_plx_OtherAssetsInstitutionsCurrent">Other Assets, Institutions, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OtherAssetsInstitutionsCurrent" xlink:to="label_plx_OtherAssetsInstitutionsCurrent" xlink:title="Label : plx_OtherAssetsInstitutionsCurrent to label_plx_OtherAssetsInstitutionsCurrent" />
    <link:label xlink:type="resource" xlink:label="label_plx_OtherAssetsInstitutionsCurrent_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_OtherAssetsInstitutionsCurrent_1" xml:lang="en-US" id="label_plx_OtherAssetsInstitutionsCurrent_1">Institutions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OtherAssetsInstitutionsCurrent" xlink:to="label_plx_OtherAssetsInstitutionsCurrent_1" xlink:title="Label : plx_OtherAssetsInstitutionsCurrent to label_plx_OtherAssetsInstitutionsCurrent_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_OtherAssetsInstitutionsCurrent_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_OtherAssetsInstitutionsCurrent_2" xml:lang="en-US" id="label_plx_OtherAssetsInstitutionsCurrent_2">Aggregate carrying amount, as of the balance sheet date, of current assets related to institutions. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OtherAssetsInstitutionsCurrent" xlink:to="label_plx_OtherAssetsInstitutionsCurrent_2" xlink:title="Label : plx_OtherAssetsInstitutionsCurrent to label_plx_OtherAssetsInstitutionsCurrent_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_OtherAssetsSundryCurrent" xlink:label="plx_OtherAssetsSundryCurrent" xlink:title="plx_OtherAssetsSundryCurrent" />
    <link:label xlink:type="resource" xlink:label="label_plx_OtherAssetsSundryCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_OtherAssetsSundryCurrent" xml:lang="en-US" id="label_plx_OtherAssetsSundryCurrent">Other Assets, Sundry, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OtherAssetsSundryCurrent" xlink:to="label_plx_OtherAssetsSundryCurrent" xlink:title="Label : plx_OtherAssetsSundryCurrent to label_plx_OtherAssetsSundryCurrent" />
    <link:label xlink:type="resource" xlink:label="label_plx_OtherAssetsSundryCurrent_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_OtherAssetsSundryCurrent_1" xml:lang="en-US" id="label_plx_OtherAssetsSundryCurrent_1">Sundry</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OtherAssetsSundryCurrent" xlink:to="label_plx_OtherAssetsSundryCurrent_1" xlink:title="Label : plx_OtherAssetsSundryCurrent to label_plx_OtherAssetsSundryCurrent_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_OtherAssetsSundryCurrent_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_OtherAssetsSundryCurrent_2" xml:lang="en-US" id="label_plx_OtherAssetsSundryCurrent_2">Aggregate carrying amount of current assets as of the balance sheet date, arising from sundry. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OtherAssetsSundryCurrent" xlink:to="label_plx_OtherAssetsSundryCurrent_2" xlink:title="Label : plx_OtherAssetsSundryCurrent to label_plx_OtherAssetsSundryCurrent_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_CollaborativeArrangementMilestonePaymentAmount" xlink:label="plx_CollaborativeArrangementMilestonePaymentAmount" xlink:title="plx_CollaborativeArrangementMilestonePaymentAmount" />
    <link:label xlink:type="resource" xlink:label="label_plx_CollaborativeArrangementMilestonePaymentAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_CollaborativeArrangementMilestonePaymentAmount" xml:lang="en-US" id="label_plx_CollaborativeArrangementMilestonePaymentAmount">Collaborative Arrangement, Milestone Payment, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CollaborativeArrangementMilestonePaymentAmount" xlink:to="label_plx_CollaborativeArrangementMilestonePaymentAmount" xlink:title="Label : plx_CollaborativeArrangementMilestonePaymentAmount to label_plx_CollaborativeArrangementMilestonePaymentAmount" />
    <link:label xlink:type="resource" xlink:label="label_plx_CollaborativeArrangementMilestonePaymentAmount_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_CollaborativeArrangementMilestonePaymentAmount_1" xml:lang="en-US" id="label_plx_CollaborativeArrangementMilestonePaymentAmount_1">Pfizer Agreement, milestone payment amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CollaborativeArrangementMilestonePaymentAmount" xlink:to="label_plx_CollaborativeArrangementMilestonePaymentAmount_1" xlink:title="Label : plx_CollaborativeArrangementMilestonePaymentAmount to label_plx_CollaborativeArrangementMilestonePaymentAmount_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_CollaborativeArrangementMilestonePaymentAmount_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_CollaborativeArrangementMilestonePaymentAmount_2" xml:lang="en-US" id="label_plx_CollaborativeArrangementMilestonePaymentAmount_2">Collaborative Arrangement milestone payment amount.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CollaborativeArrangementMilestonePaymentAmount" xlink:to="label_plx_CollaborativeArrangementMilestonePaymentAmount_2" xlink:title="Label : plx_CollaborativeArrangementMilestonePaymentAmount to label_plx_CollaborativeArrangementMilestonePaymentAmount_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption" xlink:label="plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption" xlink:title="plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption" />
    <link:label xlink:type="resource" xlink:label="label_plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption" xml:lang="en-US" id="label_plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption">Debt Instrument, Principal Amount Related To Initial Purchaser''s Over-Allotment Option</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption" xlink:to="label_plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption" xlink:title="Label : plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption to label_plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption" />
    <link:label xlink:type="resource" xlink:label="label_plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption_1" xml:lang="en-US" id="label_plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption_1">Aggregate principal amount of Notes related to the initial purchaser's over-allotment option.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption" xlink:to="label_plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption_1" xlink:title="Label : plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption to label_plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption_2" xml:lang="en-US" id="label_plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption_2">Principal amount, related to the initial purchaser's over-allotment option</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption" xlink:to="label_plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption_2" xlink:title="Label : plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption to label_plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_RightToTerminateAgreementRevenueThreshold" xlink:label="plx_RightToTerminateAgreementRevenueThreshold" xlink:title="plx_RightToTerminateAgreementRevenueThreshold" />
    <link:label xlink:type="resource" xlink:label="label_plx_RightToTerminateAgreementRevenueThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_RightToTerminateAgreementRevenueThreshold" xml:lang="en-US" id="label_plx_RightToTerminateAgreementRevenueThreshold">Right To Terminate Agreement, Revenue Threshold</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_RightToTerminateAgreementRevenueThreshold" xlink:to="label_plx_RightToTerminateAgreementRevenueThreshold" xlink:title="Label : plx_RightToTerminateAgreementRevenueThreshold to label_plx_RightToTerminateAgreementRevenueThreshold" />
    <link:label xlink:type="resource" xlink:label="label_plx_RightToTerminateAgreementRevenueThreshold_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_RightToTerminateAgreementRevenueThreshold_1" xml:lang="en-US" id="label_plx_RightToTerminateAgreementRevenueThreshold_1">Additional purchase amount by July 31, 2015</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_RightToTerminateAgreementRevenueThreshold" xlink:to="label_plx_RightToTerminateAgreementRevenueThreshold_1" xlink:title="Label : plx_RightToTerminateAgreementRevenueThreshold to label_plx_RightToTerminateAgreementRevenueThreshold_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_RightToTerminateAgreementRevenueThreshold_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_RightToTerminateAgreementRevenueThreshold_2" xml:lang="en-US" id="label_plx_RightToTerminateAgreementRevenueThreshold_2">Revenue threshold if not met by July 31, 2015, the Company will have the right to terminate the agreement, in which case all rights to the technology that were transferred to Fiocruz will be returned to the Company.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_RightToTerminateAgreementRevenueThreshold" xlink:to="label_plx_RightToTerminateAgreementRevenueThreshold_2" xlink:title="Label : plx_RightToTerminateAgreementRevenueThreshold to label_plx_RightToTerminateAgreementRevenueThreshold_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_PfizerAgreementMember" xlink:label="plx_PfizerAgreementMember" xlink:title="plx_PfizerAgreementMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_PfizerAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_PfizerAgreementMember" xml:lang="en-US" id="label_plx_PfizerAgreementMember">Pfizer Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PfizerAgreementMember" xlink:to="label_plx_PfizerAgreementMember" xlink:title="Label : plx_PfizerAgreementMember to label_plx_PfizerAgreementMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_PfizerAgreementMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_PfizerAgreementMember_1" xml:lang="en-US" id="label_plx_PfizerAgreementMember_1">Pfizer Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PfizerAgreementMember" xlink:to="label_plx_PfizerAgreementMember_1" xlink:title="Label : plx_PfizerAgreementMember to label_plx_PfizerAgreementMember_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_BrazilAgreementMember" xlink:label="plx_BrazilAgreementMember" xlink:title="plx_BrazilAgreementMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_BrazilAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_BrazilAgreementMember" xml:lang="en-US" id="label_plx_BrazilAgreementMember">Brazil Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_BrazilAgreementMember" xlink:to="label_plx_BrazilAgreementMember" xlink:title="Label : plx_BrazilAgreementMember to label_plx_BrazilAgreementMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_BrazilAgreementMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_BrazilAgreementMember_1" xml:lang="en-US" id="label_plx_BrazilAgreementMember_1">Brazil Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_BrazilAgreementMember" xlink:to="label_plx_BrazilAgreementMember_1" xlink:title="Label : plx_BrazilAgreementMember to label_plx_BrazilAgreementMember_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_FiocruzMember" xlink:label="plx_FiocruzMember" xlink:title="plx_FiocruzMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_FiocruzMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_FiocruzMember" xml:lang="en-US" id="label_plx_FiocruzMember">Fiocruz [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_FiocruzMember" xlink:to="label_plx_FiocruzMember" xlink:title="Label : plx_FiocruzMember to label_plx_FiocruzMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_FiocruzMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_FiocruzMember_1" xml:lang="en-US" id="label_plx_FiocruzMember_1">Fiocruz [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_FiocruzMember" xlink:to="label_plx_FiocruzMember_1" xlink:title="Label : plx_FiocruzMember to label_plx_FiocruzMember_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_PurchaseOrderReceived" xlink:label="plx_PurchaseOrderReceived" xlink:title="plx_PurchaseOrderReceived" />
    <link:label xlink:type="resource" xlink:label="label_plx_PurchaseOrderReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_PurchaseOrderReceived" xml:lang="en-US" id="label_plx_PurchaseOrderReceived">Purchase Order Received</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PurchaseOrderReceived" xlink:to="label_plx_PurchaseOrderReceived" xlink:title="Label : plx_PurchaseOrderReceived to label_plx_PurchaseOrderReceived" />
    <link:label xlink:type="resource" xlink:label="label_plx_PurchaseOrderReceived_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_PurchaseOrderReceived_1" xml:lang="en-US" id="label_plx_PurchaseOrderReceived_1">Purchase order received</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PurchaseOrderReceived" xlink:to="label_plx_PurchaseOrderReceived_1" xlink:title="Label : plx_PurchaseOrderReceived to label_plx_PurchaseOrderReceived_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_PurchaseOrderReceived_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_PurchaseOrderReceived_2" xml:lang="en-US" id="label_plx_PurchaseOrderReceived_2">Represents the amount of purchase order received during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PurchaseOrderReceived" xlink:to="label_plx_PurchaseOrderReceived_2" xlink:title="Label : plx_PurchaseOrderReceived to label_plx_PurchaseOrderReceived_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_PercentageOfAdultGaucherPatientsTreatedWithUplyso" xlink:label="plx_PercentageOfAdultGaucherPatientsTreatedWithUplyso" xlink:title="plx_PercentageOfAdultGaucherPatientsTreatedWithUplyso" />
    <link:label xlink:type="resource" xlink:label="label_plx_PercentageOfAdultGaucherPatientsTreatedWithUplyso" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_PercentageOfAdultGaucherPatientsTreatedWithUplyso" xml:lang="en-US" id="label_plx_PercentageOfAdultGaucherPatientsTreatedWithUplyso">Percentage of Adult Gaucher Patients Treated with Uplyso</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PercentageOfAdultGaucherPatientsTreatedWithUplyso" xlink:to="label_plx_PercentageOfAdultGaucherPatientsTreatedWithUplyso" xlink:title="Label : plx_PercentageOfAdultGaucherPatientsTreatedWithUplyso to label_plx_PercentageOfAdultGaucherPatientsTreatedWithUplyso" />
    <link:label xlink:type="resource" xlink:label="label_plx_PercentageOfAdultGaucherPatientsTreatedWithUplyso_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_PercentageOfAdultGaucherPatientsTreatedWithUplyso_1" xml:lang="en-US" id="label_plx_PercentageOfAdultGaucherPatientsTreatedWithUplyso_1">Percentage of adult Gaucher patients in Brazil currently treated with Uplyso</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PercentageOfAdultGaucherPatientsTreatedWithUplyso" xlink:to="label_plx_PercentageOfAdultGaucherPatientsTreatedWithUplyso_1" xlink:title="Label : plx_PercentageOfAdultGaucherPatientsTreatedWithUplyso to label_plx_PercentageOfAdultGaucherPatientsTreatedWithUplyso_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_PercentageOfAdultGaucherPatientsTreatedWithUplyso_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_PercentageOfAdultGaucherPatientsTreatedWithUplyso_2" xml:lang="en-US" id="label_plx_PercentageOfAdultGaucherPatientsTreatedWithUplyso_2">Represents the percentage of adult Gaucher patients treated with Uplyso.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PercentageOfAdultGaucherPatientsTreatedWithUplyso" xlink:to="label_plx_PercentageOfAdultGaucherPatientsTreatedWithUplyso_2" xlink:title="Label : plx_PercentageOfAdultGaucherPatientsTreatedWithUplyso to label_plx_PercentageOfAdultGaucherPatientsTreatedWithUplyso_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_EmployeeStockIncentivePlan2006Member" xlink:label="plx_EmployeeStockIncentivePlan2006Member" xlink:title="plx_EmployeeStockIncentivePlan2006Member" />
    <link:label xlink:type="resource" xlink:label="label_plx_EmployeeStockIncentivePlan2006Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_EmployeeStockIncentivePlan2006Member" xml:lang="en-US" id="label_plx_EmployeeStockIncentivePlan2006Member">Employee Stock Incentive Plan 2006 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EmployeeStockIncentivePlan2006Member" xlink:to="label_plx_EmployeeStockIncentivePlan2006Member" xlink:title="Label : plx_EmployeeStockIncentivePlan2006Member to label_plx_EmployeeStockIncentivePlan2006Member" />
    <link:label xlink:type="resource" xlink:label="label_plx_EmployeeStockIncentivePlan2006Member_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_EmployeeStockIncentivePlan2006Member_1" xml:lang="en-US" id="label_plx_EmployeeStockIncentivePlan2006Member_1">Employee Stock Incentive Plan 2006 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EmployeeStockIncentivePlan2006Member" xlink:to="label_plx_EmployeeStockIncentivePlan2006Member_1" xlink:title="Label : plx_EmployeeStockIncentivePlan2006Member to label_plx_EmployeeStockIncentivePlan2006Member_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_EmployeeStockIncentivePlan2006Member_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_EmployeeStockIncentivePlan2006Member_2" xml:lang="en-US" id="label_plx_EmployeeStockIncentivePlan2006Member_2">2006 Employee Stock Incentive Plan [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EmployeeStockIncentivePlan2006Member" xlink:to="label_plx_EmployeeStockIncentivePlan2006Member_2" xlink:title="Label : plx_EmployeeStockIncentivePlan2006Member to label_plx_EmployeeStockIncentivePlan2006Member_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:title="dei_LegalEntityAxis" />
    <link:label xlink:type="resource" xlink:label="label_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_dei_LegalEntityAxis" xml:lang="en-US" id="label_dei_LegalEntityAxis">Legal Entity [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="label_dei_LegalEntityAxis" xlink:title="Label : dei_LegalEntityAxis to label_dei_LegalEntityAxis" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_AmendedPfizerAgreementMember" xlink:label="plx_AmendedPfizerAgreementMember" xlink:title="plx_AmendedPfizerAgreementMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_AmendedPfizerAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_AmendedPfizerAgreementMember" xml:lang="en-US" id="label_plx_AmendedPfizerAgreementMember">Amended Pfizer Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AmendedPfizerAgreementMember" xlink:to="label_plx_AmendedPfizerAgreementMember" xlink:title="Label : plx_AmendedPfizerAgreementMember to label_plx_AmendedPfizerAgreementMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_AmendedPfizerAgreementMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_AmendedPfizerAgreementMember_1" xml:lang="en-US" id="label_plx_AmendedPfizerAgreementMember_1">Amended Pfizer Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AmendedPfizerAgreementMember" xlink:to="label_plx_AmendedPfizerAgreementMember_1" xlink:title="Label : plx_AmendedPfizerAgreementMember to label_plx_AmendedPfizerAgreementMember_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:title="dei_DocumentType" />
    <link:label xlink:type="resource" xlink:label="label_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_dei_DocumentType" xml:lang="en-US" id="label_dei_DocumentType">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="label_dei_DocumentType" xlink:title="Label : dei_DocumentType to label_dei_DocumentType" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ProceedsFromSaleOfShareInCollaboration" xlink:label="plx_ProceedsFromSaleOfShareInCollaboration" xlink:title="plx_ProceedsFromSaleOfShareInCollaboration" />
    <link:label xlink:type="resource" xlink:label="label_plx_ProceedsFromSaleOfShareInCollaboration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_ProceedsFromSaleOfShareInCollaboration" xml:lang="en-US" id="label_plx_ProceedsFromSaleOfShareInCollaboration">Proceeds from Sale of Share In Collaboration</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProceedsFromSaleOfShareInCollaboration" xlink:to="label_plx_ProceedsFromSaleOfShareInCollaboration" xlink:title="Label : plx_ProceedsFromSaleOfShareInCollaboration to label_plx_ProceedsFromSaleOfShareInCollaboration" />
    <link:label xlink:type="resource" xlink:label="label_plx_ProceedsFromSaleOfShareInCollaboration_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_ProceedsFromSaleOfShareInCollaboration_1" xml:lang="en-US" id="label_plx_ProceedsFromSaleOfShareInCollaboration_1">Proceeds from sale of share in the collaboration created under the initial Pfizer Agreement for the commercialization of Elelyso</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProceedsFromSaleOfShareInCollaboration" xlink:to="label_plx_ProceedsFromSaleOfShareInCollaboration_1" xlink:title="Label : plx_ProceedsFromSaleOfShareInCollaboration to label_plx_ProceedsFromSaleOfShareInCollaboration_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_ProceedsFromSaleOfShareInCollaboration_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_ProceedsFromSaleOfShareInCollaboration_2" xml:lang="en-US" id="label_plx_ProceedsFromSaleOfShareInCollaboration_2">Pursuant to the Amended Pfizer Agreement, the Company sold to Pfizer its share in the collaboration created under the initial Pfizer Agreement for the commercialization of Elelyso in exchange for a cash payment amount.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProceedsFromSaleOfShareInCollaboration" xlink:to="label_plx_ProceedsFromSaleOfShareInCollaboration_2" xlink:title="Label : plx_ProceedsFromSaleOfShareInCollaboration to label_plx_ProceedsFromSaleOfShareInCollaboration_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ExcludingBrazilMember" xlink:label="plx_ExcludingBrazilMember" xlink:title="plx_ExcludingBrazilMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_ExcludingBrazilMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_ExcludingBrazilMember" xml:lang="en-US" id="label_plx_ExcludingBrazilMember">Excluding Brazil [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ExcludingBrazilMember" xlink:to="label_plx_ExcludingBrazilMember" xlink:title="Label : plx_ExcludingBrazilMember to label_plx_ExcludingBrazilMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_ExcludingBrazilMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_ExcludingBrazilMember_1" xml:lang="en-US" id="label_plx_ExcludingBrazilMember_1">Excluding Brazil [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ExcludingBrazilMember" xlink:to="label_plx_ExcludingBrazilMember_1" xlink:title="Label : plx_ExcludingBrazilMember to label_plx_ExcludingBrazilMember_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfitsEliminationAmount" xlink:label="plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfitsEliminationAmount" xlink:title="plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfitsEliminationAmount" />
    <link:label xlink:type="resource" xlink:label="label_plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfitsEliminationAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfitsEliminationAmount" xml:lang="en-US" id="label_plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfitsEliminationAmount">License And Supply Agreement Potential Future Payment Based On Net Profits, Elimination Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfitsEliminationAmount" xlink:to="label_plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfitsEliminationAmount" xlink:title="Label : plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfitsEliminationAmount to label_plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfitsEliminationAmount" />
    <link:label xlink:type="resource" xlink:label="label_plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfitsEliminationAmount_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfitsEliminationAmount_1" xml:lang="en-US" id="label_plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfitsEliminationAmount_1">License and supply agreement potential future payment, elimination amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfitsEliminationAmount" xlink:to="label_plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfitsEliminationAmount_1" xlink:title="Label : plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfitsEliminationAmount to label_plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfitsEliminationAmount_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfitsEliminationAmount_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfitsEliminationAmount_2" xml:lang="en-US" id="label_plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfitsEliminationAmount_2">The Amended Pfizer Agreement eliminates Pfizer's entitlement to annual payments in relation to commercialization of Elelyso in Brazil.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfitsEliminationAmount" xlink:to="label_plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfitsEliminationAmount_2" xlink:title="Label : plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfitsEliminationAmount to label_plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfitsEliminationAmount_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_AgentFeePercentageOfNetProceeds" xlink:label="plx_AgentFeePercentageOfNetProceeds" xlink:title="plx_AgentFeePercentageOfNetProceeds" />
    <link:label xlink:type="resource" xlink:label="label_plx_AgentFeePercentageOfNetProceeds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_AgentFeePercentageOfNetProceeds" xml:lang="en-US" id="label_plx_AgentFeePercentageOfNetProceeds">Agent Fee, Percentage Of Net Proceeds</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AgentFeePercentageOfNetProceeds" xlink:to="label_plx_AgentFeePercentageOfNetProceeds" xlink:title="Label : plx_AgentFeePercentageOfNetProceeds to label_plx_AgentFeePercentageOfNetProceeds" />
    <link:label xlink:type="resource" xlink:label="label_plx_AgentFeePercentageOfNetProceeds_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_AgentFeePercentageOfNetProceeds_1" xml:lang="en-US" id="label_plx_AgentFeePercentageOfNetProceeds_1">Agent fee, percentage of net proceeds</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AgentFeePercentageOfNetProceeds" xlink:to="label_plx_AgentFeePercentageOfNetProceeds_1" xlink:title="Label : plx_AgentFeePercentageOfNetProceeds to label_plx_AgentFeePercentageOfNetProceeds_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_AgentFeePercentageOfNetProceeds_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_AgentFeePercentageOfNetProceeds_2" xml:lang="en-US" id="label_plx_AgentFeePercentageOfNetProceeds_2">The Company will pay a fee equal to percentage of the net proceeds generated in Brazil to its agent for services provided in assisting us complete the Brazil Agreement pursuant to an agency agreement between the agent and the Company.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AgentFeePercentageOfNetProceeds" xlink:to="label_plx_AgentFeePercentageOfNetProceeds_2" xlink:title="Label : plx_AgentFeePercentageOfNetProceeds to label_plx_AgentFeePercentageOfNetProceeds_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_StockPurchaseAgreementLockUpPeriod" xlink:label="plx_StockPurchaseAgreementLockUpPeriod" xlink:title="plx_StockPurchaseAgreementLockUpPeriod" />
    <link:label xlink:type="resource" xlink:label="label_plx_StockPurchaseAgreementLockUpPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_StockPurchaseAgreementLockUpPeriod" xml:lang="en-US" id="label_plx_StockPurchaseAgreementLockUpPeriod">Stock Purchase Agreement, Lock Up Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_StockPurchaseAgreementLockUpPeriod" xlink:to="label_plx_StockPurchaseAgreementLockUpPeriod" xlink:title="Label : plx_StockPurchaseAgreementLockUpPeriod to label_plx_StockPurchaseAgreementLockUpPeriod" />
    <link:label xlink:type="resource" xlink:label="label_plx_StockPurchaseAgreementLockUpPeriod_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_StockPurchaseAgreementLockUpPeriod_1" xml:lang="en-US" id="label_plx_StockPurchaseAgreementLockUpPeriod_1">Lock-up period with respect to the purchased shares of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_StockPurchaseAgreementLockUpPeriod" xlink:to="label_plx_StockPurchaseAgreementLockUpPeriod_1" xlink:title="Label : plx_StockPurchaseAgreementLockUpPeriod to label_plx_StockPurchaseAgreementLockUpPeriod_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_StockPurchaseAgreementLockUpPeriod_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_StockPurchaseAgreementLockUpPeriod_2" xml:lang="en-US" id="label_plx_StockPurchaseAgreementLockUpPeriod_2">As part of the Stock Purchase Agreement, Pfizer has agreed to a lock-up period with respect to the purchased shares of common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_StockPurchaseAgreementLockUpPeriod" xlink:to="label_plx_StockPurchaseAgreementLockUpPeriod_2" xlink:title="Label : plx_StockPurchaseAgreementLockUpPeriod to label_plx_StockPurchaseAgreementLockUpPeriod_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_RevenuesOtherThanCompanyShareInCollaborationAgreement" xlink:label="plx_RevenuesOtherThanCompanyShareInCollaborationAgreement" xlink:title="plx_RevenuesOtherThanCompanyShareInCollaborationAgreement" />
    <link:label xlink:type="resource" xlink:label="label_plx_RevenuesOtherThanCompanyShareInCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_RevenuesOtherThanCompanyShareInCollaborationAgreement" xml:lang="en-US" id="label_plx_RevenuesOtherThanCompanyShareInCollaborationAgreement">Revenues Other Than Company's Share In Collaboration Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_RevenuesOtherThanCompanyShareInCollaborationAgreement" xlink:to="label_plx_RevenuesOtherThanCompanyShareInCollaborationAgreement" xlink:title="Label : plx_RevenuesOtherThanCompanyShareInCollaborationAgreement to label_plx_RevenuesOtherThanCompanyShareInCollaborationAgreement" />
    <link:label xlink:type="resource" xlink:label="label_plx_RevenuesOtherThanCompanyShareInCollaborationAgreement_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_RevenuesOtherThanCompanyShareInCollaborationAgreement_1" xml:lang="en-US" id="label_plx_RevenuesOtherThanCompanyShareInCollaborationAgreement_1">REVENUES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_RevenuesOtherThanCompanyShareInCollaborationAgreement" xlink:to="label_plx_RevenuesOtherThanCompanyShareInCollaborationAgreement_1" xlink:title="Label : plx_RevenuesOtherThanCompanyShareInCollaborationAgreement to label_plx_RevenuesOtherThanCompanyShareInCollaborationAgreement_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_RevenuesOtherThanCompanyShareInCollaborationAgreement_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_RevenuesOtherThanCompanyShareInCollaborationAgreement_2" xml:lang="en-US" id="label_plx_RevenuesOtherThanCompanyShareInCollaborationAgreement_2">The Company's total revenues other than its share in collaboration agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_RevenuesOtherThanCompanyShareInCollaborationAgreement" xlink:to="label_plx_RevenuesOtherThanCompanyShareInCollaborationAgreement_2" xlink:title="Label : plx_RevenuesOtherThanCompanyShareInCollaborationAgreement to label_plx_RevenuesOtherThanCompanyShareInCollaborationAgreement_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_October2015PromissoryNoteToPfizerMember" xlink:label="plx_October2015PromissoryNoteToPfizerMember" xlink:title="plx_October2015PromissoryNoteToPfizerMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_October2015PromissoryNoteToPfizerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_October2015PromissoryNoteToPfizerMember" xml:lang="en-US" id="label_plx_October2015PromissoryNoteToPfizerMember">October 2015 Promissory Note To Pfizer [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_October2015PromissoryNoteToPfizerMember" xlink:to="label_plx_October2015PromissoryNoteToPfizerMember" xlink:title="Label : plx_October2015PromissoryNoteToPfizerMember to label_plx_October2015PromissoryNoteToPfizerMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_October2015PromissoryNoteToPfizerMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_October2015PromissoryNoteToPfizerMember_1" xml:lang="en-US" id="label_plx_October2015PromissoryNoteToPfizerMember_1">October 2015 Promissory Note To Pfizer [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_October2015PromissoryNoteToPfizerMember" xlink:to="label_plx_October2015PromissoryNoteToPfizerMember_1" xlink:title="Label : plx_October2015PromissoryNoteToPfizerMember to label_plx_October2015PromissoryNoteToPfizerMember_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:title="us-gaap_AccountingPoliciesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US" id="label_us-gaap_AccountingPoliciesAbstract">SIGNIFICANT ACCOUNTING POLICIES [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="label_us-gaap_AccountingPoliciesAbstract" xlink:title="Label : us-gaap_AccountingPoliciesAbstract to label_us-gaap_AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent" xlink:title="us-gaap_AccountsPayableTradeCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccountsPayableTradeCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AccountsPayableTradeCurrent" xml:lang="en-US" id="label_us-gaap_AccountsPayableTradeCurrent">Accounts Payable, Trade, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="label_us-gaap_AccountsPayableTradeCurrent" xlink:title="Label : us-gaap_AccountsPayableTradeCurrent to label_us-gaap_AccountsPayableTradeCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccountsPayableTradeCurrent_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_AccountsPayableTradeCurrent_1" xml:lang="en-US" id="label_us-gaap_AccountsPayableTradeCurrent_1">Trade</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="label_us-gaap_AccountsPayableTradeCurrent_1" xlink:title="Label : us-gaap_AccountsPayableTradeCurrent to label_us-gaap_AccountsPayableTradeCurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:title="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xml:lang="en-US" id="label_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract">Accounts payable and accruals - other:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="label_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:title="Label : us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract to label_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_1" xml:lang="en-US" id="label_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_1">Accounts payable and accruals:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="label_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_1" xlink:title="Label : us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract to label_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_2" xml:lang="en-US" id="label_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_2">Accounts Payable and Accrued Liabilities, Current [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="label_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_2" xlink:title="Label : us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract to label_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd#country_NL" xlink:label="country_NL" xlink:title="country_NL" />
    <link:label xlink:type="resource" xlink:label="label_country_NL" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_country_NL" xml:lang="en-US" id="label_country_NL">NETHERLANDS [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_NL" xlink:to="label_country_NL" xlink:title="Label : country_NL to label_country_NL" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:title="us-gaap_AccountsReceivableNetCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US" id="label_us-gaap_AccountsReceivableNetCurrent">Accounts receivable - Trade</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="label_us-gaap_AccountsReceivableNetCurrent" xlink:title="Label : us-gaap_AccountsReceivableNetCurrent to label_us-gaap_AccountsReceivableNetCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccountsReceivableNetCurrent_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AccountsReceivableNetCurrent_1" xml:lang="en-US" id="label_us-gaap_AccountsReceivableNetCurrent_1">Accounts Receivable, Net, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="label_us-gaap_AccountsReceivableNetCurrent_1" xlink:title="Label : us-gaap_AccountsReceivableNetCurrent to label_us-gaap_AccountsReceivableNetCurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:title="us-gaap_AccountsPayableOtherCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccountsPayableOtherCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_AccountsPayableOtherCurrent" xml:lang="en-US" id="label_us-gaap_AccountsPayableOtherCurrent">Accounts payable and accruals, other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="label_us-gaap_AccountsPayableOtherCurrent" xlink:title="Label : us-gaap_AccountsPayableOtherCurrent to label_us-gaap_AccountsPayableOtherCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccountsPayableOtherCurrent_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AccountsPayableOtherCurrent_1" xml:lang="en-US" id="label_us-gaap_AccountsPayableOtherCurrent_1">Accounts Payable, Other, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="label_us-gaap_AccountsPayableOtherCurrent_1" xlink:title="Label : us-gaap_AccountsPayableOtherCurrent to label_us-gaap_AccountsPayableOtherCurrent_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccountsPayableOtherCurrent_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_AccountsPayableOtherCurrent_2" xml:lang="en-US" id="label_us-gaap_AccountsPayableOtherCurrent_2">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="label_us-gaap_AccountsPayableOtherCurrent_2" xlink:title="Label : us-gaap_AccountsPayableOtherCurrent to label_us-gaap_AccountsPayableOtherCurrent_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd#country_US" xlink:label="country_US" xlink:title="country_US" />
    <link:label xlink:type="resource" xlink:label="label_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_country_US" xml:lang="en-US" id="label_country_US">UNITED STATES [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="label_country_US" xlink:title="Label : country_US to label_country_US" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:title="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xml:lang="en-US" id="label_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent">Accrued Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="label_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:title="Label : us-gaap_AccruedLiabilitiesCurrentAndNoncurrent to label_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_1" xml:lang="en-US" id="label_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_1">Accrued liabilities accrued related to the Collaboration Operation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="label_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_1" xlink:title="Label : us-gaap_AccruedLiabilitiesCurrentAndNoncurrent to label_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:title="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xml:lang="en-US" id="label_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent">Accrued Royalties</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:to="label_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:title="Label : us-gaap_AccruedRoyaltiesCurrentAndNoncurrent to label_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_1" xml:lang="en-US" id="label_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_1">Accrued royalties</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:to="label_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_1" xlink:title="Label : us-gaap_AccruedRoyaltiesCurrentAndNoncurrent to label_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrent" xlink:title="us-gaap_AccruedRoyaltiesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AccruedRoyaltiesCurrent" xml:lang="en-US" id="label_us-gaap_AccruedRoyaltiesCurrent">Accrued Royalties, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRoyaltiesCurrent" xlink:to="label_us-gaap_AccruedRoyaltiesCurrent" xlink:title="Label : us-gaap_AccruedRoyaltiesCurrent to label_us-gaap_AccruedRoyaltiesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccruedRoyaltiesCurrent_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_AccruedRoyaltiesCurrent_1" xml:lang="en-US" id="label_us-gaap_AccruedRoyaltiesCurrent_1">Royalties payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRoyaltiesCurrent" xlink:to="label_us-gaap_AccruedRoyaltiesCurrent_1" xlink:title="Label : us-gaap_AccruedRoyaltiesCurrent to label_us-gaap_AccruedRoyaltiesCurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:title="us-gaap_AccruedLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US" id="label_us-gaap_AccruedLiabilitiesCurrent">Accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="label_us-gaap_AccruedLiabilitiesCurrent" xlink:title="Label : us-gaap_AccruedLiabilitiesCurrent to label_us-gaap_AccruedLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccruedLiabilitiesCurrent_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AccruedLiabilitiesCurrent_1" xml:lang="en-US" id="label_us-gaap_AccruedLiabilitiesCurrent_1">Accrued Liabilities, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="label_us-gaap_AccruedLiabilitiesCurrent_1" xlink:title="Label : us-gaap_AccruedLiabilitiesCurrent to label_us-gaap_AccruedLiabilitiesCurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedVacationCurrent" xlink:label="us-gaap_AccruedVacationCurrent" xlink:title="us-gaap_AccruedVacationCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccruedVacationCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AccruedVacationCurrent" xml:lang="en-US" id="label_us-gaap_AccruedVacationCurrent">Accrued Vacation, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedVacationCurrent" xlink:to="label_us-gaap_AccruedVacationCurrent" xlink:title="Label : us-gaap_AccruedVacationCurrent to label_us-gaap_AccruedVacationCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccruedVacationCurrent_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_AccruedVacationCurrent_1" xml:lang="en-US" id="label_us-gaap_AccruedVacationCurrent_1">Provision for vacation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedVacationCurrent" xlink:to="label_us-gaap_AccruedVacationCurrent_1" xlink:title="Label : us-gaap_AccruedVacationCurrent to label_us-gaap_AccruedVacationCurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US" id="label_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="label_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="Label : us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment to label_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1" xml:lang="en-US" id="label_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1">Less - accumulated depreciation and amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="label_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1" xlink:title="Label : us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment to label_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:title="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AdditionalPaidInCapitalCommonStock" xml:lang="en-US" id="label_us-gaap_AdditionalPaidInCapitalCommonStock">Additional Paid In Capital Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="label_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:title="Label : us-gaap_AdditionalPaidInCapitalCommonStock to label_us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AdditionalPaidInCapitalCommonStock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_AdditionalPaidInCapitalCommonStock_1" xml:lang="en-US" id="label_us-gaap_AdditionalPaidInCapitalCommonStock_1">Additional paid-in capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="label_us-gaap_AdditionalPaidInCapitalCommonStock_1" xlink:title="Label : us-gaap_AdditionalPaidInCapitalCommonStock to label_us-gaap_AdditionalPaidInCapitalCommonStock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:label="us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:title="us-gaap_AdditionalFinancialInformationDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xml:lang="en-US" id="label_us-gaap_AdditionalFinancialInformationDisclosureTextBlock">Additional Financial Information Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:to="label_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:title="Label : us-gaap_AdditionalFinancialInformationDisclosureTextBlock to label_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_1" xml:lang="en-US" id="label_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_1">SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:to="label_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_1" xlink:title="Label : us-gaap_AdditionalFinancialInformationDisclosureTextBlock to label_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:title="us-gaap_AdditionalPaidInCapitalMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US" id="label_us-gaap_AdditionalPaidInCapitalMember">Additional Paid-in Capital [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="label_us-gaap_AdditionalPaidInCapitalMember" xlink:title="Label : us-gaap_AdditionalPaidInCapitalMember to label_us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US" id="label_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">Adjustments required to reconcile net loss to net cash used in operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="label_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="Label : us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to label_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1" xml:lang="en-US" id="label_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="label_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:title="Label : us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to label_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:title="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xml:lang="en-US" id="label_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="label_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:title="Label : us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts to label_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_1" xml:lang="en-US" id="label_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_1">Common stock issued for cash, issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="label_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_1" xlink:title="Label : us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts to label_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US" id="label_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="label_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="Label : us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue to label_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1" xml:lang="en-US" id="label_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1">Share-based compensation related to stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="label_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1" xlink:title="Label : us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue to label_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:title="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US" id="label_us-gaap_AllocatedShareBasedCompensationExpense">Allocated Share-based Compensation Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="label_us-gaap_AllocatedShareBasedCompensationExpense" xlink:title="Label : us-gaap_AllocatedShareBasedCompensationExpense to label_us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AllocatedShareBasedCompensationExpense_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_AllocatedShareBasedCompensationExpense_1" xml:lang="en-US" id="label_us-gaap_AllocatedShareBasedCompensationExpense_1">Share-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="label_us-gaap_AllocatedShareBasedCompensationExpense_1" xlink:title="Label : us-gaap_AllocatedShareBasedCompensationExpense to label_us-gaap_AllocatedShareBasedCompensationExpense_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:title="us-gaap_AmortizationOfFinancingCosts" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_AmortizationOfFinancingCosts" xml:lang="en-US" id="label_us-gaap_AmortizationOfFinancingCosts">Amortization of debt issuance costs and debt discount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="label_us-gaap_AmortizationOfFinancingCosts" xlink:title="Label : us-gaap_AmortizationOfFinancingCosts to label_us-gaap_AmortizationOfFinancingCosts" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AmortizationOfFinancingCosts_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AmortizationOfFinancingCosts_1" xml:lang="en-US" id="label_us-gaap_AmortizationOfFinancingCosts_1">Amortization of Financing Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="label_us-gaap_AmortizationOfFinancingCosts_1" xlink:title="Label : us-gaap_AmortizationOfFinancingCosts to label_us-gaap_AmortizationOfFinancingCosts_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AntidilutiveSecuritiesNameDomain" xml:lang="en-US" id="label_us-gaap_AntidilutiveSecuritiesNameDomain">Antidilutive Securities, Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="label_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:title="Label : us-gaap_AntidilutiveSecuritiesNameDomain to label_us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xml:lang="en-US" id="label_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">Antidilutive Securities [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="label_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="Label : us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to label_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US" id="label_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="label_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="Label : us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount to label_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1" xml:lang="en-US" id="label_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1">Options to purchase common stock not included in diluted LPS because the effect would be anti-dilutive</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="label_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1" xlink:title="Label : us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount to label_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges" xlink:title="us-gaap_AssetImpairmentCharges" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AssetImpairmentCharges" xml:lang="en-US" id="label_us-gaap_AssetImpairmentCharges">Asset Impairment Charges</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="label_us-gaap_AssetImpairmentCharges" xlink:title="Label : us-gaap_AssetImpairmentCharges to label_us-gaap_AssetImpairmentCharges" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AssetImpairmentCharges_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_AssetImpairmentCharges_1" xml:lang="en-US" id="label_us-gaap_AssetImpairmentCharges_1">Impairment charges</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="label_us-gaap_AssetImpairmentCharges_1" xlink:title="Label : us-gaap_AssetImpairmentCharges to label_us-gaap_AssetImpairmentCharges_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xlink:title="us-gaap_AssetsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_AssetsAbstract" xml:lang="en-US" id="label_us-gaap_AssetsAbstract">ASSETS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="label_us-gaap_AssetsAbstract" xlink:title="Label : us-gaap_AssetsAbstract to label_us-gaap_AssetsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AssetsAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AssetsAbstract_1" xml:lang="en-US" id="label_us-gaap_AssetsAbstract_1">Assets [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="label_us-gaap_AssetsAbstract_1" xlink:title="Label : us-gaap_AssetsAbstract to label_us-gaap_AssetsAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:title="us-gaap_Assets" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_Assets" xml:lang="en-US" id="label_us-gaap_Assets">Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="label_us-gaap_Assets" xlink:title="Label : us-gaap_Assets to label_us-gaap_Assets" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_Assets_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_Assets_1" xml:lang="en-US" id="label_us-gaap_Assets_1">Total assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="label_us-gaap_Assets_1" xlink:title="Label : us-gaap_Assets to label_us-gaap_Assets_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:title="us-gaap_AssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AssetsCurrent" xml:lang="en-US" id="label_us-gaap_AssetsCurrent">Assets, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="label_us-gaap_AssetsCurrent" xlink:title="Label : us-gaap_AssetsCurrent to label_us-gaap_AssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AssetsCurrent_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_AssetsCurrent_1" xml:lang="en-US" id="label_us-gaap_AssetsCurrent_1">Total current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="label_us-gaap_AssetsCurrent_1" xlink:title="Label : us-gaap_AssetsCurrent to label_us-gaap_AssetsCurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:title="us-gaap_AssetsCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AssetsCurrentAbstract" xml:lang="en-US" id="label_us-gaap_AssetsCurrentAbstract">Assets, Current [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="label_us-gaap_AssetsCurrentAbstract" xlink:title="Label : us-gaap_AssetsCurrentAbstract to label_us-gaap_AssetsCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AssetsCurrentAbstract_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_AssetsCurrentAbstract_1" xml:lang="en-US" id="label_us-gaap_AssetsCurrentAbstract_1">CURRENT ASSETS:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="label_us-gaap_AssetsCurrentAbstract_1" xlink:title="Label : us-gaap_AssetsCurrentAbstract to label_us-gaap_AssetsCurrentAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:title="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US" id="label_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="label_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:title="Label : us-gaap_BasisOfAccountingPolicyPolicyTextBlock to label_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1" xml:lang="en-US" id="label_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1">Basis of Presentation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="label_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1" xlink:title="Label : us-gaap_BasisOfAccountingPolicyPolicyTextBlock to label_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:title="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xml:lang="en-US" id="label_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="label_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:title="Label : us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock to label_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_1" xml:lang="en-US" id="label_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_1">SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="label_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_1" xlink:title="Label : us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock to label_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BoardOfDirectorsChairmanMember" xlink:label="us-gaap_BoardOfDirectorsChairmanMember" xlink:title="us-gaap_BoardOfDirectorsChairmanMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_BoardOfDirectorsChairmanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_BoardOfDirectorsChairmanMember" xml:lang="en-US" id="label_us-gaap_BoardOfDirectorsChairmanMember">Board of Directors Chairman [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BoardOfDirectorsChairmanMember" xlink:to="label_us-gaap_BoardOfDirectorsChairmanMember" xlink:title="Label : us-gaap_BoardOfDirectorsChairmanMember to label_us-gaap_BoardOfDirectorsChairmanMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:title="us-gaap_CounterpartyNameAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_CounterpartyNameAxis" xml:lang="en-US" id="label_us-gaap_CounterpartyNameAxis">Counterparty Name [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="label_us-gaap_CounterpartyNameAxis" xlink:title="Label : us-gaap_CounterpartyNameAxis to label_us-gaap_CounterpartyNameAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:title="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US" id="label_us-gaap_CashAndCashEquivalentsPolicyTextBlock">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="label_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:title="Label : us-gaap_CashAndCashEquivalentsPolicyTextBlock to label_us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CashAndCashEquivalentsPolicyTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_CashAndCashEquivalentsPolicyTextBlock_1" xml:lang="en-US" id="label_us-gaap_CashAndCashEquivalentsPolicyTextBlock_1">Cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="label_us-gaap_CashAndCashEquivalentsPolicyTextBlock_1" xlink:title="Label : us-gaap_CashAndCashEquivalentsPolicyTextBlock to label_us-gaap_CashAndCashEquivalentsPolicyTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:title="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="label_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US" id="label_us-gaap_CashAndCashEquivalentsAtCarryingValue">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="label_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:title="Label : us-gaap_CashAndCashEquivalentsAtCarryingValue to label_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CashAndCashEquivalentsAtCarryingValue_1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="label_us-gaap_CashAndCashEquivalentsAtCarryingValue_1" xml:lang="en-US" id="label_us-gaap_CashAndCashEquivalentsAtCarryingValue_1">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="label_us-gaap_CashAndCashEquivalentsAtCarryingValue_1" xlink:title="Label : us-gaap_CashAndCashEquivalentsAtCarryingValue to label_us-gaap_CashAndCashEquivalentsAtCarryingValue_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CashAndCashEquivalentsAtCarryingValue_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_CashAndCashEquivalentsAtCarryingValue_2" xml:lang="en-US" id="label_us-gaap_CashAndCashEquivalentsAtCarryingValue_2">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="label_us-gaap_CashAndCashEquivalentsAtCarryingValue_2" xlink:title="Label : us-gaap_CashAndCashEquivalentsAtCarryingValue to label_us-gaap_CashAndCashEquivalentsAtCarryingValue_2" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CashAndCashEquivalentsAtCarryingValue_3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_CashAndCashEquivalentsAtCarryingValue_3" xml:lang="en-US" id="label_us-gaap_CashAndCashEquivalentsAtCarryingValue_3">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="label_us-gaap_CashAndCashEquivalentsAtCarryingValue_3" xlink:title="Label : us-gaap_CashAndCashEquivalentsAtCarryingValue to label_us-gaap_CashAndCashEquivalentsAtCarryingValue_3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:title="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US" id="label_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="label_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:title="Label : us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease to label_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_1" xml:lang="en-US" id="label_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_1">NET DECREASE IN CASH AND CASH EQUIVALENTS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="label_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_1" xlink:title="Label : us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease to label_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:title="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xml:lang="en-US" id="label_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="label_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:title="Label : us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract to label_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1" xml:lang="en-US" id="label_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1">SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="label_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1" xlink:title="Label : us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract to label_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" xlink:title="us-gaap_ClassOfStockLineItems" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ClassOfStockLineItems" xml:lang="en-US" id="label_us-gaap_ClassOfStockLineItems">Class of Stock [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="label_us-gaap_ClassOfStockLineItems" xlink:title="Label : us-gaap_ClassOfStockLineItems to label_us-gaap_ClassOfStockLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:title="us-gaap_CommitmentsAndContingencies" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_CommitmentsAndContingencies" xml:lang="en-US" id="label_us-gaap_CommitmentsAndContingencies">COMMITMENTS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="label_us-gaap_CommitmentsAndContingencies" xlink:title="Label : us-gaap_CommitmentsAndContingencies to label_us-gaap_CommitmentsAndContingencies" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CommitmentsAndContingencies_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_CommitmentsAndContingencies_1" xml:lang="en-US" id="label_us-gaap_CommitmentsAndContingencies_1">Commitments and Contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="label_us-gaap_CommitmentsAndContingencies_1" xlink:title="Label : us-gaap_CommitmentsAndContingencies to label_us-gaap_CommitmentsAndContingencies_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="us-gaap_CommitmentsDisclosureTextBlock" xlink:title="us-gaap_CommitmentsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CommitmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_CommitmentsDisclosureTextBlock" xml:lang="en-US" id="label_us-gaap_CommitmentsDisclosureTextBlock">COMMITMENTS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsDisclosureTextBlock" xlink:to="label_us-gaap_CommitmentsDisclosureTextBlock" xlink:title="Label : us-gaap_CommitmentsDisclosureTextBlock to label_us-gaap_CommitmentsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CommitmentsDisclosureTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_CommitmentsDisclosureTextBlock_1" xml:lang="en-US" id="label_us-gaap_CommitmentsDisclosureTextBlock_1">Commitments Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsDisclosureTextBlock" xlink:to="label_us-gaap_CommitmentsDisclosureTextBlock_1" xlink:title="Label : us-gaap_CommitmentsDisclosureTextBlock to label_us-gaap_CommitmentsDisclosureTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:title="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US" id="label_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">COMMITMENTS [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="label_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:title="Label : us-gaap_CommitmentsAndContingenciesDisclosureAbstract to label_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:title="us-gaap_CommonStockValue" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_CommonStockValue" xml:lang="en-US" id="label_us-gaap_CommonStockValue">Common Stock Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="label_us-gaap_CommonStockValue" xlink:title="Label : us-gaap_CommonStockValue to label_us-gaap_CommonStockValue" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CommonStockValue_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_CommonStockValue_1" xml:lang="en-US" id="label_us-gaap_CommonStockValue_1">Common Stock, $0.001 par value: Authorized - as of December 31, 2013 and 2014, 150,000,000 shares; issued and outstanding - as of December 31, 2013 and 2014, 93,551,098 shares and 93,603,819shares, respectively</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="label_us-gaap_CommonStockValue_1" xlink:title="Label : us-gaap_CommonStockValue to label_us-gaap_CommonStockValue_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:title="us-gaap_CommonStockSharesIssued" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_CommonStockSharesIssued" xml:lang="en-US" id="label_us-gaap_CommonStockSharesIssued">Common Stock, issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="label_us-gaap_CommonStockSharesIssued" xlink:title="Label : us-gaap_CommonStockSharesIssued to label_us-gaap_CommonStockSharesIssued" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CommonStockSharesIssued_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_CommonStockSharesIssued_1" xml:lang="en-US" id="label_us-gaap_CommonStockSharesIssued_1">Common Stock, Shares, Issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="label_us-gaap_CommonStockSharesIssued_1" xlink:title="Label : us-gaap_CommonStockSharesIssued to label_us-gaap_CommonStockSharesIssued_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CommonStockSharesIssued_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_CommonStockSharesIssued_2" xml:lang="en-US" id="label_us-gaap_CommonStockSharesIssued_2">Underwritten public offering, common stock issued and sold</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="label_us-gaap_CommonStockSharesIssued_2" xlink:title="Label : us-gaap_CommonStockSharesIssued to label_us-gaap_CommonStockSharesIssued_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:title="us-gaap_CommonStockSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US" id="label_us-gaap_CommonStockSharesAuthorized">Common stock, shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="label_us-gaap_CommonStockSharesAuthorized" xlink:title="Label : us-gaap_CommonStockSharesAuthorized to label_us-gaap_CommonStockSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CommonStockSharesAuthorized_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_CommonStockSharesAuthorized_1" xml:lang="en-US" id="label_us-gaap_CommonStockSharesAuthorized_1">Common Stock, Shares Authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="label_us-gaap_CommonStockSharesAuthorized_1" xlink:title="Label : us-gaap_CommonStockSharesAuthorized to label_us-gaap_CommonStockSharesAuthorized_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:title="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US" id="label_us-gaap_CommonStockParOrStatedValuePerShare">Common Stock, Par or Stated Value Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="label_us-gaap_CommonStockParOrStatedValuePerShare" xlink:title="Label : us-gaap_CommonStockParOrStatedValuePerShare to label_us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CommonStockParOrStatedValuePerShare_1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_CommonStockParOrStatedValuePerShare_1" xml:lang="en-US" id="label_us-gaap_CommonStockParOrStatedValuePerShare_1">Common Stock, par value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="label_us-gaap_CommonStockParOrStatedValuePerShare_1" xlink:title="Label : us-gaap_CommonStockParOrStatedValuePerShare to label_us-gaap_CommonStockParOrStatedValuePerShare_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CommonStockParOrStatedValuePerShare_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_CommonStockParOrStatedValuePerShare_2" xml:lang="en-US" id="label_us-gaap_CommonStockParOrStatedValuePerShare_2">Common stock, par value per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="label_us-gaap_CommonStockParOrStatedValuePerShare_2" xlink:title="Label : us-gaap_CommonStockParOrStatedValuePerShare to label_us-gaap_CommonStockParOrStatedValuePerShare_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:title="us-gaap_CommonStockMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_CommonStockMember" xml:lang="en-US" id="label_us-gaap_CommonStockMember">Common Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="label_us-gaap_CommonStockMember" xlink:title="Label : us-gaap_CommonStockMember to label_us-gaap_CommonStockMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:title="us-gaap_CommonStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US" id="label_us-gaap_CommonStockSharesOutstanding">Common Stock Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="label_us-gaap_CommonStockSharesOutstanding" xlink:title="Label : us-gaap_CommonStockSharesOutstanding to label_us-gaap_CommonStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CommonStockSharesOutstanding_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_CommonStockSharesOutstanding_1" xml:lang="en-US" id="label_us-gaap_CommonStockSharesOutstanding_1">Common Stock, outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="label_us-gaap_CommonStockSharesOutstanding_1" xlink:title="Label : us-gaap_CommonStockSharesOutstanding to label_us-gaap_CommonStockSharesOutstanding_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:title="us-gaap_ComputerEquipmentMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ComputerEquipmentMember" xml:lang="en-US" id="label_us-gaap_ComputerEquipmentMember">Computer Equipment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="label_us-gaap_ComputerEquipmentMember" xlink:title="Label : us-gaap_ComputerEquipmentMember to label_us-gaap_ComputerEquipmentMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:title="us-gaap_ConcentrationRiskCreditRisk" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ConcentrationRiskCreditRisk" xml:lang="en-US" id="label_us-gaap_ConcentrationRiskCreditRisk">Concentration of credit risks and trade receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="label_us-gaap_ConcentrationRiskCreditRisk" xlink:title="Label : us-gaap_ConcentrationRiskCreditRisk to label_us-gaap_ConcentrationRiskCreditRisk" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ConcentrationRiskCreditRisk_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ConcentrationRiskCreditRisk_1" xml:lang="en-US" id="label_us-gaap_ConcentrationRiskCreditRisk_1">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="label_us-gaap_ConcentrationRiskCreditRisk_1" xlink:title="Label : us-gaap_ConcentrationRiskCreditRisk to label_us-gaap_ConcentrationRiskCreditRisk_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="us-gaap_ConvertibleDebtNoncurrent" xlink:title="us-gaap_ConvertibleDebtNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ConvertibleDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ConvertibleDebtNoncurrent" xml:lang="en-US" id="label_us-gaap_ConvertibleDebtNoncurrent">Convertible Debt, Noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtNoncurrent" xlink:to="label_us-gaap_ConvertibleDebtNoncurrent" xlink:title="Label : us-gaap_ConvertibleDebtNoncurrent to label_us-gaap_ConvertibleDebtNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ConvertibleDebtNoncurrent_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ConvertibleDebtNoncurrent_1" xml:lang="en-US" id="label_us-gaap_ConvertibleDebtNoncurrent_1">Convertible notes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtNoncurrent" xlink:to="label_us-gaap_ConvertibleDebtNoncurrent_1" xlink:title="Label : us-gaap_ConvertibleDebtNoncurrent to label_us-gaap_ConvertibleDebtNoncurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures" xlink:title="us-gaap_ConvertibleDebtFairValueDisclosures" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ConvertibleDebtFairValueDisclosures" xml:lang="en-US" id="label_us-gaap_ConvertibleDebtFairValueDisclosures">Convertible Debt, Fair Value Disclosures</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtFairValueDisclosures" xlink:to="label_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:title="Label : us-gaap_ConvertibleDebtFairValueDisclosures to label_us-gaap_ConvertibleDebtFairValueDisclosures" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ConvertibleDebtFairValueDisclosures_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ConvertibleDebtFairValueDisclosures_1" xml:lang="en-US" id="label_us-gaap_ConvertibleDebtFairValueDisclosures_1">Fair value convertible notes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtFairValueDisclosures" xlink:to="label_us-gaap_ConvertibleDebtFairValueDisclosures_1" xlink:title="Label : us-gaap_ConvertibleDebtFairValueDisclosures to label_us-gaap_ConvertibleDebtFairValueDisclosures_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" xlink:title="us-gaap_CostOfRevenue" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_CostOfRevenue" xml:lang="en-US" id="label_us-gaap_CostOfRevenue">Cost of Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="label_us-gaap_CostOfRevenue" xlink:title="Label : us-gaap_CostOfRevenue to label_us-gaap_CostOfRevenue" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CostOfRevenue_1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_us-gaap_CostOfRevenue_1" xml:lang="en-US" id="label_us-gaap_CostOfRevenue_1">COST OF REVENUES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="label_us-gaap_CostOfRevenue_1" xlink:title="Label : us-gaap_CostOfRevenue to label_us-gaap_CostOfRevenue_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember" xlink:title="us-gaap_CostOfSalesMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_CostOfSalesMember" xml:lang="en-US" id="label_us-gaap_CostOfSalesMember">Cost of Revenues [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesMember" xlink:to="label_us-gaap_CostOfSalesMember" xlink:title="Label : us-gaap_CostOfSalesMember to label_us-gaap_CostOfSalesMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CostOfSalesMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_CostOfSalesMember_1" xml:lang="en-US" id="label_us-gaap_CostOfSalesMember_1">Cost of Sales [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesMember" xlink:to="label_us-gaap_CostOfSalesMember_1" xlink:title="Label : us-gaap_CostOfSalesMember to label_us-gaap_CostOfSalesMember_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:title="us-gaap_DebtDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DebtDisclosureAbstract" xml:lang="en-US" id="label_us-gaap_DebtDisclosureAbstract">CONVERTIBLE NOTES [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="label_us-gaap_DebtDisclosureAbstract" xlink:title="Label : us-gaap_DebtDisclosureAbstract to label_us-gaap_DebtDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:title="us-gaap_DebtInstrumentAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DebtInstrumentAxis" xml:lang="en-US" id="label_us-gaap_DebtInstrumentAxis">Debt Instrument [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="label_us-gaap_DebtInstrumentAxis" xlink:title="Label : us-gaap_DebtInstrumentAxis to label_us-gaap_DebtInstrumentAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:title="us-gaap_DebtDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_DebtDisclosureTextBlock" xml:lang="en-US" id="label_us-gaap_DebtDisclosureTextBlock">CONVERTIBLE NOTES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="label_us-gaap_DebtDisclosureTextBlock" xlink:title="Label : us-gaap_DebtDisclosureTextBlock to label_us-gaap_DebtDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DebtDisclosureTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DebtDisclosureTextBlock_1" xml:lang="en-US" id="label_us-gaap_DebtDisclosureTextBlock_1">Debt Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="label_us-gaap_DebtDisclosureTextBlock_1" xlink:title="Label : us-gaap_DebtDisclosureTextBlock to label_us-gaap_DebtDisclosureTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:title="us-gaap_DebtInstrumentConvertibleConversionPrice1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_DebtInstrumentConvertibleConversionPrice1" xml:lang="en-US" id="label_us-gaap_DebtInstrumentConvertibleConversionPrice1">Conversion price per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="label_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:title="Label : us-gaap_DebtInstrumentConvertibleConversionPrice1 to label_us-gaap_DebtInstrumentConvertibleConversionPrice1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DebtInstrumentConvertibleConversionPrice1_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DebtInstrumentConvertibleConversionPrice1_1" xml:lang="en-US" id="label_us-gaap_DebtInstrumentConvertibleConversionPrice1_1">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="label_us-gaap_DebtInstrumentConvertibleConversionPrice1_1" xlink:title="Label : us-gaap_DebtInstrumentConvertibleConversionPrice1 to label_us-gaap_DebtInstrumentConvertibleConversionPrice1_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:title="us-gaap_DebtInstrumentMaturityDate" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DebtInstrumentMaturityDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DebtInstrumentMaturityDate" xml:lang="en-US" id="label_us-gaap_DebtInstrumentMaturityDate">Debt Instrument, Maturity Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="label_us-gaap_DebtInstrumentMaturityDate" xlink:title="Label : us-gaap_DebtInstrumentMaturityDate to label_us-gaap_DebtInstrumentMaturityDate" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DebtInstrumentMaturityDate_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_DebtInstrumentMaturityDate_1" xml:lang="en-US" id="label_us-gaap_DebtInstrumentMaturityDate_1">Maturity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="label_us-gaap_DebtInstrumentMaturityDate_1" xlink:title="Label : us-gaap_DebtInstrumentMaturityDate to label_us-gaap_DebtInstrumentMaturityDate_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DebtInstrumentMaturityDate_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_DebtInstrumentMaturityDate_2" xml:lang="en-US" id="label_us-gaap_DebtInstrumentMaturityDate_2">Maturity date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="label_us-gaap_DebtInstrumentMaturityDate_2" xlink:title="Label : us-gaap_DebtInstrumentMaturityDate to label_us-gaap_DebtInstrumentMaturityDate_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:title="us-gaap_DebtInstrumentNameDomain" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DebtInstrumentNameDomain" xml:lang="en-US" id="label_us-gaap_DebtInstrumentNameDomain">Debt Instrument, Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="label_us-gaap_DebtInstrumentNameDomain" xlink:title="Label : us-gaap_DebtInstrumentNameDomain to label_us-gaap_DebtInstrumentNameDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:title="us-gaap_DebtInstrumentFaceAmount" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US" id="label_us-gaap_DebtInstrumentFaceAmount">Promissory note, amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="label_us-gaap_DebtInstrumentFaceAmount" xlink:title="Label : us-gaap_DebtInstrumentFaceAmount to label_us-gaap_DebtInstrumentFaceAmount" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DebtInstrumentFaceAmount_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DebtInstrumentFaceAmount_1" xml:lang="en-US" id="label_us-gaap_DebtInstrumentFaceAmount_1">Debt Instrument, Face Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="label_us-gaap_DebtInstrumentFaceAmount_1" xlink:title="Label : us-gaap_DebtInstrumentFaceAmount to label_us-gaap_DebtInstrumentFaceAmount_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DebtInstrumentFaceAmount_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_DebtInstrumentFaceAmount_2" xml:lang="en-US" id="label_us-gaap_DebtInstrumentFaceAmount_2">Principal amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="label_us-gaap_DebtInstrumentFaceAmount_2" xlink:title="Label : us-gaap_DebtInstrumentFaceAmount to label_us-gaap_DebtInstrumentFaceAmount_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:title="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US" id="label_us-gaap_DebtInstrumentInterestRateStatedPercentage">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="label_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:title="Label : us-gaap_DebtInstrumentInterestRateStatedPercentage to label_us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DebtInstrumentInterestRateStatedPercentage_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_DebtInstrumentInterestRateStatedPercentage_1" xml:lang="en-US" id="label_us-gaap_DebtInstrumentInterestRateStatedPercentage_1">Interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="label_us-gaap_DebtInstrumentInterestRateStatedPercentage_1" xlink:title="Label : us-gaap_DebtInstrumentInterestRateStatedPercentage to label_us-gaap_DebtInstrumentInterestRateStatedPercentage_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock" xlink:title="us-gaap_DebtPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DebtPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_DebtPolicyTextBlock" xml:lang="en-US" id="label_us-gaap_DebtPolicyTextBlock">Convertible notes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtPolicyTextBlock" xlink:to="label_us-gaap_DebtPolicyTextBlock" xlink:title="Label : us-gaap_DebtPolicyTextBlock to label_us-gaap_DebtPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DebtPolicyTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DebtPolicyTextBlock_1" xml:lang="en-US" id="label_us-gaap_DebtPolicyTextBlock_1">Debt, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtPolicyTextBlock" xlink:to="label_us-gaap_DebtPolicyTextBlock_1" xlink:title="Label : us-gaap_DebtPolicyTextBlock to label_us-gaap_DebtPolicyTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:title="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xml:lang="en-US" id="label_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">Deferred Tax Assets, Property, Plant and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="label_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:title="Label : us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment to label_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_1" xml:lang="en-US" id="label_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_1">Property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="label_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_1" xlink:title="Label : us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment to label_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredCosts" xlink:label="us-gaap_DeferredCosts" xlink:title="us-gaap_DeferredCosts" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DeferredCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_DeferredCosts" xml:lang="en-US" id="label_us-gaap_DeferredCosts">DEFERRED CHARGES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCosts" xlink:to="label_us-gaap_DeferredCosts" xlink:title="Label : us-gaap_DeferredCosts to label_us-gaap_DeferredCosts" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DeferredCosts_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DeferredCosts_1" xml:lang="en-US" id="label_us-gaap_DeferredCosts_1">Deferred Costs, Noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCosts" xlink:to="label_us-gaap_DeferredCosts_1" xlink:title="Label : us-gaap_DeferredCosts to label_us-gaap_DeferredCosts_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:title="us-gaap_DeferredTaxAssetsDeferredIncome" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_DeferredTaxAssetsDeferredIncome" xml:lang="en-US" id="label_us-gaap_DeferredTaxAssetsDeferredIncome">Deferred revenues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="label_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:title="Label : us-gaap_DeferredTaxAssetsDeferredIncome to label_us-gaap_DeferredTaxAssetsDeferredIncome" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DeferredTaxAssetsDeferredIncome_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DeferredTaxAssetsDeferredIncome_1" xml:lang="en-US" id="label_us-gaap_DeferredTaxAssetsDeferredIncome_1">Deferred Tax Assets, Deferred Income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="label_us-gaap_DeferredTaxAssetsDeferredIncome_1" xlink:title="Label : us-gaap_DeferredTaxAssetsDeferredIncome to label_us-gaap_DeferredTaxAssetsDeferredIncome_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:title="us-gaap_DeferredRevenueCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DeferredRevenueCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DeferredRevenueCurrent" xml:lang="en-US" id="label_us-gaap_DeferredRevenueCurrent">Deferred Revenue, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="label_us-gaap_DeferredRevenueCurrent" xlink:title="Label : us-gaap_DeferredRevenueCurrent to label_us-gaap_DeferredRevenueCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DeferredRevenueCurrent_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_DeferredRevenueCurrent_1" xml:lang="en-US" id="label_us-gaap_DeferredRevenueCurrent_1">Deferred revenues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="label_us-gaap_DeferredRevenueCurrent_1" xlink:title="Label : us-gaap_DeferredRevenueCurrent to label_us-gaap_DeferredRevenueCurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent" xlink:title="us-gaap_DeferredRevenueNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DeferredRevenueNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DeferredRevenueNoncurrent" xml:lang="en-US" id="label_us-gaap_DeferredRevenueNoncurrent">Deferred Revenue, Noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="label_us-gaap_DeferredRevenueNoncurrent" xlink:title="Label : us-gaap_DeferredRevenueNoncurrent to label_us-gaap_DeferredRevenueNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DeferredRevenueNoncurrent_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_DeferredRevenueNoncurrent_1" xml:lang="en-US" id="label_us-gaap_DeferredRevenueNoncurrent_1">Deferred revenues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="label_us-gaap_DeferredRevenueNoncurrent_1" xlink:title="Label : us-gaap_DeferredRevenueNoncurrent to label_us-gaap_DeferredRevenueNoncurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:title="us-gaap_DeferredTaxAssetsNet" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DeferredTaxAssetsNet" xml:lang="en-US" id="label_us-gaap_DeferredTaxAssetsNet">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="label_us-gaap_DeferredTaxAssetsNet" xlink:title="Label : us-gaap_DeferredTaxAssetsNet to label_us-gaap_DeferredTaxAssetsNet" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DeferredTaxAssetsNet_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_DeferredTaxAssetsNet_1" xml:lang="en-US" id="label_us-gaap_DeferredTaxAssetsNet_1">Deferred Tax Assets, Net of Valuation Allowance, Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="label_us-gaap_DeferredTaxAssetsNet_1" xlink:title="Label : us-gaap_DeferredTaxAssetsNet to label_us-gaap_DeferredTaxAssetsNet_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:title="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xml:lang="en-US" id="label_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="label_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:title="Label : us-gaap_DeferredTaxAssetsOperatingLossCarryforwards to label_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1" xml:lang="en-US" id="label_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1">Net operating loss carry forwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="label_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1" xlink:title="Label : us-gaap_DeferredTaxAssetsOperatingLossCarryforwards to label_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:title="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xml:lang="en-US" id="label_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:to="label_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:title="Label : us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits to label_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_1" xml:lang="en-US" id="label_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_1">Provision for vacation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:to="label_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_1" xlink:title="Label : us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits to label_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:title="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xml:lang="en-US" id="label_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">Deferred Tax Assets, in Process Research and Development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="label_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:title="Label : us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment to label_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_1" xml:lang="en-US" id="label_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_1">Research and development expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="label_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_1" xlink:title="Label : us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment to label_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:title="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US" id="label_us-gaap_DeferredTaxAssetsValuationAllowance">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="label_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:title="Label : us-gaap_DeferredTaxAssetsValuationAllowance to label_us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DeferredTaxAssetsValuationAllowance_1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_us-gaap_DeferredTaxAssetsValuationAllowance_1" xml:lang="en-US" id="label_us-gaap_DeferredTaxAssetsValuationAllowance_1">Valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="label_us-gaap_DeferredTaxAssetsValuationAllowance_1" xlink:title="Label : us-gaap_DeferredTaxAssetsValuationAllowance to label_us-gaap_DeferredTaxAssetsValuationAllowance_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments" xlink:title="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments" xml:lang="en-US" id="label_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Severance Payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments" xlink:to="label_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments" xlink:title="Label : us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments to label_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments_1" xml:lang="en-US" id="label_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments_1">Severance pay obligation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments" xlink:to="label_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments_1" xlink:title="Label : us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments to label_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:title="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xml:lang="en-US" id="label_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">Contributions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="label_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:title="Label : us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount to label_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_1" xml:lang="en-US" id="label_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_1">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="label_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_1" xlink:title="Label : us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount to label_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" xlink:label="us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" xlink:title="us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" xml:lang="en-US" id="label_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax">Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss), Net Gain (Loss), before Tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" xlink:to="label_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" xlink:title="Label : us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax to label_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_1" xml:lang="en-US" id="label_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_1">Net (gain) or loss for the period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" xlink:to="label_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_1" xlink:title="Label : us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax to label_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:label="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:title="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xml:lang="en-US" id="label_us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract">LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:to="label_us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:title="Label : us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract to label_us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:title="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xml:lang="en-US" id="label_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent">Defined Benefit Plan, Assets for Plan Benefits, Noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:to="label_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:title="Label : us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent to label_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_1" xml:lang="en-US" id="label_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_1">FUNDS IN RESPECT OF EMPLOYEE RIGHTS UPON RETIREMENT</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:to="label_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_1" xlink:title="Label : us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent to label_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:title="us-gaap_Depreciation" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_Depreciation" xml:lang="en-US" id="label_us-gaap_Depreciation">Depreciation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="label_us-gaap_Depreciation" xlink:title="Label : us-gaap_Depreciation to label_us-gaap_Depreciation" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_Depreciation_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_Depreciation_1" xml:lang="en-US" id="label_us-gaap_Depreciation_1">Depreciation and write down of fixed assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="label_us-gaap_Depreciation_1" xlink:title="Label : us-gaap_Depreciation to label_us-gaap_Depreciation_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_Depreciation_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_Depreciation_2" xml:lang="en-US" id="label_us-gaap_Depreciation_2">Depreciation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="label_us-gaap_Depreciation_2" xlink:title="Label : us-gaap_Depreciation to label_us-gaap_Depreciation_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xml:lang="en-US" id="label_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">SHARE CAPITAL [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="label_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="Label : us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to label_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:title="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US" id="label_us-gaap_EarningsPerSharePolicyTextBlock">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="label_us-gaap_EarningsPerSharePolicyTextBlock" xlink:title="Label : us-gaap_EarningsPerSharePolicyTextBlock to label_us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EarningsPerSharePolicyTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_EarningsPerSharePolicyTextBlock_1" xml:lang="en-US" id="label_us-gaap_EarningsPerSharePolicyTextBlock_1">Net loss per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="label_us-gaap_EarningsPerSharePolicyTextBlock_1" xlink:title="Label : us-gaap_EarningsPerSharePolicyTextBlock to label_us-gaap_EarningsPerSharePolicyTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:title="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xml:lang="en-US" id="label_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract">Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="label_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:title="Label : us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract to label_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_1" xml:lang="en-US" id="label_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_1">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE - BASIC AND DILUTED:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="label_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_1" xlink:title="Label : us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract to label_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_2" xml:lang="en-US" id="label_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_2">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE - BASIC AND DILUTED:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="label_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_2" xlink:title="Label : us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract to label_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:title="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US" id="label_us-gaap_EarningsPerShareBasicAndDiluted">NET LOSS PER SHARE OF COMMON STOCK - BASIC AND DILUTED:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="label_us-gaap_EarningsPerShareBasicAndDiluted" xlink:title="Label : us-gaap_EarningsPerShareBasicAndDiluted to label_us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EarningsPerShareBasicAndDiluted_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_EarningsPerShareBasicAndDiluted_1" xml:lang="en-US" id="label_us-gaap_EarningsPerShareBasicAndDiluted_1">Earnings Per Share, Basic and Diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="label_us-gaap_EarningsPerShareBasicAndDiluted_1" xlink:title="Label : us-gaap_EarningsPerShareBasicAndDiluted to label_us-gaap_EarningsPerShareBasicAndDiluted_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EarningsPerShareBasicAndDiluted_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_EarningsPerShareBasicAndDiluted_2" xml:lang="en-US" id="label_us-gaap_EarningsPerShareBasicAndDiluted_2">NET LOSS PER SHARE OF COMMON STOCK - BASIC AND DILUTED</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="label_us-gaap_EarningsPerShareBasicAndDiluted_2" xlink:title="Label : us-gaap_EarningsPerShareBasicAndDiluted to label_us-gaap_EarningsPerShareBasicAndDiluted_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:title="us-gaap_EarningsPerShareAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_EarningsPerShareAbstract" xml:lang="en-US" id="label_us-gaap_EarningsPerShareAbstract">Earnings Per Share [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="label_us-gaap_EarningsPerShareAbstract" xlink:title="Label : us-gaap_EarningsPerShareAbstract to label_us-gaap_EarningsPerShareAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EarningsPerShareAbstract_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_EarningsPerShareAbstract_1" xml:lang="en-US" id="label_us-gaap_EarningsPerShareAbstract_1">NET LOSS PER SHARE OF COMMON STOCK</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="label_us-gaap_EarningsPerShareAbstract_1" xlink:title="Label : us-gaap_EarningsPerShareAbstract to label_us-gaap_EarningsPerShareAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:title="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xml:lang="en-US" id="label_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">EFFECT OF EXCHANGE RATE CHANGES ON CASH</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="label_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:title="Label : us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents to label_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_1" xml:lang="en-US" id="label_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_1">Effect of Exchange Rate on Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="label_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_1" xlink:title="Label : us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents to label_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:title="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US" id="label_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="label_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:title="Label : us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate to label_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1" xml:lang="en-US" id="label_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1">Statutory income tax rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="label_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1" xlink:title="Label : us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate to label_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xml:lang="en-US" id="label_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="label_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="Label : us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to label_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:title="us-gaap_EmployeeStockOptionMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_EmployeeStockOptionMember" xml:lang="en-US" id="label_us-gaap_EmployeeStockOptionMember">Employee Stock Option [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="label_us-gaap_EmployeeStockOptionMember" xlink:title="Label : us-gaap_EmployeeStockOptionMember to label_us-gaap_EmployeeStockOptionMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EmployeeStockOptionMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_EmployeeStockOptionMember_1" xml:lang="en-US" id="label_us-gaap_EmployeeStockOptionMember_1">Option to purchase shares of common stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="label_us-gaap_EmployeeStockOptionMember_1" xlink:title="Label : us-gaap_EmployeeStockOptionMember to label_us-gaap_EmployeeStockOptionMember_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US" id="label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="Label : us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 to label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1" xml:lang="en-US" id="label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1">Unrecognized compensation cost, recognition period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1" xlink:title="Label : us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 to label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xml:lang="en-US" id="label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:title="Label : us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized to label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1" xml:lang="en-US" id="label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1">Unrecognized share-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1" xlink:title="Label : us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized to label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:title="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_EmployeeRelatedLiabilitiesCurrent" xml:lang="en-US" id="label_us-gaap_EmployeeRelatedLiabilitiesCurrent">Employee-related Liabilities, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="label_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:title="Label : us-gaap_EmployeeRelatedLiabilitiesCurrent to label_us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EmployeeRelatedLiabilitiesCurrent_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_EmployeeRelatedLiabilitiesCurrent_1" xml:lang="en-US" id="label_us-gaap_EmployeeRelatedLiabilitiesCurrent_1">Payroll and related expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="label_us-gaap_EmployeeRelatedLiabilitiesCurrent_1" xlink:title="Label : us-gaap_EmployeeRelatedLiabilitiesCurrent to label_us-gaap_EmployeeRelatedLiabilitiesCurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:title="us-gaap_EquityComponentDomain" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_EquityComponentDomain" xml:lang="en-US" id="label_us-gaap_EquityComponentDomain">Equity Component [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="label_us-gaap_EquityComponentDomain" xlink:title="Label : us-gaap_EquityComponentDomain to label_us-gaap_EquityComponentDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ExecutiveOfficerMember" xlink:label="us-gaap_ExecutiveOfficerMember" xlink:title="us-gaap_ExecutiveOfficerMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ExecutiveOfficerMember" xml:lang="en-US" id="label_us-gaap_ExecutiveOfficerMember">Executive Officer [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExecutiveOfficerMember" xlink:to="label_us-gaap_ExecutiveOfficerMember" xlink:title="Label : us-gaap_ExecutiveOfficerMember to label_us-gaap_ExecutiveOfficerMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ExecutiveOfficerMember_1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_ExecutiveOfficerMember_1" xml:lang="en-US" id="label_us-gaap_ExecutiveOfficerMember_1">Directors and Executive Officers [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExecutiveOfficerMember" xlink:to="label_us-gaap_ExecutiveOfficerMember_1" xlink:title="Label : us-gaap_ExecutiveOfficerMember to label_us-gaap_ExecutiveOfficerMember_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:title="us-gaap_FairValueDisclosuresAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_FairValueDisclosuresAbstract" xml:lang="en-US" id="label_us-gaap_FairValueDisclosuresAbstract">FAIR VALUE MEASUREMENT [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="label_us-gaap_FairValueDisclosuresAbstract" xlink:title="Label : us-gaap_FairValueDisclosuresAbstract to label_us-gaap_FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:title="us-gaap_FairValueDisclosuresTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_FairValueDisclosuresTextBlock" xml:lang="en-US" id="label_us-gaap_FairValueDisclosuresTextBlock">Fair Value Disclosures [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="label_us-gaap_FairValueDisclosuresTextBlock" xlink:title="Label : us-gaap_FairValueDisclosuresTextBlock to label_us-gaap_FairValueDisclosuresTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_FairValueDisclosuresTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_FairValueDisclosuresTextBlock_1" xml:lang="en-US" id="label_us-gaap_FairValueDisclosuresTextBlock_1">FAIR VALUE MEASUREMENT</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="label_us-gaap_FairValueDisclosuresTextBlock_1" xlink:title="Label : us-gaap_FairValueDisclosuresTextBlock to label_us-gaap_FairValueDisclosuresTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:title="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xml:lang="en-US" id="label_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">Financial expenses, net (mainly exchange differences)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="label_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:title="Label : us-gaap_ForeignCurrencyTransactionGainLossUnrealized to label_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_1" xml:lang="en-US" id="label_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_1">Foreign Currency Transaction Gain (Loss), Unrealized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="label_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_1" xlink:title="Label : us-gaap_ForeignCurrencyTransactionGainLossUnrealized to label_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:title="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xml:lang="en-US" id="label_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="label_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:title="Label : us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock to label_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_1" xml:lang="en-US" id="label_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_1">Functional currency</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="label_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_1" xlink:title="Label : us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock to label_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:title="us-gaap_FurnitureAndFixturesMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_FurnitureAndFixturesMember" xml:lang="en-US" id="label_us-gaap_FurnitureAndFixturesMember">Furniture [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="label_us-gaap_FurnitureAndFixturesMember" xlink:title="Label : us-gaap_FurnitureAndFixturesMember to label_us-gaap_FurnitureAndFixturesMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_FurnitureAndFixturesMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_FurnitureAndFixturesMember_1" xml:lang="en-US" id="label_us-gaap_FurnitureAndFixturesMember_1">Furniture and Fixtures [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="label_us-gaap_FurnitureAndFixturesMember_1" xlink:title="Label : us-gaap_FurnitureAndFixturesMember to label_us-gaap_FurnitureAndFixturesMember_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:title="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xml:lang="en-US" id="label_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">Gain (Loss) on Sale of Property Plant Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="label_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:title="Label : us-gaap_GainLossOnSaleOfPropertyPlantEquipment to label_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_1" xml:lang="en-US" id="label_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_1">Gain on sale of fixed assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="label_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_1" xlink:title="Label : us-gaap_GainLossOnSaleOfPropertyPlantEquipment to label_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" xlink:title="us-gaap_GrossProfit" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_GrossProfit" xml:lang="en-US" id="label_us-gaap_GrossProfit">Gross Profit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="label_us-gaap_GrossProfit" xlink:title="Label : us-gaap_GrossProfit to label_us-gaap_GrossProfit" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_GrossProfit_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_GrossProfit_1" xml:lang="en-US" id="label_us-gaap_GrossProfit_1">GROSS PROFIT</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="label_us-gaap_GrossProfit_1" xlink:title="Label : us-gaap_GrossProfit to label_us-gaap_GrossProfit_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:title="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xml:lang="en-US" id="label_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">Impairment in value of long-lived assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="label_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:title="Label : us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock to label_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_1" xml:lang="en-US" id="label_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_1">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="label_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_1" xlink:title="Label : us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock to label_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:title="us-gaap_IncomeStatementLocationAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_IncomeStatementLocationAxis" xml:lang="en-US" id="label_us-gaap_IncomeStatementLocationAxis">Income Statement Location [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="label_us-gaap_IncomeStatementLocationAxis" xlink:title="Label : us-gaap_IncomeStatementLocationAxis to label_us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:title="us-gaap_IncomeStatementAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_IncomeStatementAbstract" xml:lang="en-US" id="label_us-gaap_IncomeStatementAbstract">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="label_us-gaap_IncomeStatementAbstract" xlink:title="Label : us-gaap_IncomeStatementAbstract to label_us-gaap_IncomeStatementAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:title="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_IncomeTaxDisclosureAbstract" xml:lang="en-US" id="label_us-gaap_IncomeTaxDisclosureAbstract">TAXES ON INCOME [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="label_us-gaap_IncomeTaxDisclosureAbstract" xlink:title="Label : us-gaap_IncomeTaxDisclosureAbstract to label_us-gaap_IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:title="us-gaap_IncomeTaxAuthorityAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_IncomeTaxAuthorityAxis" xml:lang="en-US" id="label_us-gaap_IncomeTaxAuthorityAxis">Income Tax Authority [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="label_us-gaap_IncomeTaxAuthorityAxis" xlink:title="Label : us-gaap_IncomeTaxAuthorityAxis to label_us-gaap_IncomeTaxAuthorityAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:title="us-gaap_IncomeStatementLocationDomain" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_IncomeStatementLocationDomain" xml:lang="en-US" id="label_us-gaap_IncomeStatementLocationDomain">Income Statement Location [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="label_us-gaap_IncomeStatementLocationDomain" xlink:title="Label : us-gaap_IncomeStatementLocationDomain to label_us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="us-gaap_IncomeTaxContingencyLineItems" xlink:title="us-gaap_IncomeTaxContingencyLineItems" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_IncomeTaxContingencyLineItems" xml:lang="en-US" id="label_us-gaap_IncomeTaxContingencyLineItems">Income Tax Contingency [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="label_us-gaap_IncomeTaxContingencyLineItems" xlink:title="Label : us-gaap_IncomeTaxContingencyLineItems to label_us-gaap_IncomeTaxContingencyLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:title="us-gaap_IncomeTaxAuthorityDomain" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_IncomeTaxAuthorityDomain" xml:lang="en-US" id="label_us-gaap_IncomeTaxAuthorityDomain">Income Tax Authority [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="label_us-gaap_IncomeTaxAuthorityDomain" xlink:title="Label : us-gaap_IncomeTaxAuthorityDomain to label_us-gaap_IncomeTaxAuthorityDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:title="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US" id="label_us-gaap_IncomeTaxDisclosureTextBlock">Income Tax Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="label_us-gaap_IncomeTaxDisclosureTextBlock" xlink:title="Label : us-gaap_IncomeTaxDisclosureTextBlock to label_us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncomeTaxDisclosureTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_IncomeTaxDisclosureTextBlock_1" xml:lang="en-US" id="label_us-gaap_IncomeTaxDisclosureTextBlock_1">TAXES ON INCOME</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="label_us-gaap_IncomeTaxDisclosureTextBlock_1" xlink:title="Label : us-gaap_IncomeTaxDisclosureTextBlock to label_us-gaap_IncomeTaxDisclosureTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="us-gaap_IncomeTaxContingencyTable" xlink:title="us-gaap_IncomeTaxContingencyTable" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_IncomeTaxContingencyTable" xml:lang="en-US" id="label_us-gaap_IncomeTaxContingencyTable">Income Tax Contingency [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="label_us-gaap_IncomeTaxContingencyTable" xlink:title="Label : us-gaap_IncomeTaxContingencyTable to label_us-gaap_IncomeTaxContingencyTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:title="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US" id="label_us-gaap_IncomeTaxPolicyTextBlock">Income Tax, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="label_us-gaap_IncomeTaxPolicyTextBlock" xlink:title="Label : us-gaap_IncomeTaxPolicyTextBlock to label_us-gaap_IncomeTaxPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncomeTaxPolicyTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_IncomeTaxPolicyTextBlock_1" xml:lang="en-US" id="label_us-gaap_IncomeTaxPolicyTextBlock_1">Income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="label_us-gaap_IncomeTaxPolicyTextBlock_1" xlink:title="Label : us-gaap_IncomeTaxPolicyTextBlock to label_us-gaap_IncomeTaxPolicyTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:title="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInAccountsReceivable">Increase (Decrease) in Accounts Receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="label_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:title="Label : us-gaap_IncreaseDecreaseInAccountsReceivable to label_us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncreaseDecreaseInAccountsReceivable_1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_us-gaap_IncreaseDecreaseInAccountsReceivable_1" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInAccountsReceivable_1">Increase in accounts receivable and other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="label_us-gaap_IncreaseDecreaseInAccountsReceivable_1" xlink:title="Label : us-gaap_IncreaseDecreaseInAccountsReceivable to label_us-gaap_IncreaseDecreaseInAccountsReceivable_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">Decrease in accounts payable and accruals (including long term )</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="label_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="Label : us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities to label_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="label_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1" xlink:title="Label : us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities to label_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2">Decrease in accounts payable and accruals (including long term )</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="label_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2" xlink:title="Label : us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities to label_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:title="us-gaap_IncreaseDecreaseInDeferredRevenue" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_IncreaseDecreaseInDeferredRevenue" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInDeferredRevenue">Decrease in deferred revenues (including non-current portion)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="label_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:title="Label : us-gaap_IncreaseDecreaseInDeferredRevenue to label_us-gaap_IncreaseDecreaseInDeferredRevenue" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncreaseDecreaseInDeferredRevenue_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_IncreaseDecreaseInDeferredRevenue_1" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInDeferredRevenue_1">Increase (Decrease) in Deferred Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="label_us-gaap_IncreaseDecreaseInDeferredRevenue_1" xlink:title="Label : us-gaap_IncreaseDecreaseInDeferredRevenue to label_us-gaap_IncreaseDecreaseInDeferredRevenue_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="label_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="Label : us-gaap_IncreaseDecreaseInOperatingCapitalAbstract to label_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="label_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1" xlink:title="Label : us-gaap_IncreaseDecreaseInOperatingCapitalAbstract to label_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:title="us-gaap_IncreaseDecreaseInInventories" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_us-gaap_IncreaseDecreaseInInventories" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInInventories">Decrease in inventories</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="label_us-gaap_IncreaseDecreaseInInventories" xlink:title="Label : us-gaap_IncreaseDecreaseInInventories to label_us-gaap_IncreaseDecreaseInInventories" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncreaseDecreaseInInventories_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_IncreaseDecreaseInInventories_1" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInInventories_1">Increase (Decrease) in Inventories</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="label_us-gaap_IncreaseDecreaseInInventories_1" xlink:title="Label : us-gaap_IncreaseDecreaseInInventories to label_us-gaap_IncreaseDecreaseInInventories_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:title="us-gaap_IncreaseDecreaseInRestrictedCash" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncreaseDecreaseInRestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_IncreaseDecreaseInRestrictedCash" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInRestrictedCash">Increase (Decrease) in Restricted Cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:to="label_us-gaap_IncreaseDecreaseInRestrictedCash" xlink:title="Label : us-gaap_IncreaseDecreaseInRestrictedCash to label_us-gaap_IncreaseDecreaseInRestrictedCash" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncreaseDecreaseInRestrictedCash_1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_us-gaap_IncreaseDecreaseInRestrictedCash_1" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInRestrictedCash_1">Investment in restricted deposit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:to="label_us-gaap_IncreaseDecreaseInRestrictedCash_1" xlink:title="Label : us-gaap_IncreaseDecreaseInRestrictedCash to label_us-gaap_IncreaseDecreaseInRestrictedCash_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization" xlink:title="us-gaap_InterestExpenseDebtExcludingAmortization" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_InterestExpenseDebtExcludingAmortization" xml:lang="en-US" id="label_us-gaap_InterestExpenseDebtExcludingAmortization">Contractual interest expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebtExcludingAmortization" xlink:to="label_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:title="Label : us-gaap_InterestExpenseDebtExcludingAmortization to label_us-gaap_InterestExpenseDebtExcludingAmortization" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InterestExpenseDebtExcludingAmortization_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_InterestExpenseDebtExcludingAmortization_1" xml:lang="en-US" id="label_us-gaap_InterestExpenseDebtExcludingAmortization_1">Interest Expense, Debt, Excluding Amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebtExcludingAmortization" xlink:to="label_us-gaap_InterestExpenseDebtExcludingAmortization_1" xlink:title="Label : us-gaap_InterestExpenseDebtExcludingAmortization to label_us-gaap_InterestExpenseDebtExcludingAmortization_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xlink:title="us-gaap_InterestExpense" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_InterestExpense" xml:lang="en-US" id="label_us-gaap_InterestExpense">Interest Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="label_us-gaap_InterestExpense" xlink:title="Label : us-gaap_InterestExpense to label_us-gaap_InterestExpense" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InterestExpense_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_InterestExpense_1" xml:lang="en-US" id="label_us-gaap_InterestExpense_1">Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="label_us-gaap_InterestExpense_1" xlink:title="Label : us-gaap_InterestExpense to label_us-gaap_InterestExpense_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:title="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xml:lang="en-US" id="label_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock">Interest Income and Interest Expense Disclosure [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:to="label_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:title="Label : us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock to label_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_1" xml:lang="en-US" id="label_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_1">Schedule of Interest Expense Recognized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:to="label_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_1" xlink:title="Label : us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock to label_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" xlink:title="us-gaap_InterestPayableCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_InterestPayableCurrent" xml:lang="en-US" id="label_us-gaap_InterestPayableCurrent">Interest payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="label_us-gaap_InterestPayableCurrent" xlink:title="Label : us-gaap_InterestPayableCurrent to label_us-gaap_InterestPayableCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InterestPayableCurrent_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_InterestPayableCurrent_1" xml:lang="en-US" id="label_us-gaap_InterestPayableCurrent_1">Interest Payable, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="label_us-gaap_InterestPayableCurrent_1" xlink:title="Label : us-gaap_InterestPayableCurrent to label_us-gaap_InterestPayableCurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" xlink:title="us-gaap_InterestPaidNet" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_InterestPaidNet" xml:lang="en-US" id="label_us-gaap_InterestPaidNet">Interest paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="label_us-gaap_InterestPaidNet" xlink:title="Label : us-gaap_InterestPaidNet to label_us-gaap_InterestPaidNet" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InterestPaidNet_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_InterestPaidNet_1" xml:lang="en-US" id="label_us-gaap_InterestPaidNet_1">Interest Paid, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="label_us-gaap_InterestPaidNet_1" xlink:title="Label : us-gaap_InterestPaidNet to label_us-gaap_InterestPaidNet_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:title="us-gaap_InventoryPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_InventoryPolicyTextBlock" xml:lang="en-US" id="label_us-gaap_InventoryPolicyTextBlock">Inventories</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="label_us-gaap_InventoryPolicyTextBlock" xlink:title="Label : us-gaap_InventoryPolicyTextBlock to label_us-gaap_InventoryPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InventoryPolicyTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_InventoryPolicyTextBlock_1" xml:lang="en-US" id="label_us-gaap_InventoryPolicyTextBlock_1">Inventory, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="label_us-gaap_InventoryPolicyTextBlock_1" xlink:title="Label : us-gaap_InventoryPolicyTextBlock to label_us-gaap_InventoryPolicyTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:title="us-gaap_InventoryFinishedGoodsNetOfReserves" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_InventoryFinishedGoodsNetOfReserves" xml:lang="en-US" id="label_us-gaap_InventoryFinishedGoodsNetOfReserves">Finished goods</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="label_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:title="Label : us-gaap_InventoryFinishedGoodsNetOfReserves to label_us-gaap_InventoryFinishedGoodsNetOfReserves" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InventoryFinishedGoodsNetOfReserves_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_InventoryFinishedGoodsNetOfReserves_1" xml:lang="en-US" id="label_us-gaap_InventoryFinishedGoodsNetOfReserves_1">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="label_us-gaap_InventoryFinishedGoodsNetOfReserves_1" xlink:title="Label : us-gaap_InventoryFinishedGoodsNetOfReserves to label_us-gaap_InventoryFinishedGoodsNetOfReserves_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:title="us-gaap_InventoryDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_InventoryDisclosureTextBlock" xml:lang="en-US" id="label_us-gaap_InventoryDisclosureTextBlock">INVENTORIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="label_us-gaap_InventoryDisclosureTextBlock" xlink:title="Label : us-gaap_InventoryDisclosureTextBlock to label_us-gaap_InventoryDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InventoryDisclosureTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_InventoryDisclosureTextBlock_1" xml:lang="en-US" id="label_us-gaap_InventoryDisclosureTextBlock_1">Inventory Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="label_us-gaap_InventoryDisclosureTextBlock_1" xlink:title="Label : us-gaap_InventoryDisclosureTextBlock to label_us-gaap_InventoryDisclosureTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:title="us-gaap_InventoryNet" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_InventoryNet" xml:lang="en-US" id="label_us-gaap_InventoryNet">Inventories</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="label_us-gaap_InventoryNet" xlink:title="Label : us-gaap_InventoryNet to label_us-gaap_InventoryNet" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InventoryNet_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_InventoryNet_1" xml:lang="en-US" id="label_us-gaap_InventoryNet_1">Inventory, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="label_us-gaap_InventoryNet_1" xlink:title="Label : us-gaap_InventoryNet to label_us-gaap_InventoryNet_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InventoryNet_2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_InventoryNet_2" xml:lang="en-US" id="label_us-gaap_InventoryNet_2">Total inventory</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="label_us-gaap_InventoryNet_2" xlink:title="Label : us-gaap_InventoryNet to label_us-gaap_InventoryNet_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown" xlink:title="us-gaap_InventoryWriteDown" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_InventoryWriteDown" xml:lang="en-US" id="label_us-gaap_InventoryWriteDown">Inventory Write-down</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWriteDown" xlink:to="label_us-gaap_InventoryWriteDown" xlink:title="Label : us-gaap_InventoryWriteDown to label_us-gaap_InventoryWriteDown" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InventoryWriteDown_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_InventoryWriteDown_1" xml:lang="en-US" id="label_us-gaap_InventoryWriteDown_1">Inventory write-down</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWriteDown" xlink:to="label_us-gaap_InventoryWriteDown_1" xlink:title="Label : us-gaap_InventoryWriteDown to label_us-gaap_InventoryWriteDown_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InventoryWriteDown_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_InventoryWriteDown_2" xml:lang="en-US" id="label_us-gaap_InventoryWriteDown_2">Inventory write-down and write off</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWriteDown" xlink:to="label_us-gaap_InventoryWriteDown_2" xlink:title="Label : us-gaap_InventoryWriteDown to label_us-gaap_InventoryWriteDown_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:title="us-gaap_InventoryRawMaterialsNetOfReserves" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_InventoryRawMaterialsNetOfReserves" xml:lang="en-US" id="label_us-gaap_InventoryRawMaterialsNetOfReserves">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="label_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:title="Label : us-gaap_InventoryRawMaterialsNetOfReserves to label_us-gaap_InventoryRawMaterialsNetOfReserves" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InventoryRawMaterialsNetOfReserves_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_InventoryRawMaterialsNetOfReserves_1" xml:lang="en-US" id="label_us-gaap_InventoryRawMaterialsNetOfReserves_1">Raw materials</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="label_us-gaap_InventoryRawMaterialsNetOfReserves_1" xlink:title="Label : us-gaap_InventoryRawMaterialsNetOfReserves to label_us-gaap_InventoryRawMaterialsNetOfReserves_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:title="us-gaap_InventoryDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_InventoryDisclosureAbstract" xml:lang="en-US" id="label_us-gaap_InventoryDisclosureAbstract">INVENTORIES [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="label_us-gaap_InventoryDisclosureAbstract" xlink:title="Label : us-gaap_InventoryDisclosureAbstract to label_us-gaap_InventoryDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:title="us-gaap_InventoryWorkInProcessNetOfReserves" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_InventoryWorkInProcessNetOfReserves" xml:lang="en-US" id="label_us-gaap_InventoryWorkInProcessNetOfReserves">Inventory, Work in Process, Net of Reserves</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="label_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:title="Label : us-gaap_InventoryWorkInProcessNetOfReserves to label_us-gaap_InventoryWorkInProcessNetOfReserves" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InventoryWorkInProcessNetOfReserves_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_InventoryWorkInProcessNetOfReserves_1" xml:lang="en-US" id="label_us-gaap_InventoryWorkInProcessNetOfReserves_1">Work in process</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="label_us-gaap_InventoryWorkInProcessNetOfReserves_1" xlink:title="Label : us-gaap_InventoryWorkInProcessNetOfReserves to label_us-gaap_InventoryWorkInProcessNetOfReserves_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseAgreementsMember" xlink:label="us-gaap_LeaseAgreementsMember" xlink:title="us-gaap_LeaseAgreementsMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LeaseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_LeaseAgreementsMember" xml:lang="en-US" id="label_us-gaap_LeaseAgreementsMember">Lease Agreements [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAgreementsMember" xlink:to="label_us-gaap_LeaseAgreementsMember" xlink:title="Label : us-gaap_LeaseAgreementsMember to label_us-gaap_LeaseAgreementsMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:title="us-gaap_LeaseholdImprovementsMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_LeaseholdImprovementsMember" xml:lang="en-US" id="label_us-gaap_LeaseholdImprovementsMember">Leasehold Improvements [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="label_us-gaap_LeaseholdImprovementsMember" xlink:title="Label : us-gaap_LeaseholdImprovementsMember to label_us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:title="us-gaap_LiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_LiabilitiesCurrent" xml:lang="en-US" id="label_us-gaap_LiabilitiesCurrent">Liabilities, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="label_us-gaap_LiabilitiesCurrent" xlink:title="Label : us-gaap_LiabilitiesCurrent to label_us-gaap_LiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LiabilitiesCurrent_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_LiabilitiesCurrent_1" xml:lang="en-US" id="label_us-gaap_LiabilitiesCurrent_1">Total current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="label_us-gaap_LiabilitiesCurrent_1" xlink:title="Label : us-gaap_LiabilitiesCurrent to label_us-gaap_LiabilitiesCurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:title="us-gaap_LiabilitiesNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_LiabilitiesNoncurrent" xml:lang="en-US" id="label_us-gaap_LiabilitiesNoncurrent">Liabilities, Noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="label_us-gaap_LiabilitiesNoncurrent" xlink:title="Label : us-gaap_LiabilitiesNoncurrent to label_us-gaap_LiabilitiesNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LiabilitiesNoncurrent_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_LiabilitiesNoncurrent_1" xml:lang="en-US" id="label_us-gaap_LiabilitiesNoncurrent_1">Total long term liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="label_us-gaap_LiabilitiesNoncurrent_1" xlink:title="Label : us-gaap_LiabilitiesNoncurrent to label_us-gaap_LiabilitiesNoncurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:title="us-gaap_LiabilitiesCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US" id="label_us-gaap_LiabilitiesCurrentAbstract">CURRENT LIABILITIES:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="label_us-gaap_LiabilitiesCurrentAbstract" xlink:title="Label : us-gaap_LiabilitiesCurrentAbstract to label_us-gaap_LiabilitiesCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LiabilitiesCurrentAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_LiabilitiesCurrentAbstract_1" xml:lang="en-US" id="label_us-gaap_LiabilitiesCurrentAbstract_1">Liabilities, Current [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="label_us-gaap_LiabilitiesCurrentAbstract_1" xlink:title="Label : us-gaap_LiabilitiesCurrentAbstract to label_us-gaap_LiabilitiesCurrentAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:title="us-gaap_Liabilities" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_Liabilities" xml:lang="en-US" id="label_us-gaap_Liabilities">Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="label_us-gaap_Liabilities" xlink:title="Label : us-gaap_Liabilities to label_us-gaap_Liabilities" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_Liabilities_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_Liabilities_1" xml:lang="en-US" id="label_us-gaap_Liabilities_1">Total liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="label_us-gaap_Liabilities_1" xlink:title="Label : us-gaap_Liabilities to label_us-gaap_Liabilities_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:title="us-gaap_LiabilitiesNoncurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_LiabilitiesNoncurrentAbstract" xml:lang="en-US" id="label_us-gaap_LiabilitiesNoncurrentAbstract">Liabilities, Noncurrent [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="label_us-gaap_LiabilitiesNoncurrentAbstract" xlink:title="Label : us-gaap_LiabilitiesNoncurrentAbstract to label_us-gaap_LiabilitiesNoncurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LiabilitiesNoncurrentAbstract_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_LiabilitiesNoncurrentAbstract_1" xml:lang="en-US" id="label_us-gaap_LiabilitiesNoncurrentAbstract_1">LONG TERM LIABILITIES:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="label_us-gaap_LiabilitiesNoncurrentAbstract_1" xlink:title="Label : us-gaap_LiabilitiesNoncurrentAbstract to label_us-gaap_LiabilitiesNoncurrentAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:title="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US" id="label_us-gaap_LiabilitiesAndStockholdersEquityAbstract">Liabilities and Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="label_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:title="Label : us-gaap_LiabilitiesAndStockholdersEquityAbstract to label_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1" xml:lang="en-US" id="label_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1">LIABILITIES NET OF CAPITAL DEFICIENCY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="label_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1" xlink:title="Label : us-gaap_LiabilitiesAndStockholdersEquityAbstract to label_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:title="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US" id="label_us-gaap_LiabilitiesAndStockholdersEquity">Liabilities and Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="label_us-gaap_LiabilitiesAndStockholdersEquity" xlink:title="Label : us-gaap_LiabilitiesAndStockholdersEquity to label_us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LiabilitiesAndStockholdersEquity_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_LiabilitiesAndStockholdersEquity_1" xml:lang="en-US" id="label_us-gaap_LiabilitiesAndStockholdersEquity_1">Total liabilities net of capital deficiency</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="label_us-gaap_LiabilitiesAndStockholdersEquity_1" xlink:title="Label : us-gaap_LiabilitiesAndStockholdersEquity to label_us-gaap_LiabilitiesAndStockholdersEquity_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="us-gaap_LicensesRevenue" xlink:title="us-gaap_LicensesRevenue" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LicensesRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_LicensesRevenue" xml:lang="en-US" id="label_us-gaap_LicensesRevenue">Deferred revenues from the license and supply agreement with Pfizer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicensesRevenue" xlink:to="label_us-gaap_LicensesRevenue" xlink:title="Label : us-gaap_LicensesRevenue to label_us-gaap_LicensesRevenue" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LicensesRevenue_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_LicensesRevenue_1" xml:lang="en-US" id="label_us-gaap_LicensesRevenue_1">Licenses Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicensesRevenue" xlink:to="label_us-gaap_LicensesRevenue_1" xlink:title="Label : us-gaap_LicensesRevenue to label_us-gaap_LicensesRevenue_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" xlink:title="us-gaap_LongTermDebtNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_LongTermDebtNoncurrent" xml:lang="en-US" id="label_us-gaap_LongTermDebtNoncurrent">Liability in connection with collaboration operation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="label_us-gaap_LongTermDebtNoncurrent" xlink:title="Label : us-gaap_LongTermDebtNoncurrent to label_us-gaap_LongTermDebtNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LongTermDebtNoncurrent_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_LongTermDebtNoncurrent_1" xml:lang="en-US" id="label_us-gaap_LongTermDebtNoncurrent_1">Long-term Debt, Excluding Current Maturities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="label_us-gaap_LongTermDebtNoncurrent_1" xlink:title="Label : us-gaap_LongTermDebtNoncurrent to label_us-gaap_LongTermDebtNoncurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:title="us-gaap_MaximumMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_MaximumMember" xml:lang="en-US" id="label_us-gaap_MaximumMember">Maximum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaximumMember" xlink:to="label_us-gaap_MaximumMember" xlink:title="Label : us-gaap_MaximumMember to label_us-gaap_MaximumMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:title="us-gaap_MinimumMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_MinimumMember" xml:lang="en-US" id="label_us-gaap_MinimumMember">Minimum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinimumMember" xlink:to="label_us-gaap_MinimumMember" xlink:title="Label : us-gaap_MinimumMember to label_us-gaap_MinimumMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US" id="label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="Label : us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract to label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1" xml:lang="en-US" id="label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1" xlink:title="Label : us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract to label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:title="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xml:lang="en-US" id="label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">Net Cash Provided by (Used in) Investing Activities, Continuing Operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:title="Label : us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations to label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_1" xml:lang="en-US" id="label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_1">Net cash used in investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_1" xlink:title="Label : us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations to label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xml:lang="en-US" id="label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:title="Label : us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_1" xml:lang="en-US" id="label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_1">Net cash used in operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_1" xlink:title="Label : us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:title="us-gaap_NetIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_NetIncomeLoss" xml:lang="en-US" id="label_us-gaap_NetIncomeLoss">Net Income (Loss) Attributable to Parent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="label_us-gaap_NetIncomeLoss" xlink:title="Label : us-gaap_NetIncomeLoss to label_us-gaap_NetIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetIncomeLoss_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_NetIncomeLoss_1" xml:lang="en-US" id="label_us-gaap_NetIncomeLoss_1">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="label_us-gaap_NetIncomeLoss_1" xlink:title="Label : us-gaap_NetIncomeLoss to label_us-gaap_NetIncomeLoss_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetIncomeLoss_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_NetIncomeLoss_2" xml:lang="en-US" id="label_us-gaap_NetIncomeLoss_2">Net loss for the period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="label_us-gaap_NetIncomeLoss_2" xlink:title="Label : us-gaap_NetIncomeLoss to label_us-gaap_NetIncomeLoss_2" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetIncomeLoss_3" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_NetIncomeLoss_3" xml:lang="en-US" id="label_us-gaap_NetIncomeLoss_3">NET LOSS FOR THE PERIOD</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="label_us-gaap_NetIncomeLoss_3" xlink:title="Label : us-gaap_NetIncomeLoss to label_us-gaap_NetIncomeLoss_3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:title="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US" id="label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:title="Label : us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract to label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1" xml:lang="en-US" id="label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1" xlink:title="Label : us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract to label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US" id="label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="Label : us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract to label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xml:lang="en-US" id="label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:title="Label : us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract to label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xml:lang="en-US" id="label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">Net Cash Provided by (Used in) Financing Activities, Continuing Operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:title="Label : us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations to label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_1" xml:lang="en-US" id="label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_1">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_1" xlink:title="Label : us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations to label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:title="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US" id="label_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="label_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:title="Label : us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock to label_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1" xml:lang="en-US" id="label_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1">Recently issued accounting pronouncements:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="label_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1" xlink:title="Label : us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock to label_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:title="us-gaap_NonoperatingIncomeExpense" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US" id="label_us-gaap_NonoperatingIncomeExpense">FINANCIAL EXPENSES - NET</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="label_us-gaap_NonoperatingIncomeExpense" xlink:title="Label : us-gaap_NonoperatingIncomeExpense to label_us-gaap_NonoperatingIncomeExpense" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NonoperatingIncomeExpense_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_NonoperatingIncomeExpense_1" xml:lang="en-US" id="label_us-gaap_NonoperatingIncomeExpense_1">Nonoperating Income (Expense)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="label_us-gaap_NonoperatingIncomeExpense_1" xlink:title="Label : us-gaap_NonoperatingIncomeExpense to label_us-gaap_NonoperatingIncomeExpense_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NonoperatingIncomeExpense_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_NonoperatingIncomeExpense_2" xml:lang="en-US" id="label_us-gaap_NonoperatingIncomeExpense_2">FINANCIAL INCOME (EXPENSES) - NET</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="label_us-gaap_NonoperatingIncomeExpense_2" xlink:title="Label : us-gaap_NonoperatingIncomeExpense to label_us-gaap_NonoperatingIncomeExpense_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear" xlink:title="us-gaap_OpenTaxYear" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OpenTaxYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_OpenTaxYear" xml:lang="en-US" id="label_us-gaap_OpenTaxYear">Open Tax Year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OpenTaxYear" xlink:to="label_us-gaap_OpenTaxYear" xlink:title="Label : us-gaap_OpenTaxYear to label_us-gaap_OpenTaxYear" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OpenTaxYear_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_OpenTaxYear_1" xml:lang="en-US" id="label_us-gaap_OpenTaxYear_1">Open tax year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OpenTaxYear" xlink:to="label_us-gaap_OpenTaxYear_1" xlink:title="Label : us-gaap_OpenTaxYear to label_us-gaap_OpenTaxYear_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:title="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xml:lang="en-US" id="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">Future minimum lease payments, 2015</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:title="Label : us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent to label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_1" xml:lang="en-US" id="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_1">Operating Leases, Future Minimum Payments Due, Next Twelve Months</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_1" xlink:title="Label : us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent to label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet" xlink:title="us-gaap_OperatingLeasesRentExpenseNet" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OperatingLeasesRentExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_OperatingLeasesRentExpenseNet" xml:lang="en-US" id="label_us-gaap_OperatingLeasesRentExpenseNet">Lease/rent expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesRentExpenseNet" xlink:to="label_us-gaap_OperatingLeasesRentExpenseNet" xlink:title="Label : us-gaap_OperatingLeasesRentExpenseNet to label_us-gaap_OperatingLeasesRentExpenseNet" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OperatingLeasesRentExpenseNet_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_OperatingLeasesRentExpenseNet_1" xml:lang="en-US" id="label_us-gaap_OperatingLeasesRentExpenseNet_1">Operating Leases, Rent Expense, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesRentExpenseNet" xlink:to="label_us-gaap_OperatingLeasesRentExpenseNet_1" xlink:title="Label : us-gaap_OperatingLeasesRentExpenseNet to label_us-gaap_OperatingLeasesRentExpenseNet_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:title="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xml:lang="en-US" id="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">Future minimum lease payments, 2016</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:title="Label : us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears to label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_1" xml:lang="en-US" id="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_1">Operating Leases, Future Minimum Payments, Due in Two Years</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_1" xlink:title="Label : us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears to label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:title="us-gaap_OperatingIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_OperatingIncomeLoss" xml:lang="en-US" id="label_us-gaap_OperatingIncomeLoss">Operating Income (Loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="label_us-gaap_OperatingIncomeLoss" xlink:title="Label : us-gaap_OperatingIncomeLoss to label_us-gaap_OperatingIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OperatingIncomeLoss_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_OperatingIncomeLoss_1" xml:lang="en-US" id="label_us-gaap_OperatingIncomeLoss_1">OPERATING LOSS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="label_us-gaap_OperatingIncomeLoss_1" xlink:title="Label : us-gaap_OperatingIncomeLoss to label_us-gaap_OperatingIncomeLoss_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:title="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xml:lang="en-US" id="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">Future minimum lease payments, 2018</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:title="Label : us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears to label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_1" xml:lang="en-US" id="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_1">Operating Leases, Future Minimum Payments, Due in Four Years</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_1" xlink:title="Label : us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears to label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:title="us-gaap_OperatingLossCarryforwards" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_OperatingLossCarryforwards" xml:lang="en-US" id="label_us-gaap_OperatingLossCarryforwards">Net operating loss carry forwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="label_us-gaap_OperatingLossCarryforwards" xlink:title="Label : us-gaap_OperatingLossCarryforwards to label_us-gaap_OperatingLossCarryforwards" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OperatingLossCarryforwards_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_OperatingLossCarryforwards_1" xml:lang="en-US" id="label_us-gaap_OperatingLossCarryforwards_1">Operating Loss Carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="label_us-gaap_OperatingLossCarryforwards_1" xlink:title="Label : us-gaap_OperatingLossCarryforwards to label_us-gaap_OperatingLossCarryforwards_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:title="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xml:lang="en-US" id="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">Future minimum lease payments, 2017</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:title="Label : us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears to label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_1" xml:lang="en-US" id="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_1">Operating Leases, Future Minimum Payments, Due in Three Years</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_1" xlink:title="Label : us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears to label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" xlink:title="us-gaap_OtherAssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_OtherAssetsCurrent" xml:lang="en-US" id="label_us-gaap_OtherAssetsCurrent">Other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="label_us-gaap_OtherAssetsCurrent" xlink:title="Label : us-gaap_OtherAssetsCurrent to label_us-gaap_OtherAssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OtherAssetsCurrent_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_OtherAssetsCurrent_1" xml:lang="en-US" id="label_us-gaap_OtherAssetsCurrent_1">Other Assets, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="label_us-gaap_OtherAssetsCurrent_1" xlink:title="Label : us-gaap_OtherAssetsCurrent to label_us-gaap_OtherAssetsCurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" xlink:title="us-gaap_OtherNonoperatingIncome" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OtherNonoperatingIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_OtherNonoperatingIncome" xml:lang="en-US" id="label_us-gaap_OtherNonoperatingIncome">FINANCIAL INCOME</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="label_us-gaap_OtherNonoperatingIncome" xlink:title="Label : us-gaap_OtherNonoperatingIncome to label_us-gaap_OtherNonoperatingIncome" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OtherNonoperatingIncome_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_OtherNonoperatingIncome_1" xml:lang="en-US" id="label_us-gaap_OtherNonoperatingIncome_1">Other Nonoperating Income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="label_us-gaap_OtherNonoperatingIncome_1" xlink:title="Label : us-gaap_OtherNonoperatingIncome to label_us-gaap_OtherNonoperatingIncome_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" xlink:title="us-gaap_OtherNonoperatingExpense" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OtherNonoperatingExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_us-gaap_OtherNonoperatingExpense" xml:lang="en-US" id="label_us-gaap_OtherNonoperatingExpense">FINANCIAL EXPENSES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="label_us-gaap_OtherNonoperatingExpense" xlink:title="Label : us-gaap_OtherNonoperatingExpense to label_us-gaap_OtherNonoperatingExpense" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OtherNonoperatingExpense_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_OtherNonoperatingExpense_1" xml:lang="en-US" id="label_us-gaap_OtherNonoperatingExpense_1">Other Nonoperating Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="label_us-gaap_OtherNonoperatingExpense_1" xlink:title="Label : us-gaap_OtherNonoperatingExpense to label_us-gaap_OtherNonoperatingExpense_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ParentCompanyMember" xlink:label="us-gaap_ParentCompanyMember" xlink:title="us-gaap_ParentCompanyMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ParentCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ParentCompanyMember" xml:lang="en-US" id="label_us-gaap_ParentCompanyMember">Parent Company [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ParentCompanyMember" xlink:to="label_us-gaap_ParentCompanyMember" xlink:title="Label : us-gaap_ParentCompanyMember to label_us-gaap_ParentCompanyMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:title="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xml:lang="en-US" id="label_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">Amounts funded in respect of employee rights upon retirement, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="label_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:title="Label : us-gaap_PaymentsForProceedsFromOtherInvestingActivities to label_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_1" xml:lang="en-US" id="label_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_1">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="label_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_1" xlink:title="Label : us-gaap_PaymentsForProceedsFromOtherInvestingActivities to label_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US" id="label_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="label_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="Label : us-gaap_PaymentsToAcquirePropertyPlantAndEquipment to label_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1" xml:lang="en-US" id="label_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1">Purchase of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="label_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1" xlink:title="Label : us-gaap_PaymentsToAcquirePropertyPlantAndEquipment to label_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:title="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US" id="label_us-gaap_PaymentsOfStockIssuanceCosts">Payments of Stock Issuance Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="label_us-gaap_PaymentsOfStockIssuanceCosts" xlink:title="Label : us-gaap_PaymentsOfStockIssuanceCosts to label_us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PaymentsOfStockIssuanceCosts_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_PaymentsOfStockIssuanceCosts_1" xml:lang="en-US" id="label_us-gaap_PaymentsOfStockIssuanceCosts_1">Underwritten public offering, commissions and issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="label_us-gaap_PaymentsOfStockIssuanceCosts_1" xlink:title="Label : us-gaap_PaymentsOfStockIssuanceCosts to label_us-gaap_PaymentsOfStockIssuanceCosts_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:title="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xml:lang="en-US" id="label_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent">Liability for employee rights upon retirement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:to="label_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:title="Label : us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent to label_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_1" xml:lang="en-US" id="label_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_1">Pension and Other Postretirement and Postemployment Benefit Plans, Liabilities, Noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:to="label_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_1" xlink:title="Label : us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent to label_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:title="us-gaap_PensionAndOtherPostretirementBenefitExpense" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_PensionAndOtherPostretirementBenefitExpense" xml:lang="en-US" id="label_us-gaap_PensionAndOtherPostretirementBenefitExpense">Changes in accrued liability for employee rights upon retirement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:to="label_us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:title="Label : us-gaap_PensionAndOtherPostretirementBenefitExpense to label_us-gaap_PensionAndOtherPostretirementBenefitExpense" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PensionAndOtherPostretirementBenefitExpense_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_PensionAndOtherPostretirementBenefitExpense_1" xml:lang="en-US" id="label_us-gaap_PensionAndOtherPostretirementBenefitExpense_1">Pension and Other Postretirement Benefit Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:to="label_us-gaap_PensionAndOtherPostretirementBenefitExpense_1" xlink:title="Label : us-gaap_PensionAndOtherPostretirementBenefitExpense to label_us-gaap_PensionAndOtherPostretirementBenefitExpense_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:title="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xml:lang="en-US" id="label_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="label_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:title="Label : us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock to label_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_1" xml:lang="en-US" id="label_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_1">Pension And Other Postretirement Benefits Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="label_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_1" xlink:title="Label : us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock to label_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:title="us-gaap_PlanNameAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_PlanNameAxis" xml:lang="en-US" id="label_us-gaap_PlanNameAxis">Plan Name [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="label_us-gaap_PlanNameAxis" xlink:title="Label : us-gaap_PlanNameAxis to label_us-gaap_PlanNameAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:title="us-gaap_PlanNameDomain" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_PlanNameDomain" xml:lang="en-US" id="label_us-gaap_PlanNameDomain">Plan Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="label_us-gaap_PlanNameDomain" xlink:title="Label : us-gaap_PlanNameDomain to label_us-gaap_PlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PostemploymentBenefitsPeriodExpense" xlink:label="us-gaap_PostemploymentBenefitsPeriodExpense" xlink:title="us-gaap_PostemploymentBenefitsPeriodExpense" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PostemploymentBenefitsPeriodExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_PostemploymentBenefitsPeriodExpense" xml:lang="en-US" id="label_us-gaap_PostemploymentBenefitsPeriodExpense">Postemployment Benefits, Period Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PostemploymentBenefitsPeriodExpense" xlink:to="label_us-gaap_PostemploymentBenefitsPeriodExpense" xlink:title="Label : us-gaap_PostemploymentBenefitsPeriodExpense to label_us-gaap_PostemploymentBenefitsPeriodExpense" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PostemploymentBenefitsPeriodExpense_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_PostemploymentBenefitsPeriodExpense_1" xml:lang="en-US" id="label_us-gaap_PostemploymentBenefitsPeriodExpense_1">Severance expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PostemploymentBenefitsPeriodExpense" xlink:to="label_us-gaap_PostemploymentBenefitsPeriodExpense_1" xlink:title="Label : us-gaap_PostemploymentBenefitsPeriodExpense to label_us-gaap_PostemploymentBenefitsPeriodExpense_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidRoyalties" xlink:label="us-gaap_PrepaidRoyalties" xlink:title="us-gaap_PrepaidRoyalties" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PrepaidRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_PrepaidRoyalties" xml:lang="en-US" id="label_us-gaap_PrepaidRoyalties">Prepaid Royalties</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidRoyalties" xlink:to="label_us-gaap_PrepaidRoyalties" xlink:title="Label : us-gaap_PrepaidRoyalties to label_us-gaap_PrepaidRoyalties" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PrepaidRoyalties_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_PrepaidRoyalties_1" xml:lang="en-US" id="label_us-gaap_PrepaidRoyalties_1">State of Israel (see Note 6a)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidRoyalties" xlink:to="label_us-gaap_PrepaidRoyalties_1" xlink:title="Label : us-gaap_PrepaidRoyalties to label_us-gaap_PrepaidRoyalties_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:title="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xml:lang="en-US" id="label_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">Other assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="label_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:title="Label : us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract to label_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_1" xml:lang="en-US" id="label_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_1">Prepaid Expense and Other Assets, Current [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="label_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_1" xlink:title="Label : us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract to label_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:title="us-gaap_PrepaidExpenseCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_PrepaidExpenseCurrent" xml:lang="en-US" id="label_us-gaap_PrepaidExpenseCurrent">Prepaid Expense, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="label_us-gaap_PrepaidExpenseCurrent" xlink:title="Label : us-gaap_PrepaidExpenseCurrent to label_us-gaap_PrepaidExpenseCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PrepaidExpenseCurrent_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_PrepaidExpenseCurrent_1" xml:lang="en-US" id="label_us-gaap_PrepaidExpenseCurrent_1">Prepaid expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="label_us-gaap_PrepaidExpenseCurrent_1" xlink:title="Label : us-gaap_PrepaidExpenseCurrent to label_us-gaap_PrepaidExpenseCurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:label="us-gaap_ProceedsFromCollaborators" xlink:title="us-gaap_ProceedsFromCollaborators" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ProceedsFromCollaborators" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ProceedsFromCollaborators" xml:lang="en-US" id="label_us-gaap_ProceedsFromCollaborators">Pfizer Agreement, upfront payment received</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromCollaborators" xlink:to="label_us-gaap_ProceedsFromCollaborators" xlink:title="Label : us-gaap_ProceedsFromCollaborators to label_us-gaap_ProceedsFromCollaborators" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ProceedsFromCollaborators_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ProceedsFromCollaborators_1" xml:lang="en-US" id="label_us-gaap_ProceedsFromCollaborators_1">Proceeds from Collaborators</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromCollaborators" xlink:to="label_us-gaap_ProceedsFromCollaborators_1" xlink:title="Label : us-gaap_ProceedsFromCollaborators to label_us-gaap_ProceedsFromCollaborators_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:title="us-gaap_ProceedsFromConvertibleDebt" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ProceedsFromConvertibleDebt" xml:lang="en-US" id="label_us-gaap_ProceedsFromConvertibleDebt">Net proceeds from issuance of convertible notes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="label_us-gaap_ProceedsFromConvertibleDebt" xlink:title="Label : us-gaap_ProceedsFromConvertibleDebt to label_us-gaap_ProceedsFromConvertibleDebt" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ProceedsFromConvertibleDebt_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ProceedsFromConvertibleDebt_1" xml:lang="en-US" id="label_us-gaap_ProceedsFromConvertibleDebt_1">Proceeds from Convertible Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="label_us-gaap_ProceedsFromConvertibleDebt_1" xlink:title="Label : us-gaap_ProceedsFromConvertibleDebt to label_us-gaap_ProceedsFromConvertibleDebt_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:title="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xml:lang="en-US" id="label_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">Proceeds from Issuance of Private Placement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="label_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:title="Label : us-gaap_ProceedsFromIssuanceOfPrivatePlacement to label_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_1" xml:lang="en-US" id="label_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_1">Proceeds from private placement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="label_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_1" xlink:title="Label : us-gaap_ProceedsFromIssuanceOfPrivatePlacement to label_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:title="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US" id="label_us-gaap_ProceedsFromIssuanceOfCommonStock">Proceeds from Issuance of Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="label_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:title="Label : us-gaap_ProceedsFromIssuanceOfCommonStock to label_us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ProceedsFromIssuanceOfCommonStock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ProceedsFromIssuanceOfCommonStock_1" xml:lang="en-US" id="label_us-gaap_ProceedsFromIssuanceOfCommonStock_1">Underwritten public offering, net proceeds from issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="label_us-gaap_ProceedsFromIssuanceOfCommonStock_1" xlink:title="Label : us-gaap_ProceedsFromIssuanceOfCommonStock to label_us-gaap_ProceedsFromIssuanceOfCommonStock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:title="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ProceedsFromStockOptionsExercised" xml:lang="en-US" id="label_us-gaap_ProceedsFromStockOptionsExercised">Cash proceeds from exercise of options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="label_us-gaap_ProceedsFromStockOptionsExercised" xlink:title="Label : us-gaap_ProceedsFromStockOptionsExercised to label_us-gaap_ProceedsFromStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ProceedsFromStockOptionsExercised_1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_ProceedsFromStockOptionsExercised_1" xml:lang="en-US" id="label_us-gaap_ProceedsFromStockOptionsExercised_1">Exercise of options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="label_us-gaap_ProceedsFromStockOptionsExercised_1" xlink:title="Label : us-gaap_ProceedsFromStockOptionsExercised to label_us-gaap_ProceedsFromStockOptionsExercised_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ProceedsFromStockOptionsExercised_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ProceedsFromStockOptionsExercised_2" xml:lang="en-US" id="label_us-gaap_ProceedsFromStockOptionsExercised_2">Proceeds from Stock Options Exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="label_us-gaap_ProceedsFromStockOptionsExercised_2" xlink:title="Label : us-gaap_ProceedsFromStockOptionsExercised to label_us-gaap_ProceedsFromStockOptionsExercised_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:title="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xml:lang="en-US" id="label_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">Proceeds from sale of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="label_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:title="Label : us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment to label_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_1" xml:lang="en-US" id="label_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_1">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="label_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_1" xlink:title="Label : us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment to label_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:title="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US" id="label_us-gaap_PropertyPlantAndEquipmentTextBlock">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="label_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:title="Label : us-gaap_PropertyPlantAndEquipmentTextBlock to label_us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PropertyPlantAndEquipmentTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_PropertyPlantAndEquipmentTextBlock_1" xml:lang="en-US" id="label_us-gaap_PropertyPlantAndEquipmentTextBlock_1">Schedule of Property and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="label_us-gaap_PropertyPlantAndEquipmentTextBlock_1" xlink:title="Label : us-gaap_PropertyPlantAndEquipmentTextBlock to label_us-gaap_PropertyPlantAndEquipmentTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xml:lang="en-US" id="label_us-gaap_PropertyPlantAndEquipmentByTypeAxis">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="label_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:title="Label : us-gaap_PropertyPlantAndEquipmentByTypeAxis to label_us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:title="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US" id="label_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">Property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="label_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:title="Label : us-gaap_PropertyPlantAndEquipmentPolicyTextBlock to label_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_1" xml:lang="en-US" id="label_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_1">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="label_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_1" xlink:title="Label : us-gaap_PropertyPlantAndEquipmentPolicyTextBlock to label_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:title="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_PropertyPlantAndEquipmentAbstract" xml:lang="en-US" id="label_us-gaap_PropertyPlantAndEquipmentAbstract">PROPERTY AND EQUIPMENT [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="label_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:title="Label : us-gaap_PropertyPlantAndEquipmentAbstract to label_us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:title="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US" id="label_us-gaap_PropertyPlantAndEquipmentUsefulLife">Property and equipment, useful life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="label_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:title="Label : us-gaap_PropertyPlantAndEquipmentUsefulLife to label_us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PropertyPlantAndEquipmentUsefulLife_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_PropertyPlantAndEquipmentUsefulLife_1" xml:lang="en-US" id="label_us-gaap_PropertyPlantAndEquipmentUsefulLife_1">Property, Plant and Equipment, Useful Life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="label_us-gaap_PropertyPlantAndEquipmentUsefulLife_1" xlink:title="Label : us-gaap_PropertyPlantAndEquipmentUsefulLife to label_us-gaap_PropertyPlantAndEquipmentUsefulLife_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_PropertyPlantAndEquipmentTypeDomain" xml:lang="en-US" id="label_us-gaap_PropertyPlantAndEquipmentTypeDomain">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="label_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:title="Label : us-gaap_PropertyPlantAndEquipmentTypeDomain to label_us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:title="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US" id="label_us-gaap_PropertyPlantAndEquipmentNet">PROPERTY AND EQUIPMENT, NET</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="label_us-gaap_PropertyPlantAndEquipmentNet" xlink:title="Label : us-gaap_PropertyPlantAndEquipmentNet to label_us-gaap_PropertyPlantAndEquipmentNet" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PropertyPlantAndEquipmentNet_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_PropertyPlantAndEquipmentNet_1" xml:lang="en-US" id="label_us-gaap_PropertyPlantAndEquipmentNet_1">Property, Plant and Equipment, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="label_us-gaap_PropertyPlantAndEquipmentNet_1" xlink:title="Label : us-gaap_PropertyPlantAndEquipmentNet to label_us-gaap_PropertyPlantAndEquipmentNet_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PropertyPlantAndEquipmentNet_2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_PropertyPlantAndEquipmentNet_2" xml:lang="en-US" id="label_us-gaap_PropertyPlantAndEquipmentNet_2">Property, Plant and Equipment, Net, Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="label_us-gaap_PropertyPlantAndEquipmentNet_2" xlink:title="Label : us-gaap_PropertyPlantAndEquipmentNet to label_us-gaap_PropertyPlantAndEquipmentNet_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:title="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US" id="label_us-gaap_PropertyPlantAndEquipmentGross">Property, Plant and Equipment, Gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="label_us-gaap_PropertyPlantAndEquipmentGross" xlink:title="Label : us-gaap_PropertyPlantAndEquipmentGross to label_us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:title="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_PropertyPlantAndEquipmentLineItems" xml:lang="en-US" id="label_us-gaap_PropertyPlantAndEquipmentLineItems">Property, Plant and Equipment [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="label_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:title="Label : us-gaap_PropertyPlantAndEquipmentLineItems to label_us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:title="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US" id="label_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">PROPERTY AND EQUIPMENT</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="label_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:title="Label : us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock to label_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1" xml:lang="en-US" id="label_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1">Property Plant And Equipment Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="label_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1" xlink:title="Label : us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock to label_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:title="us-gaap_RangeMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_RangeMember" xml:lang="en-US" id="label_us-gaap_RangeMember">Range [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeMember" xlink:to="label_us-gaap_RangeMember" xlink:title="Label : us-gaap_RangeMember to label_us-gaap_RangeMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:title="us-gaap_RangeAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_RangeAxis" xml:lang="en-US" id="label_us-gaap_RangeAxis">Range [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeAxis" xlink:to="label_us-gaap_RangeAxis" xlink:title="Label : us-gaap_RangeAxis to label_us-gaap_RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:title="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US" id="label_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">RELATED PARTY TRANSACTIONS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="label_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:title="Label : us-gaap_RelatedPartyTransactionsDisclosureTextBlock to label_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1" xml:lang="en-US" id="label_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="label_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1" xlink:title="Label : us-gaap_RelatedPartyTransactionsDisclosureTextBlock to label_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:title="us-gaap_RelatedPartyTransactionLineItems" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_RelatedPartyTransactionLineItems" xml:lang="en-US" id="label_us-gaap_RelatedPartyTransactionLineItems">Related Party Transaction [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="label_us-gaap_RelatedPartyTransactionLineItems" xlink:title="Label : us-gaap_RelatedPartyTransactionLineItems to label_us-gaap_RelatedPartyTransactionLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:title="us-gaap_RelatedPartyTransactionAmountsOfTransaction" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xml:lang="en-US" id="label_us-gaap_RelatedPartyTransactionAmountsOfTransaction">Related Party Transaction, Amounts of Transaction</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="label_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:title="Label : us-gaap_RelatedPartyTransactionAmountsOfTransaction to label_us-gaap_RelatedPartyTransactionAmountsOfTransaction" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US" id="label_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis">Related Party [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="label_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="Label : us-gaap_RelatedPartyTransactionsByRelatedPartyAxis to label_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:title="us-gaap_RelatedPartyDomain" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_RelatedPartyDomain" xml:lang="en-US" id="label_us-gaap_RelatedPartyDomain">Related Party [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="label_us-gaap_RelatedPartyDomain" xlink:title="Label : us-gaap_RelatedPartyDomain to label_us-gaap_RelatedPartyDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:title="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_RelatedPartyTransactionsAbstract" xml:lang="en-US" id="label_us-gaap_RelatedPartyTransactionsAbstract">RELATED PARTY TRANSACTIONS [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="label_us-gaap_RelatedPartyTransactionsAbstract" xlink:title="Label : us-gaap_RelatedPartyTransactionsAbstract to label_us-gaap_RelatedPartyTransactionsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:title="us-gaap_RepurchaseAgreementCounterpartyNameDomain" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_RepurchaseAgreementCounterpartyNameDomain" xml:lang="en-US" id="label_us-gaap_RepurchaseAgreementCounterpartyNameDomain">Counterparty Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="label_us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:title="Label : us-gaap_RepurchaseAgreementCounterpartyNameDomain to label_us-gaap_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:title="us-gaap_ResearchAndDevelopmentExpense" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US" id="label_us-gaap_ResearchAndDevelopmentExpense">Research and Development Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="label_us-gaap_ResearchAndDevelopmentExpense" xlink:title="Label : us-gaap_ResearchAndDevelopmentExpense to label_us-gaap_ResearchAndDevelopmentExpense" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ResearchAndDevelopmentExpense_1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_us-gaap_ResearchAndDevelopmentExpense_1" xml:lang="en-US" id="label_us-gaap_ResearchAndDevelopmentExpense_1">RESEARCH AND DEVELOPMENT EXPENSES (1)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="label_us-gaap_ResearchAndDevelopmentExpense_1" xlink:title="Label : us-gaap_ResearchAndDevelopmentExpense to label_us-gaap_ResearchAndDevelopmentExpense_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:title="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US" id="label_us-gaap_ResearchAndDevelopmentExpensePolicy">Research and development costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="label_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:title="Label : us-gaap_ResearchAndDevelopmentExpensePolicy to label_us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ResearchAndDevelopmentExpensePolicy_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ResearchAndDevelopmentExpensePolicy_1" xml:lang="en-US" id="label_us-gaap_ResearchAndDevelopmentExpensePolicy_1">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="label_us-gaap_ResearchAndDevelopmentExpensePolicy_1" xlink:title="Label : us-gaap_ResearchAndDevelopmentExpensePolicy to label_us-gaap_ResearchAndDevelopmentExpensePolicy_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:title="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US" id="label_us-gaap_ResearchAndDevelopmentExpenseMember">Research and Development Expense [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="label_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:title="Label : us-gaap_ResearchAndDevelopmentExpenseMember to label_us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:title="us-gaap_RestrictedStockMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_RestrictedStockMember" xml:lang="en-US" id="label_us-gaap_RestrictedStockMember">Restricted Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="label_us-gaap_RestrictedStockMember" xlink:title="Label : us-gaap_RestrictedStockMember to label_us-gaap_RestrictedStockMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:title="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xml:lang="en-US" id="label_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">Restricted Cash and Cash Equivalents, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="label_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:title="Label : us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue to label_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_1" xml:lang="en-US" id="label_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_1">Restricted deposit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="label_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_1" xlink:title="Label : us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue to label_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:title="us-gaap_RetainedEarningsMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_RetainedEarningsMember" xml:lang="en-US" id="label_us-gaap_RetainedEarningsMember">Accumulated Deficit [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="label_us-gaap_RetainedEarningsMember" xlink:title="Label : us-gaap_RetainedEarningsMember to label_us-gaap_RetainedEarningsMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RetainedEarningsMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_RetainedEarningsMember_1" xml:lang="en-US" id="label_us-gaap_RetainedEarningsMember_1">Retained Earnings [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="label_us-gaap_RetainedEarningsMember_1" xlink:title="Label : us-gaap_RetainedEarningsMember to label_us-gaap_RetainedEarningsMember_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:title="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US" id="label_us-gaap_RetainedEarningsAccumulatedDeficit">Accumulated deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="label_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:title="Label : us-gaap_RetainedEarningsAccumulatedDeficit to label_us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RetainedEarningsAccumulatedDeficit_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_RetainedEarningsAccumulatedDeficit_1" xml:lang="en-US" id="label_us-gaap_RetainedEarningsAccumulatedDeficit_1">Retained Earnings Accumulated Deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="label_us-gaap_RetainedEarningsAccumulatedDeficit_1" xlink:title="Label : us-gaap_RetainedEarningsAccumulatedDeficit to label_us-gaap_RetainedEarningsAccumulatedDeficit_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:title="us-gaap_RevenueRecognitionPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_RevenueRecognitionPolicyTextBlock" xml:lang="en-US" id="label_us-gaap_RevenueRecognitionPolicyTextBlock">Revenue Recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="label_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:title="Label : us-gaap_RevenueRecognitionPolicyTextBlock to label_us-gaap_RevenueRecognitionPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RevenueRecognitionPolicyTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_RevenueRecognitionPolicyTextBlock_1" xml:lang="en-US" id="label_us-gaap_RevenueRecognitionPolicyTextBlock_1">Revenue Recognition, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="label_us-gaap_RevenueRecognitionPolicyTextBlock_1" xlink:title="Label : us-gaap_RevenueRecognitionPolicyTextBlock to label_us-gaap_RevenueRecognitionPolicyTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" xlink:title="us-gaap_RevenuesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_RevenuesAbstract" xml:lang="en-US" id="label_us-gaap_RevenuesAbstract">Revenues [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="label_us-gaap_RevenuesAbstract" xlink:title="Label : us-gaap_RevenuesAbstract to label_us-gaap_RevenuesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RevenuesAbstract_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_RevenuesAbstract_1" xml:lang="en-US" id="label_us-gaap_RevenuesAbstract_1">Revenues:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="label_us-gaap_RevenuesAbstract_1" xlink:title="Label : us-gaap_RevenuesAbstract to label_us-gaap_RevenuesAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" xlink:title="us-gaap_RoyaltyExpense" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RoyaltyExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_RoyaltyExpense" xml:lang="en-US" id="label_us-gaap_RoyaltyExpense">Royalty Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="label_us-gaap_RoyaltyExpense" xlink:title="Label : us-gaap_RoyaltyExpense to label_us-gaap_RoyaltyExpense" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RoyaltyExpense_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_RoyaltyExpense_1" xml:lang="en-US" id="label_us-gaap_RoyaltyExpense_1">Royalty expense included in cost of revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="label_us-gaap_RoyaltyExpense_1" xlink:title="Label : us-gaap_RoyaltyExpense to label_us-gaap_RoyaltyExpense_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:title="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xml:lang="en-US" id="label_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Remaining Contractual Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:to="label_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:title="Label : us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 to label_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_1" xml:lang="en-US" id="label_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_1">Weighted average remaining contractual life, exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:to="label_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_1" xlink:title="Label : us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 to label_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US" id="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">Expected life in years</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="Label : us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 to label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1" xml:lang="en-US" id="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1" xlink:title="Label : us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 to label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:title="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xml:lang="en-US" id="label_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="label_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:title="Label : us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 to label_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_1" xml:lang="en-US" id="label_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_1">Weighted average remaining contractual life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="label_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_1" xlink:title="Label : us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 to label_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xml:lang="en-US" id="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:title="Label : us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage to label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_1" xml:lang="en-US" id="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_1">Percentage of options vested</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_1" xlink:title="Label : us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage to label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xml:lang="en-US" id="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">Aggregate intrinsic value of total outstanding options and restricted stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:title="Label : us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 to label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_1" xml:lang="en-US" id="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_1" xlink:title="Label : us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 to label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xml:lang="en-US" id="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">Aggregate intrinsic value of the total vested and exercisable options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:title="Label : us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 to label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1" xml:lang="en-US" id="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1" xlink:title="Label : us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 to label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xml:lang="en-US" id="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">Expiration period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:title="Label : us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod to label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1" xml:lang="en-US" id="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1" xlink:title="Label : us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod to label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_2" xml:lang="en-US" id="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_2">Term of option</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_2" xlink:title="Label : us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod to label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:title="us-gaap_SaleOfStockPricePerShare" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_SaleOfStockPricePerShare" xml:lang="en-US" id="label_us-gaap_SaleOfStockPricePerShare">Sale of Stock, Price Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="label_us-gaap_SaleOfStockPricePerShare" xlink:title="Label : us-gaap_SaleOfStockPricePerShare to label_us-gaap_SaleOfStockPricePerShare" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SaleOfStockPricePerShare_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_SaleOfStockPricePerShare_1" xml:lang="en-US" id="label_us-gaap_SaleOfStockPricePerShare_1">Underwritten public offering, common stock price per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="label_us-gaap_SaleOfStockPricePerShare_1" xlink:title="Label : us-gaap_SaleOfStockPricePerShare to label_us-gaap_SaleOfStockPricePerShare_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueGoodsNetMember" xlink:label="us-gaap_SalesRevenueGoodsNetMember" xlink:title="us-gaap_SalesRevenueGoodsNetMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SalesRevenueGoodsNetMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_SalesRevenueGoodsNetMember" xml:lang="en-US" id="label_us-gaap_SalesRevenueGoodsNetMember">Revenues from sale of products [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueGoodsNetMember" xlink:to="label_us-gaap_SalesRevenueGoodsNetMember" xlink:title="Label : us-gaap_SalesRevenueGoodsNetMember to label_us-gaap_SalesRevenueGoodsNetMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SalesRevenueGoodsNetMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_SalesRevenueGoodsNetMember_1" xml:lang="en-US" id="label_us-gaap_SalesRevenueGoodsNetMember_1">Revenues from selling products [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueGoodsNetMember" xlink:to="label_us-gaap_SalesRevenueGoodsNetMember_1" xlink:title="Label : us-gaap_SalesRevenueGoodsNetMember to label_us-gaap_SalesRevenueGoodsNetMember_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SalesRevenueGoodsNetMember_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_SalesRevenueGoodsNetMember_2" xml:lang="en-US" id="label_us-gaap_SalesRevenueGoodsNetMember_2">Sales Revenue, Goods, Net [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueGoodsNetMember" xlink:to="label_us-gaap_SalesRevenueGoodsNetMember_2" xlink:title="Label : us-gaap_SalesRevenueGoodsNetMember to label_us-gaap_SalesRevenueGoodsNetMember_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet" xlink:title="us-gaap_SalesRevenueGoodsNet" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SalesRevenueGoodsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_SalesRevenueGoodsNet" xml:lang="en-US" id="label_us-gaap_SalesRevenueGoodsNet">Revenue from selling products</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueGoodsNet" xlink:to="label_us-gaap_SalesRevenueGoodsNet" xlink:title="Label : us-gaap_SalesRevenueGoodsNet to label_us-gaap_SalesRevenueGoodsNet" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SalesRevenueGoodsNet_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_SalesRevenueGoodsNet_1" xml:lang="en-US" id="label_us-gaap_SalesRevenueGoodsNet_1">Sales Revenue, Goods, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueGoodsNet" xlink:to="label_us-gaap_SalesRevenueGoodsNet_1" xlink:title="Label : us-gaap_SalesRevenueGoodsNet to label_us-gaap_SalesRevenueGoodsNet_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:title="us-gaap_ScenarioUnspecifiedDomain" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ScenarioUnspecifiedDomain" xml:lang="en-US" id="label_us-gaap_ScenarioUnspecifiedDomain">Scenario, Unspecified [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="label_us-gaap_ScenarioUnspecifiedDomain" xlink:title="Label : us-gaap_ScenarioUnspecifiedDomain to label_us-gaap_ScenarioUnspecifiedDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:title="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xml:lang="en-US" id="label_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">Schedule of Related Party Transactions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="label_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:title="Label : us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock to label_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_1" xml:lang="en-US" id="label_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_1">Schedule of Related Party Transactions [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="label_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_1" xlink:title="Label : us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock to label_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:title="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US" id="label_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="label_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:title="Label : us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock to label_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1" xml:lang="en-US" id="label_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1">Summary of Stock Option Activity - Options Granted to Employees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="label_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1" xlink:title="Label : us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock to label_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:title="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US" id="label_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">Schedule of Assumptions Used to Estimate Fair Value of Stock Option Award using Black-Scholes Valuation Model</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="label_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:title="Label : us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock to label_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1" xml:lang="en-US" id="label_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="label_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1" xlink:title="Label : us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock to label_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:title="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US" id="label_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">Schedule of Deferred Tax Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="label_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:title="Label : us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock to label_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1" xml:lang="en-US" id="label_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="label_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1" xlink:title="Label : us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock to label_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:title="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xml:lang="en-US" id="label_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="label_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:title="Label : us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock to label_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_1" xml:lang="en-US" id="label_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_1">Summary of Restricted Stock Activity - Options Granted to Employees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="label_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_1" xlink:title="Label : us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock to label_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:title="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xml:lang="en-US" id="label_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">Schedule of Inventory</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="label_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:title="Label : us-gaap_ScheduleOfInventoryCurrentTableTextBlock to label_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1" xml:lang="en-US" id="label_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="label_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1" xlink:title="Label : us-gaap_ScheduleOfInventoryCurrentTableTextBlock to label_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xml:lang="en-US" id="label_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="label_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="Label : us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to label_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:title="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xml:lang="en-US" id="label_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="label_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:title="Label : us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock to label_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1" xml:lang="en-US" id="label_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1">Schedule of Stock-Based Compensation Expense in Statement of Operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="label_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1" xlink:title="Label : us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock to label_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xml:lang="en-US" id="label_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable">Schedule of Property, Plant and Equipment [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="label_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="Label : us-gaap_ScheduleOfPropertyPlantAndEquipmentTable to label_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:title="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xml:lang="en-US" id="label_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="label_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:title="Label : us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to label_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:title="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xml:lang="en-US" id="label_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable">Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="label_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:title="Label : us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable to label_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" xlink:title="us-gaap_ScheduleOfStockByClassTable" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ScheduleOfStockByClassTable" xml:lang="en-US" id="label_us-gaap_ScheduleOfStockByClassTable">Schedule of Stock by Class [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="label_us-gaap_ScheduleOfStockByClassTable" xlink:title="Label : us-gaap_ScheduleOfStockByClassTable to label_us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US" id="label_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="label_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="Label : us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to label_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:title="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xml:lang="en-US" id="label_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">Schedule of Information about Share Options Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="label_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:title="Label : us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock to label_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_1" xml:lang="en-US" id="label_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_1">Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="label_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_1" xlink:title="Label : us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock to label_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock" xlink:title="us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock" xml:lang="en-US" id="label_us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock">Schedule of Options Granted to Service Providers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock" xlink:to="label_us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock" xlink:title="Label : us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock to label_us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock_1" xml:lang="en-US" id="label_us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock_1">Schedule of Share-based Goods and Nonemployee Services Transaction by Supplier [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock" xlink:to="label_us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock_1" xlink:title="Label : us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock to label_us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit" xlink:title="us-gaap_SecurityDeposit" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SecurityDeposit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_SecurityDeposit" xml:lang="en-US" id="label_us-gaap_SecurityDeposit">Cash deposited as bank guarantee</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="label_us-gaap_SecurityDeposit" xlink:title="Label : us-gaap_SecurityDeposit to label_us-gaap_SecurityDeposit" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SecurityDeposit_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_SecurityDeposit_1" xml:lang="en-US" id="label_us-gaap_SecurityDeposit_1">Security Deposit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="label_us-gaap_SecurityDeposit_1" xlink:title="Label : us-gaap_SecurityDeposit to label_us-gaap_SecurityDeposit_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="us-gaap_SegmentGeographicalDomain" xlink:title="us-gaap_SegmentGeographicalDomain" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_SegmentGeographicalDomain" xml:lang="en-US" id="label_us-gaap_SegmentGeographicalDomain">Geographical [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentGeographicalDomain" xlink:to="label_us-gaap_SegmentGeographicalDomain" xlink:title="Label : us-gaap_SegmentGeographicalDomain to label_us-gaap_SegmentGeographicalDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:title="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_SellingGeneralAndAdministrativeExpense" xml:lang="en-US" id="label_us-gaap_SellingGeneralAndAdministrativeExpense">Selling, General and Administrative Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="label_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:title="Label : us-gaap_SellingGeneralAndAdministrativeExpense to label_us-gaap_SellingGeneralAndAdministrativeExpense" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SellingGeneralAndAdministrativeExpense_1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_us-gaap_SellingGeneralAndAdministrativeExpense_1" xml:lang="en-US" id="label_us-gaap_SellingGeneralAndAdministrativeExpense_1">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES (2)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="label_us-gaap_SellingGeneralAndAdministrativeExpense_1" xlink:title="Label : us-gaap_SellingGeneralAndAdministrativeExpense to label_us-gaap_SellingGeneralAndAdministrativeExpense_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:title="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xml:lang="en-US" id="label_us-gaap_SellingGeneralAndAdministrativeExpensesMember">General and Administrative Expense [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="label_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:title="Label : us-gaap_SellingGeneralAndAdministrativeExpensesMember to label_us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SellingGeneralAndAdministrativeExpensesMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_SellingGeneralAndAdministrativeExpensesMember_1" xml:lang="en-US" id="label_us-gaap_SellingGeneralAndAdministrativeExpensesMember_1">Marketing, General and administrative expenses [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="label_us-gaap_SellingGeneralAndAdministrativeExpensesMember_1" xlink:title="Label : us-gaap_SellingGeneralAndAdministrativeExpensesMember to label_us-gaap_SellingGeneralAndAdministrativeExpensesMember_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1">Vesting period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">Outstanding at beginning of year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1">Outstanding at end of year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">Exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice to label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice to label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:title="us-gaap_ShareBasedCompensation" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensation" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensation">Share based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="label_us-gaap_ShareBasedCompensation" xlink:title="Label : us-gaap_ShareBasedCompensation to label_us-gaap_ShareBasedCompensation" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensation_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensation_1" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensation_1">Share-based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="label_us-gaap_ShareBasedCompensation_1" xlink:title="Label : us-gaap_ShareBasedCompensation to label_us-gaap_ShareBasedCompensation_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">Number of options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1">Weighted average exercise price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1">Number of options or restricted stock granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:title="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationAwardTrancheOneMember">Share-based Compensation Award, Tranche One [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="label_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:title="Label : us-gaap_ShareBasedCompensationAwardTrancheOneMember to label_us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationAwardTrancheOneMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationAwardTrancheOneMember_1" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationAwardTrancheOneMember_1">Vest on the first anniversary of the grant date [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="label_us-gaap_ShareBasedCompensationAwardTrancheOneMember_1" xlink:title="Label : us-gaap_ShareBasedCompensationAwardTrancheOneMember to label_us-gaap_ShareBasedCompensationAwardTrancheOneMember_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:title="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">Share-based Compensation Award, Tranche Two [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="label_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:title="Label : us-gaap_ShareBasedCompensationAwardTrancheTwoMember to label_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_1" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_1">Vest over the subsequent quarterly period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="label_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_1" xlink:title="Label : us-gaap_ShareBasedCompensationAwardTrancheTwoMember to label_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">Forfeited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1">Restricted stock awards forfeited, share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">Exercise price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice to label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1">Exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice to label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2">Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice to label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_3" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_3">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_3" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice to label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">Option granted (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_1" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_1" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">Exercisable at end of year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">Dividend yield</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">Exercisable at end of year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">Forfeited and Expired</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_1" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_1" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">Common stock available for issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1">Vested</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">Expected volatility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1">Shares of common stock approved for grant</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">Risk free interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">Forfeited and Expired</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_1" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_1" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">Intrinsic value of options exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Total Intrinsic Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">Share-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="label_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="Label : us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy to label_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="label_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1" xlink:title="Label : us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy to label_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">Exercise Price Range [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:title="Label : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis to label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain">Award Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:title="Label : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems to label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">Outstanding at beginning of year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1">Outstanding at end of year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">Outstanding at beginning of year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1">Outstanding at end of year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:title="Label : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">Number of options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">Number of Options and restricted stock outstanding at end of year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:title="Label : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions to label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_1" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_1">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_1" xlink:title="Label : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions to label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">Number of options exercisable at end of year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:title="Label : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions to label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_1" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_1">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_1" xlink:title="Label : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions to label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">Exercise price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:title="Label : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit to label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_1" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_1">Maximum exercise price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_1" xlink:title="Label : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit to label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_2" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_2">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_2" xlink:title="Label : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit to label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">Minimum exercise price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:title="Label : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit to label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_1" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_1">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_1" xlink:title="Label : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit to label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xlink:title="us-gaap_SharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="label_us-gaap_SharesOutstanding" xml:lang="en-US" id="label_us-gaap_SharesOutstanding">Balance, shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="label_us-gaap_SharesOutstanding" xlink:title="Label : us-gaap_SharesOutstanding to label_us-gaap_SharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SharesOutstanding_1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="label_us-gaap_SharesOutstanding_1" xml:lang="en-US" id="label_us-gaap_SharesOutstanding_1">Balance, shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="label_us-gaap_SharesOutstanding_1" xlink:title="Label : us-gaap_SharesOutstanding to label_us-gaap_SharesOutstanding_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SharesOutstanding_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_SharesOutstanding_2" xml:lang="en-US" id="label_us-gaap_SharesOutstanding_2">Shares, Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="label_us-gaap_SharesOutstanding_2" xlink:title="Label : us-gaap_SharesOutstanding to label_us-gaap_SharesOutstanding_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:title="us-gaap_StatementLineItems" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_StatementLineItems" xml:lang="en-US" id="label_us-gaap_StatementLineItems">Statement [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="label_us-gaap_StatementLineItems" xlink:title="Label : us-gaap_StatementLineItems to label_us-gaap_StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:title="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_StatementOfStockholdersEquityAbstract" xml:lang="en-US" id="label_us-gaap_StatementOfStockholdersEquityAbstract">CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN CAPITAL DEFICIENCY [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="label_us-gaap_StatementOfStockholdersEquityAbstract" xlink:title="Label : us-gaap_StatementOfStockholdersEquityAbstract to label_us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:title="us-gaap_StatementOfCashFlowsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US" id="label_us-gaap_StatementOfCashFlowsAbstract">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="label_us-gaap_StatementOfCashFlowsAbstract" xlink:title="Label : us-gaap_StatementOfCashFlowsAbstract to label_us-gaap_StatementOfCashFlowsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:title="us-gaap_StatementEquityComponentsAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US" id="label_us-gaap_StatementEquityComponentsAxis">Equity Components [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="label_us-gaap_StatementEquityComponentsAxis" xlink:title="Label : us-gaap_StatementEquityComponentsAxis to label_us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:title="us-gaap_StatementTable" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_StatementTable" xml:lang="en-US" id="label_us-gaap_StatementTable">Statement [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="label_us-gaap_StatementTable" xlink:title="Label : us-gaap_StatementTable to label_us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:title="us-gaap_StatementScenarioAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_StatementScenarioAxis" xml:lang="en-US" id="label_us-gaap_StatementScenarioAxis">Scenario [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="label_us-gaap_StatementScenarioAxis" xlink:title="Label : us-gaap_StatementScenarioAxis to label_us-gaap_StatementScenarioAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:title="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US" id="label_us-gaap_StatementOfFinancialPositionAbstract">CONDENSED CONSOLIDATED BALANCE SHEETS [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="label_us-gaap_StatementOfFinancialPositionAbstract" xlink:title="Label : us-gaap_StatementOfFinancialPositionAbstract to label_us-gaap_StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="us-gaap_StatementGeographicalAxis" xlink:title="us-gaap_StatementGeographicalAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_StatementGeographicalAxis" xml:lang="en-US" id="label_us-gaap_StatementGeographicalAxis">Geographical [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="label_us-gaap_StatementGeographicalAxis" xlink:title="Label : us-gaap_StatementGeographicalAxis to label_us-gaap_StatementGeographicalAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xml:lang="en-US" id="label_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">Exercise of options granted to employees (includes net exercise)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="label_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="Label : us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised to label_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1" xml:lang="en-US" id="label_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="label_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1" xlink:title="Label : us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised to label_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US" id="label_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">Exercise of options granted to employees (includes net exercise), shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="label_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="Label : us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised to label_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1" xml:lang="en-US" id="label_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1">Exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="label_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1" xlink:title="Label : us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised to label_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2" xml:lang="en-US" id="label_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="label_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2" xlink:title="Label : us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised to label_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:title="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xml:lang="en-US" id="label_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited">Share-based compensation related to restricted stock award, forfeitures, shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:to="label_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:title="Label : us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited to label_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_1" xml:lang="en-US" id="label_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_1">Stock Issued During Period, Shares, Share-based Compensation, Forfeited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:to="label_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_1" xlink:title="Label : us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited to label_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:title="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US" id="label_us-gaap_StockIssuedDuringPeriodValueNewIssues">Common stock issued for cash (net of issuance costs)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="label_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:title="Label : us-gaap_StockIssuedDuringPeriodValueNewIssues to label_us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockIssuedDuringPeriodValueNewIssues_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_StockIssuedDuringPeriodValueNewIssues_1" xml:lang="en-US" id="label_us-gaap_StockIssuedDuringPeriodValueNewIssues_1">Stock Issued During Period, Value, New Issues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="label_us-gaap_StockIssuedDuringPeriodValueNewIssues_1" xlink:title="Label : us-gaap_StockIssuedDuringPeriodValueNewIssues to label_us-gaap_StockIssuedDuringPeriodValueNewIssues_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockIssuedDuringPeriodValueNewIssues_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_StockIssuedDuringPeriodValueNewIssues_2" xml:lang="en-US" id="label_us-gaap_StockIssuedDuringPeriodValueNewIssues_2">Common stock issued, value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="label_us-gaap_StockIssuedDuringPeriodValueNewIssues_2" xlink:title="Label : us-gaap_StockIssuedDuringPeriodValueNewIssues to label_us-gaap_StockIssuedDuringPeriodValueNewIssues_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:title="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US" id="label_us-gaap_StockIssuedDuringPeriodSharesNewIssues">Common stock issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="label_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:title="Label : us-gaap_StockIssuedDuringPeriodSharesNewIssues to label_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1" xml:lang="en-US" id="label_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1">Common stock issued for cash (net of issuance costs) (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="label_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1" xlink:title="Label : us-gaap_StockIssuedDuringPeriodSharesNewIssues to label_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2" xml:lang="en-US" id="label_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2">Stock Issued During Period, Shares, New Issues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="label_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2" xlink:title="Label : us-gaap_StockIssuedDuringPeriodSharesNewIssues to label_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:title="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xml:lang="en-US" id="label_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">Restricted stock granted, value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="label_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:title="Label : us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross to label_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_1" xml:lang="en-US" id="label_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_1">Stock Issued During Period, Value, Restricted Stock Award, Gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="label_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_1" xlink:title="Label : us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross to label_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:title="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US" id="label_us-gaap_StockholdersEquityNoteDisclosureTextBlock">SHARE CAPITAL</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="label_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:title="Label : us-gaap_StockholdersEquityNoteDisclosureTextBlock to label_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1" xml:lang="en-US" id="label_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1">STOCK TRANSACTIONS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="label_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1" xlink:title="Label : us-gaap_StockholdersEquityNoteDisclosureTextBlock to label_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockholdersEquityNoteDisclosureTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_StockholdersEquityNoteDisclosureTextBlock_2" xml:lang="en-US" id="label_us-gaap_StockholdersEquityNoteDisclosureTextBlock_2">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="label_us-gaap_StockholdersEquityNoteDisclosureTextBlock_2" xlink:title="Label : us-gaap_StockholdersEquityNoteDisclosureTextBlock to label_us-gaap_StockholdersEquityNoteDisclosureTextBlock_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:title="us-gaap_StockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_StockholdersEquityAbstract" xml:lang="en-US" id="label_us-gaap_StockholdersEquityAbstract">CAPITAL DEFICIENCY:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="label_us-gaap_StockholdersEquityAbstract" xlink:title="Label : us-gaap_StockholdersEquityAbstract to label_us-gaap_StockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockholdersEquityAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_StockholdersEquityAbstract_1" xml:lang="en-US" id="label_us-gaap_StockholdersEquityAbstract_1">Stockholders Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="label_us-gaap_StockholdersEquityAbstract_1" xlink:title="Label : us-gaap_StockholdersEquityAbstract to label_us-gaap_StockholdersEquityAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:title="us-gaap_StockholdersEquityNoteAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_StockholdersEquityNoteAbstract" xml:lang="en-US" id="label_us-gaap_StockholdersEquityNoteAbstract">STOCK TRANSACTIONS [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="label_us-gaap_StockholdersEquityNoteAbstract" xlink:title="Label : us-gaap_StockholdersEquityNoteAbstract to label_us-gaap_StockholdersEquityNoteAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:title="us-gaap_StockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="label_us-gaap_StockholdersEquity" xml:lang="en-US" id="label_us-gaap_StockholdersEquity">Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="label_us-gaap_StockholdersEquity" xlink:title="Label : us-gaap_StockholdersEquity to label_us-gaap_StockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockholdersEquity_1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="label_us-gaap_StockholdersEquity_1" xml:lang="en-US" id="label_us-gaap_StockholdersEquity_1">Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="label_us-gaap_StockholdersEquity_1" xlink:title="Label : us-gaap_StockholdersEquity to label_us-gaap_StockholdersEquity_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockholdersEquity_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_StockholdersEquity_2" xml:lang="en-US" id="label_us-gaap_StockholdersEquity_2">CAPITAL DEFICIENCY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="label_us-gaap_StockholdersEquity_2" xlink:title="Label : us-gaap_StockholdersEquity to label_us-gaap_StockholdersEquity_2" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockholdersEquity_3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_StockholdersEquity_3" xml:lang="en-US" id="label_us-gaap_StockholdersEquity_3">Stockholders' Equity Attributable to Parent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="label_us-gaap_StockholdersEquity_3" xlink:title="Label : us-gaap_StockholdersEquity to label_us-gaap_StockholdersEquity_3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:title="us-gaap_SubsequentEventTypeAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_SubsequentEventTypeAxis" xml:lang="en-US" id="label_us-gaap_SubsequentEventTypeAxis">Subsequent Event Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="label_us-gaap_SubsequentEventTypeAxis" xlink:title="Label : us-gaap_SubsequentEventTypeAxis to label_us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" xlink:title="us-gaap_SubsequentEventLineItems" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_SubsequentEventLineItems" xml:lang="en-US" id="label_us-gaap_SubsequentEventLineItems">Subsequent Event [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="label_us-gaap_SubsequentEventLineItems" xlink:title="Label : us-gaap_SubsequentEventLineItems to label_us-gaap_SubsequentEventLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:title="us-gaap_SubsequentEventMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_SubsequentEventMember" xml:lang="en-US" id="label_us-gaap_SubsequentEventMember">Subsequent Event [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="label_us-gaap_SubsequentEventMember" xlink:title="Label : us-gaap_SubsequentEventMember to label_us-gaap_SubsequentEventMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:title="us-gaap_SubsequentEventsTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US" id="label_us-gaap_SubsequentEventsTextBlock">Subsequent Events [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="label_us-gaap_SubsequentEventsTextBlock" xlink:title="Label : us-gaap_SubsequentEventsTextBlock to label_us-gaap_SubsequentEventsTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SubsequentEventsTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_SubsequentEventsTextBlock_1" xml:lang="en-US" id="label_us-gaap_SubsequentEventsTextBlock_1">SUBSEQUENT EVENTS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="label_us-gaap_SubsequentEventsTextBlock_1" xlink:title="Label : us-gaap_SubsequentEventsTextBlock to label_us-gaap_SubsequentEventsTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:title="us-gaap_SubsequentEventsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_SubsequentEventsAbstract" xml:lang="en-US" id="label_us-gaap_SubsequentEventsAbstract">Subsequent Events [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="label_us-gaap_SubsequentEventsAbstract" xlink:title="Label : us-gaap_SubsequentEventsAbstract to label_us-gaap_SubsequentEventsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:title="us-gaap_SubsequentEventTypeDomain" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_SubsequentEventTypeDomain" xml:lang="en-US" id="label_us-gaap_SubsequentEventTypeDomain">Subsequent Event Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="label_us-gaap_SubsequentEventTypeDomain" xlink:title="Label : us-gaap_SubsequentEventTypeDomain to label_us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" xlink:title="us-gaap_SubsequentEventTable" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_SubsequentEventTable" xml:lang="en-US" id="label_us-gaap_SubsequentEventTable">Subsequent Event [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="label_us-gaap_SubsequentEventTable" xlink:title="Label : us-gaap_SubsequentEventTable to label_us-gaap_SubsequentEventTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsidiariesMember" xlink:label="us-gaap_SubsidiariesMember" xlink:title="us-gaap_SubsidiariesMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SubsidiariesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_SubsidiariesMember" xml:lang="en-US" id="label_us-gaap_SubsidiariesMember">Protalix Ltd. [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiariesMember" xlink:to="label_us-gaap_SubsidiariesMember" xlink:title="Label : us-gaap_SubsidiariesMember to label_us-gaap_SubsidiariesMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SubsidiariesMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_SubsidiariesMember_1" xml:lang="en-US" id="label_us-gaap_SubsidiariesMember_1">Subsidiaries [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiariesMember" xlink:to="label_us-gaap_SubsidiariesMember_1" xlink:title="Label : us-gaap_SubsidiariesMember to label_us-gaap_SubsidiariesMember_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:title="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US" id="label_us-gaap_SupplementalCashFlowInformationAbstract">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="label_us-gaap_SupplementalCashFlowInformationAbstract" xlink:title="Label : us-gaap_SupplementalCashFlowInformationAbstract to label_us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SupplementalCashFlowInformationAbstract_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_SupplementalCashFlowInformationAbstract_1" xml:lang="en-US" id="label_us-gaap_SupplementalCashFlowInformationAbstract_1">SUPPLEMENTARY DISCLOSURE ON CASH FLOWS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="label_us-gaap_SupplementalCashFlowInformationAbstract_1" xlink:title="Label : us-gaap_SupplementalCashFlowInformationAbstract to label_us-gaap_SupplementalCashFlowInformationAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xml:lang="en-US" id="label_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain">Title of Individual with Relationship to Entity [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="label_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="Label : us-gaap_TitleOfIndividualWithRelationshipToEntityDomain to label_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:title="us-gaap_TitleOfIndividualAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_TitleOfIndividualAxis" xml:lang="en-US" id="label_us-gaap_TitleOfIndividualAxis">Title of Individual [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="label_us-gaap_TitleOfIndividualAxis" xlink:title="Label : us-gaap_TitleOfIndividualAxis to label_us-gaap_TitleOfIndividualAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:title="us-gaap_TypeOfArrangementAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_TypeOfArrangementAxis" xml:lang="en-US" id="label_us-gaap_TypeOfArrangementAxis">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="label_us-gaap_TypeOfArrangementAxis" xlink:title="Label : us-gaap_TypeOfArrangementAxis to label_us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:title="us-gaap_UseOfEstimates" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_UseOfEstimates" xml:lang="en-US" id="label_us-gaap_UseOfEstimates">Use of estimates in the preparation of financial statements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="label_us-gaap_UseOfEstimates" xlink:title="Label : us-gaap_UseOfEstimates to label_us-gaap_UseOfEstimates" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_UseOfEstimates_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_UseOfEstimates_1" xml:lang="en-US" id="label_us-gaap_UseOfEstimates_1">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="label_us-gaap_UseOfEstimates_1" xlink:title="Label : us-gaap_UseOfEstimates to label_us-gaap_UseOfEstimates_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:title="us-gaap_VestingDomain" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_VestingDomain" xml:lang="en-US" id="label_us-gaap_VestingDomain">Vesting [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="label_us-gaap_VestingDomain" xlink:title="Label : us-gaap_VestingDomain to label_us-gaap_VestingDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:title="us-gaap_VestingAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_VestingAxis" xml:lang="en-US" id="label_us-gaap_VestingAxis">Vesting [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="label_us-gaap_VestingAxis" xlink:title="Label : us-gaap_VestingAxis to label_us-gaap_VestingAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:title="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US" id="label_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE-BASIC AND DILUTED</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="label_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:title="Label : us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted to label_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1" xml:lang="en-US" id="label_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="label_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1" xlink:title="Label : us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted to label_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2" xml:lang="en-US" id="label_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE - BASIC AND DILUTED:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="label_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2" xlink:title="Label : us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted to label_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>plx-20150930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--Created by The Vintage Group, Powered by IRIS Carbon-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.protalix.com/role/plx-lasa" xlink:type="simple" xlink:href="plx-20150930.xsd#plx-lasa" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-lasad" xlink:type="simple" xlink:href="plx-20150930.xsd#plx-lasad" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-cd" xlink:type="simple" xlink:href="plx-20150930.xsd#plx-cd" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-ccsocicdp" xlink:type="simple" xlink:href="plx-20150930.xsd#plx-ccsocicdp" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-scnd" xlink:type="simple" xlink:href="plx-20150930.xsd#plx-scnd" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-scrsgted" xlink:type="simple" xlink:href="plx-20150930.xsd#plx-scrsgted" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-scsooarsd" xlink:type="simple" xlink:href="plx-20150930.xsd#plx-scsooarsd" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-std" xlink:type="simple" xlink:href="plx-20150930.xsd#plx-std" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-daei" xlink:type="simple" xlink:href="plx-20150930.xsd#plx-daei" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-sapd" xlink:type="simple" xlink:href="plx-20150930.xsd#plx-sapd" />
  <link:roleRef roleURI="http://www.protalix.com/role/Disclosure-SUBSEQUENTEVENTSDetails" xlink:type="simple" xlink:href="plx-20150930.xsd#Disclosure-SUBSEQUENTEVENTSDetails" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-toind" xlink:type="simple" xlink:href="plx-20150930.xsd#plx-toind" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-sfsird" xlink:type="simple" xlink:href="plx-20150930.xsd#plx-sfsird" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-sfsit" xlink:type="simple" xlink:href="plx-20150930.xsd#plx-sfsit" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-sfsiapaaod" xlink:type="simple" xlink:href="plx-20150930.xsd#plx-sfsiapaaod" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-sfsi" xlink:type="simple" xlink:href="plx-20150930.xsd#plx-sfsi" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-sfsoa" xlink:type="simple" xlink:href="plx-20150930.xsd#plx-sfsoa" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-sapp1" xlink:type="simple" xlink:href="plx-20150930.xsd#plx-sapp1" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-sapt" xlink:type="simple" xlink:href="plx-20150930.xsd#plx-sapt" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-sap" xlink:type="simple" xlink:href="plx-20150930.xsd#plx-sap" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-sapulopaed" xlink:type="simple" xlink:href="plx-20150930.xsd#plx-sapulopaed" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-ccbs" xlink:type="simple" xlink:href="plx-20150930.xsd#plx-ccbs" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-ccsocf" xlink:type="simple" xlink:href="plx-20150930.xsd#plx-ccsocf" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-c" xlink:type="simple" xlink:href="plx-20150930.xsd#plx-c" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-cnsoierd1" xlink:type="simple" xlink:href="plx-20150930.xsd#plx-cnsoierd1" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-cnnd1" xlink:type="simple" xlink:href="plx-20150930.xsd#plx-cnnd1" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-cn1" xlink:type="simple" xlink:href="plx-20150930.xsd#plx-cn1" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-cnt1" xlink:type="simple" xlink:href="plx-20150930.xsd#plx-cnt1" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-lferurd" xlink:type="simple" xlink:href="plx-20150930.xsd#plx-lferurd" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-lferur" xlink:type="simple" xlink:href="plx-20150930.xsd#plx-lferur" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-scfvaoogd" xlink:type="simple" xlink:href="plx-20150930.xsd#plx-scfvaoogd" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-sct" xlink:type="simple" xlink:href="plx-20150930.xsd#plx-sct" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-scsbcead" xlink:type="simple" xlink:href="plx-20150930.xsd#plx-scsbcead" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-scsooarsgted" xlink:type="simple" xlink:href="plx-20150930.xsd#plx-scsooarsgted" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-scogted" xlink:type="simple" xlink:href="plx-20150930.xsd#plx-scogted" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-scoarsgtcdaospd" xlink:type="simple" xlink:href="plx-20150930.xsd#plx-scoarsgtcdaospd" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-ccsoo" xlink:type="simple" xlink:href="plx-20150930.xsd#plx-ccsoo" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-ccsoop" xlink:type="simple" xlink:href="plx-20150930.xsd#plx-ccsoop" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-ccsocicd" xlink:type="simple" xlink:href="plx-20150930.xsd#plx-ccsocicd" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-fvmd1" xlink:type="simple" xlink:href="plx-20150930.xsd#plx-fvmd1" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-fvm1" xlink:type="simple" xlink:href="plx-20150930.xsd#plx-fvm1" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-toit" xlink:type="simple" xlink:href="plx-20150930.xsd#plx-toit" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-toiditd" xlink:type="simple" xlink:href="plx-20150930.xsd#plx-toiditd" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-toi" xlink:type="simple" xlink:href="plx-20150930.xsd#plx-toi" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-toiotyd" xlink:type="simple" xlink:href="plx-20150930.xsd#plx-toiotyd" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-id" xlink:type="simple" xlink:href="plx-20150930.xsd#plx-id" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-i" xlink:type="simple" xlink:href="plx-20150930.xsd#plx-i" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-it" xlink:type="simple" xlink:href="plx-20150930.xsd#plx-it" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-paed" xlink:type="simple" xlink:href="plx-20150930.xsd#plx-paed" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-paet" xlink:type="simple" xlink:href="plx-20150930.xsd#plx-paet" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-pae" xlink:type="simple" xlink:href="plx-20150930.xsd#plx-pae" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-rptd" xlink:type="simple" xlink:href="plx-20150930.xsd#plx-rptd" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-rpt" xlink:type="simple" xlink:href="plx-20150930.xsd#plx-rpt" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-rptt" xlink:type="simple" xlink:href="plx-20150930.xsd#plx-rptt" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-ccbsp" xlink:type="simple" xlink:href="plx-20150930.xsd#plx-ccbsp" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-st" xlink:type="simple" xlink:href="plx-20150930.xsd#plx-st" />
  <link:roleRef roleURI="http://www.protalix.com/role/Disclosure-SUBSEQUENTEVENTS" xlink:type="simple" xlink:href="plx-20150930.xsd#Disclosure-SUBSEQUENTEVENTS" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-lasa">
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_CollaborativeAndLicenseArrangementDisclosure" xlink:label="plx_CollaborativeAndLicenseArrangementDisclosure" xlink:title="plx_CollaborativeAndLicenseArrangementDisclosure" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_CollaborativeAndLicenseArrangementDisclosureTextBlock" xlink:label="plx_CollaborativeAndLicenseArrangementDisclosureTextBlock" xlink:title="plx_CollaborativeAndLicenseArrangementDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CollaborativeAndLicenseArrangementDisclosure" xlink:to="plx_CollaborativeAndLicenseArrangementDisclosureTextBlock" xlink:title="Presentation : plx_CollaborativeAndLicenseArrangementDisclosure to plx_CollaborativeAndLicenseArrangementDisclosureTextBlock" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-lasad">
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_CollaborativeAndLicenseArrangementDisclosure" xlink:label="plx_CollaborativeAndLicenseArrangementDisclosure" xlink:title="plx_CollaborativeAndLicenseArrangementDisclosure" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_CollaborativeAndLicenseArrangementTable" xlink:label="plx_CollaborativeAndLicenseArrangementTable" xlink:title="plx_CollaborativeAndLicenseArrangementTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CollaborativeAndLicenseArrangementDisclosure" xlink:to="plx_CollaborativeAndLicenseArrangementTable" xlink:title="Presentation : plx_CollaborativeAndLicenseArrangementDisclosure to plx_CollaborativeAndLicenseArrangementTable" order="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="plx_SignificantAccountingPoliciesLineItems" xlink:title="plx_SignificantAccountingPoliciesLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CollaborativeAndLicenseArrangementTable" xlink:to="plx_SignificantAccountingPoliciesLineItems" xlink:title="Presentation : plx_CollaborativeAndLicenseArrangementTable to plx_SignificantAccountingPoliciesLineItems" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:title="us-gaap_StatementScenarioAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CollaborativeAndLicenseArrangementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:title="Presentation : plx_CollaborativeAndLicenseArrangementTable to us-gaap_StatementScenarioAxis" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:title="us-gaap_TypeOfArrangementAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CollaborativeAndLicenseArrangementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:title="Presentation : plx_CollaborativeAndLicenseArrangementTable to us-gaap_TypeOfArrangementAxis" order="2.5" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember" xlink:title="plx_ProtalixBioTherapeuticsIncorporationMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_ProtalixBioTherapeuticsIncorporationMember" xlink:title="Presentation : us-gaap_ArrangementsAndNonarrangementTransactionsMember to plx_ProtalixBioTherapeuticsIncorporationMember" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_CollaborationOperationMember" xlink:label="plx_CollaborationOperationMember" xlink:title="plx_CollaborationOperationMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_CollaborationOperationMember" xlink:title="Presentation : us-gaap_ArrangementsAndNonarrangementTransactionsMember to plx_CollaborationOperationMember" order="2" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_MilestonePayment" xlink:label="plx_MilestonePayment" xlink:title="plx_MilestonePayment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_MilestonePayment" xlink:title="Presentation : plx_SignificantAccountingPoliciesLineItems to plx_MilestonePayment" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_RevenueRecognizedOverDesignatedPeriod" xlink:label="plx_RevenueRecognizedOverDesignatedPeriod" xlink:title="plx_RevenueRecognizedOverDesignatedPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_RevenueRecognizedOverDesignatedPeriod" xlink:title="Presentation : plx_SignificantAccountingPoliciesLineItems to plx_RevenueRecognizedOverDesignatedPeriod" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_RevenueRecognizedPeriod" xlink:label="plx_RevenueRecognizedPeriod" xlink:title="plx_RevenueRecognizedPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_RevenueRecognizedPeriod" xlink:title="Presentation : plx_SignificantAccountingPoliciesLineItems to plx_RevenueRecognizedPeriod" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_LiabilitiesAccruedFromLicensingAgreement" xlink:label="plx_LiabilitiesAccruedFromLicensingAgreement" xlink:title="plx_LiabilitiesAccruedFromLicensingAgreement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_LiabilitiesAccruedFromLicensingAgreement" xlink:title="Presentation : plx_SignificantAccountingPoliciesLineItems to plx_LiabilitiesAccruedFromLicensingAgreement" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:title="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:title="Presentation : plx_SignificantAccountingPoliciesLineItems to us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:title="us-gaap_ScenarioUnspecifiedDomain" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ScenarioTwoMember" xlink:label="plx_ScenarioTwoMember" xlink:title="plx_ScenarioTwoMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="plx_ScenarioTwoMember" xlink:title="Presentation : us-gaap_ScenarioUnspecifiedDomain to plx_ScenarioTwoMember" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_UponFDAApprovalMember" xlink:label="plx_UponFDAApprovalMember" xlink:title="plx_UponFDAApprovalMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="plx_UponFDAApprovalMember" xlink:title="Presentation : us-gaap_ScenarioUnspecifiedDomain to plx_UponFDAApprovalMember" order="3" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ScenarioOneMember" xlink:label="plx_ScenarioOneMember" xlink:title="plx_ScenarioOneMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="plx_ScenarioOneMember" xlink:title="Presentation : us-gaap_ScenarioUnspecifiedDomain to plx_ScenarioOneMember" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_UponNearTermClinicalDevelopmentMilestonesMember" xlink:label="plx_UponNearTermClinicalDevelopmentMilestonesMember" xlink:title="plx_UponNearTermClinicalDevelopmentMilestonesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="plx_UponNearTermClinicalDevelopmentMilestonesMember" xlink:title="Presentation : us-gaap_ScenarioUnspecifiedDomain to plx_UponNearTermClinicalDevelopmentMilestonesMember" order="4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:title="Presentation : us-gaap_StatementScenarioAxis to us-gaap_ScenarioUnspecifiedDomain" order="1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:title="Presentation : us-gaap_TypeOfArrangementAxis to us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-cd">
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_CommitmentsAndContingenciesAxis" xlink:label="plx_CommitmentsAndContingenciesAxis" xlink:title="plx_CommitmentsAndContingenciesAxis" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_CommitmentsAndContingenciesDomain" xlink:label="plx_CommitmentsAndContingenciesDomain" xlink:title="plx_CommitmentsAndContingenciesDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommitmentsAndContingenciesAxis" xlink:to="plx_CommitmentsAndContingenciesDomain" xlink:title="Presentation : plx_CommitmentsAndContingenciesAxis to plx_CommitmentsAndContingenciesDomain" order="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_FundingArrangementsMember" xlink:label="plx_FundingArrangementsMember" xlink:title="plx_FundingArrangementsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommitmentsAndContingenciesDomain" xlink:to="plx_FundingArrangementsMember" xlink:title="Presentation : plx_CommitmentsAndContingenciesDomain to plx_FundingArrangementsMember" order="3" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_MilestonePaymentsMember" xlink:label="plx_MilestonePaymentsMember" xlink:title="plx_MilestonePaymentsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommitmentsAndContingenciesDomain" xlink:to="plx_MilestonePaymentsMember" xlink:title="Presentation : plx_CommitmentsAndContingenciesDomain to plx_MilestonePaymentsMember" order="6" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_OCSMember" xlink:label="plx_OCSMember" xlink:title="plx_OCSMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommitmentsAndContingenciesDomain" xlink:to="plx_OCSMember" xlink:title="Presentation : plx_CommitmentsAndContingenciesDomain to plx_OCSMember" order="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ProbableAggregateMilestonePaymentMember" xlink:label="plx_ProbableAggregateMilestonePaymentMember" xlink:title="plx_ProbableAggregateMilestonePaymentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommitmentsAndContingenciesDomain" xlink:to="plx_ProbableAggregateMilestonePaymentMember" xlink:title="Presentation : plx_CommitmentsAndContingenciesDomain to plx_ProbableAggregateMilestonePaymentMember" order="5" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ProductsManufacturedOutsideOfIsraelMember" xlink:label="plx_ProductsManufacturedOutsideOfIsraelMember" xlink:title="plx_ProductsManufacturedOutsideOfIsraelMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommitmentsAndContingenciesDomain" xlink:to="plx_ProductsManufacturedOutsideOfIsraelMember" xlink:title="Presentation : plx_CommitmentsAndContingenciesDomain to plx_ProductsManufacturedOutsideOfIsraelMember" order="2" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ResearchAndLicenseAgreementsMember" xlink:label="plx_ResearchAndLicenseAgreementsMember" xlink:title="plx_ResearchAndLicenseAgreementsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommitmentsAndContingenciesDomain" xlink:to="plx_ResearchAndLicenseAgreementsMember" xlink:title="Presentation : plx_CommitmentsAndContingenciesDomain to plx_ResearchAndLicenseAgreementsMember" order="4" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_VehicleLeaseAndMaintenanceAgreementsMember" xlink:label="plx_VehicleLeaseAndMaintenanceAgreementsMember" xlink:title="plx_VehicleLeaseAndMaintenanceAgreementsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommitmentsAndContingenciesDomain" xlink:to="plx_VehicleLeaseAndMaintenanceAgreementsMember" xlink:title="Presentation : plx_CommitmentsAndContingenciesDomain to plx_VehicleLeaseAndMaintenanceAgreementsMember" order="9" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_YissumAgreementMember" xlink:label="plx_YissumAgreementMember" xlink:title="plx_YissumAgreementMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommitmentsAndContingenciesDomain" xlink:to="plx_YissumAgreementMember" xlink:title="Presentation : plx_CommitmentsAndContingenciesDomain to plx_YissumAgreementMember" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseAgreementsMember" xlink:label="us-gaap_LeaseAgreementsMember" xlink:title="us-gaap_LeaseAgreementsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommitmentsAndContingenciesDomain" xlink:to="us-gaap_LeaseAgreementsMember" xlink:title="Presentation : plx_CommitmentsAndContingenciesDomain to us-gaap_LeaseAgreementsMember" order="8" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_CommitmentsAndContingenciesLineItems" xlink:label="plx_CommitmentsAndContingenciesLineItems" xlink:title="plx_CommitmentsAndContingenciesLineItems" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_AgreementMaintenanceFee" xlink:label="plx_AgreementMaintenanceFee" xlink:title="plx_AgreementMaintenanceFee" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="plx_AgreementMaintenanceFee" xlink:title="Presentation : plx_CommitmentsAndContingenciesLineItems to plx_AgreementMaintenanceFee" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_AnnualIncreaseToMaintenanceFee" xlink:label="plx_AnnualIncreaseToMaintenanceFee" xlink:title="plx_AnnualIncreaseToMaintenanceFee" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="plx_AnnualIncreaseToMaintenanceFee" xlink:title="Presentation : plx_CommitmentsAndContingenciesLineItems to plx_AnnualIncreaseToMaintenanceFee" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_CommitmentAmount" xlink:label="plx_CommitmentAmount" xlink:title="plx_CommitmentAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="plx_CommitmentAmount" xlink:title="Presentation : plx_CommitmentsAndContingenciesLineItems to plx_CommitmentAmount" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ConsiderationForLicense" xlink:label="plx_ConsiderationForLicense" xlink:title="plx_ConsiderationForLicense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="plx_ConsiderationForLicense" xlink:title="Presentation : plx_CommitmentsAndContingenciesLineItems to plx_ConsiderationForLicense" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived" xlink:label="plx_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived" xlink:title="plx_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="plx_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived" xlink:title="Presentation : plx_CommitmentsAndContingenciesLineItems to plx_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived" order="2.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_MonthlyRentLeaseExpense" xlink:label="plx_MonthlyRentLeaseExpense" xlink:title="plx_MonthlyRentLeaseExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="plx_MonthlyRentLeaseExpense" xlink:title="Presentation : plx_CommitmentsAndContingenciesLineItems to plx_MonthlyRentLeaseExpense" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_RoyaltiesOnSaleOfProducts" xlink:label="plx_RoyaltiesOnSaleOfProducts" xlink:title="plx_RoyaltiesOnSaleOfProducts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="plx_RoyaltiesOnSaleOfProducts" xlink:title="Presentation : plx_CommitmentsAndContingenciesLineItems to plx_RoyaltiesOnSaleOfProducts" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:title="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:title="Presentation : plx_CommitmentsAndContingenciesLineItems to us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:title="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:title="Presentation : plx_CommitmentsAndContingenciesLineItems to us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet" xlink:title="us-gaap_OperatingLeasesRentExpenseNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeasesRentExpenseNet" xlink:title="Presentation : plx_CommitmentsAndContingenciesLineItems to us-gaap_OperatingLeasesRentExpenseNet" order="7.25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:title="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:title="Presentation : plx_CommitmentsAndContingenciesLineItems to us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:title="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:title="Presentation : plx_CommitmentsAndContingenciesLineItems to us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:title="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:title="Presentation : plx_CommitmentsAndContingenciesLineItems to us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" xlink:title="us-gaap_RoyaltyExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_RoyaltyExpense" xlink:title="Presentation : plx_CommitmentsAndContingenciesLineItems to us-gaap_RoyaltyExpense" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit" xlink:title="us-gaap_SecurityDeposit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_SecurityDeposit" xlink:title="Presentation : plx_CommitmentsAndContingenciesLineItems to us-gaap_SecurityDeposit" order="6.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_CommitmentsAndContingenciesTable" xlink:label="plx_CommitmentsAndContingenciesTable" xlink:title="plx_CommitmentsAndContingenciesTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommitmentsAndContingenciesTable" xlink:to="plx_CommitmentsAndContingenciesAxis" xlink:title="Presentation : plx_CommitmentsAndContingenciesTable to plx_CommitmentsAndContingenciesAxis" order="2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommitmentsAndContingenciesTable" xlink:to="plx_CommitmentsAndContingenciesLineItems" xlink:title="Presentation : plx_CommitmentsAndContingenciesTable to plx_CommitmentsAndContingenciesLineItems" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:title="us-gaap_RangeAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommitmentsAndContingenciesTable" xlink:to="us-gaap_RangeAxis" xlink:title="Presentation : plx_CommitmentsAndContingenciesTable to us-gaap_RangeAxis" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:title="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="plx_CommitmentsAndContingenciesTable" xlink:title="Presentation : us-gaap_CommitmentsAndContingenciesDisclosureAbstract to plx_CommitmentsAndContingenciesTable" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:title="us-gaap_RangeMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:title="us-gaap_MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" xlink:title="Presentation : us-gaap_RangeMember to us-gaap_MaximumMember" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:title="us-gaap_MinimumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" xlink:title="Presentation : us-gaap_RangeMember to us-gaap_MinimumMember" order="1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:title="Presentation : us-gaap_RangeAxis to us-gaap_RangeMember" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-ccsocicdp">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:title="us-gaap_AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="Presentation : us-gaap_AwardTypeAxis to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:title="us-gaap_RestrictedStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to us-gaap_RestrictedStockMember" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:title="us-gaap_StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:title="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:title="Presentation : us-gaap_StatementLineItems to us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:title="us-gaap_CommonStockSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:title="Presentation : us-gaap_StatementLineItems to us-gaap_CommonStockSharesAuthorized" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:title="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:title="Presentation : us-gaap_StatementLineItems to us-gaap_CommonStockParOrStatedValuePerShare" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="Presentation : us-gaap_StatementLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:title="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:title="Presentation : us-gaap_StatementLineItems to us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:title="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:title="us-gaap_StatementTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" xlink:title="Presentation : us-gaap_StatementOfStockholdersEquityAbstract to us-gaap_StatementTable" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:title="Presentation : us-gaap_StatementTable to us-gaap_AwardTypeAxis" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:title="Presentation : us-gaap_StatementTable to us-gaap_StatementLineItems" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-scnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:title="us-gaap_AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="Presentation : us-gaap_AwardTypeAxis to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="Presentation : us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" xlink:title="Presentation : us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to us-gaap_AwardTypeAxis" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="Presentation : us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="14" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:title="us-gaap_TitleOfIndividualAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:title="Presentation : us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to us-gaap_TitleOfIndividualAxis" order="3.5" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:title="us-gaap_VestingAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" xlink:title="Presentation : us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to us-gaap_VestingAxis" order="4" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" xlink:title="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption" xlink:label="plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption" xlink:title="plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption" order="84" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:title="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_DebtInstrumentInterestRateStatedPercentage" order="54" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:title="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_PaymentsOfStockIssuanceCosts" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:title="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="74" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:title="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ProceedsFromIssuanceOfCommonStock" order="2.75" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:title="us-gaap_SaleOfStockPricePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_SaleOfStockPricePerShare" order="2.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:title="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:title="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:title="us-gaap_EmployeeStockOptionMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to us-gaap_EmployeeStockOptionMember" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:title="us-gaap_RestrictedStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to us-gaap_RestrictedStockMember" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_EmployeesMember" xlink:label="plx_EmployeesMember" xlink:title="plx_EmployeesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="plx_EmployeesMember" xlink:title="Presentation : us-gaap_TitleOfIndividualWithRelationshipToEntityDomain to plx_EmployeesMember" order="2" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_OfficersAndCertainEmployeesMember" xlink:label="plx_OfficersAndCertainEmployeesMember" xlink:title="plx_OfficersAndCertainEmployeesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="plx_OfficersAndCertainEmployeesMember" xlink:title="Presentation : us-gaap_TitleOfIndividualWithRelationshipToEntityDomain to plx_OfficersAndCertainEmployeesMember" order="1.25" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_OfficersAndDirectorsInPrivateTransactionMember" xlink:label="plx_OfficersAndDirectorsInPrivateTransactionMember" xlink:title="plx_OfficersAndDirectorsInPrivateTransactionMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="plx_OfficersAndDirectorsInPrivateTransactionMember" xlink:title="Presentation : us-gaap_TitleOfIndividualWithRelationshipToEntityDomain to plx_OfficersAndDirectorsInPrivateTransactionMember" order="3" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_PresidentAndChiefExecutiveOfficerMember" xlink:label="plx_PresidentAndChiefExecutiveOfficerMember" xlink:title="plx_PresidentAndChiefExecutiveOfficerMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="plx_PresidentAndChiefExecutiveOfficerMember" xlink:title="Presentation : us-gaap_TitleOfIndividualWithRelationshipToEntityDomain to plx_PresidentAndChiefExecutiveOfficerMember" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BoardOfDirectorsChairmanMember" xlink:label="us-gaap_BoardOfDirectorsChairmanMember" xlink:title="us-gaap_BoardOfDirectorsChairmanMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="us-gaap_BoardOfDirectorsChairmanMember" xlink:title="Presentation : us-gaap_TitleOfIndividualWithRelationshipToEntityDomain to us-gaap_BoardOfDirectorsChairmanMember" order="14" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ExecutiveOfficerMember" xlink:label="us-gaap_ExecutiveOfficerMember" xlink:title="us-gaap_ExecutiveOfficerMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="us-gaap_ExecutiveOfficerMember" xlink:title="Presentation : us-gaap_TitleOfIndividualWithRelationshipToEntityDomain to us-gaap_ExecutiveOfficerMember" order="1.625" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="Presentation : us-gaap_TitleOfIndividualAxis to us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:title="us-gaap_VestingDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:title="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:title="Presentation : us-gaap_VestingDomain to us-gaap_ShareBasedCompensationAwardTrancheOneMember" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:title="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:title="Presentation : us-gaap_VestingDomain to us-gaap_ShareBasedCompensationAwardTrancheTwoMember" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:title="Presentation : us-gaap_VestingAxis to us-gaap_VestingDomain" order="10" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-scrsgted">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:title="us-gaap_AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="Presentation : us-gaap_AwardTypeAxis to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="Presentation : us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" xlink:title="Presentation : us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to us-gaap_AwardTypeAxis" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="Presentation : us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:title="us-gaap_TitleOfIndividualAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:title="Presentation : us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to us-gaap_TitleOfIndividualAxis" order="2.5" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="2.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:title="us-gaap_RestrictedStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to us-gaap_RestrictedStockMember" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_EmployeesMember" xlink:label="plx_EmployeesMember" xlink:title="plx_EmployeesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="plx_EmployeesMember" xlink:title="Presentation : us-gaap_TitleOfIndividualWithRelationshipToEntityDomain to plx_EmployeesMember" order="2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="Presentation : us-gaap_TitleOfIndividualAxis to us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-scsooarsd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:title="us-gaap_AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="Presentation : us-gaap_AwardTypeAxis to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:title="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:title="Presentation : us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" order="1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_AwardTypeAxis" xlink:title="Presentation : us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable to us-gaap_AwardTypeAxis" order="1.5" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:title="Presentation : us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable to us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:title="Presentation : us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable to us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:title="Presentation : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis to us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_OptionsAndRestrictedStockMember" xlink:label="plx_OptionsAndRestrictedStockMember" xlink:title="plx_OptionsAndRestrictedStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="plx_OptionsAndRestrictedStockMember" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to plx_OptionsAndRestrictedStockMember" order="2.5" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:title="us-gaap_RestrictedStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to us-gaap_RestrictedStockMember" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:title="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:title="Presentation : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems to us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:title="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:title="Presentation : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems to us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:title="Presentation : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:title="Presentation : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:title="Presentation : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems to us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:title="Presentation : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems to us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:title="Presentation : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems to us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_FivePointZeroMember" xlink:label="plx_FivePointZeroMember" xlink:title="plx_FivePointZeroMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="plx_FivePointZeroMember" xlink:title="Presentation : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to plx_FivePointZeroMember" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_NinePointSixSixMember" xlink:label="plx_NinePointSixSixMember" xlink:title="plx_NinePointSixSixMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="plx_NinePointSixSixMember" xlink:title="Presentation : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to plx_NinePointSixSixMember" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_OneSixPointSevenMember" xlink:label="plx_OneSixPointSevenMember" xlink:title="plx_OneSixPointSevenMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="plx_OneSixPointSevenMember" xlink:title="Presentation : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to plx_OneSixPointSevenMember" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_SevenPointFiveFiveMember" xlink:label="plx_SevenPointFiveFiveMember" xlink:title="plx_SevenPointFiveFiveMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="plx_SevenPointFiveFiveMember" xlink:title="Presentation : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to plx_SevenPointFiveFiveMember" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_SixPointEightOneZeroMember" xlink:label="plx_SixPointEightOneZeroMember" xlink:title="plx_SixPointEightOneZeroMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="plx_SixPointEightOneZeroMember" xlink:title="Presentation : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to plx_SixPointEightOneZeroMember" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_SixPointNineMember" xlink:label="plx_SixPointNineMember" xlink:title="plx_SixPointNineMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="plx_SixPointNineMember" xlink:title="Presentation : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to plx_SixPointNineMember" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ThreePointZeroTwoZeroMember" xlink:label="plx_ThreePointZeroTwoZeroMember" xlink:title="plx_ThreePointZeroTwoZeroMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="plx_ThreePointZeroTwoZeroMember" xlink:title="Presentation : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to plx_ThreePointZeroTwoZeroMember" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_TwoPointSixFiveMember" xlink:label="plx_TwoPointSixFiveMember" xlink:title="plx_TwoPointSixFiveMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="plx_TwoPointSixFiveMember" xlink:title="Presentation : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to plx_TwoPointSixFiveMember" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_TwoPointThreeFiveZeroMember" xlink:label="plx_TwoPointThreeFiveZeroMember" xlink:title="plx_TwoPointThreeFiveZeroMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="plx_TwoPointThreeFiveZeroMember" xlink:title="Presentation : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to plx_TwoPointThreeFiveZeroMember" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ZeroPointNineSevenTwoMember" xlink:label="plx_ZeroPointNineSevenTwoMember" xlink:title="plx_ZeroPointNineSevenTwoMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="plx_ZeroPointNineSevenTwoMember" xlink:title="Presentation : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to plx_ZeroPointNineSevenTwoMember" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ZeroPointOneTwoZeroMember" xlink:label="plx_ZeroPointOneTwoZeroMember" xlink:title="plx_ZeroPointOneTwoZeroMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="plx_ZeroPointOneTwoZeroMember" xlink:title="Presentation : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to plx_ZeroPointOneTwoZeroMember" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ZeroPointThreeNineNineMember" xlink:label="plx_ZeroPointThreeNineNineMember" xlink:title="plx_ZeroPointThreeNineNineMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="plx_ZeroPointThreeNineNineMember" xlink:title="Presentation : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to plx_ZeroPointThreeNineNineMember" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ZeroPointZeroZeroOneMember" xlink:label="plx_ZeroPointZeroZeroOneMember" xlink:title="plx_ZeroPointZeroZeroOneMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="plx_ZeroPointZeroZeroOneMember" xlink:title="Presentation : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to plx_ZeroPointZeroZeroOneMember" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_TwoPointThreeSevenZeroMember" xlink:label="plx_TwoPointThreeSevenZeroMember" xlink:title="plx_TwoPointThreeSevenZeroMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="plx_TwoPointThreeSevenZeroMember" xlink:title="Presentation : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to plx_TwoPointThreeSevenZeroMember" order="5.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ThreePointThreeSevenZeroMember" xlink:label="plx_ThreePointThreeSevenZeroMember" xlink:title="plx_ThreePointThreeSevenZeroMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="plx_ThreePointThreeSevenZeroMember" xlink:title="Presentation : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to plx_ThreePointThreeSevenZeroMember" order="7.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-std">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:title="us-gaap_AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="Presentation : us-gaap_AwardTypeAxis to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" xlink:title="us-gaap_ClassOfStockLineItems" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:title="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod" xlink:title="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="3" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:title="us-gaap_PlanNameAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:title="us-gaap_PlanNameDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:title="Presentation : us-gaap_PlanNameAxis to us-gaap_PlanNameDomain" use="optional" priority="0" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_EmployeeStockIncentivePlan2006Member" xlink:label="plx_EmployeeStockIncentivePlan2006Member" xlink:title="plx_EmployeeStockIncentivePlan2006Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="plx_EmployeeStockIncentivePlan2006Member" xlink:title="Presentation : us-gaap_PlanNameDomain to plx_EmployeeStockIncentivePlan2006Member" use="optional" priority="0" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" xlink:title="us-gaap_ScheduleOfStockByClassTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" xlink:title="Presentation : us-gaap_ScheduleOfStockByClassTable to us-gaap_AwardTypeAxis" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" xlink:title="Presentation : us-gaap_ScheduleOfStockByClassTable to us-gaap_ClassOfStockLineItems" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" xlink:title="Presentation : us-gaap_ScheduleOfStockByClassTable to us-gaap_PlanNameAxis" use="optional" priority="0" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:title="us-gaap_TitleOfIndividualAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:title="Presentation : us-gaap_ScheduleOfStockByClassTable to us-gaap_TitleOfIndividualAxis" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:title="us-gaap_VestingAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_VestingAxis" xlink:title="Presentation : us-gaap_ScheduleOfStockByClassTable to us-gaap_VestingAxis" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:title="us-gaap_EmployeeStockOptionMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to us-gaap_EmployeeStockOptionMember" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:title="us-gaap_StockholdersEquityNoteAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" xlink:title="Presentation : us-gaap_StockholdersEquityNoteAbstract to us-gaap_ScheduleOfStockByClassTable" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_OfficersAndCertainEmployeesMember" xlink:label="plx_OfficersAndCertainEmployeesMember" xlink:title="plx_OfficersAndCertainEmployeesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="plx_OfficersAndCertainEmployeesMember" xlink:title="Presentation : us-gaap_TitleOfIndividualWithRelationshipToEntityDomain to plx_OfficersAndCertainEmployeesMember" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="Presentation : us-gaap_TitleOfIndividualAxis to us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:title="us-gaap_VestingDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:title="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:title="Presentation : us-gaap_VestingDomain to us-gaap_ShareBasedCompensationAwardTrancheOneMember" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:title="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:title="Presentation : us-gaap_VestingDomain to us-gaap_ShareBasedCompensationAwardTrancheTwoMember" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:title="Presentation : us-gaap_VestingAxis to us-gaap_VestingDomain" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-daei">
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_DocumentAndEntityInformationAbstract" xlink:label="plx_DocumentAndEntityInformationAbstract" xlink:title="plx_DocumentAndEntityInformationAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:title="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag" xlink:title="Presentation : plx_DocumentAndEntityInformationAbstract to dei_AmendmentFlag" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:title="dei_CurrentFiscalYearEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_CurrentFiscalYearEndDate" xlink:title="Presentation : plx_DocumentAndEntityInformationAbstract to dei_CurrentFiscalYearEndDate" order="9" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:title="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate" xlink:title="Presentation : plx_DocumentAndEntityInformationAbstract to dei_DocumentPeriodEndDate" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:title="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_TradingSymbol" xlink:title="Presentation : plx_DocumentAndEntityInformationAbstract to dei_TradingSymbol" order="6" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:title="dei_EntityWellKnownSeasonedIssuer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" xlink:title="Presentation : plx_DocumentAndEntityInformationAbstract to dei_EntityWellKnownSeasonedIssuer" order="14.5625" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:title="dei_EntityVoluntaryFilers" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityVoluntaryFilers" xlink:title="Presentation : plx_DocumentAndEntityInformationAbstract to dei_EntityVoluntaryFilers" order="14.03125" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:title="dei_EntityCurrentReportingStatus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCurrentReportingStatus" xlink:title="Presentation : plx_DocumentAndEntityInformationAbstract to dei_EntityCurrentReportingStatus" order="14.29688" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:title="dei_EntityFilerCategory" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFilerCategory" xlink:title="Presentation : plx_DocumentAndEntityInformationAbstract to dei_EntityFilerCategory" order="13.5" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xlink:title="dei_EntityPublicFloat" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityPublicFloat" xlink:title="Presentation : plx_DocumentAndEntityInformationAbstract to dei_EntityPublicFloat" order="17" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:title="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName" xlink:title="Presentation : plx_DocumentAndEntityInformationAbstract to dei_EntityRegistrantName" order="7" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:title="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey" xlink:title="Presentation : plx_DocumentAndEntityInformationAbstract to dei_EntityCentralIndexKey" order="8" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:title="dei_EntityCommonStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:title="Presentation : plx_DocumentAndEntityInformationAbstract to dei_EntityCommonStockSharesOutstanding" order="16" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:title="dei_DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalYearFocus" xlink:title="Presentation : plx_DocumentAndEntityInformationAbstract to dei_DocumentFiscalYearFocus" order="4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:title="dei_DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:title="Presentation : plx_DocumentAndEntityInformationAbstract to dei_DocumentFiscalPeriodFocus" order="5" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:title="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType" xlink:title="Presentation : plx_DocumentAndEntityInformationAbstract to dei_DocumentType" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-sapd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:title="dei_EntityDomain" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember" xlink:title="plx_ProtalixBioTherapeuticsIncorporationMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="plx_ProtalixBioTherapeuticsIncorporationMember" xlink:title="Presentation : dei_EntityDomain to plx_ProtalixBioTherapeuticsIncorporationMember" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsidiariesMember" xlink:label="us-gaap_SubsidiariesMember" xlink:title="us-gaap_SubsidiariesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="us-gaap_SubsidiariesMember" xlink:title="Presentation : dei_EntityDomain to us-gaap_SubsidiariesMember" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_PfizerAgreementMember" xlink:label="plx_PfizerAgreementMember" xlink:title="plx_PfizerAgreementMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_PfizerAgreementMember" xlink:title="Presentation : us-gaap_ArrangementsAndNonarrangementTransactionsMember to plx_PfizerAgreementMember" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_BrazilAgreementMember" xlink:label="plx_BrazilAgreementMember" xlink:title="plx_BrazilAgreementMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_BrazilAgreementMember" xlink:title="Presentation : us-gaap_ArrangementsAndNonarrangementTransactionsMember to plx_BrazilAgreementMember" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_AmendedPfizerAgreementMember" xlink:label="plx_AmendedPfizerAgreementMember" xlink:title="plx_AmendedPfizerAgreementMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_AmendedPfizerAgreementMember" xlink:title="Presentation : us-gaap_ArrangementsAndNonarrangementTransactionsMember to plx_AmendedPfizerAgreementMember" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="plx_SignificantAccountingPoliciesLineItems" xlink:title="plx_SignificantAccountingPoliciesLineItems" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:title="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:title="Presentation : plx_SignificantAccountingPoliciesLineItems to plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_EligablePaymentReceivableUponAchievement" xlink:label="plx_EligablePaymentReceivableUponAchievement" xlink:title="plx_EligablePaymentReceivableUponAchievement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_EligablePaymentReceivableUponAchievement" xlink:title="Presentation : plx_SignificantAccountingPoliciesLineItems to plx_EligablePaymentReceivableUponAchievement" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_SupplyCommitmentPerYear" xlink:label="plx_SupplyCommitmentPerYear" xlink:title="plx_SupplyCommitmentPerYear" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_SupplyCommitmentPerYear" xlink:title="Presentation : plx_SignificantAccountingPoliciesLineItems to plx_SupplyCommitmentPerYear" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights" xlink:label="plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights" xlink:title="plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights" xlink:title="Presentation : plx_SignificantAccountingPoliciesLineItems to plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" xlink:label="plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" xlink:title="plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" xlink:title="Presentation : plx_SignificantAccountingPoliciesLineItems to plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_NumberOfSubsidiaries" xlink:label="plx_NumberOfSubsidiaries" xlink:title="plx_NumberOfSubsidiaries" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_NumberOfSubsidiaries" xlink:title="Presentation : plx_SignificantAccountingPoliciesLineItems to plx_NumberOfSubsidiaries" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_CollaborativeArrangementMilestonePaymentAmount" xlink:label="plx_CollaborativeArrangementMilestonePaymentAmount" xlink:title="plx_CollaborativeArrangementMilestonePaymentAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_CollaborativeArrangementMilestonePaymentAmount" xlink:title="Presentation : plx_SignificantAccountingPoliciesLineItems to plx_CollaborativeArrangementMilestonePaymentAmount" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_RightToTerminateAgreementRevenueThreshold" xlink:label="plx_RightToTerminateAgreementRevenueThreshold" xlink:title="plx_RightToTerminateAgreementRevenueThreshold" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_RightToTerminateAgreementRevenueThreshold" xlink:title="Presentation : plx_SignificantAccountingPoliciesLineItems to plx_RightToTerminateAgreementRevenueThreshold" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_PurchaseOrderReceived" xlink:label="plx_PurchaseOrderReceived" xlink:title="plx_PurchaseOrderReceived" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_PurchaseOrderReceived" xlink:title="Presentation : plx_SignificantAccountingPoliciesLineItems to plx_PurchaseOrderReceived" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_PercentageOfAdultGaucherPatientsTreatedWithUplyso" xlink:label="plx_PercentageOfAdultGaucherPatientsTreatedWithUplyso" xlink:title="plx_PercentageOfAdultGaucherPatientsTreatedWithUplyso" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_PercentageOfAdultGaucherPatientsTreatedWithUplyso" xlink:title="Presentation : plx_SignificantAccountingPoliciesLineItems to plx_PercentageOfAdultGaucherPatientsTreatedWithUplyso" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ProceedsFromSaleOfShareInCollaboration" xlink:label="plx_ProceedsFromSaleOfShareInCollaboration" xlink:title="plx_ProceedsFromSaleOfShareInCollaboration" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_ProceedsFromSaleOfShareInCollaboration" xlink:title="Presentation : plx_SignificantAccountingPoliciesLineItems to plx_ProceedsFromSaleOfShareInCollaboration" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfitsEliminationAmount" xlink:label="plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfitsEliminationAmount" xlink:title="plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfitsEliminationAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfitsEliminationAmount" xlink:title="Presentation : plx_SignificantAccountingPoliciesLineItems to plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfitsEliminationAmount" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_AgentFeePercentageOfNetProceeds" xlink:label="plx_AgentFeePercentageOfNetProceeds" xlink:title="plx_AgentFeePercentageOfNetProceeds" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_AgentFeePercentageOfNetProceeds" xlink:title="Presentation : plx_SignificantAccountingPoliciesLineItems to plx_AgentFeePercentageOfNetProceeds" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="Presentation : plx_SignificantAccountingPoliciesLineItems to us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:title="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:title="Presentation : plx_SignificantAccountingPoliciesLineItems to us-gaap_CommonStockParOrStatedValuePerShare" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:label="us-gaap_ProceedsFromCollaborators" xlink:title="us-gaap_ProceedsFromCollaborators" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ProceedsFromCollaborators" xlink:title="Presentation : plx_SignificantAccountingPoliciesLineItems to us-gaap_ProceedsFromCollaborators" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet" xlink:title="us-gaap_SalesRevenueGoodsNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_SalesRevenueGoodsNet" xlink:title="Presentation : plx_SignificantAccountingPoliciesLineItems to us-gaap_SalesRevenueGoodsNet" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="plx_SignificantAccountingPoliciesTable" xlink:title="plx_SignificantAccountingPoliciesTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="plx_SignificantAccountingPoliciesLineItems" xlink:title="Presentation : plx_SignificantAccountingPoliciesTable to plx_SignificantAccountingPoliciesLineItems" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:title="dei_LegalEntityAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="dei_LegalEntityAxis" xlink:title="Presentation : plx_SignificantAccountingPoliciesTable to dei_LegalEntityAxis" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="Presentation : plx_SignificantAccountingPoliciesTable to us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:title="us-gaap_CounterpartyNameAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:title="Presentation : plx_SignificantAccountingPoliciesTable to us-gaap_CounterpartyNameAxis" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:title="us-gaap_StatementScenarioAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:title="Presentation : plx_SignificantAccountingPoliciesTable to us-gaap_StatementScenarioAxis" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="us-gaap_StatementGeographicalAxis" xlink:title="us-gaap_StatementGeographicalAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_StatementGeographicalAxis" xlink:title="Presentation : plx_SignificantAccountingPoliciesTable to us-gaap_StatementGeographicalAxis" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:title="us-gaap_SubsequentEventTypeAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:title="Presentation : plx_SignificantAccountingPoliciesTable to us-gaap_SubsequentEventTypeAxis" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:title="us-gaap_TypeOfArrangementAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:title="Presentation : plx_SignificantAccountingPoliciesTable to us-gaap_TypeOfArrangementAxis" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:title="Presentation : dei_LegalEntityAxis to dei_EntityDomain" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:title="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="plx_SignificantAccountingPoliciesTable" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to plx_SignificantAccountingPoliciesTable" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_StockOptionsAndRestrictedSharesMember" xlink:label="plx_StockOptionsAndRestrictedSharesMember" xlink:title="plx_StockOptionsAndRestrictedSharesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="plx_StockOptionsAndRestrictedSharesMember" xlink:title="Presentation : us-gaap_AntidilutiveSecuritiesNameDomain to plx_StockOptionsAndRestrictedSharesMember" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:title="Presentation : us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to us-gaap_AntidilutiveSecuritiesNameDomain" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:title="us-gaap_RepurchaseAgreementCounterpartyNameDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:title="Presentation : us-gaap_CounterpartyNameAxis to us-gaap_RepurchaseAgreementCounterpartyNameDomain" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_PfizerIncorporationMember" xlink:label="plx_PfizerIncorporationMember" xlink:title="plx_PfizerIncorporationMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="plx_PfizerIncorporationMember" xlink:title="Presentation : us-gaap_RepurchaseAgreementCounterpartyNameDomain to plx_PfizerIncorporationMember" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_FiocruzMember" xlink:label="plx_FiocruzMember" xlink:title="plx_FiocruzMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="plx_FiocruzMember" xlink:title="Presentation : us-gaap_RepurchaseAgreementCounterpartyNameDomain to plx_FiocruzMember" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:title="us-gaap_ScenarioUnspecifiedDomain" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_UponFDAApprovalMember" xlink:label="plx_UponFDAApprovalMember" xlink:title="plx_UponFDAApprovalMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="plx_UponFDAApprovalMember" xlink:title="Presentation : us-gaap_ScenarioUnspecifiedDomain to plx_UponFDAApprovalMember" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ScenarioOneMember" xlink:label="plx_ScenarioOneMember" xlink:title="plx_ScenarioOneMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="plx_ScenarioOneMember" xlink:title="Presentation : us-gaap_ScenarioUnspecifiedDomain to plx_ScenarioOneMember" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_UponNearTermClinicalDevelopmentMilestonesMember" xlink:label="plx_UponNearTermClinicalDevelopmentMilestonesMember" xlink:title="plx_UponNearTermClinicalDevelopmentMilestonesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="plx_UponNearTermClinicalDevelopmentMilestonesMember" xlink:title="Presentation : us-gaap_ScenarioUnspecifiedDomain to plx_UponNearTermClinicalDevelopmentMilestonesMember" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="us-gaap_SegmentGeographicalDomain" xlink:title="us-gaap_SegmentGeographicalDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd#country_BR" xlink:label="country_BR" xlink:title="country_BR" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentGeographicalDomain" xlink:to="country_BR" xlink:title="Presentation : us-gaap_SegmentGeographicalDomain to country_BR" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ExcludingBrazilMember" xlink:label="plx_ExcludingBrazilMember" xlink:title="plx_ExcludingBrazilMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentGeographicalDomain" xlink:to="plx_ExcludingBrazilMember" xlink:title="Presentation : us-gaap_SegmentGeographicalDomain to plx_ExcludingBrazilMember" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:title="Presentation : us-gaap_StatementScenarioAxis to us-gaap_ScenarioUnspecifiedDomain" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_SegmentGeographicalDomain" xlink:title="Presentation : us-gaap_StatementGeographicalAxis to us-gaap_SegmentGeographicalDomain" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:title="us-gaap_SubsequentEventTypeDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:title="Presentation : us-gaap_SubsequentEventTypeAxis to us-gaap_SubsequentEventTypeDomain" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:title="us-gaap_SubsequentEventMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:title="Presentation : us-gaap_SubsequentEventTypeDomain to us-gaap_SubsequentEventMember" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:title="Presentation : us-gaap_TypeOfArrangementAxis to us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/Disclosure-SUBSEQUENTEVENTSDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:title="dei_EntityDomain" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember" xlink:title="plx_ProtalixBioTherapeuticsIncorporationMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="plx_ProtalixBioTherapeuticsIncorporationMember" xlink:title="Presentation : dei_EntityDomain to plx_ProtalixBioTherapeuticsIncorporationMember" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsidiariesMember" xlink:label="us-gaap_SubsidiariesMember" xlink:title="us-gaap_SubsidiariesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="us-gaap_SubsidiariesMember" xlink:title="Presentation : dei_EntityDomain to us-gaap_SubsidiariesMember" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_PfizerAgreementMember" xlink:label="plx_PfizerAgreementMember" xlink:title="plx_PfizerAgreementMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_PfizerAgreementMember" xlink:title="Presentation : us-gaap_ArrangementsAndNonarrangementTransactionsMember to plx_PfizerAgreementMember" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_BrazilAgreementMember" xlink:label="plx_BrazilAgreementMember" xlink:title="plx_BrazilAgreementMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_BrazilAgreementMember" xlink:title="Presentation : us-gaap_ArrangementsAndNonarrangementTransactionsMember to plx_BrazilAgreementMember" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_AmendedPfizerAgreementMember" xlink:label="plx_AmendedPfizerAgreementMember" xlink:title="plx_AmendedPfizerAgreementMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_AmendedPfizerAgreementMember" xlink:title="Presentation : us-gaap_ArrangementsAndNonarrangementTransactionsMember to plx_AmendedPfizerAgreementMember" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:title="dei_LegalEntityAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:title="Presentation : dei_LegalEntityAxis to dei_EntityDomain" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:title="us-gaap_CounterpartyNameAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:title="us-gaap_RepurchaseAgreementCounterpartyNameDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:title="Presentation : us-gaap_CounterpartyNameAxis to us-gaap_RepurchaseAgreementCounterpartyNameDomain" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:title="us-gaap_DebtInstrumentAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:title="us-gaap_DebtInstrumentNameDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:title="Presentation : us-gaap_DebtInstrumentAxis to us-gaap_DebtInstrumentNameDomain" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_October2015PromissoryNoteToPfizerMember" xlink:label="plx_October2015PromissoryNoteToPfizerMember" xlink:title="plx_October2015PromissoryNoteToPfizerMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_October2015PromissoryNoteToPfizerMember" xlink:title="Presentation : us-gaap_DebtInstrumentNameDomain to plx_October2015PromissoryNoteToPfizerMember" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_PfizerIncorporationMember" xlink:label="plx_PfizerIncorporationMember" xlink:title="plx_PfizerIncorporationMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="plx_PfizerIncorporationMember" xlink:title="Presentation : us-gaap_RepurchaseAgreementCounterpartyNameDomain to plx_PfizerIncorporationMember" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_FiocruzMember" xlink:label="plx_FiocruzMember" xlink:title="plx_FiocruzMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="plx_FiocruzMember" xlink:title="Presentation : us-gaap_RepurchaseAgreementCounterpartyNameDomain to plx_FiocruzMember" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="us-gaap_SegmentGeographicalDomain" xlink:title="us-gaap_SegmentGeographicalDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd#country_BR" xlink:label="country_BR" xlink:title="country_BR" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentGeographicalDomain" xlink:to="country_BR" xlink:title="Presentation : us-gaap_SegmentGeographicalDomain to country_BR" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ExcludingBrazilMember" xlink:label="plx_ExcludingBrazilMember" xlink:title="plx_ExcludingBrazilMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentGeographicalDomain" xlink:to="plx_ExcludingBrazilMember" xlink:title="Presentation : us-gaap_SegmentGeographicalDomain to plx_ExcludingBrazilMember" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="us-gaap_StatementGeographicalAxis" xlink:title="us-gaap_StatementGeographicalAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_SegmentGeographicalDomain" xlink:title="Presentation : us-gaap_StatementGeographicalAxis to us-gaap_SegmentGeographicalDomain" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:title="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:title="us-gaap_SubsequentEventTypeDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:title="Presentation : us-gaap_SubsequentEventTypeAxis to us-gaap_SubsequentEventTypeDomain" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" xlink:title="us-gaap_SubsequentEventLineItems" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:title="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:title="Presentation : us-gaap_SubsequentEventLineItems to plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" xlink:label="plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" xlink:title="plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" xlink:title="Presentation : us-gaap_SubsequentEventLineItems to plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ProceedsFromSaleOfShareInCollaboration" xlink:label="plx_ProceedsFromSaleOfShareInCollaboration" xlink:title="plx_ProceedsFromSaleOfShareInCollaboration" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="plx_ProceedsFromSaleOfShareInCollaboration" xlink:title="Presentation : us-gaap_SubsequentEventLineItems to plx_ProceedsFromSaleOfShareInCollaboration" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfitsEliminationAmount" xlink:label="plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfitsEliminationAmount" xlink:title="plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfitsEliminationAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfitsEliminationAmount" xlink:title="Presentation : us-gaap_SubsequentEventLineItems to plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfitsEliminationAmount" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_StockPurchaseAgreementLockUpPeriod" xlink:label="plx_StockPurchaseAgreementLockUpPeriod" xlink:title="plx_StockPurchaseAgreementLockUpPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="plx_StockPurchaseAgreementLockUpPeriod" xlink:title="Presentation : us-gaap_SubsequentEventLineItems to plx_StockPurchaseAgreementLockUpPeriod" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:title="us-gaap_DebtInstrumentMaturityDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" xlink:title="Presentation : us-gaap_SubsequentEventLineItems to us-gaap_DebtInstrumentMaturityDate" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:title="us-gaap_DebtInstrumentFaceAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" xlink:title="Presentation : us-gaap_SubsequentEventLineItems to us-gaap_DebtInstrumentFaceAmount" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:title="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:title="Presentation : us-gaap_SubsequentEventLineItems to us-gaap_StockIssuedDuringPeriodValueNewIssues" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:title="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:title="Presentation : us-gaap_SubsequentEventLineItems to us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:title="us-gaap_SubsequentEventsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" xlink:title="us-gaap_SubsequentEventTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" xlink:title="Presentation : us-gaap_SubsequentEventsAbstract to us-gaap_SubsequentEventTable" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:title="us-gaap_SubsequentEventMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:title="Presentation : us-gaap_SubsequentEventTypeDomain to us-gaap_SubsequentEventMember" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="dei_LegalEntityAxis" xlink:title="Presentation : us-gaap_SubsequentEventTable to dei_LegalEntityAxis" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:title="Presentation : us-gaap_SubsequentEventTable to us-gaap_CounterpartyNameAxis" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:title="Presentation : us-gaap_SubsequentEventTable to us-gaap_DebtInstrumentAxis" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_StatementGeographicalAxis" xlink:title="Presentation : us-gaap_SubsequentEventTable to us-gaap_StatementGeographicalAxis" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:title="Presentation : us-gaap_SubsequentEventTable to us-gaap_SubsequentEventTypeAxis" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" xlink:title="Presentation : us-gaap_SubsequentEventTable to us-gaap_SubsequentEventLineItems" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:title="us-gaap_TitleOfIndividualAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:title="Presentation : us-gaap_SubsequentEventTable to us-gaap_TitleOfIndividualAxis" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:title="us-gaap_TypeOfArrangementAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:title="Presentation : us-gaap_SubsequentEventTable to us-gaap_TypeOfArrangementAxis" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ExecutiveOfficerMember" xlink:label="us-gaap_ExecutiveOfficerMember" xlink:title="us-gaap_ExecutiveOfficerMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="us-gaap_ExecutiveOfficerMember" xlink:title="Presentation : us-gaap_TitleOfIndividualWithRelationshipToEntityDomain to us-gaap_ExecutiveOfficerMember" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="Presentation : us-gaap_TitleOfIndividualAxis to us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:title="Presentation : us-gaap_TypeOfArrangementAxis to us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-toind">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:title="dei_EntityDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsidiariesMember" xlink:label="us-gaap_SubsidiariesMember" xlink:title="us-gaap_SubsidiariesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="us-gaap_SubsidiariesMember" xlink:title="Presentation : dei_EntityDomain to us-gaap_SubsidiariesMember" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_IncomeTaxDisclosureLineItems" xlink:label="plx_IncomeTaxDisclosureLineItems" xlink:title="plx_IncomeTaxDisclosureLineItems" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_EffectiveAdjustedIncomeTaxRateThereafter" xlink:label="plx_EffectiveAdjustedIncomeTaxRateThereafter" xlink:title="plx_EffectiveAdjustedIncomeTaxRateThereafter" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_IncomeTaxDisclosureLineItems" xlink:to="plx_EffectiveAdjustedIncomeTaxRateThereafter" xlink:title="Presentation : plx_IncomeTaxDisclosureLineItems to plx_EffectiveAdjustedIncomeTaxRateThereafter" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_EffectiveAdjustedIncomeTaxRateYearFive" xlink:label="plx_EffectiveAdjustedIncomeTaxRateYearFive" xlink:title="plx_EffectiveAdjustedIncomeTaxRateYearFive" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_IncomeTaxDisclosureLineItems" xlink:to="plx_EffectiveAdjustedIncomeTaxRateYearFive" xlink:title="Presentation : plx_IncomeTaxDisclosureLineItems to plx_EffectiveAdjustedIncomeTaxRateYearFive" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_EffectiveAdjustedIncomeTaxRateYearFour" xlink:label="plx_EffectiveAdjustedIncomeTaxRateYearFour" xlink:title="plx_EffectiveAdjustedIncomeTaxRateYearFour" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_IncomeTaxDisclosureLineItems" xlink:to="plx_EffectiveAdjustedIncomeTaxRateYearFour" xlink:title="Presentation : plx_IncomeTaxDisclosureLineItems to plx_EffectiveAdjustedIncomeTaxRateYearFour" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_EffectiveAdjustedIncomeTaxRateYearOne" xlink:label="plx_EffectiveAdjustedIncomeTaxRateYearOne" xlink:title="plx_EffectiveAdjustedIncomeTaxRateYearOne" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_IncomeTaxDisclosureLineItems" xlink:to="plx_EffectiveAdjustedIncomeTaxRateYearOne" xlink:title="Presentation : plx_IncomeTaxDisclosureLineItems to plx_EffectiveAdjustedIncomeTaxRateYearOne" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_EffectiveAdjustedIncomeTaxRateYearThree" xlink:label="plx_EffectiveAdjustedIncomeTaxRateYearThree" xlink:title="plx_EffectiveAdjustedIncomeTaxRateYearThree" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_IncomeTaxDisclosureLineItems" xlink:to="plx_EffectiveAdjustedIncomeTaxRateYearThree" xlink:title="Presentation : plx_IncomeTaxDisclosureLineItems to plx_EffectiveAdjustedIncomeTaxRateYearThree" order="5.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_EffectiveAdjustedIncomeTaxRateYearTwo" xlink:label="plx_EffectiveAdjustedIncomeTaxRateYearTwo" xlink:title="plx_EffectiveAdjustedIncomeTaxRateYearTwo" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_IncomeTaxDisclosureLineItems" xlink:to="plx_EffectiveAdjustedIncomeTaxRateYearTwo" xlink:title="Presentation : plx_IncomeTaxDisclosureLineItems to plx_EffectiveAdjustedIncomeTaxRateYearTwo" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal" xlink:label="plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal" xlink:title="plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_IncomeTaxDisclosureLineItems" xlink:to="plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal" xlink:title="Presentation : plx_IncomeTaxDisclosureLineItems to plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_WithholdingTaxRateOnForeignIncome" xlink:label="plx_WithholdingTaxRateOnForeignIncome" xlink:title="plx_WithholdingTaxRateOnForeignIncome" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_IncomeTaxDisclosureLineItems" xlink:to="plx_WithholdingTaxRateOnForeignIncome" xlink:title="Presentation : plx_IncomeTaxDisclosureLineItems to plx_WithholdingTaxRateOnForeignIncome" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:title="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:title="Presentation : plx_IncomeTaxDisclosureLineItems to us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:title="us-gaap_OperatingLossCarryforwards" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" xlink:title="Presentation : plx_IncomeTaxDisclosureLineItems to us-gaap_OperatingLossCarryforwards" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_IncomeTaxDisclosureTable" xlink:label="plx_IncomeTaxDisclosureTable" xlink:title="plx_IncomeTaxDisclosureTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_IncomeTaxDisclosureTable" xlink:to="plx_IncomeTaxDisclosureLineItems" xlink:title="Presentation : plx_IncomeTaxDisclosureTable to plx_IncomeTaxDisclosureLineItems" order="4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:title="dei_LegalEntityAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_IncomeTaxDisclosureTable" xlink:to="dei_LegalEntityAxis" xlink:title="Presentation : plx_IncomeTaxDisclosureTable to dei_LegalEntityAxis" order="1.5" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:title="us-gaap_IncomeTaxAuthorityAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_IncomeTaxDisclosureTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:title="Presentation : plx_IncomeTaxDisclosureTable to us-gaap_IncomeTaxAuthorityAxis" order="2.75" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:title="us-gaap_RangeAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_IncomeTaxDisclosureTable" xlink:to="us-gaap_RangeAxis" xlink:title="Presentation : plx_IncomeTaxDisclosureTable to us-gaap_RangeAxis" order="1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:title="Presentation : dei_LegalEntityAxis to dei_EntityDomain" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:title="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="plx_IncomeTaxDisclosureTable" xlink:title="Presentation : us-gaap_IncomeTaxDisclosureAbstract to plx_IncomeTaxDisclosureTable" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:title="us-gaap_IncomeTaxAuthorityDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:title="Presentation : us-gaap_IncomeTaxAuthorityAxis to us-gaap_IncomeTaxAuthorityDomain" order="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_RestrictedAmountMember" xlink:label="plx_RestrictedAmountMember" xlink:title="plx_RestrictedAmountMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="plx_RestrictedAmountMember" xlink:title="Presentation : us-gaap_IncomeTaxAuthorityDomain to plx_RestrictedAmountMember" order="4" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_TaxBurdenDistributionLawMember" xlink:label="plx_TaxBurdenDistributionLawMember" xlink:title="plx_TaxBurdenDistributionLawMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="plx_TaxBurdenDistributionLawMember" xlink:title="Presentation : us-gaap_IncomeTaxAuthorityDomain to plx_TaxBurdenDistributionLawMember" order="2" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_TaxYearThereafterMember" xlink:label="plx_TaxYearThereafterMember" xlink:title="plx_TaxYearThereafterMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="plx_TaxYearThereafterMember" xlink:title="Presentation : us-gaap_IncomeTaxAuthorityDomain to plx_TaxYearThereafterMember" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_TaxYearTwoThousandNineMember" xlink:label="plx_TaxYearTwoThousandNineMember" xlink:title="plx_TaxYearTwoThousandNineMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="plx_TaxYearTwoThousandNineMember" xlink:title="Presentation : us-gaap_IncomeTaxAuthorityDomain to plx_TaxYearTwoThousandNineMember" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:title="us-gaap_RangeMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:title="us-gaap_MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" xlink:title="Presentation : us-gaap_RangeMember to us-gaap_MaximumMember" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:title="us-gaap_MinimumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" xlink:title="Presentation : us-gaap_RangeMember to us-gaap_MinimumMember" order="1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:title="Presentation : us-gaap_RangeAxis to us-gaap_RangeMember" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-sfsird">
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_SupplementalInformationAbstract" xlink:label="plx_SupplementalInformationAbstract" xlink:title="plx_SupplementalInformationAbstract" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_MilestonePayment" xlink:label="plx_MilestonePayment" xlink:title="plx_MilestonePayment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SupplementalInformationAbstract" xlink:to="plx_MilestonePayment" xlink:title="Presentation : plx_SupplementalInformationAbstract to plx_MilestonePayment" order="41" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="us-gaap_LicensesRevenue" xlink:title="us-gaap_LicensesRevenue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SupplementalInformationAbstract" xlink:to="us-gaap_LicensesRevenue" xlink:title="Presentation : plx_SupplementalInformationAbstract to us-gaap_LicensesRevenue" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" xlink:title="us-gaap_RevenuesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SupplementalInformationAbstract" xlink:to="us-gaap_RevenuesAbstract" xlink:title="Presentation : plx_SupplementalInformationAbstract to us-gaap_RevenuesAbstract" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet" xlink:title="us-gaap_SalesRevenueGoodsNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SupplementalInformationAbstract" xlink:to="us-gaap_SalesRevenueGoodsNet" xlink:title="Presentation : plx_SupplementalInformationAbstract to us-gaap_SalesRevenueGoodsNet" order="71" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-sfsit">
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_SupplementalInformationAbstract" xlink:label="plx_SupplementalInformationAbstract" xlink:title="plx_SupplementalInformationAbstract" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_SupplementaryBalanceSheetsInformationTableTextBlock" xlink:label="plx_SupplementaryBalanceSheetsInformationTableTextBlock" xlink:title="plx_SupplementaryBalanceSheetsInformationTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SupplementalInformationAbstract" xlink:to="plx_SupplementaryBalanceSheetsInformationTableTextBlock" xlink:title="Presentation : plx_SupplementalInformationAbstract to plx_SupplementaryBalanceSheetsInformationTableTextBlock" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_SupplementaryIncomeStatementInformationTableTextBlock" xlink:label="plx_SupplementaryIncomeStatementInformationTableTextBlock" xlink:title="plx_SupplementaryIncomeStatementInformationTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SupplementalInformationAbstract" xlink:to="plx_SupplementaryIncomeStatementInformationTableTextBlock" xlink:title="Presentation : plx_SupplementalInformationAbstract to plx_SupplementaryIncomeStatementInformationTableTextBlock" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-sfsiapaaod">
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_SupplementalInformationAbstract" xlink:label="plx_SupplementalInformationAbstract" xlink:title="plx_SupplementalInformationAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:title="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SupplementalInformationAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:title="Presentation : plx_SupplementalInformationAbstract to us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_AccruedLiabilityInConnectionWithCollaborationOperationCurrent" xlink:label="plx_AccruedLiabilityInConnectionWithCollaborationOperationCurrent" xlink:title="plx_AccruedLiabilityInConnectionWithCollaborationOperationCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="plx_AccruedLiabilityInConnectionWithCollaborationOperationCurrent" xlink:title="Presentation : us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract to plx_AccruedLiabilityInConnectionWithCollaborationOperationCurrent" order="60" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" xlink:label="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" xlink:title="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" xlink:title="Presentation : us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract to plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" order="70" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrent" xlink:title="us-gaap_AccruedRoyaltiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedRoyaltiesCurrent" xlink:title="Presentation : us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract to us-gaap_AccruedRoyaltiesCurrent" order="50" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:title="us-gaap_AccruedLiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:title="Presentation : us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract to us-gaap_AccruedLiabilitiesCurrent" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedVacationCurrent" xlink:label="us-gaap_AccruedVacationCurrent" xlink:title="us-gaap_AccruedVacationCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedVacationCurrent" xlink:title="Presentation : us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract to us-gaap_AccruedVacationCurrent" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:title="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:title="Presentation : us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract to us-gaap_EmployeeRelatedLiabilitiesCurrent" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" xlink:title="us-gaap_InterestPayableCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_InterestPayableCurrent" xlink:title="Presentation : us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract to us-gaap_InterestPayableCurrent" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-sfsi">
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_SupplementalInformationAbstract" xlink:label="plx_SupplementalInformationAbstract" xlink:title="plx_SupplementalInformationAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:label="us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:title="us-gaap_AdditionalFinancialInformationDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SupplementalInformationAbstract" xlink:to="us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:title="Presentation : plx_SupplementalInformationAbstract to us-gaap_AdditionalFinancialInformationDisclosureTextBlock" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-sfsoa">
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_SupplementalInformationAbstract" xlink:label="plx_SupplementalInformationAbstract" xlink:title="plx_SupplementalInformationAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:title="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SupplementalInformationAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:title="Presentation : plx_SupplementalInformationAbstract to us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_OtherAssetsInstitutionsCurrent" xlink:label="plx_OtherAssetsInstitutionsCurrent" xlink:title="plx_OtherAssetsInstitutionsCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="plx_OtherAssetsInstitutionsCurrent" xlink:title="Presentation : us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract to plx_OtherAssetsInstitutionsCurrent" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_OtherAssetsSundryCurrent" xlink:label="plx_OtherAssetsSundryCurrent" xlink:title="plx_OtherAssetsSundryCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="plx_OtherAssetsSundryCurrent" xlink:title="Presentation : us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract to plx_OtherAssetsSundryCurrent" order="50" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidRoyalties" xlink:label="us-gaap_PrepaidRoyalties" xlink:title="us-gaap_PrepaidRoyalties" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidRoyalties" xlink:title="Presentation : us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract to us-gaap_PrepaidRoyalties" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:title="us-gaap_PrepaidExpenseCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" xlink:title="Presentation : us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract to us-gaap_PrepaidExpenseCurrent" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:title="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:title="Presentation : us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract to us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-sapp1">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:title="us-gaap_AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_NatureOfOperationsPolicyTextBlock" xlink:label="plx_NatureOfOperationsPolicyTextBlock" xlink:title="plx_NatureOfOperationsPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="plx_NatureOfOperationsPolicyTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to plx_NatureOfOperationsPolicyTextBlock" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:title="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:title="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="2.875" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:title="us-gaap_ConcentrationRiskCreditRisk" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_ConcentrationRiskCreditRisk" order="2.99951" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock" xlink:title="us-gaap_DebtPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DebtPolicyTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_DebtPolicyTextBlock" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:title="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_EarningsPerSharePolicyTextBlock" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:title="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="2.75" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:title="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="2.98438" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:title="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_IncomeTaxPolicyTextBlock" order="2.99219" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:title="us-gaap_InventoryPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_InventoryPolicyTextBlock" order="2.9375" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:title="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:title="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="2.96875" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:title="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_ResearchAndDevelopmentExpensePolicy" order="2.99805" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:title="us-gaap_RevenueRecognitionPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_RevenueRecognitionPolicyTextBlock" order="2.99609" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="2.99976" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:title="us-gaap_UseOfEstimates" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_UseOfEstimates" order="2.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-sapt">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:title="us-gaap_AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ScheduleOfUsefulLifeTableTextBlock" xlink:label="plx_ScheduleOfUsefulLifeTableTextBlock" xlink:title="plx_ScheduleOfUsefulLifeTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="plx_ScheduleOfUsefulLifeTableTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to plx_ScheduleOfUsefulLifeTableTextBlock" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-sap">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:title="us-gaap_AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:title="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-sapulopaed">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:title="us-gaap_AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:title="Presentation : us-gaap_PropertyPlantAndEquipmentByTypeAxis to us-gaap_PropertyPlantAndEquipmentTypeDomain" order="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_LaboratoryEquipmentMember" xlink:label="plx_LaboratoryEquipmentMember" xlink:title="plx_LaboratoryEquipmentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="plx_LaboratoryEquipmentMember" xlink:title="Presentation : us-gaap_PropertyPlantAndEquipmentTypeDomain to plx_LaboratoryEquipmentMember" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:title="us-gaap_ComputerEquipmentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" xlink:title="Presentation : us-gaap_PropertyPlantAndEquipmentTypeDomain to us-gaap_ComputerEquipmentMember" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:title="us-gaap_FurnitureAndFixturesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:title="Presentation : us-gaap_PropertyPlantAndEquipmentTypeDomain to us-gaap_FurnitureAndFixturesMember" order="1.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:title="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:title="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:title="Presentation : us-gaap_PropertyPlantAndEquipmentLineItems to us-gaap_PropertyPlantAndEquipmentUsefulLife" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:title="us-gaap_RangeMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:title="us-gaap_MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" xlink:title="Presentation : us-gaap_RangeMember to us-gaap_MaximumMember" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:title="us-gaap_MinimumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" xlink:title="Presentation : us-gaap_RangeMember to us-gaap_MinimumMember" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:title="us-gaap_RangeAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:title="Presentation : us-gaap_RangeAxis to us-gaap_RangeMember" order="1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:title="Presentation : us-gaap_ScheduleOfPropertyPlantAndEquipmentTable to us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:title="Presentation : us-gaap_ScheduleOfPropertyPlantAndEquipmentTable to us-gaap_PropertyPlantAndEquipmentLineItems" order="3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_RangeAxis" xlink:title="Presentation : us-gaap_ScheduleOfPropertyPlantAndEquipmentTable to us-gaap_RangeAxis" order="2" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-ccbs">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:title="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent" xlink:title="us-gaap_AccountsPayableTradeCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableTradeCurrent" xlink:title="Presentation : us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract to us-gaap_AccountsPayableTradeCurrent" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:title="us-gaap_AccountsPayableOtherCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableOtherCurrent" xlink:title="Presentation : us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract to us-gaap_AccountsPayableOtherCurrent" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xlink:title="us-gaap_AssetsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:title="us-gaap_Assets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" xlink:title="Presentation : us-gaap_AssetsAbstract to us-gaap_Assets" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:title="us-gaap_AssetsCurrentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" xlink:title="Presentation : us-gaap_AssetsAbstract to us-gaap_AssetsCurrentAbstract" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredCosts" xlink:label="us-gaap_DeferredCosts" xlink:title="us-gaap_DeferredCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_DeferredCosts" xlink:title="Presentation : us-gaap_AssetsAbstract to us-gaap_DeferredCosts" order="3.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:title="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:title="Presentation : us-gaap_AssetsAbstract to us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" order="2.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:title="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:title="Presentation : us-gaap_AssetsAbstract to us-gaap_PropertyPlantAndEquipmentNet" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:title="us-gaap_AccountsReceivableNetCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" xlink:title="Presentation : us-gaap_AssetsCurrentAbstract to us-gaap_AccountsReceivableNetCurrent" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:title="us-gaap_AssetsCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" xlink:title="Presentation : us-gaap_AssetsCurrentAbstract to us-gaap_AssetsCurrent" order="15" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:title="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:title="Presentation : us-gaap_AssetsCurrentAbstract to us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:title="us-gaap_InventoryNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" xlink:title="Presentation : us-gaap_AssetsCurrentAbstract to us-gaap_InventoryNet" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" xlink:title="us-gaap_OtherAssetsCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" xlink:title="Presentation : us-gaap_AssetsCurrentAbstract to us-gaap_OtherAssetsCurrent" order="4.75" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:title="us-gaap_LiabilitiesCurrentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:title="Presentation : us-gaap_LiabilitiesCurrentAbstract to us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:title="us-gaap_DeferredRevenueCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" xlink:title="Presentation : us-gaap_LiabilitiesCurrentAbstract to us-gaap_DeferredRevenueCurrent" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:title="us-gaap_LiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" xlink:title="Presentation : us-gaap_LiabilitiesCurrentAbstract to us-gaap_LiabilitiesCurrent" order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:title="us-gaap_LiabilitiesNoncurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="us-gaap_ConvertibleDebtNoncurrent" xlink:title="us-gaap_ConvertibleDebtNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_ConvertibleDebtNoncurrent" xlink:title="Presentation : us-gaap_LiabilitiesNoncurrentAbstract to us-gaap_ConvertibleDebtNoncurrent" order="1.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent" xlink:title="us-gaap_DeferredRevenueNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent" xlink:title="Presentation : us-gaap_LiabilitiesNoncurrentAbstract to us-gaap_DeferredRevenueNoncurrent" order="1.75" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" xlink:title="us-gaap_LongTermDebtNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LongTermDebtNoncurrent" xlink:title="Presentation : us-gaap_LiabilitiesNoncurrentAbstract to us-gaap_LongTermDebtNoncurrent" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:title="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:title="Presentation : us-gaap_LiabilitiesNoncurrentAbstract to us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:title="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:title="us-gaap_CommitmentsAndContingencies" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:title="Presentation : us-gaap_LiabilitiesAndStockholdersEquityAbstract to us-gaap_CommitmentsAndContingencies" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:title="us-gaap_LiabilitiesNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesNoncurrent" xlink:title="Presentation : us-gaap_LiabilitiesAndStockholdersEquityAbstract to us-gaap_LiabilitiesNoncurrent" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" xlink:title="Presentation : us-gaap_LiabilitiesAndStockholdersEquityAbstract to us-gaap_LiabilitiesCurrentAbstract" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:title="us-gaap_Liabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" xlink:title="Presentation : us-gaap_LiabilitiesAndStockholdersEquityAbstract to us-gaap_Liabilities" order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" xlink:title="Presentation : us-gaap_LiabilitiesAndStockholdersEquityAbstract to us-gaap_LiabilitiesNoncurrentAbstract" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:title="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" xlink:title="Presentation : us-gaap_LiabilitiesAndStockholdersEquityAbstract to us-gaap_LiabilitiesAndStockholdersEquity" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:title="us-gaap_StockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:title="Presentation : us-gaap_LiabilitiesAndStockholdersEquityAbstract to us-gaap_StockholdersEquityAbstract" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:title="us-gaap_StockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" xlink:title="Presentation : us-gaap_LiabilitiesAndStockholdersEquityAbstract to us-gaap_StockholdersEquity" order="6.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:title="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" xlink:title="Presentation : us-gaap_StatementOfFinancialPositionAbstract to us-gaap_AssetsAbstract" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:title="Presentation : us-gaap_StatementOfFinancialPositionAbstract to us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:title="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:title="Presentation : us-gaap_StockholdersEquityAbstract to us-gaap_AdditionalPaidInCapitalCommonStock" order="1.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:title="us-gaap_CommonStockValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:title="Presentation : us-gaap_StockholdersEquityAbstract to us-gaap_CommonStockValue" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:title="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:title="Presentation : us-gaap_StockholdersEquityAbstract to us-gaap_RetainedEarningsAccumulatedDeficit" order="2.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-ccsocf">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:title="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:title="Presentation : us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:title="us-gaap_AmortizationOfFinancingCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCosts" xlink:title="Presentation : us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_AmortizationOfFinancingCosts" order="6.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:title="us-gaap_Depreciation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" xlink:title="Presentation : us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_Depreciation" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:title="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:title="Presentation : us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_ForeignCurrencyTransactionGainLossUnrealized" order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:title="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:title="Presentation : us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="17" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="Presentation : us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:title="us-gaap_PensionAndOtherPostretirementBenefitExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:title="Presentation : us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_PensionAndOtherPostretirementBenefitExpense" order="5.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:title="us-gaap_ShareBasedCompensation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" xlink:title="Presentation : us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_ShareBasedCompensation" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:title="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_CashlessExerciseOfStockOptions" xlink:label="plx_CashlessExerciseOfStockOptions" xlink:title="plx_CashlessExerciseOfStockOptions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="plx_CashlessExerciseOfStockOptions" xlink:title="Presentation : us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract to plx_CashlessExerciseOfStockOptions" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:label="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:title="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:title="Presentation : us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract to plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_SupplementalOfferingAndStockIssuanceCosts" xlink:label="plx_SupplementalOfferingAndStockIssuanceCosts" xlink:title="plx_SupplementalOfferingAndStockIssuanceCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="plx_SupplementalOfferingAndStockIssuanceCosts" xlink:title="Presentation : us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract to plx_SupplementalOfferingAndStockIssuanceCosts" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:title="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:title="Presentation : us-gaap_IncreaseDecreaseInOperatingCapitalAbstract to us-gaap_IncreaseDecreaseInAccountsReceivable" order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="Presentation : us-gaap_IncreaseDecreaseInOperatingCapitalAbstract to us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:title="us-gaap_IncreaseDecreaseInDeferredRevenue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:title="Presentation : us-gaap_IncreaseDecreaseInOperatingCapitalAbstract to us-gaap_IncreaseDecreaseInDeferredRevenue" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:title="us-gaap_IncreaseDecreaseInInventories" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" xlink:title="Presentation : us-gaap_IncreaseDecreaseInOperatingCapitalAbstract to us-gaap_IncreaseDecreaseInInventories" order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses" xlink:label="plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses" xlink:title="plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract to plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract to us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" order="1.75" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:title="us-gaap_ProceedsFromConvertibleDebt" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromConvertibleDebt" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract to us-gaap_ProceedsFromConvertibleDebt" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:title="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract to us-gaap_ProceedsFromStockOptionsExercised" order="1.5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:title="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:title="us-gaap_IncreaseDecreaseInRestrictedCash" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract to us-gaap_IncreaseDecreaseInRestrictedCash" order="1.5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:title="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract to us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:title="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract to us-gaap_PaymentsForProceedsFromOtherInvestingActivities" order="1.875" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract to us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:title="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract to us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:title="us-gaap_NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_NetIncomeLoss" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:title="us-gaap_StatementOfCashFlowsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:title="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:title="Presentation : us-gaap_StatementOfCashFlowsAbstract to us-gaap_CashAndCashEquivalentsAtCarryingValue" order="12" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_1" xlink:title="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_1" xlink:title="Presentation : us-gaap_StatementOfCashFlowsAbstract to us-gaap_CashAndCashEquivalentsAtCarryingValue" order="11" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:title="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:title="Presentation : us-gaap_StatementOfCashFlowsAbstract to us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:title="Presentation : us-gaap_StatementOfCashFlowsAbstract to us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="12.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:title="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:title="Presentation : us-gaap_StatementOfCashFlowsAbstract to us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="Presentation : us-gaap_StatementOfCashFlowsAbstract to us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:title="Presentation : us-gaap_StatementOfCashFlowsAbstract to us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="Presentation : us-gaap_StatementOfCashFlowsAbstract to us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:title="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" xlink:title="Presentation : us-gaap_StatementOfCashFlowsAbstract to us-gaap_SupplementalCashFlowInformationAbstract" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" xlink:title="us-gaap_InterestPaidNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" xlink:title="Presentation : us-gaap_SupplementalCashFlowInformationAbstract to us-gaap_InterestPaidNet" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-c">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:title="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="us-gaap_CommitmentsDisclosureTextBlock" xlink:title="us-gaap_CommitmentsDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsDisclosureTextBlock" xlink:title="Presentation : us-gaap_CommitmentsAndContingenciesDisclosureAbstract to us-gaap_CommitmentsDisclosureTextBlock" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-cnsoierd1">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:title="us-gaap_DebtDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_AmortizationOfDebtIssuanceCosts" xlink:label="plx_AmortizationOfDebtIssuanceCosts" xlink:title="plx_AmortizationOfDebtIssuanceCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="plx_AmortizationOfDebtIssuanceCosts" xlink:title="Presentation : us-gaap_DebtDisclosureAbstract to plx_AmortizationOfDebtIssuanceCosts" order="1.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization" xlink:title="us-gaap_InterestExpenseDebtExcludingAmortization" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization" xlink:title="Presentation : us-gaap_DebtDisclosureAbstract to us-gaap_InterestExpenseDebtExcludingAmortization" order="1.25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xlink:title="us-gaap_InterestExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_InterestExpense" xlink:title="Presentation : us-gaap_DebtDisclosureAbstract to us-gaap_InterestExpense" order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-cnnd1">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:title="us-gaap_DebtDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_DebtInstrumentConvertibleBaseValueForConversionRate" xlink:label="plx_DebtInstrumentConvertibleBaseValueForConversionRate" xlink:title="plx_DebtInstrumentConvertibleBaseValueForConversionRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="plx_DebtInstrumentConvertibleBaseValueForConversionRate" xlink:title="Presentation : us-gaap_DebtDisclosureAbstract to plx_DebtInstrumentConvertibleBaseValueForConversionRate" order="2.75" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_DebtInstrumentConvertibleConversionShareNumber" xlink:label="plx_DebtInstrumentConvertibleConversionShareNumber" xlink:title="plx_DebtInstrumentConvertibleConversionShareNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="plx_DebtInstrumentConvertibleConversionShareNumber" xlink:title="Presentation : us-gaap_DebtDisclosureAbstract to plx_DebtInstrumentConvertibleConversionShareNumber" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption" xlink:label="plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption" xlink:title="plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption" xlink:title="Presentation : us-gaap_DebtDisclosureAbstract to plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption" order="1.5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:title="us-gaap_DebtInstrumentConvertibleConversionPrice1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:title="Presentation : us-gaap_DebtDisclosureAbstract to us-gaap_DebtInstrumentConvertibleConversionPrice1" order="4.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:title="us-gaap_DebtInstrumentMaturityDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentMaturityDate" xlink:title="Presentation : us-gaap_DebtDisclosureAbstract to us-gaap_DebtInstrumentMaturityDate" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:title="us-gaap_DebtInstrumentFaceAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentFaceAmount" xlink:title="Presentation : us-gaap_DebtDisclosureAbstract to us-gaap_DebtInstrumentFaceAmount" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:title="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:title="Presentation : us-gaap_DebtDisclosureAbstract to us-gaap_DebtInstrumentInterestRateStatedPercentage" order="2.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:title="us-gaap_ProceedsFromConvertibleDebt" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ProceedsFromConvertibleDebt" xlink:title="Presentation : us-gaap_DebtDisclosureAbstract to us-gaap_ProceedsFromConvertibleDebt" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-cn1">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:title="us-gaap_DebtDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:title="us-gaap_DebtDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" xlink:title="Presentation : us-gaap_DebtDisclosureAbstract to us-gaap_DebtDisclosureTextBlock" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-cnt1">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:title="us-gaap_DebtDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:title="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:title="Presentation : us-gaap_DebtDisclosureAbstract to us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-lferurd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:label="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:title="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_EmployeeSeveranceObligationPayment" xlink:label="plx_EmployeeSeveranceObligationPayment" xlink:title="plx_EmployeeSeveranceObligationPayment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:to="plx_EmployeeSeveranceObligationPayment" xlink:title="Presentation : us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract to plx_EmployeeSeveranceObligationPayment" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod" xlink:label="plx_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod" xlink:title="plx_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:to="plx_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod" xlink:title="Presentation : us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract to plx_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ExpectedDefintedBenefitContributionDuringPeriod" xlink:label="plx_ExpectedDefintedBenefitContributionDuringPeriod" xlink:title="plx_ExpectedDefintedBenefitContributionDuringPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:to="plx_ExpectedDefintedBenefitContributionDuringPeriod" xlink:title="Presentation : us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract to plx_ExpectedDefintedBenefitContributionDuringPeriod" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:title="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:title="Presentation : us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract to us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" xlink:label="us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" xlink:title="us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:to="us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" xlink:title="Presentation : us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract to us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" order="4.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PostemploymentBenefitsPeriodExpense" xlink:label="us-gaap_PostemploymentBenefitsPeriodExpense" xlink:title="us-gaap_PostemploymentBenefitsPeriodExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:to="us-gaap_PostemploymentBenefitsPeriodExpense" xlink:title="Presentation : us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract to us-gaap_PostemploymentBenefitsPeriodExpense" order="3.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-lferur">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:label="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:title="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:title="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:title="Presentation : us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract to us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-scfvaoogd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ForfeitureRate" xlink:label="plx_ForfeitureRate" xlink:title="plx_ForfeitureRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="plx_ForfeitureRate" xlink:title="Presentation : us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to plx_ForfeitureRate" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="Presentation : us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="Presentation : us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="Presentation : us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="Presentation : us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-sct">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock" xlink:label="plx_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock" xlink:title="plx_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="plx_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock" xlink:title="Presentation : us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to plx_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:title="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:title="Presentation : us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="2.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:title="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:title="Presentation : us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:title="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:title="Presentation : us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:title="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:title="Presentation : us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:title="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:title="Presentation : us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock" xlink:title="us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock" xlink:title="Presentation : us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-scsbcead">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="Presentation : us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:title="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:title="us-gaap_IncomeStatementLocationDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:title="Presentation : us-gaap_IncomeStatementLocationAxis to us-gaap_IncomeStatementLocationDomain" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember" xlink:title="us-gaap_CostOfSalesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_CostOfSalesMember" xlink:title="Presentation : us-gaap_IncomeStatementLocationDomain to us-gaap_CostOfSalesMember" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:title="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:title="Presentation : us-gaap_IncomeStatementLocationDomain to us-gaap_ResearchAndDevelopmentExpenseMember" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:title="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:title="Presentation : us-gaap_IncomeStatementLocationDomain to us-gaap_SellingGeneralAndAdministrativeExpensesMember" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="Presentation : us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:title="Presentation : us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to us-gaap_IncomeStatementLocationAxis" order="1.5" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-scsooarsgted">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="Presentation : us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:title="us-gaap_PlanNameAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:title="us-gaap_PlanNameDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:title="Presentation : us-gaap_PlanNameAxis to us-gaap_PlanNameDomain" order="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_GrantYearTwoThousandTwelveMember" xlink:label="plx_GrantYearTwoThousandTwelveMember" xlink:title="plx_GrantYearTwoThousandTwelveMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="plx_GrantYearTwoThousandTwelveMember" xlink:title="Presentation : us-gaap_PlanNameDomain to plx_GrantYearTwoThousandTwelveMember" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_GrantYearTwoThousandTwelveSecondMember" xlink:label="plx_GrantYearTwoThousandTwelveSecondMember" xlink:title="plx_GrantYearTwoThousandTwelveSecondMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="plx_GrantYearTwoThousandTwelveSecondMember" xlink:title="Presentation : us-gaap_PlanNameDomain to plx_GrantYearTwoThousandTwelveSecondMember" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_GrantYearTwoThousandFourteenMember" xlink:label="plx_GrantYearTwoThousandFourteenMember" xlink:title="plx_GrantYearTwoThousandFourteenMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="plx_GrantYearTwoThousandFourteenMember" xlink:title="Presentation : us-gaap_PlanNameDomain to plx_GrantYearTwoThousandFourteenMember" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" xlink:title="Presentation : us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to us-gaap_PlanNameAxis" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="Presentation : us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:title="us-gaap_TitleOfIndividualAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:title="Presentation : us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to us-gaap_TitleOfIndividualAxis" order="2.5" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:title="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" xlink:title="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_EmployeesMember" xlink:label="plx_EmployeesMember" xlink:title="plx_EmployeesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="plx_EmployeesMember" xlink:title="Presentation : us-gaap_TitleOfIndividualWithRelationshipToEntityDomain to plx_EmployeesMember" order="1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="Presentation : us-gaap_TitleOfIndividualAxis to us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-scogted">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="Presentation : us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="Presentation : us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:title="us-gaap_TitleOfIndividualAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:title="Presentation : us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to us-gaap_TitleOfIndividualAxis" order="1.5" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" order="3.375" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" order="4.1875" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:title="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_OptionsAndRestrictedStockGrantedToEmployeesMember" xlink:label="plx_OptionsAndRestrictedStockGrantedToEmployeesMember" xlink:title="plx_OptionsAndRestrictedStockGrantedToEmployeesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="plx_OptionsAndRestrictedStockGrantedToEmployeesMember" xlink:title="Presentation : us-gaap_TitleOfIndividualWithRelationshipToEntityDomain to plx_OptionsAndRestrictedStockGrantedToEmployeesMember" order="1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="Presentation : us-gaap_TitleOfIndividualAxis to us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-scoarsgtcdaospd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="Presentation : us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="Presentation : us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:title="us-gaap_TitleOfIndividualAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:title="Presentation : us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to us-gaap_TitleOfIndividualAxis" order="1.5" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="1.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="3" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" order="7.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="1.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="3" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" xlink:label="plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" xlink:title="plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" xlink:title="Presentation : us-gaap_TitleOfIndividualWithRelationshipToEntityDomain to plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" order="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" xlink:label="plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" xlink:title="plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" xlink:title="Presentation : us-gaap_TitleOfIndividualWithRelationshipToEntityDomain to plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="Presentation : us-gaap_TitleOfIndividualAxis to us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-ccsoo">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:title="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:title="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:title="Presentation : us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract to us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:title="us-gaap_EarningsPerShareAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:title="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" xlink:title="Presentation : us-gaap_EarningsPerShareAbstract to us-gaap_EarningsPerShareBasicAndDiluted" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:title="us-gaap_IncomeStatementAbstract" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_CompanyShareInCollaborationAgreement" xlink:label="plx_CompanyShareInCollaborationAgreement" xlink:title="plx_CompanyShareInCollaborationAgreement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="plx_CompanyShareInCollaborationAgreement" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to plx_CompanyShareInCollaborationAgreement" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_GrantsAndReimbursementsReceivedOrReceivable" xlink:label="plx_GrantsAndReimbursementsReceivedOrReceivable" xlink:title="plx_GrantsAndReimbursementsReceivedOrReceivable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="plx_GrantsAndReimbursementsReceivedOrReceivable" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to plx_GrantsAndReimbursementsReceivedOrReceivable" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:label="plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:title="plx_ResearchDevelopmentAndEngineeringExpenseNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to plx_ResearchDevelopmentAndEngineeringExpenseNet" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_RevenuesOtherThanCompanyShareInCollaborationAgreement" xlink:label="plx_RevenuesOtherThanCompanyShareInCollaborationAgreement" xlink:title="plx_RevenuesOtherThanCompanyShareInCollaborationAgreement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="plx_RevenuesOtherThanCompanyShareInCollaborationAgreement" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to plx_RevenuesOtherThanCompanyShareInCollaborationAgreement" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" xlink:title="us-gaap_CostOfRevenue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CostOfRevenue" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_CostOfRevenue" order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareAbstract" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_EarningsPerShareAbstract" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" xlink:title="us-gaap_GrossProfit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GrossProfit" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_GrossProfit" order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:title="us-gaap_NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_NetIncomeLoss" order="14" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:title="us-gaap_NonoperatingIncomeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_NonoperatingIncomeExpense" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:title="us-gaap_OperatingIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_OperatingIncomeLoss" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" xlink:title="us-gaap_OtherNonoperatingIncome" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingIncome" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_OtherNonoperatingIncome" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" xlink:title="us-gaap_OtherNonoperatingExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingExpense" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_OtherNonoperatingExpense" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:title="us-gaap_ResearchAndDevelopmentExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_ResearchAndDevelopmentExpense" order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:title="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_SellingGeneralAndAdministrativeExpense" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-ccsoop">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:title="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:title="Presentation : us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to us-gaap_AllocatedShareBasedCompensationExpense" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:title="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:title="us-gaap_IncomeStatementLocationDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:title="Presentation : us-gaap_IncomeStatementLocationAxis to us-gaap_IncomeStatementLocationDomain" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:title="us-gaap_IncomeStatementAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:title="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:title="Presentation : us-gaap_IncomeStatementLocationDomain to us-gaap_ResearchAndDevelopmentExpenseMember" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:title="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:title="Presentation : us-gaap_IncomeStatementLocationDomain to us-gaap_SellingGeneralAndAdministrativeExpensesMember" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="Presentation : us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:title="Presentation : us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to us-gaap_IncomeStatementLocationAxis" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-ccsocicd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:title="us-gaap_EquityComponentDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:title="us-gaap_AdditionalPaidInCapitalMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:title="Presentation : us-gaap_EquityComponentDomain to us-gaap_AdditionalPaidInCapitalMember" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:title="us-gaap_CommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" xlink:title="Presentation : us-gaap_EquityComponentDomain to us-gaap_CommonStockMember" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:title="us-gaap_RetainedEarningsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" xlink:title="Presentation : us-gaap_EquityComponentDomain to us-gaap_RetainedEarningsMember" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:title="us-gaap_StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:title="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:title="Presentation : us-gaap_StatementLineItems to plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:title="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:title="Presentation : us-gaap_StatementLineItems to plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="Presentation : us-gaap_StatementLineItems to us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:title="us-gaap_NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:title="Presentation : us-gaap_StatementLineItems to us-gaap_NetIncomeLoss" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xlink:title="us-gaap_SharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" xlink:title="Presentation : us-gaap_StatementLineItems to us-gaap_SharesOutstanding" order="9.9429" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_1" xlink:title="us-gaap_SharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_1" xlink:title="Presentation : us-gaap_StatementLineItems to us-gaap_SharesOutstanding" order="0.2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="Presentation : us-gaap_StatementLineItems to us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="Presentation : us-gaap_StatementLineItems to us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:title="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:title="Presentation : us-gaap_StatementLineItems to us-gaap_StockIssuedDuringPeriodValueNewIssues" order="10.97188" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:title="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:title="Presentation : us-gaap_StatementLineItems to us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10.45737" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:title="us-gaap_StockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" xlink:title="Presentation : us-gaap_StatementLineItems to us-gaap_StockholdersEquity" order="9.94289" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_1" xlink:title="us-gaap_StockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_1" xlink:title="Presentation : us-gaap_StatementLineItems to us-gaap_StockholdersEquity" order="0.1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:title="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:title="us-gaap_StatementTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" xlink:title="Presentation : us-gaap_StatementOfStockholdersEquityAbstract to us-gaap_StatementTable" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:title="us-gaap_StatementEquityComponentsAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:title="Presentation : us-gaap_StatementEquityComponentsAxis to us-gaap_EquityComponentDomain" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:title="Presentation : us-gaap_StatementTable to us-gaap_StatementLineItems" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:title="Presentation : us-gaap_StatementTable to us-gaap_StatementEquityComponentsAxis" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-fvmd1">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:title="us-gaap_FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures" xlink:title="us-gaap_ConvertibleDebtFairValueDisclosures" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures" xlink:title="Presentation : us-gaap_FairValueDisclosuresAbstract to us-gaap_ConvertibleDebtFairValueDisclosures" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-fvm1">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:title="us-gaap_FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:title="us-gaap_FairValueDisclosuresTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" xlink:title="Presentation : us-gaap_FairValueDisclosuresAbstract to us-gaap_FairValueDisclosuresTextBlock" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-toit">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:title="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ScheduleOfOpenTaxYearsTableTextBlock" xlink:label="plx_ScheduleOfOpenTaxYearsTableTextBlock" xlink:title="plx_ScheduleOfOpenTaxYearsTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="plx_ScheduleOfOpenTaxYearsTableTextBlock" xlink:title="Presentation : us-gaap_IncomeTaxDisclosureAbstract to plx_ScheduleOfOpenTaxYearsTableTextBlock" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:title="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:title="Presentation : us-gaap_IncomeTaxDisclosureAbstract to us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-toiditd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:title="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:title="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:title="Presentation : us-gaap_IncomeTaxDisclosureAbstract to us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:title="us-gaap_DeferredTaxAssetsDeferredIncome" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:title="Presentation : us-gaap_IncomeTaxDisclosureAbstract to us-gaap_DeferredTaxAssetsDeferredIncome" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:title="us-gaap_DeferredTaxAssetsNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" xlink:title="Presentation : us-gaap_IncomeTaxDisclosureAbstract to us-gaap_DeferredTaxAssetsNet" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:title="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:title="Presentation : us-gaap_IncomeTaxDisclosureAbstract to us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:title="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:title="Presentation : us-gaap_IncomeTaxDisclosureAbstract to us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:title="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:title="Presentation : us-gaap_IncomeTaxDisclosureAbstract to us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:title="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:title="Presentation : us-gaap_IncomeTaxDisclosureAbstract to us-gaap_DeferredTaxAssetsValuationAllowance" order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments" xlink:title="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments" xlink:title="Presentation : us-gaap_IncomeTaxDisclosureAbstract to us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-toi">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:title="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:title="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" xlink:title="Presentation : us-gaap_IncomeTaxDisclosureAbstract to us-gaap_IncomeTaxDisclosureTextBlock" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-toiotyd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:title="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="us-gaap_IncomeTaxContingencyTable" xlink:title="us-gaap_IncomeTaxContingencyTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxContingencyTable" xlink:title="Presentation : us-gaap_IncomeTaxDisclosureAbstract to us-gaap_IncomeTaxContingencyTable" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:title="us-gaap_IncomeTaxAuthorityAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:title="us-gaap_IncomeTaxAuthorityDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:title="Presentation : us-gaap_IncomeTaxAuthorityAxis to us-gaap_IncomeTaxAuthorityDomain" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="us-gaap_IncomeTaxContingencyLineItems" xlink:title="us-gaap_IncomeTaxContingencyLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear" xlink:title="us-gaap_OpenTaxYear" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_OpenTaxYear" xlink:title="Presentation : us-gaap_IncomeTaxContingencyLineItems to us-gaap_OpenTaxYear" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd#country_IL" xlink:label="country_IL" xlink:title="country_IL" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="country_IL" xlink:title="Presentation : us-gaap_IncomeTaxAuthorityDomain to country_IL" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd#country_NL" xlink:label="country_NL" xlink:title="country_NL" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="country_NL" xlink:title="Presentation : us-gaap_IncomeTaxAuthorityDomain to country_NL" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd#country_US" xlink:label="country_US" xlink:title="country_US" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="country_US" xlink:title="Presentation : us-gaap_IncomeTaxAuthorityDomain to country_US" order="2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:title="Presentation : us-gaap_IncomeTaxContingencyTable to us-gaap_IncomeTaxAuthorityAxis" order="1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxContingencyLineItems" xlink:title="Presentation : us-gaap_IncomeTaxContingencyTable to us-gaap_IncomeTaxContingencyLineItems" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:title="us-gaap_RangeAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_RangeAxis" xlink:title="Presentation : us-gaap_IncomeTaxContingencyTable to us-gaap_RangeAxis" order="1.5" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:title="us-gaap_RangeMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:title="us-gaap_MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" xlink:title="Presentation : us-gaap_RangeMember to us-gaap_MaximumMember" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:title="us-gaap_MinimumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" xlink:title="Presentation : us-gaap_RangeMember to us-gaap_MinimumMember" order="1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:title="Presentation : us-gaap_RangeAxis to us-gaap_RangeMember" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-id">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:title="us-gaap_InventoryDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:title="us-gaap_InventoryFinishedGoodsNetOfReserves" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:title="Presentation : us-gaap_InventoryDisclosureAbstract to us-gaap_InventoryFinishedGoodsNetOfReserves" order="4.75" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:title="us-gaap_InventoryNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryNet" xlink:title="Presentation : us-gaap_InventoryDisclosureAbstract to us-gaap_InventoryNet" order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown" xlink:title="us-gaap_InventoryWriteDown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryWriteDown" xlink:title="Presentation : us-gaap_InventoryDisclosureAbstract to us-gaap_InventoryWriteDown" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:title="us-gaap_InventoryRawMaterialsNetOfReserves" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:title="Presentation : us-gaap_InventoryDisclosureAbstract to us-gaap_InventoryRawMaterialsNetOfReserves" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:title="us-gaap_InventoryWorkInProcessNetOfReserves" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:title="Presentation : us-gaap_InventoryDisclosureAbstract to us-gaap_InventoryWorkInProcessNetOfReserves" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-i">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:title="us-gaap_InventoryDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:title="us-gaap_InventoryDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureTextBlock" xlink:title="Presentation : us-gaap_InventoryDisclosureAbstract to us-gaap_InventoryDisclosureTextBlock" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-it">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:title="us-gaap_InventoryDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:title="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:title="Presentation : us-gaap_InventoryDisclosureAbstract to us-gaap_ScheduleOfInventoryCurrentTableTextBlock" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-paed">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:title="Presentation : us-gaap_PropertyPlantAndEquipmentByTypeAxis to us-gaap_PropertyPlantAndEquipmentTypeDomain" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:title="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="Presentation : us-gaap_PropertyPlantAndEquipmentAbstract to us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_LaboratoryEquipmentMember" xlink:label="plx_LaboratoryEquipmentMember" xlink:title="plx_LaboratoryEquipmentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="plx_LaboratoryEquipmentMember" xlink:title="Presentation : us-gaap_PropertyPlantAndEquipmentTypeDomain to plx_LaboratoryEquipmentMember" order="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_FurnitureAndComputerEquipmentMember" xlink:label="plx_FurnitureAndComputerEquipmentMember" xlink:title="plx_FurnitureAndComputerEquipmentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="plx_FurnitureAndComputerEquipmentMember" xlink:title="Presentation : us-gaap_PropertyPlantAndEquipmentTypeDomain to plx_FurnitureAndComputerEquipmentMember" order="2" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_EquipmentUnderConstructionMember" xlink:label="plx_EquipmentUnderConstructionMember" xlink:title="plx_EquipmentUnderConstructionMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="plx_EquipmentUnderConstructionMember" xlink:title="Presentation : us-gaap_PropertyPlantAndEquipmentTypeDomain to plx_EquipmentUnderConstructionMember" order="4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:title="us-gaap_LeaseholdImprovementsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" xlink:title="Presentation : us-gaap_PropertyPlantAndEquipmentTypeDomain to us-gaap_LeaseholdImprovementsMember" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:title="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="Presentation : us-gaap_PropertyPlantAndEquipmentLineItems to us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges" xlink:title="us-gaap_AssetImpairmentCharges" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AssetImpairmentCharges" xlink:title="Presentation : us-gaap_PropertyPlantAndEquipmentLineItems to us-gaap_AssetImpairmentCharges" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:title="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:title="Presentation : us-gaap_PropertyPlantAndEquipmentLineItems to us-gaap_PropertyPlantAndEquipmentGross" order="2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:title="Presentation : us-gaap_ScheduleOfPropertyPlantAndEquipmentTable to us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:title="Presentation : us-gaap_ScheduleOfPropertyPlantAndEquipmentTable to us-gaap_PropertyPlantAndEquipmentLineItems" order="2" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-paet">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:title="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:title="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:title="Presentation : us-gaap_PropertyPlantAndEquipmentAbstract to us-gaap_PropertyPlantAndEquipmentTextBlock" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-pae">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:title="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:title="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:title="Presentation : us-gaap_PropertyPlantAndEquipmentAbstract to us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-rptd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:title="us-gaap_RelatedPartyTransactionLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:title="us-gaap_RelatedPartyTransactionAmountsOfTransaction" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:title="Presentation : us-gaap_RelatedPartyTransactionLineItems to us-gaap_RelatedPartyTransactionAmountsOfTransaction" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:title="us-gaap_RelatedPartyDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" xlink:title="Presentation : us-gaap_RelatedPartyTransactionsByRelatedPartyAxis to us-gaap_RelatedPartyDomain" order="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_CompensationToTheNon-executiveDirectorsMember" xlink:label="plx_CompensationToTheNon-executiveDirectorsMember" xlink:title="plx_CompensationToTheNon-executiveDirectorsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="plx_CompensationToTheNon-executiveDirectorsMember" xlink:title="Presentation : us-gaap_RelatedPartyDomain to plx_CompensationToTheNon-executiveDirectorsMember" order="2" />
    <link:loc xlink:type="locator" xlink:href="plx-20150930.xsd#plx_ManagementAndConsultingFeesToChairmanOfBoardMember" xlink:label="plx_ManagementAndConsultingFeesToChairmanOfBoardMember" xlink:title="plx_ManagementAndConsultingFeesToChairmanOfBoardMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="plx_ManagementAndConsultingFeesToChairmanOfBoardMember" xlink:title="Presentation : us-gaap_RelatedPartyDomain to plx_ManagementAndConsultingFeesToChairmanOfBoardMember" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:title="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:title="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:title="Presentation : us-gaap_RelatedPartyTransactionsAbstract to us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" xlink:title="Presentation : us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to us-gaap_RelatedPartyTransactionLineItems" order="2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="Presentation : us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-rpt">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:title="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:title="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:title="Presentation : us-gaap_RelatedPartyTransactionsAbstract to us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-rptt">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:title="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:title="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:title="Presentation : us-gaap_RelatedPartyTransactionsAbstract to us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-ccbsp">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:title="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:title="us-gaap_CommonStockSharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" xlink:title="Presentation : us-gaap_StatementOfFinancialPositionAbstract to us-gaap_CommonStockSharesIssued" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:title="us-gaap_CommonStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:title="Presentation : us-gaap_StatementOfFinancialPositionAbstract to us-gaap_CommonStockSharesOutstanding" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-st">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:title="us-gaap_StockholdersEquityNoteAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:title="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:title="Presentation : us-gaap_StockholdersEquityNoteAbstract to us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/Disclosure-SUBSEQUENTEVENTS">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:title="us-gaap_SubsequentEventsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:title="us-gaap_SubsequentEventsTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" xlink:title="Presentation : us-gaap_SubsequentEventsAbstract to us-gaap_SubsequentEventsTextBlock" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>13
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0````(`+6,:4>4SP1@@0$``(0.```3````6T-O;G1E;G1?5'EP97-=
M+GAM;,U7RV[",!#\%91K18QI2Q\"+J77%JG]`3?9$`N_9)L`?U\[0-5&*8*6
M2'N)X\SNSMAKCY3Q^]:`ZVVD4&Z2E-Z;1T)<5H)D+M4&5$`*;27S86H7Q+!L
MR19`AH/!B&1:>5"^[V.-9#I^K<!:GD/O:0?$VI.$&2-XQCS7BE0J;U3MZZ+@
M&>0Z6\F0DOI`#5<!3WIS9OT+DZ$$V0A2`[LG32-.+D/HC`66NQ+`2Y$ZOQ7@
MVOAWR(%Y!@5;"7\6\7[O4@NBCG$E-WNJYTVHXL*W21)0=Q)#,_&8,BYCTXQ:
M_,B(\S^NI;&)E10SR]:\05!UUJ8XII)QU=:JM;;+#ZV7ESPF$%>50]XW-@1:
MSUM.20B>!]214/I?W(>3DFD+)Q'&P`XO1<DLY&_>AOZVWXWO`=WIB'VMWW]K
M>@TZ4@\=FL19.H9(=%PCT7&#1,<M$ATC)#KND.BX1Z+C`8D..L`B!(NC4BR6
M2K%X*L5BJA2+JU(LMDJQ^"K%8JSTRUE)_?,Y_0102P,$%`````@`M8QI1TAU
M!>[%````*P(```L```!?<F5L<R\N<F5L<ZV2RV["0`Q%?R6:?7%*)1818<6&
M'4+\@#OC/)3,>.0Q(OW[CMB`PD.MQ-*O>X^NO`ZIK`XTHO8<4M?'5$Q^#*G*
M_=ITJK$"2+8CCVG!D4*>-BP>-9?20D0[8$NP+,L5R*V.V:SGVL7.U49V[M,4
M1Y26M#;3"&>6X9MY6&3I//B)]!=C;IK>TI;MR5/0!_ZS#0//>997'L=V+YRO
M+0O]C^AY%.!)T:'B1?4C9@,2[2F]@OIZ`(4QOCLEFI2"(S>C@KN_V/P"4$L#
M!!0````(`+6,:4<8Z>6=,@$``.8,```:````>&PO7W)E;',O=V]R:V)O;VLN
M>&UL+G)E;'/%UTMN@S`0@.&K(!\@9DA"$A2RRB;;MA>P8'@H8"/;59O;UV51
MT8='72#-!@269K[5CSAKEQ9/."C?&^VZ?G+)^SAH5X3WI>B\GPHI7=7AJ-S&
M3*C#:6/LJ'QXM*V<5'57+<HL37-IEW/$Y?QS=G*K2V%O-8CD1=D6?2G>C+V[
M#M$[.=]@$Q:$X\>$_UEOFJ:O\&JJUQ&U_T,AOQ8(&0=E<5#&`MK&05L6T"X.
MVK&`]G'0G@64QT$Y"^@0!QU80,<XZ,@".L5!)Q80I$094QX2%6N>6@.1:^#I
M-1#!!IYB`Y%LX&DV$-$&GFH#D6W@Z380X0:><@.1;N!I-Q#Q!IYZ9XMZNTY9
MK)^][77KUM9\&TZ*%O%V_C'@^I1Y*FE8U-J'32CGZ^J?CGGJ)T3^^J6Y?`!0
M2P,$%`````@`M8QI1]E&DRLC`@``Y@8``!````!D;V-0<F]P<R]A<'`N>&UL
MO57!<ILP$/T5#:?VT&"[:3KQ.,PHH*1,;7"-<,\*"%L3+#&2XHGS]1404XAQ
MTW(H%U:K]]ZR;T',N!I-EU(45&I&%7C>Y5Q-3?+&VFI=3&U;)5NZ(^K"0+C9
MS83<$6V6<F.++&,)]43RM*-<VY/1Z,JFSYKRE*:?BD;4<F9E%5@4.4N(9H([
M"Y9(H42F`7I.:#ZSWP(JAE&.:/(DF3XXHQK33E68*"$Y=4TM)R.YHC7J=[+"
MN&)7$'ZPZ]6<\4<5%UAX1-,VJ[M1JV^)I*DIVE%ODA7FV\'TF9=<=TOXAJ9M
M[.GFT8LUE:KL=#RY&)FKL>"8K[4I21G?+`F3RIGM]71/$RWDZYCV>NB44I&4
M0U=K;)Y/6>"!*%J&-]:>2$:XMH!B+V8YL>JR=;:*\T)IZ?P4\E%M*=5J9C?)
M*FQCVS&[=,;7%<)$7:3==.:\VM;IN\Q@IG.JPFQ)I/Y/5E0]'8T87UNM[H\2
M@/`4(*[-ZPA\7I<RPVM;TD1N&'@HB)`'3!2%<]^#V"QNX1P&+@+_PHFPN2U0
M,(!S.8#S90#G:@#G:R\G\N\#_\YW88`!=-TP#K`?W(.E8;L^BGHY?K!&`0Y7
MY_;OH+\":SB/$5@@&,6KTDW<7QZ'[G>`5S"(H(M]\]C]L/@V0C]BHP)06?L,
MZD^]C#^_UPOX@,F#^0P^#A#O'V)'W*.:L/R,>K]E#>DOO7NGR(F+_?B3\^+-
MZ6!W_VK.+U!+`P04````"`"UC&E'(!SV?#\!``!I`P``$0```&1O8U!R;W!S
M+V-O<F4N>&ULS9/!3L,P#(9?!?7>I=D$:%77`R!.3$)B",0M2[PMK$VBQ%/7
MMR?SNI8!E]V0>JAK_Y]_UTDA72ZMAV=O'7C4$*[V=65"+MTLV2"ZG+$@-U"+
M,(H5)B97UM<"8^C7S`FY%6M@XRR[836@4`(%.P!3UQ.3LE`REQX$6M_AE>SQ
M;N<K@BG)H((:#`;&1YPEY:O9&MN8@@WZLHB.*Q%P;I5>:5!W[5#V.Q4[(_@Z
M'.6@^O;T]4\/E&%)5[D/NJ]JFF;43*@N#LS9^_SIA?Y-JDU`821$5=`YM@YF
MR:GSV^3^8?&8E..,7Z><I]ETP6_S27RF'X?)SOP-ANMNB'_K^&20MHL:*[AP
MMZ11M%QZ)9""(+UVJ*VY"$>8;V*"A=WR$R1>#NJ$=-BVT#;6JU#2^1JBP\V)
M*UM;WQY3/Z*S6U5^`5!+`P04````"`"UC&E'F5R<(Q`&``"<)P``$P```'AL
M+W1H96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29
MA.U.'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(
ME/)X8-DOV]:[MR_>X%<R)!%!,!FGK_#`"J5,7K5::0##.'W)$Q+#W(*+"$MX
M%,O67.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UE
MHP$35T$FN8BT\OELQ?S:WCYES^DZ'3*!;C`;6"!_SF^GY$Y:B.%4PL3`:F<_
M5FO'T=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BV
MR]*+<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/
MTVMWW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3
M(`!8<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X`
M-\313%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.
M:Y1_::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V
M]I&E)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%
MG\@MNN01.+5)#3(3/PB=AIAJ4!P"I`DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMO
MFCU7H5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7`
M\:V</!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0F
MS>@S&L%&KQMUAVC2/'K^!?F<-0H<D1L=`F<;LT8AA&F[\!ZO)(Z:K<(1*T(^
M8ADV&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYB
MSHN0$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y`\FIS_I
M,C0'HYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z>`HWEL:\4*Z">P'_T=HWPJOX
M@L`Y?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3
M*=@YG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E
M-XH2GD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU
M)CA*]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^`VVZG=PZ.)Z8
MD;D*TU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8
MS\-#AWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+:`'@Z]1`O)256`Q6\8#
M*Y"B?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]5
M6_*POFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8
MO./FQW%.4[@2=K8/`C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V
M^I=WP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41`71%`B.5'`86%S+D
M4.Z2D`83`<V4R43P`H)DIAR`F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK`,
M!2$7<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:
MOB9@2\-Z;ITM)__;7M0]M!<]1O.CF>`>LX=SFWJXPD6L_UC6'ODRWSEPVSK>
M`U[F$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X`Q\U*M:I60K
M$3]+!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F`6/,,H68XWX=%FAHSU8NL.8T*
M;T'50.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0`
M```(`+6,:4<]F'Q/5`(``-0*```-````>&PO<W1Y;&5S+GAM;,U676O;,!3]
M*T(IHX41V]F:=JMM&(7`8"N%YF%O1;9E1Z`/3Y8SI[]^^G#LQ)"F2=/2O.CJ
MZ-YSCZ3K7(656E'\L,!8@8917D5PH53YW?.J=($9JL:BQ%ROY$(RI/14%EY5
M2HRRR@0QZDU\?^HQ1#B,0UZS&5,52$7-502_=A!P\;<BPQ%\//_TMQ;JY@RX
M<?1Y-/(?+VZ&^+E=N(#`<?S,(AA,+Z'W<M*QOYM7KPVHIP=2/\L])+\ZC/P9
MZ@'QM2'VVI./PUSP_@(FT`%Q6#V!):+:/S#NJ:!"`J5O6"NP"$<,.X];1$DB
MB0%SQ`A=.7AB`%L4K1\C7$B;VV48YAG[?299)!'TV]_+TR4]NQW,]@BEV]O3
M0!R62"DL^4Q/0&O/5Z7>'!<<.Y'6;X]W(=$JF%QN!-A!YTV$S+#L,@=P#<4A
MQ;G2`9(4"S,J41KI0BG!M)$15`B.J*%<1[2&IDTQI0_F$_R3;W$W.7`^YHY]
M"(R*M:D/HC7[,K"'ZFVR.>Y-VN-X09-W"70T*DNZ^D%)P1EV8ATT$^UL'WVP
M@SX.T9H5+(0D3]K?%$*J`2PA6&*I2+J)_).HG.-&M17L-?DNA<=N^2TUG?[4
M>C6Z!-_[>(Y.;J&[FB58SNS?XN&2OESMOS+[=<*!S/>MFB,DG.!P3,?\L-*F
M'U?:V]342:1=OU*:UW:&C?:SU7PZ%"0UH8KPM09DG@MW1C?=Z@M]X]&<6=/W
M'+NJ4**?F%M9-%F&<U13=4^60MG%"/;V+R,_F'9>\XXB@KW]&V>D9M^L@OX=
M&_\'4$L#!!0````(`+6,:4<>I!!HJP(``*,'```/````>&PO=V]R:V)O;VLN
M>&ULE9514Z,P$,>_2B9/=R\'U+9J1YQ!BAYSE7J%]IY32&W&0)@DM9Z?_A*P
MNEP9QSZ13;*_;';_9*_49"_DTUJ()_12\DI-I(^W6M<3QU'YEI9$_1`UK<S:
M1LB2:&/*1T=L-BRG4Y'O2EII9^"Z8T=23C03E=JR6N$WFOH*3=62DD)M*=4E
M;V$E816^OE*3#>-T1:4R8$3J.B$E]?$+QX@3I:.":5KX>&A,L:>=";FK;W:,
M6V/DCK!C88>K/DB4BX*VL&S+U)^W!8P*NB$[KC,3[.%<'WN#X6`P;AEVVXK1
MO8)`.X%(KMDSS<C:QRY&9*?%+>.:RBG1]$Z*7<VJ1\/":,.DTJF];K.S9!4K
MV:N-VUAJ*_8_A62OHM*$I[D4G#=>=J%Q,B>H]QD3HV9Y9Z,FZX6MA(_'K@$^
M,\76C#/]U\?-F%-[$^>_JS3I_QBAJDG.H<2(5`6**FTH**[:XIG4V!C,YKAH
M#I839@8R+KPV51`4SI-IE*31%)E1.I_%TR`SQDTP"Y(P0@`T`*#!ET%I9C[W
M40)`9P!T=BIH"$!#`!J>"AH!T`B`1J>"Q@`T!J#QJ:!S`#H'H/-C4!K?)?%M
M'`9)AH(PG"^3+$[NT(-!AG&4`M`%`%T<@^)D%279?-%UN@1.E\=.MT&\0*M@
MMHS0?12DRX4M<`8UYT+1N3WQ9_/P%\H609(&81:;9$#OCF1[-)LN;]+H]]*<
MB2(;?L<9RM3KT>FGJ?/.(`H*U>M1*D@>^F;^?D[5=^@/]>GU"/3S4*!`/:A0
MKT>BG5"F5!/&N[%`97H]TNROZ3L+HJ`VO3YQ'A6W/R0H3:]'FT=E[L=`L7J7
M;T_HQZMI&@>K:&%[BFJ.,(]R;AN-^;2"&8XLP]KWIOGXV'8(TPQVG(=F;E[-
M!&G>T99\:"W7_P!02P,$%`````@`M8QI1X+*/D-.`@``]`<``!@```!X;"]W
M;W)K<VAE971S+W-H965T,2YX;6R-E=N.FS`0AE\%\0!K;`Z!B"`EJ:KVHM)J
M+]IK)W$"6L#4=L+V[>L3++OR`C?!GOS_?#/@0]Y3]LI+0H3WUM0MW_FE$-T6
M`'XN28/Y$^U(*_^Y4M9@(:?L!GC'"+YH4U,#%`0):'#5^D6N8\^LR.E=U%5+
MGIG'[TV#V;\#J6F_\Z$_!%ZJ6RE4`!0Y&'V7JB$MKVCK,7+=^7NX/<)(2;3B
M=T5Z/AE[JO@3I:]J\O.R\P-5`ZG)6:@46#X>Y$CJ6F62Y+\VZ3M3&:?C(?MW
MW:XL_X0Y.=+Z3W41I:PV\+T+N>)[+5YH_X/8'F*5\$QKKG^]\YT+V@P6WVOP
MFWE6K7[VYI\HM#:W`5D#&@TAFC6$UA".!O/J@*E,]_4-"USDC/8>[[#ZVG`K
MY4PED9D]KK/)EK@.[E7T400Y>*@T5H$FBH-1P%$!9&XG`/DN.])V]#7@:!3A
M,B`<`.&T@U#;HV5[--BCJ3W2]OAC?5/%P2B294#L!,3:OID!&$6Z#$B<@$3;
MLQF`4<!@F;!Q$C;&#S\B8BUI#<)(4`#C94CJA*0&\FFE)-,^K&3%4LF<B,SX
MHYE7924KNH"!DZ'#,D,R`QDTFQ44Z*;879G.?))!(T]OE*[8OQ"Y469_PKD%
M9C5HQ0J#H9MBMC&"<Q2K02LH[LT.S5Y&X=>O[6@U698&09A]_D1@<L@VA-WT
MY<.],[VWPIRQ8W2\X/;Z5`?O\B+O\(W\PNQ6M=P[42&/>GTN7RD51!81/,F2
M2GD%CY.:7(4:;N28F4O)3`3MACMVO.B+_U!+`P04````"`"UC&E'[G<HB'$#
M``"P#P``&````'AL+W=O<FMS:&5E=',O<VAE970R+GAM;(V738^;,!"&_PK*
MO0OC3U@ED39457NHM.JA/;.)DZ`%G`*[V?[[&L:D2>HXO@1PGAF_MH?7>'[4
M[6NW5ZJ//NJJZ1:S?=\?'N.X6^]5770/^J`:\\]6MW71F\=V%W>'5A6;,:BN
M8I(D(JZ+LIDMYV/;<[N<Z[>^*AOUW$;=6UT7[9^5JO1Q,8/9U/"CW.W[H2%>
MSN-3W*:L5=.5NHE:M5W,GN`Q)V)`1N)GJ8[=V7TTB'_1^G5X^+99S))!@ZK4
MNA]2%.;RKG)554,FT_-OF_1?GT/@^?V4_<LX7"/_I>A4KJM?Y:;?&[7)+-JH
M;?%6]3_T\:NR8^!#PK6NNO$W6K]UO:ZGD%E4%Q]X+9OQ>L1_!+5A[@!B`\@I
M`)@W@-H`>A40H[)Q7)^+OEC.6WV,ND,QK#8\&KP=DIC,43=F,T/JQL:GH?5]
M2=@\?A_R6(2<(2N+W"9R2_`3$IO^G2+()(*>BR`8+^['TRF>G<=3C)>7$N6(
M-#@(1"@C++U-Y4AQ)H6\KX4YM3#4<M4+/]>""..2WH9RA"!-V7TEW*F$HY+,
MH\0B$H1'B85(0NXK$4XE`B<_\2A!1%#JD9M;2(2LCG0JD:@$/$H083*5ODE!
M2G!.DOM:4J>6%+40CQ9$@`O?K$P0#WC_,J>2#)5XRG&%2)9QZ5&"$`!)`TH%
M$J>6L7EX4SUB+)-Y"BJW#``-D`)N*>AKE/ND(,,SEGD6,K>83)D,J!=PVR2@
M3](`GP2W48*U0<\BKBS#$N]23YDR#@%JW%8)Z''4YY66`<B8[W6<,,ZRD-EQ
M&R9P.R:?'F1$RKW%9RDI0JK/;9H@[#KXU`CKS2GW[243)@B$5)]T5Y\UQI#U
M=AL>H%,QG^-91D@I/0Z0GS`F`O9'<-L>9`'K;1D.UY\7EWHL)@D-L#[BMCZ"
MEL5\2VF9#$*Z<=L:02]B/H>U#"',M_.<*!Y0YH2XU1#[->13@PPD'+ROW8F3
MJ0@H4^(V26(-\,IO+CXG+6-VNB2AM[E\XBA+9(@BMU$2^\5X58'GS&IBTMM,
M_C]S6XG;(@D:VW557,X-,I^,1P+XYL9RG(LD9&[<-DG0VZ[KXE*1N+5)7PH2
M-S?I^.QL=2AVZGO1[LJFBUYT;XYIXYEJJW6O3)KDP=3DWAR?3P^5VO;#K33W
M+1XH\:'7A^E\?#JD+_\"4$L#!!0````(`+6,:4<UM['E#00``/81```8````
M>&PO=V]R:W-H965T<R]S:&5E=#,N>&ULC9C+CJ,X%(9?!66?PL<VV$2I2!6@
M-;,8J=6+Z365.!<UES10E9ZW'\`V22@X81/`^<[E]^78L+X6Y:_JI%3M_,G2
MO'I=G.KZLG+=:G=265*]%!>5-_\<BC)+ZN:Q/+K5I53)OC/*4I<2XKM9<LX7
MFW77]KW<K(N/.CWGZGOI5!]9EI3_;55:7%\7L+`-/\['4]TVN)NUV]OMSYG*
MJW.1.Z4ZO"[>8!53TB(=\>]97:N[>Z=-_KTH?K4/?^]?%Z3-0:5J5[<NDN;R
MJ4*5IJVG)O)OX_06LS6\O[?>OW5RF_3?DTJ%1?KSO*]/3;9DX>S5(?E(ZQ_%
M]2]E-'BMPUV15MVOL_NHZB*S)@LG2_[HZSGOKE?]CR3&;-R`&@/:&_1QQ@V8
M,6`W`XX:<&/`YT;PC($WB.!J[5W/14F=;-9E<76J2]+.)U@U>-DZ:3P[5>>M
MZ;2J:WQK6S\W'JS=S]:/0>@=LC4(G48BC=R<N$W\T23H8BP"[<R1`*$F/(;D
M\-1)_,7)9)K,ILGN^XII>_[<GEM[?F_/M;WWF*+HD%SWA$8X(S`-A1JB+/"G
MH4A#0+E`XL6&`@_$<U7>J"I/JQKDXMVKT@AXW)N&0@,Q@&DHTA`CDD]#L88H
M]8+GFOQ13;[6)!!-&EE2QA'EH:%`!!)192A?2*2#8D,)+OSGNL2H+J%U(;EL
M-<(\0A!9&H*`!(@J#4DAL+'2D,_NPDUJDJ.:I-:$9++5R-*C/B;*4)(,2]V#
M*D.!Y`%#=$D[/:B<H2P851;HOD%RW@9FE1-DJH8&"C@"11IB$EO(L<D(^(P9
M"&145-?<^D!4&6;)R;#B/^BRF`\$63>1Q9JL&=(#<<\)8#-J/,"X/KT7^L@<
MVAIFV90H9&V$/48`FY$6\RFV"&*+"2IGU$6@X^JH6:^8.FK2ENBLM)A/"58;
M+084*-(+<<])H#-V>&#C^O0>[R/#LC7,$@C#RDF/R>'IZE$?ZWL+*_X68SR8
M44]@_``">KOWD4!;PP`Z=.:8@E5_&PLK_C86FS,AQT\?H#=['SM^&*89,$#+
MB<4D09>;P:C@R+C&%F/,FW$NAO%S".@]WQ\,QL.1T3!+)BF9QD*+20((%ED,
MN!PN\H>#H^4H<#&G6/;GD8<3-9CM7\[P,+[[@]YH_<%4E`\]9#9C\D+X-!;>
M88BWZ(:!/XW%-VQ6.0K&^T=ON&+&DJ?CVRTE0P]?UX=A`A9P)@0R]T-+TD"`
MAY%1[],+`@Y8$>A]2BKEE[7BWKW49JH\=I\3*F=7?.2U?D_K6_M/%F^T?2D>
MM&]A%<)(>P2K6'^0N+G?K"_)4?V3E,=S7CGO1=V\BG?OS8>BJ%63-'EI))Q4
MLN\?4G6HVUO1CH;^+*$?ZN)BO[+TGWHV_P-02P,$%`````@`M8QI1Y/`@^<J
M`@``^`8``!@```!X;"]W;W)K<VAE971S+W-H965T-"YX;6R-5<N.FS`4_16+
M?<>\01%!RJMJ%Y5&LVC73N($-#:FMA.F?U^_($R&/#887\XY]]XC?%UTC+^+
M"F,)/BAIQ-RKI&QG$(I=A2D2+ZS%C?IR8)PBJ;;\"$7+,=H;$B4P]/T44E0W
M7EF8V"LO"W:2I&[P*P?B1"GB_Y:8L&[N!5X?>*N/E=0!6!9PX.UKBAM1LP9P
M?)A[BV"VR37"`'[7N!.C=Z!KWS+VKC<_]W//UR5@@G=2*R"UG/$*$Z*%5.*_
M3O.24A/'[[WZ=].MJGZ+!%XQ\J?>RTH5ZWM@CP_H1.0;ZWY@UT*B!7>,"/,$
MNY.0C/84#U#T8=>Z,6MGO^2^HTT30D<(!\*09YH0.4)T(<1W";$CQ,]F2!PA
MN<H`;>_&N362J"PXZX!HD?Z=@IF"<RVBE($P:LHT88(+'3V765#`L]9QD'`$
M65I($MZ&K"WD(@)5_LDB0F\J0VCH=Q*L+"*)[M3P4&3S1>1FF5%?9CSV*K)>
MA8_Y<<^/QOS8\I_(GTSF3RP__MQB9B"-==)"PB2_C5E93)!%MS%KBTG3[#9F
MX\I)X\?]I)/]I%8@><S/)OW,GO8SG\R?/_;30H+\GI\6\^V>5VN7ZOH0??+3
MZ>37QPB.SC7%_&@FJ@`[=FJD_56'Z#"T%Z&>"U?Q93!;!1/QM1KR=B9?Y,NB
M14?\"_%CW0BP95)-(S,Z#HQ)K,KU7Y2UE;J&A@W!!ZE?,^VYG<QV(UG;WS/#
M95?^!U!+`P04````"`"UC&E'M3IM>W@$``"+%P``&````'AL+W=O<FMS:&5E
M=',O<VAE970U+GAM;)68RW*C.!2&7X7R/@VZ`B['58D--;.8JJY>3*^)+5^J
MN7@`QSUO/X`$`7,D-%G$1GSGZ#]"_)*U>13EK^HB1.W\SM*\>EU=ZOJV=MWJ
M<!%94GTK;B)O[IR*,DOJYK(\N]6M%,FQ"\I2%WL>=[/DFJ^VFZ[M>[G=%/<Z
MO>;B>^E4]RQ+RG_?15H\7E=HU3?\N)XO==O@;C?N$'>\9B*OKD7NE.+TNGI#
MZYBP%NF(OZ_B48V^.ZWXCZ+XU5[\>7Q=>:T&D8I#W:9(FH]/L1-IVF9J>OY'
M)?WJLPT<?^^SQUVYC?R/I!*[(OUY/=:71JVW<H[BE-S3^D?Q^$.H&CJ%AR*M
MNO_.X5[51=:'K)PL^2T_KWGW^9!W`D^%P0%8!>`A@/C&`*("R!`P"(,#J`J@
M7P'4&,!4`+/M@:L`_M2#*P>K&^I]4B?;35D\G.J6M!,0K1N\;),TF9VJR]:,
M<M4UOK6MGUN?;]S/-H]"\`C9281A/1))!`V$V_0/BL`KJ`?<A1LZV$N"$8.&
MQ23Q+(E6)NEETO%8$3E6_K0+OT-R*4(B+XQQ#^FQ6&&8AY0OJZ&@&BK5!--N
MV%B-1$+JZYE8,HA;/#P&ZF!21VC0(1'J8X,.IF897M;!01V\2Q!X!AU<30!J
MT"$9:C%)?%"&+V48GOY.(B\DP)Z>VBLJ\)"I)$4A&G!BJ$IA&%&?+E<6@)4%
MX/0?=[.3R`L/&$)Z;*\PZC?SWU";7;88S*:M+01K"^53LYA\R`,3=,T+YJ"8
MYYHGSC!G]$H0K$2:<6"8#I%B0L(]$B##JQL/)&/("P,+51A6A4&[&C.18JB!
MB>>,7@GLXHB`AC550BR4S!B]$MC!D?3>P/0.*.8%L^<%9?J8%(8"8C-S8"='
M#+30,?/>,\PT>LQB]&:,7BWL]T@9/C>-GG)\YC5_IN&3'$(D&'%Z1;#U(]C[
MIV/C6XS-C-$K@:T:P5X]68448W*CO04363#QG-%7!!LT"A==;:>8D"*&"#)L
MC/8]23@G'C>^?[8Y8UU._5X87DFP7`$"WR(#O`)@M+P6*08%C!-B>'(#1PEE
M%HI@]\>P^T]&6C'FW:J"K+:K&/9_#/O_5`NQV+$JR&K+BN$5`%/0<:=/BL*[
MUNECHM;;5@R;/V;+YH4MC'W.Z)7`QH[YLGDI!@4^>UX`)@8V<,SS#5ORR#)?
M#.?35P@O%%@M%#9C!!L\7C;X2#$OF"*"`U-1/=BN?S8O.6S1.%S>XBG&/(-F
MC/YW.FRAQ%O>XBG&J&3.Z)7`5DS0XI8J4HQ9R8S1*X$MF.#%'Z:18J!?D]/C
M"_R_?DX2S7'*\GG*CO0G)8RCT"!]/X#-5&>AJ4;+C+$FH[Y*:?%#@K>NP1P"
M6S%9WF._]\RS,'=T")B)\MR=UU;.H;CGM3S!&5J',^%WW!XB/K7OT'J/@/8(
MK6.HO2EW'1$*W&FT-G>ZDTWW2])V<TO.XJ^D/%_SRODHZKK(NK/)4U'4HBG1
M^]:LMA>1'(>+5)SJ]JO??"_E6;&\J(M;?_0]G+]O_P-02P,$%`````@`M8QI
M1[70[-;I`0``(`4``!@```!X;"]W;W)K<VAE971S+W-H965T-BYX;6R%5-N.
MFS`0_16+#PCFUNY&!"FAJMJ'2JM]:)\=&"Y:&U/;A.W?UQ<@;$2R/&![..?,
M&>-Q.G+Q)AL`A=X9[>3!:Y3J][XOBP88D3O>0Z>_5%PPHO12U+[L!9#2DACU
M0XR_^(RTG9>E-O8BLI0/BK8=O`@D!\:(^'<"RL>#%WASX+6M&V4"?I;Z"Z]L
M&72RY1T24!V\8[#/$X.P@-\MC'(U1\;[F?,WL_A9'CQL+`"%0AD%HH<+Y$"I
M$=*)_TZ:UY2&N)[/ZM]MM=K]F4C(.?W3EJK19K&'2JC(0-4K'W_`5()U6'`J
M[1L5@U2<S10/,?+NQK:SX^B^/.&)MDT()T*X$)8\VX1H(D170FPK=<YL7=^(
M(EDJ^(AD3\S/#O8:+HR(5D;2JNF2I`T>3?22/>/4OQB="1*N("<'"1:$K\4W
M,X3>%CVT]/!^@MPADNCS#-&<(5[7$+D:@H\I$@OIG`D'"1/\`)0[4/`4Q9\[
MB3>=Q,[)3;'/:R<.@G?XULH:E6^A[GI)-KTDSDOT8%<<)$BP>QYLS3VD\^2O
M3AX#4=N.E*C@0Z?<L5BB2],?0W-R;^(G?1FXWKW*9&E/:OA%1-UV$IVYTGUA
M#W'%N0)M#N^TU49?5\N"0J7,]*N>"]?!;J%X/]]'RZ68_0=02P,$%`````@`
MM8QI1R;)"4CI`P``E!(``!@```!X;"]W;W)K<VAE971S+W-H965T-RYX;6R-
MF$USHS@0AO\*Q=V#U!(?3CFN"FQ-S1ZV:FH.NV=BRS8U@+R`X]E_OX!:Q,XH
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M=OZ]FO]D#,/<`8`!L`0L_;@#!`:(]P`Y5VJ4S77]40[E=M/I:]"?R^EM\Z<1
M[Z8D8^:@G[.-)?5SX\O4^K9=RTWT-N5!!&Z0W"!\(:(QN;,'"%WA,(?#YQT4
MAHC%XQZ$[4'<UB!,#?'C>&GCY6V\-/')O<1T1EI3A$%67&:)^!PK$`,N4_E8
M3>RL)C9JTL?QB;.:Q,1G]S+CVVH,PB5??PX5!DHRC]>2.H6D1@C11VX0GG%.
M"#$02)X]5I(YE62F&\8(*98!0HEALF3]6,C:*62-G1#EYL@DA`Y$I(<.SIQ"
MYN8'Y>8(`3&4"F16X#'[.'=K08-A@M)B("$(J%@@\!`#SMG'`<5XS%\NW/4(
M3!%3]0A\;HR3CQ>QA*<^-;G]C4L41(RI'*&5X%E*"4(L3CUF(X_=>F+40W24
M(R3HT8>9.'C8)7?[)4<W9)1C(K22XN,R<:\',9Z*Q$.0VS<YNB*CG!.A<?Q(
M(-^7Y:1D/L\H<\\*=$?./%*XK8^C:7VT^KME%J&53`BK+BPU3@J/38G;`('9
MD7/?T2V4(R2I(8C,:NVQ3H+;``$-D!-;BQRA54R-/PMQ\'`+`+<:=$`NB>&'
MT"HFURE+93Z&#.[-':";<H\%!MS^!^A_E-8<H5@091<(29]W[?8^L(Y%>1]"
M#[3$_EK<S@?H?-0*E(.U-$Y-24MEF<]K<OL>H.]1N](<%M^+R=WKPB4L\_ET
M<6\<`7T/J)TC0K%,$\J)P>X>Q=ICZ02WBP*Z*%`[2(2$!-JY#)8PX>.C@CFG
MIT`?]3$<X;8_8>V/JLE"DO(;"WF)<>__!+H?^'R-NO=_`AT+)&'G"(G?=HEW
MWY.68NG'K7YT\['?J.XX'X+TP4Y?VL%\B2^MRT'+"TR'!1_:<_Y4F..2]S3;
MS;D\JK_*[EBU??"JAT$W\[G!0>M!C<+8E_&YGU2Y7VYJ=1BFRW2\[LRAB;D9
M]-F>`2T'4=O_`5!+`P04````"`"UC&E'J+?,<Z(!``"Q`P``&````'AL+W=O
M<FMS:&5E=',O<VAE970X+GAM;(53VX[;(!#]%<0'+`YQ=JO(L91L5;4/E5;[
MT#X3>VRC!<8%'&__OH`O:U61]L7,C,\Y<V"@&-&^N0[`DW>MC#O1SOO^R)BK
M.M#"/6`/)OQIT&KA0VI;YGH+HDXDK1C/LD>FA32T+%+MQ98%#EY)`R^6N$%K
M8?]>0.%XHCNZ%%YEV_E88&7!5EXM-1@GT1`+S8F>=\=+'A$)\$O"Z#8QB=ZO
MB&\Q^5&?:!8M@(+*1P41EAL\@U)1*#3^,VM^M(S$;;RH?TN[#>ZOPL$SJM^R
M]ETPFU%20R,&Y5]Q_`[S%@Y1L$+ETI=4@_.H%PHE6KQ/JS1I':<_^7ZFW2?P
MF<!7PI<L&9\:)9M?A1=E87$DKA=Q=KMC@-LH$I2)2VK!H4O%<ZS>RAT_%.P6
MA68,WV`N,V9%L*!^MP6G]^@\T?GG]/U"WV\=[F>'CY\+Y(M`OA7([V]QB[DL
MF*?_FK#-F6JP;;HZCE0X&#\=Z5I=;^>9IYE\P,NB%RW\%+:5QI$K^C#9-(8&
MT4-HGST<*.G"^UD3!8V/X5.([72EIL1COSR0]966_P!02P,$%`````@`M8QI
M1WN/3*2B`0``L0,``!@```!X;"]W;W)K<VAE971S+W-H965T.2YX;6R%4]MN
MW"`0_17$!P0OWK3IRFMI-U74/E2*\M`^L_;81@'&`;Q._[Z`+[&JE?)B9L;G
MG#DP4(QH7UT'X,F[5L8=:>=]?V#,51UHX>ZP!Q/^-&BU\"&U+7.]!5$GDE:,
M9]D7IH4TM"Q2[=F6!0Y>20//EKA!:V'_GD'A>*0[NA1>9-OY6&!EP59>+348
M)]$0"\V1GG:'\SXB$N"WA-%M8A*]7Q!?8_*S/M(L6@`%E8\*(BQ7>`2EHE!H
M_#9K?K2,Q&V\J#^EW0;W%^'@$=4?6?LNF,THJ:$1@_(O./Z`>0OW4;!"Y=*7
M5(/SJ!<*)5J\3ZLT:1VG/SR?:;<)?";PE?"0)>-3HV3SN_"B+"R.Q/4BSFYW
M"'`;18(R<4DM.'2I>(K5:[GC#P6[1J$9PS>8\XQ9$2RHWVS!Z2TZ3W3^.3U?
MZ/G683X[_/:YP'X1V&\%]K>WN,6<9TR>_=>$;<Y4@VW3U7&DPL'XZ4C7ZGH[
M3SS-Y`->%KUHX9>PK32.7-"'R:8Q-(@>0OOL[IZ2+KR?-5'0^!A^#;&=KM24
M>.R7![*^TO(?4$L#!!0````(`+6,:4>K%<$SH`$``+$#```9````>&PO=V]R
M:W-H965T<R]S:&5E=#$P+GAM;(U3VV[<(!#]%<0'!-^25BNOI=U45?(0*<I#
M^\S:8QL%&!?P.OW[`K[$JE9J7\S,^)PS!P;*"<V[[0$<^5!2VR/MG1L.C-FZ
M!\7M'0Z@_9\6C>+.IZ9C=C#`FTA2DF5)\L`4%YI69:R]FJK$T4FAX=40.RK%
MS>\S2)R.-*5KX4UTO0L%5I5LXS5"@;8"-3'0'NDI/9R+@(B`'P(FNXM)\'Y!
M?`_)<W.D2;``$FH7%+A?KO`(4@8AW_C7HOG9,A#W\:K^/>[6N[]P"X\H?XK&
M]=YL0DD#+1^E>\/I"98MW`?!&J6-7U*/UJ%:*90H_C&O0L=UFO_DQ4*[3<@6
M0K81OB;1^-PHVOS&':]*@Q.Q`P^S2P\>;H*(5R8VJGF'-A9/H7JMTCPMV34(
M+9ALASDOF`W!O/K-%AF]1<\B/?LW/5_I^=YAOCC\#X%B%2CV`L7M+>XQYQ63
M_]6$[<Y4@>GBU;&DQE&[^4BWZG8[3UF<R2>\*@?>P0LWG="67-#YR<8QM(@.
M?/OD[IZ2WK^?+9'0NA!^\;&9K]2<.!S6![*]TNH/4$L#!!0````(`+6,:4<(
M@\*$H0$``+$#```9````>&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;(53VV[C
M(!#]%<0'%,=VNE7D6$JZJKH/*U5]V'TF]MA&!<8+..[^?0%?:E61^F)FQN><
M.3!0C&C>;`?@R+N2VAYIYUQ_8,Q6'2AN[[`'[?\T:!1W/C4ML[T!7D>2DBQ-
MDGNFN-"T+&+MQ90%#DX*#2^&V$$I;OZ?0>)XI#NZ%%Y%V[E08&7!5EXM%&@K
M4!,#S9&>=H=S'A`1\$?`:#<Q"=XOB&\A^54?:1(L@(3*!07NERL\@I1!R#?^
M-VM^M@S$;;RH/\7=>O<7;N$1Y5]1N\Z;32BIH>&#=*\X/L.\A7T0K%#:^"75
M8!VJA4*)XN_3*G1<Q^E/ELRTVX1T)J0KX2$2V-0HVOS)'2\+@R.Q/0^SVQT\
MW`01KTQL5/,.;2R>0O5:[K*\8-<@-&/2#>8\8U8$\^HW6Z3T%CV-]/1[>K;0
MLZW#;':X_UX@7P3RK4!^>XM;S'G!W']IPC9GJL"T\>I84N&@W72D:W6]G:<T
MSN037A8];^$W-ZW0EES0^<G&,32(#GS[Y&Y/2>??SYI(:%P(?_C83%=J2ASV
MRP-97VGY`5!+`P04````"`"UC&E'AMB3C:(!``"Q`P``&0```'AL+W=O<FMS
M:&5E=',O<VAE970Q,BYX;6R%4]MNXR`0_17$!Q2'I-LV<BPE7:UV'U:J^M`^
M$WMLHP+C!1RW?U_`EUJK2'TQ,^-SSAP8R`>T;ZX%\.1=*^,.M/6^VS/FRA:T
M<#?8@0E_:K1:^)#:AKG.@J@222O&L^P'TT(:6N2I]F2+''NOI($G2UROM;`?
M)U`X'.B&SH5GV;0^%EB1LX5720W&233$0GV@Q\W^M(N(!'B1,+A53*+W,^);
M3/Y4!YI%"Z"@]%%!A.4"CZ!4%`J-_TV:7RTC<1W/ZK_2;H/[LW#PB.I55KX-
M9C-**JA%K_PS#K]AVL)M%"Q1N?0E9>\\ZIE"B1;OXRI-6H?Q#W^8:-<)?"+P
MA7"?)>-CHV3SI_"BR"T.Q'4BSFZS#W`;18(R<4DM.'2I>(S52['9WN7L$H4F
M#%]A3A-F0;"@?K4%I]?H/-'Y]_3M3-^N'6XGA_??"^QF@=U:8'=]BVO,:<8\
M_->$K<Y4@VW2U7&DQ-[X\4B7ZG([CSS-Y`M>Y)UHX*^PC32.G-&'R:8QU(@>
M0OOLYI:2-KR?)5%0^QC>A=B.5VI,/';S`UE>:?$)4$L#!!0````(`+6,:4?Q
MC-<XO@$``'L$```9````>&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;(U4VVZD
M(!A^%<(#%,^[F3@F,]ULMA=-FE[L7C/Z>TA!7,"Q^_8+B-8VIM,;@=_OA/Z0
M3T*^J!9`HU?.>G7$K=;#@1!5ML"INA,#].9-+22GVBQE0]0@@5:.Q!F)@B`C
MG'8]+G)7>Y)%+D;-NAZ>)%(CYU3^.P,3TQ&'>"D\=TVK;8$4.5EY5<>A5YWH
MD83ZB$_AX9Q9A`/\[F!2FSFRV2]"O-C%0W7$@8T`#$IM%:@9KG`/C%DA8_S7
M:[Y96N)VOJC_=+LUZ2]4P;U@?[I*MR9L@%$%-1V9?A;3+_!;2*U@*9AR3U2.
M2@N^4##B]'4>N]Z-T_PFB3UMGQ!Y0K02O@<N^&SD8OZ@FA:Y%!-2`[7_+CP8
MN+0B1ADIIV82*E<\V>JU"),@)U<KY#'1!G/VF!5!C/JN183WZ)&C1[?I\4*/
MMPGCV3W*;@LDBT"R%4C\%L/W6]QBS@OF"RG379/4"\2?F"R8Y+9)MFN2>8'T
M$Y,%\_%SD4UW<)"-.P0*E6+L]=P<:W4]9Z?(==<;O,@'VL`CE4W7*W01VO2H
M:ZA:"`W&/KA+,6K-3;`N&-3:3K^9N9P/Q[S08EB.^GK?%/\!4$L#!!0````(
M`+6,:4>;D9!TI0$``+$#```9````>&PO=V]R:W-H965T<R]S:&5E=#$T+GAM
M;(53RV[;,!#\%8(?$,JTTJ2&+,!.4;2'`D$.[9F65A(1DJN2E)7^?4GJ$;4P
MD(NXNYJ9G>6C&-&^N@[`DS>MC#O2SOO^P)BK.M#"W6$/)OQIT&KA0VI;YGH+
MHDXDK1C/LD],"VEH6:3:LRT+'+R2!IXM<8/6POXY@\+Q2'=T*;S(MO.QP,J"
MK;Q::C!.HB$6FB,][0[G/"(2X*>$T6UB$KU?$%]C\KT^TBQ:``65CPHB+%=X
M`J6B4&C\>]9\;QF)VWA1_YJF#>XOPL$3JE^R]ETPFU%20R,&Y5]P_`;S"/=1
ML$+ETI=4@_.H%PHE6KQ-JS1I':<_?#_3;A/X3.`KX3%+QJ=&R>87X4596!R)
MZT4\N]TAP&T4"<K$);7@T*7B*5:OY2Y_*-@U"LT8OL&<9\R*8$']9@M.;]%Y
MHO./Z?N%OM\ZW$_=^>>/!?)%(-\*Y/.(C_^.N,6<%\S_3=AF3S78-ET=1RH<
MC)^V=*VNM_/$TYF\P\NB%RW\$+:5QI$+^G"RZ1@:1`^A?79W3TD7WL^:*&A\
M#!]";*<K-24>^^6!K*^T_`M02P,$%`````@`M8QI1R:6L$L\`P``N0X``!D`
M``!X;"]W;W)K<VAE971S+W-H965T,34N>&ULE5?;DJ(P$/T5B@\0TEP2++5J
MO,WNPU9-S</N,Z-1J0'BDCC._OT&",@X`>*+0#Q]ND\W33JS*RO>^8E287UF
M:<[G]DF(\]1Q^.Y$LYA/V)GF\I\#*[)8R,?BZ/!S0>-]992E#KANZ&1QDMN+
M6;7V4BQF["+2)*<OA<4O6187_Y8T9=>YC>QFX34YGD2YX"QF3FNW3S*:\X3E
M5D$/<_L)39^!E)`*\3NA5]ZYM\K@WQA[+Q]^[N>V6\9`4[H3)44L+Q]T1=.T
M9)*>_RK2F\_2L'O?L&\KN3+\MYC3%4O_)'MQDM&ZMK6GA_B2BE=V_4&5AJ`D
MW+&45[_6[L(%RQH3V\KBS_J:Y-7U6O]#7&6F-P!E`*U!ZT=OX"D#S]3`5P;^
MS<`?-`B406#J(50&H:D'K`SPG8%39[>JS3H6\6)6L*O%SW'YQJ*IA!<EB62V
M>,4FR\*KQ:=R]6.!`G?F?)1$"@,=S++!H'[,JL8$T`_9*)H6X<@@M9&"K8L"
M5!0#+E8U9@"QKA&!-Q#G*,EVG.2YB=8;E^LU<KUN83Q%X(\3^`V!WR7P*X+H
M3D=40?(Z737$G;@NZD>MC5`;(]16A^K5%6AU!2HQP5<W05>8PD0$7)\,`-<*
M2,(0(0+]P$W#B".,(K<?N&T8,4$!AG&1H59DJ$2&XP18^_I@\]>':",@B@!_
MU8H[6I]K#!!WW$FD=1(I)^2KDRYFTV"B<2?(U7JIEB5%Z`ZX:4$&+R9">C_J
M"Q<:E!V!MFP(S.N&/'T4ZLL1>OUJ5RW('TK)=U!_,/J/$/(516!`$>A3$CR0
M$GTWH=`D)0TH'$K)=U!_,%@?C&K-$!M0$'U*R`,IT7<>4FT5DO[^7BJ09R`6
M]*T'35<9="\@K5A`YF(!]%'`>/V7#0@;?,U`WWJ@&@:;##F^7JW_@%K]!@FJ
M8?#=?E:.Y[?:-BB8&+0FZ/L*5#=@@RD']/L4/+!1@7ZG`F)27=)37:<S-6>T
M.%8G(F[MV"47]6S6KK:GKB<HI^Z[]16:KI%F?8.FV_I,=:-?S,[QD?Z*BV.2
M<^N-"3GK5X/Y@3%!9;SN1`X5)WF.;!]2>A#E+9;W17VRJA\$.S<'Q?:TNO@/
M4$L#!!0````(`+6,:4<W]<7$#`(```P&```9````>&PO=V]R:W-H965T<R]S
M:&5E=#$V+GAM;(U5S8Z;,!!^%8L'6,#\)1%!2JBJ]E!IM8?V[)!)0&MC:CMA
M^_:UC2%L19)>@CU\?^/(0]YS\2YK`(4^&&WEUJN5ZC:^+ZL:&)$OO(-6OSEQ
MP8C26W'V92>`'"V)41\'0>HSTK1>D=O:JRAR?E&T:>%5('EAC(@_>Z"\WWJA
M-Q;>FG.M3,$O<G_B'1L&K6QXBP2<MMXNW)0K@["`GPWT<K9&)ON!\W>S^7[<
M>H&)`!0J912(?ERA!$J-D#;^[31OEH8X7X_J7VVW.OV!2"@Y_=4<5:W#!AXZ
MPHE<J'KC_3=P+21&L.)4VE]47:3B;*1XB)&/X=FT]MD/;^+,T98)V!'P1)A\
ME@F1(T0W0FP['9+9OKX018I<\![)CI@_.]QHN#`B6AE)JZ9;DK:X,]5K$69Q
M[E^-D,/@&6;O,!/"U^J+%MA;HF-+Q_<-2H=(GCM$HT,T;R(:`N+U<X%X%(CG
M`K$[A>1SR,QBVJ$-ATD"?!]4.E`:IL^C)(M1$A<E_>R2S%T<)L+/3=)%D]29
M9/=-]@,F7D4/0*4#K</_./IL,4KFHJP>1!DP:12M'QR]`Z5I]CS*:C'*RD5Y
MX+)WF#0(_G'Q9[>/@3C;J211Q2^M&B[?5)T&WP[;VWN#%WE'SO"#B'/32G3@
M2L\`>V%/G"O0_L&+/IA:C^9I0^&DS#+3:S%,JV&C>#?.WND#4/P%4$L#!!0`
M```(`+6,:4>.08E1BP$``#L#```9````>&PO=V]R:W-H965T<R]S:&5E=#$W
M+GAM;(53RV[;,!#\%8(?8$J4G12&+"!.422'`$$.[9FV5A81DJN2M)7^??F0
M5+4(T(NXNYR9'2ZI>D3[[GH`3SZT,NY`>^^'/6/NW(,6;H,#F+#3H=7"A]1>
MF!LLB#:1M&*\*.Z8%M+0IDZU5]O4>/5*&GBUQ%VU%O;7$12.!UK2N?`F+[V/
M!=;4;.&U4H-Q$@VQT!WH0[D_5A&1`-\EC&X5D^C]A/@>D^?V0(MH`12<?500
M8;G!(R@5A4+CGY/FGY:1N(YG]6_IM,']23AX1/5#MKX/9@M*6NC$5?DW')]@
M.L(N"IY1N?0EYZOSJ&<*)5I\Y%6:M(YY9WL_T3XG\(G`%P+/QG.C9/.K\**I
M+8[$#2+>7;D/<!M%@C)Q22TX=*GX$*NWIOQ2U.P6A28,7V&.,Z9<,"SH?]J$
MSTVJ=1.>!2K^?X%J%MBN!:K)`?_;99Q]`)EL,X.VN\WNGS9L-9A!7.!%V(LT
MCIS0AQFG@72('H)(L=E1TH>7O"0*.A_#^Q#;?+DY\3C,3W7Y7YK?4$L#!!0`
M```(`+6,:4=F"DQ&<0(``#`)```9````>&PO=V]R:W-H965T<R]S:&5E=#$X
M+GAM;)66W8Z;,!"%7P7Q``&;_X@@)5M5[46EU5ZTUT[B!+2`J>V$[=O7-@-+
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M`)X"PB'Q`632_$(D*7+.>D=T1/]Y:*OD7)LH9T<8-Y6A,)-[/7LO4!KDWET;
M@0;/-`?01&C2>,K?"L&NS0`#)'QN$(P&P3S+``RBYP;A:!#.#4(PB!_+C(RF
M';($3>9GON\_!T564`2@Y!$TUQQ&3?H<$ELA,1ADCY!T7@UH-@E^3DFLE&3\
M/19*&34KED9JA:1@@!\ANJL^:P'1)GM.R:R4#"C!0BFC9L4B1;Z58J:U1;2`
MF43Q"@ZR<Z`ALZ5%-HE6K#*$[1SHVRQ;X@PBO*9E4&#G!&"Q8A6AT+I!H'#]
M#H'LG8LBR`(O53N*@A4<>_.B&"S6++3$7FWR']7:^PZED$6TL".""*W80I"]
M\5"V8A,!$?;_;0EO=J(UE%_-P2V<$[NU<CC0IMGI<K#'YD3\E!=Y1Z[T!^'7
MJA7.D4EUKII#\,*8I(KO;U31I;J^3(.:7J1^3=0['P[T82!9-]Y/IDM2\1=0
M2P,$%`````@`M8QI1PC$LZ_U`@``=`T``!D```!X;"]W;W)K<VAE971S+W-H
M965T,3DN>&ULE5?;;J,P$/T5Q`<$;',)%4%JLEKM/JQ4]6'WF29.@@HXBYVF
M^_=KFX&2:AJ<EX"=,V?F8`YCYQ?1O<HCY\I[;^I6KORC4J>'()#;(V]*N1`G
MWNI_]J)K2J6'W2&0IXZ7.QO4U`$-PR1HRJKUB]S./75%+LZJKEK^U'GRW#1E
M]V_-:W%9^<0?)IZKPU&9B:#(@S%N5S6\E95HO8[O5_XC>=BPR$`LXG?%+W)R
M[YGB7X1X-8.?NY4?FAIXS;?*4)3Z\L8WO*X-D\[\%T@_<IK`Z?W`_MW*U>6_
ME))O1/VGVJFCKC;TO1W?E^=:/8O+#PX:8D.X%;6TO][V+)5HAA#?:\KW_EJU
M]GKI_UF&$(8'4`B@8P!);@8P"&`?`?;1!7UE5M>W4I5%WHF+)T^E66WRH.&=
M(=',GK1L6I*TDX]F]JV@89H';X8(,'2"6?<8$I,1$VA^-`GU,0(*!/3K))L>
M0^=3L"%%--7!^A2)`T$T$+`I000/8CE/$*,5Q%`!NQ8YQ6P&3#2?)$&3)$`0
MSQ.DJ,S47>82K6#I('/`)/-),C1)!E5F\P0D1'7::4>AA*!%$/`&":^EQA;4
M@C=Z4)Q$69BZE$OQ7/#Z$W*=*[W*!3X*'=+@+B$,TCC8A.`^(7<8A>!.(3%4
M<>,=6H\@!Z\0W"PD`0H'MQ#<+N0.OQ#<,&3IHG8`.5B&X)XA&;@N=?A,XZ:A
M=YB&XJ:AT"R2Y8T7&4#,02S%_4+!"HF#Y2C#Q;([Q$9X%='\QW`]@%('VU+<
M,!3Z1NK2@1-<;7*'VA2O(H4J/K5QLV6:K"V@Z,+!=12W#(4&DC('B@S7F[GK
M92%:!0L=5G<`N:PNPRW#AC[C8%Q&4;6,WJ'VBPW4T!J6MU874-'"9:.&FX9!
M`R'9K<<*(/KYL0:336[#NX/=_$MO*\ZMZO>XX^QXP'BD=I/\`2_R4WG@O\KN
M4+72>Q%*;[7MOG@OA.(Z?[C03?ZHCT#CH.9[96Y3?=_UAX)^H,1I...,!ZWB
M/U!+`P04````"`"UC&E'Y@Z0P%@9```#:P``%````'AL+W-H87)E9%-T<FEN
M9W,N>&UL[5W;<AM'DGT>?46%0QM#18`00$K4)3R*`($FA1D0@`%08Z]C'QJ-
M`EEVHQON"RDXYB]F8G]@'_9M/\+S8WLRJZJ[T1>0\GAG8S<884L@NBHK*RLO
M)[.2K:_C.!%IH'Y*93],@^0/7YV<=+\2GS=^$/_AJ]LDV;Y_^3+V;N7&C=OA
M5@9XL@ZCC9O@Q^CF9;R-I+N*;Z5,-O[+DT[G[.7&5<%7'[Z.U8>ODP^#T$LW
M,DB$&ZR$$R0JV8EAH"FH,!#'(KYU(QE__3+Y\/5+FJ/GO1-789#<QIBSDJOR
MT[G<ML5IIR5..MW7Y8?C\*XM.MWZAQD_O7I^ON\MXR1RO>3?&F<N=EM9?MCM
M'']3_JZ'T2N><>&[-^6G:]>/*V2R-:8R4B$QN!(#-ZF,L_M_]KO?'=SDA8H]
MUQ??23<2%_BR(N;R2+-N[=AO3LO?+")WI8(;,=]MEJ%??CH=?5O^R@A\)F\4
M21GKCMU->7>D?._CK>O)/WP%[8IE=">_^C"=31:]T?!;<3Z<+#XZL][4N5X,
M^_.6&([[[=\UK-3'WB+L:P@M^BS^)'?E<?TTBLJ2:I+Z\7'WY/BTV[#4A?)E
M)/J8=Q-&E75ZGB?Q'$]7>F03P^%F`S6<)Z'W8TO,V3;$)$WB!`8$65?XGXP'
MSGCN#`0^S2>CX:"WP`_GO5%OW'?$_*/C+.:PLNOY0!P]?R&>"Q6(Q6V8QJ!7
M50?I0:^TZ;RJ+'4]FSGCA>C-YZ#YOO+8C6_9RCWZ(']*U9WK0[2512`*\C2Q
MB*0G,6CI2S!(NE21^"2YA4S=.)95,L/@#M3#2%6=QR),<):>.=KZZ1?7X\$<
MNB-FSGSJ]!=B<B&<J^EH\IWCB-GP\B/$=CV=T//%<.9<8><5!9]-ILYL\9WH
MC0?"^>9Z.*51+3%V*D,'SH4#Z>&4/O9FE\Z\GN-Z3C-Y;=T="XN$['I>E,*%
M5(ZA68[5PUY+2&B%<X`DTX?$Z"MWJ7R5U,A[-!E?BH4SNQ*C8>]\.!HNADZ-
M@H0XL2A1M(4@3&K(F!5VI*->&`328Y]\KY);_.S[[C*,M)M&)-*?FFG`IPNY
MV?KA3DH1J9M;2##=8FXD$Q5)\GKU&_9#N+1$1IM#6S9#FP?T)U=7PP4I1/FP
MZ_V;J!#H38?P>`*J,^P/G7'_NP=Y$(%,1+B&!6X5/5K)M?*4#+RJVZMW&_,%
M_F*>R1Q(NWN+(08\VH&</CIL5]W+%[+4'*EGSB=G?%TU,AS)M#?^[O=SN,7>
MS"'C[T]&H][Y1-,4O<N94VOI_<F<'403Y<O99#X7\`<7P\I<^!>G-^M_9"\Q
M`('1A/V$<+Z=TG[GXJC[HJ+&,HXA]!N*D3$;?"359IE&,2MN1>X/+E+KE>;.
M:#0<7[;$I3.&7$<\NS>X&HZ'\P7)Y)-3X/*DPJ4Y#1C_"/NO>-CA&#%H"+*6
M1O,(Q/#)E?,P!<BD9A_XBCD0%Y.9`#@0X&LX&30.PV.C`CA3,E2<_7PQZ?_I
MRV>`H?/>?-C7@A^.KJ&S%<_W9X?B"92Y]PD"NW3$^/KJ'!1!BXG.*U2OR0Y8
M/Z^FUYF$"VP\9MDOM:BCJ4N>_A;^$5CHQ:.-?@8?YD:>COX#!!,_W#*H=#XC
M88BE^/Y*;I8RJABJ8]WS'#Y0>5+CG>.E&R,J`0G1;/;R+='S_=`SOG\-`.F%
M-X'Z&<,,8NV',0SE^Y$*I!@F<A-7%BO2]@JT*[8L`TF0D3;36VU4P%`U47?R
MP?T\)'`^YH^],0``'V[%PS]:Y.>N[P9>-2]HV".\A\_0,PE%3-`2`92^K]!]
M#`&$K"12'OVD:;GW;K1JV>"#N+N6*DEKDCKGLXP\!0%BF&%`NSA-V$;K6!RI
MP//3E8EHTDRK^)\Q'OHA/"7%>NBMV+(R5(%'CJD;S\Y(M-60C_ZV@FE:Y?MN
MU4;^09DU+=5;K111HZ3/5:MC:%O?P(8F$0&(IIM4;W?`T")I'#N3#&TX>FT(
MO@J?0EIRZP;X0VOU;V\^50_V7+S\'SC11QRE4;I8)W);I)5(AU)643WC\`1-
M5+@IA!61H_M5SKW?FW\4%Z/)GQ^/X`I3+F:3*Y''^%X?@*`>VEM#K"K9#VF<
M,&*!+)$21E:N@/>>HD3`FC"^I<^</*9T)BI#^8#C@'GJCC%N96T^1_&P7Q^0
M1GJJ]MF%"F#\"KHOM8N/M=4>42W+W^%;#XI[(\5*K9$T`5'+N.*-^CPD)L8Y
M.P,__C^2C8Q(+$>7X."%P$!M1O!U*4%K6@4*LD6*1)[A"TGW-B$2L9^S>+J2
MRT2H.$[)!4**L0&=_/U*Q9R`'MAOX:`XA>7)A<2D<F@#Z4421T:35^4\U+HR
MHA>$P;'-0+?$=!A4!#\,<F)N37&!F`D/5!**S*CFJD)QF'LH)R_RGR>3M='K
M075_R#R'XT_._"'SG*9`9ZZ.(=N(EH%&$L=DDMLZ!:'BBC9<HVC6#:[D-HQ5
MG4+]:N5D4WM0.(HY^C+AF/SAL'!J`FPC,Q#>G:(-+F'1VF<<9,BYN+"EI6]U
MY!)PIDX6Q29C=M%U:<?`Z<^<WEQGJ;0O0OK\@2I-GWJCFLK"!UOVLZZ_;H[H
M+<2Y<SD<CTDP&%F?+#V6E(/O&XG,KZ?3$8>CWNP[[`3YV95.M?%?075!H^ZL
MQ'BRH&&3T2=ZD!]O-0CL+308SOO(EZXI71L7IE6U')8)K8(5JVJQ8G@Y'@)9
M]*CDV>]/KL?,ZQ2A%FBC0NN!X0?*%=BD([H(T`^0>.:VA4U.IA'5?M1G<:["
M!3R;NY4I,`_"%IQA6QQ1M8RJ9\C%=KI^IF!X<;J,U4JYY-U:#)A_^2NE66ZP
M^^5O0(KD$FC<_2VF[X[#^X"`CYVT:^7+CI)5&^,I\*IPBPB\<3WF@`J&3)'*
M46NZ1@"),.#%5H74D`O%0#QD>Z"8AR*"!ILEV59"D^S.R/02J0!^=:0W)`WW
MOX_9KV%?"?@D-OO2]YW/O_R7G4>!'4<=TRKQ+D:&*(Y^^6L^\&\OVN(Z)FLF
MLMGW9FRKN!@"I=T*6[_8JJWT*?$T[M6R\=!6VD!AQ2T@U4R4%J"1BY:@@.\6
M2RD#VC5)UY>?:PFV1!YX,GG9W"A!\-(>'6S>0(]H)F)[&*UD1#`VI0P^%I<N
M/B!6XA%'.SJI"W>)_9AORFQS>BQO6"Y`<48TC9+(&$,ND+`*%;;B0N_`">=Q
M$><WGY7V^K4D##+`G(T;_2@I0-GMQNZ&(O5*Z:H!"1N\@=']LR318N?`<_$Z
MI<4-^Z#D%D1&5,N"8?ZSHW&W%!P,`YH;8EMI/;W&T>+9/`$#D/5YY/ZL?!AK
M'+G2+P`4/3'6IECF,T@IU3):MDH]"DK8(&V*4=@=1$UKQHE+N`SCB(('U62[
M+)H?"-"6VW`78BZW"2=QXJ33>5<R<MK.AH01:`8;7(.@N*\%[[OWV=H(G)CD
M4YY1H'O>_M1NU=7X:8J3$D!!EG@E<7:PJECT;JB$3?;J7/5@J21KWYRKW8D5
M=#8=$@^#LJHF]^&>$V3UBRS^A+KM^4VP3I[#C8VKG!=FMG_YFYB`27<G]'79
MB=:KZ_:\+2["<*6+85%ZLU=$`L/8QL7`;B-7F=CU9<FEK56$V%3P!N;8L1+D
M>..G'NR&+-1?NTQ#!3]H<9+^"!G\O-O0]K8^G#,?N[8T+<K9@GBPYD(X]9AQ
MZIZ?<%>I3^$1X(;@'9^22^<&WD@M((V;`(!0G_AN*Q'(2G;2%B0W($TVU%K>
M[R'B!OL!T"+V(GE#A8<0FF928K[O(,C&:LEHG,]%+*KT%=DH4<N\1*ZN`?F)
MZZV_BT.QN*+_YHJ2((J#FB<(WG"!<ZOE/W,"&7V3-]99/Q&;KI'21R96(PSQ
MCQR"]S6@&B&W;I0``K1(*S,T:I9!ENJG,14J81U<J"0=A#?%[H1[$TFM!$N-
M_9<RN2>>2S%]GX%&)$`4--LM#%(('2K>LZ1]XS$;[EDFV/%,O"34;J?[>M\K
M2P9FM#%0@BIS*X74-C4#8./ZC)-M=U38[EQO-UM)'&GCM23*G)`1Z`VX-,)>
MML3ZK.IXYVP$VH&/R&"275L@OZ+4.:%]TXRFM?8W&8<^2\J,8H#&M0QSG/LW
MGI1[[FNNA0L5_JQ-U^(KQY>LZPR)3%6#)K@FPW%W3`/V"M+@[KDX/6MW1"]F
MU;..G;S5_FY8OW@_U-@1K\V.3,J'KPL+F["7[QT'`.]W`Z,A*Z5`7#]1QTT@
MM0>%T++?E`,IB[A0:^`TV!1],LD]"JE:OJ@V(\XZXE5'=#OX_Z3]&A$@PC8B
M]DTK8"#E0WX^PX88B?`8^$6\;E,$^6,*X-A]RS'D])`56,TF?A;2NPU"/P3H
M6EAI5S1>"ZNDZ>3`+Z!#[M__\^__$8I)?._ZJU#TH_1GCDPJ]/#19`,(CQM[
MXIJ:HL"LH]F.GGR4K@^*++>*7]31M^!XI$?.5J[7.L32B?[1#5+"#W0CK,<G
M^=YR32+$':N;0&O84AH8G&CGMPY3>)&W'6'8IW3`E#PX1ACWGF@`"'>-M=E?
M$TFU!I1@#+G$F=\+;`#G%5B%YF*%I28VT-,X"0.M."VN`T6$MSFRE?`:!RY2
M8[8*Q%:@UT06I%GTAU`).AS;YV."\GV^M*G_E5,1\$!QG;"WVL`F$9L1.%,F
M$5KGGPO`2*C@1LJL:-^>A7Q#3QJY)\8-L2(9L@7#[%'$_*PV&(-ENYTB_L(<
MV#4<#'1Y#2/(7,QKJV-4<F4\)^&';SC5-2=LF-31`.C6>+E8WQONAT(769[.
M&8J2L@I3NV>2<N;!W6!/9W643%B3K3\H$"XK.6\RD@0`V,>RLFMQV9*8B1(5
M)G"\M$>V`:TL2J>YD0S7'#%=<VG#)"KV=C!+)6X"@!DV/)L_9)EKRJDO.>P\
M]6W,G,NHND(M3\OLG52+U!<K&+26I2WOJ?E!3&??'G<[0-`4A_SMK7M\V1L=
M`VNY=6EN/KT^M]U+5HE&!(_?RE)>4MDXW%!"9))?.J?;=.-2DGAT8MDY*V.A
M4-\*)VHQOJAF8#D*TE"SD$>2K^#90%(K2.B.O3I1PLIKW]UL-++-=Z&/`[@=
MGSV<1LQ$@%63E)CPW&V<^OGVS0F!J!$1]G%J]M'MD`B*R7A.=B^I9@F(@0P_
M[R*U#(/4T_&JR\<R&+,PM=LHAL?:(_"@)Q#U6BTC2@Y:QGFX)A/B_2]).VY=
MG[4<#+^R#)^T<GGM3R%UAW>())-=$7<FR:GEPB8BF2^#%B&`DVCY+,U9[*S[
M*4KCLC^PM/51&_2)3)2%GSE!UL<(8M<'A9B^3`R.R;.8+)$H^P$RU*HJD1-C
MET5)C;9D($TOX?+$EK`E;;!<`;-732"KR-?9C`]NE3)D78?)TBB(=+M_*1<R
MXZ8.9!C>KU$1BP%V2M<@8>`N?6*>TG2]3I@F$*`TXB2GE!7&V^+<ENW(R=@;
M'8:<$`?BMV>P&$$MI:\,]_T9HK."WB'3-TZ6%(JN7L`Z>5MFODB<]#S@*XL"
MF,LXROPX`C@=2*C#KD^#^=*",.%*W_%J@$Q7V"X2\NZ)V.@FMR!\MN2=Z?QW
MJF^\M=OFJ.#I6BA79=+`35><!R*DK@AO\B=D`7SH*WNA`"WAY$/?FAK5S&&%
MA2X0_-:-3,1C%,)W=SI#U[=3N@P(%ZR@#3:@LE%Y'M5\5O7Y*6#@9:\WM=4!
M12A4;0KLJ;Q?'A&_A("@HB&U=UK7#X?NVUT4)K+XN0LTUT%X!%I82SL("!W4
MR80C(>L;(IO!XG!=B,X&OF!!MW#Q?$1U#*P5D<^'&4$]^&:1G*E\P6<`Z$`,
MY(:B,Z*UJZ)\X=Q-P/Z3/%FP`M+-)Q0.60U`+S\M(XP5W$-VR7>8#I>F2(Z6
M*<7A5-<S[V29&2Y&;EPR$U9=KU@+Y81J)]V(K1F&^>MT,;X-4Y\*!^0`5J:`
M]T,:E"IX!=(/$#3JU]-G/9-TP4LN`MG3!N#Q^$_9#HAYH9/J`>3!U4K;I]X"
M<5^K3]%4,GZX)#>G<\\-W[&I+W5=*`UNCK(+$?,-+."9UQ99EU'6NL$F[^D;
M<N6GM+_2`-C0:#KG(E^DDQ4>M21<`J#*^F?)&K[O):4*%&80DZ#,A7*O:0;9
M]P6F/%378_)<=-J=3I?2RC=ONZW7;TY$]UWKS;LWK>Z[#GU[=M9M==_RMV]/
M.JU7;RN_0D*7<^/%9%9STU5X]-"MUHDX%L7AMF=_1]XTKSO;W^0Q#82E\]46
M&I-HC`36H8_4"$)\_VR/R+/BW&=$D?YX]>Q(Z\"*"BJ143O3_O+BV<R]%Y2O
M1(JN[I\#[[SNG/#?9]VS9W\.HQ]I`L+A#6$LT3T]>79!D.26`$E(!O^J]?;T
M#?Y\UWWW3/=DJVR?S\59Z_3T'?]]=O9&#-+(9B8!06432;1J5R6R'P()H$1<
M!]M+L\!K^ZS2TM(;SL2GWNC:$5=.C^Y"ZQJ;ZT<]=*RGXI=_%PU3BW!A@WBI
MXR<Y4JV;VFAB#ZJ__\`,UIZ![#YW&?5-)6T@_6RV*ET,(NYYYHKF/O=:U!)"
MSB@*-UD9B\O<@5Z#H2Y=!N_5L=R\CZ>EL9G@O,$W%0I7.T";*FK8Q^4RA="K
M.[@U0BKLD4L1[0PFF'#-Z;\;`6?BT](G+8MM(-(;O57P#I%WN].;V])%&<3Q
M,_F')>7#63M*&A2^4`$\4*R[*0@P:4:*A+G*E-PB&16`U_#O#(5B6]XE/X9$
MSD-N0(Z,2B7OQ8C14O>]^"8-$TX_.!L_0GSA`"Q7+S0^X9!E+K?RBS^7[]WX
M%T(:!*0#L3Y^?-H[?1)=K6!NU)TIW=["I?+]OI828V/#LY%(V_Q\\A[`/9.6
MV4?&:*9:1HP4EW_26P[+VVN)99HPJ@RY>*O=OE$*[,FU2YZ^!_"J'A&MQ\=T
M?PMEPF83TM$(:Q:)D,*[=Z[R:>JC9($#JQ?%:2:*(35CZ=H#UV$S@OMN2*=1
M($O/3)&"BG;T2Z09$H%WPAB>EYKFFNI6H:6T5GEDG>::HHG\G.A6,*LWP2I#
M<+'.F&1$IK>CBCF`B(A4_*,MV9,FQ;$%<_G^*@*T@::`>>$04PM;-)BS^.4>
M,8+D97_MIH39%9E=RL!;4>;&E[$X4':!9E\JXBR2$X6#''GE7Z*BR@">U013
M%5?BQ*O7[4JDU[]PL)CUQG/JO)F,JZTME1'-`:+AEYLX;+RBL%%#C.]1Z?<'
M3DYKHI[&.7E[KDX0$[BI[,J01G-/-/MR*CMV6^\Z[UH=*L>W@7YT@?@UI6[:
MPW7;[T1'G.$AQ4X1J\_5CJ+SN?/--?\.S:>Z7JO\5E,X=ZP7#T3-U[S],EG:
MO;T(H]+'`Y=AAZZ7FN^Q6N4[JU;#K=S<7DYT_Z%;K0?NLAB:&S*A'7#@AJ5P
M2?9EMU:OVB</RQ>P+ZS<M7"W=]8W61!QSGIKKVJL9;]O]S'U`+]NG;V"*KYY
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M8P7[%&L@,`>N,J2QSO-L]F5]$&'N8QX,=UB)W>5\S+X%3?RE="=2>&#SZ:8W
MIIFB38YJ]#NCZ+70Y'_R*E>ADZWRHA\)=!30I4Y>DJ]@VSQ)SK.OFF2]<OQD
MQ/]2>?&/SK`E$/]V;_%BAEZ>]+J.4J4X611J5@4/HZVM<S:^IBZO3ZQ3BL(-
M)3S2?@8Q&=]E2F>U6S[(:.&V712OVQ_)^ZO:%<NM)L45&YM!FI:8VK()=T':
M#LA_7CWY-]W<0[J!YUS\YQ!GM+Y),-W.;R_\WT`E1H=N:+8AM</Q_;]6=5.5
M;PGD0%EA2!<$_[<WABGGL]Z_#D<'@WMMJ#KX]MEBZ*V\>3>/O(1S:][[5XC!
M]>_75@U0XD/>S'X/[">/5^%]]<6"]4W2^2X/1MR]?^;"2*.R0MXB6.D-?$0C
M7U'>]*]WB/R=O!P_<92D8$@)IDB2\[,\%CKT[D7>'!CNQ>!LTI=CCBO**FQ;
MH)$`9+W)*36\?=-W8]T7J3EX$$)D[U0]HL(&TWP!A:VGOI#ZMD._+J[J1SBA
M:'[[K>Y-IX4LF,R0.JW9_,K23^8->/6ON7U5O^S%7@^I9CGKLZ(:$C7YT.8K
M[SNDU`!N0.R4]"NKU?I*Q^:&=R%5ZZC(5(FIW?:;ZL09->FNJ3-3V7>R137_
M`D>W?79@45^M.835BN&L_FL2J96&[J)P@X!J?9RHFQ1']Y:RL!JCZA[XL2_J
MI5<65E':22W^T9S<F1`;Y\[YI]2-$OYM@_IS'V>)&34IN[Z?_PJ%?64B!7@V
MA+\(LIXRA=-ZV51[51N]<Z,'J\280V_H;@I(AUZ5:]HL'S&DI:W@2\+@@(NI
M8633>J3Y[`LG:^0KU'#>&+2Q['&ZM=66NDL=ZS57#6ZS3!*I\LK=/4+"OQ(V
M4V/JER[P&)A0[-T@S$#E#PJ:?+.]R"[V#\!5.X-B6JL!S%Q1O8UJVJL:MV%S
M4_[GDDX*S;<OXSCY\-]02P$"%`,4````"`"UC&E'E,\$8($!``"$#@``$P``
M````````````@`$`````6T-O;G1E;G1?5'EP97-=+GAM;%!+`0(4`Q0````(
M`+6,:4=(=07NQ0```"L"```+``````````````"``;(!``!?<F5L<R\N<F5L
M<U!+`0(4`Q0````(`+6,:4<8Z>6=,@$``.8,```:``````````````"``:`"
M``!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+`0(4`Q0````(`+6,:4?9
M1I,K(P(``.8&```0``````````````"``0H$``!D;V-0<F]P<R]A<'`N>&UL
M4$L!`A0#%`````@`M8QI1R`<]GP_`0``:0,``!$``````````````(`!6P8`
M`&1O8U!R;W!S+V-O<F4N>&UL4$L!`A0#%`````@`M8QI1YE<G",0!@``G"<`
M`!,``````````````(`!R0<``'AL+W1H96UE+W1H96UE,2YX;6Q02P$"%`,4
M````"`"UC&E'/9A\3U0"``#4"@``#0``````````````@`$*#@``>&PO<W1Y
M;&5S+GAM;%!+`0(4`Q0````(`+6,:4<>I!!HJP(``*,'```/````````````
M``"``8D0``!X;"]W;W)K8F]O:RYX;6Q02P$"%`,4````"`"UC&E'@LH^0TX"
M``#T!P``&```````````````@`%A$P``>&PO=V]R:W-H965T<R]S:&5E=#$N
M>&UL4$L!`A0#%`````@`M8QI1^YW*(AQ`P``L`\``!@``````````````(`!
MY14``'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+`0(4`Q0````(`+6,:4<U
MM['E#00``/81```8``````````````"``8P9``!X;"]W;W)K<VAE971S+W-H
M965T,RYX;6Q02P$"%`,4````"`"UC&E'D\"#YRH"``#X!@``&```````````
M````@`'/'0``>&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L!`A0#%`````@`
MM8QI1[4Z;7MX!```BQ<``!@``````````````(`!+R```'AL+W=O<FMS:&5E
M=',O<VAE970U+GAM;%!+`0(4`Q0````(`+6,:4>UT.S6Z0$``"`%```8````
M``````````"``=TD``!X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"%`,4
M````"`"UC&E')LD)2.D#``"4$@``&```````````````@`'\)@``>&PO=V]R
M:W-H965T<R]S:&5E=#<N>&UL4$L!`A0#%`````@`M8QI1ZBWS'.B`0``L0,`
M`!@``````````````(`!&RL``'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+
M`0(4`Q0````(`+6,:4=[CTRDH@$``+$#```8``````````````"``?,L``!X
M;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"%`,4````"`"UC&E'JQ7!,Z`!
M``"Q`P``&0``````````````@`'++@``>&PO=V]R:W-H965T<R]S:&5E=#$P
M+GAM;%!+`0(4`Q0````(`+6,:4<(@\*$H0$``+$#```9``````````````"`
M`:(P``!X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L!`A0#%`````@`M8QI
M1X;8DXVB`0``L0,``!D``````````````(`!>C(``'AL+W=O<FMS:&5E=',O
M<VAE970Q,BYX;6Q02P$"%`,4````"`"UC&E'\8S7.+X!``![!```&0``````
M````````@`%3-```>&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+`0(4`Q0`
M```(`+6,:4>;D9!TI0$``+$#```9``````````````"``4@V``!X;"]W;W)K
M<VAE971S+W-H965T,30N>&UL4$L!`A0#%`````@`M8QI1R:6L$L\`P``N0X`
M`!D``````````````(`!)#@``'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q0
M2P$"%`,4````"`"UC&E'-_7%Q`P"```,!@``&0``````````````@`&7.P``
M>&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+`0(4`Q0````(`+6,:4>.08E1
MBP$``#L#```9``````````````"``=H]``!X;"]W;W)K<VAE971S+W-H965T
M,3<N>&UL4$L!`A0#%`````@`M8QI1V8*3$9Q`@``,`D``!D`````````````
M`(`!G#\``'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"%`,4````"`"U
MC&E'",2SK_4"``!T#0``&0``````````````@`%$0@``>&PO=V]R:W-H965T
M<R]S:&5E=#$Y+GAM;%!+`0(4`Q0````(`+6,:4?F#I#`6!D```-K```4````
M``````````"``7!%``!X;"]S:&%R9613=')I;F=S+GAM;%!+!08`````'``<
+`'8'``#Z7@``````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001144204-15-063825-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001144204-15-063825-xbrl.zip
M4$L#!!0````(`%"%:4?LF*+W`T<```FS`@`0`!P`<&QX+3(P,34P.3,P+GAM
M;%54"0`#2!-!5D@3059U>`L``00E#@``!#D!``#L75ESXSB2?I^(_@\<3\3T
M;$3))GB(E.N8</FH4$R-[76Y>G>?*F@2DC!-D6J0LJ7Z]0OPD$@(I$D(NMRJ
MA[+-`_@RD<@+0/+#/V=C7WF&.$)A\/$$G*HG"@S<T$/!\./)-.HXD8O0B1+%
M3N`Y?AC`CR=S&)W\\],O?_GPUT[G$D,GAI[R-%<>1U#Y#06Q,X3*%QQ.)^^4
M^_`%XO1N_Z'_3;ET\%,8=#KTY=D3]M$Y_5\A$(+H'$6AH0'KX\DHCB?G9V<O
M+R^G]/9IB(=GFJKJ9]D3)]D+/@I^KWF:WGYR(I@_/HUQY=.],W(W?Y#>\-#B
MV>)SW;/T9O%15(<XH(QS%QAF*YA?].1IT.OUSI*[BT<CQ'N0-`O._O??7[^Y
M(SAV.FP';C@-8CPO@X^@>SH,G\^RFZ0-H'=4T-%!_IH'$?\5<H,^;I0?)W(Q
M=)S)XI6!$STEZ+(;]!6S_,K$GY7(F>`P=GPT.W7#<?*XVM/5$R(8BO*!LN$\
M2@A\@`,E8<MY/)\0V8O0>.)3:I-K(PP''T](TYV\A=-9Y)TH9VD[J8BY81##
M6:P@[^/)50Y,!3\>PQ_I7[U.WO/B'1C$*)YGUQ97D4>O#Q#$2H(.EBC*67;9
M_]?))Y4,$Q$7S08?SMB7\Z[..'UE/4T@1J'']D^&&L=79+Y]6I*1M[*\Q[P$
M`Z_P"J5UV;%7>"&_6N@ZOY1QL(JI_0-C8SIG8@Y'\CLR.&)T@$;E_\`XDL&6
MS9&K7(DL)IYQ0!)3FGA&^XEG;&;B56JS'P\P@@YV1Q>D)_@,_7`R)M1>SR8P
MB."_X?@)XATP?LE/.*1X%I>S&QZ!,9OXR$5QBE'Q$'DN=4TRTW+>)][)&'Z+
M"0-I&U]#UXG)`Q<S%)U\RA]J0/^',VZ72ZAG/*QO1FE73LBC[.RI[!R"WOD&
M?>*8#;_``&+')QR\\,8H0%&,":.?8<;$Z$\@1:TX<=1%%;KH*$^'(T_[HY_Z
M28![D.ZWOAGWNW]@#G<I(-E8B)8Q^\=E.!Z'P;<X='\_;$VRT"'7?TP)8D+7
M)`S(GU%9EZS0NRU]L1U!SX?UPO,05:2.?^\@KQ]<.A,4._Z?8HAK:7^;P_T`
M8P<%T+MV<$`LY8$[!0W'F4_TVQG@:M?P.+MW/+OWU/FKEIBCF3]*1E7*ZV@Z
MCJ$C$R@=]<4.W(@-1GM'QV%/'(?M#O=1M^\R+-CH`!^S-[L;U@VF*8_9F_U3
MTQL?[J.:WJV:WECVAK]0?%3:QR5?OF0<]?X^Y?4.06*.IF.WV9O]D9'^T<+L
M-"S8X';JHWG8$_.PW>$^ZO9=A@4;&N":_:/3IPAYR,$HW\KVXS-V?B+_8HAA
MPKGLZ@T*73S]>9CBX$%T_A4.'?\Z0<IL]%MAP6L#WT8"'^<3>#>XP-@)A@D_
MT\XG_NR<RVB9?5_2XV<03XA[,+]UQG#9=6DTCSX,/9W7[0#[.!V.TV$W>WD2
M\=ND7;_/CG]^1N'C"&)G`J<Q<B.Z%1I/0IQL@,YD^WZ`?D+,#,2;D'$ZULT9
ML26YY[+[[?@>)2%,2'VS,O>ZHJEDP%'6)&Y>M-[&H5=K/W;H9,&#M1(\'!Y3
MS?9,W6QR=96IQ].@>WH:=+]DAZOECK*SI[)S`,K\>/+S@$Y^'H(N.LK3X<C3
M_NBG+%K4.YK^XWH\\<,YA,D2V]VD$"V6[I`QH&0_PWO?"6C)L,,6J8L7!WLT
MA"L+424S9$:.E(/E@+4)IW<3/U(1V=`ZB5ZRCD=9/,KBJ^98;V^.BP(LV;UK
M)<#?1@Z&GYT(>G1YE`Q#:L*2H<=.0$3Q+H!'8=^HL/\&HYBX"(S?T'Q@CA/O
M34Z\QY?P./'V<>(M!N8X\78\\=*``="]!`>1CRXYL:"X!4+N@AM0Z2$/NI@/
M_YC2)-CS<O/"!1$$#WK<Q:`?GQ]:K!4?JLIA^+*J?+B,V](B7=WPR(2P2%M\
M@>&0C/((N8Z?PL@*5Y]_?I#1X1;6XC<28R9S:)/3LW8B5B^6\V?U]<SUI[2,
M?+J1YK`GZ!Y,CQVOXN]>1=7HA\0YX<G;VYFG5WG3!8]>U*@>ZBS<O0QN2`]L
MR"E.I*6=4UR27<E.<2*M+3;^O7W!WK-=@<?Y=7!JOM+V']I4V!\9W("C]<;U
M>UNAO9Y!=TI31W>#`7(A/DKLFEH3Q3[A93_PT#/RIKE7O,A<<ME]E-DV,GL4
MSC^1;#3.B=RY<4A^TL>)QS9&413B^6T8P\<P?:'.DSU4D=J#7,@5?(K[Q./"
MTW+_#<=C_WWFM^"P'F?.<>8<[LS9(],T#5`ZU[Y_NV)$?PR=:(KAI^S+J.?D
MB;RA_%:Q<=I25<OW$"<+S4P/B4NY0BA]\9:($`F"PI71;PRKR`I^BX7NKF!`
MY#*H[S`;'TI'U*3'U4;SNP6Z7^5>PK>H8FA>@_1JZ_?3E4$IMSTAOPJUW(_A
MN*)EJA,0N=VLW>7^8SI1J>:`:0^/SA"<*)E,/]"/M18_C:G0%I*K5+(5#[IH
M[/C1QY..?O*IV^U:1#%_..,U7N[V(HI@'%U.,28/Y/UJJ_WF!\5J^S4LV^J6
M.BXUWZ!G791BT]34ICU?P0$M$?(9!N27F.[!2!^^"3']([L>W8:!6T9G"/(%
MF-U>"5QK!)((,`79"TS3E$D`L9-$?\=S^FQ\$7BTIDMRP*<@_%U!9O=Z9EGX
MZSIK#\L292'0;$T0%^$V)%ST+L,HCG(@MBA_5'8DEVTWZ+8G3+_>M-]4E!9*
M4!4DU.P9/8VC$VH[$U6YEFU8/`54[HP6&D,Q'>.(#/@EZ0@1=S9P$5PB:*Y\
M9Q$Z#Y#_\82XI'#QY>XV?357M_5]7;C)-I/HWID[3SY\Q(X'&<T.1)6GH3+S
MN::S]JA$-:+>,X$45'?Q"&(6E:CN`Z!G=.M@%7MK#TM8]YE&3Q!6KB8>(/%@
MIBO#)ZH$N[;)5X/E?EIA$=6,7:O+5XUU6+XBYPGY*":SF77>1/6EIMEF&<AJ
M)XU!B.I1K:L!M14(HMF>B1E%1(QHA+[J]&BB[FS7LBRCA*6R+P:2$]&#R_0'
M->K/CI]HX?C2P7A.M/!OCC^%"W@<)=P(GFYHAEV&UZ3?MMSCZ.V&8FUTA;C'
MB#\'$D=I-^.8"32K;JJ)0^)H[&9VQ-)T3032US`8/D(\KA@U457=`V4T_&X8
MMSE-3Q')2_3X/?'H,(P13O-T@4<OP&3_.[U0B!FBPMSFT""JW#7-*(=;D@%N
MAWI1<Z)IC!;?*/6U-.BBI@BH)C`KS8`8%E&+!%3+[H(UL"P0B-HA$CFJ:J5E
M?KU?T:0*T`W5JJ1\#9.GB]H4T["8S):`R4N.X(Q"WX,X2HO)+G")&I8.\2=!
MF5.KO31&(6I+.J;95=NA*(PGX6(-)HX]$0S"7^M2$"#'6`@&[NT`YI',`W0A
M$3_BV]S"F,UJ<G1YL]C7M'1NW,3KK3TN@Z.?FVD&VS8$<24VB)O[-3@:NIF]
MMT`YNESMHS$&CHYN:'55K14&7K[?$`T%NKI>]GBJ$_[D0EKJY&L8+4R$P2CD
MRBK3KR@@8-A,+%OJK@D2<Q4)]\.CKR#1@,'$;C5(^*=$%Y"Z4I@##%`>(WZO
MK9!94IC5M?76P*[@!)-&RG!L.8RR&5-:[*L!BIX4IF@&L!NBN`DQ1,,@G>;N
MG!XLCAR7/O?%00$5M^\!AHZ/?D)OL1*C2IIQC-II@T4"%4#.;+69]3%Q*FJ#
MG2RVR<HT+8C0Y(AMMWG450:R/@6ZE&$`;<)F'@ETY3L?H+O@8IRX!#=3NCNG
M'SS`:`+=^&Z0'X5_0,-1''V?A.16WNJ"(DD&24OG\/K`I!,HQ\YIIE3Z%N[<
M.,0Q^IGHNKO!#0J<P"7!5&DAT)1C%G6=\7!KNA8`*<="ZDR.KCE(XG(0117!
M*YC^[`=,?F^!5([Q[)`';<85?`6!*&`Y=K;3!98F%_!J,++84R#'ZNK`9O?7
MO(YA#=1RK*QIO288[4'G<48AW=258TX[NO8:W$+G(CCE&,T.8-<4U@+*+(S2
M$I.NBZ?0XR3VNI*,I*$SJ[-BL*22)BD,!)8NGS2:VG"BT3T.Z3Y'[_/\>T3M
M[-V$[L"D)8B(I_J<+E@FNRZFY%IV,PR6),JQGT3A&XP`KH=O([3*,<,=S3#4
MS=%*)"#9+O,87KA_3(EC5+E#:T&7'*.=[-DH.MZ-@:Q-@!PC3FRX%`)69R=Q
M7F.,W!@F*?[%)CR.'1>`W=-?T0WEWOG,IEL><>A"Z$4W.!PGH1)5^%%9_!;0
MY1ASH&E<CC=$TVB2<]ZKF^26),-O,I'T>N@V0JDDU\%FP@J9E!:EH%!W+[J>
M0>RB:)G#L>1X$:9>3K>^VK\H7#F>@:&O@[9BH!:!8$,QDN,!L)Q?#]Q&")5C
M_HV5I05I=%X/!FF*9.:.Z`FS!R>&=P%_<7E!E:2('3`;WMI@D4"%I##>MDU)
M5/"?N4_.>[$F>K$97E(Z75--9I6F#1H)=$A*J&M=U08;I:-B:X?-64#5FRR@
MVEV]M_YNQE90N?MBFGB[J@Z$=Z'05&W.[WY0B#%3SZW>7;?EV&J0;1(7PB*#
M##DV//>!UR!CZ?K'$!,GBWX<O+`@;TO*<0/59"*-4G?-L$A*9:L6NU6@%DNS
M@,P6M87UYTH$8RR;8]-$'*NNO!"K>N=2C[,))].8/^@9GC!(WLV.[]?'LV5'
M4'P+6H^S%2?'=.%YB'I0CD\EID],^@3%CM\$'[`-W3!E8:RV-#_X7X%_=<L(
MT&UIZ#C&I9$=)*:;/</SZA8T[S_3*,X3+OSA2?9T/+%[.AX@:2Y",?P&\3-R
M8>H./$`W'`9)*R6#V>-8'ZX&6DM&F+VVFR9N1ZR49`%WPBQJ;_E[A);&(9'9
MI,Y^1(S*W8`HS0%$\10OM72/8UREBY-9\!'6P"R7<#F67"II)5W3CZ(I]*ZF
MF.C.5!#2,@VUB9D>QP7@#V>=5<OJ011([=_>)*>'[165V`IF(S(3(:^GLFFX
MO([0,HF.UF`ET4ITRR;R-FN2P]TV"M2F@;.H;]!V.VET-XUIF2A:5GN)DKN]
M6'A6]/1N5U>[!K-UL]AU4W\%J-71\,[<4*!R#XJL[V,0-\^2=5R#Q';5(,6$
M3==LLR<-'O<X2:-]`5:W[5!62W[U@41!R5=U&_2D2'[UT9$=2G[U\;\U);^K
M<]2Q&$A>:0YCK1#,`.RVGWT)?@!;&J0RJ;#.^/0,ZT\0_0"VR(E@@F:WW*KW
M0;D.>>9V%UPLM@1+$TY4Z$3-I&7V9*"3$NVD/2T);9JZ%C$'G91V*8BEAGJ`
M+3"S$:UA6/L7Y`*VB(WHWBB9M-7'$&Q]F^JQ$C)NK0['57M2-35OA#PI`YA`
M![8,3XI7`J<)M(UZ4C7U<-;SI"S3;I>GK0-9??95T),RNZ#7+L0IC-"]@^]P
M\M&H-"S/"YPN\3:M9;`HC<K*G7JJ%LU5@\XKT:8">S&-1R$NGDX#S4KK5*6<
MD@(43`&;RCYWY$BQU7G$DFXU*W&RK`%;LT<ZT/6S76P-GXU!W)YT-$TT-]0Q
M&Q:1Q@GD==!*D)/&*6`9.+<F+&RQ'C$'?0MRPE;RD0YT^ZQO&@[OQ3QEZPEM
M!FV]J\Y6$-J8KJ[HOK$U:^5A"D%I&F9MB!.-8R:)G*@.CGAE@)ILIJE,,YLF
M4'LM@R.AY5/`%@F2FB`QF6IJ.UL_!6S-H8W)ZQH0MY'I97?M[VR1ERUY).D4
MPN[HV:IY:A,TLU66*E?B=AHTLQ68^"@E!LW4+\E.]D?)9LK'D1-0]\0)YLD;
M9%Z%ON\\9=^-7'SB9PE94H4FS;"6]32$($FC2,X6(0#,;*>Z!(K:$2#G<(RN
M9H7FF@(0A2NI:)26K=NW@[N<*A'QN9DZ&T!2J:BNQ6QN+?76"(B<PRF6P7PD
MI@;(%TR<S7L<#E"A9+\<@V6SQ;T+?34`(><(:+(@T`@$B=&@@UUZS.2*<,H/
MDU,,3"$H(*EN$K`-YFQT;?="2"450$KW"[1#FI1+PD[Z98P'B,9/4QPE\S$K
M?0*].[Q:AP7(*GEDF\OS-RUPK`E>4K'`XN$A(?#Y`!5&AQ[,"8;$%X/4U<O&
MJO@A+$G5D0AVO6@/&P-9$[T<ZP(LH!OBZ!>N-?1]<OL+#"!V?%KOQ!NC`$4Q
MM4W/D)VHDFHF=35V2ULC&.M!EV2P-'M]Z(N*))PDBJR224!CRT)P>FT!2U:%
M)!MH>DM8U$6]#8,P?W!E:.48.F(\RDY15<=MX<FQ;KK!?*U+$%[*YB4Z.7:,
M^;Q'1:\MH4D*?)AZR(VPK=Y?&5991?HLH[PV7]EU:X22CO/KNBF$,,^EY/F'
MSTZ$7.J*(7]:W/?&J^#3@).\S(A&X*JGH%NH/5`/0A"QF#&I1JSI@HC_!]("
MGM"[>";C,82W4YJVNALD+Q8RTY6$"%B;U72/FF3'>ST#%(X?B"&32YV`T>)3
MI]F:;9M`+G47OA^Z-$O'7XECIW/CXCP_:L.>)@EI]INQS9"N1UWC9;2UJ;,8
M8[4-ZAJOS#7S)QMM_+),;>MT-MYE(I'.#E/>1(1.7EZ'5]2'P+?:^A\]M2<S
MK\.KTF.68#5;I-&ZK9,E[8#R"O$(\(^XY=JVLCJ\FCL"O`6::FT_J\/6VQ&6
M5V--\")Y$;8"CR#G#37[XME6DSJ\6CP"G._FM6&VF=/A%>`18+RFF<:V<SJ\
MDCP";"?/:1O-Z?#*]0BPF'[!P)*7TN'5Z1'@7J>KJ;;DC$Y%T9[6:CCY4I[\
MC`Y;ID=4T=I,7"TGH\,6[!%EGB4_H\/6Z1%DG+&1A`Y;ID=TE@*5^;R]M(1.
M1=&=UC.6>&::$$+NMC]>_1H1ONFV5IZM;;\7!BJJR+3FCZV"QDB:IHQXA5X:
M<*DZ9:0:&TYR511Q>8V;-8A[NTER\>JTO,;ZBB17S]`M2]NG))=649BE=I@J
MDEP]"YBRJ6N70-!XM5NX8[5^&D@S[2VG1S2VYDOE6*U/'6"_%KH%ZIH:4)G)
M'^+&;IW.IF98:I)KC93LVGL0-;:NC6ATKF??)-[UIDJ-K80C&CKFG\O9\IY*
MC:VA(^KDF\8RX[!)N))2J3H``G!KMS)J;'D=T02(;C3>RL@'PI;0$662Q1;/
M;K6G4JLH;M.6'[KYVG9&#Z+SZR!&\?P&^1!?$FTV#/%\":3QXN2G"]>%/@U@
MB&.4-/;AK*+U9==7H3NE,G*#(M?QTS,%-^1:M`30N"#+I__6TQXK&ZWJ]_^(
MF6=Z;;R=A6:N3%Z_BT991E^21X@EZ@<>G/T+%EC=M#3)R2<RIF0.=C4;%'G,
M-%R6,NH@1G>#>^)SDL?2&1IXW]`P0`/DTF+<Z7>WZ-&.T$<N@M$C0?*96+C?
MEQ`;;U3Y]'<_?N^A9_KJK]?>T,'?+BX`F9^FE6S>4G]5HGCNPX\G`])>9^",
MD3]7SI5?']$81LHM?%$>PK$3_/K^Y._#^/TO?Z'M3?)WW-`/\;GRM_1LPWNE
MT`:GB7=*<N6=$A%1&&1/1^@G/%>`.HGS"[3I<R4(,9D_V;5G!R/"&N;J2^*2
M+R_Z,(XA[D03AW[FHG`=!;`S8AX.\818I>A<<:9Q^%ZAK.PX/AF&<T*<@^/L
M$B*#2#M6)[/L2DP_NCL@K="V`OA>>1FA&":]%F"_("]\(:T#\FN(O26HI"$"
M_>EW1-JB#1(/*/P==L@;\2B[GS$"P]@=+=L<.WB(`OI(G#R6C`@=CR?ZR^W=
MX[4"E([RK?_EMG_3O[RX?50N+B_OOM\^]F^_*/=W7_N7_>MO](6SI_S5L\EQ
M6/=R6)WQY/W?0%==&24RF9=_Q,FB%]'W_L3Q:/Q)H]?D[PQ9\O?J#&\PC%5L
MYW&X"3ME<$Y4A/B,7Q%4KD2EP].)PTF&);OP%,9Q.#Y?#MDO?\G&!.<,?X8X
M)CK=SR60M%$627J.'@WF1=T:>_G;.?VG)@J6<_TL]FH?UNC3I4Y\.(@97>&<
M,EJ`WV@EU$5#6317T]I9C(O,.4LD]JASMJ9SRN(;<\0WKI@?K^BAX\CM@[5(
M?IK=4VM2F./T3?FCHY_JY)\$;?QVALA#T<1W""-10,$K?T7C28ACP@)"NA\Z
M<=9W,C(DW(L)\IGR&86/(Z(V)W!*S`-A=C]P3Y5_D)'R(?U,"B0>^`N*1PJ*
M(R6:/D7(0P[]2/([)1Y!)9N2AO4^B_KS"_;[_WJG.(&7O/<R(LW-.^%+0,+`
M12/S=\H"QM?8.R7/8Z@\H9`PF3#$31`Y/@DN:,OTTS$#&CJ1)L(@Z=Q;)F"3
MKLB#8WK2G+28?O9="0<*AN3R$_W>7$Q?RBE5)J1KB()(20K#Y$UF5/P:T?L3
M0B<9UCF%>4G<F.M91IUEO,_?5^!L0L*GB/86S:,8CI5_+)G"ODC9<JI\CV@Y
M#-K=XG[V[KLB"`5%.8GT>4>9H`E,AI:0583W&HFGRF.)-$3KVZ2,S?B5<E89
M.80=$`:4&Y3K/IQQ&WQ'FG#]:5+58\%'(MX)>J(DG*0@#X4Y)#:9ODF$DT@T
MQ'0V3]V10CKZXI!?(*:WDJ^KT1&\<9X(/=D5%G:2G87#A"]QF+.FDA,+8/'(
MB1/1*I#B$'DD2"8T#X!I:W"&DF\#\9MPIQ@3BL@[_]_>ES^WC2,+__S^"U2^
M-[695Y*BPV>R,U6*CZSW);;7=F;W_31%49#$"45H>,11_OJO#X`$#QVVY43*
M<+<J(TLDT&@T^NX&L+Q/$KT99KF1@W'T8`AC4K,#@!I@`T#S>XFHA96[0"JC
M!"?7X,-(CH4R'+6(&((_W1IG!E!]U@`P--1<A>GW8T"=:ZG)`.#Z;>A\]7PX
MU%'H2)]0K!`+^L6(CV@1SH#B29K*AHD;"Q<#2K@H)!X!G!4O3$.>-X9OX#D<
MP072I/-J'\L97L(4`5(N`G$K9S$YU$6WW3XN''Y<SA21$3"`"UB&2("W,N)]
MYSZ=^U+B2SY`&5GCOFW]UD)21?=$@-P,R)IX&;YREN"M8TX@/DC8.SA5D>@#
MM;IS^_R>?>A;)Q=Q[^M]-BLSB$^'@QU009%TXWN58YY$CJ$<22"K(9)?CM_"
M4I"S.%&!Q=Y:([0RN$@90N%6V]&[HQG5JNQN;=@5,`IG+CH-@5F)S-L_MFY;
MXERI(7'1TS`9"SN."$S"8B7GIT56DK'QR/%E0?T8>6$4VQ):LV*8&3'I)R[(
M,I2:_LBA,;S@#V9QR-.%#+[.I\AB0"5T.>3#TB_/WF[N;)B,2/-5,`;TA=.\
M+'>&B0\<'59&=],2)W60MP*LR+J!,XT#%7G,E><S*3I%6=82R,/DGPD)T\JU
MW`/;6R#C!G,"+Y3CQ'=BC$@XW*:&[A6$25ETD,N:>*2X*X_OH1S%T5))GHF4
M`&7YQYD_CQ0>1=`/<.OO/M`9U7\APV>QRCJG#+%!D9[Z/69JB3[L&;K/,TCP
MT>S(G_ERY12\T"@V$@ZV`]:IF/77+&,76$;-XW=LPV[!JI%DL#(#`JZK60XP
M[TIFE6KE*3.9`C,`%:Y*'<?!KD>P7:$VLBT[D;[.V<YY<5`V;6>`XT"&#503
M9_IZ=3.M_`+6603*)&R=2RDRR*J`NP!K$TZ:!`#PX/<#&=_C&@K&>!Z`A28\
MCL#@-W`GP;8##FNKMGEM5B,@300@R^#*C17;!9W]O-D$3\B0%@8C.<1:@Z%D
M@8L=42FP?)8N][VUW%M>;I;S\#*O39NABA#9$I$7Y."3Q,.))=->5JT%T8_4
M`Q\](+UY2UPG89206:[HC45SYA<=*9\PIY\BSPLWJ>/M=>V4"H&7_N;%F+'O
M2_`9`5_I*-%229!/@^^#IQ=`Q.,EPC.^65>`\(:A`;K_-MX]/#J]@U8[9X<(
MX&$^64*U$W!;G8#]B+B(43%0"\T3(K$*(D6&71-CB`@A'XQ%,]K%D)$MK`ZT
MVC'P0]2VT.E1_2(K4RW@E:OHMV&^*3HMZ'3@X>0\+_I=ZAR^E.C7\A8:N.`O
MIR"_;0O;?#[($_U/K^P?]PH_HJ<1>./85P-T/S6839,3S?+/E-&QF&D8!H$,
M-YJI(/(P`HL+MN'HM(N`P$(->IB!(\>*?=YJ@,U0A$%H(P6:!M=(LA=@'$WW
MR.V+3LPB<#A#NCW,55&'CN@',R>[4!:M74C?`TN+6#'_]K?(K(*M'107`;(J
MS;C(0$AF)<[5Z;;V*SD7TF8H?28-<M$L9YIZX_)44S.^;61\YT"$HR0DDVV(
MM.<#)_3)V1I)*2Y5+,5^J_:K[9X*7]M<.[9A5X'X9P+GM7-$GK7>,O7?J/0H
M,NZD.PE@)\=S<6=TDX6JOO;75*OXZ,8Z!^59R_MNKZ.IJ-L]?*/$573O^$,E
M3L+D:\Z?YRD7OBK$.X433HWTY%D]##&P3W".O_Q#.C[,2%I)R:!DH6=9:-)%
MEY0<C3@X@'+FGPZ(-1@+TX[Y^3C#1::G8>PP`M)@H3Z0.J`7LY5H2\"12L*\
M!-2!'0K?8H0C9B%LZX'P66.`+0H':27FO8D^@01%L?]GXH56J"Q#R%A]EF%@
M!+4+RD$<8IP)M4LP,8%J@F3DN#%U%1?P"5Z+T=CD1\!`DD:#T"$LI1VD@#TP
M3R/4)S"YIR$F<(2::+/P`*3X17$S0ZDVBW'3%NR'I<H$*L[6Q4H!(976-X(Y
M?49>YK8K;PTFU/HI]F9)",86:4*Q0!D4L_?ABS<%[08`RVDKW:-J,PL/+%!5
M]2)J5K@3K+"67;NV8;6"OZT*/C-73.-)V2OP1@[M4/((\%8Q<8#]D_LVRDH>
M@.,.I*_NT\B.=H(D,W2ZZM&0[<HH5@%+29`KK@M+@M505*N03T&F-**:)*@,
MV7"U1*+M#@7C`U62]-8<#LC=9U,[4XPJ1<54(1*.\01S8X"L&E22X04)#:&,
MD,L08,1/YC4L@L+",@WWZ?&DUB9B[74D]4D/:SES^K8(RQM2)?N8?11E%P7'
M&TT$,07$BK^%TLK,J8"H)+Z!B-PDHO0KUON,$`:++R"?DT,Q5)TT9'Z>.C"\
M\TFF$M_*B4OW10W@J'`.$--$FEA&&4]F:A44MNX>)#A:H407$HX.*3E(A)[\
M+".#;W+;8I\G0@TGLQ"07IJ#,L!XH4<J<Q8XU-/42L!6RI1:\N_"+I4D_UWQ
M_,Z`0SAB)&46'['96][#^%/M(]Q^%4*SST#J)$8YC"B;E6M9,R'$<4DP^71\
M+>+;)/-!60<8/Z>7VIP_9SP6Q2\*EC1VZ`0YIP#':V-R%9APALWK"UX$HM!0
M8FB:HGMD^K($0]<\_J'CDR4@V%;5"2BDM[#<`1&C1K6'=`=95RUK=FS#+N#L
MZRL,Z9B6_#M+BP;PQ`?J,[4U2=.YTT*"A%1A5&.S2H2%A0W%I.;2:)DNSN4!
M%%V<*IA!)^:E6>2O:]K;1MJK.<0N[%*)0[SL_"RN;_[3[+2[#4'Q=5AB\UW_
M?;/?P.J2<@5/=A2KRW9R=3@X1@BV=B.MYD';.H*M]=.Z'M0K)@EL=IV=NIU$
M4Q_M7=BE\M'NFJ-]4,S(5"&ZJT`_O[L\+Q=J9;F8G.UNE9NA>XK>]N?-(4CN
MSQ1BQ9'@%(]\9SKEY/J,([":`+83?*9^#C2(`&L@02!<9Q8E?L9*M.8`@VIV
M4_.$K:2VFB?LPBZ5>4)/\X1.&T6S7?^:'=%<'2M)9G$JU9=YZ`U4D+B<[-0A
M=>'TDH0\1P+L+,E*U<`%6P!4@)$W"+'6IZ']TXXN?")>,D`+8.)P[EQ]^+>2
MK.K#OPN[5#[\>^;P=QN9',\?/W0/*!<^TA$=XDG7]8"5)[H480-+P?>^HL@G
M'4/K"/,L*SCC+.].3LW8.O]FJ!.*62E((W)D<X2@#K`"43.%W2`W:JX4OJK]
MNSNS8U>#6)=<9(6S:3E;T>>/#L.RZ8`!"PI/8/6JCIO#H8^I:\5,$C+*#5.<
M`27IX;`>QC5,T;$()#9*X/8<:>4NL*I9E$NE4P2X;@^B`<ZW+D$0.0'/B12F
M]R'PV+V!YU%)3)=:,)M"YR@F^%%Q<,UN=H-X:W5DQS;LK<EQP1B"]O]SO2!P
M&96$KDXCQN(9CS2.0O9+FN;BZ3@EVA)8*`0<`0.6Q!/LP='$P:3F7#E7>M#3
M4*BK0BX[HB0J'Q].RYZ&7IR$NC*L#L!O:P`^38?N=,44\#*)<N%FT'[]>**2
M\227:1&H?'ZT$T4)K,S%%/4`B6L,NJS)G-(DAS(EP!P_$V?#AE@)EOS.3'LH
MDDJ86-<2%R..?U/Z61(@1;F<$H"5N!&W2.),`:[H<W)W"V25;S!RJ&^3H.=L
MBL[*\^S#@GEH@:[(C*3\E`,8%7+<BY*L>Y7KTIHR4D01<T%1(.N4JF^9JE,F
MP/]O'69M/0T=-76SS\J\V&JFFQZJF&8/8/90'RKZQE)`*T1#UN!S4?Y!;M78
M==KU@1A^>7&2A)$*KQ4ERMG-3A_<OO;[](!="WDI1UJG8ZS09[33;O_TY@'M
M8S?>*7;YTIZ1N`;%'K0YHJJ&?;ED>$9@J6L["C.[;_NZ\*]H@;MA7K$L6_Y)
MN%A<FEVI-&X;_)2?Y7)C2VJEEP1.,J1>(:Y"EAKQITCY9)(-#7OG^J)8IA7-
M^5QSD\\.9M',"77N&:6FDPCDEDUI3W\4;S`FV&HFM8U<2:Z+C?K29B+Y'B96
M!=R[?O^ZV#Z*F*HWM<#U`E0JV!,L^H4T>3`H%8E?G3!B%Y];+Y)XA,>D93$.
MY@(!H%EUI7<5CJB_"%F',R_01=NP'<[8Y+C#A,X0&THS2E]B=K7FM>CI`JT3
M,46A+ODS[8DW)"];9M9REXR1XX79Q)FS+$K\..M"8!!$G2=)PZ`S#.-ENZ>1
M,6R)],;.%>.0+L)J#`/E41(.-Z7\+(O`D/:#RL2`U1'7;FA)G1KFH):LF=ZW
M;6?K!^`-D7PD0XA`(?:QHP_Z2(:Z]>4?25#H?6D-O6)`S0/Z?,!N)*KK:.Z=
MPP&!I37_-R4;I!C!=:*G0(34Y[/'[?+V&C"XSV<V7_F@X:%&>K=XV#(C[LST
MH#E!TY'ST)[;6.OUVIW]O;W.<6VU/=9J*U1>9YMG28K<N60/'XE";2`-')^D
M5321,L:JIA(]97VW@!5[U"@0#E*.M"NIF2JDX!\D^.7<K;:9:INIMIF6$I>[
M2S;3)7`2'Z\D!GV)VT5MI\&D&<7.*D7/!3]=9<M>,GW-;GXW;;OD_?5MKM-N
MR.*%WAI@5NMGCYS"@:$)K9;<ZUMUA</7ZEI]T&F.HKVEVS)B?GRLW$\-;*8F
M/CM^(O,]&]JM=KN3]TI:<)?E)0QXBP/:BU#9K;ZD<4G'G6C=OR7,S<.P<+"G
M9)2SJ')5MD>-PZ-.8_^PNZ`D%Q&<>^&X<7A\V.@<%[I.9/BP`>84(I\,6AM@
M-4NK8JF!8NB1P;%@$.H@PC^!YI"0A*'B:]!686,B;<2QDS\@'HN/L'GX$E]A
MV]5N-]_I9=V-`]1AV*&L]=7LR5Y;*Q@(!'>CU-%2ZLS.)=$%C!X<=!J=HSQ&
MR\\=-XZZ[<;>T?Y:B$SS-":A?#RPV#TFB;B\S!1]&?L`TSV;=);@X8?H0N:O
M[/[(I]PB6'D?8>'Y.?^;OI/=/%A]U^JWNGFPUH]J_:CV*=<^Y2V!O_8IUS[E
MVJ=<\X;:IUS[E&N?\A;[E$N6TPI[IW17/%F*9"C>DOEX9=G:J6UTE+>-+L@:
MZJ!M]`(8@<??\OLO8,FN![L*ELS%Y?F+7X^/C]KMWO%A[B+Y);,RA#/_RVOZ
MB9("\4`"BR%9>Y,:_?1^_]X)A]&EC*]&<.9'DM/Q;K7-;Q9P7#;N]G+&W1X;
M=[];D'V@/5VZ0#`&FYVCWM[?7VT$WKP!>^:$F'H=7<N0?EYDN7;;M>5:6Z[;
M:KG6GOW:LU][]FO/?NW9_XMX]C.-=(4"D]=V^C"3F2BSM.@V+EC/.1SV$SJ=
MI%-=C8IC]ZF1;:83==94^%;KKYTC.`QP%K)U;0349UU]=UV-</7JC^%DP\'>
MI=7W*O?^\%%[#\<63NTNK7ZO<N\/'[7WP(R`%SWKZB^`-P=8Q7GCW']PT&<(
M`)!Y!(:3##];5EQWO\H,+2[FX^VIO9)F#Q:RW^Z"=9.M8_6DCP?RH`SD7K/3
M;?8Z*X`\`-&Z$2#_K<)/%\$UWRF^`,K#QT+96X#)Q9,N@/(<ZY@F<OA.J>$B
M*"O]#FML^-Y1[[`:S,6S/@',XT<B<^^X<[PA,/\-1U&>XG4G!JK>VFZ!Q3#N
M(UF2[[)JQ\V4"T`Z]2(7%.<DE&6?1:]"/G]#G\53#)@E5LM*(Z7DARB8GU=W
M9Z(KFN+B\K>SR[NKFXNSVS63+3=@DF46V>K"Z4W,LD$,IC2''M22ZKO/5ZJ7
MG+04*XO0QM"&PDCYOKI'Q_.WP_4FZ6@]Z[V4EZNG3MWH`SRJJ3O+ER/TZ+<.
M#<C/X_8;4.O')EU'.XM@7>;3DP,=W\XCJ'UN1_L_O1&O_F<)`E>Y`-F%6.T%
MM&,O+MUIMM*[)S3^V2?Y`E9W'SJS7U[P?U=Y$I]U\`VL!@@%Z"GXY46W<O(-
M<'Q1!:4F6./M?>L[(-_0L04C4]`R.^`8LPK&FS[N!497/O/Y:7.V^G?8Z<T,
M_CRH7,8Y"UA\-C(N+-@FZQ^;C'.">0-4_.2],'R\NV)C]I]S8U9US*J./M1B
MI18K3SV/I#'7TJ26)KM*O7NU%/E>4F15Y/Y)I_S)PU7MZ2*N?[!P\$V1ZDL<
MS,-/E%XX1'LWU!F-*HF<8!AQ)IJW.OU@PRA[&"6(`9SR<:B28-@T&8^N*^5H
MM%K50./XD0?K<.^GS?M0;IQ[,37.]L?A?$WP.Q;T:]#KPQ&%J_JB&^W!M(LV
MKY"0B411">.F,/S?ZV+57CW=>/I0.GG4BMN%)2]<?G%=G<9^NUM>VP,7^HAM
MWB>B^L:[N$S'>?HAV94UU0?T^Q_0345@TAR<QD'GH#['F]8(:&'/H@]L'"<8
MRL[PX@79YUFHQG@;S::4L5WG8`OH53_2##F80H1MON-HR/YS[-O35O_L'*S2
M%JMWI2)U_?'0KZBPVH;5_;7W]ON<N&?1$WK?0]O?S?W?:G_"QK%BDK?$&+.W
MGL6)L&4G>3VL%YS#NBI6=(QO.%>XN?M$_R2F]P1</9I#KNWJV&L<]0ZWRD3:
M@DW^\;EX??9_W+._:>UHKW'<.:Y9Q%_-=7*G8FJIH]-Q:]UGQ9GNMHXPQCM4
M":;*/OQ<%]A@9R'#W"DO\3,A:W,*T$&CUZNY6ZT`U0S@QV(`F]:"#AH'![6A
M]/`&&<O^VD1?M..E?=&>M_QF6ZN'3A-J)+AF[X/]_&5R>(USB`_29:M?/$RA
M\>?Y!A?X>7'27WU7XK9T2.NT*L+?A?S)]+>4YF&C?.RY@3TI[K$RM#G$:E0U
MRJP!;OPA7!51]\E0PO>)N4]WT7$IMY585F":+T6E+AD7U.J#J?N:6J%PN7MU
MMR[=DPM[@YA2U8IF"H]N)8&MPC8!76&=[D0.$U]>C5+<G/`-IW?(92O*;RM:
M)'SCEF%UT6%==+@QCT!='5(7'=9E(G692%UTN%OE(K58J<5*77182Y,?@'KK
MHL.ZZ+`N.JR+#NNBP[JFJ2XZW)8"O1]Q3?4!_?X'M"XZ_*8QX\=J!#N4.5<7
M'?X5<X?JHL-MV96ZZ/#'W=NZZ/"ON/];[4^HBPZ_$1^K"X^VN_!H;5='773X
M="?@#T/0]=G_$<Y^772XO<K/#KE.ZJ+#NN9H=VN.UE:`ZJ+#6@&J&<"/QP#J
MHL-M+CJTZG76K++)U^:<9)</G\I!?.YXX6]X^7-6O)1=)-C;>\Q]A_LO?MW;
MWR_<TK?&M'DXJYZH*!S:_Q'O[7ORM?%X;U_/W,^]WWXCSOL7-^*W_ON/9^+#
M6?_VX\W9A[/+.Z*K0?6)W&2%:&^_M;>_M,1UR^^'?[8%W%DUJU/I\/$;`>GK
M&]GYZG@Z`/D?],-3..T1U3B.O,`)7`\,#R>*9,S7EON>,_!\NA2W)<ZSM[T(
M+*P(+QH,J&QV%GHN7KCM6%=MA]*5WF=X9@1PTU.1`P)'C6!DGJ,A8-Z9`[9X
MK`27C<I0..FL\P;F\<'3),C@--$SCHN5@S!#?"]E@(C^)&,8!J65!XA`T&.:
MSUJC&#KQBON^MW>3?P@J=5P7+TO&DNP(U(VA$PZ%C%"`H9L?]LRFSHDG0R=T
M)W.F*2`OA5<S?X7GU`#OC:6B2*30)+"^\()9`MN?(&4"2>G]MP?V`B0UNEY^
M$"H'*%Q^ECX@!,2\.Q$./#V4D1MZ`XE$[*O[9[XZLR::10MXCSLC.J_%OQ*%
M]<O$8R+Q,@F<X1\)7G/Z,[$'%R_OUFP@8GK!;01ZDU'D$9U4LP-B>YK9P:<<
MKT.*K:3'L8<W)>-P$]#"@8`-<<Z1XC3,FA!K?O-=2:?[6EQEO$&33TH?J?S2
M3"-0L?B3*4T5J:HA!DD,>F(8*C"J''QF,#>2!TC)J7?ZN^YT[[7X6"$'<)M)
M%MQ/0%&`HQVC_A'"5MM[A\J,\]GQ?'QUK9,/4J'ZX/?J@_]]%W`1@/B.93CU
M`E0TLGW,=W=)8F#TJ$S@;]2(0L32G03>GXEA$5/GBS>%9^@]("+46RLH##00
MG*OX9)560HJ'%&!IH@":*2.<8`BZN!M4W$B0CB1#U&;GP@WET(M%Z$6?4-)Y
M."&(JR@B$0;39.NK*>X[JK86NS`7KZ?&E!=$<9BPF>4%KI]@4R&/K:9[%7Y"
M,G6=F8<1'_VRH5(/-=G$\<'P\;#)#CKCD'V1,:?)"29VG3"<XS#?@A!6]6K:
M<C)X)O"KB<#-7%:H7:"-$^%OY=Y3)((6-YK:VV_MY_%2ZE*4:C,.6S2B:ZN[
M#^U(M-1WQFZVF?_E=75/GWX(5OJ8YGT[SQZY=N;X5?\>#+]W\$1\"BM-)\H<
M<@>5+L->L]O[_6PZ\]5<2FHT=#7#R3X0(O._7`18E@C2^MIW@FZ[?<`/+?<X
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MNF/KN0K$!_1SB&ZOHA_JW]`RS4XB_C'UXEA*5ELQRH-/CU']H0B/L/773CN'
MH^9<.J%0,[:[E9@E,"^<Y/P[C>/V<0..2>Y5$5$S29P"()O"^W2$<12TCM5H
MY+EH1J-1K0"B4$C-?2)Q[\43#";)+S)TO<@$K>2?8&+A`#F5N],ZS!>FB!D,
M1K/KKI]Y["`K$X;3::!27B>0V350^W>FW'[V);ZM26CO\`W^;OXZ>O,S.Z$8
M09'XC+XF0'%8P.I()6$%7F?4=/.--D-#>-=^J9LW)'XR".5)`NLM)P@`]#!R
MPKDQ:'A[R76.",:OP+YPV-=B#P3V;0Z9!50RRN&?,*:P'MC%)A))ZZ1883*(
MX#ET=-A#4>AFX:I;XC>8'J'1$!L<$N0<%`+ZB`%D)`,WH=W)J":D>?\`<8%/
M8@3!ER%3/+PQ2GQ?)#,RLDY4."-/L+BS8I(83Q`G$Y12^,()@!@JGW8^GI#1
M#C(HTE&FD1=DK@"D`-YV8_WC0J;D:HXKK4NS-+UIM"OP$^]1$IG6Q]0\J'GK
M@I3#<T,O-9'R\8&I&DJB_8%<9G]V6ODT/5&R.@E$Y?OJ'H?EWJ'8/!EVTP%<
M.)DT?BV&6F$7<T_Z0X39GJM=H$^*T0#><9>!=TDMS,7G5`TMCG``9S<_R!MR
MH35'&/7SM#HE</.BXKO%5L'P*E)Z.JOOC63QG<C[DL<.@;K(Y!8+<G'6U40V
MI`*"4N0Q97.3WDS!J>@._$P:7Z>]"96ON)(-622\H(@,^NBBA*7J?L//:7XL
M:L$,8K*]$2.[<L4/Q&;TH,'_K?E$G]G$F1;,UR274U3O?7-4?[P]!0!I(05_
M!JH%#T#UYM"Q(:JF?[2,Y$DM6Z\Z%>XY3OY>\>!O:"T;8H[VR#>X)Q&,CVM!
M69:BZ^#IZ%JP=IP>U0IW(J\"N4%G7'=_`PQW&78VX!N^3'`EF),:Q2#XZ1B=
MJS"WT=DF;,#+N7H3[N[5XS;A(I;3,L?N/M')O`Z&O@6_V(#+<^.X__6Z]ZR\
M92B]UWTTXO#1<]\99^BH]DA6>89&0`SR[Z]*8V53Z#SL<]#_'/__0)\\"X:G
MMO]SO]HQ5S5;L]GI-GL=GF_1P-G4I\JE<"4ONS3O^OZO[#-/73EP-B_L-V;>
MW\ZG`^5G\U6KHU7S7;__#T^4&RF;X`SH)9[?R+$781YI?`G&>#;/^A=(7-]<
MW?7?7_Q'O+VXNOO'V4W_^NSCW<7);4-<7)ZT_HMAJ)JLC..[^<P"H5K1J0*A
MTV[^*X]4'"ECON]!8P@BV0^&M\ELYL_[8S!]"/<*DP\\QS]/8A`0FN2)_*^"
M2QE?AVKDQ=&9[TV]@`_+%#,2,B#WJ\)S`$^O\SN\#/S(^_+64V#(ALY,@GWM
M@GKC:F/9.O>I=7^&E0?ZVSY[1ZY'WE<9IC"O%;WK[EOANXTO/\/LM?95\?=W
MZJV\A>>BD2>'=^J&,YYI[WTY9.&8H:XBL@G,\J#9.2)\>$//"3T9:62\#9VO
MGE_`PN_GGG+#Y.M*G!S`^3OB@A^-E(=#GJWZ!+NJ4N8;/&2QSQM]XPVZV`'A
M=,D+<\RBMK1_N+`2Y'?>[RHR644)E4K.@5[PHX'>Z+J/EJQ[_?/R*$3L;0X1
MV7=7H_XP\>-W3@+".;R&,5']N`LENJK^[<63CW#@(I4A8%VQ^/0S4(F$CB'_
MAZZ@H$'E&59%)='!^A+Y62N)-G?O6)8%0T/_Q:\<TX@H7("41FMF<;ZL/@N,
M[><"8Q_?WI[]Z^/9Y9TX^PW^+<;%JI*=ZAW]_CN:C_;]Q7<IC4ANS2[Q?[/D
MOJM`7+FQPAR[3K?J?D?J6T_A%YV6JW5/P9)6I#+'%`;ASQQ7Q.@!Q@X:)B<7
M54H`;\XS%`=HB5LI!7KS1:<E0$9%"49H5DR;AS92_I"FX@"DCAFYF5Q7`8<W
M]3#*/#"=H@\1]O(K/Z1&XLR7)*`!`/TT!<-<CEI1N$6X3C01,]:.%P1(>P>M
M=F50J"7Z$57CF4`55OWEE^/@*O-%?[BXD/5E^-K`")!=1*'#,:H%T%)4KO)5
MUAY:XF,:KUT/V_>P$!+E'FA'5$?F!,G(<=%D$,,P&5-P,G8"ER'@T1IVZ-`$
M&76\CU.\AQXY?5OB(A!89HY_-0H9OWAYHK581\Q"-86O\;9)S"'E#5J2*MKJ
M5NY*`\AV!I0KN0(O'[QFJL*PO0O69.)3U-%7F&JN4U;M".,R1+8R1HFQ3(+8
MBW2$D2H]O>QD=MO=]@.PEFUC>?L,NG14.CTWN#":T]S-F8;S`JJ'53S@$%-F
MU8S(G:==<G`H_GO0_NG57OLGC(#"^L:^&F">=@-)TT_0^V`(%X=[""$:*H^0
MS\RP+@#3AQ'03AOF`S@,]`U>BS;9*&#MISGD9KV-%#8:0Z_!AI.!PP)(8(C%
M_/,B##A#BCUFAKAC$?V0WG]*<>R%#%5JZQI&X-_^%IE5T.^XD"!`GJ,Y$%%@
M,B,6U.FV]M/P,^VK[Y@\DJ6[EO&#6H+O@@0G';KZNIUZP[9QPU:J7&"3J[S>
MY>A$*>.:LK6N3)MI8()8JC2Q.E8A-&TIN-\XV#MNM`\+:2M9\E@IM0U3R2("
MAM@<L/@QP#)&D9>FIRW-%VL7U*%RB4:%H.,4-19WD8QQ;EBV5N\6X::D8"UZ
M,!4F$\P\2W6N0F[>42$Y;^C,!3HVFL!Q:1=0!FBXJ=6#GF=HT%D0NH#/(:C#
M0`JAD;:E1*N)`W_E2,$&Z7@!1"@#'+.XJ,3'*Y)J%CEM'G"K-O`/^BGSXQY4
MAD`Z;=O1PP[Q2B_WZI2.?2!>H-TU+]9.`5QK490<7;&FRC#+8]94Y9Q/_=`/
M`B[S/EXZJ'I?C:YF.ALONE:^Y\XKG'#?]Q[P!]W5_3!IM4BZ5`F2==PIFQ`0
MCY64U?*E)(\K!:>^#CQ6,PV+_L)T.4M=-JOO!X<Q\I(7NTIXHWEN1[/[%/3Z
M\RK*HLL7S,/=+'W;[D.6=Q/J]@&#%8,N!#4=Z)T,X(3X2T9;T4#LKZA:?5.?
M8YY\XPKRC1><C]H/N0/>8OKO_D'K<%&I^>9VI]?JP?\VP(U_G"T:>M',=P"1
M7H#`YWI;CGSEQ'INVAD3?16%\&L#ZS9:XB5Z5R5U@?'GK`B3`]8*4K)YDU5Q
M:`78*N1@%PV^=S^!X>9-=8\Y_^D@<U#1#1COXV&KP9UI/`5(!H2X!)'C4^V-
M$WCDL7(3*^=^+<<5*.-J.L".!-0'R:P478NQ1.=-+HT_4^/A=S!Y9(P5(`#F
M":@Q9U_TZ@[WWICWT2&$UWF1C3./8CD5+ZW2EL*+7-_R,:U/2'_7[Q8=HF:)
M^+PC9MY,TM;"LFSP5BTQ5UKQ-^S$X&$:B(4OQBR92@-L*\=%3C-??JD<L*&;
M.2!8*1Z-.S'&6++IT3$&F8QO`G%2&SL\S0E&%"*A0]#XDT3+#7?PW!G`>O0W
M1;`QERB6X[GVJ6K4+,1$"EC:],A:"OD$HX0*9T(<37[QN':F<@B7$\=\T_8(
M^_KIY4:42!4,84SMJKU3Y"W.[R6B%E:.7;G09S\WX&.=B(4R'+6(&((_W9JT
MY`P?96@0;&TV?X2MA=]N=8S&N#<M=RQ;W6EKIZ+3&.<)*,524]DP`>O7A<>\
M(7DM82+@K'/=R6Z<>11<($TZK_:QA`%PR>3USSH_=-OMX\+AQ^5,$1D!`[B`
M95CE9[YSG\Y]*?$E'^\[ML9]V_JM17$J,(H"Z6:!(GSE+`&ZD4X@/L@AU@/!
M0OI`K>[</K]G'_K6R47<^WJ?S<H,XM/A8`=44"3=^%[EF">18RA',@QU79;-
M;]$7C;W=H@*+M7-$6AE<ZS4-J36CK=*,:E5VMS:,*H3GHD.^W2[S=KIS_5RI
M(7'14XR-]H?8$(LD%3()BY6<GQ992<;&J35L7OW@,E1+0FM6##,C)OW$!5F&
M4M,?.32&%_S!+*Y!9;[!U_D460RHA*Z.+)'TR[.WFSL;)B/2?!6,F^B7S<MR
M!Q/'Q$RGC.F*8N2M`"NR;N!,XT!A1!"Y,B;W=HJRK"4R#QH&#"O6<N]$BV3<
M8*ZC>V.,TF)0&.AK0KU160RQZ*`N8B$WLBR/C\U[)95_&DF>B90`93DGP.%1
M!/V`^AM]H#.J_\IB::QSYIS9[P$Y`0;_0A`3008)/IH=>1V56SH%+S1*W=RP
M';!.Q:R_9AF[P#)J'K]C&W;K85(+-1HD!@1<5[,<8-Z5S"K5RE-F@@T!J*B_
MK([C8#HFQ4:V92?2USG;N1RDRYNV&`,+,#[HD*V*5>5I/3WE-T08=/*Y&(!8
M543E`%D0">'![TTO\8(QG@=@H0F/(YA0)8<G*7,B4VWSVFPY0>S"SHE9FJGF
M!&E>!<YZPZEH0W&6+O>]M5RN?K"BJH6V$XM2-&R)N##]K7(MQ92X)R6\63E?
MRU/?7,[=ML28L>]+\!D!ORI79*,)<;43<%N=@,^;J@BK`ZUVK!ND/"11<1']
MKLITVW":VY(F1VFWC4+#CE>Y;,1B-X]OF"Z7S\XH`O)7SZ/+M^<IM!=]:H)=
MCFIJQK>-C.^<,J=#,MF&2'L^<$*?G*V125??7[.7<*W";Y,*7]M<.[9A5X'X
M9P+GM7-$GK7>,O7?J/0H,NZP8SWLY'C./<A&.>E04/6UOZ9:Q4<WUCDHSUK>
M=WL=347=[N$;):ZB>\<?*G$2)E]S_CRNPRS$.X433HWTY%D]##&P3Y":=?U#
M.C[,2%I)R:!DH6=9:-)%EY0<C3@X@'+FGPZ(-1@+L+7'S\<9+C(]#6.'$9`&
M"_6!U`&]F*W$I:WT3&"'PK<1-0TC(6SK@?!98X`M"@=I)>:]B3Z!!$6Q_V?B
MA5:H+$/(&#O=!490XP4`<8AQ)FIC>!]8-2=\D8&K+\1R^!$PD*31('0(2VD'
M*6`/S-,(]0E,[FG0135-M%EX`%+\HKB9H52;Q;AI"_;#4F7PGI1T7:P4$%+3
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MDOC&RT"3B-*O6.\S0MBTQA'<RU8G#9F?IPX,[WR2J<2W<N+2?5$#."J<`\0T
MD2:64<:3F5H%447!K;FW2<+1(24'B="3=.<6XYO<MDD8Z5)5]DK0LVD.RH"[
M#^L6K_E"GUH)V$J94DO^7=BEDN2_*Y[?&7`(1XRD52&7*\G+<[?:1[C]*H1F
MGX'428QR&%$V*U^`F0DACDN"R:?C:WCQ'=VU:0=E'6#\4;'W0-YX+(K?7-VG
M$^2<`AROC<E58,(9-J\O>!&(0KE7/47WR/2M+&\L`<&VJDY`,6WA*)5(JE'M
M(=U!UE7+FAW;,*M?"AW3DG]G:=$`GOA`?:;N=VDZ=UI(P#<EH!J;52(L+&PH
M)C671LMT<7W7(QHE4X474G!B7II%_KJFO6VDO9I#[,(NE3C$R\[/XOKF/\U.
MN]N@6UA\6&+S7?]]L]_`ZI)R!4]V%*O+=G)U.#A&"+9V(ZWF0=LZ@JWUT[H>
MU"LF"6QVG9VZG413'^U=V*7RT>Z:HWU0S,A4(;JK0#^_NSPO%VIEN9B<[6Z5
MFZ%[BM[VY\TA2.[/%&+%D>`4CWQG.N7D^HPCL)H`MA-\IGX.-(@(L#,%UA$Z
MLRCQ,U:B-0<85+.;FB=L);75/&$7=JG,$WJ:)W3:#>Z1F-:_9D<T5\=*DEF<
M2O5E'GH#%20N)SMU2%TXO20ASY$`.TNR4C5PP18`%6#D#4*L]6F8"]1TX1/Q
MD@%:`!.'<^?JP[^59%4?_EW8I?+AWS.'O]O(Y'C^^*%[0+GPD8[H$$^ZK@>L
M/-&E"%N"5PM^I8LD0ZKG)AUAGF4%9YSEW<FI&5OGWPQU0C$K!6E$CFR.$-0!
M5B!JIK`;Y%8WHMRU';L:Q+KD(BN<3<O9BCY_=!B630<,6%!X`JM7==P<>QI2
MUXJ9)&24&Z8X`[Z0%&\CQKB&*3H6@<1&"=R>(ZW<!58UBW*I=(H`U^U!-,#Y
MUB4((B?@.9'"]#X$'KLW\#PJB8$QF=0[=(YB@A\5!]?L9C>(MU9'=FS#WIH<
M%XPA:/\_UPL"EU%)Z,HH+;;R2.,H9+^D:2Z>CE.B+8&%0M1YW@N()]B#HXF#
M2<VY<J[TH*>A4%>%7'9$250^/IR6/0T][*C)E6%U`'Y;`_!I.G2G*Z:`ETF4
M"S>#]NO'$Y6,)[E,BT#E\Z/Q\NV0+BO`A@Q`7&/094WFE"8YE"D!YOB9.!LV
MQ$JPY'=FVD.15,+$NI:X&''\F]+/DB"]'9ON<:=,0Z!8SA3@BC['Z@GR66:5
M;S`RWDG@A"CP@CQ%9^5Y]F'!/+1`5V1&4G[*`8P*.>[%DM;`:[63M>Z]TGD/
MYZ&:WCH^O$1-=R^"DUP!<MI^MO(*O[7;Z#[A`KS>`1]7?=G56F!O\IZS@R7W
M`BY;U9++WZI1=&8*+CE18YU+P#JM]C9="7=0<0_@X\GB][<W#[A([ALB"EN)
MQ>=2VA>O\16+G$F4HJ/Z"M]O=D%<>Y^7O`)>ZV9C;%Z=WJ9HIGX/7WZ<%:XG
M/JB\(G=]?K#P<+SX];ISU#[5%PFO!.AQP%?>W+<^\&>F[_L5MWU/(3]^*."F
M;?BI',075"A%-^:"6"[<3GK8?B07TNTW\/'K],(=+(*]4_S",IZTG#/O=35C
M7K6*96O]@"(+3,O<7;R':S>B?\:U_XJW^/`TBY9H`\^+!-7GT^N14C%>$/0>
M_A!?Z"MLF?7+"U@/@?M"?QLJ5$LG<3Q[_>K5_?U]Z\L@]%LJ'+\"U/9>X<^O
M\,$7-+@9'@1Y;E3X&^UN,RBP-^G_\N(SMISOF"\G(>+Q_P%R.UW@TJ\V.>!>
MNSB@04!N5&,TP`A3'P;%GO$R:'Z\+<QC7NX\!$OF)<24^?^-N1<JTG45H'-&
ME/V/.J)*(E#,LJ?__BH'>N5Z^F$>4:#>&2!'0&!%',6J8C7PSHH%Z2=>89%D
M,UV8H%R,7UYT#+(+`".Q_8K+P,&\U_@O_/G_`5!+`P04````"`!0A6E'.\I]
M5H,,```UJP``%``<`'!L>"TR,#$U,#DS,%]C86PN>&UL550)``-($T%62!-!
M5G5X"P`!!"4.```$.0$``.U=7V_;.!)_/^"^@\_[>JZ3]+J'%LTMTC0I`F2;
MP$GW]FTA2[1-5"9]I)S$^^F7E"5;HOA7DD,FO9?$EF>&,\/?#,D117W\Y6F9
M#AX`H1"CT^'QFZ/A`*`8)Q#-3X=K.HIH#.%P0+,()5&*$3@=;@`=_O*?O__M
MXS]&HW,"H@PD@^EF<+\`@]\@RJ(Y&'PA>+WZY^`6/P*R_?5J<G4W.(_(%*/1
MB#.G$'W_P/],(PH&3`M$\Z^GPT66K3Z,QX^/CV^>IB1]@\E\?')T]'9<4@\+
M<OYKDNT8JL3OQML?JZ10(QHB;F&\%YUJB'^_9HKL*46E']_FI,?OW[\?Y[_N
M2&DB(V0RC\>__WI]%R_`,MH30S/QJ*(WA1]H?O$:QU&6=Z?1DP,E!?\V*LE&
M_-+H^&3T]O@-,V+(^F\PV/8@P2F8@-F`__\VN:JUN2(XBU+X]";&RS$G&*_2
MIU$<3RE3-^?.-BL&*`J7JQ24UQ8$S$Z'G/+DZ/C=T?NW1[S-G_:LXX[-4QS/
M6BNP9>ZFPBH"24L%MJP=/8`HAH`DQVV=L.?OIDB&80*SMJ[8<7=3`K9M'W;O
M"(8FW`&)N*Y`'*7Q.LU#GR>HFESPE`&4[&''=;"-U;R)LI$4QS7!*4\VF-0U
MKB;D642G>5IA@\D\BE9C;LH8I!DMK^3&C8Z.B^SR4W'YCS-*0;9+%6DT!6D^
M)$E^S&#&[1%_'/M5_7Q-"$"9U@*!1FK(CJ9N3Z6_STC=M(C$I43VL='9]51?
M4(SI>KG,I8U@!I8E_XS@I=+MV,Z<\[VF@P^#.L<@PP.%#$P20-BD9#AX!'"^
MR/*/WOKT/**+,Y3P?Q?_6\.'*&5*TK.,36K(ADV7?HO2-5#TM1.O@`%+WE"P
M(2(`=_."#CI%4U4$6381%K*N832%*<P@,*0,-:&`&1FAOV08QWC->N$VVD33
M%-R3*`&&U&CF$!.ECL-_:&@Z#K<Q6QX5S59JR54G/=B`8,%\E^'X^P*G3$/*
M@SK;F,-#RZ8.%@6;-T=8FVYMK-D\S_&A[SGL8+(Q2*1-54-&UD2PD?(5H]AV
M]&C2JF.B2NO-SL]@!I@.R00\`+0&1EN-](*]&OJ@HD-B"':WVA@9>\YJ.&C$
M!QL5YE@P1T!@&)#UO$UL&WN]VM<*@6'U<PG(<TR5A0(IC2+Z"QK_O:U>9NO,
ML5UF"S**/CT)HT^O$$LN3/;F*U`E=QF)T*-UDE`Z5#/WU]CDN`2N2PJK<X4U
MR$VV`,1I*2CCT"\%ZQS^D=!J*:@QNX>E8%UZ6(@YQPS.)(-,S<]@FADG?D9Z
ML;JFI@\**_J)GZW5+2=^&O$6:`E[NM0RJA1SI4"CB(WX$('D$T#L0W:;1F@[
M?%QBPK\4U\U+R-9RFA,N5SG^,:6=E'5RB\/$S;6=`H=OP\!A.?!,0`S@`Q][
MV"3%;@*@8U',`.0LH0#)8O2WL-EQ<JB7;`&6EU(=5"_PNY<%:[+#"K!KC.;W
M@"RMYDIZ8K$>HB`."A[Z69*5O2VG2"K98<'CEN`5F\AM^&B1,9QS;*^63%'U
M8MN&18"*GL4_8-0#N8.QMF.V7F0!CW\%`@^`^#Y0IF6^)+S%-",@@P1P?=E5
M?@$L5RG>\`N5:0AUN0]QH%9$$/;=BG_<6B>ZPWJX98;L7:FP8D>X.:*?U.J)
M]?>F`IK(VM6RK(QM4\92"2YO4@0RZ.9PM]D1J"84$"$C](\&X[+&:)_C8D8F
M3]?W'\>B;Z[9]T/OH,UWC(>U:?$6$(B3*Q03$%'P&6S_JRJJ+418;6%4B?`6
MJ!>S&8BSF]G%4[R(T!Q,H@S<(+GR"F>U$2$XRTV$_[!OA0_<B\OD^<)%H6HZ
M<5,DK#OAO(K#-&2+C0?(DM2GS3<*F+$W;.G!W(/F9W$&'[;C*$;LPII=*W[$
M2`7F?H0*\.XJU*>+&7KP$EQCJO%8DZ;I@"J-_P#NJ9NQG1OD,=M-AVH4"VV_
MB#"]A"A"<<]AZBC4+DRMA?J'===QJ5>W]CM2=56MKYN3LB?3_O@20<1C[P:=
M+?-[#9=K/F^^0A-`5]L!-E_E`S#A;=-O*\Q^*@L!`L;[$UAT1!\"_6.[OY3=
MNX,/E=_[4+2)^U&`HP'?P$7[GK0Y"K4;#:R%^JMH1WDU,;]#3G`,0$(O623E
ME0.)]JJ*=3LI8D7:54JP><853+@O5SHE%TLM:S5J5^UL,LHKFORTRR+/,OFQ
M5BVL.[)L(",9_#-7[F:VF\'I=K3;L(@[8K0L_N':_Q+4P4F'7I'J50D+CM6L
MEV^"N5GE]EP\`1)#NB]_-W<)V/$UMPJ8^()%I^M*$+=WEQ-$+?42-BF8]`D+
MI^(`D2\!,@+C#.0CB@*FMFR-ITE,;,&"M,-4S=%9AYZ;F=5I0O153\;:U>&?
M93)FK5I8>SCN%A$!GYB)R3E>K@"BN9J*7*(G%A^[5Q#[!V?_4R\KQQQZTJ52
M(BS`E>O->WP6L[`C0+E;T%"9L!>@*$K8"`@6K#W4(YP=^%RE"!O%FJ#V6M>\
MQ(2I@;9[<N+-/8E8^,7<PK*`^PVQD22%?RK7$VU$",AV$Q$LMCLDX@Y./'1Z
M=E.MP/?/@>!;NY.UV+AZ\<0''=6>JA827+8WBQ)>([C;N_#0V';2K(#VO\.8
MCS376,(>6^MUM8+/N+!N\+U&[+JZZ]"(M="GP.G[4'':?+#1&JIJ5B-:9:P_
M!F"-3GM^S,I4*K=_'04R=6AJ71[7HK[[;,5CA&J-Y\?`J-I-SP_.FBXE*H^#
M1:5P0@R;R[`K9`T2\]%JW819IUR]L!\#X"T<ZR\MZY4L0R*8`U-6!,105_^5
MD32>W*N2O$9,:IQP:*35FRXWXLCPX^.YK_Q%'?]_S-_/&3/K)>]-D%0APCZG
M(-NNRZL[,EPK[GV+;YY=TY-X_^G&"E/XX*Z5)R*=<L*).3TIU7P4Q6\54Z7I
M%Z)^P,F.R391%$PO#ZE.;NB&/U-3FF<YO#SOO'LYE+_%3`8(H(8*O(*JL?P0
MJ#PNT6J:\&.&+I[B=,U?U%?-/W;F&MGU?M"P^X]E5<_BSMZ0![(@K+X8LFVG
MK\<4I4]DU3>@<BVN*%WSUP;*MAD[<%2>J3)R!`T,=YNML6`E.K`D7KY:S_=9
M.O?1T_9X#_6Z14>J.$>G3NK]P*"=.OS=5-N(2%/\6+S5T\IF-:?)!3)._Y&J
M[53)R4+VCI"'K:P]V4%#VG8"F]XW=-Z56/CNBOQ]:#-,'B.2F-Z<X"#!!#>=
MA!<,.VO']`0_77O!'3Q=5[V\L#VCP19Y<BX3VD2N%XPPK0-Z0I781EA/?#34
M91_*:\5TJ[K3EZV4R^.P[\`#"Q>6H\LME;:HZ]Z"":%=6GC!:.[-L3TAOXL^
M86TH;V]:[T'1>PS\&)#WC/`=H-\%"FC7^S7N`DR`#?J>2VN`=KN;X@Q(\WV2
MGP,%X!7*GY:E=`(H8%W#GYO[S,:%%#O!T%*,"8Q&,2\8DFXNZ@F8QD8U.[9]
MU.J@OS+=X5_5Y\.82?3X:Y0!`J.4@^5FQH%`'C3[W6P9589K&/U'K[0'92\N
MM#5?53G?-R-]FZ%&?%AG/.XT_B\FWW?9Q`E)9DX5E'2<+PA+U@YH"2:=_+`*
M:#N5+R&"=`&2+Q@G;F@R<ZK0I.-\06BR=D!+-.GD:XIHOHZCQ]XF#,]RA/)S
MOMFAK,,;K=)0BN]VD%'Z#S9YMV`7"Y4;@O<<M;<[R`260WT@Y;9\#Q8;1F90
M-0&64`@=7J/PW]&Z?L0V=LF[62*VVMDU<>4(W/G.@W0W3/%((\T?SKU?1(A7
MPB*TR4\,N6+?4M:%>+OA_&Q.@.I8XDYR*CMG6LKQCQ09!'!_OI'CJ-)HN;NF
M96,'W7+5$E,M(?0*$'-(@#CA(9!Y/]\8QN>1NJ?NI32-]YO7:(+%@(U-5AVN
M$&1S-ER7,65;*ZP4"GE-&\TA`H"P4:^XZ=(LE+7DKHT?#MS^^]\PO^CF#Z>Y
MAW-3)8:Z@ZB?'"&O4.OWO5OQ"#G$P.,/4VW!@MOYHXXNQ\:KN<G0:&_/PLK?
MST$BE/&77$\`7$[7A.;C7W%J`DANB/((C9;<U3=ON'"_2%QU\U%GA#DW+WEN
MUFM.NP,IDSG_`A#+V2E_N"Y9\O):QC/X`]`G-S=F\8A.2^;@A]!.WFBU>K=M
MJ=PK%<H`^A4C7+=,CR\CO5BG5-/[1Y&QHF=KK6-=3R.V3$:!5/?R@D)573TZ
M3.2RE_A*R0/`AK'KQ=?ZFNU6P$354N-%O](60CO?J:&I=I^[@=H$F'#VM7?#
MB\.F]G9P$7:TGQRYW(TK?N!_IA$%[,I?4$L#!!0````(`%"%:4>3,_&[HCD`
M`!=#!``4`!P`<&QX+3(P,34P.3,P7V1E9BYX;6Q55`D``T@3059($T%6=7@+
M``$$)0X```0Y`0``[7UK<^,XDN#WB[C_4%?[]>K9/8^>V+X-EQ\=CJBRO+:J
M9N>^=-`49'&'(C0@Z;+[UR]`239%XI$``1!0,:*[0I82R$P@D4@D$IG__A^/
MZ_S5`R)EAHM?7W]X^_[U*U2D>)$5][^^KLLW29EFV>M79944BR3'!?KU]1,J
M7__'__O?_^O?_\^;-Z<$)15:O+I[>C5?H5??LJ)*[M&KWPBN-__WU37^CLCV
MU\N;R]M7IPFYP\6;-ZQQGA7__!O[YRXIT2M*15$V?_[Z>E55F[^]>_?]^_>W
MCW<D?XO)_;N/[]__]&X/_7H'SGY=5,\-VL!_>K?]L0V:2;K."L9A^M)U+@'^
MK\^4D!?(+M'??VI`/_SRRR_OFE^?0<L%#Y#V^>'=?WWY?)NNT#IY`<[4P&]:
M=)?9W\KFR\\X3:IF.I4C^4H(P?YZLP=[P[YZ\^'CFY\^O*5,O*;S]^K5=@83
MDA*<HQNT?+7[^/7FLC\E5"[>+;+UNQW,NR3/*<E-#]73A@I5F:TW.=I_MR)H
M*21_/[>,JC\Q>OZMZ>W=<*KH9U2PE?!F@==)5E@DL=^U#7J;KMZLT?H.$9O$
M'O9K@=(5)8JD]1UZ\SP0%NGE]FY7'M`RJ?/*C4#L^VY3O">W2ROK>$-PE>39
MX]L4K]\UA&[RQS=I6F*\45/(8#^^__"G][_\]+ZAI-UX.`EIEBX&$+%M;H>,
M(8.Q:S^,D#PI$]/!V+4=1L`F0:;XMTT'3H2Q)`Q&7::%*?)MTZ'HZ7I*2'E?
M&4_`81=#R<&#*,%VB!@X'M;&HAG5=)'@<C-@3`Y[L2,O0X7%!B%W*3+66B_-
MAY%1X<QX_>[:#B8`5T\#2-BV'D8$V52F%&R;#I2%9%/G>,`>TNY@("G&`U%:
M&8<!(S`(_5E6ICDN:X+>W'[]='O^GU_/K^;GW^@_MV>H2K*\-"`,TFF;9&J@
M9D7&CI3LX'N`#SU6J%B\"`@C&FZK-CCV6'*<'G2=LV,L)H>\M"WV95+>-?9U
M7;ZY3Y+-.\;D.Y17Y?Z;ANTW[S_LSJW_MOOZ]W,Z2/@)H5M$'K(4W:X2@C[1
M<^[B%*\WU"IOCL\G>;X[2,^6-XAN@47V!UI<(Y)A"E=6)1T,=%FA]?,4Y,D=
MRANOB4LL55:Q,7:&Y=U8L\)<&HLZ1[.E'9[FR=W+4NC,C5-<G1ERA.MPGE[6
MZ`G9S]CN&*OEC5D2O'8OPMCO3)P]#\ZKO[URQ-NK"K_RPU.S#NG4O7Z%R0*1
M7U]_H#\UWH6_,;6.%K^^KDB-7K[$147U]'F.UJBHZ!Z![MF'$5?Z94%W`W1;
M)55#TMYA>?*8B70IH$5GU4E;A,;YV8&[$<;[81L8]V<'OD<KND/D,SU4))#Y
MPV8L<Q>W!%][H<+P`!;<,LG+GD[V*%<WJ$24PM5)L3A##X@:W8R?\T>F8]"7
M`_]P1[HT6G9D#-32IJ3QO-T@,>O,)Q["O8ZX;?&V!4X'GZG8#1IDB:/^<*C=
M[G%J7<!1_=RI<4(G0(<<T!>!!MDQCA;\<=F)J$")Z#7NZ!%H8[^JQ(/I:S1J
MOFU932)[DOXQ.$F_13GM\_XW5""2Y%03GRS6=$C+BE".'M".HU*Z:QKUT3T7
MZO41^$XZ9$2&[:EFF'4%]=_?<7QASIUDS77H:`OE>>P5GBXQ8%?D.8#CZ8$]
M,5)'$1=(Q)9'UXQDS#&0?+Z]U.OW8*WQ^XO?)?',V/F_ZJQZ8EL<+NB?I<0I
M`6HC$A5^F]'X[Y`C=4A(8;ON:3ZL=P<$;*ZP'I/R!<3#U%Y+<@P1'!DHZ6M<
MW%8X_:?46!+"=62%`^?9YI?."(9SQ#?2>;VW!4+<:^"N`/ZFP-N&`)I2OJAZ
MQV]8UQ&LIL$:^/</(>C@PT!)%TJXQZ=7-1S>>?9DL6B83_+K)%M<%J?))J/'
M":E*!K7I^FGD;0)5U3J<FJEM&(8(!.F&!7\4:'&>D((>J.4>$#EP[ZJ`#QRH
MS(!X,Q,61=<]*?DI."EI[)/+LJS1XJPFE(>M!_%;DM?H"GUO?A&?F#3:]DY.
MH+9^10IZ"M=GV^APKH.F)VH_QR)JC2>Z-)0U06.8L/4:1R1M<L;MB9L(3U_>
MWOXI%HEKEE#SVVS#QJ@\?Z1'HZQ\\>EJ*#II/QI*3]!/1"()'@[+RE".LB>H
M?XE%3+=+SX*<`CK249CQ2RI\0&PK4EU9#5"I7J%J>YGW&9>BW9H+TY&Q#DR(
MXB-CPT`R^-WU)OVO%J><]XSA=_[=_PTJ*Y*E+#:`">G)]X0LZ,9?S987F"Q1
M5M6D9YU9ZFTWI(-["TF&[`Z-AK390MR7R[>_!'BH:-3JK*Z:G!94VXJV1A%<
M=^?KPX4D55!V3/8M89<]2?B%2L+'O_XY/&%@8KW".26RW/IN9(82%Y!G"'4`
M@Y0'%4.FA@R_3X%$A&=:GRS^NRXKQF(YQP+7;B/X=WUE25DNLVH?A;>UXG:1
M=@R@.7L('?)^T/9\^J[1ABC[G@?;8"5YHY"[+G_Z8/-ZU+9%N=UV[-J5AWW:
ML2[W?8:T`EP,DS]+LX.>*[L__UEQ93)>(.=X#YZG2,XIDO/'B>24>=.XRF>G
M8@R]I+`NM?REJBY#VE(<#))U'RH0>P0Q&JT8P>N$S$@S*MM;#<IQPZA`B#5:
MBN,RQ2U#%$E]E@TD3P=)!.$=+7:VB^>DKE:8L*=B:L$2M1`+5+]%X(*D8'&8
M``D[CR%8@__HD)"DN&^8__3T`G*=/+&O&C-_ZRFZ+.@!H&Y.O+-JA<A\E12[
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MYJI'S#Y>R(`(ITN6'\ZV4R/S[U@H8T*8=KA9'\;S"5&I#S&,&T$R5D'OS\%A
MPE[]S^DISNGLX6T602JPG[.4)1)LB3$OW,B@96O^P2U]GC]-6.)%+DDLL@-I
MT<#'C6CBXHE@&V>GA-FRQ:+$S)7"=K9D`:QWDT].,[9EB7`U#Q?W@;_#$*?3
MF"&57L+%C*Y=N6D#`>=K(`YX5.:+!N<V#1806O]BL]>*LX)?$$`*PS%16C"!
MFR@B;H:9*/U>1YC3[+Z@)*8)U6=IBNNB8I&/.,_2#`GK4^DW;,\^L*$M#K]D
M.2HK7*"=3XW#BPBD174?Q(_(&@PU!C'5LY=@6/8R+.S=5(2#-D`AMI(-`U2.
MIS^T5E,U<%?/UPTN+LY.3C8;@A\$*0&5<*UU)(`+5/]#N#+;`^0].XWR%<[S
M%4K(')'U*06F>B!OU9=Y7NY\!^"`'CJRH=5#P%)C/A+F\F2",X*P8+H;D1I1
M]9G<93D=&%2>UH0PY=A8U.GV#Y%+6JMQUQ,-;!RR*3!H(`88"89X3>71[L,Z
M<ZO+S'$WT!C310H((7;V1(^[^[2D8R<O%W0>MFQ0QD_N"4("VUVW:6N_@3<-
M>8$/&(2!8J>-U6EP+U>P;N@66-3HI5C5[`&1,U12/MD;*^YC$.UV+9$"M@M=
MGDS8'RA,>BB=9EB$21)<=N#2$JU\>)$(E0PHDMCYCWG:)&B\D*=K@C>(5$\L
M9(P96^S)T8;[A*1C,L,;=LQE2,,`:L,+R825>X<U%U9P5S7WD2]"8X:Y==:U
MAH![GE53P*^&#L0<?PX*,:,4LS2D3Z,E=/VV6UHS^;<'%DR>GM$(74M*V+91
M+X;UZR[2F0>LQZ?>DGK!]VRX*_%$$.L@Y/?3D^)QGD9+Z`IIMQRWEC900^(A
MPZ$HDRTGH:W8=5";BJ2'L!0=-B`#+]34>@O_!3MHS#E8_=]'7]2D:%*U4<K8
M0XFZ0D2]06BT:FT5H%;!;QKZO`_=/G0P1I`02<CY;T2<;1[6"+I][!H%(FO2
M4X`6XQ9L?R"^".3L,TI*Q'(;7Z[9I>\V*DSZG@+0HB-ATA:!B!=?E>GS/$2-
MZ6"+(.7629K6ZSIGCM(SM"$HS;:5[M$F1\T,%XN3-295]D?SO7"0Q)>H5KOO
M7[-:ZCX0"9<J4$>#:4'56J?,?QC+,PU?"XKP%#<)EE)I=#.T2<MP5#<)1!#%
M5J,FUT--1C"Z&.)1RA)5=+](,L(X.ETEY%Y80U`.W%6$`N!`I$FNUB",VE!2
M<CRZ5\PCY/(VN1(2/.-8K[-J_[B`+BIVG88*5>2V3K.#9QV09O:>J`BQB=_,
MP9K`>/)P':,]&=B(44Y@LAKG2V@1$->85RZZ$L3Q#6NT@,F/<2((76:XET%:
M;6`,^4_WHC,GZJ6A=J@"\`&617S)'VY8E*`\35D?HIN<K`TQ&B=?Z&2NZ[64
M%RY,AYL.C%_[BS?8&$8_U[YJ]=<VI/C]^'\D/SN]%9[->K^U5%7K-W_A4O!U
MC^4<Z"B>PZ-4O\=85(SD2K;W.T^]^+]>U;*`L)H=G5GO79;V.PWX2K1/;'=X
M-!58]QJ3U\<8+^D=V&6]3'.C6F:<279AF,G3Z_DQS<*[,_J2/*H-&AY,UZ`Y
MA`G+H)'0KV70</OQKQ.N"5[4:55^28IZF:3LHGS!2MQF"S1;7I8D0>)GM-IM
M#Y.(0=L&;#"9CH"Y0:6/T;],G11%G>2714K8A>4<?Z'T5ZA@^?,O$,\9!FO0
MDAY5@R!$1N@2TV)WD$,,B"GD-`AP>U;?*V9DX>J@&2,DK2E-WL[E(PE$4\`>
MA)\)88-8;*)P,QB'YOI8C<'_O?(-?DIR]M!Q5MPFNQC79M/@R(`2MOT"3`P;
MA`P(%2Z4R4&Z5HUD!$E`):((5ZUGUOMWKF*U`&]T\#I0W2@((>$K"FV>S36&
M!BJG\05\TVU/BMIFDT.VC3419!#R(+;20`P.,\\4*/S//]59=\S0.;FGI-TG
M%>JFSI(=!G5:'AX%82V#D!?A0="`^T''0"U\@"0:UIV-!3N4DGWMX9VNX[H8
MI9`';D4!9!"2(=0D,`8'1C[(4?B?_ZY`BNT-!:0DKV$,E@6,.W--H.K??QJ3
MG6OS637M"9LMGTWD.?Z-GI>J&Y2B[*%7:7E8)VUY,>@D"%$2JI+!PS)(RPS`
M[E\,OZ%5EN:H>31!.6N96(`SD'[CEMCI-`Y"W/B:RW@,S)69`4JGR74LQ1,T
MB^/I_''#L8#D0-W(@@Y0$-+#558@MHR5D:+W"&1B*^)R102"Y;VIBT;-Z'!H
MIE5@&'2S,XV76/1YH]5/*PIJRD\JJF@:A'1)U9#!$`Q63EHXG4J@(AKH9,VR
MFW%/YGP0;J3/'B1<80"P9.GY0:?OWN3^XGIR_Y&5)3/4]_Y%D9TKA6M-LP`N
MB+GF6Z\0SLP-57GO_5!'FV6#^8=N2NLJ?[JAQ#1;'=_8!$"VC\\BR""F77Q&
M!C$X[""L0.%6`"SE&$1T#\JJIS.TP64FLAT$4-V,@5VH<"4$QMC@S5_4?5\R
MPHM_WQ5Q*NX;V2Z9E.\$_`J)Y`34IB,UBC;ARY`.TX,E"H:L+U_AQ0EW.+FH
M613C[H7/WJ5X5J-3Z:'&K!.Y!"H[B4XD]8;%MHQ"L?>%-KRL-4#6+HOY=_P/
ME!#1XR'C?LQ$M]W/T4BO<'!\"3"'@+X,AY<,!,X=Q8KL2'&O)V,Y;O5T3)(L
M&B"/LMPGH2_--@,&/$OS!:Z)%6'N=60JRZV.CDB41</C3Y+[%/0%.;@<.V5:
MC%=XX>1[0A:*%-1<F.Y%P2',>%Z-54+0)RHE3;)7>CI*MHOI)3S_T],+S$YX
M&N)?."@6++O35;*6YZYWB:KK7W&"ROL[:[X@8:]#RB]]W2;LP(WCDJ`84B&@
MLB)96J'%;873?\KSKLA@NX$,?%C/-3)=3B[6&QA^EGH'!!Z$3T@)BT`\YVSP
M9LO+8I$]9(LZR?^>5:L;E#?C5*ZRS1R?4^.B>I(J<L->.B*MW<MHHW;^B-*:
M55^<+9=9BHAT5<N!.V,@`O:[KDWG$VMRS5VSFLC;RU&!=(1L1ULZ&B,=D8J2
M>[[>Y/@)22HK@]NTLR.IVT0C029C8$N0]'#WY>GMQ_!.^;UAD!Q4I+`J=6T]
M81/,)I;3C&WM4C`1ZYJ_IC@C2%:CM*U$IE7/5Z)[+`1WK'L(!'0\WG`W3Z(;
M,_.:FISH&I&&6-$@*L"[0R,$#^Q$`9][K#T89D<()44'QV$5)?X37J@M$K7]
M$;>UX<^V`%L2X:G[/>F-[,XVPB(+8/CNR4<,'Y@*LN34@`[0*(X--7$1B.Q+
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M2P:1#"]D=<(=8K*U,<@P_=!;`W@*0MX<`$PXS607EA7WD&0Y,W(O,&E&Q+$Q
M)T+GR*;KH_NAUZ_>9(2\B*&<.$T)YW(E=TW7IDQTZZJ!W4N4U.X@:5:BYI[T
MAHW9UPT]LS>?/F=K\8-[#RA!*]H6RN-=U4XF9;25;9D;ISG8N,<XXT%JU!)J
MWB$15E(GR>>(K#G'/4<86L="ZQAB7GWNA]SA8G-)?`3IZKZADCW8DP1K<B`Z
M^](!Q-B<2%\0<&'XW(SV^(HWWAC&`G>9M/IK;R[\?J)(B,1?K<U=`UV/Z0K-
M"GGE:8,>8(<K?@]^=3M_8M5''P#W,OGJ!_>8X#&6OT&CFN2Y5RO544"/#Y/4
M.NF01%L5J='+EW2S18_5>=Y@^?5UB>[9AS&C7`A.$5J4%U1V]L$0K*Q4<R%-
MS?$4;0GDQ[MH->Y&O@`;QVQ=#AHH']$P>G3%D$.)SQ++!D&/G^RDJ27+G'8@
M,3YH=[P2+!Z>T8271U(,>9,^878WL7R."CI=)1E9)_((<EBCCL2J&D5S&VPT
M"K8?U`*1&XO@$81PB4_A_@*W>#3$H!;.T%UU6934BF2\75+SD5!.;NCV?%O1
M?Q;7='[I#\F]*`)?OX..NM#IX!AV.N,!\[#E&=`60Y8U;??7[Q_&=("A95+G
M%5\F=3Q@/2X<^,`^QN@#FW_'`WU@O1ZT?6"M'J+S@8FXM^T#Z^.)0?Z>'^XA
M\I"EB,_F%2X>Z,"@[6/`<LZ2ZK5_9P]&KG#U#\3*T.'[0A(([1R?Z)FH?7S'
ML+_[F@X/YH![5OHO&L(+H'$V"MO0P`M,=E\QN`^^%[F4"%\K7T#$I`X&3ES,
M.D+.7S_F/3S%\?P"%"W.:D)MH"U+WY*\1IVTA;N("4E8^Y"^NL:I65_'L!IM
M#*./J\1!9/;#RYT7*CYT'%Q3DM-LD^3;&G*-HQ,MYOB2#5N27]<D7=%Q(+,'
M1$[R'#=IM+<1>IR(->M]MV+5+/8=\_)P.<R.X]/LD\VY=8]F;]D&P%ZA[\U/
MFIN)H#%L]^@UCGD]#!JH\?8'$5V<@EH!5A`H,4Y(>4_7ZVB5!.Q)T910<<H.
M-5)VJ"EB+Z2(O>@"]G8)Z211[SR0;M32`<CHS$AO_D#52_S4'9'=_'%''0/9
MX"ZF=H\'@4_1EOKXT6HI3-ED8\DF"UPK1Q"-)=D=_(5C<8F(48%-E0*F2@'C
M&$+"&*C12[#I64*P**BAME!X4VY\5)I2+D7HJ'0^!2%G:S%)N01<L$=@D$6=
MX?2CU0RGW/-2(S:LXN[\.YZO<%TFQ6+^'>4/_(?2.DU:)RIU$[]Z2%P=P8!!
MZ99Z>&("]^PT27:`J94^X^^^4RL)4+I,K=1#>;R[KY-)B2VUDH@;_RGPQ8KG
M%J6X6!@H>UY#D,H_;!B'XI<P:T7]<_L_YM2VS3^[UQ%;DU44_.L"A:V3%1?%
M\2IU*X,>\EE*1KW3O+5@I7V!:U(A)*Y5`F^D4-;=1J$K:BF3`Y6TH&__(F$L
MV0U79TF%+I*,-*&T'-EQT+NUU(B=WF-6LFZ'.NB4B'S"G282GE*-0C'\V&OJ
M1TDU:C.-KZ=#A-#!RO5]_QUE]ROVW.H!D>0>'1S+3<\8]BG0/8+8I"#FA3[^
ME(5P@''`7#]`1*$IQ@B3QU.$_!0A/T7(3Q'R4X1\(#%Z/V*0\6Z3/2D6G??(
M.UN<XE6&(1OWT2XKK-]'5*',0\?(:G%A8UJFR%N'D;=3E-'@**,/T"BC*43Z
M:$.DC0VG\W_5E.&7'`3EK%HA,E\EQ4YA/F>_N<%Y?H$):V3[%#2("%LG)D,B
M?@A?C,N)"\$=XX:_8]8;._YG=556"56HQ;W,2<5&9^E&=PPFQ'*4O@DAX4[_
MY+G_(3WWPQ?5$7KZC0<EN)N!X]N'IO=>82F08893Q&_#C!@_ZG=D\9UJ;)F4
M(9]LAO,8[1,G^.C0Y;E$656SMR/%XOQQDY&MK\BEP>N#)LL[U4":(E$V?HUB
MCV(0HYGL97@F%8==^6O`>'VKJFC443`FMNY4'IG!#6?_&-2)RCVQ5Z2C^@2-
MB+#M%M0D(A*M$Y9G<,A$QVCUN!F/8WZG+!J8IHK+95&1K"BSE/>@;@S4EHT=
M&.I(-(]37X_!)$7@W='B*@8M(*L<T$KG\<RX\/1BW)%./0E!1Y&L-WOGBZ&#
M'=J!P9R?&-:8'PMHW#"0<6,_HE$!07D\S:8V1BO?\D`XS7(1G-*YJO5K8P_'
MXTZ1[/%$HC*"\4JJIBHTH\(9NS_`\M_I/?:.8@2;0Q.[FS.^&GLD"B0HF\-L
M:H_0YM`="*<9@8)3.DYM#B$>=XIDLCG<3-61V1QB=F-8_E,-VJD&K7D-6H41
M/49NG=#+SPHO+[>OH"E])\4"5.O')2IK80`R5*-IO4[N`VYV"Q!L9Y@$L(&I
ML"%B@?4&QDR'&1#8UFIRPB+(8S%EC!)DC/(X!R^B)LXAPH7IC$4'YNARALC&
MP%^N$#X5,2QU:_9FO+GXICQPQY('KO^0SB0/G(<$/7Q]824F$VQ;<Z?\@#`[
M09$`@B)X&CUJ;J\I,Z%)9L(IT5:`B;:F<O.QE)L/3P>[\]%_:QSTKA[;&:+W
MEE*MBSXP?U%@R=2DDQ5R.+HI9^8%=8_`OQ!U3E*[E8]#5^+/%ZUN`@%,\?O/
MC!E9X,!(>EP^75$K<A%KQ_#TV7A0#E,R>=<.?/3>E$,7_:0;C"<K:M4@X.R8
MGT0IQV27.V+$`Z"0`F_Z@4/!I"*&3%G46D+,G.X[AE'*FR4L""M=)+C<!!R)
M]0-<K4Y!*^,'K4S7V\=RO3V5.8NXS-ES@:M3^D>=5\P,/\L(2FDO+&59LP7?
M(O*0I>B:8$HC(LJZ9Q8Z[1="&]1I5+=NUD?10:DT&\0=<R#:5`+%(B'A3O]4
M`F4J@3)ZHL.I!,JPP3`OFAB2*H)/B\-B?2!D[G842?&]B*9JJE<3NK8_LKHT
M4@9'JS\3HA:>:BG_P'%+4RWEF$.\`SD13CGPIQSX4P[\R'/@.W]ZLB/WI%AT
MGNV[<=B[P=/WX=O&$Z-;W^E8._#T.Z)W*C=IW:$2<FP/C(\8#,"IS$#(GI>P
MR@G`'2L6RP9,BM3E/6A<2G:JVSO5H##!'HFJ""H?]%2#PE8-BJ-6.E,-BL!4
MQE'5FO!VE:=14^+XEO-44V*J*3'5E`BZIL01O12=:DH$KS*.JG:$-QM"HT;$
MT2[GJ>KT5'7:UB1%X)MT6G5ZC%?=)6;OND-[S[V].#BIJQ4FV1]H\97R1EKW
M""SC;7EHQ[$)[`DT2/'80@92-<.1!?L6',3:IZ<^<T,>B-M!JOEJ?"C2\9Z2
M6Y-UC>?E5J=(8X\8RJO..W1+/,;_.-WR\$CBTQUBLJ?)Q9ABG*$^+P:EK*Q@
M<KG7CI;WW*5$*RU[F]-B6TF+N%-;]G:X.H:7_E.%NB$5ZO2BG/7CE?4CCX^S
M#)W^('DM1J=#GE.EP97'_X\(OL9T5MD']O^L0$)15`.WI%`&'((`VE'S6'-D
MW)]%#B4/0)BIT(7Q-M/2*<J.K0,\)!@]]QS&J"6S1\E@!&;/064M@;W"A8FO
MH*/]Q2$;F)'%FD]:%&_LHSY?__XA_A,V6B9U7AW;$;LW,T=_R/;R$&0J+*E/
M4`S/W&P*ZM<-W<)W=P/KK/*AC04H72KE'LJ(#W8&D0U.)FJLVRH?'$:@!2!N
M.1!L9]W]$*XXG8'QZH2#$>8_Z<6S>V96H/GWQD&C]KZ)8'G.MSYL"!+GQO>F
M&)?17&]"NB)0AU;'9QOQ.ENVPFQWGG$?]I$:NTM3288]XB7ISVH"3]\Q&%``
M9IV^.9-O5G,*A*[H(+#_U?N5!)RW97'!(UXBBEU+/3JC;5PRTF)Y\GAG:8CZ
M*['S2.L&L3&D/Y_BHB))6M5)/D=D_5&VMX5#'6_O"X&ZB!>^>F\,88"#V3L#
M&@RG;['D>RM3M;?H`17TR*#>6L70O)V5!QWQ^E)LK,JQ&6U?E5`6[2O`@89N
MZUWD"$=",78?1T(>]HB7I?\CH7+ZCNE(*&%6MR3L\&V+*K"7D\)%]H"D'DP`
M=&O;DD)'O#[XVQ9\;'QO6Q#*1I:\9C.%BYX`7"1[/?#C%C[YZ(PJ?2+2^N)G
M-<A+*H"WV2-;%$K)X\)Q1*X#=[2R)AN/L82,3U-/NOX<IDUNZP#=MS!"<G4-
MI\ZEJVL(=1$O=7^N+FO3?PRN+@N#X52Y\3=.MI,_OTE113T`H-N;J`PZXO4E
MV$K!8^-]0P50UI.\OT2RK?93_]RILWT=YOOYH+53VD0(VOSL((QXO1GL9PXF
M*:@MRBI_3M>^8M>!>@Q`#;A[SX_B-=`9H?%V(#W/P5_<>P[8$?-Y;Q3*GP2J
M)71<J*.3-/58^!8O&44]F?KKT1DVWU!)#QG[A(8724:<FC4J=):-&C&ZB%>6
M4Y,&.$&1&C1*[IRN>.X><IL]-NKGG!WW9X7\WDT-W-I19,`1BS]_8P&/C._]
M!4!83^A^\25TTK!?,1!'R(XZQ%<Y$F,)%22<]\-[Y]+$3/*&'F9,2>_05*!M
MR1*"'I]\P4;%NY2IR.K+FO,T5TSB]S=\]#^AH$GA6E(F@#LZ$8.,AV_YDM/4
M%R[GCSCI]KS7K(WLBU/Y20';&?P$@$<G7Z`1\2U@"J+Z$J9X^C)*COZ[%"7C
MI>@_7V]R_,3<;DU%=/YDG>0-!?33;'F#4GQ?L"G;'K).<5F5O2-KQZW@"$O'
MFV`=2P#9^.WP!$O"[P"7,/>^55P^4NZ[$F%NKGUW,\%5T99YX^?6=\%3_"GU
M+PNZ'Z#;*JD:DC[ON)=D/`2TZ*PZ:8O0.)<FQ0.U@7$_7IHZR`1B,YZYJUN"
MK[U287@B2!O*],1L>9ODJ)0F!1+"=02(`^?7O(?-#(9SIB,F_=0\XMYC25#L
M8BM2KUC]1*P6Z02L]/BRL5K?0H094D?91"1)*VWN(;#DHVYWD?#R*=V@$E$*
M5R?%X@P]H!QO&#_GCVS=\?W?!BW[J>?4+0/?>_2Y'[8;Z>"+0.QN44[[O/\-
M%8@D.67J9+&FHU-6A/+_@'9\R0T;HSZZ)W6]/@(7RB$C,DP\S3#KYNSQ[[BL
M<%:8>"VY?OGM:,Z3Q[.L9/S51%CM$PK>\M'+P6W=+7"P\+QN$%`Y[1Y\7N!!
MQEH,':PD%8Z]CU_9]['X@"B+N^N0ZDGI_A$!<\W6/G!`K`*,=3&XDMVQO3S"
M>>H9YTHF)?M0%TO?()?T[LVC4Z+T[3U^>+=`&1.8G]D')B<_M^2$?O7[>5&)
MY$+T\VZ(^C^/9\?5=V6VR!*2J8PU(6#7(N,`^C&[A*..-=@X$-]NCP<6D[@G
M_U77Z+KY!SU>S%>(H&19(2)^A2*';#\_$4&.841+%`/680RHG3I//Q1=1^!L
M;J(2Y.Z`/D3WV-^&&(V3+W3^UO5:R@L7IL--!\:O4/,&&\/HYTIPJ[^VCN+W
M$XNX2JQ+5;5L88UKMRY\T$$`J]F`G$!Z[O(1:^=!3:;/Z#[)MQLJ9W(E$"W#
MJ0<1X@2K6=&:8EEWYC<@#OW_,H*QTC[NV6"=KO9#PNTBX!)>TG)MXOU7K/&[
MARA>'Q$XDRV=MA6W8O[.V\H+L2'';9UK,+L';N=QSWL[^SN>KW!=)L5"^C`(
M`LXYS_#!PS[4`%@<=+*1]A^!!OF2/*H/!3R8[J'@$":L0X&$?JU#`;>?"";Y
M?+E$*;N->I;JFZ1"+):D2+,\V][S5Q=HP:ZPV)U730EY.@`6B(;%GKNQWC9Z
M]B.&.K<I[@9.^_+%!2FCV)#63Y>@*QBCHZ:BY_[PO?V+^_2IR>.GFJ(KSMBM
M=797-]?(R7>9^0!H<&A`2!L$:T+`V30U(B`8_->7>E8))XO_KK<9%UJKG1D^
MLX)W\:W5KB4@P';AJ7-3IHUNRO40^9>:EY*>)VM<%Y50@<@!6W(A`@Q388#8
M,E(4BI[]%\E1B^(%KGE3K]=02T5L&\:J(SAL.U(2!YA"%!UZJ#:2G%8[+<%I
MVL4J-WVF'8E-&Y'_(A,`^EAR03.Y:;?4DYQMRVAEA\.X*^DY0.4_U35`+=(?
MS3:L5D.]#:MI&*OP<-AVM6&U,?G/5RLG\"6V15MX^DW!XM-N&J,`"5EW($(<
M7/ZS!/X]JU8KG+-2F#NR9L4%)BB[+[;$<J0'W*8E-H`V8<J++K-&@@)'XC2E
MGQVO_FR#V!N3XOXS+LO3A)"G)28L5Z8H]D?=H..#ES4(3XJTV33VF`,PC)#%
M;R?1)V59KYL42S<HIW\OYI@RB@BAGQAG5%<25*3H!CT@4B8Y1_$,[.G0\VO6
M4WCB96]@C%374-3:J?Y&>7*&JZ?Q4F4]3P,KT4-7-QW'IYXHB$)J9&U$437\
M-N-'$[7HDB664L(#^/:8X`DV5;QK0`5_<I<N#QOW2E"(Y1@?P(WQ*LPX.C=E
M/G?RQ/C]:?\'8_6G%JN[KW^__-QAJO_#COSV#^%=:`C)UK[`X/042R#]].YC
M>O<1A[B._<383X8G]5XY*(I'B69(*$]X,A/I6R$C80`]&-*:?\BKH0`>E-B+
MGS>S`[Q%ST_/4$:P=K_>"JS=EQ\ZUB[[(5QKMT>VL;7;ZBF""/'9!A6[)PUB
MYW$7HN\M?H$8:8JA1WLQ-\,.\[Q^(YC^Z15(-*]`3+3TE<@G<27R25P%[9/H
MD6VLI:\D/HG@4K*1336><WQWW7"=D.II3I*B3-(=;U+_.+19+U&FJED`I1L$
M1):?G@Y^`95F,.A+6'I!JR\?GG>P$'!K)9@/#5^M*XCA%S<P(2)^OSV,:YD+
M0;L#F"+@=A#$,$DO-L2`$K;'2W%G,'M8@UF=Y<G!>9@D6(C+?TZQ+TF1;*O9
MGA0+>F(HZ0#30\,%0N4<GZZ2C*R38K;\A!.R$+Z1,>^D%7YATHEGHUT\<=C2
M0"C%[/"MS0!\L91',-G,!`M;2ZDKJB%HD"5:^T!R8G#.F^\IPG0N_G85F1/5
M\J8"2^OB?EL)SZLCX'G[A+"<+5O?Z9EOLAY@]AN_A_&V'NBIQ'Q`!I]%3%#[
MST1TVBI<,\?S%;JBZ@`]HK1F\?EG&4$I[8B?,=>X?<OBT6P?FK$SA'U-.\<,
ME:Y$C5!Q-=G4.=XD:#Q?V37!U":KGEB-6V9%GO^KSIJJ)2IO&;QA1\U"&@;@
M,1.2"7.2P9H+_6*JYCY<81HSS'6&:0T!5R.H*>![P("8XW=Z"1G]]#2GN"7>
M+HV6T/7;;AG>B##:I(<3C9;0$6FW].\2TYEB/&0<]-;N"_;VXM7!&L.1V%6\
MVO&$%7OQ"@<1!>7<B_LYN<.$P3X]+QOAJ44)VSJA2&#]GD9TM`/6XU-/>;W@
MVY]-U'@B4%=3W/U8<?>^_>E`TQAB#P@M187O7$X"R"C@H(Y@E5W4A`Y+31!E
MY2)[9)_D]9C4#3KK3]8@:(VMS?$0M:V!S#Q._EC./,(;FA%//9(K&W>''MCE
MC<]C3X#7.#I'!O'=G_M#@X67$\#+O.#>3IC/+G/#UQ4B\D,&$+HSYT+H*+8M
M&*\V]BP5I@C$2,CQUQ(MZ_QSMA2YUS5:0C>K=LM`1$WJ7M<?`@N>=1VD$0C@
M](1DK"<DX9]VM1[?FIQI`6]QP[NG'O$QQVF>E.5L>5OA])\]S=@U.62P78.#
M#QO`S7-#TJ>GAD#89;.PA?!^F=/"QY6R?(*XM\@JWK@+DXN'?U<L[K^W+M^_
MC>Z">,X&:;:\+!;90[:HDUQR)R6%[4B2`'9<;2^>2JS'I4+9]_"T)4O>/\]+
M&8YPL)RC3106"S==99LYYE7?5(D-K!>50*EZ\>X7D$^L3,*T!H0K>US<4JD#
MXK0DC]Q;R=ERF:6(E.QM`K6-*-KS]2;'3TC@]=9JT[JE!+3Q:YJ;3@8V&P.8
MQ,AIV-]FPG%/FDSHOPQ$E\D"(UPI,YA3U)\Z^SBB4'Y#)7N-);&X.!`=43J`
MB,"Z$G,TQ*;B]1KB5$NU"Q>&/]VCV3B\@>[/+MQN:?7'F4\WMHBEX_@J(>A3
M0L]X[<<')RQS.GN]0N5V)JA:/:"'[G%=IP>_)@Y_!K$-[F6"U+\/,<$3F:#-
MO^.!@M;K05O06CU$)V@B[FT+6A]/W'N4T+[ULDO)K%>=;0IFD0[;J,:<UJT$
MRA][<&$ZD]J!B<#6E'$UQ-KD]\O+N17:ID$(NUQB+N?RT],+S'7RU.2(8'R]
M,%<LV&755;*6AXBY1`7;A@:B\FY$\^5'O679'%*N_!\0!MC;[!`4E+6U]V8U
M"F#6%*>1VE9*^(X(2^#]VDU.IQ3K#Q!?(3L@LBW7:N*"$L[(M;K07HQ)K\O,
MSE$4.\Q^#42UCVD([VF4/7KF@'0#!0]`(K"")3P-,8*YW?;F^^<`YEO^P`%B
M=XYN,7('FS/'&J^O6SWRIM7C-?#!)GQ9I%2_9`^($?+Q_?L_"V^"=9JU+H-A
MS3Q'^@JM*$-&I5-^>*&KU7M?#-['M<#%CY5&-Q[TUCCPL='`53[F=JTT3$1V
MR=:.+W^C@%5Y65PCDN&%0#K<(-$U;S61^%5.\)!,EV-I&,7IAJ3P#H5W:A[O
MNCR>/VXRT@"KEXC-_GFKPT[_(2\,!R,X8$U8I2:N;4-XGN6N^;^C['Y5H<7)
M`R+)/3I_I&>TK$37)$N%8??^*;#F3S&@(.1%-\HL.-JJ'-`;WI65B5YJ_ME=
MQ-XPKDLZ!.P<0_FVO:=!<-G:W^2X0EYVCD?6\[X'HLR2YXOK(#&V8J]J-J,L
M3+:LDCQOM,@%)CM>N%:?-WPMEXQC?(&M%-\CK+=:_%'76S%_&GOS,6&YK1RV
M#'XP-0L-4-AR-'!1!+9N/(RC9R>#C*#>ZOAS`/M)8V*>)16Z2#+R+<GKKGWE
MJ'<;>P6O]\`DW.WH>=P')+3TY/HO,6K]9[Y.RK)>;\]?YX\;E-(3UQE[D82*
MQ0WEW_96H(O7UOX`QQO8DAIKQ#WO)-I4]I;A7X]M&7[#[#%@GE5/OA<B'[./
MI=C%_",M1NFH![0<!73V%N0OQ[(@;[+RGQ<$H<NB0H0:N[Z6HPROR\7(Q_LC
M+$7`B`>P$*54AA7@8NRRE"F@.2)KJ8_"*4);SG$`PI"7G(\Q]NPFAY/77V3/
MLS5*B363W'5\QTIV7V3++&4I_M*4U3)DGAV<9VF&RIY0M'TF6@W;[A!@0UNN
MH[V'][:^*[-%EA"*AL./#*Q%/1_,S[HU&'8,9NY@Z<$Q[1TO4@Q!!1]=$YPB
MM"@OZ)B>XCS?USJ15!63P_?3\HK@0Q83778'R`L<E:4P'4&IU#W&[`&U-HLO
M64Y-+%R@_4[15'CE:`RS#@Z*I>IU$++X#!Z0@?K'$'=8X20)I?4&/:"B1K]A
MO"BO4%?N(*!=>Y4+&K(L:3!I00M)L3B-D:@WF_R)FJSKK&*B>8W(/U#">S>B
M@&P;5R+(D.<;SN)`):%"8NE^GSO;US5)5_0`,F,]WZ`443W%BV21PK5F6@`7
M^CQ#V!LXRW(4+F^I/V<I/7VRQZ5;23NY)ZC9A:XQ/>A569)?U*PBTVXO:GP_
MLX+J&VH)+;.*=RRQU66[`N+@+D,7,LN#-E`>K5%CZ2):JIZV]M$<?T*WU)0J
MEQE:S/%N$9T7S8`LMA&%$MVEWPE'L>ET$KI`#AX82RK1`+^E:U>NT#6HYIBY
MVK(BJ=#SRMB98W/:MESAG+=/:K=MB9A&V]`ERW08!@J4/EI+MX5\Y?4<W#Q;
MGBSJO/HMJ=,5(M=4R%E`YYP@2N.")=S]2A5PB7FZR[2/MNK2[R-T^1HZ+$,5
MES'ZL*[%V)D#%\T5QG5"9N2V8F0W=P^4Q>9V0G#2UVC9+S^G;AFR_)D/@06W
M@`Y2R>W0&-D3*7.++*^9)^P6I36A`X'*\\<TKQ=HL76VLH)[S2W9;'F>D((.
M1KGGBNOO=-)W-UNCG;YCD&@7PVA!YNV2U5\5%KWWYWEVS_+[[`Y-6QN6??%U
M0Z<Z7674#F$_<'9ZW:;M3"S@IB%+X8!!&+B=:V/MRY"9@YYO-K;NGY@7>+9L
MQ/BR:%TFX&Z2%OV&;0,1V#!TZ3$:@*&FH![.ON18=-V+;IMVIY\FB*0H4<DH
MW+Z4X3_NM=(7X$81T%?H(F=KF!S=,\+)Z`NFQ5N&H;Y&JJ";`SV;>-&]MS,<
M%GW4'!RA"[CK81W9BRTFK[\@+%[)G-Q38BX0:CL2MD0UFPE'O($M6L*J;!&Z
MZ.FQ/%"0H,CZ8F'QND-*,J]`K5XC:+BCAS*U`Z[D==D=>CL/Q]>7C;^^CJR*
M+0N41/^J*1'GU'*H%-4N%-#=D!\1M,_<OYI3BG69U9.V7C)@%9*@8E8YQ,I3
MH:O@U0(S6N)@U<3(!06>3EB`1R$C(1>"Z)`K+[`E@Y5+QTC%'Y1S(18,C>H-
M(BP2L0BZ_((MQ2$NA.!;=<@2$MO0';`TQ6ZTQYA9*!E]LV7+I2$Q1Z2PW<K!
M?-@X3!$(HP,-$3F*H$2DG=KQI%A<X2)Y^895#"R3M'E$)]UZ#'OIWA;J]N+=
MD)%/++8U(/QJU#S<!U=]ACA=5E7X1)(_LOS9L20LHR"%:QV]!7!^[1;3@<9P
M7OG5<_3P[@_A<GPN9_]ZF?V!B'KVI7#MNS8^7%2S#^'5YNS+\;E\C7>R;EY"
M0X4``M[VT$K!HQ()#<YM2@8(;5"OZ48Q5H3'I$#,%=GAR96]`CM0^;-8AEO0
M)4K?WN.'=PN4,7G\F7U@8OAS2PSI5[]_1O=)?L[BZI\XARD)Q&Z@N!!A'YS4
M3!D>EV0=.]`[T"G>4L/UJ8A^;DWNX<_>3BBRL<1*P@\FD-/5?K:X703G'=LG
MJU!Z2_F`'&]8%]"/>2$<<:S!1F]JVSUV?5N"GIR>$7;Y<#YE>+Y")-F@NLK2
M\K)(,=GL(L#$!P?MQH>1>^#&XT_X(':50F#8>W\C'K[V':CIGKGB2U'S;#--
M32TWM0;KZC%]CZ?,,$!DDY#J25$25P;:>R/#`PW;Q-)@<Z!K6HK!4FH,.])Q
M@S;[)Z[[LVF7>.F]EW;[CAQIM/?NAY;.(AX^!ORD?1RD;='21^;>]P@T(U2P
M/1_DB$:"^7!C/6ZY0@#&>NA_U#(B#)]U<L7@(L,IJ?\03CWW]]9T=WZ/9(IE
M7-F95CZ&OGDQY@M=;SN(T$4X^AXB<PY:WT1@7D$/V\B81FWSJ)@1_1O"]_00
MM:*662X+`U7!=]T18O@X;%PHPT.#095HPBK]M8U>;A,KC^I2P7?%1@SO/QQ4
M.358GU%^2)<(TX&D*#$X\'#NO1R-'),G)B@_[?]@,O)32T9V7__^Z:8C#/T?
M=H/1_L%S3*=R,+&$;OXDBKIDD\CIRN6I8OMPGNJ=;5"%T*R4PK5?G_/A`IPS
M*%?Z4ZCN.:P-WI:F%L??^M;5TOA;*\H:&('K2%T'80_>IJA(2(8AMB`/5F0'
M'L)&9@-*&+5E_W%16$H9:DE$=A1^+<H-2C.6PD^N453P75$1PX]G^W&G!>LS
M*5<D;2P'TJ'LW:45L<<^*Y#0@A#"M!^B]F$\6P[*8<0P;OBS*.K]^7FIL%>7
M<8TLL<W%V<G)9D/P0R*V`:5PK5D4P`4ZDQ"NS&93WK.E@"#AC%ZAA+#<EZ<4
MN+$IT`/*\:8)B=P7'.!'E`SHH2,%6CT$+!_F(V$N.28X@[KOM&8%B,\5ONT`
MT+G"V!#0/%-8-`5&?;`U+*'?IR=^!Y)3B0>,=M-&RC'&<4+R-^@#SUD^"+64
M)=_E`E1>)D*;@9;"J,$G/F9<N1+T0E<<DJQ>"YX#7YK\QK-MY<N38G%#31^2
ML?*7#2MB$U:K7?L0"FOG^446=":P.?,:DM:/G]!#&%2(O2,%*'YG-9(*E%FO
M@>E`F"D<O!9\MJO]%N`]RTJ68:PFZ,WMUT^WY__Y]?QJ?OZ-_G-[AJHDRTN#
MTKQ.DKU\%E3OA8++$[VTP*=\S$Y3'?4GQEH69A5&:[F7I]3+HZ=>UI4N)PF7
MH0+G(,VR1:?^5.=O3,%T6=T/*I_N:OJ-6H"8G3,NR[)&B[-ZMZXRO#ME7*'O
MS4_B>`2=QKT`!5CC\"1R$/O:LF>(+:R["S[M36DE0R'CMX7)6+=M="(F9=ZV
MA`F060J/GFH:A%C3P/<&K57)P->.K5&_P&+Y@FW]N>X3E\_TRZ^;[8(4.6=!
MC;J>646C,,5-FUTC^='`$M0-U!FZJRZ+LB)U$]V05,S%]G265**"D^H&G7U5
MUB`\B=%FTW@'!6#H28I9<647DG*1I/)2D"IPJ92TP6.1$2&+EB2$TW]//LR*
M)KO))<ZID@(!5>0/=U\1Q<CT5C-D;FG+^N:^=Y\JG2BA?0;N@"9R6'T3&8JI
MJ@E<.*:J)E-5$SGL5-5DJFHR5369JIKT$B`'5]5$U^S0KF4"-3JF"B93!9.I
M@LE4P62J8#)5,.G%J$T53*8*)H<B,54P"=E8F2J8_`@53&S=$DE.4V)`Z<U0
M^.<H)6-&ARA)KT$II4,ZE0]Y5.!261CUY:)D0H3"H/?0L(]!+!">WP7.T@I3
M%<2^OZ:CDI4E)D]7N$)SO-U`A7:-9LN6B0-NZ=?:4<X#'L(X0##Z[P%U407E
MO+6D0(1VBF\5(C-(AND0F-EA6XL,-RY^F/)H4,M!LRB:RF30*H4V/-)[*H4V
ME4*;2J%-I=!:CV:G4FBV2Z&%J*6G2FA!>F".M1*:KA]&M_X9U!.C5_5LS#H0
M4]6SJ>K95/5LJGHV3`RFJF=NIG6J>C95/9NJGO%B,AGKL^5EL<@>LD4MK7@F
MA>W&9/)A0[9A(>R9Q61*.PZJHD6/U+]GU>H&Y<U&6*ZRS1Q+#JT#>U&)D*H7
M_S&9THF5B9;6@/`C''BXI5('Q!F4*_3\$:5-/L+9<IFE@JM.&'!'ND3`?DTF
MTTG"FES#1$B.O"U<"J1!R=`H.DUH8P6BU:2A6X[4&C!TRYMB&]/N^D&JS>K:
M8$8U9J%VF$%EV3&SA4R59:?*LE-EV:FR[%19=JHL.U66=5595I2Q?O<]^^<N
M*1']YG\`4$L#!!0````(`%"%:4>3J&`^;\(``,RD#``4`!P`<&QX+3(P,34P
M.3,P7VQA8BYX;6Q55`D``T@3059($T%6=7@+``$$)0X```0Y`0``[;U[<^,X
MMB?X_T;L=\#6;D1713CKX>SN.]4[HPVE+6=IQREY;&7UK<G8Z*`ER.:T3*I)
MRIGN3[\`2$I\X,T#$I(=<6]76L1Y2/C]SCD`\?BO_\^WIPUZQDD:QM%_^^Z7
M'W_^#N%H&:_"Z.&_?;=+WP7I,@R_0VD61*M@$T?XOWWW@M/O_I_1__Z__=?_
MX]V[BP0'&5ZA^Q>T>,3H]S#*@@>,/B;Q;GN&;N*O.,F?3F^G=^@B2.[CZ-T[
M*KP)HW_^C?[/?9!B1+R(4O;G?_ON,<NV?_OIIZ]?O_[X[3[9_!@G#S^=__SS
M^Y_*UM\5S>G34-(^C*C;RT/[EOZO[UGK7W[]]=>?V--]TS3D-21J?_GI/S]=
MWRT?\5/PKF(@#?^6L@^OXV60L1]3^3V0L`7]ZUW9[!W]Z-TOY^_>__+CMW3U
M'?GU$,I_OR3>X%N\1O2_GV^G0IN__D1;_!3A!]I;BS@+-M?!/=X0QYF>[&5+
M.C8-G[8;7'[VF.`U7^$F26KZJ(._4@=_^2MU\/_DF/FIL]/N_>6XNJ$?79-_
MU>SB;QF.5GA56J:Z)=W-3#-P,<U[W?&RIG5#@1,G]:^SW7PCWO[REY]_??\S
M\Y5\\(]9D.T2/%_/MSAA6$MOXDVX?%D0QSX0-?\L=3#WF1)]F2S,Z+?1E/FI
M_I6HO=J72G`:[Y(E;GC$_O,/([^T?N0:1O(O8F;J:4-<I*$/1^\^WWV'PI69
MAE'>!,W7Z-`(?<F;(=H.L8;_WW_]Z?![M'_#<5+'1I`LRZ]%_JGX*8H6/RUC
M$IJVV;O:K[).XB=31,16'5;\_HQ5Z&](2Q9E,3(RY1Y___C%!($9R:3XNAL,
MF<6.0"0Z1A]Q1)YN3A=IAZ[I`6O46`]H.S=!VRI>[IXP*;FHJ@Z`.P<`W+D@
M]N7M3AB$YWV"\+P%0NLJXB)^V@;1R]UCD.!I=!%OB!]Q;G;\D&!,@<4I)$S$
M*K6$GEAG@IEXU[VBT+0FIY:6DE'1ZD]_2A%KB:81JK5%^\;#<\T(([%M_W'X
MIB->IYQ'N#2K-/1BO[;=[ABE)0>=`Z@@-65(#2.TK"$U*$5^/'6H2BL4-V`%
MJ5.T#!F5*AJ%L;91`*R2:N5B_NEF//OC3W?H[K?Q[01-9^AB?GT]_C"_'2^F
M\QD:?[R=3#Y-9HN31ZFLA'&$4L!"YF,21%DZCE:W.'RZWQ&<40OI+5[B\!FO
MYDG^K^!^TP2\I72EK#&2[DQ+"U^[%SEF1N7<--$URALCTAK5FZ.R/9HGZ"`Q
M/$UML!1W[&`.90VTU)GK+9I=E$:FYL&0S>9F<FP'!-M)'=M)B>TX*?[-^HF"
M##W$SSB)V%?;(/KR(<QV^2B;*JH76=L@R2*2=-&:*4HQP?`C:[?"SW@3;UG@
MQM^V.$IQ2K0M=TF"5QZ49'VR2%J@]<$CD'+-Q!YTU69J&XY&I(:[QFF*WJ$'
M$9M>&9AE=5PO8`:LZFZ+D'5YB%;$ATGT$$88)V'T,,E#UPSS9JDLI"M5G9%T
M9_9:^-J]JC,S*B>MB:Y1V1A56K,:K](>%0*(2`Q/81LLQ1T[F$-@`RUU`GN+
M9A=5G:EY,&33JNY656:=H0C[,.O5)Z2E)58?H`8IL4SLZ958RC4Y7:"MKK3,
MM(UN)W>3\>W%;V@\NT27D]\GU_,;.C>&)O]Y,YG=3>[.T&SBP4Q9K\B6U5N]
M(!NPWJ)+VE:[#9ZO/Z=XO=M<AVN\H$6=;%61OE"ENM(1ZLQ7?<^ZUU):MN1L
MU%`Q*MO0%^QY*T2;H2^LH5^+BPR`$=MU&X=R:N$ZTSP!HHLR2--J5U#2HD<$
MRR8J3QF4TAH''I8@%8V&&>BY(DV3G5%Y7D%E7$/E28-05HXX`"%@\7&=SUO'
MR<OD7[N0U3R?\-,]3C@UA[)MI=20M.W,'Z4?W0L+F0DY2<22H\,CM'^&ON1/
M/:@<U-T;&_4"APM"F3H%!@&/BV)`;LP22#3UOQ(H2;-[5S!Q<KEU&/T4;G":
MQ1&^"5X$RS=%32I!L]VD,]Q%5KN'2(YF.:!;`J/])ZCX:'CD"GLIUOE5.2AM
M-JV#LX<>=Q'7N#;,>I]&L4/_;_,//9B@M0.`-%"900!DB-%2"CV@X!HP1,`Y
M!P'[51A'BP396,`0">TZ'P`)[TV0\(R3^]@8"^_-L?">AX7O4XS1+,XP.O_A
M:/'P'@X/[R$GG7$4)&&\^!H+QWO"-K4IY58;@/D1@5V(">.V:M6D1U-B5'Z$
MR&<>%=WB[HJU?EWNW$6C;7.JHH?.=S-)RS-B"(1\"I8#!0^J&%LL**93S=``
M-%G:U`H_-\JS8`H&4LQ\WL81N@HW=!U-O$8W>!4&61(NT31Z)H$\?,C7A]X0
MO?27FWP:GT#T4,Q]&B(&<&:3]L;5Y7B\W2;Q<[`19CEINTJF$[3K#'"I_>X9
M3Z1>CF^^5('PP^<>X5?>C;'V+\Y!,;=]'<F]@L-%1A0;L@`*S8PE5%!08B5_
M=OQ(D>9(6ZQ`3D96-GX]XW&2D-YC*X=O\3..=C@MEK&D=)\8R54WF""0G1[%
MB8Z===5VHEOK`MA7V?%[0.Q9MW=!M?'25O.H)HHJLJ@49DLJ2PVH4($..H8G
M='>,QJ!0X>[EM-39W.!YA`QRL[N^BS..V$337IU/085/295/Q;)DMD^?TFF[
M5^+!X-$7/BGV\`_+**#=_K;6X8\`Z.*)*T*10?5^X_H96N_8*4<\(J4<)KT1
MJ8T6'XD$..:?;,('NE2JF#`_[(^C-?=X^1@29P2OYTU%*W6MOFCG@&'J9?>J
MU<"B/`IH*QJ5+<M5`963!A`;5E9:#T]R8^#$73J40V!=%76^>@A:%X6BD6T8
M`-,R\`W"LN[M'<0@Q9JV,>C:S,@P$(;/*QBN+\U@'^THAH-7B&%9)>48PW9U
M4O&[LM\TQ<L?'^+GGU8X)+_M+W^F_Z!%U)_?_?Q+<<;Y_TD^^L>8V%M1FU>;
MX*'!!^'SX@?A/._$/*&];J4-3ZV8.NW6H_V?B/X]+/[%?1(K?\8&CEOM#F!5
M]ZQUW7Z3T$VXX;</8;QXQ$FPQ;LL7*;3:!DGV^)<'>$+/'/A2NUN(MPY@YA[
MVKU^-[(I3QX&JD9E6_2!+HZHM$:UYAZ]0+2`4=RM<SDI1%])/8EX"F,7%;VA
M=2A(TZK>%-0>S.7VAVII>>\>UR`EOH$YZ"+?T#08K,\5L/[Q589H:9W?`Y@!
MYT1OUN&_<:)92JG:5BLG<=ON/%3Y`5`724PHR"64'.6/_"UQE-T;&_4"CQLB
MF085A@"/DVI$:LP22*S6D$')A\(""$ORLJ$CFF"*`J%V\!I`:LD63.>O)B[)
MLW97+$$>^;3;;C<O%_'34YC1&'.#DS]PP-V#(V]9W8DC:ME]";[<!X!=.4(#
MBE7X`KE1_@`=GM#U:H@^&Q[LJAZ-#7YZWI)[OD1CX7W?6'&RB4=BR@HWY3TJ
MZTT<)VA+ON<CO2LT>(IW=-+^,<@0W9U(GCW%"4;+79K%3_2@[WA-GF)$-(79
M"WHBGZ.4^)ZN7^AR%+0,-CA:D3YX*3IB&3]1>'X-LT<F2%+#$].R"M/E)D[Q
MJKIR+/4@VT.`5KZWJ`-L8?89"72#[S:2V+%#[?D^WBT/\8[B[N5DXIU\DU$7
MZ$`.M(N`,6;Q8A%_P'<L"(3TC-'BT.Y)Q+[`ZC9\>,Q2W@C<6DEU:&ZAI'N9
M;.TYP&#>QK:BGC97.2IE4"Z$%C'Z@-%>COY=2*)2%.6RP].T`_!B&!CP:G9C
M98UB_CB(X&1BPLX+:%*XJ*G"B+1?Y0.W^Z()I1*MK'"2!>1YDH-A%[%F1U%B
M#4=`^11,[Q2$F;0Q-PL^FV/G`C@#N?4AO9MH3YQDWV_WV*,#>`9DA'0BJ7]&
M0![X&2[I.OQQM,I!L=]?<1-G%!#!YHIMLRB6HWT@CJ[FT0QG-TF\#KDU*Y3*
MZO&AG55V/R@2Z%L!'$;:W1/%49-=#8P*#>PZF2+8'.ZHW&M!N9K]HFBF",TC
M>ML,*G0-'W;`X!R[@!/O(,R.JAOG91X_]9P<Y0KADUL:LH-AWXCHF(CR,VF]
MHB)()=W9">BZ&L0AQTP\/S"1[E)-<R;NKU]'VST3BTVM6U\.P/64=+*"W#/2
M`1;KLQU]\SQ?W^WNTW`5!DF(>06XK%FEJ.8WZQP@9-:[%[\"[7+^<H5&^:?T
MMI3JY\-33MI]L>Y/S2$&KWD=[#U"PD51)K1C#@]:/!4`B=<D8!^>>#`WV`TA
MTHK%#B,@E057,72U(#1B`9'S*D1.*89(TZLE0D!O)&9G2-SB9?P0A?\F^?89
M)Y<X#1\B>H/C#4[">,7)BT9RM5N(M>0`KK8T\*][*M4UI[J^4D?+J&B&#NT0
M;8@.+5'>='CNF,$DMNY![EV5&O+-6RH]`J>;BX1U#0,`-;\\.(=J<H!J3*&Z
M.D!URQI[4`FXQJKBSF`W:`6Z)UC'$G1YH6\5`JSG!F"E-4J"-XQKZ6.X?078
ME=\*[`B[+NL<_<I&OY9QER"<URNV%8JD)O&V!C%B@WF=H85WUU#II7JPKQ?:
M%<*)`L<LZ1M`QTUB[RN5VR=O8;IF&Z^VIP0=HYQK`AW`O%H_FS):E5/\AP6`
ME_FJP%W2O@RXDG4[Z1$>A*ZM!_BX64/_71W>K.^&R2FSNEJ;!S9'*[1_A5XY
MO/D@BKX<+E;W8.MD-TA*CI>U0W>5_5;Z9(?*>DX4LVI&7OK:.^"`).USS<=O
M-+'%AD=$<7"$N:YEM\>7FWCA@B]T]<?T8C*[FZ#Q[!+=?;ZYN?X#C3_>3B:?
M)K/%&QT,#B3OD0YN*LXXFI."7W[NCDYS?OW(:0Y)::$WH"F.9T6;EVWA4>TI
MVC_VZ,0+K0X7\4P%$0&96F)"SO0-*L<WQ/#MV0.L40_5(.;+)6>P`-,M7SI`
M#/("-'K'!&8+\R[B)WKM!+-SBU-Z&V>&5W<9"??CKT&R2F<XFZ^OXF2-0[JH
MCUU/P5UC!Z:S>F1+=YW=SSV`^EX`Q\``N*(X0J&SA1'[;[%@OJH$';0@I@;E
M>MB2^OD:552A7-?P00(.T[$32/$.>^BJNW$LQ"DPT,GA.B!..68CNX'[C8_.
M^2@_N<<S1L*<!M39"_!S@T`\<DW(\X*0[^X9(9=50K+%*/DQ#<F!FRGC9D"5
MGJ&(<#->T\WII=XS=K';&SEUD'8,Y(0\1-'>&=CZ'K:R'S9Z>5'-NPQ4(!7#
M44<C\#CD)OZ`19YA">59<>ZV+*<%>7'V&5M]NE\MA?^U"[,77E6PVK%K6^D9
M3<6Z57HT#;]`\&$KED_$<U67@U%OZ%K<IRK<;?T-7WF_48V/)%^I!EA97^V2
MB&D=1\R1'6'&A$3P+4U-PI>8!E*52EE+JG,,,?"M>^6K9TP>"G1TC/:-V(*<
MLAG:M_/HA:<).&++GN,P4T.ZSD!OX.BB;M0UVQF:M`Y4@M.75Z4NH2FMT%R`
M$_(UZE[U9WJ,ZD4<D32T6TH7LNB*5!*`6J3[S<V:7G4/_1J6%!<TJQ2,#@1B
M35"UC4<!7QL)L4U/\6Y?5H@V;ET>'G5.KKO7L=D-@>QZ^]>,0?D]]J`HA(SF
MU1'%@EY`.(NC=_@;7N[H(LG+,,%+HBB5K%&TD*\M6C22!UAP9N$OQ+)&,[.J
M96@FVD:UZ>P%N\P3$0G$$?&(IG;(BCMW-G<MFX&>YN(VC_'M9H6EJ0.`6,_7
M8'+1?I!!![3[,MCH&^N*E9O]H!UT4/*TW<0O&-_A9YP$Y+>>WV_"!^9'<2(C
M;UBB+50=F&@(=2\2M3T#&)SHV%(4AVH5H[(-VC="AU;ED</#,]$`$[%=C_'*
M0Z5PHT#T`X-.ABIZ5KOBD0U72D2F>T3&!T061^]Z\&[1'23E8Q9P4(*\]],P
M`_UZ3]-D9TR>:V+2@Y=P#C$I>Z7F`)-V+\B*WX_]=BE>_O@0/_^TPB'Y#7_Y
M,_T'K5#^_.[G7]Z]_X75*.2C?USLDH18O`K39;"AUPQ.HM5ED#6AKM.T^&GD
M33M13<>+;K6'PH*835+!4?$$Y8_8[;Z(/$3TZ;"\T>K8V*0#&@R1B1QX800:
M^X+\VQ:S=],E\Z[#X#[<A%F(TX)ZZ56<%(>FBPXTZZ"E6K+;:.F>J.Q]!RCJ
MK8PK,IB%SE$I5"G[*V)EW9_2993[ZT<\.0BI"_AB("3P<J"YMD92/!8Z.!E?
M6+H!3@TV`BG)<:CV-A5RE.4>6_M8W@CBRY&S0[)#/FX9@!\P(QL+N^!#'4L?
MX.EQ;DB/O-RCEYLC3,H]6I"\<I)(!U)#D`1P+6)I_A*OPXC\]P..R+^RBSC*
MDO!^1U/`)5M"KBPM#35PRDIM#6`1PM!GN')2W[!>0-#5=P@%I00J1%!5!N5"
MWE60IACC4M\.J#S2:VKB$]Y;M+NL%DU<`$5^K4I\P[XV!`9&/V@]J&O352UH
M8A\6_-4:<%G%.NF;.,*(U'U/,1D4U7AP0QSP889\"/SKE'R]X!^PU-O?M/@I
MH*8C6FQ>X29M-%I62C=AR\ZD5?C0O103&Y!S3R0W.EP$7'F"R*/A.:3JT-C@
ME^<P0B!11W[O4'%1Q\A,6<&&;>G=`^>I`ISUJ0!'6DQT@0Y(<2#2#5T$R.S8
M(>?\])$C2\.=D`.95DGEE(7_S@]=7%_B^VR:ICMJZ").,]Y9*)H2U32KDNA.
M`SV?`-*NTI""#0KY4;4!/5>$-D%E&\0:><`.30C$%GW$XXI<LL&9H<'F)'%K
MF.P$O/K9'!'I_B!]1/C;EIWB'T;+S6Y%1E]AA&@@HN<$[!^27S\DJC!:4:C2
M.S+B^XS$*T2&"$0_G8P(TC1>ANR4@:]A]LC.\RB/'6!2(=O;PF:+?T3C#;%`
M+U%#RV!+_4U+!_:.-9WPX$68"T[(:P]`5L#4(@H;X#6)AKUNI#AOQ&-"C1RN
M93Q>LE^:8IY]O@K3)>70B:)16L]`HA&ROHFB7;"91LL$!RE>Q.K9`RV!:G6C
M$.C.*RV/`&H;E1T%F>3BH_PY*AO0/3G^S33H=7YLWCT\RD@%&XP9%F1.:AJU
MQ2Z`8Q5-#KFPA!SY21LC31\*!W#,R<L&,-3!%`UR$^`U@]I<)]"=ZX#N)#$G
M+0[@,`>W3I]5:LD+7:O_OOR#U@_O*^OUBX__\>&V`>#V@^)K5Q]T(D?;0K<,
M7],GQGBEV>C#[?A_3J^'12OGAX[%/U$#>X<&!XQ).LC^]`0R)MW@-)U\P\DR
M3/%\S<YBF^>C5TZ1J2=0/1]!(=!]P[B61P`G(*CL*+:!R\5'Y7-4-J!S:/EY
MO46;X8.O9N?'YMW#V\4M%6QLVQX69$Z.(5!;[`(X=M!`"3E<0BY>%\=GQGDK
M#XI,>,S)SPX`0QW,-91R$^#W3:K-=0(=6P]SP%J!,O20!%%QD"LN-CR>9+23
MWP\)A[R![ACGE0L6XI8WBO=\Z:N#B&]F'>Z&5_FUKNC+^#[-DF"9>7&FD@6>
MK"]VE;'50(W]):X]8WJHJ[Z!;_BFM<T;HA4]/!BF80__4]E=!/<;N\14DS3*
M285D#]2M^=@'9TN#7<F:ZQG5&K(#E8NFJ-(6?6&MCX*K==`8TI2'.#-^,@VF
MU.P9KHYO15::!H%NXZYD"7A9\]<!W8[)Q1Z\P.?)/H4959VO*N+F#GZ3^JFP
MC280!V-RK8*<[=K4K#S2LBXP.GR"\H]\0+R@EYJG3LKZLH[@>M/6R9&N>]S1
M::=M&V:]7YQ96O9_P#[T8>;0"@"JDT4-(``S`]A4"C[GQS-@B`!Z2]/NGNUP
M(Z,JNG!RV03$T>)!.F=GA@?0>;E2=\INS8CHKXZC98C3\;>0^^9.3X*;Q`02
M@."6^@29XD2&=!'/EZ\$P+2X&*;2!'VAC;P8P.AA0,`('>#PZ<&5%+%E(+2Y
M3:]BDYV05T^^/.S15J>)/,U4W1U[;L87+5.7,5UN91:ZZS)ZP;N4<4FHNE].
M`_C>E#61"@VJ()XW\SN,-_"@2R<NC#3IE,MJ$ZH_]/4<T"M&.R)1'=1/'XNV
MP=T*C98!WN80Y<L"9ODY$^(3E*7M*L<G"]IU/CM9:K_[P<DB]?)3D_E2H_+C
MXNP@CXY+EO=BK/V#<PY*YK:OGY*LAPT7I<QU&.%IAI\,!Z(M,;V"IB+F,JNT
MO'-:UE2M6>>3@Q)50J$M$6OJ=U)I0T0WKXC`I9E8]N+:N:5O6/9<[]3M=H>H
M1M7SBD!J6_]T@&E/PUSQD@P]$;V<`/=66\\KI[E`=]F%0H&*7OZLL]!$@BZK
MU"LKY*+:7.H+=3V'>OW5$TH5"@QZLUS"!0)M8[H%!F%C>92&*YPP^%S%2;$*
M@QO"I2UKD5O0$H`Z4A\@XK3(@(H<?+E1[0&[2*1XY`,/Y!T:&_SR7,QS)9I0
M[QDJ;H*KV)05;/)06@4.O45@DS_T8O5%=^0HXJ4]=H!69O!UPR_0$-NQ@\ZY
M!#HG@ASYJHT.R`%<P\&.#]J?'T8,/N,D"TGR_A"D^/=@L\/$;OYQ2IRX;4\4
M=]12R<=66CI3J(/OW?.XG7$YXVQTCO*3$O=2J"*&J!QB@JPP.(BBV\$GN+NB
M+P:"`H?B%MKJ]#\:/K@H5FS=`.<&+7+>V-$5&)[P`Z3HLK$+79#9^@!/#U+(
M,0H\,PK0*FYYH$#R1@%9%3@(!?JH'@\F[QZ#!,]V3_<X,2D<I0IT:D:!`G?D
MEWKLL%(4V;5D.E^=-`-64AZ30;F0Q[R7HTN/\CH(U>(Z5Y$FS?U`>:_UG]@#
M2,2KJKXWS'-Z?U#4NRWM^"9[J^K$YD%!3VJYHB/H*5ST07XQ['V0AFFEKGN5
M,+<JY.!AWOT,SW60WK,??)>^>PB"+5TK^I>?\"9+RT]8I5=9-%I\_(_QUR!9
M+8@5SOXN:9OB)Q.TZ41;J=UN=9=(M9AS?(D1^Q/1O[W8AB7OJECKEVV0@-OV
M@'.]CK<?AQ0EQ3A:32+BV<LT(F'KB548Y3D[O-&'@5AUS*$EUCT7&7@',+[0
MLZ9(-SI*#DNEZ=*+O!VJ-/3J:"0CB,2VW<?+*!KBC3QB`TO[R\/7:[QD1V*L
M_M<NS?!J&BWC)[P(OM%)AL4C3G"PSKB#?E/1ZG7AVJ+=;XXU]+([!0TL*JZ(
MU54TVK=$95.4MT6D,9O`1H?FP[/1&#EQEQ[EW?^JJ:)Q\:M_J'5RT;>);1@$
MLZN]WS`LZ]_>40QS;[>N,?`+NTT,`X&8WGNQ6H647,$&902U]+W)&:);]]C]
M6-GKPZ_T%FZW^`5\02*W^0<.DBORT+A&:@IJ5T@'0<<,;7KHNCJJV.M"RKT:
MG:Q"&R/:VG=2MN!B0$D!U/3I6"HP(6/O,.V_'*I9AH"L9BGTJD#;H0KJ`ML>
M*J"]J7[KGYI9$-36:Y^')%C1^[]6N+C_BQZC4*V'_O(J8&M?_'2";;^%#X&_
M7>%3$30K?)A@'\2L>-A+X9/;Z\Q'JD8_AY#61T'&*EQ,R=B&FB$5B0)C*O8)
MTX$*G](R!&397:4GET(ZHK9KY6.)V[XJ'VIJ@,JG-`L"6\/*Y\^O`K8=*Q];
MV,)=C*HZ>RM_-<<]9E'TN'+25OUQYP.V>-:ZGZO5T"H_3JO6>%2\#?;C:#EA
M?\2JWY!S5%:U6?V$+&F?.BS`YY'=Q&-%SJC\9G(])(>*?WT4W[FYKAF!:M$N
MO4GC8T@&5:`8YH(VQLP2`9$WS0,]PG.8HKLT#`!5D[G&5P'6CN6V'5Q[*K:I
MI?YK[=(J!%HE[U?/7P$VN]74EMCL=2YQ0:3MBIF:I%$Y4TCV0,":CWV4-*7!
MKMS+]6AG"M;\&/A8!XTA(WF(,V,DTV#*R9[A.DR)<S`-`EV3,N<5@;=CL6,/
MWYX*GMQ6_R7/P2X,>@TG&-^_$O1V*X<ZH+??DNAK;%<0'>3,RB$JUP<Y#_[U
M4@HQ<YWY2+3H9Y*O\5$PL0(44QZV,&;(P:^Q,0/[@^=`I4]A&`"J1F7/:P!K
MUX+'"JY]%3O$T@"E3F$5`JV2V9WC*&FZ8;-C.6.'3<A2YFF[B5\P3C]AP2%!
M@A;5\J39HCMQ^#8!2HZ68@4'&NU'^P_0E_PC#W;)BGHHUOA)>;"MMVP`U'5?
M.\G?'!-&_<YR<JOG/3ACV:;KY?G4H/,A3YBG*V!OXC#*_B=.8F$LDK2JQ"-N
MJ\XXE=CN'I?XRN48Y<F,V.IC]BFB'WL4I61]%VO^T!S`<EK70=L;&EQ$+I$9
M8V30"-;$1O[DN)$A#68VV``I_'EZH<M\D0US:)`2_B\__OSSSR<2+*0UN14D
M`.OMJSA9XS#;)9@6]+P4QVU0S6Z-!MW!RK4(D-.:>A7(K#<?'?[VY"AG0<_$
MZM^2A\-:PP8$W?:PDSS5MF#2VRP['?J;SB!X4%R;=[@\&VEW.4P.JJL$3S]M
M]48]?M[J\:/L<&FNT>]PR`RSBU9A]#!.$M(7F-T/)AY/J=I6\XZX;7>LJOP`
MR$82$PK@"B5'Q2-4?>93%:7LWMBH%W@8%\DTX#X$>)PD.JDQ2R"Q],>#DC<C
M-"`@R?-C1RA!3D=]#,+H.D[3>31^BG?$!+5*9^-O<;K%RVR^+N?";L.'QRS]
MO(W)HRQ,F$.<2`NCL!*.NRKL3#N8;]0]L'?V0T[:CNI'5!Y1!6@>H4(%RG6@
M:80*+6B^1J4>E"M"5!,ZJ!H^"@!A.(9'$2>:=%-<#SE'SC47>1#`(Y>\HQF5
M,>_[#='Q`R),"@KNK7/ND6=)P;UXC7#)O23GWHYR+]FK\V`PZA_YI,G<'_J!
M#*8[NJ`W^/XU)V"$'\B0<"4??@,XY)1_9'C/DM[W5$]G_KW13P8JO^D'.+7Q
MD93\6;$(9O$8[](@6BV^XLTS%LYPZ(I4*VNE2/=PHND50'6LMJ2(`RH%(]9B
MOQX1E8U0WLJCZ1!M+,0V?<5CH4*TP;/A<>>D4M2QV0V#K-J3H]"7F10W&)27
M8J`HA"FG5$:@WU9H&>P(0E+RT"W-)Q_PY(4'+-AZ*1[N,/D=5Q8E!$]0JY"H
M"SJD$\]#ET5%PYXMHVIJ5*$];WP4M.,"1I-\$K#I$;"J0)>&@P"UWRJD91D"
MM!H5R2N$K669TA6XCDN6FJG^"I>661#<'E,1`P9+NX*F,RP!BYO]-J'+,%UN
MXG27X.LPPM,,/S5OBM1M7BEDY,T[4TO'F^Y%B\**G#U2X5%E;^;A.?I"6R#6
MQ`,::75Y;-HM',+(Q.HT&1!6+DH,I3U[B-%R@@^R`\9.#6+28@$&9)`K1CAV
M%L']AK?$6]54'GF+IB[H4?/"2<0M+1A3(1<415KVU,\@6^]9%?IY.%#@GHDH
M,>\:-3T%U(,M.P2)`RE[?"H(,HV=!A@"CIGL,*1I=!T&]^$FS$*<7L7)31)O
M<9*]W)`>9A?J_FL7;@4+ZZQUU*.LJ0X((MGY#1*7C4TKZ6:H<52*T$5P%2%$
MI%`IAIA<?E%U*>D%12T1U^1N)^`V*&VFJ\5U__'O*,-8.`',A2(G[8^%VU38
ML"9LV!:"9Z2K*1WH'"(NA3U8F384'U1)KE=&@,PQFEN%GFZT\P":$.??C6[(
M#_5("1&O]P2H(_\5`U\V7]D[\`%G,2LFQ\MELL.K*_)C7X=+'*5TR\=#@D7[
M*TQ%*]6?OFAG@IMZV;W6,[`H9[&VHE&UFBN:(MH6[1NC?>OA26P,G+A+AW((
MJZNBSE,/0>NB0#.R#0-@6HY5(1P4$*:0(;59">&@;.]!!=8/AJ7UEEL4@U17
MVL:@BRHCPT`@IL<R%L#=Q`2NQ,VGZLCBU8!65BLY!BU@9?0IB()\LRNIO2[B
M*-UM,F+K"N-T$5\\!F'R%$3S]8<X2,0+V>R55*HE&R6=J6OO>?<*RLJVG,46
M*D<'&38?=I!"5`PM8E0*TKVD3-2C11P=H!?#`(%#?W-E]4!P)%1P49=9>@%-
M"UJKO1&C*RR\H`;D>Z5/P;?P:?<T?B"IF.ZEO`E>V#D1\_5M_!)L:.9>Q&R1
MUBU>XO`9K[C9TE9)+5N:*P$($;:>0V1+"]NJL&"L<E3(H+T0*J5H$-C+T>B0
M+],M17V("-:XBV%0P(T'ILJ:\>`H>.`F55IY`<T)FBIO,/FY,AJ94;`G1K(G
M0_H8[S8K%,49PM^6F/3A`^-&OG/[-3-#D2O[Y@;(=(B%6>B)$4L7P*EQ7E"#
M4)E2@\$=98]5EA0?QNL*7[+'(!.2)GE+*"OIY,L`M(&<D`DW.,WB:&]6/.LB
M;UDM%D4MNW-=[@-`V2<TH""K0&ZT?W`HW#P:M"FZ-#;X[7G,X$LTX-\W6)S4
M1A)35L!A$P)MZ/BR^Q\"./):I`-T0$?@<90];EYNB?9KNIQ@\FV+HY2W&%[1
MLAH>12V[(U[N`T!X%!I0H%P@-RH>(/H$L4>H>.8!R!4]&AO\]#R(\R4:$.\;
M*TZBH\24%6Y8="R0DY!G/VT8<G#^U(,7V1#0D<?'#N"!&74)=(,/K21V[+!S
M+L/.B4!'.E[I`AW`D<<LC/(+2N[";^3_A.,.:;M*6A6TZXQTJ?WN*56D7@YN
MOM2(?ES<C$0^9?_OSVA#WI&Q]F_.P32W?1W1O<+#1185&[*`"LV@)PT6:?:T
MA0M(YN1KALZ;8BLV:"$Y\]<?__I7GV[6Z@P068ZT!@A@?IQ?W`ES8NM9)0]6
MGG7&:LM.]WQ752F'XJ'EB/S3(^BU?_U8^J-Q`+9O4P>5D[YSD8SJRC7[D28=
MVI.^S&+I]J,TEZAZ$G(V:KY>ATL2^^E:%)QD01BIK[W6EJF&$+5,=WCJ^@40
M<C1,*2"LU#`JF^2+M_)&^ZLP?)KTUP=$;-5?/(ZH9!O<\0%^3J*FEM&.4&11
M5@Y&;P*P(RC*`S8P&!T%^,LPP4LBE4ZCFR1\#C*\2((H#98483K1WD`!/_1K
M*8`DHH''H$E!SZXV+774U1FZEZ"'2!0RJ"+D9_8P`9B(O^8@%5!90Y&0USX"
MW7'ZT?4`$O2MQ/0&>RT`#`I\T.P6X;OP6SYI@I^Q)(M)&U:SE:!A=[)*/0#(
M/B+]"L+QQ4;D<S9_6\SFTD<^D4?>G;'^#\^C`E>@`?E^8>(D=HLMV4"&Q6(.
M:+P9&72&C#Q^6H,&Y!6`0#7T.P")&2O,G'\W^N6O/_['SSZ]!@``BNQ%0`>@
M0+X*V-+80#/V+4ZS)%QF>'67Q<M_LF7!>+6(->8!;754TZVYCNY<L?4;($E;
MF%80RUCCJ!!A!?-!"#$I5(C1[5]>3C5:8RX&@0"/T*:Z&EP_!@8XJ3^LG`!F
M`ZM:C/G@34TS$!ODE5#/?+`<3Q:_/?O=UT%ZSW[\7?KN(0BV/]%\^1/>9&GY
M"<N@[W[^Y=W[7U@.+3[^QS@A7N7;N:G+LS@*#I]4AK[\+-I12_'C6VOI%$<Z
M^MXME]H;%\</6YVCJ@`[B)&(O*O(5">@2"Z]C)^",!HXEW9%7@P$@T;\L-1V
MB"!07(`OK,W+:/.BV7V!T%M!W+7\U2IVCZ"NM<K;]C6K44;N"VZ]5I_=:TW-
MRO*TP6=7(EK`#_1U0FYJ7VD6Q_.0O]+]BPWBQSQ[Q,D=3I[#);Y)XN=PA1/E
M-`F`TG8*Z*04BK8`WPPLD73S18OP74SL(T)E6%E14WE_24,&TX0*56BOR[_(
M`8%M7G"!XPPG^G10S@U0Q\Y%AUFVJU>N>5G-U7QFGFE2T[.9(0^)J5,8>$1-
MR/*"J+ZG%T7M#V9I'C<@K"$,)2N%@K9DYPADZ&/WE*]O4!X_=/6,RH:5L_-:
M)VIXE)Q-01-WZ$T.ES4UU`GK'5Q=9$43TR#092?<Z8#7E_35!W2EB<@E>(%3
M"CU9+:7GK$_3=!>0GW6^OHB?GN*(#9)G.)NOB[WVO/NN[134$XR1`@CB6G@,
MDF[,["JI:Z)N5+;/+XPI)>B9K;E,,:M$I.AGI9P75+8!6)/1]B!MT-I`48O=
M/@/=4:(R]0`2]$7:RF'/+ID)2]C':[3,89\RV$>8G4!9G+F2>G!@3_^X5R6T
MGI`/LI[1T"3T.D<+\Z#`/_]N-*U`/7T,R"]V5J)\SX)EG'IP^/``2)<ML.P1
MZ8`+,HGEU6Z9I9^":+<.EMDNP:OY+DO#%7%@FB8!WLAF!\QDZ^6;KBP$J<W\
M!"G:M$TJ&:RI:50V1=6VJ&A,J[.\N5]3!88(:K+7"H`-VNKI:#'6/_PZJL4,
MC`-AN:C`M-#LT=Q!+UA6E5M.T0PYAW"+4TQ^V\=QM,JO:L/[B]K$;[7UA2K)
M1D>H,TOU/>N>7K1LR;FHH6)4MF&OGHI6AYMB?7HA;`"+V*[3.&13"]=9Y@D,
M760)3:M=(4GS@@J4ON0#=Y"49@!X4`+'_&(IU9A=WR&+\Y*&]=C.;0A!)(D'
M(#&<KU])$I[8J++.+W_@5W26=683_NJ.;P">(]`">9\@<11A199L`%-$T@9D
M/(J='0&CBI&6D`&-A>6E.//H+MB00KNLPGGA4-6V&A'%;;OC7>4'0%R4F%`@
M72@Y.MPO.(\0?4@'D.5C#_"N[-[8J!=XF!?)-&`_!'B<Q$NI,4L@[:_LR^\E
MJ]T]=A^D))#2-T,47N31MOR!5_@9;^(M><I>)I'/_Q>FGZ]WT0JO/'AG!`4_
M>=#M"$"0]SMB[="O<N26;/%W7@UEVHC+@;8'WAG:[C%\0N"3O9SI##Z[5R[5
MS;XI7O[X$#__M,(AW>?[9_H/6A3\N;*]EWSTCT42K,+HX>[EZ3[>-(`L?%Y\
M9<[S3I01VNN6YGEJQ8QHMQX5?Z+\[V$Q+.Z36/DS-I#::G=`I[IGK>O0.Q(*
M@B2,YQ$6#L>%;2IU)Z=-YW@MM-N]SN2IEH?EML2H_`C1(ZC\&7"+NRO6^G4Y
M$;35MAXY>^E\%W4BWX@A$&A=R(6"!\6=+1:DQ9PI&D"*M[96Z**-;\$4#*1(
M^[PE91D.EH_HZG+,#F>8[!)2D`7T8+I5N*07UHP?<+1\0<&6U&7/@4^OY:TA
M(RO!C"$#N,KE;OF(5SM:T,VW.%H$W_[`09(NZ*+I!?Z6?2":_LG->OIBM42H
M(P9`!WWO(-*EEC455S24C,I6=(Z&MD.D(6(MT1?6%M'&B+7V@BT&*(EM>Y#+
M*+5XDV3>(---+M>TVQVE><87XK0)TU-'J:)8<(%3H))"PQ!\E:%I%`"FYQ68
MQDV8GCPJY?6($U0ZJEH$9Y'LMQB;E#)6N@3UC:$N4,):?0_82LC4!7U&FVEN
MY"+Q\3^'@P9\+Z7L4"J,$5U`+PH;1CK%L>1H.&16LQEF0G-/')&I5MK%!SH%
M,CJ]<<>X%!R"/9#K-]@1Z>RP]*OP&=/_%T^?*YI6DZNP:7?>*[P`2(UB"PJR
MB@1'^6T.^<T.]//\?SR:*U-U;6S2!3S*"$0:C.@?-DY&\#);=A!BX9P+(E]6
MN\%`2!YW.X$(9J@M4@X^O)89LL00&4;_QX]_^8M/]X4`H48Z1.Z&&LBA,-V)
M_(&N=[F(G^@N6!9&*J<M?W@Y-"E./1E_#9(5JP(N@PQ?!6'R>[#9-0'J2'LU
MHT-J[TY#^.\*4#>`.J7@.*"M$6N)6%-458<J^M"'%U1M5QYZQ)3FXP=$U2*J
M%S'%'D07!Y2('>.0%\'@K#2"WJF2VDE5!^Q>;P1GM2.C;K[6<EFE>/6JA?N7
M_+",HMVVH'C`*/[`*+ZB%%]3BC]3U3ZL##DBCLNKVR-@.4P-#>@/>-D-[%M_
M)"?%_=6>EW3&+\@JG'WCJ1VLCI6G[5'+L#Q];\+39YS<QWTR]7VO3'W?9&K,
MIG_I'HCL$><IEGS*R/O&6SN8'2MOW_LRVT"EHBRAQZ@$FP5.GL!G'(06P&8=
M.!8&#HK"[^S+,(7GH,O(V+8'-51ATGO5B-1^3T<_6A%3!C"BJG@)%U-;EB#C
MZA&0'WXE@@/_>F7_?JHB;1U22\_MQ*LSQ-ZC[[9T]V<8^[!BX0@9[7`>HE].
M>S`?T?;):$["Y2L%OFO]$OH<[/4"DSXD=*K]C?W=`'KL[!]^EJ/MDV\S'7P/
M^PT"[[\;3;YMPR2G_5OFAH#7L7/7AYF.V8XN\9BOIU&:!9L-_3R]BI/?<9J%
MT<,-PRGDO(>)/8A9$#U[PX50D]]CP&)*TTU',57+.D"1E=MA9U)7+"%B"A6V
MT,VQ1VXC`L+$<0O.@\1T';M`$?X4PHQ7*T:T'1XPY,"L*HGRH$/O9:D&G34)
M.L]%T,G+Q6.>N_4TZKB9!?(L[@P[0Z3EH3=K6+2]'3+LG'\WFJF#!KWW*?/C
MR()3BQI.9H]\BQJ0J_[#ARA<ATLR"AXOE_049FHFWH3+$*?7882G&7[B'9=L
M)E@=+VH*=H^+1AX"C.!T[2D"E)Z:4:4=.C1$94OTA;9%K+$/6VG,X!+;=R2/
M^%H*&@RV@ZD;(K(=MJ8DK`GI$K`0<DN^FF>.B5?:ZD"Z7(6:<*R=[URKHT*?
M9SPT:7,L/P=#GU_]H=#)R%K/:E=$LC&N'B9]&)\Z`Z5\I`@.2]#S#<)O;%?G
M)'QXS.81_I\XB<4G'"@;UX*\N#$`K52>0`1UB0T5=82BA##?BDWJ["D[298^
M]VG7L;J?8[/>X/)")-3DPR`X<A.6I=9L,96'80&JO#G_``Q3BFC;%54P,V)B
M]>#367)3UJ`Z_V[TUQ__RR]>G88`AR'I+$UW#('.C^169J'LZ'YA(TY&KC8"
M0WK;,EP&KNG6`W1%I!(;Z:<>XIG3:UP<"WN7A]Y#8SYJ':/`9?YL6#%%1#U?
M,DSXEB7-$:&5%?4Q`9H%*VI=9;^&"6-(L&SWZ\\^9CL++.AD-P,L0&8S^M:)
M>YX?V]8@3G`F<M6<IR?7'>HF_@%D1DUS"AYH:1FQ9L(#9_/M*![1Q@@IL74G
M\JBE(]]@FT_X=)*SM0T#8)5E=@.T^C`KZ1BN\KK`$6!AJ@<M2^`%A;95"+R2
MLD-T\O!KBZORHL454/N[\G$2D>_U\G>\V?SW*/X:W>$@C2.\FM)]F\V*1[M]
MY4I(1?O.5T1J^=.MLM$Q([]"4BX]RA\C^ARQ!JAL@?(FP]\RJ=?ML7'/<&ZA
ME,K5;Z4T`Y?]Z&"WW6[8ZJ1@,XW6<?*4KUJZ3]G>&-ZX0$^B.B)0271/7'H^
M`8P"E(84.4HA/[K[?'-S/?DTF2W&MW^@J^EL/+N8CJ_1W6*\8!^CZ>QJ?OMI
MO)C.9^A+*>A#MM+$16S1<;S\))=L9"9#!+K-2+_'FQWQ)'FY"C>D/!)F(D&[
M5@9JM0/*/`+[4!FGK5XGTS2ER@RS_QSE#WS)*Z).Y.03>7^W\TBC/2]_J*`!
MG3=NZ:'5.SS^%G+7CVH+J;-'3<A5`N%XYBR'U&U9I9&JBE&U#:HT0D4KDCQ(
M.W\3!P\5.KE#C":-]%$1ULH@,A2Z32(7NR0AWMSB;9S0]4IW69#MQ+E$WKR5
M4D3-@3*+W!NH!".THI-G!,)ENBD>H_USE#?P)>TH^IN3?;00TDY"?#%>+M+$
ME%O:L#QX$63X(4Y>A&SAMFJ1I-$*B!M<VU"4:"K784)=IB0`^Q25'_L">W['
M<=`NZ^$VR&NM>=B60P&DRIJOUS@AM!E'^4U<="8@(#_)19QFJF)+2U90<RED
M04LO+3]A*S"52?U"3*ZI7H^5;=G;DOS]2=D<L?9^E65Z^!%69R;P$Q5I4AWB
M6LT;]#IYTV=D'`C)[(U?%<MQB67Z/N5P-"+#\I)*^/#.KR<PR]_].88SS#M`
M;6O@[P&-+$.A^?R[T;2*5A3%&7K!&=H&H0\'R_0%7.F[0-?`[?N=X,WN?A,N
MKS9QT'S#(6W3&@'4V@#5_QR[4-5_7;5.[5^5*"O__#/$/O2E[N=U%J?J%_=I
MN^:OM.55_+*NAZCWDY</P88RY.X1XRRMS#FI+Z6WU\(?`^AK@4P_IKZ#C@L,
MC&MG(FV=HYH0*J10+E:;R_7RMOD.\!,E+TL<"Y*8KC9A.O.;$(Z'&D9N@).C
M,?R0TZ/)CM=-#MW!26_T@!ZP:-MU.'0Q\@&>'>?B%W]G#::\<C)H#GCZ(T/?
M@Z!;_!#2]2]1-@N>FOQ2-6L-A9K-@$9#?.M0`Z*6=ITQ44.H'!8=/D;T<U]&
M1H+NXPR.I!W='A_5F_.&2`I(P(R2IM$R?L+T72+[Q'J<9*I'-%+2UP.;^4S]
M!QXM&9@W2'K:6ALE82Z']H+'-68RAJ(X%UJB6I@+=?5)LJ'O!'$^>C)RQ`%9
MVB.H-[I88\0CPL"/IK0M.QU/&7GA@B_2,563.V_DT!]9]4F.OD=7%YC>+K.9
M1BO\[;]C\5(S0;OVBLQF.ZBEF'S[8&LP6^JU%E\VI/:K+O//$7N`R!-?1EFB
M7N2MLY1V>'N<U6C/75FIP(;U2&L1?/NP2U8XNJ0#N?!^1XEU'7P5'AJA)U`9
M.ZD$.B<T/8^ZCX:4=N2922$^(L]1W@!56R#2Q*,=RYK='YMW$">5R`7K.6-@
MF+D84VA8[`(Y.DJ0@<Z7\YO@(2<M[N%`!WFF++%T2RJ@<9KNGK;YOI0-^7NU
MB"_Q&B<)^5?P[3*D:W`P^37IKI4D#3;\`-Y%4SVRVVF"X&*7[P"2"RP=4#+6
M2B\C,I5$!U%4R*)%C$II1-L=Y%&IP`N6=X)ED_X`&&]$!1N-K7!Q7(1QE-6L
M77%"'IH']_S(@F\X1?3J,'JYV([29Y?2I<_9(Z8/44(TI@A_VV)VI`SIWWN,
MP@AAHG:9H:^/))5FCW&*T6IO*44)LX4]6"?M`\]4^7<PIH%,L-G:AIYBZ^*'
M&Z*=YWE*AT*K"B%1D*8XX_'IC4YUY/A&)\!#+HF!/W"0+!Z)B6!-X"^;H9"U
MK!>P_)80,4#F`T@!*C"@I"Y7CA&3/D&'1WY-.TC[M$DC#0`T2,*3:)&@7[28
M55]Z&4%HQPHVM'2B4P7T&L0Q*?U69:4T39,`;\I7)Q1;\X0\I(NDSMB?)XLR
M56UCC3/@V01FXFN\>(QW:1"MI"?AZS3GA%5^<S"VR+R!"[`"*WITX0I70NW7
M&)4-?#M'7ZO/N8300`F/$SPQ/C$&P)6S4"PT9@\PFZ",WB'B_J]Y;'ZAV#Q5
M)&K%YVY8M(S4'=Y$QT]/<<1V7>8'L<YW69H%K.?%KZ4UA-KOJ*5"4"^L-3P#
M>WLMMZ7U*ENF8O]>FS7*#X(X*P\BKC3TYC6W#BIX[[SUT<1Y`2X1YKX--T&A
M?9%$GF%V;0.]A(@P77J/GT;K:HDD:]T]DZE]`9S/E1I3I#&)[(@]+"Z48=>N
MT7+)J_O7=/H\-NP87E822S62TE"H@B^/%+:L846+H_<__GSNTZ4TD#"2ES<`
M0(*9(I?H-YH&5XSA%&;L470N"T\GBBSI+#,$LB!GB[_&S,A=^.TJ?);,;,C:
M5?,UOUUW(LCL`Q!`H%X!?*[4B.([ASN]Z(T^\0GITHZ,M7]S'K9Y[1NH[A,>
M3E[*"PU90(4M+#MEL,B3K"5<8!(K5S/XFV6A%1NTD%QZ_N-?_^)51=85(-)<
M:0L0!_F1I6-J0CZV5;?FY$IN:S"$2WR!RYM\(WH@Y\E6PF)>/K+`Z%O1J-';
M7`JHX<&C`4>*3X;>\>0RT8K,66.KGG1?![JT\G`7?('F9)Y^5YE99,L>7BQ+
MO_<R2X-`22=C=X(28/;^O(VC&7W[A).G"](X7`:;2_R,-_&61J!/X0:G61Q)
MKOZUU%#)\L8:.O/(TN?NU8"Y83G-3/6-J`":L14#1`25,J@BA`Y2'C'4%F8Q
M0+]S>&RHJ<YM[P'OHERQ<0$4_+2L,82_+V^'A@"_M"+J$_Z0J]5^QX_A<H.O
M<9#B<;3Z%)`,B]FRE?$#R;/4O#C3F0M7DIR)<&>ZFWO:/;49V903VT#5J&B+
M6&-V0T:E.3JT]RB56>`H[M:['`;K*ZF3UU,<N\A8AM:A,$WS5!W5@1C5OF2H
M_C`MS4ON40V9C?X>9H^/\8:N-2JVQ<RCJSC!X4.4KZSD)"%MF4KNT9#I3%5M
MO[IG&AU3<C*J-8PJ3=!^1_0\0D6S8NGK\,33QT-LU5T<DBEEZ]SR`GTN\H.>
MT8Y(I-G@M6-1&O*AT0@R4:NV`CU=JV>Q*QC/ZV"D.VKCB.T(^/SCW8]L+RV]
M+3C_=1"[NY,\C]>LR39XR8N6IV#%>H5^>!$_;8/HA6TQ",FSE*["I1(WZ_#?
M./E3BB)ZOU(2KT,?3B%W!G'9I#$XQ.'.MUO&NRA+7NC.@O?E'[30>5_975!\
M_(_I=8,O[0?%EZ\^Z,3%MH5NY4=-GYA,E6:CZ=WM>'+MR?"3\XO'XM^J`<5#
M@P/>)#UE71;_06\$?-H7WL+Y&&F[2ODK:-<YR$OM=R]S1>KE,9PO-<H_/HP<
M/<&CNAMC[5^<$SBY[>O!4@\<UEBF;^W8>SRZI^N.IL?%5_'J&(W6%5Q+6W=&
MMX8OW3$N-R)'NDQVQ)8JY`L8V&Y8]IRMJ_8'^#J]'1MV"8<$$JDZ%0;#DXO!
MF<J<-;;H@.RUH4LZ`(/`%\B@2Z8?>KBELF4/+S+$^OG'7__C_%2A)!OH@$`)
M<'7,WLP\PJI=F\JVO,S=;@O'`I$?@%F;8T(3^"W):DPE#WW<`J7N83X)%(#@
M$J`I(X!_G_AQFJ6YQBRQU,C0-33Y\KX,"DMZF=D23;!9N:7=64[F6K(%$\O'
MOWBURQ<,/%JYV!8\+O(P6PU+<[[TD"F=YKQLS&T.1P")-X`YF6]%$_T\X6HL
MS3<#L#&/9X=,:?4YGQ9JE'!YP1$34*-_7#G-U2)[]AAK9.S7@C*]Y-T)9[`I
MG&?`6187&>L`,Y;+W__ZZ^DB2BNC=T.4B[Q._T'_?ZZ3U86->3F=TQB.#T)/
M`/,YSX8F!=JBU2C+_LG^9^YGC!7W,Y\/*EQPN=`2$C"A7QPYS=]\:[:8:N3N
MTT>57M:VQA5LQFZK=Y:O^::L8<5R]<\__W*:&-+*T_88`LS1-P1LX8I$EW&T
MNG@,\7KR#2]W6?B,Y^MUN)2<GF\H6<G>VI*=B6+H8_>\KF]0SAQ=/:-]0[:-
M@#5%^[:H:.P1R4Q1$W?H3@[Y-#74F>@=7L%/432Q"P)<6E:\05?6LSV#%Z0N
MT;5E5*3HE;\FIF$03"J8JS!),Q0G*,4$.RN4!-$_Z<+IN,!NL3(:YR<[9X]!
MAIZ"%WJ)4;#=TM2.5^C^A;6YCX-D105688*7)'>GC!6_A0^/F-@H->,]/PH;
M9^CK8XP>@Q3M-EGX1+<./`51\("3,-@@\E6V<92&]^&&>D!785<<H@:H=(+I
M4NZT7+/==N5'-(U0L%J%^3WGM-&2T;7E#OK^8C+_@7W+8).R^YKRUD&8$+_*
M7Z0PD:!M^6-[<.%9+_R6589.^0U8,\[9S4XI,7B+Z6VF]'(N=L9V^I'@E-WV
M=$&>$T"2O]++$D6D_9QT?G*'DV?BV$T2/Q/'$_&.;*=V*O6H(SN=PZG3[]^]
MUG7EGCP\N[$Z*M2RF'A0G!_#GZ)"-65>13FZK,5JIA\5!M#>@D<5C%M"Q;UA
MEQ,[G=BK1]I7%2;`AQCNO!P@7M#ABU[$6(@BQO@M8O00,:3CJ6.-&2!C-3>>
M.1C9N7-TB,!QWDO@\&`T=?210S92.]K(`3@*K!UAR1;IMU<J5@9S.LU%9T.W
MFL,>M2KP!OATZ+85@S-6F\*M$WSS/4KLS:P_U8-6GXL/7I6CI,I'F9CDX-5^
M<05_]Y'*F#W`:(%[_N/[__!I730LFO2/A+;&$_RAT$T##LHMI;T.H#K7BEL>
M%"_`4).5$D!0@TSL^YN7=%.[E@#W4D-785C+(X`$K[*C>W&8(,E7;@[S.<WK
M];_@_C#35"\5%-TA-@C.'%YV:)OR50I&[WU+^N#8TKSXL"NZ@*\_["W]JRUV
M@MBY9E3SH0B`AYZT$("#'F`QP"8;&A>87Q'09AA'PH)`7ZA2%.@(=2:4OF?=
MBP,M6W(R::@8L3;H#W;J/2FNRV:H;.=1,#?`16S7:QQ>J87KW/($A^#%@Z;)
MKH!D,P<___+G5P$[:2T!#SR0FD+#C(.Z0M-J9_21^N(6TU5E["C2,%K'R1/S
M#&UQD@5AQ`XVC=$#BYHO-&I2M'I0;CA$J:SL<(!2P/)CO%PF.[RZ#H-\">,T
MNHBC""]IC]*#4"_B#7$M3E@7STD7LW]<[)*$]#^G,@'15RE:.NKK3&:0[].]
MU.GJAISVW;2/"G&TES^CRUD/*A#5@6I*T%[+&2KT#!\@8+`;@\.'$U0ZZ:W'
MFZ-F&'@1U]T;AU2CI=]>DN1>M#QP["OEV++&L;@41^_0LNCZXDSQ-[*)D>0Q
MW4#JTVX>."A=NSODDG.DX+T(DN2%UK7/P6:'49#NMUD$&W:C4/J(<896=',(
M>1+?;\*'(%^#%$:,>2O2/(EW#X_Y)A76DLXA;(.7X'Y#_IV$*35@P.GO5\05
MVH+(Q!'.2^TX*3^B[D6T-M^4,D3]\H7>BA2NT2:.'G#R@P=5N7=Q0%;+>Q,'
M[$8`O!L(5CBDMP_\F?Z##@_^7+EY@'STC\N"PE=AN@PV=%QR13Y)&]%%HV7Q
M<TI;=HIM&CYT*\3E!L0Q2"8W*A^@_$D^S\B>#<M-G1Z-#7[Z!ILD$@>>F&"E
MRPB87L*0WN2A^":AX3)[&4>KR;]V(;M2\VZWW6Y"4CQ*Q[VV6NJC77,M$`6!
MK>\@(UL+X\J$;ZQS5`JA0NH,E7)L1?!>$NU%_1JZ6L.OF3L[XKB1+TVUM;+D
M<1#"Q4#4R@=P9N0G"11,H#4KWC,A+9N^;@*HAHZ]4P!JF&ALU\W@T,H->!X`
M#02KPS[2T5L%M7Y$G]-\8RPI839D?)#O]Z]/YY1N;(K11(C3$QH?#D=LQ5BP
M?V(/->Z[P4D8K_1&?IRVPK%?K2WPZ(_C!_3XKV["9`18E6R-`?.'?HX">;TK
M&0>*P2`>"59D9&-!&7;LC]Z@>[O&:8JS=!JEQ-4="]_B@9^>0/4P#(5`]XVG
M6AX!'$^ALJ/8_BD7'^5;,/,&](7BH8E'XR[-WH_-^X>W*5(JV-C=."S*X$\W
M4)OK`C<ZR*E^?(K(DF_5!\,6S.9YN0D7N^#5%CL!C(P>Q@\/"7Z@8X-E.8X(
MGF@)>"8=29S11V7!'S`#9"RP"8KS<L**L1_+R%BVHY=!XV];O"P:WV,B&FS"
M?V-V.MB2;G!^(O]NCA.^+PXRXX\0SOP:(CB@BG1O.AQ5(,\,.UBZVT6KY$6K
M9.$VY1<KC::0%.=Z`5J@-"UH4[DNV"A*\H=^EB/\GA5Q0(8#`?9K(D+4]X4:
MEP5'VY`=?&B1D7]P*DC1+2DLL`)=1M25NRT@VK8L`2,K&CA5@;R**->84!"@
ME-EY]?5"%^QKU@@VV`>L"RKK2)[Q.$D("O.;VL,-3C/2@3?!"_U[S$#%J1;L
M%%1J"%,%G5EOYW'W>L/8KCPJ&*H;U=JCBL`9VHN@0N8,Y5+#D]$27G'W#N?0
MUDQ1G<R>PQR\0+(P#XEW]EIZ31(3*<=)ABR`_K0'^C9O7"3+UXAS:7'6'])!
M"CE#DP[*.PL/0.%^+@GP0MA[4&P-@'M98=8C[@&+N$M\G]'YHX0!]28)HV6X
M#3:YH=M\+G`13Z,P"X/-#6'28Y#B9/Y,JLO-)LZH4'[<(:>^`]==*?T`=7<.
M(>#?LWO!".F2/-C`61I15>B@BRZ3++05-24J]-$35@N-:*_R3W]*$57[;J\7
MY8J'CU3P1(B=XH\3W<!LU`/?2=+8Q1V1L,[U1&E:21]FF;9[-A^FF69QAFOO
MG.A43UA0>[NG=HIBRNQ@S^R8Z?>@"#D6:DM+=M_)#5+HPWEC-`8@\O>Q:L0+
MZUM?[#ZGR[?KG#ZSYO(;E<WQ=XQ4!AR[W(8/C]DB7N#D*8R(!_O9FEMZJ-H.
MTP/6TL=XL^*,38QE*V,/`]G.4<O8S^YC!Q.3\E"CKVG$FM*Z?M^X.OE6M$=[
M@>&CA3F`XD[]RN&ZMHXZE[V$+_@DLIEE(!RS@K>X;+&2],J"]_X%_;^[S0MZ
M_\L9/;KJ+Z\'Q=+RTS6.0<I'?6L.IHC-C$.!F1W(E@?>;-\%X1I%<8:><!O.
M^?6B%_'3-HA>T-=PLT&/P7-^C6C"XCLM"O?QG7X<'&)\&*&OC^'R$2T98X@P
MD]G?;9KAY6,4;^*'XCK6KS@A'R9!E*YQ?@Y&C*[">)GL_IW;9BL,LET2':K1
MPC</QHV]$4]6+#HG'N1M]^R-W-Z4\`!;:;OJ3?;\=MTO4I;9[UZ<B=0K+D;F
M2K7><GIT\*>\&V/M7YQW5R^O?>-FWC[!X6*Z4&S(`BB\%^(G!!7YQ>V68.'4
M'-:A[T,2_#O<J$.?M%TE]`G:=4:WU'[WT"=2+T<T7VJ4?^PEGN7=&&O_XAPT
M<]O7T=PK.%R$/K$A"Z#0T'?"4)&&/ENP0(:^HJ`7ACSN\TJH:SSOC&*NO>ZA
MK:E6CM1ZZU$YZ/$'EOQ>B94_)`>$M79U\#GM6Q>1J6W`H)]I)#K^GI8&'-V^
MA@PPY;N*>;+"R2U>XO`9\]X72-M5AY7\=MU'#C+[`,-*@7K%:($K-2H_1NQS
M5#X8'JWR3HRU?V_>.('7OC%.Z!,:X//I8BL6&&$CRA(E,4-)<C(HD8\G+7$"
M,H?-U^Q@OEILR`8L]8M!V+3Q?@'1EH\BM-HE[+H0TGC+3G/Q8,ZW,[!D<[G6
MP(*<H\4$?00;#WB^'J]VF^QCL%L^XN2&H(7VW2+!=*$`/83X\W;SDL:\1&NK
MHYJ$S75TYY:MWP#)V\*T@H?&&D<'$4I+)H0**52*H4(N/WX\E_2`EM:(BT$`
MP".SJ:X&T8\!__`5BI4'P$1@E4V-"D&-"MN2"F&$BHFE8JOUY@5E;_3@X<,#
M@L"47\96791F5DY`LZ1=TFUU2,,AB`]UW5`,D=:#?3,$L(Z</&TW\0O&=UF\
M_.<THHZ04O6&()!TRU^%D\$F8I5J44^L,_M-O.M>$VI:D_-:2\FH;(58,[1O
MAVA#1%MZ-&%IA)'8MO\X?-01KU/0(URZF`W7MML=H[0H>T,IIS=[PRE(_:1E
MR*ADTAA5:!L%@.DYO7^9`%&.U5<#4UEYXPBF_9V"?HT?@LV$^)"]C+^%O+//
M!2TJ)YZW6G0^YUQ@L_OIYFW%\C/-F^U'[`.4?X*^T,\&)H"LBV*-WY1S6'FC
M9?V(<E5GVU]317+U"J]T%]CJ-*]>/"5MWOTN$0UONE?3"BN*&T%DPJ/B*?)X
M@:56C\>FO<*[^$(BUKCA8CA4N:B%E?;L$<:V)+TVC,GO30)!F>4BE"X7IBR(
M6DZ=P'O,N18E?PQV$TK56O?RH*%5[[X3UOAPQ0G]<_B2@-L;W&M,./U5+0:J
MS?B7E7![U/[E;1(O,5ZE5^2KW`4;/%_?/08)IK?'5NZ+Y;VQ-1*LOJ;5%.P^
M\6[D(<`+65U[BFEU/36CLEU^_BYM2:?065LR=D2UUL-'>D.XQ/8=R9L5UU+0
MF`KW"Z;P[TWUS4+@M;CUL8+8M$!LRA!;W"!7OYQ\6;SXV45TE4_U8)%63;,N
M#HQ>QD]/.%F&](SIH+S*;K+!GKQ5=<X"^?M39SR`>5.J9\K%ZU%]RR!D.&<+
M(=-=D!\)28$KJM;KVZO38EMNT2K,TA[Y0XW@;\M'>DXE$PCHKNU'_\X([8%F
MTI>P[F@&^;KUVW*S6X710[X@1?Q^5=:N^D*5WZ[[_+_,/L`K4X%ZQ<0^5VJT
M_[A<Y>//4%O>C;'V+\Z;E>>U;TS#]PD.)^\MA88L@,+>3)XN5.1O&BW!`KG]
MYSI<XBC%XVC%+L1]V:?!FSBC+XB"S=4NVR7E^<L?@A2OYM$,9R1*KTG.G6Q"
M=@8&`8SPF@MG-BHAUX&-SHQT]KV[AWH7KLG9#V]Q5*A$1"?*E5:JN+U:E.LM
MK^=`3#.:1XCH1H7R,U11[\W]'>YX$_<"4T[(`[=5#Y>O(@J`SW^X\;#G<$`+
MB3(@!"0@I'E`V)^OA;;[@+#.`\*VO*\'5[CORYTFQ\I]:<%S;.P'F<J!]\K!
MK(\;)_L.`>??C1:2^:,]T7%://M3BJ@E\F.PYP1-013MZ,&5N4VV2X4=Z%S,
M4JCFA/(RW8-YGZ.-'[+9I*.+'X!S5.,'8O(*X^J^A-PTFRSCK5/2DZ@N55))
M=%]7HN<3P((EI2'%BA*%_(@U0*3%&:IL=YNORV$%:S9\'-`%06S12[RE)7+)
MQNJ2H>$&7DGKV.N$N_Q"$?:6@B*OOF<L(LC;GC3RY,N:`+$'4OFI;#BHXW1,
M=@-@46/5#CDFU1(**"(1_A>MGL@O74<FN[^X@DY$C-!KC$F1=M@&3*3H2[P@
MAW><H!0GSR0EIU3L.5SEC8,T#5-V__$NI>78=H.+HY1;Q]1M*^\5@X@I7E9'
MA/<X^XIQ5)S#3#^A`T>_CDEVPB)9C07*(L#ZA^U:*`_PV/?Q-?GP\_:&'7#"
M*8'TA2I5D(Y0Y]B@[UGW6DC+ECPJ:*@8Y7MU]J<:55[;TW;H\Q;E+8<GE0$L
M8KM.XQ!++5SGEB<P!*^1-$UVQ2.;#R1_O]MMBP.0\DWSY"?9XN5^K4EY?-(J
M7SR2TFQ%!_ED9)]2&Z<,5FDU!0]7D)I*PXR#LDK3:F?,DN)J3,J=(,G*JDD<
M5(O9+?)Q7M*P_@C0ICOF/2A['()>5OPX`#WD=5_Y[1+IG'1BLG@,HJ),Y2V/
MVCO#J8HZZ:E>`V:GI_M--%W\[UY.V9I7W$ICI;6\GR9%3`Y1P7+T\J=4L`3^
M$$6&)WHW+,9@L.!=#F.CKW%1S#$Q!/X&,FLO'%"%UH.WD]\GL\^3NS?8RZ\C
M&PCX,->465EV<669M2,NT%^?MOL3G<?)@@VI#(OT$;/TD='T45M)7U]%OY\[
M\Z!$')Q"THO%AJ(08+DY7V;Q/4[HYS?D5P_3-$Y>Z'WEBS@?>PC7R1M*5DI*
M;<G.<<+0Q^YEH[Y!.?]U]8R*ANQF0G1HRJZ<IQ?-%@-(?Q9;F\(F[M"?',YJ
M:JBSU#O`NECQ;V(:!+RT6'N#K[1W>P8PP&D/ZR"]9S_J+GWW$`1;>N3#7W["
MFRPM/V$YJ'+V0_'Q/\;+)5U.$T8/-_$F7(8X'=^G61(LF[,;^@+%SZ<CT(FY
M^AYURS!:=L3<U!`?W4T_SJ97TXOQ;('&%Q?SS[/%=/81W<ROIQ?3R1WZ4C8=
MF(L&((C-NZG!.[7@@6X68.N=8^E-\!+<;_`B"5;X(C^86TXRF02?97P)2)K)
M?`+EF<"0-M&X\J/R(2J>GB'V_`P5+;SBE[3_1033`(V`83Q)(<6&01KH1)JN
MO4Z0H_46^_LTD26LFJ"QY4.55/HUCE;DDV2'5]=A<!]NPHPDFL)/O?+)1I,\
MXNMI<L%/D^^@P]IGG-S'%KS5],.8S5IZ#XEEFTNQ!6\!E0LV*7J7SP+^S<L@
M8`1"57"P0+0B9.AH5(82O^G11UK3]L,)0=CJ:AE%WJC10()GY.C\!JF+;:-W
M2,8C#&T7W##CO#TJ8<PH)%%%=#],\75&8#C>B%X9#<X;N&/?F>WDA9:M[\L_
M:,7ZOE*Q%A__8W;=(&'[0?%#51]T(GC;0C>VUO2)J5=I-II-%K]-;J_'L\L[
M3V:O.3][+/[!&M@]-#A`4=)=_8^'\HL^*15F.-.;TI*)"$8X?!'09"3SRD%)
M)C"GGU^X"@YI)-D_)B,/#V<?I"`0I@,-Z(BB/D]4'-X'`IS9*$"_S!':ZH:W
M6DE_:'!&M^EZ.I\*ASOM.KT[\GR:^6(K9HS>7?`DY#-9=0D78PZ>3RYGIAKV
MC(<1-7GY,/HLGVCRBW8R**B*?PE^%"5^55)9RO<+.E>17F2J$^)J<7[_VHRU
M\#3,0^'-=#+&&G&N)E=J-B!OK].UUPUXY]^-YJ<;S4RG+.S1-<P4!.UO[A3$
MX4%C"H(^`)F".%B`F8)@^M13$.33T>?9=#&Y1'>+\6+BVR1$Y8=O34*T.J4Y
M"?'YKCT)P>FP7DM3P=1;M)J1'T-5I1H(MPM6+6&HD&[@*5@]H6=3*[[KJ!IQ
M9KN]"?LF2.%E`'.D<5*!AA)N5O`-J6:UK\F02]<X%&B+PIC!=G-HFH_%R&?L
M=,-\\WA^\DUUO\]\BWVX-:E?E.L4U`YQ/O1,"G7Q-GX)-G;)2DN4GZH4HI#T
MU_(2-$VI+&KS7:YHS_5],Z^HJX<.$7%-L"4@K52%D+*^(-/5$AP]PS`0K2:D
MY+6!5#>W.("ICWG%+)6890^WM.PE1W3A'"<3^#<1*NUE78+9,4J;1&YQU&=$
M[Q;$V0$:Y6?E:YW30I)M=-;&D@\QN#W\,)U],IUP<CUR=\<@KJT.(_-#4,;?
MMO2L>;\*'TE7ZX^E;0?/!N-EUX!R\.938J@#GJJU-&\%[NFARWYRQ@!?/H3I
MWX,EFWG3BM&"QOP`W6H,22:!)Z`\:MO0IE!3=,^>\H&?U!'UKX@W<CP(*-,0
M$O*E3_RX+(]YIFR!5-SI_ARF=-J<'E[_7#0X)1SI!E]+)`T==G=/._8NY!)O
M$[P,F6ODWQO,CMB*5N.G.,F*>Y](9V]QDKW<$+C0>9;)OW;AEG/>JBOU[=`.
MI!Z*S*#?%BQ]0'FE%2=@C(TJFE!5U1G:*\NW8E74G:%2(?D757G&FNRU>A.5
M8$G!BV,N:,>)>R!FN)'R%(FMF==_S:D=X0=J42NSP[G7'\?9704XI3OP@PK9
M5Q6=^?KIBK(W!MLB[F@Y/&Q]M%J%U+M@<Q.$JVET$6S#+-A<L'L#V#GXHLI'
M6[!9TV@(P@0U;0^!ZA`=>QK11ZUF=&B#:"-V%'S>#.7M\@LF/`DF^DAIAPE3
ME+7HKU3`(;8_"'4S4-8S"P%5-I-Y`.N6-'M'CY_.&[X&?*H3E!.$>I)4KL(H
MB.B]RM-H'2=/>8(,T^4F3G<)7N!OV8>-3HXQU"-,.=IZ@/EMZ#]T0M(W;T)Z
M7:W5"+"7014A=)!"7Z@<8H*^'"]BC4))N+`#M#AV:.J3A1+/N>$X%9IXX8`D
M-%'>?;ZYN9Y\FLP6X]L_T-5T-IY=3,?7^7X>^C&:SJ[FMY_&B^E\]L8-@\S:
M'SL\R;NULH![H8.1C-X0#N1,?"._G`[<-"YNT-/0'*[1"K@<KOFQ2<\,#+I5
ML/1J!BU9[<I7`+T^J?>_=FE&IW/217R+Z6\=LH,TIM$R?L+7<4H^OPC2QYOB
MTNL/+Y]33+Y`L1<G>A@OL_"9+5=0'>/JT%2+Z"Y,`<4'=[\":('AQ$V=D.3`
M\*BB%27X7[LPR?>8):4!=A\\R8GL1G'Z[R4Q0<B>W_(>E[I1L%?NR^&;+EG%
MB9C..=P.M/`F>?'Y544,\"6%KGP<)F#DTW^'D$'@LM=,C^I"N6[T/=7^`WU,
M#:#2`KI_0=]_SF/'#VAO!QT,^7<6Z=&'$8UAU;$&DH$'9Y4O)"ACV=3M-$UW
MY(N0_R4#3GP1IUFJ4PE:JI15?,8JX>.TY;=R$(W-/3&,N:8&FI&U^5+P,,H\
M*^Z;S[6<H5(/8HH\#)RV6)8'R&X,D89!0]6*<'=\O',T.=O1(;<$I,5-\;8]
M9?0*61NV3)B.>L[8!XQGRS>>Z6#'>Z;Y7T#06X3O`U((T6N%<92R>>I;.E)/
MPPS?X>0Y7.(;G(3QBA95#Q'3\GNPV36#0]]F;0J13F;["YH`OTZ/!4TW;X%B
M;A<G:H71HET8559+'>R@JB&TMX0*4RBWA2K&$+-V1%$=@J1VD1\N/%CEA@[F
M+?/'Z0>FX2J^KDX/'Z'8RWXJ_RX//<MJZ*F<W):7E?&6?GY,Y>-1!AJ8,O2H
M0LVPY>R&*<<K]@T^-+_!)#])0524&@DW2TM-89@X;.0I4)FG:U,C%.JI&NW;
MH6I@J]5415M/XI@9@-K1R`:`K8BBI803%_P#L)MR0-\T%))EJ?DU(5>=#9UB
M=]C,5-FU-5\7"_^B!^F;&`V19A:2BL!05\,K2+K*S6E05*9@5'V*XC5:X?NL
M,<7*ME.RSU=AR@Z*]X2S.O!H,U4?5"UV2D0YG!P6BN"+*%2VNB&1+6IH8''?
MPJM7:N"H4V<%,-P-FP&B+%R%FUT6/I,1U'*7L&4$L^`)7\9/01B)LH"F6#,3
M*,5@**CI'1`)U=8T:*A2,JJV0(<F9X@V0E_R9KZL#=*%1YN39L!JL5(ASF&F
M*22'YN;DVW*S6^'5%?G%:3VYRXJH,@F2B,24]`8G><7YPE<P_A8*BSOW%K4B
M`I!%A\$$]#=Q&8>@'+4-83#V1=$/?:&/O8YZL.S1#)@N**L7:T$LZX9I-W'B
M:"(\J2IWX@/;('7#1NU2MP_QN?X]O8C$>Y><Q]S"DC"ZEHH0#72HHHJ.!$ME
M=,%`/A=^AG*%)Q&.&P2`#KQ<?@&'V-P&>##UC[YNYN3!/.N)QW2Z9IZ_0J=]
MOB6__6.0T@G#RM+-*,Y0&!6T)@,B9I6>OGUSA^[Q,MC1J>Q'C/!ZC9<9^AKO
M-BOR``7$PW>EBV\$-T?F$5)\V)FI-,79]&D;A`E=%W!!W'K`PH&KM'&S>A$T
MAHEG4D^`Z@N1#8U`PQ<=L<_1X0$JGGC"='GWMJFK`X<6$[E"'&KU#Q\W^4UL
MRA9'-`-5,+0\/0RIXWDG%`T?<95G,G`;\2(L^*YFKF5H0AB>/5`7&8WO[B:+
M.X\`K[.U5M:C7'C+-K.Z[WGPEZAM[:8=SUZ4LD_\VZ9MA0*],*>-`P_"FC2<
M2<,8*(A=0-<`L"5,?<*F"I-:2!0A$+3S#,NP.`LVNEG'*.S0<+.@VE%P=+VI
M&5E$_>E!)%%<:,5KPXTKP-</\>Q"1AFCRZIJ$D7,\>UF*FY'"5"K>0]5M:T(
MP0Z[W6%\,KQCJB%31*OR^F?_HI89##1CF!X0_(EH6B,_05M9A',R&A#XX2#B
M60P(FY+-".CI*$'4MW(V&(T<&S(*;O2!''=S:UQ+EA!B1W!\OKVE9R/GDPR^
MG"8(@!RS>&J(G4'CZX<@#=/Y>KQD2_3#Z.$FWH3+E_Q_59<"F`DW(K"N,`BQ
MS#R%B=':-M6,TU0U8NWHTH=#RS.4MT)?BO]Z=ZB_(8I:C+5"89/`>DK:C/80
MQ4[RA8%I*#C3C+(']`WY@4C,]&CS7S^P568>M\#U(3=5NWX<K>["ARA<ATMZ
M=5O=^1"GFAFKDTI^'K-4"1D7.GTKT)QGZXEVZ+`SP`\G;*=B14,E>:)2AX=W
MX8!`6125(`@BB%16JH7QZUAIYS))VSODEG]L0__TXVQZ-;T8TV'BQ<7\\VPQ
MG7U$-_/KZ<5TXLF+:?^HI5L&>$"N84N&.$A6\_5EF.`E,9%>/-+E*T$DO7='
M3ZB9]A5",!%&RS.@U*VRI1$<Y"I&[#E-O_L6J&SBV>T[FI!H<]P$2BT.2X4Y
M+#6#8'\LO*"Q`2?;(,E>Z$95R89.6=,&X_A-07@F\P*&70(+:DYQ!4?53XO]
MU1[M,Y1V:HLS&A!H,H4GTN:'%F!Z9$60/I(L2O]#+QQ_#C;T-#F]F58CV29O
M]&1AB&3B)Q"S-$UJ4$U+TXC=BT+'C.P?E9;^3[6:P:C-5`L4MJBKHX/#9=]`
M[&0`IV\9",WLK1V%,3XT>3U058ZJ7()UT'$2W\-Q=A$DR0L9U<E.H3>2U<I%
M+5F'-!;XJ4/B+3NY]2XC]80ME=O6;8G<U#3Z,+X>SRXF:'Z%+L9WOZ'Q[#+_
MQ^1_?)[^/KZ>S!9W:+Q`'R8?I[,9G70A+6\FM]/YI<^,%^%*D_%R6.KQO:%#
ME^\#HMHL.>6XGD0K(%1W2E!M7=K(GI#/7R&F+;,8#*HY6<PEKL][*[IXEJ$P
M?5X91"R/J/H"QNWYD+@][Q6W[_L8\_*,0D'VO73<&V2H;.[352R]H/C]D"A^
M[]T8(K_>8!HM$QRD^!+G_S6;UI*JT)O=$JAP.3\@]=KI7)?(LO4D`5^A=.8K
MOY.IE$'?EU(_^!P*%$C3G570P:OFU`)7E?8,@R^H=[+/Q]@!6/C3D<ALLD"7
MDXO;R?AN@J8S\7#DM8+>=D;-`>P'GU^[VL1?9Z23R#^GT3-.V478T6I_MO;A
M4NS+,%UNXG278,4.)RBUG!S:32U8A('X=G"YMJ,W>@&HDY$\)U,59ZA0@O9:
M6*X^G(=_4(0.FKS;Z06&<6X@`V0/+[1U4<\/=R?`2V>ORCH[Y9Z@;,WCYYN;
MZ\DG4A>,;_\@9</5_/;3>#&=SQ#YO^GL]\D=6P-)ZXBKZ6P\NV!_72RFOT\7
MT\D=FLT7M-G\^G?Z@)4:5]?SO_NRP<Y?PFI5(WY1=MBJ91.DZ7S-KMR^#B,\
MS?"3<.&6K&VSON"WA0E.,C^`*@&!"8WHP94<L8_I.DCV`'VACQ![YDL.EG9N
MFZ<:6&A1CR?#X9,6=/I<VOCT%.;W@-*!2,S60..(KH`6KG!42K06.DHD@-8[
M*GV"3-52:SI+(,7RHXOYIT_3Q2>/!MT:_<U9`ZD+DA:/Q)*\%9$#(@OZ6#R5
MJ4[`8@NC#H_S6<]J@],$F[IB`H+;L'7.P:]#!:9<@JLE)`[E7"%HSDD\<Q/0
M^0:-J,=3X758EW6_C&QJV$C8QA&6$FXHN#F,\B)K7='6C/75R3'_EG`[P:%)
MW`=`HB_1OYF5]"?B;73HE_GNIO)L_'9>KME.GAMIK*84_R:]K?!D4MF93V>;
MZ#*J_330W6\TB",VOR!=]"YHQN%TO1D8;7G6X9C9T*Y'OIK0*/^DF-/R:168
MJ.NX])%T,H\AU>9\$O0`!S<O6'A&S'%1%E<E,L[0__7SCS___`O:!@EZIBW^
MAL:[[#%.PG_C%7J'`C8S>HF7^:[G][^<(4+=]VP$3O[QYS/TRU]^/OOY9_;_
M**67`:7_-[M\GHC31O$N2S/R#_K*4T?=K^_/_O*77\Y^_O6_%-K8,_+I7W]^
M?_9??ODU__`,D?_98CIUCS<OQXYLK7K/#-N#UW2%,^QZJ'3*\*`.YKS6XIA>
M;PW-99XO;@C=L&3$ZIIL@]HY"[TC![>391R1H$)"E*J4E"_]P<C%:%QDQAI%
M[11Q5X3<Z0GBR23T6B$*;DN.0+_1)IQGG-S''<*3[L8;H?3H<[3"R=<DS#(<
MH>WN?A,N24FPQ@D[';5V]V2EBDCCS:D!3[G?IBOPVGMJ!JP`#D6E;A70EE!5
M`E4)-Y1K^^2R(JA9LR!=1;Z,Z&D>T<O*>M_`4VYQ,*#FEQ`X2H951CYJEO6)
M-N>%0\-4)[")"HC*P/(TX69>2U@"SI?!W4V0S).[+,CPB@TZR^N`U2%>)2D.
M]6)):!*J?`2GHL2@$2&%>AJT).U0G*"\93Y'2'>.Y73UCJ)*R,BHJHDW"6%%
M&J3$'1ZL9IG#9G@@M0R"VW9"V<]6O@Z4FB064)RZ&+P*;3DY34+3+@Q.SYMU
M]AZG:$OB:OIZXJK)Z!86L9Z,>J5''`O;B<L>T(.,A?;!2QJ#XXK;4O5WF'X=
M22SN0AE=M`X>;K67$L&#XX4;XY3YX8V?[EP/1T0UV5,3<3/^YGCE:/A=MV0Q
M^JXJJ-.F&'M7&GA'(#$&U*-O,7*4@^^*J,;HNU^\N5Y#P#?8#7CM,CT^?="9
MS_E8PV[H69_MCN",'O2PI>O(5`6.K'4[MO-;0]%,Y@M81!<8T>(45W94/D#[
M)_X50=)NYC%)`Q<<"O&DN.S1`E*?M"$_8I0E[-*6VS#]YT6"5V%&_R6DCE*B
M11^)!!"%E#Z!IBF9-1T^B>5'M8=T+=J2/40)>9HO-2//5A@E>(G#Y^!^X\V`
M70T+#MUTL=2FG%"21[L!`0C_:DQNJA/^\A*IBD#ZZ1G*6Q1_>']M`3`4-4HH
M&#`.7$!%SSC)0A)1+O%]1D^DR"^>%N<!>?MV%A"UAZ*@W!\P^@G-:%%/(#VJ
M/$+T67Y`4_[4&UXI>IS'*BV0<!C%E^/R:1A<.1H"RZQU`%@1V?<0B^+,GUWI
M<+C2B=6=D>53G+X*PH2]8#ALDQ(?+:(M*8_=?$D7;)/YZ"2>"PP:$X^KAQ/C
M:;MB94.EI9>\E.)%Q5`-L"F8RM.@Y.RP2.TC0PCM@D"69@T&T?PE\?(H$@@X
M4$V3"AA4!TXT:39?W^)G'$GVN7+:M))'K0T0^3AVH1)"7;4.CZH2(_HGG;@I
M/O"%(KR.XI!!W)]MT%?:\N#MN-LUH^NO><='^(&NQ=")KTT;A@A@E?;\;D$O
M%[J=_#Z9??;EHG(;$&C$/GT8>!#/[H(-3A7OA@3MN'&MU@X0Y!S[H$5$VX8N
MS*M2S6"7>O<"2-27`M2+NYV/^TI[$?9[0`C\'#//@`5`\EF''"+LXQ/"AV9D
M-$/(H!&2EJ':9QK)&S=BI:@Q"!WDGL`P0FA#30J!**D19K]/;A?3#]<3>F;W
MQ+]CAA1=W**(%B2:+.$+M:FB":%^V3*-B!L[^B:_>@T]ARG\AAR6-!N",83O
M`1P[6OKUF-$0&]'/T.%#P@GRL4=\$'0DEPO23N?QH"[`YX`"($-E"]5YJ(K6
MTGP!?22EPA?`.EMLR31OU`X[;20.?]AA=,:D'B3D^4)RIN0@&(*NQ&5FK"%$
MJW(69[T^NA0*3\HZO2NB!J_9#RFA,J><_S,-X^@F"9?X%ZWB1$->6K-(Y1V4
M,AK^`D=S7=NFU8],V^CP"=K2CWS;K6<.(D6]I(]#>1DET:.JKCR"LHNDHF\8
M$,G[Q'-H?88J[<L_&-*9R.O#MU:Z<HUPCU+:IR#;)6'V<AEDHK>0:@%ITJH+
M.*`VSR,73&[8,25N3;S-T_(QHL]]Y"6WXQ5$E(!%SKNJH(IHO0+,R:(3A;DN
M2*,YH?S[%%%E&,]M<05V$H;$A)N3'!4&.V'K_(`MM#K1L*4\R@((8$,>7%%W
M:Q8\X<OX*0@CK8*@W5Q:#E2;.V!4VQL7I4#-BBF%*L+M,H`^1%_RQQ[-%$F[
M6\$F(4#D3#J(J7@D@=10'+H*EGC\%.^$^WM4S:4<JC9WP*&V-PXS4LV8*94J
MPJ,;`MHP3>/DA2V>/4,!>^`CASC=K>"0$"!R#AW$5!SJ#5)N9UL:=NSQQ)U+
MH8_1^"1A95A'VP#+40U=,>#B"#FIL0[X.J<1*XR6X3;8G&BH,BR=K3#E3]D\
MC0BB<)K=DFH^/YGN!B=T+W+PH#>SIJ-`6A;(%3B@GH['+J*\PJXI*Z7JVEF@
M;(YH^[/R_-R#B(\TUL*6@M@&^)037:9(17VO,-[#9*#2/"38:=&S1W?BZ82.
M:R@;5D*NP#SX.Z+\_!&=A6>"EIQ<U6H)1EB!#\"\;%O1HU]3SM>S`F2]R:64
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M$=P1D5YDA>)`G@OI&<[RQH(<T&P,2C^^)["<:]G0)UI#],"NXL$9NO"Q0!+T
MKY!)4CR(Z%,7$K.F1_PXG=W@F+(%4BU0^UDE=(.0=@RV`Y%/$5=Y<+ZRO3SN
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MIC<%D_^R\F8<K3[@"*]#Y?H5>X6JY&B@T$T`,?Y&CE*GB1\6445?/3^QTG_O
M'Q0:Z*EJ!QUL55RIQ=,H9`Y?=5"RI80R0FDKU@A8QT.S?M*VF3LN^58L+'T.
MV=F$)(V@YV#)&KUQ2(8.KUGD5Q4PC0C`ECA-;W&*2=<_$D\O\3/>Q$9;,#35
MJ#*^4HV;`*3IO:/LKK9N$6-42OF9/*0GH#(Q5,JQU%V1]#3RZ`)0'6_,H*R,
M,0IU&I'%3U+TDXMUG(!G!\V[-?RO*AV&\^CN:QG;&Q',TZUS*OB56O>O"O9O
M"G2SJ5A2E4!YDF["@]A'1VF2:]""^QP]_&1X/&\/)7A1TUP)-B6OVQHTJ#PD
M4AW=XJIK&02T-$<=$!J\+H2:YQX@C/J58;3'G'<D1R;4_YO@A29*^#E=H06P
M25Z.A8&GHX3?>>AI8)YC+N>IVO9`)HK/T%XQ*C5[&M\`>`(X$Z8B(]S$6,L2
MY$S9$3#>LQEIOG^]4I_6)0?:;H,7%-]OPH>3F+4>AKP.Y[7[I>_0Q5,8T2W4
M49:$]SOJ*STS8O*TW<0O.*%7["68?AHD+]5&BO/*(92V2Z1.2J%B),`W@PV*
MW1S2BH)=3(RJG_E3J$``E!?>X(#/B6<=E'-#V+$3RL%6\*[>N.93L1*;:D#5
MI^SLL#-4:D$U-?66?AU*[R,3=6H+C[CH0P51E#?4Z]RI]!8OXX<H_#?=BS_/
M'G%""Z($/Y*:*'S&^?Y\NAAPAK./01C1?W[`ZSC!I)22%Q9N;/'K#6A;D%'3
MS>\`&DK!7=2.K\"6]T&WT%O$VT(U.NBFJP68=E137YSO@;ZG:G_(-\Y0*_L/
M[IDI.AGD561VQ#51P'9*;4$4A[4I#.ZO)Y*XFOYQY.E`(:7<F_#]`WGR`XJ3
M?&\"7<](--%[Q<-X]18+X$%Y@M'`APJP5KQ2I]FT%_LF-W&:T?HUP73&BW[G
ME):T!.^[!(_OR<-@:3*9U$&[QJR2E79GH^$.W]7=H-C.*;NQL8VMT?5T_&%Z
M/5W\@:[FMVCRZ>9Z_L=D@FZG'W];W*'/-_,9NITLIK>33Y/9`GTI!;TY(A\6
M\UK#X^ZDTADE6UC1&RY#L';043-[C7`5)_2/\F6!S@E&=GK4HUV5'E?UIY[_
MSD:I2O-6Y:)"JVATR<1824@_J"P!\/!<)4L<ZE1_1I#6J.OD^K1J-C_9T=?(
M2\,+!S2A(Z:KS[/+.S2EZ?ON9G*Q0/,K57I_8XC-V,<Y1P8>LY"AU3)D+^>%
MJ;7=I)4UJTV`*-^V"I7K:IIU^%D1&%7_\H51G`[BD$78C6T6')KR`.ZTLQV%
M[H8!LU[/7S96?A2Z#O%K$F88K>*O$3WY:1U^(V5+P*A^K+#0"(^ZP`"\M[JB
MU.BNZF><W,?&X-"]H;HF<A)!0>/F:>W>'_2&Z?WX=KZNKCV[Q1NZ48/=DG'W
M&"3X/DCQJEQ]III]`U':3)L=E<(0#.2;`:7FKKYH,+>;B='=;^/;";H8WTP7
MXVO_)LQ@8-J.$Y#P;\653LHYD0B65OU%KDF01&'TD-[@A/FG=YNPIE0C]BBE
M0(*+IF\PT4-M3!T>5#I&90-Z=SUB3?R_:587(2W:FT&KR6N%=)NX7F#2R?A#
MQV9G<)8OTMGK\RV!9TH;G38$E4,6:!`..EO3].U#D(9+>LA!N-F1S,;>^!RR
MGZJF[:A-D5"TM3DAM>%W<9.`])TPY[ZN;F["8L+YT3VY^%FQ5*^BP;O:MBM<
ME:'%#O^J@*.I51V(CH)0O61/$U^<,8MFV[]/Z(N6R24:_SZY'7^<H-GG3Q\F
MM_1=#!LGWM%_7<P_?9K/T-UB?O'?T><[TGHZHQ_>?%Y,9Q_1]?SN#MT0H7QD
M^0Y]&-]-+]!X=HDNI]>?B?:_O?&/#S%/&0@V]VEKW\TT:1=OW+'P_(V%P[!0
M-5L\.`N'G(-6^&Q7D-L5WOW$HB$B#D1<(2/FR:+)_F:X.-IH8,WZ;MPVYG`_
M&(7>):MCKC-`:9FI-80[;4!V+?J,(=E7$6=6K,$,F&!*,EIZV07/$X=JQ\K(
M'*H^53J&<XZ&DXJ.)SGZF1;L-.\GF]CS?LK.?#1B.>FF/YKH"5&]S(MUG/BJ
MSFRI`_NI(<RXPC#'V+#OCM9KO,SFZ\FWY2/!!;X-,CR/+H*4GI)-_S/YURY\
M#C:2\S]M5#0#NI$*&$I:>`U)4C/S&K0U43B:7%V5NP/^\^*W\>SC!-V.%Q.4
M__L.$3I?C.]^\X3--@!K,]P>IBW.&ZCBQ`&_P0X^'C:U#8MU-E)F[>EZ[%("
M41$41XBV9N-E]H^*W&N%OCKA]09^#Q+C_FB!1?"-NDI/(8B6X29?T#S.KO`*
M)\'F+@NR'7'DI=98FB]!-'/3:$?-@`$'Y#M"1J&N#NF&IFYV1GLEY;%(]*@,
M%K'JBLY0D*%"%]HK:PKY%,E@4"\(<)"4XD>]3A9$P?!$^.IF+`OD5R_$9:=8
M[UD8YBS,"`N3-Q8:@^C(>#ALK9(?A(GO</(<+G$Y&TPW-50.V=XP#\B_YNO#
M84HW[!PMMOGA.HSP-,-/PG&^&RO-&@;:"DQ\=//=@6H;<.<TPB6PS5&I$!4:
M\[GK=VPS3NVVCS-T4$N'=)6S)7/-B*E&7ZARQ+3[,N_MB$#M0.R4J:V0#&N-
M$YX=AX0!`G46+_\YWU)O/^&G>YRH0JZHO2AXMMO#AD&1/\`!C6/&(#2UI"M!
MACY#^4/T)7_L6Y00]KF8[PJ8")G;E)-PL&]DN1E62*UU@!@=`A2H(C_AEGSM
M1Q*H\BU7*<U6I&1\(@]3AK_3!9ZZC@>`GO\U]RR.GG&:X=7X:Y"LTD6<!9OJ
M<YJ89G'V!\Z:*>LJ3HJ/:+M?NI3DX$[85.R`3O17T(/_<CW6^Y"^`PT'X%PR
M&2WLK:+<[!EBANLW"%+3I&6&7G!6&5&<E4,*>L9@Q0//`G:_[+<;;KB*0E:C
M$3!G+`<KKSL:NBWI^OL*OH5%6GQ^CI+#?,BR&N*61,T92@[MO3I#_W7&,OTR
M^55$L],LZ/NNW?LNTWW/04=2?`^;4'HKJ4\\W0R0689*(3UF"]]#S'%5M$,7
MKZTZ-:U$FEK-BO.[HM]BACO`GG#4\**<+(Z7O`Z#^W!#RER<7DBO+-&6$Y1W
M$CG0&*KT#[;<DIG3#V5B+?ORYUV2MT&51F?HPJ?;1/0A(@PHNN@2A06AO)C>
M@P/3:9*66P5`*$V:-\$+\6W#]BN4,"U2I"_[%1Q"4SMG08)SV!SRKUV8O=`T
M%T?$E\OX*0A%]W%(VS9S!;\M#`UE?@#E!($)#99Q)4?YQVC_.?J2/_'EQ;RT
M:]M$TD!"BSH\&0Y=M(#3(T&^X>6.+MR=K]>D=$SDBZFDC9L4$32&X8C4$R"2
MB&QHL(0O.MI_CHH'OBU@D7=PFR@Z@&@QA2O$H4K_`#(K</3/VQ(;L\42NSDG
M3/"2Q(64E3,M;*4G"2YU#=,)7H-6*U=!F/P>;'98_ZQI'9%&8):+@+!+QRN8
M(*VPI*:75,'H:CR]1;^/KS]/T*?)^.ZSI_?Y:J&@13`#[#1))A-M4\T(<</2
M374IB):,!N&@+U_0\LL=Y<PN`Y%K&-''B#VOGYONW?T?>F#0XIWNW1]263WF
M]0H])U-&:HL=,<@N@N6&_M,%GK*P@H3>L&56G.#P(<KGIY8OBR2(4I*)PCCZ
M2`;CUW&:TG=KP4:R],1&13,K&*F`8:J%UU+0_IK3-L(/;.Y/35PS!S18;*)P
M=!5&0;0,@\U^SO<,13A#W]-)F,T+^;0XVV85KM>8:L3I#YXPW@9P[0!@#]M6
M-#!0Q0D.?H,?^@0G8]NPR&?I+&^/2@%4D4!4!'U/A7XX0P>YUPI]=2KL#?R>
M)LIT'*W8GQNV=B#5NU&QLS[M%*K4YSBD:'X?U]%%[4:70*/2+HTY^:1E5=S[
MZQZ[P]<@*IDQ0C]`*?2:1"O/2>9FZ-G)&X=L8SE^%[&FI,!=%@K>F".&A<?<
M&3;M[Y(HS,AXG?AX%7ZC_TJE[X75`LW$+1&`"1I*CR!C@LR8!N7%XJ/],\_>
MY6GT>)NQNBAI$5(HR&'<<,@"'S3*+74!5IXL2FC10JQ\?M(X4X=^$*0-&KS+
M(>0\N@LV>+Z^2>(M3K*7&P*6C*X^VCZ)ETZ;"3>"NJXP"`W-/(4AI+9--34U
M58TJ$S/TK&W:F)Z!4S9'K#W:"_A!6D,4M0ALA<(FE?64M&GM(8HU$XOI9+R!
M<2A`T[S#($T/<"JPO`Z_X14*TA3[<F1\/_A5)B.W"!XV227$/^+7.A1FHG:+
M9KJIMH!A8]LF4.*H*=8@4Z7]B/V!\K\\X0>G;]HD$'9@"^>'EAPPN^QEPQDB
MNF-.(ZPV]!MU-PN0M^Q^J-OYU=23Y0:F':X.;9I=/FB0FCYM@S"AL7).[T'>
MQB1CS=?7<?1P'3[CU9AE++T7'UU4-<*>G2H0YG3Y%H#3+99NJ'EHI7ATD$*D
ML'EFR]9(6;,A8N\V5,ZKVJ83$EN<!\!U,S38J&S'D"-C"?34D;4/;DA"LUJ%
M)G&"2DG*%"K[C@FC7/K,^S>!P[-(F6*'X]&P29M=*4%OF,#4Z^OB1//QMU!T
M*8.&1#,%RR1@8HC:)Z!`(36D$0TD\J/B%J7]4U0^1E]H`U^XK-'_;<IJ@Z;%
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MZ3IR#;(!E5?'[>AA07=0I77\CE16>V`U^'$\^U!P$4=9&#W05:/7BELEM61$
M28LO`YN[9'X!IS"!*8-,QM5036B5!A[>D*@'!G%^T\"0,,WQ9"793@MZ0U:(
M&OE.W%Q9)3K(<F)O7%6*QKF-(RRH%CW,:)+>UJ@8#?)86TRG:O0G>QV&?LHW
MXQHBZDD,\'=X&EXYF\8P?&DM4U"EUN&YAR>I:,%`9T9#^S6S1%1K3J-/R#G9
MR:8TV`U[])UO8QKM5*&F?A<+!C8/WJW6*[=%<+]I`EN[O<:@I&CO;$!2\\?=
M8*0T8S<0R:6%@Q#VV+=`+NQSK;$'#R8ZXPXFIS?FX"-K`#9I+B%4-!=QR=$B
M)X4WP$RR6LTG$J[PZ`A6&JFZ74PGPW5W`C$)F?J%EMLBR'(QG%B\1%D6?//E
M:@$X+.E7/-9H&KK227"0XDN<_W<:C9?+>!=EZ2U>XO!97O1HB[9CMH8H%,FT
MO02+Y3H6M3BG5C0J6Z'ORW8_T.7995-T:.L--_5AP^.I*>@XC%6JX++7)\@Z
MVBFI;1H&O47VR/%+0!N4H$T./4'W[,?9(T[\VEW@',4ZF<<1CCW-2#?!"_5N
M'*W()\FN=@6/<8[24::=M>3*'`<%G6\"6TC:.=(E9$A5C\KVM1"RS458_`BH
M4+!)T?=AM-SL5F1@S+8M(?*=GY`G!Y]VQ*I!D#'`OG[0D2DU"4/><@E\ZY*]
M%ZZH5,O'@GKRIL*K0D/U_L,W+O$0XR6;.&F^5SZ=F_!)^PJB#LXXH]7Y6XX"
MY=6YW[PZ]ZI\OL1KG"1X=8N?<;33G\T1R"F+XI:<HQ@C\,]IJ=NV:1,SFEIJ
MP6%5/"1C8/:T%A"B.'JW+"XHW<8)7<GI;600X4<C",BAIV9[0UZ'V`.AUGU1
MR3,(`%I)J5BV1$73TP>H1:'7':*>S=+,MS@)Z"OGBV`;9L%&O:7/4($R\8@5
M..*RRF.GJ4ABW(;>0G6C"W933$J9'9>-BKE85KAN#I7/WWRENA);&IS7Q*>:
M^B)%.C'`&XR[3UQ2RY`0EZ2RO0@J9'S<(-LCUBT2G0NT>Y;ZIA%)R,2:R7L(
MCHPRP=5D'/&=XY?C-XQUBS;$KFJHC:7"PP-?V<K#@09!Q?!1,[(BJT/"GE'G
M/K$TC76$G"1]3%\#_BQR@CT"/8O\MY@DI'!)(M]%D#YJ!W^^F#+^-\4<D9'O
MG2LVMJS9T+&A1,3'0S-$V_G*20$\-&@I!9::EW5Q'6H.`LG>%C]QS'9'9YXO
MGLEGY5&JR0&6*[R-4U^.OW:'3(N<T16;`V>.#-->GN2W\5[B>_+/8E)__$0G
M\O_-CF409A`S\58FT14'HJ^9MZ#39-JF=8BLJ6Q$-]O0<>DNV!`^YU+ES<N^
M4-D001Q*6V&P36P]-3R">XEB^/&*@5TX$.=9J8!NT?@,T>9G:"^`JA*O#=@:
M.<LUM'W*87JI2B\CN:&L4U[:D*_-,"\YI$T5,SXH8>\&!4ZN/N'9,(8#.SB`
MVCMN%)C&124.O(AR^6Z]<;1JQN;#405T`9AZ,W,W=8*X::X.E%JVWP8V$EMX
MH<]18^6'V)Z+LG?CS7A?/YN&K?WT<"-V1\@*`T9'$HCBBJE:<0`Z,EHYVBC>
MP1EW_*+)\F[YB%>[_#+%%K-N\3)^B,)_X]4;C40P\99(7J3\8DUW?H>]>-V:
MK+$@73<;@T8-OB<.(D++D#[;&Z*'7%GL@/"+LH*^%1)2B@41V>I"8BKUB!U7
M4UD<*[;0J4U3%8_.4/'PE%"D';3M<.1)P`U7,ZR.M+56PA!;M`+F1\VVDZ!:
M6C"A1"Y3#:.A9V5/L]<DL.=UKQCMK+4,Y@YQX"Y`'M0;PZ`1$L/5&2*?'C<:
M#**?'AX&CG?Y^J47W0/PY,U;$5#4'(@"<F]`8Z+0E`XK!,(C#U?A*3J80P\M
M2+19PA?CT640$,$'5(D=>PR52W;8LV,X2A$*7QIQN"O"_(C,5V$4IH]X]3&.
M5RG)%_/U+4YQ\BQ9T:\M*8K7,DE8UJE]=!'%I58-R"C1,RJ?H0?ZT#/Z:4!#
MS$1M7`DI*=8@8:</H'26%10F03#9R!5[@+*6K#2GT]=EZ]>!6/TT`HQ9/Y*+
MR24A:A%1.G%Y8X/:*Q<)Q/ZF$(F"T73V^V2VF-].)W>>L<_PG@9MJ`C9IGE+
MPZ``<Y8,NMP&(E5Q"/^^7T4#C3O].-\9>7Y$=MGL=;N)*')#SE>VK;J(S/HS
MUA4!CR=B%'.3PJX4XELP)^FTPYU%2I.IZ9I(M1#V:$[:M-/UPYJRVP'/7*PH
M-3I)47N):\.`8>^?%XM;]YOP7XZV^]7'#6IW_[!'`Q:._#T),WP9?Q5O-Q,U
M%&6P2D-8=+<\``YM5?T&`#^(58H]]N&[%?G4,Z2WNU&,=U&7"S&_%Y`@WST\
M'"V%Y)JQP4E]6/#UI)"BGQZ-L`*?*@^J71T]S#5DA9=S/E[8JG+V)XK7ZY-`
MCW9V-4./%YGV-OCZ*2#1)@PV9F^5E(*B3"P1A"63TD/@3"VS9\`PL9KJ8(6T
M0OMFOD_:J[$BIJ$NSH2D%"J0D'1XC+HM%^1F(<!*RPF*T:?RZ6N`I'Z=`0I*
M/V8:#U.@RH-UE1+J-TC@QXHJ?7(VN6]X+JY8OOKBR,-C0-6]KC.5KWVHK5!2
M:QI?B*\A9D/BY)_3Z":)ES@U*]+4DL+Y$HDD\)A'Z2/TC(K,H,E02*RG6JG1
M9O0,K:*A[[6:!F0D8R9=O(F'4$(-LC&5!V!U/+\CMPN"6EJRE6#=YL]?!S8-
MIH=@T3EHX79-SZ`;/R08TU/^TD_XZ1XG@H0B;=M((8*V(#R4^@&3)D0FU!3C
M2X[8Q^CP.?J2/_&D+I-W;8M..DAHTH<KTR:,'G!Z)LACO%E-GT@X?-:EB5R"
M1Q:1!!QEY#X!$D=H2),^`OG1_B&J/O612HKNYQ-*"S-<6O$E!>32!%J/%#O<
MS"(_U$#<L$DH3D,8'@D]`*(/3[\&:]IBH\IGGNT\EW1CFQBJ+F_QH27`H4%_
M\'!RK)O`C`U.]H>[H?*^OHUOE^1V@XNRK+<#S+!%^\&=&?G]=&-FNZTX;%;;
M0E.C[0=X\*R9,.)%1;(>0@\/O*,%IV-ES!#B0$*-@XR4'?W`QG50;5BRQ,\A
MM![N1_8YN%JCR"3$&N/(ET!;Q'W%6RVU@+)2!7ZGI?8(<*92:LRF/*E<[_CY
M]G8R6Z#KZ?C#]'JZF$[N/+G&4://->H4S3=:8D&=JJ4W;$&O\5=8Z@(M&J9Y
M8R7OWIW"XLRB+K9!FB_A6QVOU0$:GC7.2&+*B1H%O(.[%K[UX2S%+WPGNZY6
MS2-@I3(]]EXW"6/2?O<E4!TJ7_U24RRC,\!W5Q2(_7(XX+>M.#D:1!,`/I<&
M$BSHC>;,"]&VK.;8KD_D.5F9H;;8$8*L.)W//J+%Y/:3WV,?,.#932=80L^7
ML#^.5G=9O/PG?3E'L#?YUR[,7O0S@):X.!DHQ*'9J>4M>(I0636BJEQ9-7&P
MK5#Y<Y_SAAZ"9$PVP:"$TE(U4G;[A&+7Z49M'`[.+`D=4@^:319H?H4NQC?3
MQ?@:74ZNIA?3R>SBC]<&:I-,Y0C67N<OR[QEF:]Z8GB_^0F$R*)\=!Q\M>=I
M1W::L[(G"+J>41(;[8Y%[MP3BO+=$,M@&])'*[P.ER&.EB</T<XIQ!RD`Z>,
M);U@*;W%SSC:B6YG%;1J)81&*R#R<6V#EG%-"SJTJLN,+O$:DY'L"B7Y)RFB
MD$79(R;$8FU9H$]WV^WF!07E@FKT-<P>T<TZ_#=.?.$6OZ\Y5)*!HLV;6FL>
M37I`#_Q[T+9Z8_#D;SSSCU#QV7%C02.*FJ%AV!@91P\+G#S1^[75Z_NDC9L1
M4]`8!OI23R#CI\B0!A/XHOOZ^(5N>R-`C?"278'.HN4RWA`M<9+?BAYO<>+1
MQ?**_F\S1P<O+?IPA3@LZA]?X!%6;,467BS>DB?OV!)`^NP,3;XM-[M5&#WL
MEYM\"K)=XM.;6!!@J2-S)V@-&J<_!=_"I]V3=#,8MTTC*C?:@)"%:Q>&(4W5
M:EK4)4;%GY[MV^+W5`OFL@YM8KO6M@UI>;_WB.,P4N.8UZ:)XWH;&!SS[`+A
MN*%:`\<UB5'QIV\XYO94&\>2#FWAN-J6@V-IO_>'XQG.+H+T\2:)G\,57GUX
M^9SBU32Z"J,@6I)4.R8UW7,^+R)_L6JOJ,$(&T4@M+'_!H!UNI43:A9:J!U=
MC.]^0U?7\[_?H:O;^2=T-9V-9Q?3V4<TOEA,?_=I244'\+5(WAG(S4A@KK`=
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M#TYV'+4M&`*CC-^;V)=SQ&VZ7B>`:G<^V(5Q=:UN[HIKVS`%P/D!`&@=)VR%
M,@GU8;PZ8CRH+H,SPD/["C@(/+QW4S`V+)BBX3U!PV2!KN=W=^AJ?HL6OTW0
MS>1V.K\\8C2\AT3#>__F5CC30G8K*#046;^BZ>=EL<8W<+^"0NX$Y(RO>`4%
MO67J;G%,*RATP-=A7K?;"@J)PBZSMX.3HJ<5%"H/7'!"8P4%[VWDL:R@Z(DN
M@*\^(`DS]!R$YO2)71K64&3]*J.?B*/Q#=RG8;D3D#.CXC0\)\7S^*C2L`[X
M.LQ_=DO#$H5=9CD')T5/:5CE@0M.:*1AWEN[8TG#/=$%\!4!)&%\3,.<=9?=
M5QH8*K7>9]#_"T[#;];W0FOHE0:Z)FP67Q_C2@-38'=8E`VWTD!3>9>EVMX2
ML<^5!B8NN69D;:7!ML+)]9Z)1[+:8&#*`>Z)Z(-T`Y<87\?+9;RC;CV0+Q"1
M?R[S:QEOXDVX?,G_=X&_91^(&_\4%A5V:EIEA*D:H'AEYSU4J6!L72<4&2HE
MH><K.HB@NLP9RMNC+\5_J2!BDMZ,7BP1R`D^G;#<#C9FZGCAY2A8X6C]AX43
M\/2@N?D6+\GSS0L*TW1',G-P(,NVIL&;Z:^A&*&1@/OFQ+!)EKA73C'D+]HG
MW[;TM"]1-E6U;Z9-<7N82*#R!Y+P$EL:O!9*CXH=]^-K-/G/F\GL;G*'WM&3
MI#TAJ[++VZS41$F+?"(Y#LN&`A;X=+'44`=<L4%;Y>%^"6KQ_(?3@Y<ZN@,`
M#&Z-HM""H_6*4GM=D'9>C6'3V<7\TX3`K(AE/YQJ,%.O=(1`6WL%9'_5P9RX
ML`B^_8$#T=E7G!:-"J#6`H0W')LPH;BN6$V(:OL1_0.1OQ#]TP^P\SJG!6]Q
M#S;A7&G9!K#3;G8R?FOJ-^IOFEQ9CV>DQU^.ML>5"5.WSP<=Q.Q?DE[C(,7I
MU2[;);@X>>TF>&%#K\L=OI`>%FRGI!WLC)1`$<7"<U@FF3F@1343E:.\`7HJ
MCAW<4"FT+1J>(0H<;QAJ`S,>B>WARF&Y@3)N(/`=]M##-@OKT*@O<E`QNLM%
MSE#!A/(`SE(,$;DS-*-SXXNO>/-,6L11]NC)V[IA6*&3_7KDA4\Y]);X4XQ`
M9E@S9?)EY!FR*>,B,O#]<I?_6O:,B=_0,&*?_L0PAO./O:2M```JEDIQHZ!D
M75;)P/[AYCCO<(QU1!L_J]`VJ&A$TX@G>]5=`-`T*W2"H$\Q7Y2>IM'B:TP'
M>:)UF]9Z[$9/53U]5I)M__L?0]5\`"LH*UHU1E)_]9+[!JBS+1N%`+:L&P_Z
MK$O'X;DPT,"JX8`#*A@-K\[H^(J>OT2DV0SP<0VLG)`$:G@%2A,_$J[R&"5)
M2U'2!#]"1^(#,-4-CU?BR56H6CMJR3,:ZAR@H>Y[(9%D1VGT"A0G*^5%=JP0
MP\+[?H<H/73E-*"B'W4-P>)'Y%3%^2L"5Y"Q2DN1[6"EHJC?"JWU#888KE2=
M`"S2#FHU!BS_Q3-FFT//OA@3P=BZ%MLK[%",#4^)P48M=0]<,,)NW$+%CW+@
MXH0L<$,74+IXDH)),7`1),G+.DZ^!LE*G6I%`L*4VA8`CA,BCYRD2(XQ$^*W
MQ-E>S,.Z7G9\Y)*V0&43WS@L!("$JPK0B!G9%)0QKW>@N4L\7$M=<-9()!1E
MM>>G"#*#P-\%9IX$<M6<&;&*85[\M#19O_JI:.IYPKOU'09Y_5/U`G+6^Z!7
M8T3U'[YQWQQ_'>:W16"VG]_>:^PRP^T!,X9[&51WP0DQ+%\(4?FC'%DY(@W@
M:R%8V@R;E+-'G(S3%&>I8IVZL&$SI7(:PL0%H0>0"9%G1(/6;;$1^PP%[$-/
M*"CNPS;#5/W=HD]+@,.._K`!GA+X%FR@P0(Z`T?^\1DJ'IP"2M1AU@HGPP?)
M]E9)6:04M^:%2UYK.%Z(?8$.G%Q+FA3AR+9V]WI$$$D'\UFB1`27*&TI`5OZ
MAI"3^"HP8XV@0Z3EG$AP6F#2B[L=X.17!)8?%Z-JKHK!L&=ZJ+R1@NG7G$`1
M?@@RO+*(PR:'Q0B%.6?%>$H?Y;D*FMA0TD=XIL)`:'(>D,W.AY&(\T+RQ*O]
M16"@,H_*QK`:-"[G%TA>Q$_;('KYA)_NL>C$#DG+1C3FM@2ACL0'&,[P#:C)
MPI,;Y1^BXE/T)?_<D\,E9=W98H>Z[YNTX$BT&:$#E#ZID,_N7<7)31(O,5ZE
M5^0G8[3EW&HCI(F5EA:%#+4`T<O*=]#RQ]P''7::Z1R-G^@QC"E:[Z)5?CTV
M^?VV>)FA>(WPTW83OV",DO#AD33:;6/Z/`L3=ECC&8I\V>5HBT4._[N`NAT;
MC+3QXL81L`.ZG+,Q#TX-6OSM3X:@-\]^7THA"KT?4%X9\NYH>]V44-:1?9-B
MX*HS]W41CY?_VI'`23PF57'V<D/@FHVCU81\NGT2O\PR5R!(L#H*0*.'OL>P
M84/+KGZ\T%!W"!0$JT5K5#8_0TS@#`71"NUE_(H1!N`2A@=C@(KB@EJ1."1X
M"'+-[&A;/6HZ`(EWEAK)+_1(%SV1,G%;-&0(QZ\9X=JYSRW&O<AX\_5=%B__
M.4W374"ZZ2).,]5(4B8BR&I\$5"*R[R"S5P"2_K<Y2HX9"?"5?8<E0T0:^$7
M4Z4@$')3`SHB+O)$Q>P;"'!.SG=5&NR&/)HG/D<KG'Q-PBS#$=KN[C?ADL!P
MC1-2HI^A9?ST%*8INYB))H^PQ.7RE'&IG26Z(W/83(`CVK4D,[&AV0UQZ#!Y
M1#ZE'^133/2##SC"ZS"CR2R]#H/[<,-&;S/20]+5?HZL-/,-M!68B.'FNT.&
M&'`/-6(2L,U1^3';/:::%?4D:CEB13O0.:5?*S+"6N,$T]?`<_`)6P?N]4YS
M-JK-5;):))_?K6ME#^IZ4:&8S?*D9ZBB^PP=M+]%!1C`GDA<\+<N*UR7+UJS
MT&!23S4UN(^A?)_[JH-:UCL&OX:^T<4C4893^G8W6"X3>O_AYL1*&@'HS`*3
M%+E&(:>NR3"<#`W_7LL#CFE0]&NE]3*'>[6TKV^\=TNR@(CW/CFFEV&ZW,3I
M+L&JN[6[JK-(FWQUO041V;?I.:$*7(&)+USEH^OI^,/T>KKX`UW-;]'DT\WU
M_(_)!-U./_ZVN$.?;^8S=#M93&\GGR8S3R[\ZPQ1JZ"C`7J;^,-3:Q>,/*31
M$(E9Z(<[%E53]EB1LE-T4("^>'>QO3_<`LGN;MDU;-XG8)X%3WC\+12^IN8T
M:>;G6A.88,&Q"D3_NF8-0E<%1O0O1/]$7^@'OC".UTEM%HF[LL6+2E,.UF4=
MWC]Z+^.G((P4^*TW$B"X;`2*X;IE6!3O=>OCN!"I(CG_R#,L-SI,B&9NQXKP
MG#<6(UH`@!XQS9M236]P$L8KQ?2DOF03_3J2,)30]Q&()UH&-<BCH6?$?T>2
MGJ&\G6<3+09P:7//&&LM0JHU<%CJ$U#=+$[2M`N"6#KDN,//.&&KC[RZ0=`U
M.M4#`T?X'+;<3_`V"%>W\4NPD>UQ%#1KIHU6,QCJ":P#)82V=@TN-85&Q2=H
M_Y$GM!'U7)LC\CYNT:'1G(/]?M#@)NKRC)C#@L73+,C8_H!IF@3D"W^?8HQF
M,?GLKX$GEP[9@T0=-8UAXD,\+$)S.753.]=L?)]F2;`4KL,TU\"/HGH:("EE
MXC,\US2M:Y-02U_MR,>_><5&(P2)B&H!0P&#=30)R>TGEL'?(QB:!H4R>UM0
MU"!E.7IXT=\XMA)]*<5\F>+I&?.Z><LYZCW*=O+3A*5MI1D,]MQ8J1\N>&QR
MJ#!?LLE+STZ/E?>L@F5Z)PUS952\Z0$W+L<.'$N6`*J&]F).QJ_192?H&(9B
M,_`,'%X/IW)<Q!OB;IQ06^)9%D7[5I@5M@>BC,(?4-*(;>G01B0]NEF'_Z8%
MT$."B].:=EL"8H*@XIX2E.`E#I_QRA=*J4#`H94>;MK$$LCQR#40U.!K=)FA
M#DC+@W3E:"14>WQZX-*(V]WAY5'\CIYQDH7W&WR)[\5%LE)"&L,;$@ZHQ?7)
M61QO6C/E5UV>W6:XK7%LOU,^7J/EH3F*XLR?&DF-"07K9$"2LZXFJ>)=S^AS
M&]K;ICJ!CQ?>#W"C+4X3;891WAYOWD3Z\N"(^?HF"9^##-]L@B5^DLV,F`A+
MXK],&)R,:D_A62FU:49/B:H&3Z>5%%&T1?O&_I%6`T%2_FHC4$9DL1(YISU!
ML*-I'6W34%!N)YUM`>#M:P2P42Z"A["'&>HB?GJ*(W;>D5%RXLAIY:6:G$-"
M<_QSF8WJYFS96]4BR4%YL_P$.I_9R\.()G'%\-)C;$5>EZP#(+/'+-.T"@!1
M]:ETD7"T??JPM4PUW8#K38)AWLRW&3V0</(-)\LPQ2N-!".5DR08@1PXC:7^
M.2*QR*89A?E:1A=!^MC@*"Z>TE03YP+^T54.%"E==3`F(RM77D[60>%IEF6>
M<7(?@T#4(L^(](PFKQ&31BD$"I6<%.(*E^?N*G.Q00A`GC>K\SQ?%^W0ON$K
M@.CY$!`]]Z7*"39LE&]X$8FY!EGEH](`3V8]GUU50TKKA@Q7Z&LP/27-O;^J
MP0)@<NH;H50:`N2:%,'`-ZB[?/^H8QH4Z>VIXKL"ZS?'<`%/SY@WJ\T<HG[H
M(3_?*^5I;MJ"[=2G%(0*`YH>@G%?;4^+\"HUHP:?ZW1&7Q8!79#@WPE0^I#A
M$=L,;APV*Q1P2>P+5%U--.N8A<`LVP6[?,2K73TC>9J)'.)4)^\X0*J?6>;#
MRX+8EATTIB^IFV>JDF[9V_;1<::I&>Q`VXH>>:XY0[2A7Z>>&2!&G[Y"N&FS
M]Z#!@+X2K'K`WIMX$RY?K"M%@;@NCUOB;LDL\+:/=-PVW8';366C6BKV;R+$
M##OZC):C3YO6#34&W!X6OPYF/O3MPL&WF/.09:A<`GTI_GL\PR)PC-N7GF`H
M][,,59[GHBFGF[K`S[O0],\QU0V/:%%I&=W<SF\FMXL_T'AVB2;_X_/TAAX5
M[^'!%;KPT&>N]L$L"GD#I@I!Z0%!/Z=XO=M<AVOA.:?ZDKHDK4JZI6G;QSZJ
MRIK5#GRMZ!'4DF<$K[0-VI!&GG.6@Q=]U@K!ILW;@P8#Y@Z!U-[JQX9)$*!J
M5(UY8W3]:A!K7QQVQ*R?)2&==Y$?(:\OJ?T&K"+I^+U"RT?7[\"J!KN\4#CH
MT9N9].L4>P/,&+Q:$`%._\W"7H/)JP4Q6CW@[PP;C^8J(KJ,92)NJ5KQJH^J
M,#?7@:%4@6#D=H9F$U]N^M(!@3X%V]#1YAX]T$*?=/T`KK?BKK35#6\:Y1QI
M=:K`LR_<C*$'N;1<;,1H57D69\&F6[S37U4N4Z&!0%*34&]/%H@:2\FA@#CP
M`G*^8Q^3.#5>R%`3TJT["B&W7*QYYC@1E+8ZT#!7H:(A:^4Y`^N0T.<@#TK:
M'&3"!BSD0]`#%EZ'$9YF^,F8B2U!7396!-TRLN6A8U96[75@YD&-:N4J;8E8
M4]]'[&VPZ/-4!#1MKNX5&/!5#%(/.&MPB[B%"ET>.[SFV,+K/D;[UK>"FR@4
MS`9X3G"SJXCM4:E->KT+A_W&=F\3"QVNZC93>7CEF2>T<2VA^7TC=^_0MY^J
M``?_H&^=;@D$\2?\=(\309KCM&ADL5H+$")S;,*PM*Y83<%J^Q'[P[/W.+S>
M:1%#W(5-U%=:MD$MZ^>>$2O9I]%ZSD,KX)Z+ECU`I&KOGSBT+E'JT3Z(=H_P
M$:JQIV'?3H#.@?<GW.)-D.'534!"_R()HC18LN,F]`<5%AJ:^#;1`,,`<Y\!
M1Q1FUC6H9*!O=#NY'B\FE^AF3`<5B]OQ[&Y\L9C.9W>>4,\"3FUR6F.R15]]
M31R"^PQLZ.&$J6E07-/!1-$<L?:H*N#W4*)OQ"L'$GUA?MAA!-]/U02XKIA>
MBH.>_-;USBGCS2:^E4K$O/9PREL;'KH$UIWN5HEK$]6'J6Z!:^.G>!=EZ7Q=
M^<R,IC(->HSE:W!)7IG/3GDL,&Q-::X^,;O/4"%`C[RH?.XUT:4`T^6\!DHU
MZ<_3I!T)M*`^>%!(/[Q4G\BF68P5:(Y3>0J<5O-BC]V6\ER[]G4\1UTC''@U
M)V0.'^TJ70E!W1*]K4B_0M>`\3!LEVXE$3>4L!=THXC8`W@V&FP#X8@UV>77
M>P%Q1TIYI+5[HRT@Y\7@>S-$)%7LMM<5T\QLP'OM=;USF\6,=MHKE4@F5+W;
M;*^-#NW$I;G57B6NGZ0\V&A_B[<$Z8]!BO>78E_02ADG6^KM+'B2;WXTEF^1
M55L>B+6&_D+15]^L#H]UM8VJGR/ZP+M$:8H?#IWM(-CFM:8>'L%M4=PGTU-,
M.N9Q'*TN\3/>Q&Q!S.3;%D>IZ#`-+9D6HZ4R0"S6\`N*N7)3.FR5:1B5C]D*
MZ$H#5+3PA:<Z2.!P4Q]`;3Y*9'D<'!AWFN\@?\V1%^$'6A/HO&!7V>P(0?:Z
M<7(W&=]>_,86YEY.?I]<S_,CEB;_>3.9W4WNT/>__'"Z2-1XBPB'Q8'?%$H\
MRX]HL\D%=4F3C%!*NN=GW4?0)3`Z5CNRM-!33Q>K2KI8QFGFR7XV$ZB8$96+
M,R.R%H<_FE&V;Y#"+V?1,PF"T7SYBKRH\?\P3M<8[I9R.J#8W_0C7P>O+VF2
M?F#7S>O[V`.O3=;9:^A1<AI]R5L>`X&52_:-T69$7^$2?PNH]DK>+`F79-3"
M[O)3T57<MDU07ELH2HK]`",AUX06[3B2H\/'Q6V4WA%+TK4\*BF1P"%/6X9+
M%PW@#$$0>A<S(3']#]U[]AQL"(_3<781),E+&#W\'FQVDDDW&RU"4FEJ`::;
MD>_01-0U;D)1/9U5\K(+N6FR9/^H")VABUV28%_N5K`%G(3J-L@5!P$M;;+P
MX#$%G-SG9>,#.!>*<6#)AA7>QFGXRB&O,^KK%?0#CP:S((SP:A(D$7$H5524
MLL:M[,=O#,1PF2>@-!88TN$J5W0T7BYW3[M\X=0E7H?+,/.NO)3V,X>!&KAH
MTXPGQ&-3[SB"G_L36K&%41[9\R>H?'22,-*(UUV`Y%7TK82&(C)H1F*QH"(J
M\P2=,$OLH<-HS35J3CF.FEH47^4?^LDZ"324#%3"2L7%M@(U+P>$I.O`+[`(
M@4A^0N#4&J\!I<8Y`P:G`^>29QSM\"U>Q@]12!>WZET)JBW7RB1*.2#6:OH'
MFD?4-G5(J](R*IJ@2AM?^*F+"@X]S0#5YJ9"GD=-3[`(GT!T#`)`,4\?+3`>
MPR(!=T#52"/P4/4AB:BW!?&;\5,$_+8?OG50RIENZVD(E61*/=RT(^@[$3_T
M-^74FPNQ[QH/CN;S.4;,@5&)L^G?CAT0NO'1`!+#1K_X)=AD+XH-&=Q&S<C7
M:`2#<ZYEH*C7U*T![;K(J/C;LTT3_-YJ0UO6JRU8UQIS0.V^]]W$N+8)4QBP
M^%8``1>_3Q@M-[L57I%_L"72]`"6).?],8-$'?V,8#)HY+M[#!)\'Z1X=1$_
M47<"6IFR3]/Q+GN,D_#?>/4Y6N&$K?.9;UGE2J"13K[A9!FF^"8)EY@=05I\
M$MQO<-XN_3L.'QXSO!H_XR1X(,4OW8@71@\7<<2B_B[8+'#R="X(N9YYUXCU
MWG@'$F:\^3:0V<V?+Z6.I[[X.F(FWS%/4-65,Y0[@P[>H!UUIU@JF1MB1_"G
M9ZCT"3&G$/-J_RGUJVA/FI:NH<(WM'<.5;Q#U#T_\H8O725,6+XYR,^3GGC9
M3M">.'9:D=U)Y>K3=SN:$$]K]7W,#8J8F^QC[K(2<S?AFD1M?##U%H"/*0`K
MARJ>^.EM"/9P<#9.$OJ=Z.ZD#R^')C?!"_UH_#5(5E=!F+`EIN,TW3WEWYB.
M-NG25/JU?C$:;T$:U!I"P1ATF#LA?Q'GR1#(6=OL!F)^5/[)$A*=3WK!0>+)
MEOL>6*.97QPP52]A0!C6S0&O(CI`KR=P[.F0P8%6LZ(I"U0Q@.Y?4+5=800Q
M*V>(VD'YQHZ*I3.TCSR^3S\<:\"QK%&/+>1X6$E:5M/S799F0;0BY;*'T_S=
MO7,YS=_%._\F@[K_UAY.\W?Z4CW/`77PU>DT?\6OMVE^L+CD=I8)+'`ZG6.R
M]]+Q'--;9#^6:?Z.W^UH0KSA-/];S#VFF-OOS/X)1ET/QV,:PTSV/[_C-"/?
MZ)9^T?2&_"3D*?FJT)/Z.K:@YO/EMH:=K-/Y'0:>I5.XZ'!Z3FH98EZ._0<5
M%E!NX@P=C/B<MJ!(!C<;9\!IL&DXF4W`&;AC#2$]%LP0G@X42V@Q6X%-O$9Q
MGN_1,Q'`J[<P`(_'$PP$QUGU%:7M[PSITXA\G3`^O'$`7\VA:0ZJ]E.:&S9V
M:_X:.L&;#$GN8Z?A6^VLP_BM,CX:/SPD[.X5%)+!6!BEX1(]LU>N))YG<19L
M4%R9.2XC/#W',SF<9IC24>&1QWM=BL&%?#-2@\5\A5G`L'_<8<2;!1\Z?@X7
M0X`6>^S?2>5VZ(*RW%)U'<A;B'$%\9,-,D==7E9624_+].RTP%0;!"XQ90:]
MR`[J7\2'.0(=9]VG"(EY1:'YB(MB,Y\Z8/5E98M+67>>1OS7(!EX!M`F-G0&
M$!N&SP%''$Q\*S85G@X92Z`+SHJE,[2W=4H%IU\!QWG1Z4?(.<["<_)M&R:L
M<5Y(0]>9(OU0965;_["!7_1]?2@:.;XYC.LM:Z/#)VC+/CKR:"O$-EQP5=`'
M+)(V[0`&3M\9ZDTEQG6L1X("U5D5EM^\L;PC)(^8YYQZ:&BF&^UY<?^FD.M?
MGX0__VY$%V(>EG*\4=4>4\=,U?8&B!Z'+L$&S]=LG3%;5$Q<8EZ+1B**YLV!
MA;`Y3&Q2>`-44HBM:(0+D?"(/J'<9\_.BNUC-W27&7WN22Q0=7>;VGH`:?%4
M(,:AW3"0<K-(46;,'ENTE&3;![XF899A,M[;W6_")0';F@2<Z.$,+>.G)U(A
MLH4D:,N01\:$*#U%Y*G+N<[8&W;RB3B5%J>)?XSC53K#F?0R2[4`)XJ+!,!(
M)_<(MF24F=.CG4#\</D!13-*BQ"_3>+5;IGY=DVA!A"X+-,"#X]E?$$^SP8"
MG+,X+S'7!7+5:Q4*T.'-ABX>?!6@TPKNW6$'-YH6FX`^$D)NJ1/FSO/J-47%
MXS/$&IPATN2TX:8<;\+`;>@18=,M@TK"H(9PR*F>@K@UD0YWCG%CMK_<,6.-
M!5OT>.(0.N!O)$0V[)##WA.(@N^IX,8JK>LA9]BQVA)'01+&GZ-TBY?A.L2K
MRYCNSQ<%6%7[9I05MX?AB\H?(,I(S&BP1B@]*A^=H<I#]"5_[$O%HNSS-H4T
M8=)BD4B.0R5M9/7)ID>\VM$IF5O,;B.^"9+L99$$41HLV7JA!5TII+H'V%9-
MBWNF:H`H:><]9&5D[H(.BPV5CDH).N-2R"`FA*I2OI#<$G,<[G=";SLDF*GC
M18JCX`%XF6=C'YX&K#S4(@+ZPB3]N]AX.&ZHR\[>V3%PN5HZRUYS?&B^[*X<
M3Y6.B??/(?DJ9BFWJV)A$K97#!R.NGY#Z/#4P1^3<&5MIA:^1"OBSFIGL9+!
M;ZGL"*):9\A+XAP0G<1QS]:`+!(>/57=O#2"<:L/SK*B8_?T%"0O^Q4MY3')
M>V*^*\F*/I)L1VL2`HG)TW83OV#L75GN(TD-RA.?:.I="5-=C%=UG^XDRA?Q
M':XPL"YGNAO1*&VZ&'$6.[M_<\=1M).#=O&T@\E:/51IACZG10Q-L_");O6N
MW.#2BL+L$,E=2E\R?=@$RW^^(UIC^A9A[P'Z%*_PQM\X#$`HK9@,1ER=Z&QO
M3"]2GUB`<#=I`^9=W_&A.>$CV1O4&#(=F%^-*L<T?O(_)%B5;/X&!4]*N4N\
MQDF"5XO@&W$59^DX6EV'P7VX";,0F]9L5MJ$Q9FA-N`@:_5=G)1;IIZ8Q$TS
MW;7P6(HB(HMR8=_BFQT>)8&L"\#%\<I(JRPP'1%CW-4?YFXX(TRSHN!0AIT8
M55%P!%7#L*PRJ`.&X94GF9V_J?)V?_8M*U?(]VA\\CD*LTYOH)R8E$_@`)MT
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MNF@2W2`MUP)AJ1@5FB63*`?U^2"G-%"<GXF8B2*,>A<[7;!,$FC=D5H<DP%M
MR@*XRQARQ+%>>W#CR)[KF.^L_G3T>W@:^RW'9M#6^\@!/I?2KDCH/B48#T2!
M[?:0&HXEU#B>*G?A[8`QI[7^DDYEOOO0/L-]\HW^FU[(1=H$67Z8.Q&8;W%^
M&K!W$^7''TT,AO['&T\\F5RX26*"Y.SEAC`Q&T>KR;]VX?:IG`I1UH]ZXL)R
M4"4.''+UO(4NUI163>*@0EDMJ)5MSQ!KS=89[-O[.C;61)0D&AEA4AQ:Y&ID
MD<(0U3X=O?/AI?9$*P98Z#(^A(>KJZ<32"3?HZ]#2/@N0)Q#PM.L>13)&;W4
MIO[8TYAB@U"+8TG4@!='&P.=-L>3Z/#'HQ-*Z*?I>)<]Q@FMG]BQ^)4]+S2P
MDJ]4W"N(V:GNM_0"#[V`Y=*HZ<DF'8WV<Y0"R"_3TXDH77T%.'FAFPNZ)ZDP
M*^A@!NVHG?H&8F:*Q>G26G%C";/G:[AVRD_S$QX@XX)BL1>P<8MS(6#CT2`I
MA7K[X>5B$Z2:+[V%$N)@WI:`CL0BG\##*,>040QLR;<GUF@`8@V\C3A"!,C"
MA0(V$JXW):5$56+-G\*M<H]:6ERDUMJ[W*5&,]9O6(X9Z.^E\C+^OOT4629N
M=:^G]*UIE4[5:UE3Z;VLWD8K(&X8ET*V]#.M>K3MF!<X]@SW)\K:%VE=#_@$
M,]S;,+GO4P?!?J$^SR2$<'K(<;-H6\`Z3I[RF!_<Q[LLC_3[74_S799F0;0*
MHX?CB/"`].MQ%`QU6&EG!_H<#1]=V.GCC"X''OL0=61G>;F:L_-Y.=LI!J_N
MA[@>9?CR9)'*X>NQ^Z#&T6H61[B^'B>MO.XBA?UNN]V$.+&I>#O;T"AN.]AP
MEE`Z?V_')6L7_^SRA+W%6D+@;+,O%S??)/%S2%CIW2I"2#IHQ6LHUND$9FM;
M>C'XI,C=1V'8S;F>N2TK]YA2MLZNHK8D>UI=/<,F'@O51U73^1X.K"HU7P/"
ML/477NZ2,'NYQ-LX#86W"?-;-6N@9BN80,>W#5F'M"QH1)N&S.@B2!_1*O^+
M!(D@1?=!]$_TL`M808`](;N@(]MTE?9XBV[UUAS"]`$-\"S&46^,#)9)BH]0
M\=EQ8T$=?`W1,'``?*#OA#[B^"$)MH_A,MC([_U5M6\%16%[(`XH_('B@MB,
M#B=$TJ/J9[Y=]ZOL:@Y5]-#1IHQ`CD<>74#U2:(-T?GP$4<X"3:D"!JOGL(H
M3#.Z?>X9%_OKA(PR$6[12T\8B&LFGD(13].F#@NU5(V*=F>H:,G&.O6VY99)
M7XAJA"`.:RT0V*:PCA(>G[U#L&8A]6N.X0@_T$T'.G6VMG$H,+/J:W)]/9U]
M)'">S":WXVLTGEVB\>6GZ6QZM[@=+Z:_3]#D/V\FL[O)'?K^_(?7A&F-6LXE
MJ@>N_'1<3#_AIWN<=,I=#1U6*6ROH\<XT/`;=,AM9A\J'I0:1^K4AK[D;;TI
M1FV09AD6^("UBPV%+ML0,2#NX><33(T#PYYFPT]!\D^<M<J[H,X!7,B]D2`!
M2I$P-!@V8:H6VXK6VK+_^1VG%';Y,1F_B/*I`Q/-=`MJ`B8J.?C60"$+UC.-
M>`9I<*2S/4"Z.^"LV"10*"X.'?,D&+K@2CM6NF-D*Y`"FN+$V=/FO9NCP:`=
M[#<`T'JG9.[VC;D@Z#IZ[AYG"46/%\I>IA$I"W=L7],\>\3)XC&(BH5G;-U9
M.HWR;PE=7EF:ARJ]C,T/&YXM?RT?`K>YZPY#NJDSHV+QY9%'>5NRP66`;G0'
MRPV&;@#FC=,...`36WWZ[4^\^0?,"#.WBBIF$;.+,F*X7%=^EB\L3^D9M2<Q
M"#VZ(.>N!#Z:,'>BI?,LCI[)$`&O9CO9J[Z^[?=6/+?L>Y[,!+^73B[+9P'N
MLB#)ABRBV]]@R*S6]&94V32/`I*^\$,81?2/>(U><)"<>NH1$;+'W"./"?VE
MGH8??>:>(P]+9D5V'I@FD<XRJEZ_@4>!B=;;C="$H]5;4!H>X:\X+'%J8M\#
MT_FQC/YYCOL4C\[['/_OC9-_,O-O`6\XYKSF@'?N\R2`\+R_XLN4YZ#LYS3^
MCL.'1_+EQL\X"1YP[9P4VYD`)TZ83@<`.]%/CG/RR_7Y7@WZ"P"D.UB71N6?
MQS(![8:,YDG(95`PSD.@SE@DH[?@U/L[.'CO?8M-NN_CY`="GQU*[KWUPUNW
M,U1Z@`H7&B?XO45%'SCU%A>+G\.S2MVHHC:J?)TF@=XJR0Y1M8A]*`]IR\H3
MGT.2:>BP(K@N$9UBJ)^$WRDQRQ+H*8'(,D_HPLC#N`LZ#W0;;S97<4*%AELK
MP7&B_P43-2>.Y2T`YY<[BI7'@B_@Q0N!JDNC8HHV7J,X;^9S['1.RB&FZ\7!
M88`9^XHS@TS;'WN0.I[5RD+O?8M1_:Y<;KVYW)^HFZ(OU"M4N.7+*0.O,E#Z
ML)K#HU!YG$5\\84JJZ1D$T3TZZ[=%/*='8$JYCLX,FRN[/P+#IPMN_CO,%_:
MNP61,?<YL6)?^4H!?1G?T^-@EMFQ)\CN40$N24)%*+`T:>T08*I\?='2KW,S
MNGT-'\,F'6KLXUM0Q#=<QK?M$;TR/>F@YJ[Z/^JP=M2C@/KFS8])G*:.RGR)
M)>`ZGFO)B]0C^0T\RBQ\+]TG#I[=$SFN0X,#X`%>33CH^,VQ"!^@CXK=9I4C
MR3/W\4`,[ZDXY%MNOPY#<8)(IV4DU]*B,&47XSZ\Q0(7T#RQ:##\;CN);[[L
MJU.X.$P@@-DK)SP-AWY"S+R%#U@DGUKX\'KOFNC[7(<1GF;X"7STUE(,-5BK
M*!XV6K>^X<"AN>J/PSA\,-,]Z*(O5!MBZH[]_4,;\'#A5$0FL-BY-P`8*L5$
M'3PN4O?HQ;G+1SR/L/P6'G,->I&.K\%E2)/Y[#1V"0Q;!RFN/DDTRNN[0@(1
M$=^N'K'`F&YPT0"J9A3A:=(.%WZ@O<\7<D+[H+`OCZ%'=`L!`?<Z3,@?012%
MS\3[('FA<R/T`9L#0:L@>^W@MYV_`(>_C^]_*GXNOL8=$V-+@W%BK&CH*52T
M?.XK,58-0T2(@S[MQ$A$CBXVM#%F$1M$0#6/#'M--I%A0+0/E!CK]D%A?TB,
MSVS1.$;I[C[%_]K1P>>_=D%"OL3FY1BN;G&&=H!,"(-W'S,AP-+OJSA9XS##
MJ\%N3A%ZT-MV1HX'GF\3$OYF?KR)M?)_R#U";7]&^X^\CKM.^=?CAAQ5$`";
M1#3WI,^-."<0B?Q:3VSIOU>QB%:)M\WE(@'5E:)UV?@,I=3<6[`:%O.O/%P-
MOSS%PF=?EJU8NNY7K.KU2.B]^==S*Y2G`7"X@Z$]"X!>+[!1G:Y77S$TQ,G0
MYAY`'PMMXH$?QZZ:_V;]SA*`^M_#F:L&_NP/@SZJC7P.2`A_\*EU)#!./7">
M.#CP])3#D>$-47$:9N&S7Q&IKW.@C3QJ1"7T/:F.5_%F$R0I?9>4SQ3\\!:L
MAL7\*P]7_4T5`/IL-%70UY4:AO[[%:W.CVT7[*G%H\XC]U.)1^V1N__QZ'W/
M4Y?`KOL5BMX#WY[1WJ+W.J[..+8(^/XM`NY_"'_G+HV^)O0B)JD1IR>\#/T^
M3?K-?7C#+W*P[UW>WXWRC\N#'-BHFXVTTV,9:MNAW_&&[%YW8KO>A.TEF[TY
M7USL7=]D!CH?7%(*SG!&=ST5+Q!WI-O?@@0$A$\B3!SG6O/BJQ0U97"_P2[>
M(,-:!Z[=M*U[D08,?RN/JCU]S]UG#EU?1I6&*,@0CE8T`[S@X-AOLK>D'GA.
ML.,^=*K0]`(^AYQD\/&M.#5QVYO8`UW.5LR>RJ3FB<0VYX6P[]'M.$OGJR!,
M?@\V.SQ.T]U3^86WF&[XN`R?PQ4I%FZ##+QH-K4+52[KVQTV5YG^/CZ4R`8^
M.TQ0VEZ,RK_02X@WQ[(*`(Q0<(G"DLM@"4+7/F!J.+4PXDVQ:^2P!U$$J,"E
MYA"SARH&:;V;FT3[6$6-OH6J_OCPBH+5<5:P[2H]/_;>_31OW8Z["=W2CF^S
M)_7O[T,%*O&QURF1PNIKFGAMD,'E-`27=PZG&XIK-%Q.+/A-<6^J0ZF#`S#<
MZ?1F;N(M4,"A]X1"Q5'7:I6U)^-H14K1,&$:G&X`[\,GX!JPHT]>)!.0W]6C
MVK+K]W&?I;IY>#A^#@6D7&7B1[-%JA>.@V<LR-`#G=LZ^0:?!U]]1/2M%._^
M93P/B-`E?L690X#-W3F]#5NO,!X['VV<4D0^SE%,/@*;K]G3=/P<A!LZ,"._
M!%M,#3U`T30'-?90FALVB6K^&CZ,&-2N.LQ]*N,CHN^)I+#B4-?R.3W7%85I
MN@NBH\\RNL2!2R!F5`7+#`JS@$'_N(.#-\6SCI_#Q0:@DO=P^WAN!XUK08:9
M>HLPKA!^LC'F.&M&Y8&N]#:>`>]"X9OO[2*4IGG/C_+F_UJ^G^+=\GK(`[P;
MSO1X=G=N^?4<W"V@=H^G=DN#"UB&,G2CS].ZCSJ\'=F]*ASG_8ESY;U[1_]&
M[>BBSH`WI?@2=XZS<I:M7OX]WA`U&_(C]+U'C6^YCUUJ3<O^;C#A_T8^)!$C
MKP?:9=+P8[3?"O*\?W#D.<2"7_WL!)&2&RQOZ'O0TUZ08XTLWDSK&KKL16#I
M:P/;P>JI;V'S*'0-LXW-@^!UG*5N8^9[ESW&2?AO##X;K++C:"E!Q8Y7KPE;
MW]^OMX-5]_I[*7BPZN9=X%[_D6<")9><O?L3T=;5*[^]/7?O^KR/$'[-A4J]
M'"!4[&O)E#)]65M@M-TF\3/!#GWU_W!ZK_Z'X'UO+_O[9/YQ5FZ\RO0V3/]Y
ME6`\C4@<P&G6UQ2ES*[+"4J^7?\F$62_CP]1W<#GGF<0N%Z,Z*=H33Y&8?$Y
M2DYSA"]EEMOQO0:IG8[M>?8=C^R/.9YX/24I=-B#<.)X.I+%*FH3E49/=3;2
MLUC5[TRD)]'J.&M9W8U=0QW$,-1A"T/G'M/?QX=:UL!G#_8!O^[##P;<4#OT
MEMD!ML4>2S3QII(U<MB#8#+(P0%OH:H_/KRB8'74A6QYXL#^VRSB+-B0.CT)
MHS1<LD+>42UK8MK-^;$*TU[D()-?R:.B5M/MWHZEE#LRVO^-GMF\2+Q&<2Z/
M<*'@1-*'$>M<G3]IPGGH%*+C@K,S*D\EXOA6^&K[[$?`<70T+JZ=DL7LHD-D
M8Y;?@EC?!'EU8<S#>CCWGI3O4P+-*`N?\0V)`NE-O`F7+T;EK98FK6I5H<EA
M*M#Z#LYK2947MI%:KK<6=I<5,9\#HQ[H-..<"8+U@I94HVX,\I0._10Z:A><
ML$%6AI35!9M.VPLC)HV*KOU2_'>!OV7H`XGJ__S_WFA41XUG1/(P-[-/*VL<
M/T<KG-S1=;'Y-V'>?WBI'8UY2\N5\;<P-<K=():T<GM'2PZ#'<AOX#(4=G70
M-E!VLSNJGT",V!/TA3[S.B3"4$(S9$+R3R^@=K*H&W!AR3YT.*Z,!5/18)#]
MSX+X1[(,_7:SX`E?QD]!&-F^*NA@RO35@)6I?B;F.OP*/4W#V7D(,.EF8WC$
MGB'Z$'W)/_,Z&`/QP7R^JSO[C&>W+$Q:S&9!<'WH@*R57MK)Y3J,\#3#3PY*
M9`UC<%6RU-C0A;+&+S%XK2SWT6FY+#,MF7C(=5=V0:,=U8Z8^G):@ADX0_RZ
MFYI!S([7`1^,;9`%N#Z[`6MPB5'0,MPDF@P=^/7?RLQW69H%T2J,'IQ>[RRT
M`[P\AV/'BS?CPN^O$^2W['W9718DF?OE-SQ/W;_Z;EL=53ZBESS?XX<PBN@?
M)W75LY@8X"^?51R$?L_<L@?_4OEHZ&[V,B@G_"1:#4#WGM:Z\.PV*7]R][H/
M27;GRTJ&H#OGI90OA#_W:YD;W\$A>'X.NX"M8N"T[G8?-%B<GV*P.#^-@=H`
MM[@;6G<WJ#N">X@-?RN?!X"#W[FNZ\OK&RP.<X6O71QPF#SZO93W)`/1,0Q-
M/;CM7-^;US2,]3H,]3GD]3(0^3@\EOKK[Z!9Z;8_$<CE`+LTC`K+C;>H;_%M
M&+J\UOCFWXC>\EVRQ1I($$LN5]OTL`(2Y#?P<)U-Y_6/W>PZ76%S!,LI8:CE
M=FE-A\64G2PZ7E3CZ5)*J]1U&V\V5W%"'[J?E^48<S<-6S/FVPB#\TMX=+R-
MT-%>!Q!5TZ/#+3+%R34^QV8P<KBLVL5D=%BB5XPZK<B/A?R^G30C\7(H[D.?
M)E.=^?Q"[:#"D-?EWK&%E#[G-0<(*L>ZT[Q=S):7\52^9_'-^QCIJZV['/W+
MK/LW(Z#^K9R7D"X\[WGZ0.)+I<@L/F+'@]`C_8DXG5'.+S2+C_+=F3N&NIU$
MT`X13B<6Q%XXGFPXE1C53Z7KQFUO0I3\2*.N\Y[5NUJK5?+<_Q'WZ04WRP+Z
M=,+;Z978Q9/@?H,'*+'%UOLHL7G6_4U?XM_*]Q*;Z_E`^8OC2WL>MSR!G+9Z
M/=6TA(S])!QE-.@EW;2]Z"G=''LX.HIJ6N"V-]&HOVJZ8OL55-,>!K=AJFF/
MPMOI5-.?MUN<%(>;/(59'R6TP*3+NKEETK_L)/A5?*V0V^[VG(B:#AQ.5=WZ
MOBX9F#=NLX"<K4X#?\.TXVA_?#'"K&Q]QLE]/'2<&*)D;;LP^A1\"Y]V3_O[
MNMYB1C\X/?FHX7C_%9"3O6RZ`O1UX(`AV5X%,;!EYHJU\LS@6QQRC?O3CT,G
MLT_J.O[:]P!58-+I.<5-D_XE$<&OXNL`M>UNW\<7-QP8?0JCUU%TBOCC^.1A
M*6N=AOJ&:=>G$!]=K/#Z_0K/UV%#A>LW*<S<B1><7L2@?@>^@T:AX=^(5/<6
MR*I$7CM>:5=O!Q=C>?9=G,/4L*,9TFI2HP\!D5F2D)&R9Q[%"6XO\LDMZ7`N
M'ZOM!23J`QLVIW29'!C8LF6!$)JI3@XC>E';$"6P$X,US2YF\UH&;,!1SIO5
MMPF>`$"TYI%,`3+HC$T69&S[WK7J)BAAPV8*Y32$P;_0`R#X\_1KH+\M-MI_
MYN,E0^*.;!-`U>DM_+<$.`10`V0`_,_7K/)]C#>D"$XG_]J%V<OX/LV28"F<
M>C21%;%$+@M+'!T_@;FD,&E`+ZFFT<5\=CF9W4TN$?G7W?QZ>CE>D#_N%N0_
MGR:S!9I?H8O?QK./DSLTG:&+\<UT,;Y&EY.KZ<5T,KOX`WTIE?G&4RUTB:EK
M`$XAFV4Z)`0WPO8@G+\(TL>K3?PUU:>Z4$3,<(X(-+&%7H'SF6?)B,9M!4KV
MWC'ZCN]^0U?7\[_?^<Q5,3QD%%6!2L+,EJB4D&HH#L##/#+0J:DX(G^FU9N\
M1424R8B8R)>!I:+,+V`N"DP9D)&K891_B@X?^W5%O18"Q&33`(Z0;3Q9"=VT
M\#8`WQ9T0;N*8+5&(D85C6`I5+,,S)E2MP%)<I'JF(Y]XAL=ZOTEQC^O7X6`
M9XTE".?W_P"0OEOB*$C"6"=U\-J*`%YO"XMSGA_`<&^8,$!]37)4_N5G)N!V
MJ)@!DOX7$J$J(^&#%"Z#C'"NPBB(EF&PN8G3D+[5TQ_I*$7%(QZ)*/3(1^DE
M^`A(9M%H)"16)!H1?1A?CV<7$W3WVV2R\'H<I`:/;#RD"SW)N$BH0CH^T@?N
M`&S^B..')-@^ALM@HY/H1.U%O&VWAR6KR!]@AG+,&-"R)3VJ?N)G`A1VM)AC
M"FP(B=64D[!)":<^*10O_SE-TQU>7>Z2,'JX86_-?P\V.UQ9\;)?[2(\Q-M6
M3XMRQGJ`J&CI/^1B7PL?=/AKJO6P;[1RB@H!;$1/*"2HQD_;3?R"<8J^#Z/E
M9K<B_XIPME_%^X,O0<`6DIS@T`W=[:!AJ(\73(Z$*.`K7:T<<,`3MB:5K3#-
MI5`NAG*Y,\0DSVJ+4-/]\M/5&T?4BXH&8,FPBS;YWN8+8P"RL88BO70L5>0R
MS&A\`_<)6>Z$=:21J>V<DCU;BVB/3]VXHX]US;`C4:@==WSDC:LC$^P<<<$>
MFJB/(^_V1`#;S.N8`G`+@LU-0Z\8MO/`"?J!KT(M%:<HC(I:]XU3503YQ:EA
MUU#+W.5NO;J*DS4.,\O*5D^E48VK4ME#P-+[5KW5O4IWND8QA8%:-%M6HUF"
M-T%1$"?-.S6"/(RM<S4[M@7C>$IB36`;QC$CNIC%,[EJT\CF/0E[FN32]\4M
M!U537^4>)_&6[;VJ-_:I$.4]_WR<,V,S?#/\E3T1OP\VD#5X4561=3[GWO*S
MIQ=25;O=)M</FD8$7D\DC^<9.\Q#"\G8:!FDC^A[.J$5K]GG='LMR?UIEA[!
MRZ8VE(PFST5(-)DNW^LPFR(?!,A]OC"J&P7"L>:+(=(^;^!W!0H*X4[O?+J"
MV/7\4L.:T912UWE5CFTH-)]SX_(9>J;-7A%T+2=X8*#K[32.98TE$#:9FNDI
M.0D\[>]E"4BEU53%H[377!8!QFS0U;&6:B@Q'$8-`UBS<@IBAA"HJ&HKLQH?
MT#?BQ4R?WV,%8(1WFT#HC/%^7N995EL=)^"`ZJRV,JU)M2,9-T##N=/[M>YP
M]K``8R7B[?Y%!VO%WM9^3.+49LY+J<M@#DRBR_D83/D]>IHCD_G1;70FUCRZ
M;;[Y*I:)'<V`38U"HP&<+JA-AG-"G6;#.R\YTN?TF]P)1Q31G)ZK\"AO72R$
M83K>6-2&BX<\&O[-5.V(IUF<X<LP76[B=)?@!?Z6?2#V_RG+U";RO.RL)P\7
M;4S\A<["FK8UPXJ6MM'=;^/;27EJFD=1P0@W_$A@`3TN]W7T"/CN(WI=KI?6
MM@^(898.%_.+_XX6M^/9W?AB,9W/[EX?E/42F6,PP\Z::%ET,7&B;1@2Q^7T
M2='X3Z@XKHNV1P<!](6*(";CS7;U'F&N-8_B&N:#SZ:8'6>K$E!67N"GO*@\
M<EI;&1[K(A0?M4^;_9NOC-0YI443)FK&R4YD&0Q:3B8&Q):Z(&L_Q"^>EJG`
MOV.!(&%F4<'8`,W#0;5Q`.<):0V?G;.-YYG+RJQC+*^IX(PCCH!R7"QH%EC6
M$;XJK%M(>7'B5M,Q;<IIT\P9M4SHM&6SBWI72_$,V7!I?W&0KTPQ88<Q(W18
MX`P:+F^6XANS`4CE;JE3@(A%O:(#$H=S*&:3)=;C*^NI$;96MS6F.@FLF$];
M:&&E/1$!AI7WKLLW9L$*)N\%4V7C+$O"^UU6'FY]$R0X\N4NU&[X>>\&/^^'
M+,9V]RG^UXZ>I_],CQPG]F2'G\I;-\LR46L8MLA]`2*,T(@&9P2RH\,#Q)X@
M^LBOLT\5_=PFBQ8P6GSA2W%(HXFDP7ASK;K@3]%<SIQKZ,O^%-XXX<ZUV<5_
M(N$V>SR\!5#5VRK^B/"A(-"UY%Y`740-1J%/^.D>)WK\J;>5DZ=LZX(Y=3^<
MT&9OPI@SA22',/D3/\G2Z%H54[A(4-`DEU%R1`"<P0B2*A=[J=K+B9*"+X=1
M^>.$,*GA.BVA=(LXJ8^O_95]KF*0$"8*%J6RE_A#(<O-1C6IM0X08Z\8/W^X
MF_R/S_06U<GO]#;&T\.5>HX.`%G#OE%L>*5ZEZAHKHC3T.\/%=ZXB=)F[PQ%
MPKP8[=O+0E5G*XFD^X)0(*8FD0\O!=LC_,OX*0@C_9FH>GOU7%39WM5L5-T?
M9_-1>S-6,U*%M&A.*G_L)Y,X?:XS+\6%B<;,5"ZG-3<E0-9P;))=22IIJN`0
MY/6D$B_<,$?_JE*>(&=0[=6]I;).59)$YPY3CHB:&D/?9TK<"5=AD(0X5<XV
M\1MR&-%L",8'O@?`XYJ6$3U"-,1&-TF<!9OP&[K.5C]Z.,$DZ$TN%:0]SR-"
M78!/@YY0`KZ^EF_!!B1LL%OY]*10HC7$-<?)P(/:[7;#CO4/-A=!^GBUB;].
MHW6</`4Z5]V:2;<"JZ8T$(^,?(6BEJY1';;IZ1I5&R+:$M&FJ-+6P_&S&9`X
M;+5!8IO`6EIXK/80RH[F2?5M@V$ZGT.]N;F>?)K,%N/;/]#E].[B>G[W^7:"
MYC-T,;[[#5U=S__NS<1J/W#6R$AN`3UH[EK0[SQ?3Z-5^!RN=L'F[V'V>$NO
M=J`WFSR&VT4\B<@/\R*=9++4TLAEQEI``H&E[S"YS=RX.AZ8ZAPQ`7J8WT$$
M?24RJ"I$X9V+>3;998N]5KSH!N)FU##4UHX>7=DP8`R1+(R4ME7%`\!%D5(_
M''%;>T$D7Y++4Y\60\K[5LTWC8607!D-[@R\")+.=<_7E?O?9`R1M6TRA-\6
MAB$R/X`8(C"AP1"NY(B]BR$$J=ZT%T0K-(NC=T'ELP7Y9TI*+W:SJU<4DG9^
MFT(:6&E1B"?#H9`6M/JCT.>4N#-)LY`4S\+SS_F-&J1I-@)A"]\RX)BQ94!-
MDH;(Z'-^HS$N/Z%W2F:/&&T3O`V2?%*#/%^'41`M0Y)<THPTHWWOR1%\@NYM
MT4(*@R8?ZHW;1.@!+M"3T1SMIFBALP4%7O:?G:&;>!,NR0"@^*]WB_SL`**<
M`3"#R*#C^=\INZ,'Z6B=VZ81)!MM0$#/M0N#^*9J-=SK$J/B3\_&MOR>:L%9
MUJ%-+-?:MJ$L[_?><2RIDSDM^!@&K(DY-D'QJUW_5ML?L.M1(<OK'1%N-8K6
M2DLA9@<N4/^.PX?'#*_&SS@)'O!L1]]+SM?L:/OY+B.U%!F-1@\?@C1<CJ/5
M9;C9B6]>[J:LP0-;92"4Z?9-``MH:T?4;+14/?K[9/KQM\7D$HU_G]R./T[0
M[/.G#Y-;-+]"[*C;._JOB_FG3_,9RD_[^7Q'6D]G],.;SXOI[".ZGM_=H1LB
MQ"3>?1C?32_0>':)+J?7GXEN/\)!1SRW(@<(/YI!QDYI.QX=(=^@1R`=O'!%
M-SJB*251(8IR63K*R:\@017Y,\0TL`FD0L<;F7B0\9).8`?36)IW<R%E!V><
M\>K<12)#[U`KE7ER7*DG]%.=T3,P_?9G_50[[9K\BWQ8?D3^AUY73S[Y_P%0
M2P,$%`````@`4(5I1T+PW,1G6P``A-@&`!0`'`!P;'@M,C`Q-3`Y,S!?<')E
M+GAM;%54"0`#2!-!5D@3059U>`L``00E#@``!#D!``#M?5MSW#BRYOM&['_P
M]GE=V^WNZ8LGSNR&K@[%D24=J=QS9E\Z*!:JA-,LHIH7V>I?OP"+K`))W`$2
M1(D1,VY;2B"1B2^3N"0R__W_?MLD;YY!ED.4_N.[#^^^_^X-2&.TA.GZ']^5
M^=LHCR'\[DU>1.DR2E`*_O'="\B_^[__YW_^CW__7V_?GF4@*L#RS>/+F\43
M>/,;3(MH#=Y\RE"Y_=]O[M!7D.U^>W5_]?#F+,H>4?KV+6F<P/2/OY,_'J,<
MO,&C2//JG__X[JDHMG]___[KUZ_OOCUFR3N4K=__\/WW/[YOJ+^KR<EOE\6^
M`4W\T_O=+VE2*.@:ID3"^-!U(B#^KVL\D`-E=]!??ZQ(/WS\^/%]]=L]:;YD
M$>(^/[S_K\_7#_$3V$0'8B@G?DN-.X=_SZL?7J,X*JKIE&KR#9>"_.MM0_:6
M_.CMAQ_>_OCA'1;B.SQ_;][L9C!#";@'JS?DOU_NKUH\MQDJH@1^>Q>CS7M"
M\'Z;?'N;1#D1LFI=O&PQH'*XV2:@^=E3!E;_^(Y0_O#]AY^^__CC]X3GOQV:
MOK=FO[3@O[0=0&S*/;9G'><HAO%R:SJ"0WN[@>1Q:JJ%75-;]EF^QF[+>`A-
M<]MAY`A%66X^CGU[RX$4QD,HK)DO(P`-N>^:6LH>;8V%KYJ:LS^'>9R@O,S`
MVX<OIP\7__GEXF9Q\1O^X^$<%!%,<H.!J71JI[$"06/KK=M:3MDJAYGQI-6-
M[8=06(R@<#&`:!M%R$8/30?V0[$8A`/VR'1!4;>U]B#;#^8NA+2U'H`Q%JNF
MUNS-N3M@7B9H&YE_S*D.;%=7CR8.^]#4P>)N9;.R6UD/P92[->,T1Q!D2U,S
MI-K;#B2U&$3J8@#F[!TP+\RY%];LDQ7(2N.%P;ZUBT%8C<%^7[%ZCA!:F^\K
M]NUM!V+\78KM/TMQ_A@#X[W^H;F;39[5?I/NPG8XR&HDR-$@*G'B981R\^U7
MMQ?[[R>R^'PB)P.P.9I!UJNIYH#'\GS(=ABKYXWQ5[1N:ST`"_[6[/$NV=1Q
M[II:LU]"XR.A?6OK09@/P`%S5+Q8:&#7VFX0T)0_M&=MRMF:L2GN[5%OL8=T
ML7O$?9C*OFMJS=Z<NRWS;&OL;79-K=F;<W?`W(*[-7MR\F"^YJC:VMX]&%\]
M#'3V[O;077V0]`7LQ]TH4[`FU^O7T2-(Y,-B]95D6:LK<I7[D5SE?OBY&GF;
M@_U0%T31PX^79D,/>IN!'*1%=?]]C7_0&@/X5H!T>?#RA(_JA77%H^&2H+C5
M<4)NW%$F!^WO9RA)HD>4X0$^@Y-T>0UCD.;@),NB=`TV>.@'*#7=)43,JC^C
MY@4LB)CZS=][D'F!Y^@4=_V'I?"]?@RU0/735@<-M).LK9HHVQ^$XK_V4-8.
MM*@IWF^C#/?W-GZ"R1Z@JPQM+"8>N=/;'27NF[^_T>WV38&TVU!#0=D29/_X
M#N^KL-I7(,MJAR50:Z73`F0Y:'N)]TPW,8('6<XN9$B9%]%C8B9NJZ66I'7+
M(W8,+-V,Y@IJY@?C=X6F![A.X0K&45J<Q#$JTP*FZSN4P!B"'-L\N"K`)F>`
M2:\AA275AA.'4AL.R$(I1B"JV#?X465;P^='(_C0D:6K*'^L5%KF;]=1M'U/
M</4>)$7>_*1"VMOO/]1ADO]6__CW!RQG)<`#EBC*(#KY!KOP4J*ME2>A#0U$
M.J+;X4;"R<K3N('*`C.X75%C%T!%2-N!"H<V5*BHB.X&*AQ.-51^>/>31[!0
MH\JQ-#<(8_D@"?Y;'L5$^OPSV#R"C`,CPUXZ`-/NQ=7'_*Y><9]"M'@"6;0%
M90'C_"J-4;:MIAJE3/G-&E,?=9W&W@S-=I:1I:(Z5F@XG.:CKS,,=YM&I_L7
ME-YN@026*N3LG0J#/'3H:2C#+=C$C)LO@#N0?(8)R`N4@KOHA8R,`0P>"06&
M/HG7C[SF[@`IR<GXM*OQ:::VW_]AF^#?6]R#9Y"6X![$"`OU%UC>/H/L'.18
M1'+V?0?PBG7)0(=6.PHRBNT"Q)&)1JS!I<BT1MPODT2<.L;4475,.!H).1VL
M_#H%K%S#Z!$FL,`"8)&R$BPOL79W6RDLW,DZ`X#S^=)M2J%)O6F`\#+4BS7>
MU/G6`/QY9``ZVB?O9*.D/2LS,HN[Q6"\^P=O>ZS5N+LK5FP<&&:M=&.%6EW.
M-6Y_TL4M_F(_(O_(;<XGOZ3Y%L1816!YCC813'FGQS+Z[@DRG][994O-8O$5
M<?>[7!KZ"J5/XWUG*U<W4A.0LW'E]K^_!.GW.Z5CCR];E%Z>GYQLMQEZCA+N
M_`OI*`QPZ,+!@8J@IEC@]&UU_R6TZ-L42"VZ1\.P:(HFG)F4"6AKT52_AY.F
M:5CT#8BR!<@V9Y@8?[.3<[QK2="6+!3WYRKL*P>+'CI>0*N'<%!EIQP;SZ'%
MM4;DWZ:@6N&E,=)?&O&4R.+3NE/F]\^[5_:@+O'%*7)U*\A1(I-[:UFOR[6K
M6C_Q?;'#X+[-!A:-_&>HV@F!E.R#&)$`&BU:UT62%NYNO;B,F+L8K39J`K%W
M,Z,'.JA-$3)3`3/00<CQ<,,EY>0^^NZR3$EV0=K4N8L%*2V%`@'M5&>?O0A0
M%5IOWMN??`$/]QN&[FT;?[XEE()KSD#G6DU@FYGF<C@<Z;J:Y]NS!^[,]GY'
MS27UN[!FCR>4S7Q1?;KWO7<9>B01;B?K=58]I.JB0Q0II=.R'2:EUC*LN3=3
MB`TRE#D>#KT=XF99QMAW1&FYPDOP,@/+V[+(X1*OYZ_R+`+\PSWMMFWLJ+8-
M#CU&2K'$CRI/]\%-]WC<6)=/5-1M<[O(7PZH-VK%'<@;A046;378H$2%&>_\
MQQP>OX$G&"?@&D0Y"<S^C`>$=^(DL[4"3/0;4W#1:1P6;(S58@,?':8UC#ZZ
M@]&_8)Z7FSTG+F*$=!0X.'1AX4!%6)LIY_3?K%Z_]WA_OH.AV(,HT7;NS3FT
MX>!"1VA3;$AX'&+:1CAOO!:\ZM1IIG;J>,U[T6DNV\&\#A[U$K!>/$LH*0FX
ME%/%<7\ZD([,>D"^[D;+<9E,Z8+V)$W+*+E*XXQ8W0+)X:+4@$:-I$%XX-'1
M@"V&)+R:C^;?IH"E@V`G&Q*4)_2=;1*FGVQ(@D.(1$I+3/1[-XU:'`8$*3DA
MV#U^ND19O2ED8D%(V8($AS)`9*C(;`T0#I/&6TSBU=+GZ!O<D'U`?3K9W#?<
MKN[12Y20&-T%^I1%:7$/8@"?`>MYB7DG]-V002?!(<]:4Y:@-.%/OYJ?`&"Q
M?$_)RST>=;5%N?BVY7@V"24-/1YE>/A2DMD61#PFGMZ;L(^N&SS?I@]1`FY7
MS4$ZZ\1:1DL?5/-I@T.+JMR6>!&P\13W[O2%TEX\_?=)2DW9KY,D38/"HH56
M+*"IQ_5P>Q(@4NL\".FZ\M?Y94FN$3_#E*P%FB7`>0G.A)@UZZ2#7MU.@L2Q
ME:8<(%J7OZ>'RH-@FZQ*Z@7)#5"$,KN-&+G=-L<`5*$>W..RRZ[)K?#NA[%W
M&J-ZV:MT\17]"T09+T6<<3]FOI;NYQA0K*VO\3PN/83#/?HQ0_T2E9D3K/<Z
M,@4[U=%QHYVGL3'A3HVAV>J%N==3-W#,%;CQ[KV>C/T[U=-Q8YZKLU%]/#4(
M*IXF0-3O]L0O[#-6,5$'JUVB(&$HE-0!PKK]>TIOYR@+"HC+#!8OYV"+J++K
MW=PG;*INQI,N59#P$<OJ`#\]!LV!_#2N;@3B\`M!J#51B_":1ND'18GD[TI5
MTV>+&2H\*VUGSSX>!?:M=4@M4MPF4-[@GCPA%>2I[_V^^T$__#X8.,AD,YQW
M1K<3*$H@BO;=UW4Y><R++(IY7V>C/CI`T>S#>[(-,YGESD:A*H_1$!0\CXN:
M/`Z]CC"@GT'!\CP6!0G<2%)'T@AE8=)TI.G0>(<_2_](320.FJD>:6_9Z<GJ
M\:*C*=WMY<53RJ+I3FF;9O)3*A!)<TK;/4TH@U+_B]]=#FB+W\V"U.IE(AF.
MXAS%,%YN#1(=.0J1^1IE2Y)`2K#29-)T@U[:-/X.-9XPU$ZC'.`/[(:<TM0@
M/B1D.7TYT-2G@M7@#Q*DR[LD2F^B#1!GA1V05?=X91!6WHV>#2PTJHIYQ4WH
MH;6.<`89DO$I=.+[`!K@12Z,"[!\*%#\AWCE**+MKB'9M-XA.R@BD9ZN>#D5
M!QABZSO*'EJP$-[GH.R=-O&*2/*.I42$_H)@E_]=YKMMYP*=+)>0H"%*[B*X
MO$K/HBW$ZY)J(J_RO`1+\B=Y-W>&\EXHMLLNN^L'JR[]NP4^--`@>I/E4V5>
M/]CQ]_1\SMUA&THKX2K?EY^4Q1/*2#48P=&:I`7C((W;(A"(JDMMA$!A]T'?
MIE*2W479;5;I8?E;E)3@#F25L'*@R5KR`<=O&1[P%+5@"T`^&T^9!T;:`?-6
M?Q=_EK!XN4KQZJ[<O3DLGD"V>(K2VVV5'?H292L`L;JN4F8A,X\CT-TONQQ!
M(`;F;U:,#'74X0;]=HA:L9V7&2GQ5$FU^[ZRU;A7`7>G8]]E;T]DTV4H-N9.
M;V9&8\4_Z+>>>\7<KBHM/*$$2Y/OO('D%EVK+6^O+V[K7R^L""XQ$4]2WU%:
M9M.&%,65&9Z(6=L6VTQ,K8MY/.93V]RH'=$]D4RKO5B=3F=N3Q<GJ3[I\:*V
M#ED]-GL;.T7ZN2[-X]2D),Q\4SK?E,XWI4=V4^K1<@XA?K<K6K1[D)##I.JX
MO!+LD1(LEZQ!W73:L0;;3CU6Z'T"RY*DHC%'D7#!Z[K_7@5@9_U[]SV.D(F&
MUS['0]D)T*Y&Z&S@$XJ]<S\=EIL"5^.1[R=\1K,:GW#V]@>NSM]Y&P^7'1\W
MVIVK?DP3<3%X*M.R-\-:$-7=KJ[2)7R&RS)*!#LV(6T'_AS:XT:TBH+&!"EG
M/$WLP#NS\EQN@/<;R,F;'@'<&!0=D+4HCAM:?&6,":C6*-R78#)VJE627U"]
M$R/+4(QT4DB\@ZL!.5`OMIUS\(]K=]]I-,8LF(;Z2L5H'B<Z'[ZGE(5,&SP'
MC\4A(.`N@VD,M_C+4=4%J'>!"W25P@)&R5V9Q4]8RNSV&60G28*J@,E=[`##
M^ISW3=F=P[Z/T.*&TOS@MN9PX(V5:4>NX,X>D?];^[8JKK`GP<HO[K$&=H%Y
M=R"+R5RL>0=Y^AUTCT@U.C@R([+6X:"68C*Z)D0]S$"NB\TV02\`/(#L&<:`
MK<8;E#YC^<'NDB1?D'M2^O?D-/,&%?\"I$`$6J<DM'H7!72)LOI'A.X#QZ#\
M#*)CE&,/XD@-V^M<CN(<QI:PV1_.#J:EK;%]R=AN8_80EC,4MC,X'"^&:?>'
M(E+[`&'9$T^5)AWK$S<Y4@/2T-,H-B`>3]`O[.XR%`.PS"_QM#9RD5)%\)G4
M24NBN-(6#\]:C;O(5FQ\K!@WT=TX:%<<65.X(E#WS922>LFHA7E&.R6XM]J]
M*J3S->81Y*U![2M`_A+FZ_Q=U;G=J]P,+]TD+Z9EY-VP%2[YD<)843^CH)<_
M%F]E2SV';]7/4*N+L[QY@_HI0[GS>"XY)U<!7B).QVID@\_*./8YA!BFJ6(F
M<BMEK).;DN3"JL-3\I/G""8DW.02996:7-NW(CM71BYE-UNZS?Q,V]RELGBJ
M+3TMBY<EE1J,ST`V/JD$5I,V;MTT69.TZGXRKC!/3-CZZ`KY)<4B5CN3W5J&
M/#7,+[Z!+(8YJ#8K5<KH+]LMR*J_7<,-OT[2""R5C-P5RU=E[X/,DT?3=R5/
M<W`:IA<09<.Y`5^K7_&3O>HTUDEV1#4^5ALST=TXUJ(X,M-D+5/9P++%K-(<
M=M(WUT'<@M,GF[[4[$+6U^LR$RW-^K0:V4";`]XPUY#[:)+#5U.8W5Y*SPM6
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MH98BW`-*XO(^O/NYOZ*;@H)Y>8'M]L6J^NVF_M7F.H%SB#H/E/"4@4G#3N!E
M<4(P:$A3=5J$EXOQ$[A-@=`7&?2@%H;$[L&[4;%G5QXKI*`0CB&U."H$]+`Y
M&==&F,1Z3"[JXBNRQ&FO!VV<4CT<`TYY"G&/4XJ3<>D)/D[]:9_WP15](L3:
M[7Y$.SU15NZW!D>6KTFYJ+D.QUR'8Z[#H>AZYSH<`UC.7(=CKL,QU^&8ZW!8
M#7RNPS&%.AP^/R/N@COG.AQ30;MSU0=:A\/L^G<NPS$Y0(=5AN,'KV4XC.U'
M6CJ^G>S`M=LW9._JXZ#-WK_%3>M%L-W\3?NAL+9L00?(#Z>F??K1W<OKT5T(
MA_]H/J3'?W8B3F<P<"_2$\XTU&Q;N:&+=#F[DI'X_\Y+YC\[DV"<26\.C]2=
M:+_KWKF3AR+*BN-U*)<H6P&(M>5M@\,=P6@NA3&"V:DXGL7`G0I#/-.\ZE-)
M%S&8KGZKO*\W?\)F/YHSZ;*?/8G+^0O<C71E"SP=\IQ3P&&@SYQ38,XI,.<4
M8-K=,>84F((:C^P!D:_@Z!RA*,OGZ.@Y.GJ.CIZCH^?H:&:GKR4ZNOJI+`OO
MZ4L_#Z]-R+0;IIIQU+9,O;NN\8.KG<Z3]XAK6VD""L-V-''#QF;;#5(A8'N"
M$7[&,@O6R@-R<I?-G\_I%1K3\#/FW20'$7$"2U8+N?I2]:XLABS8T;\?&;!4
MQW5`KS@F9=_J\Q:RB0NEM$IK.D$K-SC1<<)I2/N>S'G.D)_2H2Q:YU!H`/D&
MLV$G)TOLM+*[^^B3=*ERAZO1@DX<*VLQ4:R[N\_5U]O(M[I*`YS$^ZXYU&`.
M-7"0I-WA:N;1D9.O?T(6@[4I_A/`]1,6^^099-$:W`.B&9BNSU!:G=&54;(`
MV>8'T0IH.J-CK9JF,+J)FKBS34UWL34%G0^\0!.HI;=&FX(Z3$NF3R+XSZD6
M;\LB+Z)TB=4T02=H/[HAG:#-Z&8GZ!D1Q^$$;=1A^HYBPDZP'RK^V%T",P/"
M+R.85046/VAY-7?LE-R4"W:OWN\XG[.).1(7\ID6HI[2"RL+Q5`KRROL-&&:
MPWA0[R!GZ-@_B!C.'L+]O`7K(T02UE[BYW#7#ZY4OWOP?KOJK\;&N"N3<Q_R
M_DS$_;6YDM%GU*]?&4/<(\QL9:FE_KG7F$Z&SWT,)\/B/CN9@6?TN)P,2]R@
M2RPZU=*7[19D]8QL(.]ARA@LAW0G/9:S#QEB[H[#<?1D-$UK9>DMF.%$E_`9
MW"&8%O\/9.RZ71(J*FR(275<EL&.%)*K9PPDMX.#F&.JD??K%)!W@PVO&N`#
M_(;_Q\6>D(Y"'X?N->!/147C(Y`SJL;[C;TC8T=3I@`/;3=*\`S89:7EA'3L
M)(?P->!024GC`Y$WK`:)8U]@,I%8C:P:(_'<Y/]<+,I(*33R25\#'A45-3XB
M^0-K,#F)Q6%C-1<D(@!;D7"-*">F<2D@?A7(5%66!VP*AE:C\^.4P$F6&5)0
M]HD88*2)7A,(N<KQ!SYZ2+X*9C-1M\"_.^RK%E^1T"<J4%,X%%*_!D"JJVM\
M9`K'9AKO,@A"OZ)FUR5<10KI:%2RZ5X%'A54Y`&)[%%YBJ808K`R&C)(L9>4
M4S/PR*1^3:B4J\L?-IEC\_1H@HE0,J[]2J/:CN&A<Q&J0$TA5$C]&A"JKJ[Q
M$2H<FZ=[7#%"\1Y,MLZ4TK+0V:=]5=B4J,HC,OLC\Q3$),9EY>.)%0EWX"KD
M+'0RR5\50.4*\XA1YN`\/0@2PY3\A?S_5@6D7&(61!G$KPJ@,F5YA"=C:%.*
MNF@MDZM%B/H&B4/.VR'UR%\#1#44YGF/U!M<LTD:O;",Y+A3%:I*#9B'GJ\8
MKCI*\WGT*83L+RX@ZZD21#'7@)AK0,PU(`YN:4053ZT&A)X+2SQ'[Y\E49[?
MKBJ??BU)HBND[0">0^OL]EXVB;PY_(0IBO.H`/OWYJQK?_>]T_$"+GOW[@+$
MH$!#*Y1C_<Q1[:,$7([&6ZX"MW;1/$\B-2RC)*G\X"7*2(X&F*Z9%5U'X^?"
M=M3X';DU&2A]5/M2&]\1)D]32(BP=SDG>5YNFNP(6T#29)*$2LYS@R@S=)4;
M1('A].US=+7K&N@8`_05A>S91*L_:F=U3\)?<^RR8C(Y:VY]KR%YN3),,:]7
M8),:RA[=',5C"_]EN8E.L#N"647,7+@.UK\K@^OW_PJ,3*+4T0VK/Q[3,(HI
MI:4S69;3+F:G"^%BTS$+W9-4+1:!V=4PJK4R+6=#.L)T;BJ'RG42F.IH*6^2
M87:2Z+9NV)Q?9AB/P-D=A\$(CLAP!YN8P>S:Y8A-@[ZV*(<%?)Z^Y6OIRO5W
M5<C$U9>5P^2(3-1&O:-_73F#\A3`YMG*1*=5Y_`9+D&ZO(\*XZ^J*[ZN;%&=
M[RLP3\-)&-UBU<?I*0/3A(WX-Y3@;A)8O(QMQFS.8QARE_,K-V7A1$S*F+LC
M]9008X+F?`_S/RXS0+*\`SQCQ5C&+.([I"FS^;Y20U:8A$F8,7N<OA*,N+'B
M)I!1$#[,(NG81IO$NS#"L%^E@-W)A=HR)P$I2L6Q'KI/VFBZ?94Y[@-5-A`E
M!.409?@;]H_OOK=`OWGD*S/R[6*S3=`+`)4KN$K)#2A)88HEP2Q_YCXXT6E&
MQ:&I-9L,:-CO1@QDEP"I_?!#K?]!P#4)U_H0/X%EF8#Z^W3Z4GVM%B3U.V]I
M(V_1792(6GC'GXH\E`\3O5/AO5OB<Z`]6J=GT[`(IL^:OEY5`O?M],OAT-CO
M:U&T8*5DI]]VQRHN,[2'*`NB)A+ZNR0'7F64"!:D0MJ.@^30AH8L%9'M(,;A
M8!KTXAM/=7B!`$4,B@YV6A2A(88OGAU.6OV:WM[Z1D=K:;J[,&-N$93I.\@1
MT/O'T9!O,I&^SK1>I-L-D\:Q8'AA7Y42>9Y0@D7(+_XL\;K@!A7@Y#&ORF_S
M-AY*C;I[#TDC_TA7DPJ9;,!XJ!6R;)U,BE@=S2KNG[!XN@=)I:;\"6X7Z"+%
M&GP1GM`9]B);^<EZ<5859+6",9Y_['[.0%;@OAM?D_,+A*BVH6N%R-MX-T'3
MJ41F:N%8I>8H]I4_Y-R=&NH4YH=WOFQGDZKSTCV)UN8:JN.L5]5"M\BD86]9
M+%S:H)?#U<H,K^#PMX^74,^B![4+6W8/WBV1/;OR*U<%A7"LK\51X=*4S2GL
MQ;)44EY>9XL>M&$ZI?S/#F"JF<W9`J;]W,P.<^#Z4S[O&RWZ0(B5V_WN=GIR
M\E7UDYMM&0%HD)R-N;`_1W%9G3*DR]VJXRI=H6RS0P![@ZW;C%K>JS6S=)TY
MB-^MT?/[)8#$:_Z-_(4(_C?*6>(?_7Z"1[(DH[E,HG5'1N[O:V$8O_=F2=KS
M@>3R=4Q+E06Q-T;7!T<UTM2>E1G1UB7,XRCY%XBRBW1YW@^_4R&E)IQ/&MS<
M*TIM"0,^ET.4Z$B(:(:]>SK"AX.0CL("ARXX(*C(:XD"#HO#/<M($,`+J"5>
M`#R\;!Y1PIAZYN^I*>_\/KBI%LEG.<6=K@_OGD>:VMT`_PF2Y#]2]#5]`%&.
M4K"\RO.RM\M1IJ>F7D(?'!1TY+>$AH35/ISFW4\___#3R(#Y#24EEBQ[N80)
MWA-Q@<*AZP&D1Q<H,,3R.@%$C\4!"-__^&%T)-0KE7NP11G9)3Y@\4H^(,3D
M/5SPR`.%AY+T3E#"XW0`RP\??_[UUY'!4D'V#"]BUBA[X6*$2=6#1H<J4$2(
M9'4"A`Z#?9WZ=V,[BKOR,8'Q98*B[K&(D*8W[RV:0&>=+Z>3.6]UW\SX+R//
M]SU80S*XM"`A-]PI9Y/U9KU+%NC$"Z5U,O==#H>4U.,N"_"@LRBY2I?@VW\`
MOJ_GT/47`EVZ0`$@EM?-I[_+XI`G8%P(H,T&I54\4W4YD]^615Y$*=GO\O&@
MT*@/#F&C4)&BK@DWL!'R:[XBXYU,-!(<SD`O\4]8.PL))>/LL4<9'$;49'9T
M_MAC<G@RY04,N_-0-3@P:+F`:-$&#@F^W$Y!T6)S2,8_,BQ(?+<`"?2O&9._
M^W6P\\V0SM$4[WH^W/=[+:L6;6WKJNDM7YC1=[Q?]Y8DKL.([VJEG$*T>`)9
MM`5E`>/\*HU1MD6[U,3<>&+]QE3D@4YC;S;$G1=DJ8&.)77Y-,'!.OTW=_K!
MA:4^E(\Y7,(H@YS8=3EA-]J-03A)#"E+IH`745]!QT_2S['P9^8&I='A)R0(
M+\??&!*J+02/82\=9&GWXLQ1K^!?(#M99Z!BQ??)(CK:_;+IO$<?FDX34A>?
M5\Q1C_/>1;,YCO^DF0F;TRSZ"R9RV`CI*-APZ$*'C8KX;F'#X3C^TQ(F;*IP
M0;!4=3HJY!2(Q.2A8TE#&6XA)68\_BMZ=O%(N$[A"L81WC+&,2K3JCX#2F",
MERO7G.*P^@TIM*DV="7A&4KPL*O%^3.@IO*>U"0O096G,\U!3DY#=[4IV.6[
MG/1%Z<&B+Z]G&)H3C]QJCG'DH3:@QBHM!M)\#,:N0LG.?9?`-7DW7B=!N`<Q
M@,_D!U^V&`9X[K`\Y!<,%.LVI4"KWC1`C!KJQ1J2ZGSW81U30.!#N=TFU7T2
M+.KP97)WP/I6B"GICP./,D`XJ4EMC1XN&T\U<]G;Y3*+GZ(<G&R(.`MT"AZP
MQ/D*@N4"[0`/J@.4!"QW%0U9>VGC3NB-MD$G`8+/6E?6N#09@:=2!TS(7L.8
M+`3P@G]G8?L5_!TJ\)\P2B[+HLP:KUV]2;U-;T!QEZ$59`+859<4G.V[#!#<
MCO5H#77[\1S"M_P#OZG(3A]<,\`L(J,`RB8+$'0*\EH#B<W#TVV!UF[Z,TQ`
M7J"TP?C.ZVMLH<4=*.R;>1T$"#4K'0VV0^9Q-SW)&@*>U4)B@4A->IA&!=A[
MXGI[O\!M<Y*JC8%,[;84*#7:!HA'4\U80U&#L:>R.L+=SBT94[W492%.2,?8
MLW3H`D22BL3.=AX=)IZ*#;,1LC]6O%V=+,ND^!25\1/([K#4Y)IAD0$,]R7)
M?/8%+RASQ$*/:1\TLO3["!%UEIJR1Z3^`'R5P>"%I<4`+/-+/!$/496_E,2.
M7Z746@%U@^CT&[;#T90:AHA&$YW80U"1JW'YABF>P5PDL%HX$#CP-B2#\7!X
M2L/@$2#PA]:T]W,<Q@"I!S7^S>EDC4=]"0#].=J-OG(-K$@2M19T,(FL18#`
MU=."-0RE[*BWOB'&CV+IES`IR?'"`XC+#.)%4'[Q+4[*)5B2[Q-)[5CN%'B[
MNHBR%&LKQ]JHOEA,1SY(W]U84S=]!X;_(35K92F.!];8E,-DH2/:%/6J\R[*
M;C.2!P0LJUJFC:`<B]%HV;$'I9:!HEU?*TZPK,2V06J8KP?H?<AAZX%ZR:64
MZ3NH%-`'BD55#3A!H("9^VS*8SYJPEO>O#XU_H30,L<+*@[B1*3=ATU,TD!Q
MIB"W$XBQ^9B6YQPDLDTD$ZN6JUXCU6!HWQ5=-:5"1@`T`]:^0IT.1]/H(C</
M,E6?)5^#=914@5$OC$*&`@KJ<7*/(B`,R24T!@NSZU#+&5KN>TY?V!T(BF>.
MP-'MEEO,,2";&'\&C&ULE*&:ALOYMMDSHC6086@4+]V:T;U].9^TMQ%GD08(
M;P69K7')YN&T./RHA3^CHKJA>(A!&F40"1`EI.UN;-BT`6)*16IK4'&8F$:<
M3`95GP!:9]'V">M!5)M=2L]#5Y\^9(1)I'>'LCXCT[<^WI%6/N;@SQ++=/$,
M=IFH1#@34S.RSC"I0\28DN3V"..Q";7$)I'@=D4%,0O0):3M8(M#&R"R5*2V
MQA6'B=.D+".GD.(=42!I]CA&[JA.9^V,K:&7N>WC0U*87MZ@>TP@:.`_?8E<
M&I634XUZ]'R.2B>F@9>C9Y\;D*V>L-"R:C.E$RJZF;-+"7(K?+NM$LV<I,M[
M@*<4Q@58[M(X<Y,!:;6CKR;4VOFW+]6)0^;ZX!F:A/7>W-18NG_G-YGI<'M$
M*3T1Y9JMUD0Z&;3\3)0>;*A.]QYLF^?^3<QL]Z!-Z'VUVW?<L$9[[Q8B/.5$
M]CKA8)S%E@:G!COCMRF.DY?M4JLI)D>6T?:2<4XK];$Y*I">`CCP4>;;3L0I
M2HWL'3^7$,59^1<7,\S?4SCI_#Y<;(@$=86'#H]F[S\B!AP=6=9'_%_2?`MB
M2/+9"#]M4OKNL26?WA7N25ZQR_.3D^TV0\]1PL6_D(ZR`PZ==WN0JQZI"\JQ
M`RZ/!O><OJ>2_[,>_FT*^#M('@V]6^S3A#/],@%-IY[1KZ<@6JX;N`%11M(K
MG&%B<IUT#IY!@K:M?!_\LP7#'CJN0ZN'<%!EIQP;=Z/%-=C0![#NWH6*O\,R
M^NYWF$_O*!*T.GC-7HC(/S;_(-+^2$E;__CWT_N.6/U?U..G?^'?6*1*1P)1
M>#;`ZY38`-W91+*W[\Z18+K>)9GG>E,A'9V$ETT7QF2K"FHR]X*^0[UJ5`MC
M0OK;#9Y^67Q:(0+\_IV:FT\=<P-YD/[G1*;G+J^6KOD\0CTH9D28B+_:,GIY
MT,]D#GYE03SB>!\M=+$Y24)]C@Q;TMIE7%HQIJ;SO96"A(\HK6\NCX\`3X,4
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MQ=#JD8N119$/7<V^KDZ17WS;DH*`.<GR0C)D[0NR,58RUGU1JQV+OJ9F<_U)
MEA2YU]67FD%>JU:Y5V`_I5(EMB4K&4!VU:7#^J<!P=JQ]@S1;3\*TXS"<_GI
M2<+21=%I5?#IEIJ>`L3F2M/3JS0]MNO5K"\]EB_F5Y76KF0U2+&TJEIE]SS^
M&O_PRQ:OFB!:,DQ!O5$W(ZFD43!@U=:`(?I4^-1P^ACDTX+VQ?+GJ"!I-5_.
MHX)7\5;>0!@+TFX0!-ZT)3?`F@H/T_C59Y`]HJDA[3**Q;7(9>1"E-'D`6.,
M*[4SA-$<3"\\)H*ORE5?Y7D)EN=E?>B`_7-5_OD&?*U^P[\#T6C;NP]1:AL4
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MJRF"V%V'^JR@9Q#_A,73/4@JM>1/<+M`%_SLCI:]R/R6K!=O6KOX!N*J8.'M
M:@5CSLMI->*.#GC$WDW/=(J1IB)X25_UV-,6RV-KNBP3G>A.86)XP?QV1JHZ
M+]T`?VVNH:^6Y^3(DTB.3,*R"@33Y>O(@3QGK)TSUFI'*9)<$!NPB+X=,HGW
M-NU4?*(*.169*"9W]J9ZM0)Q]5QE^=]E7H#EGNU]5`"26QI$JX+]S%JS*?WR
M6KFI-[`KSQBRTD;''&1<]Z^SE;E-Z<V%>-3_`E%VB7^I#;5N0V6@'1H>"<PX
MFA@$9`=>IL??GB"&2GUOUFVH![&JX3%!K*^)X2!6\3(]8?0#L=O4S(E1[;0`
M5K4[(GSU]3`8O"I64RJ@*Q_R`K<VPU>KI1;"ZI9'A#&6+@9#6<VL68N]"V0U
MMOB*S'!V:*>',M+NF##6T\-P"".LII1$H![;29Z7FRT1MSJT!,L%.J^'5HF,
M!</S$0.2(B'+HX2!-\N>*`0:]Q0,)MWHRA"EQLR-\V<.`5QRP/Z$$I+ZK!;H
M-KU$&8#K=*<$!D25VU!@5&@3#.QTY3<$F`(;3Z^8'=V+-FZ^Y=[O08S2&"9P
M-_/%)<`B1@F)1ROQ0%Y:Q+Q+5'<]=V]<7?0<!-"'TZ6!.3@=3-!EX&ZW@"3_
M2-?7*,_/HBQ[6:'L:Y0M>9$\\@8=B(L:!(5<9<DM`"GBX2DG@.KE#>N1DPJI
M^-+&]R,G)0F0]A65&D3V\5_RW@^;E[FFU(#3K/T^1C:SHO<Q'\A)A[<OPW[4
M)V7QA#+V/*L1=[X(/.+)S[Z6M)I`D/7=G+*^^\4G*.Y)L(X`![W?=PME'7X?
MS&SS9#*<8*J[P\KQU1;3\^_>#E,E>9:NT(+GZ%@MO,<*JLC#7]EH/-T6,!(L
M;GJOM_U#9>^2A?'H,G+IUW`RR;HEWSGA%U$GCI?-1_Q5=.)*F'N;>X"Q">,"
M+'=9C+B5,L2$U+Z&1SC!"6:7RE"25'ERVZ4R>'U;[6AXERJG)>XUQ4X&LWPL
MJW#?Z"MW@M4:M*](A`V"F7`MR0TG7L;C$%?@$`"[^^0FP$\T\R+*]I2S*4.:
M:P59S2>9W;GIN_J!;EOK6^#%$RKS*%W>P!1(P2$B9R"$31X<3!2DML0*FT/0
MQ^S5ID_XJ(%!P=H[LV$SHB2?HV]P4VZ$LC!I.M)T:+R;`4O_2$TD#MRI'NFE
M;*<GJZ^<HRF%J7Q*633=*6W33'Y*!2)I3FF[IPD<Z_#/KKH'6]KB]PJWT[UT
M1??S]"Y?Y3`S>7O'3J=.<L17+Q2CY"I=H6RSFT'V:9%&"SJ1NJR%JZ7.9YC@
M_19*F]SVC-'S2*CA]DF\GN:JZALI"<@XUY4P:!8P_8Z;3:S3=]XC?AKJ2@EY
M78.)\W'@4'4^#SVJ4#"C)J89;+A]-^N"0->[=<TNR9$ZCZR[\NV1A08=B:!V
MV.EWWGR&PP0/J5#4&,(GA);Y#>"F"A:0=A^#,TE#`Y*"P'9@8C-H'BDZ`)2_
M)6$QKPC%PF0OIU$2I3%X>`*@R"FVU67<`NO^%'?\AUA`W5[80JOW$HH)NU&3
M^>K4B/>4,D:T!-@=)N[3BAIC5;<?'EK5^PD6KX:J<H18=>[N'J3Z^U9%VRA"
MK_X(P\UZ\B2.R<5RCG?E!"DGZ1+_)"LQ*F#T"!-80)"?E1DQ&\E^Q:*GSFK4
MJ*=0/(<[==FM98WX#Y&9S]QR.P-^(25;TQ146=+(@ZY6`=?Z]0!*:Z$8=NVD
M/\KJ+?OS?D!N`U'D7J6<@W>#43;?4,O1-:E#)O&XM*.&NPSA\18O6!T7?Y9P
M2WQ"Y1T@YBTT`=->VL#7[^5(X&ZIOD%`KC^FYDQC;&@[6]00W=RCERBA-,-?
MN(BH^XL3-G7H^-53AUN<2GDW^4V"QF-?!V)$\NG9F&31'QDJI2H9%)<L[LTM
M9M#(_"V*!6MC-6(V)GO$1P9(L3(&16./=1,V&B84+S;;!+T`4*=V47:6RNVZ
MZ27D[8X%J[HJ&@:V"J/PE:['U5LH/`R0%[5^Q+`5$_?>0;&)CP6@2LH8!I4\
MULU!N0,H^CLIG\_(G2R2EDM(AA(EES"-TABV!DB]RN3<JUGWTUU:Z?<3W.FX
MI:HLS\;UN1_!O1J*9G?APEU@[&TCN+SXMB51B_A[=%L\@>PDST&A>)5FT$/'
M16CU$)IS,%>/G5O0XMLL92>1^ID:**GA"XOJ/:G@'D"M`66.L@;>5ZHFH$$&
MRN"L4C78-P?W,K:3RFU*#?:A3)?9BQ*VF*1L5'5(CP1/(@4,@J0.P[#/U6M5
M[*\+Q)_3'AG[FTF1A0HR1<'=`(S/S.$6VOLR3GR8(Z05+LV"=V@Z*A@$<%V.
M85_('#*^G$7Y$]8%^0^YJ'^.$D`J0Q95YE.8KG^+$NZC,\->>D^+-'L)'<-V
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M*CRK=+6D;OLZK5XUJ?E3Y7;L?-2B=L$!4T\3EK"4,J-`^?/W8>Z6JF/FTR@'
MRS.T(1979]BJ,)`NKZK[-?@,R`<D%_I0BYZZ.;!->@H,RO;:L@*W$7OZ0O67
MGX.$^Y<<W*XN\@)NHH+[2H%-U`%IER@P_`EEM()6M^<]:AQ\M;V%PYHD99^C
M8:EWR/$36)8)1@:&QZI,KN$*R#-@*S>B7R,K-`K$5HUT8!P1J\+)74BL-TN>
M#7E<L>LH5AJ6>('Q`/&:>@5C<BK1&[5B>+)5E^R@9<,N`_$G`^C/18"SX3B.
MP!>5"=I&P"1__NR2;/:\^R\=]WBT^O#Q-KJ:S;N[6^7F@;D50[W8[6.5>?+*
MG4[A7N7T98%YTP505:]4^BU5;U/HEM/3"!E;N\"WJD;Z+54U0K?T;GHZ,ZYR
MQ\15"_>MK)2_TCT3S=?*!)G;RNM=30"4O>P9,NM#*]%2FT@![721P9ABI">Z
M+A8.')M-I(#3!!PP.>LL\?I/#!9%ZM[K'0YU:(#1$]\.,E)>$Z@[?UEF*22/
MA;$8E_`;^5LNQ(V\03?N7-`@5/0H*\$-@$3L&L?CX@!Z2FLDO!$%5P78:"\:
M>PU55TA4P^FIXW!JJ:N/?DM5A=`MIVNI_?E663%RM:)KL7OV2@M&FFW0&1CN
MHW0-A!\*!D4WA(.F\";)Y^@;W)0;H2Q,FHXT'1KO!L/2/U(3B6,#5(\TV#L]
M36!1\QFF\BEET72GM$TS^2D5B*0YI>V>)K"YJ08J.$/J_9[E:UCG0;ZFD7?&
MP7>;HBGLGEBT>N%-GP?1M4]15;[EW&-"CL94!Z'T1:>9'[NB>4OK,?1,\3X\
M$P]:S3R7Y5";%(ON9]G/M6`</^:^+P2/K0:U/PTNLF@IR5BKT$*LD78+[P;O
MKJJ;HEK$%X@6I=WX_(/>F'8DJY*@:D&4U4(,T7:+(X6H0"VC0+3-WU?5"T<8
MK=(@R+XQ3*(N$CM$GD42BB(480IVPU8XDLC!0W^KMQ:PZUZ,4VZ1A=4T(*RX
M6M(H*#2UTD&ZX-"J"Z2*%6[1GR"]WWD]XC.4<ST&DZ:7ZJ]%$P!$1%)I0Z/3
M6;,I#O0>$$N#-_C+4Y#BOQ1D9[N3_!)EY!_US_,;E,;"Q9QQ/WUPZ?83!@"M
MM&,"4EV&+E]43>D&]P;PJ[K(FZC>V59-`D"BALS:H!/W'722R693=`]B`)_)
MO@C+I+:]%37A[&_932:"+HTMK(+H0I`I[%+9+().7M^2765IK[*D#PH^`N&,
M\=+NLUG(ZW_KIK`)M"D=95,P*I0R4<I(<U@&2HI`O3)/86XQ]ZGY^(LN%@DO
M&^*4%E4*:!*(9@J:=I=--<\@L=$OB\9!")^P@Q,683AHD8IIBAE6Q\V99ZBI
MK;5OBK4OA-7O?3V`RNH&R>"6G`,]HPLD-?9!?_::(\$ZN9?8O8F).6>M7>+`
M$*DDLQ7H>!R"W@GV15?V=LI>+C@L266UPA&K=^.3JRGL%2F!#J>]ZA]/?AL^
MLEAM?-98>P99`?&7B!1@DEYD2.G[]=5X]%,R+,$\(GWAY2;6Y]>IL,;C$_B[
MNLYW2.7>3$PO7A"$#3=5X6WA)N"SAUNH&R.4KA<@VRCY-C%QUZ%SB,.#F9+8
MMACC,0EZ`7H'TGR7/ZLZ5+A#6&Y0P*PJ4X!_2GX`-ML$O51/,@ZWS3E3;[Q[
MV&&X=*]N77,)SQ"&5;2M!3D?7=`WSI1,)'U=@>(_GE""!<K)[4'QHKZ$5VK.
M7\U+FOM,N[*!154OA5RKH"JK%TA)3B_NTE[:HI]^A=]B2O:O-L?(1!=RLQ8R
M[R1DX3.MK37,#.`ZGSN=CU8`GQYMZ+GYEBB#3OQQ<!@%'NXTV%X&F,S%<=T`
M4(+)K5YNZ\<#K5&P9'$S?H36+#VR'=JY]FSZ.%?@ABMOPQ7W\>!312O#0)3#
MN4:I?@'D*=SO:.\,M?>"ZKN_P#"IK`F':!3QK'$8:,DO5?^H[!&/S@>.Z?4$
M?N[G0*_6'K!BJK/`V]4E3*,TAE%RA_*JB)[4YZDW[:%0I:EW7&I)V(NUU_-[
M*KSZL?=#[O0"4KCAP:RCJ5#G'O2]U<ER6:D`*R."RZOT+-I"O%8CYX\HK:3F
M.`KUAMW'-@H-)X!9G<^5MBZX&%7Y8*EP"SPVA))%^$*'0\:XFVB3!88OB9Q6
M:.KW'?3QXCTH(O*>^R+*4IBN\Y,X+C=E@GW_DKSTCB%OX:/>L%?F6=XP,+QI
MZ\(*@2K<PB]B&L<YBE?^,@LN_[O,=Q>*"T1J:N,%4/42^"K%PP37*,<_)R_N
M[C+T#+%XIR]?<H"_+K=;D$7D]O$D+N#S;CTD2:8S(*O>6F((5JZJXWS"L"9#
MN$U/-M4[C\N2`.<JO0?Y%L1X)7I1!6D`<`_73T7^98OPKYHXCHYVW75(U=FQ
M[="[7QL4:V@`K?.>J@T@1U,3R';\VN$&'W=>+P5KXL-]KPBPT%D!_]H56&_V
M?NE:E-M)I4G7$PF;'+V=&&AN9$M0&V'@!W_G``\ZAI5PW##Z/DDO<IXF>378
M%6C&$U;;(S(]9WH&V2/RC\U+E`&X3G?1+/'+(HO2',N+16L^4%_2#."%\U^'
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M3H>,)`%Y?O$-9#',\:*ZNN2\W1),=,^3U1M0=S*R!MY]@K,Y1@8:XO@`VS$U
M=R6RL7B*]6)"L5FN7J54K!I)6\]++LY`IW$?%&`-^C@Z#-OJ<6!8&PS/T]>-
MB?2'<KM-JA5EE-RN\&!V*JA,\RK/2ZP(P+K/,VI+(5NC[=$AVE1O`R-98UA!
M/ZGKGT7T\_@K'V;QFTJ/L5A-O6/=X&!)>"PEU0\'U.KC$!\SL?AKKS2F?B2K
MDNQ6&]$JG2EC7-S9T:)>0X<CV8%X1*;Y*"9R#]X7NY-T3]D(..VD>.^U.SIH
MBS4S,(I[S(,^*.K+UU1:T/'7C#92F+;:'!U$^1H9&)XMQMIKY&FM,D@E*\;!
M+F-'(3FW-.^H`V.3CEQMDS'3&(!E?HF!V^R%;E?4`Q\\N-M5?1O#VBN;=4!M
MF'4[\&[5%O..'.B,8^KZHVJVQ[JC,<[M-85/D[J:=@GT2ORSVF?VS^K==FKL
M%=B=!FXG@^C6J>VX&J%-DNPIY,BA_4<G]3PO$D3>HE\9EM_B2)"NKI5!8"QD
M'W2^`EHR^FJNN;#CA8XKMQ.`E=/N""&KHJ'!@<L9A'EJ@XD<`'$T=+@2L=RT
M*'2DMCP1=C2A`XE[/,H,QG@_2J10/I-@-Y,>2W2;3=7\56`@/*$0ZD?/^@5C
M$1]6=,=@8/Q!G%@P%&2_9]'LU-@IA+5GT;0+I[H=Q&IL1VB\'IS$AB6J:ES4
MP2S[M4,5C,S0`&]U:-9+=ZVHV\N1F(B=]@:Q">TA[3\LOVKLW*?U:6ED7J"3
M^,\29D`U$-"\`XX!J'1P9-C7UMF@L%<9C?:MY,303N\4^Z\;5>"NWX/H<$#6
MP[$`WEAKPR!>9SC'>-NAGY_+O".U'8)&;JWI6(%NGIOA<YSIF8MJ]IM!QAWT
MB;*Z0NUWY)J=&MM;6#MR3=MSJMM!K,QVA.XK;HUK3P=GPC>//DT?[33-\8"7
M*_E06*09!AV+2.5P;]Z3R!8[*DWX=0P83;R^V"6U(/%_R)+V&2]V275(C(TL
M>\$P$";*UFG+>'NKT-:[?2K--++3B;RV0(]U*]>V&LO&1K774]@C0+2\2+UO
MS@?'ZN\?9K0J:&5<O&I_5'9XQ:/)BFDB]JX:8/=:4@NXXBZ4T,OKXDA`K*2A
M09#,X]P`^ON@BV2:S([#W!T.9LQN-/O/:*#IABY6JUUV[F_Q4Y2NP3U6W&W*
M1C+')9ETT7%)>ET$!WH+#5D"7(^S^XJ'`4R.]:L<RRDRX>\^,6"X$Z4>B3C,
M1`GY&Q?"/L*)LKZ5L)PHE=N%0(^LJ'PEC6:NTA7*-CN82$ZO]%IW#[)46P<'
M8S.]6&)7F6D#V%`SS^!A8+=)B@MB<^6&4S.I>M'3'2K_2--$#E(5F0<N-7[M
M*.@.'W<.T%/I,V]5S\C#5[B[[B:+ZNJR;0WPVDTGI:5)'XP*E!I]>*V[68_S
M,*X%GO;3A%\)5JT17R/,1MX=A=FT(T.U\+*FZ0RB6]53Q#QXEY+F"()L^<&;
M:R%O*95]B)BX5WZ)3>PJ342[`A;A)LNAJ-B"2@0A;>'=OB53@DPDYU@QFU63
MLD'*(O!:SLURIDXZ002\^!8GY9)L]RC9)0M-U>:<%:B\>0"(M-2)-CSU^>VQ
M^L-1@%4-DVK0"QEA`P')Y=LS7^N0=%Z#&*Q!JL]<BGLMR1J52E%!ZBQ48067
M*-O]F)07(7<CC'6)12_46L6HEP!LV8V&C-8T1FSW-=X-<N<,D'2<*\-AW%5E
MD)MR\P@R'70*.U`!)J>#T#&IHA>W<.1P])0Y7`&&=QG$N_]ME.Q*>=^#A+S%
M6Z"K%!8P2N[*+'[")I;=8K%.D@151P"['"I2A#KHFPM>J[Z#Q+4[;3J`O-5@
M@D^XHV#^6$$Q^"!8.6FU9RRF%-L'`'5;K1AO'C08-@]H`CTR:4OZ.2K*#!8O
MY_U%L'H#(23;#8+%H$!N1Z!K<V@<XS&`[#**P>[CH`2Q/KD08#1YL/#BRNP(
M7'3_0<>\M,5JSGS()J\*M5C>@2PF^EJKN3.5#H3H$W<0+!XU].((H6*.^_U[
MF/YP3GVK#D3K]+9RY*FDL'4`-%_'QO.A\>BBRN)8)-1"8:<4N:+W/3&.35'[
M>!QI]$DQV^^(M[&[!`8GZ;)[$7T`%ZD7)C-PV^XX][OZW07D(ASIS/K&6)]_
MZ$XFP6,NLZ5'/[."*:B"#C/X6!+1[K#&"4C3995(\P[A^0(%S*KX9I)O33VJ
MUG'O/4_FJ'=7MS@7FVV"7@!X`'@A6Q7E>4S@NL)+G;.1<3VCWHBZ=U%I-`'_
MXW;VD:'"N&[)R?":NQB584VIW#9QK23E^GZ\5/E-*K'N95E@87=OZ%GH->^%
MAK-)+T>+;VN5C@1XDW&Z?SAK;P&57O!_3T&*_U;0^CDO2>EQ*?HU>V`@7[F'
M8T>]F2K'1;SR&&NT_QKD42E+>5@_]7<N(VHBFD-IE+W01)(+)A>=*BP$=3H]
M1IL:1.'#FYFK80>=!+H6OG8O1.Z=6#G)Y;M.X5_5:WJBUS.TP?(]$64_@T,&
MR!M0?(I@2OYZ"E:(;)N_B0UR&%YL.W7-ZQ68[Z#3,[I5NY8F\$`@HD90.3:B
MQEHY==HR\1,5C9;=.TJ5EL=L6/JJ&\],E,;6A"^[`+W/L\_YZ#.PHT]'3D\T
MW`;RZM>ZMMUUW:-Q=T?M,]TH>41':CS@T.^5\GCU'"&T]GBSM%?K[8JLYO!4
M5!+6SQ*J9^_5>YS'*`?+YL!0YE6==-IUII:=NCJ/O$39"D!R6LIY"<DFH$X3
MNP3^G9&;^4(*\O.\BM4(FI._+F?W:07'S%:W%Y=6R$F6D02EE6=\Z6GDY&N4
M+2\CF%7O.D_RO-PT-;MW9Z(+D&UX3VN&9]C-B3<@PR.RJ='G9S`;'4.2H(\4
M*ZE/Y8HYU5',.23Y/=,EXW,U.E^6!QB6[[$Z@A%G:QQ_,*Q`03_B&40_OR$\
M3200X&5LQ\#F/(9KZ'*>G8.#&0O3/71%"KINIE,-W</\C\L,`/J%V1CN0<1W
M2.?`YCN[!NO9"LLQL`5REW[&UPEC,9\M!G.V^!`_@65)*J?O$KZ03,/W&(L9
MK$(X"Q3_D7_"Z";;7=$K&R=]42>6%GT=D1]UJ=5!ST$M!AGV/FDO-_O+4$G>
MJ&17W>1%Z;6:NXZ["QD''1^1A0VF[^&7(@Y&''C2!I8*Z$47K0*R^-I!]+``
M,[9$>R8*5FG#Y)58J+-Y\&*M-J,/^_"@K8S>O4QGY=!?2WQ)86'U/1V$I=BF
M';,\?@L?<H[&MG?'LGA*4>O:^@]/8[-G&`/.X4I2C062^AB'</!=T&LU(>JF
M/Q`_KMT[YW?41C_L[(QH\<X%J<W]Y\#-G;-/(3_-3\KB"65$!5]2+"RU'*K"
M.4]?+KZ!+(8YJ)*\WI/C5NLMM#/&NEML!XR/VA.,-%_^M^@.)`H[XI"AH$\(
M+<GQX0U*0=N1YHL,ZP/K&*OF]*6JK0E!9N(&K'DH6+P%CU=BW*YFP8L=6PS>
M7<"@KQN^_#$&T?R$8)+7?!/=I)$=[%@;-)K7T)NS':^C]MC#S4IXF[*=$(<[
M2X_9,<G;]WWU^NMZW"??8+>&JT:+7HY+08NI27Z.-A'DUQ%5:*,F?=/&N\FK
MS"<R4P''+@4<VUD[A9PF8#S$EO%B+DI`_ADP"KA)Z7KUS'MT4X5'9[Z1NK!Z
MH-CQ:5<E[_4?=.S'/58'GHXGO`DX!\\@05LB?YV'00@KC98=H"FU#`]Z^@JQ
M!:,2Q\,EJ[]U.$APG^M/(`59E.#1GBPW,(5DI5/`9U`/6.S%C/KHKIOU^@@/
M@C9*L@6C)N_#[9\W6+I935_#%%QAY?!6K`-QZ4#;.1?OX!]VZX;&FB".60TB
M'6V.SJ7B?4>.&1KJNTU?TRP<(5WVU/-9*T)1EJ\+,)^WOHKS5ND3HYSWQDCM
MC-51_YIWWAK]>_>1XU]MFVK?^PVVQL`G<.Q#[M-OH@T0')*R2+HYX%HDWH41
MGGNRB3@"3>9DDSD)2%$JCDW0?;92P77ZLH(I\XE=]>[I7R#*%E_1X@F5>90N
M%U]!\LP^)-)I0CV8DS>9S+3V-^$&,DNF^;#)5NO;4T2M)F`>\,(V71K`AM50
M"3SMAL%"2""_(R"U.7C*":4,ITM49@4`J1:4V(TD,.HV"A!"0KFMX=/MW7U`
MG]=C!E<+7L;GW^0LP7(XK)5#^\`@Q)PLLG-8=QV[RJHRS=/6`;#N7/5C6HB+
MP4_@LF-!-'>[NDJ7),%;&26"_:.0MH-^#NUQ`UI%06-BE#,>^F6\LUPKIN90
M+1O.HP+LLP@Q5FP#]$[G8W'9NW^$N_.J:&CM\XS!6H1][A:70_?T5&T`>ZLK
M#D1Q@9T"2?7KW.:X')S9'8/#;'N:LS!Q^V,,O]F*:!OA,\@>D?_`.F.%5'_\
M!O)B7VI3F'G>,0M7>QLFBR,SVQ'F85"['6;\8;_E-%5%G?6F\F;Y5;K3QJ<,
MY<Z/(^2<7-FPB--LRH:S,FV+%HEA&N<>R@>9N]UF*N6?`*Z?\,+EA-2'7X/6
M\W93DW<_`EU7X'($K]5%##:+TW`=+L4S30`W:9=2_526$*.?#N,:?079[F]P
M`WD!AV.P5'(:KEB^*B\QR#QY=`NNY`DZ%5SO\/V?L'BJHA2).WR"VP6Z2/%<
MO0B#W`Q[D=W&R'IQ=4S9A+>S'W$)**ACPAZ%=]]@.BE(162.W6KR;`[@>KQX
M=_E34",O)M+."%05VHV>U.;:5:VO5Q5H?E`Q/ZB8'U3,#RJ4_.#\H&*..)LC
MSEY7Q)G/K`]SQ-FKC3C[8!AQYMFA7_Q9XE7^58J_>&6ECMOB"62+IRBMSS9O
M4/H,<ORQO$=)<HDRTLBU\[<:A*L/A>$@PIOR^=XVE.-6.[L(^H[72/2Q[H,#
MK=YCJ9'Z4)M\%F]*4=JJH?@X=A8,/K.K&'SVCLY1,`0V#N0\"C^!=;P"L"C)
M-5FZO/BVA=GN6+EQI@/Y#66^COV(`M_9KXP^NT?G9Q04$/2=LJU^;LLB+R*\
M.4_7@RY/N'P<NQ4&G]F-##Y[1^<V&`*;OO7:5F[F(EW.KL*0S^_.'YW,SF),
M9]&;OU?D+K2#X'?NXJ&(LL*[PR#Q>5=Y7H+E>9GMG^[L8OGH$LY-X!YWCV+<
M4=?@#3J:+=I>_],S6`.)3-^;33J&W,A'B6+MB<)7PUQ860]DN,^_\D"F._VR
MYQ:-3%X?)AD-PO7;),U!A/L!L3<XE\^9;.;>]0?(6#-.7T!I:L13FL6)^*_Y
M5>5K>54Y+;<UF5>8T_!98[S:#,-AJ=]P#N&LW'(?+DA@=E(NG-0@LQVF@W*E
M"D^YVZ;AG*37HAY<EI,QC1VE,+NW$=R;2V0<I=.S5-`<`2&?.;^'H7Y/0&='
MYG6VC])E*:O"]-KF&.,NINN@QHC1F%W4=%S4X#$=03HIY]$>(<'X>I!\F2Y>
M.4XC'YYC"9M%^[L??PF\>M*T`.<J2F':H+.0LKF&?/?A5Y?("VA%UKNW79"T
M2U=ID<$TAS&K9HD/UL,<ZDM8S^[$U;P%X4#4Y*I=QL<PO84HUO`&?*U^Q<T"
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M0*2^A4ZM$*2Z`9H7?-1^>#`GWYE<\IU]AI4S_(\R*<CQR3G,0(Q[(0E9JI29
M#R![AC&XRQ`>(]X;R;+Q..BTGY['JE/OKLA-OAYWBATD@8_5\*QR).CEEQH&
M]</P4<E3-=O&T.H?*=^5$PMR^!YP"F"8LVG16C?,IA7'.4+><FA=1%F*5Y8Y
M7EHVJU488S2?PZ3$:*]`?<C;(TN>9=E;9P%FW)NWY6LG)&ZW[:W37E#K_8X@
M'&7:==;1I6EGWIV.+:208X5RO)/A,&G_93H\TT.5B6SYNIK3=#&:/F0"3D("
M%3/7:N9")VC?(@/6TX&BI;),4<HH<)N[2O$2!#Q@W50G51*3DU!W(,>E=K5W
M),=M4;H[7+M*SU""AXMVM?].UAFHN#*V@CK-J)V=6C/O9B2;(V2L!(X9<1@V
M^R@U1I[2I#!AM8M/JC9^</-88@9DC/D]B`%\QE_P;/<W1C)3P]84R+1:AX(U
M<Y6804Z+7_,F90K(N\?28NT_G8-GD*!M)5NZO$C7,`6`G/M??"/W"^`&L/R:
M06L*>5JM0T&>N4K,D*?%KT;>K\K(^[A#7@K6477^5$2)<P`^@[0$AR)<AI]8
MJWY:H#3J)QQXVJO)%*A&G$U7NY,(UB-II6]7M>2<%2Z3IK.N[="$`#85\?2!
MQ.E5.Z*S[=>F<LBMH58WIYWF$V#,O['GGUUN7\.:J\$GHZ_M,)\X5`\U[C*T
M@KSC`09%QW6V*$)"#5\T<Z"T^C0M]%W8K0+=0`,O9W?R7O.?KC%I.O#HT(0$
M$)%XYA#I]-HX$/W'$I-`"4K1%I`U9;K>257OAGB(D=%WT<.G#PI)BF);H(K/
MH4&8=ES^)#Y1MVVI!-Y(0-E!%9,R)#S)135'$K/O!D/?!^FEJL5RWT)X.!)3
M=['$HPX*3THB6V"*UW^#JS!SJ??$$G_\9.0R9`7YZ5,4VB&V>A\^]:,MA5.+
M$>'5G#R37?_A\%F,,:4V':!)VH2$-AWQS2$GX5+C3OT`9EJP>P`)[G/]":38
MH!(LX\ER`U-(U%#`9\D"7Z]Q][&38N.0$&FD$'-HJK+33L,EP*C'T-JMO]C:
MNC)R'13.>3"65"/`?R-GZ3%:I_`OL-R]]*HJ8EY+BCP.Q*4;2.::BS??50\2
M+-DRB'V77N..#E4;>_==0T$*62J2%]'G=KBTKU0=9M`WI)UOQG6M)T&U3(46
MXJC`=HNI22Y\7*K41DUZ]L-1_XL5YGPB,Q6HK5-HCK3]23A-H'AS**&TKNO!
MNW&Z:K7A!^#%K1/OE-?4#%NM&/QPZK;8M`PSN@DX$.%)`?-ALT%+G>.<R3P^
M5OO,J![MZ#P>%G)6/N9Q\GQ^S`,;]CMZJSZ,CF^F\_Y=&X(V2K(%HR;OHWB3
M/NQ7"XUUS,++,32$=*VH-==2'4#U>J"AOAOV-<W"$4XG#4(,XZ6_T]H_2UB\
M$#VC%`LG/`,0TG9/3MFT_LX_ETM()BY*[B*XO$K/HBW$\R'\]"NUZ9YVBMMX
M=P_B.41FPO-.*%F\6N>,8AZFG^K$^]N+S0:E5?X<(;ZX=+TW&#VZ<'`D$](4
M.XQ^38^C?>/E'A18.+!L@NDEVU\1<6_'RR8.!SY*XIIBB->Y:;[F2=QK'-8[
MDBM4/F$OU6J?T-4C3/9:KY.%K$H@FM^`XG9UB;(5@`5YV;/+"-H1SFF?U.-,
M!WUZ-SK!A*-A-,=;^?<&TCS5=#``3\;K&MUN<>T6T<>.98\H]I8=Q-4VZ[_+
MO*@R4"P09WE?:>>QKQW\M<YAT1P"[#;V]4:?$(@JAH[%MK?9&YKMQ.W,D_ZU
M#'*\,08=#G.LSQK5`&SPHE&,-O9C1J=/S\>N_T+G[N=M*7ATK.HK;;I`@"*3
MT`@LC$Z;,.1W'__V@W9)X&G5#3+!C;ANSW$@1[GFC2%VOG^GO8:<?L69ZE/K
MH.",O!^U>C.B?D(!IJ6&S&"KSS3LXHES`27OB+8O?F0":97"16$FR1'9\`WX
M6OV&?_BLT5;#%5-MPP:K4!/.72[%:)_1X-W'7S[\JIZP,0!D[DS1$)J<QCI>
M]6C`*=:%>^_)A.???OKEQ[$SV3J$YQ-*2*V<W26E"(I,0A;L.H0A04PDHSF<
M.KW2>^I?`]Y4FZ.'OZT^)OPXVECS$?3]N[!KN=9BWZ[Z,DI><FFUY841B-OZ
MUXOP>1:3B"?I5!Y$Z4T;4A179E8B9FU+:S,)->YO+T<G\"@7O"E6:L.#%[O-
M=-`FE(E^9:`06"P#&XM7*^:?S<-IS*!/77/C]*5A7C+-]N+J63TZM=EIZU'!
M4LU5RN[<"4K]O'!8/6^6'[P];[B,8%8=<*A7<U1ITG'(XB8>X]#39Y`5$&/M
M'#P6K%%R=*#1LA>KKM#2N[4KS3&RT0?'`X@8MZ/;%1BZBS?QYAIFSS`9X1=X
M%D\QSS\TI.^U41"?:A.<']#1@:4'D+`*W?8+!`MOMK^+S%I$WPZZ5<I@(VS!
MS&+#:>$LOGS_A/9V"U+,[%\@RG8/87GFK-N,CAA7:N;=J%7F"ADK0IBN@,ET
M'Q6NQ"SH\.^#B.?UV+&8)WD.J@J%US!ZA`DL(!!#U%%OW&1'FKV%`FBW:C/#
MN?48CN"[MH2%O_?\(7[:W$C>`]I=1C*?%R]W2;2K3/EG";>,&H[F'73THM-!
M:$[%6#EV?D2';=!?SIZ@S0^$%3D46\EPVFT5/#B%:G",R"ZOH$/Z>M+UJR^K
MD,H`-Z6ZRN8HTRRDK`\ML\K)4RHPU!-I7T2)O(LZB[+L986RZB6L*LSD/<C0
M)^HA>%`JJ\<Q5D5\35^_3=,E$MW4/ZN3"[;2E*7+4Y""%2R4$:W=H0S@&AT&
MCW=3Y3F&O\8P@LXNTQ/\*L5+\ACD^3TS*:RJ#2AV(T.^M)O@\:ZG*,<HES(/
M^@E\3UQR_[+//?DU2F/E?1B_I0S!K);!@U:J#L<X9?&KH:G^8F!:Q<?,OS@/
MV$`SHH.[Z*5*?^%\7<+EX&RAPN`0O%$X4Z^OI0QC7.[>Z'H[OI^/[J<@N>QN
M4*6)7/:`;_DT%&#G'\2,CN"^#A4O\WV=1\G/4$K.C4`:OXA>WDCI>5+WZ8.U
M=8GHC@R]SV4"M5SVHSLIBR>4D:=$LDI]/&(>4#K$$Q)5H30?GUPJ[L0*\G&G
MC6418IEE!M'BP[2%7O]3,@7*4*\ER9Z5VBAXT&NK%-!NY*?"YSC2,B@ZLK4H
MI@-\X>P@%0%ED&=QH)'?ZGD"QWDYB-^MT?/[&)5ID;T0E/S8_(,`Y$<*(/6/
M?[^Z[N"B_XM:6_0OIH,"GE-#`DF47=TA#3[=ES.W9C)?-[SYNN'-UTUH\]63
MQ&*^;J[I2R0/\_7E@3-?AU]TYHO\(JCYZDEB,5^DKPE5")/O)H0++?7GKEQ&
MXI46NSY7<`I36&@YT1N;#P]O8Y:UB?"H!)NTWN^[Q6L.OP\+`CS!;*:;ZK.Q
MC'<_^9Y<<:&B/@5K@MDEB4:4Y'/T#6[*C5`6)DU'F@Z-=\BR](_41.(`E>J1
MAF:GIPEXGL\PE4\IBZ8[I6V:R4^I0"3-*6WW-*%O<=^W=AVOMOC=LY]6+],H
M$PI]7E`\8VE0]J)Q02%MT3MH$K3P>,Q6C^J2E)-^`LM/"-4%>TCX4_;,39^A
MT9*G"5%+[T:H,L/(1AW<E1*7;WMIK,"OB51X]TN8+S7V0O)?:+!(>'B;RHL,
M,V!IO,300Q#]`D,?)U-X@;$7Y9]X;PW.T5?^-1*/D(<9BC!8Y/"$=80?JOMF
M)1&XN[F/OGZ.\)!@E.A]"Z4->3`3-`P6=JK*<`1#`;N@7\T>[`QE?^R#T[5@
M*6_)=7^"EL$"4UD=KARD@)^[AS*>=FWSIFT*DLM#2>5-Y+)/*Y34S/@M0DGU
MK/XH0TF])C1[K?9^2#2T']]9F1$#T4PQI=:<FU-*UCPTGV"H&#O_H,XT=%^Q
MC8"_(UUN#IW3EP7F+;BRU6C9L12EEMZ\"'=T9&S"X%N-EJH:H5MZ=QLZ,XYL
MU,+Q'`K\:0^BQ'<"(;S<<4H^V\KM5,$VJ4\X?_9$%5DTFW,_X;+FT[5%M0^Y
MEGITS5'\.9>QMK)(9F9<_(U'&:%]V?-BA@,HT5(Y<`6TT\4'P^DB/=%UX7#@
MV&2_%7!R/_N799;"@JPRTR5YO%SB=9\<!QJM*$0HM0H1&_KJL$>)$D^K"",F
M7O8LON"U?':&4NS,RIB(P06+:A,**?(F(<)$4Q'V&)$S/&0A\+:HN091#DCE
MLZL-W@$^5[5]<F%`FD*+SM)%V"(T*.FKP0Y)2OR<O;(88*=P+7GQI]Y0=:]P
M/8&W?R=Q7&[*A&3D.0<8U3&LYA__/0%U>I*3#<H*^%?U<]T<T*Z[[ZC67??3
M->\^O-#@^M5U!=>LEX_NQJ9]<3FM5%-5&B#L#B.8$7G.GJ)LS;U(%Q-W\<\A
M#A7-*K*[P2:'4[-U"C.U*E<'GS*4:W_76HU4OVEUHT`!J*4+)T"4<9S0.T?M
MDR\5Q7(O.CC:51V$DHYIYA-ZDS&(HGFKU#'T?,U_1^GMNM!?<,%\5Z%R42@)
M-%!OJ'Q-.*'@`J.;"6V5N+B34&%Z!,$%L[.8LK-0CTTTZ4)50].,773K2HPC
M&MTXE:.,<\RV'NO;W8/J@.8NPNI>9%&:1W$MF_`P5+59-T.!M)F_!`SLH9UL
M2-*9_'9%_4Q/)Z(>U-3#[L&[9U'&`'*A(]Z+<\D@6@_1=9A/(*B),][\](7^
MC2@CC'8':H!D=C`)-0EC"_F$`K$G$SEH,)D<P].)%U3GRK,T)U&"S"@#.HW^
M`BV>P`U*WX)O("X+^`S.809BW!'[EMBX/15_H-E^4@ABQQ[8:$0!0.VX`TUF
M[J-4/D=IM*XNJ*OHF#0O$Y(OZA*`?('.GLC=0)3>KDY1E"VY(#+OA$*222<!
MP,E:-]J8,N$XX2^]9).OVDSQJSZ!+?[AV%GMPZ,6R&S0%S>J6:NO2=FH$"',
M"&=SO6FN)L31SEK#F.0]CHDBY;LFWFY;>J6C,1R%_=.U/$OF$2I?OHD:>1J8
M`YI&NK5LZ^^V;?ZT2H:F?GANT(.B>J9Y=&[R\337D8-/IA;S(S@VG[V*=Z\B
M_YIIY@W0ZT9[F3ZY/`+#K-!-D@JX79P?6X:!.'[,M][\S0,6ICK6N%U=PC1*
M8Q@E=RB'%5#%/D>G:=><E)IZ\SUG:+-!Z4.!\?7PA`TMO\KS\C"Q'3U(J#NB
M<ZF].PRM^42Z\O,V+0I,:?_`9>:NH.T4`'=;%GD1I4N8KE51QV@B@UZKR?'@
MCZ^)H4#8XFB<A78B'Z3<W^JW4BEYXX=506)SBI<;5,@R9*DUZGV!Q(W\K7N9
M`U/?2VNW5U+,-/?1BC./[+7#=1RB`;36M>J,31>TSR![1-X]R$&DMP]?3A\N
M_O/+Q<WBXC?\QX,_MU(^YN#/$HMY0;*5R3;3,O*NQ7#)_3F1SI"D3D-&+Q%Y
M4DY!-GM(7VZ>^7-8M0R?SV*,G6O]&_+'8Y0#_)/_#U!+`P04````"`!0A6E'
M52NK8OP4``!;Y@``$``<`'!L>"TR,#$U,#DS,"YX<V155`D``T@3059($T%6
M=7@+``$$)0X```0Y`0``[3UK<]LXDM^O:O\#UY]VJU:Q'2<SD]1DMFA9SJA.
MEK22G)W<ERF8!"7<4(`6(!UK?OUU@Z3$-RG92:`Z5N4A@MT@NAO=Z&Z\?O[G
MT]JW'JE43/`/9Y>O+LXLRAWA,K[\<!:J'E$.8V>6"@AWB2\X_7"VI>KLG[_\
MY;]^_FNOUY>4!-2U'K;68D6M3XP'9$FMCU*$FW]84_&%RNCM<#:<6WTB'P3O
M]1#Y2;GOE;.B:V)!$[AZ_^0S_L>'LU40;-Z?GW_Y\N75EZM70B[/+]^]>W>N
MWYXEH,HM`WQ]<7%Y_MO=:*ZKW0.S9N`>XTBB0Q.L0F.>'J2?(%Z=X^L'HG;@
M^-8-=@AIX+?GT<L$5%*OLN(?SN%M`L@%Y^&Z'-8-Y'FPW=!S`.H!%)7,V>$U
M(^40Z!*%6-FJ=^=2^(`5@:5)9C4LRG/TR:\!_FV4$N_&?\J`;J0(B,^>7CEB
M#>"7;R_>75TDP(X(>2"W6=8KZKQ:BL?S^"4B7?4N+GM7EPF:2UDY"KQ`\#=9
M<-"$)2&;'8I'U(-N??Q"-RM!(4$@V4,8T%LAUS?4(Z$/72/D_PF!"H\A"ZE/
MUY0'&8#4ZX#()0W&9$W5ACBT!3=`I2Q+*Q7A'``"T&==EI1N-HQ[(BZ"0NS!
M[Y-N/*.>I37L/?:/#V>*K3<^2DZ7K727!:GTDL_]OI'T%7`F@<#^42-=W7T`
M10')NF6C_7>3*HAT"K44#`!4(C94!HRJE`J>OQ15#O$/I0I0G-`WF2B7>H<2
M!2B,,X-I\LG#H30!"O6_+CE8SP((L/#'_6Q8K;:10@!%+J$PNC(WHD\_[2I-
MJMU+XQ<8LZR>=2.<$*U'^B<,S]:`!RR`H1;T7*YUE_SY/%]#OO)047?"?]&_
M\QH:8\<@=9@Y+6B/F.UIY7AQ:<+=YS/=<1[4GNGZJ9[IKX'3<^`+C;G>GXQO
M!N/YX`9_S2>CX8V]@(=K>V2/^P-K_NM@L)AWO"_GO1(BS7Q\K.?^53ONSQ?P
MW]U@O)A;DUMK,AW,[,40`#HY5,IADQ/$ID$2;YXG">MO4R(!<T4#!MSZ>R>9
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M;*G!<1$^<[:=QU(E@2`C@/J^?G4$_Q?DP:>JXW_YD)GB/FOB?=V@V?&YEL\^
M463/:?U4Q^N?+BXN\LR&_HQNN66/P1F_GTY'GRW[XVS0#:*53-\0NN<Y/M2S
M_++`\ND,<SJ+SYKG@W_=#Z<=LRM[N$=E*%-]/'JN9_GKDEYN7P]'0^#Y[61F
M#>ZFH\GGP<":#3_^"I'G_70RMF:#Q;#S'6NR`*D$0`/_KPK\[T_N[H8+'>=W
MW"WU6%+L54W\?5/@[_Q7>S9($EP=ATO[+T_YY/A0S^.W)7T8_)+98G@]&ECC
MR6+0L;F,S8%(Y4OPH9[-/Q38O+!_`[\/#/)P#%:CXW*YN?!4BLWZJ9[//Q9-
M!CI[>KRS9S`L#L?VN#^T1ZGL^7`,@^6=GGOJI%`F!9F.,F5#D/G3Q4\%&<P&
M(YT%G]KH#G:9E1:N=Y#QO9M8_JZE\]W%F0W>23J=XC1P_;(896;\DX[9#8Y*
MD/%4@@97Y;(88>9=E2Z/TNBT!!FOI:F'%R/,G-O2,;S1?PFR#DP3RXM!Y4$>
M3">0)E<FZ\LTB:,8@U8[,QWO&[.X;C:-6[]6Z:?+8G1:E\>U_G9#`\+\3@"5
M;J6;<2N;V%^,6JO<RH[QS=E=-Y_>;6)_,9@]*+_;2:7!`4VOG6R213&H3>5Z
M.TXWQ57<30=6O(G;Q7@V%UF-B91`_2/]>\?[)MXK(8A4RX!F9)`JK97%Z\8H
M=QZNUT1N+>%9DPTBZ5TF,ZH"R1S<]3D/A/.']5$2CD^!L`;KC2^V%#RE3GI-
MTO,>B1#+C.B2HGJY%</EG-QN"9/6)^*'U+*5"M=:=FHO1I6(K)-2HY1$7KU$
M"\TJ1M<Y">7DT*G.84(I&KU6!J\D`L^*I3-M+Z0T>@!R7"+4)JL\F1?UTFJ8
M)-XK4=F@E%&M/D"%?@#/ZA]0HZ1.(&2$-PE65%IS*A^90ZVI%(_,I;*3<5OG
MH\3S:))K,?2O<3O"0)\\P?BR7,R=H)H%]>!0DI535%(OIF**("^F%8'B:P($
M@(:M-Y0KS11K\(2_P??P?>'HHDY*C5,FW,W,F>!CO7R*.82229,NFFHO`248
ME5DI)$7UDBC+(!0D@<?,N*%/T:H-86`"M@8[39E1<"LY^[/SR-O,=*53#M%C
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M1[8F?WU&FY8D./BCMT=NWX+:VSCJ6E"*>$[]0"4EO7U5A?;$EWCH!GTX&Y,`
MQKJ)-X&87W]*14?<+>A3<.T+YX^=Y_E["]#H(H3H"ICW05(^#.@:QQ>@*GQ0
M`0M"Q-:W[7PXTQ>RO&<`<F9QYOLXS?#A+)`A@!.`EL0)/IQYQ-?7UFA@^#X3
M[D)_RPVCMM20B,M\"-_JE3]#WA?X#1%AV4M)->B>RG;0$:%1<]:"@U,@MR]-
MY@/Q4<D_G#F2NKAO\RCJ]8I"97-W1MGZ(91*OU0SZE#V"-Z`C'YA>_9,.`CI
M='@Q`R^,2&=U0Q^I+W1>"V@<\"7C%&KBRWAIRSAUWL'O!R%]4UZX].%H5B0K
M>R9>E/\;,8_J[:(EBM\&UDC-'T6J*^1VE\>\H^L'NC_9[/<:D`Q)KE@3QE^`
MGNCY*'+NF$]5`+UJ2K99HU5\<SI*.7<H)X"Q^"+RPBEY99Q0[C>"W][8]@9"
MUT?BYTFH>&T<&:F![I':$NS_4K].II%C(Z=P7`2;-Z72H?K6O/3(>705,3N`
M%YNH]&L:CLA[#FJ8,?#9$BN-M6D_V*$T;6?%@**L`K;'.)D18AJG8JY!_U;@
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M/KU`56D%4+KL.\O\&32]"&-.R>[=AI+K5H.>(Z%A0&5EUJ,5L'':LFOA/7>I
MQ/W14)E39@::(8TC+MTY%Q@]C07OT2?JA&B\=_N_BP;O(#3CR$X.*)C#J"Q1
M#28/&$HC5B'+U0;V9+Q-S(9H\Y,0,V+D@?D,;VN.J5%@BF+O.N?#'(5\<JRY
MP24,\/\UY?`K`#6.;J@'[)LP3B&5LJ4UXLFP9!=VW1&DC&.-MS25?*L$.!T2
MUT(&[,_(<_-NZ$,P5"K$>OM"I4/21L#3(1G,,/&''`9^\$\6HE*X#7"&I4_[
M1*U\JM3@"5K#%(6@&7VL^.23U-C5`'<R<CPDSCHN.LLYYP$:L>_MKS2U?I&=
M4VZ-<`2E;O!^M<6^'S[0X5?UT>)<:90US+AAN3>G$SGLVZYT.,`#8#GE#O@2
M]A-39416`!XG.9=!E2I.MGQUR16:?J.]X%94)J#&>=$U;1XQKE6BG1Q3T.89
MG,I6%RQ-$Z3))@94P8WS5N#"QU8R35P%P,F,EMICTQ$Y%@(]$,,$##Z.21I]
M`"20%16C59B1($7^4<BG8XLKR=N3I/-9T6Q$"[94X'W;5%^SRW@CG'"WL@H^
MOAUR3\AUM.PN_D"*VE;0IAFP@>=!=(K.C_N_H8+P-#HR9D&>L)?B?#DE7I!)
M8[7&,"P"J&\XSC+?PLNVA.[A3X],$;:6YQ[^Y,B<\(.$J<%/CLC%2M*#R(P1
M3H_0+^(@,A'<-"*3<V\+,P/Y%\;Y\FCIIH+QX'^H+*R(+'UI'@F[*;2L\Y8O
M-ZS3W(;ZS-941J+0?6I`C)/"1VC!2"@UX5%.0F'C47]G5&&>?.(ERA"M;\*E
MBC,:,)E;V_C<>D['^];;'F*3MEB)4!'N+KY0_Y'F^T$SI'G=H;+)<^H([K8G
M,0MO'*&[`6J?/BU)@M1#F18[E+0VE_2HAC`WV9',:`QY:OX2!HGD")HI*+4.
M\I+I_`RYAZ*>CAU*D:0/VZ/NK13K*-.#HT]QUUI[#$.XT#P:WQ%.HB$V2N+A
M8?A`RBWX;@O17Q$&`3^?>->"R(+M.@;7.#MV1Y[8.ES;2Q`>[CI.)O8GWDQL
MB8^R7@AMI9-]>6D&'(YKF#>6W]-4\,4J`<R3I.#!RM_.H&2$1BO>"9,BI0K@
M9)*Z8Q@[=6`R9T_P)R^KBM?&26K2G^>;GBHRK[F>!R9>ZFD.&/6@/96!;PM0
MD\G;K60;\JEDCYC^!.NE2.GROT/QS".<4]"22&%PN7J!P(KWYA$2K>70.\DS
M"V[CBVX6HKK#'HYZ.N2W)M9TTG;"2%U7M-,Y($<?$1W?5+2[J*B"^F?591R#
MH(4/6.G.!\O[*R6;)]LAF$BJ0ZFK,.9(UN)-/)R&%USW8KVP/MG_FZ'X(+R3
M\8:`,#=TP",E//3@&Q",NW@K%/38B3=4DM#"1O$#4(R3?W)$1FI55Q)P%G2]
M#:R)!,9&.4J!EA!5^MX\0I+H;\+G!$_T2+I=BI9JD&\:(1YP=`2X0U5'1Z1>
M&2>,_;DJ>&O)@CSI.TN:3V&I@\X0:<K>O733*_R<W>#?@OH#JS"3)>BV:P<>
MI_3P;Z$'5T*8UY%+M]BE)LFNMWN0V)G1.^ZTQ&[`U<'+?_7JK:9]>T=6:H;G
MT)ST>A[15"]VQ*:%Q%]0N7XI;I94G.:H(;NECZ8QV=N/*^B([R?;ISZ!?2G9
M9?25/Y-A+'78FOC?FZ]LR9G'')Q1B2X$PN;BV7_EZXO;PILVR5;;[MQT6QM8
M<R?>DN31`"?LP44J6VI2!V/>"!0W%O/,582DWYE'0&KG4]:UT:MS"S2U`S>/
M3#Q$1A?@?K::);Z-@,89C_(&QZ>-9#?2M($]SGA\B[TTZ=9//$^?@8GG`V&7
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M'LTFN/^6LB6/W)8]G2U`O^E42G/>\3/#D7E_B$Q.<!6OC9,1&HM=K*\3Z"6G
MBM<"F4O2A-.*T:P&Q%QRM(%'"93Y'/50YA*%/_!OR81D'8QQ!$TEQ84'T?+I
M%:/>(#E1+EY:5UR]T!+!.%*;IQ-?8FG32U=O'!LS?ILVJHW>70'*/*)V84(#
M60UPQA%6MK<+MYX'M+C6M`VL<03&FV"2;3%;O,F)<ZI7_:)W5GY.<#^4,K.M
MYIG5&)++;';_XBDL/#M2WV(1;Z)*[Y_2>3H&)JB,28<CGPQKM!FVE=*9V5VC
MBEQH@CN5%0@I.N8A=^6VCM(<Q*G06'5337[!;?&4M\/P3H4?V=.#II)QAVV(
M'Y&QR]0.\3I9XB<79TB\*<#V?:%/VHK\G*H#B9Y5Y<F8"KW]?2$PI\/P]H1=
MO!Q/[*%SH#`OD%ILV1[E9-@079)3F4NH>&V<"W$MR9_,KR2CXK5Q9-PR`3[,
MG\6#1#+%QC4[,0D3"6%/<7]KQ6M#=*0-?;O;SR:>[4+X]Y&$#HRK4T#$-.A"
M4C21Z&3>;_RM2IW(<P3J-\TV'G+JNUX`P+%%>+`-,!8OOJXZLZ<>VK@N;,-O
ME[H-YK`>RCBBTEMVHNT!93?EEF_QJ8,WPU5J=3B]XX>8V8\&@$)?+7]MG!R?
M>Z_7P&?:8\$U63DO^2M4;4;O:!%'+^'W+:5I$QT1II4@?5Q_`Z!I%EO;WMV=
M>8E$1U!XORDLD&X!FY:H(<O'DWM*=7R[6!%^V,7A1Z*?CLLR<0(!Q@ROEH=^
MNF9*";D=@TXO1#1Z%7+?;1&^IW7\^1PI5>!`K0D\_A]02P$"'@,4````"`!0
MA6E'[)BB]P-'```)LP(`$``8```````!````I($`````<&QX+3(P,34P.3,P
M+GAM;%54!0`#2!-!5G5X"P`!!"4.```$.0$``%!+`0(>`Q0````(`%"%:4<[
MRGU6@PP``#6K```4`!@```````$```"D@4U'``!P;'@M,C`Q-3`Y,S!?8V%L
M+GAM;%54!0`#2!-!5G5X"P`!!"4.```$.0$``%!+`0(>`Q0````(`%"%:4>3
M,_&[HCD``!=#!``4`!@```````$```"D@1Y4``!P;'@M,C`Q-3`Y,S!?9&5F
M+GAM;%54!0`#2!-!5G5X"P`!!"4.```$.0$``%!+`0(>`Q0````(`%"%:4>3
MJ&`^;\(``,RD#``4`!@```````$```"D@0Z.``!P;'@M,C`Q-3`Y,S!?;&%B
M+GAM;%54!0`#2!-!5G5X"P`!!"4.```$.0$``%!+`0(>`Q0````(`%"%:4="
M\-S$9UL``(38!@`4`!@```````$```"D@<M0`0!P;'@M,C`Q-3`Y,S!?<')E
M+GAM;%54!0`#2!-!5G5X"P`!!"4.```$.0$``%!+`0(>`Q0````(`%"%:4=5
M*ZMB_!0``%OF```0`!@```````$```"D@8"L`0!P;'@M,C`Q-3`Y,S`N>'-D
M550%``-($T%6=7@+``$$)0X```0Y`0``4$L%!@`````&``8`%`(``,;!`0``
!````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140104974540128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORIES</a></td>
<td class="text"><div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-family: 'times new roman', times; font-size: 10pt;"><b>NOTE 2 - INVENTORIES</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in;"><font style="font-family: 'times new roman', times; font-size: 10pt;">Inventory at September 30, 2015 and December 31, 2014 consisted of the following:</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in;"><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></p>
<div>
<div style="display: block; margin-left: 0.7in;">
<div class="CursorPointer">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 85%; /* margin-left: 0.7in;">

<tr style="vertical-align: bottom;">
<td style="text-align: center; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td>
<td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; border-bottom: Black 0.75pt solid;"><strong><font style="font-family: 'times new roman', times; font-size: 10pt;"> September 30, </font></strong></p>
</td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"><strong><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></strong></td>
<td style="text-align: center; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap" colspan="2">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; border-bottom: Black 0.75pt solid;"><strong><font style="font-family: 'times new roman', times; font-size: 10pt;"> December 31, </font></strong></p>
</td>
<td style="text-align: center; font-family: 'times new roman'; padding: 0px; width: 20px;" nowrap="nowrap" colspan="5">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center;"><br/></p>
</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: center; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td>
<td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; border-bottom: Black 0.75pt solid;"><strong><font style="font-family: 'times new roman', times; font-size: 10pt;"> 2015 </font></strong></p>
</td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"><strong><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></strong></td>
<td style="text-align: center; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap" colspan="2">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; border-bottom: Black 0.75pt solid;"><strong><font style="font-family: 'times new roman', times; font-size: 10pt;"> 2014 </font></strong></p>
</td>
<td style="text-align: center; font-family: 'times new roman'; padding: 0px; width: 20px;" nowrap="nowrap" colspan="5">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center;"><br/></p>
</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="font-family: 'Times New Roman';" nowrap="nowrap"></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"></td>
<td style="text-align: center; padding: 0px;" colspan="6" nowrap="nowrap"><font style="font-family: 'times new roman', times; font-size: 10pt;">(<i>U.S. dollars in thousands)</i></font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; width: 74%;"><font style="font-family: 'times new roman', times; font-size: 10pt;">Raw materials</font></td>
<td style="font-family: 'times new roman'; padding: 0px; width: 1%;"></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 1%;"><font style="font-family: 'times new roman', times; font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"><font><font style="font-size: 10pt;">1,502</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 1%;"><font style="font-family: 'times new roman', times; font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"><font style="font-family: 'times new roman', times; font-size: 10pt;"><font>1,616</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-family: 'times new roman', times; font-size: 10pt;">Work&#160;in&#160;progress</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><br/></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-family: 'times new roman', times; font-size: 10pt;"><font>132</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-family: 'times new roman', times; font-size: 10pt;">Finished goods</font></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt;">4,837</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-family: 'times new roman', times; font-size: 10pt;"><font>4,919</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-family: 'times new roman', times; font-size: 10pt;">Total inventory</font></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-family: 'times new roman', times; font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt;">6,339</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-family: 'times new roman', times; font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-family: 'times new roman', times; font-size: 10pt;"><font>6,667</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></td>
</tr>

</table>
</div>
</div>
</div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.9pt;"><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in;"><font style="font-family: 'times new roman', times; font-size: 10pt;">During the nine months ended September 30, 2015, the Company recorded approximately $<font><strong><font style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 13.3333px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: inline !important; float: none;">1.6</font></strong></font>&#160;million for write-down of inventory under cost of revenues.</font></p>
</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. This may include, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the major classes of inventory, and the nature of the cost elements included in inventory. If inventory is stated above cost, accrued net losses on firm purchase commitments for inventory and losses resulting from valuing inventory at the lower-of-cost-or-market may also be included. For LIFO inventory, may disclose the amount and basis for determining the excess of replacement or current cost over stated LIFO value and the effects of a LIFO quantities liquidation that impacts net income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.6)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 6<br><br><br><br> -Subparagraph a, b, c<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140105106933360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">
<p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px;"><b>NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES</b></p>
<p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px;">&#160;</p>
<div>
<table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman', Times, serif; letter-spacing: normal; orphans: auto; text-indent: 0px; text-transform: none; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; margin-top: 0px; margin-bottom: 0px;">

<tr style="vertical-align: top; text-align: justify;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in; text-align: left;"><b>a.</b></td>
<td style="text-align: justify;"><b>General</b></td>
</tr>

</table>
<p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin-top: 0pt; margin-bottom: 0pt; font-stretch: normal;">&#160;</p>
<p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;"><font style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 13.3333px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: inline !important; float: none;">Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &#147;Company&#148;), and its wholly-owned subsidiary, Protalix Ltd., are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company's proprietary ProCellEx&#174; protein expression system (&#147;ProCellEx&#148;). Using the ProCellEx system, the Company is developing a pipeline of proprietary recombinant therapeutic proteins. The Company's initial commercial focus has been on complex therapeutic proteins, including proteins for the treatment of genetic disorders, such as Gaucher disease and Fabry disease. The Company's strategy is to develop proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications. To date, the Company has successfully developed a treatment for Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets, and the Company has number of product candidates in varying stages of the clinical development process. In September 2009, Protalix Ltd. formed another wholly-owned subsidiary under the laws of the Netherlands, Protalix B.V., in connection with the European Medicines Agency (&#147;EMA&#148;) application process in the European Union. The Company's two subsidiaries are referred to collectively herein as the &#147;Subsidiaries.&#148;</font></p>
<p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;">&#160;</p>
<p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;">On May 1, 2012, the U.S. Food and Drug Administration (&#147;FDA&#148;) approved for sale the Company's first commercial product, taliglucerase alfa for injection, an enzyme replacement therapy (&#147;ERT&#148;) for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. Subsequently, taliglucerase alfa was approved for marketing by the regulatory authorities of other countries. Taliglucerase alfa is being marketed under the name Uplyso<sup>TM</sup> in Brazil and certain other Latin American countries and&#160;Elelyso<sup>TM</sup> in the rest of the territories.</p>
<p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;">&#160;</p>
<p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;">Since its approval by the FDA, taliglucerase alfa has been marketed mainly in the United States by Pfizer Inc. (&#147;Pfizer&#148;), the Company's commercialization partner, as provided in the exclusive license and supply agreement by and between Protalix Ltd., the Company's wholly-owned subsidiary, and Pfizer, which is referred to herein as the Pfizer Agreement. In October 2015, the Company entered into an Amended and Restated Exclusive License and Supply Agreement (the &#147;Amended Pfizer Agreement&#148;) which amends and restates the Pfizer Agreement in its entirety. Pursuant to the Amended Pfizer Agreement, the Company sold to Pfizer its share in the collaboration created under the initial Pfizer Agreement for the commercialization of Elelyso in exchange for a cash payment equal to $<font>36.0</font> million. <font style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 13.3333px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: inline !important; float: none;">As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to Elelyso in Brazil. Under the initial Pfizer Agreement, Pfizer and the Company shared revenues and expenses for the development and commercialization of Elelyso on a&#160;</font><font>60</font>%/<font>40</font>% basis globally, excluding Israel and Brazil. Under the Amended Pfizer Agreement, Pfizer is responsible for <font>100</font>% of expenses, and entitled to all of the revenues, globally for Elelyso, excluding Brazil, where the Company is responsible for all expenses and retains all revenues. The Amended Pfizer Agreement eliminates Pfizer's entitlement to annual payments of up to $<font>12.5</font> million in relation to commercialization of Elelyso in Brazil.&#160;<font style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 13.3333px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: inline !important; float: none;">For further details please see Note 5.</font></p>
<p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;">&#160;</p>
<p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;">On June 18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#147;Brazil Agreement&#148;) with Funda&#231;&#227;o Oswaldo Cruz (&#147;Fiocruz&#148;), an arm of the Brazilian Ministry of Health for taliglucerase alfa. The agreement became effective in January 2014. The technology transfer is designed to be completed in <font>four</font> stages and is intended to transfer to Fiocruz the capacity and skills required for the Brazilian government to construct its own manufacturing facility, at its sole expense, and to produce a sustainable, high-quality, and cost-effective supply of taliglucerase alfa. The Company is not required to complete the final stage of the technology transfer until Fiocruz purchases at least approximately $<font>280</font> million worth of taliglucerase alfa.</p>
<p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;">&#160;</p>
<p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;"><font style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 13.3333px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: inline !important; float: none;">Fiocruz's purchases of Uplyso to date have been significantly below certain agreed upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the low purchase amounts, the Company is, at this time, continuing to supply Uplyso to Fiocruz under the Brazil Agreement, and patients continue to be treated with Uplyso in Brazil. Approximately</font>&#160;<font>10</font>% of adult Gaucher patients in Brazil are currently treated with Uplyso. The Company is discussing with Fiocruz potential actions that Fiocruz may take to comply with its purchase obligations and, based on such discussions, the Company will determine what it believes to be the course of action that is in the best interest of the Company.</p>
<p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px;">&#160;</p>
<p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;">The Company will pay a fee equal to <font>5</font>%&#160;<font style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 13.3333px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: inline !important; float: none;">of the net proceeds generated in Brazil to an agent for services provided in assisting the Company complete the Brazil Agreement pursuant to an agreement between the agent and the Company. The agreement will remain in effect with respect to the Brazil Agreement until the termination thereof.</font></p>
<p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;">&#160;</p>
<p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;">In addition to taliglucerase alfa, the Company is developing an innovative product pipeline using its ProCellEx protein expression system. The Company's product pipeline currently includes, among other candidates:</p>
<p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px;">&#160;</p>
<p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;">(1) PRX-102, or alpha-GAL-A, a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder in humans.</p>
<p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px;">&#160;</p>
<p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;">(2) PRX-106, the Company's oral antiTNF product candidate which is being developed as an orally-delivered anti inflammatory treatment using plant cells as a natural capsule for the expressed protein.</p>
<p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px;">&#160;</p>
<p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;">(3) PRX-110, a proprietary plant cell recombinant human Deoxyribonuclease 1, or DNase, under development for the treatment of cystic fibrosis, to be administered by inhalation.</p>
<p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px;">&#160;</p>
<p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;">(4) PRX-112, an orally administered glucocerebrosidase enzyme for the treatment of Gaucher patients utilizing oral delivery of the recombinant GCD enzyme produced and encapsulated within carrot cells.</p>
<p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;"><br/></p>
<p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;">Obtaining marketing approval with respect to any product candidate in any country is directly dependent on the Company's ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.</p>
<p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;">&#160;</p>
<p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;">Based on its current cash resources and commitments, the Company believes it will be able to maintain its current planned development activities and the corresponding level of expenditures for <font style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 13.3333px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: inline !important; float: none;">at least 12 months</font>, although <font>no</font> assurance can be given that it will not need additional funds prior to such time. If there are unexpected increases in general and administrative expenses or research and development expenses, the Company may need to seek additional financing.</p>
</div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><b>&#160;</b></font></p>
<div>
<div class="CursorPointer">
<table cellpadding="0" cellspacing="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 0px; width: 100%;">

<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in; font-family: 'times new roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;"><b>b.</b></font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;"><b>Basis of Presentation</b></font></td>
</tr>

</table>
</div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt;"><font style="font-size: 10pt; font-family: 'times new roman', times;">The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (&#147;GAAP&#148;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt;"><font style="font-size: 10pt; font-family: 'times new roman', times;">These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December 31, 2014, filed by the Company with the U.S. Securities and Exchange Commission <font style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 13.3333330154419px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: inline !important; float: none;">(the &#147;Commission&#148;)</font>. The comparative balance sheet at December 31, 2014 has been derived from the audited financial statements at that date.</font></p>
</div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><b>&#160;</b></font></p>
<div>
<div class="CursorPointer">
<table cellpadding="0" cellspacing="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 0px; width: 100%;">

<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in; font-family: 'times new roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;"><b>c.</b></font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;"><b>Net loss per share</b></font></td>
</tr>

</table>
</div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Basic and diluted loss per share (&#147;LPS&#148;) are computed by dividing net loss by the weighted average number of shares of the Company's common stock, par value $<font>0.001</font> per share (the &#147;Common Stock&#148;) outstanding for each period. Diluted LPS does not include <font>18,781,572</font>&#160;and <font>19,797,190</font> shares of Common Stock underlying outstanding options and restricted shares of Common Stock and shares issuable upon conversion of the convertible notes (issued in September 2013) for the nine months ended September 30, 2014 and 2015, respectively, and <font>18,661,182</font> and <font>19,820,485</font> shares of Common Stock for the three months ended September 30, 2014 and 2015, respectively, because the effect would be anti-dilutive.</font></p>
</div>
</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140104961595504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 34,248<span></span>
</td>
<td class="nump">$ 54,767<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable - Trade</a></td>
<td class="nump">4,573<span></span>
</td>
<td class="nump">1,884<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other assets</a></td>
<td class="nump">2,716<span></span>
</td>
<td class="nump">2,202<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">6,339<span></span>
</td>
<td class="nump">6,667<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">47,876<span></span>
</td>
<td class="nump">65,520<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent', window );">FUNDS IN RESPECT OF EMPLOYEE RIGHTS UPON RETIREMENT</a></td>
<td class="nump">1,569<span></span>
</td>
<td class="nump">1,555<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">PROPERTY AND EQUIPMENT, NET</a></td>
<td class="nump">9,957<span></span>
</td>
<td class="nump">11,282<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCosts', window );">DEFERRED CHARGES</a></td>
<td class="nump">90<span></span>
</td>
<td class="nump">113<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">59,492<span></span>
</td>
<td class="nump">78,470<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract', window );"><strong>Accounts payable and accruals:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Trade</a></td>
<td class="nump">4,057<span></span>
</td>
<td class="nump">3,951<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Other</a></td>
<td class="nump">11,946<span></span>
</td>
<td class="nump">15,496<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenues</a></td>
<td class="nump">6,850<span></span>
</td>
<td class="nump">6,763<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">22,853<span></span>
</td>
<td class="nump">26,210<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>LONG TERM LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible notes</a></td>
<td class="nump">67,774<span></span>
</td>
<td class="nump">67,464<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenues</a></td>
<td class="nump">35,127<span></span>
</td>
<td class="nump">37,232<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Liability in connection with collaboration operation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">912<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent', window );">Liability for employee rights upon retirement</a></td>
<td class="nump">2,249<span></span>
</td>
<td class="nump">2,253<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total long term liabilities</a></td>
<td class="nump">105,150<span></span>
</td>
<td class="nump">107,861<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">$ 128,003<span></span>
</td>
<td class="nump">$ 134,071<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">CAPITAL DEFICIENCY</a></td>
<td class="num">$ (68,511)<span></span>
</td>
<td class="num">$ (55,601)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities net of capital deficiency</a></td>
<td class="nump">$ 59,492<span></span>
</td>
<td class="nump">$ 78,470<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, which are not elsewhere specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Liabilities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Liabilities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.3-4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph a(1)<br><br><br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 4<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br> -Article 7<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3044-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-03.(a),19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.25)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of deferred costs that are expected to be recognized as a charge against earnings in periods after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.10)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section A<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section A<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount for overfunded plans recognized in the balance sheet as a noncurrent asset associated with a defined benefit pension plan or other postretirement defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 715<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=58740216&amp;loc=d3e1928-114920<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 715<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=21915240&amp;loc=d3e1703-114919<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.6(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 330<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 35<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655945&amp;loc=d3e3927-108312<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19-26)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 7<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22-26)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 22, 23, 24, 25, 26, 27<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term debt, net of unamortized discount or premium, excluding amounts to be repaid within one year or the normal operating cycle, if longer (current maturities). Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount, as of the balance sheet date, of current assets not separately disclosed in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.8)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This represents the noncurrent liability recognized in the balance sheet that is associated with the defined benefit pension plans and other postretirement and postemployment benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.24)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 715<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=58740216&amp;loc=d3e1928-114920<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 715<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=58740216&amp;loc=d3e2410-114920<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 715<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=58740216&amp;loc=d3e2417-114920<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 715<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=21915240&amp;loc=d3e1703-114919<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 7<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140104968590560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN CAPITAL DEFICIENCY (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited', window );">Share-based compensation related to restricted stock award, forfeitures, shares</a></td>
<td class="nump">2,501<span></span>
</td>
<td class="nump">1,834<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares (or other type of equity) forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140104961592976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (14,863)<span></span>
</td>
<td class="num">$ (21,474)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments required to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation</a></td>
<td class="nump">1,419<span></span>
</td>
<td class="nump">683<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">1,811<span></span>
</td>
<td class="nump">2,418<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Financial expenses, net (mainly exchange differences)</a></td>
<td class="nump">102<span></span>
</td>
<td class="nump">869<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitExpense', window );">Changes in accrued liability for employee rights upon retirement</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">149<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement', window );">Loss (Gain) on amounts funded in respect of employee rights upon retirement</a></td>
<td class="nump">28<span></span>
</td>
<td class="num">(25)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs and debt discount</a></td>
<td class="nump">333<span></span>
</td>
<td class="nump">332<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Decrease in deferred revenues (including non-current portion)</a></td>
<td class="num">(2,018)<span></span>
</td>
<td class="num">(6,172)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Increase in accounts receivable and other assets</a></td>
<td class="num">(3,187)<span></span>
</td>
<td class="num">(578)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Decrease in inventories</a></td>
<td class="nump">328<span></span>
</td>
<td class="nump">1,127<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Decrease in accounts payable and accruals (including long term )</a></td>
<td class="num">(4,396)<span></span>
</td>
<td class="num">(1,736)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash used in operating activities</a></td>
<td class="num">(20,427)<span></span>
</td>
<td class="num">(24,407)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">$ (460)<span></span>
</td>
<td class="num">(617)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInRestrictedCash', window );">Investment in restricted deposit</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(93)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Amounts funded in respect of employee rights upon retirement, net</a></td>
<td class="num">$ (56)<span></span>
</td>
<td class="num">(122)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net cash used in investing activities</a></td>
<td class="num">(516)<span></span>
</td>
<td class="num">(832)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Exercise of options</a></td>
<td class="nump">534<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net cash provided by financing activities</a></td>
<td class="nump">534<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">EFFECT OF EXCHANGE RATE CHANGES ON CASH</a></td>
<td class="num">(110)<span></span>
</td>
<td class="num">(885)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">NET DECREASE IN CASH AND CASH EQUIVALENTS</a></td>
<td class="num">(20,519)<span></span>
</td>
<td class="num">(26,081)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</a></td>
<td class="nump">54,767<span></span>
</td>
<td class="nump">86,398<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD</a></td>
<td class="nump">34,248<span></span>
</td>
<td class="nump">60,317<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="nump">146<span></span>
</td>
<td class="nump">122<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTARY DISCLOSURE ON CASH FLOWS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">$ 3,105<span></span>
</td>
<td class="nump">$ 3,079<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) on amounts funded in respect of employee rights upon retirement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase in liabilities for property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to issue debt and obtain financing associated with the related debt instruments. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.8)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 9<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3044-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 24<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 830<br><br><br><br> -SubTopic 230<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 830<br><br><br><br> -SubTopic 230<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 830<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450189&amp;loc=d3e30690-110894<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 830<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450189&amp;loc=d3e30700-110894<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 830<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInRestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow for the increase (decrease) associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 12<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3179-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 13<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3213-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Investing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInRestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for interest during the period net of cash paid for interest that is capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 26<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3574-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 24<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 26<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3574-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 24<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 24<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 25<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3536-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Net Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Other Comprehensive Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 9<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash outflow or inflow from other investing activities. This element is used when there is not a more specific and appropriate element in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Investing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 9<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3098-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3095-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Investing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3213-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of pension and other (such as medical, dental and life insurance) postretirement benefit costs recognized during the period for (1) defined benefit plans (periodic benefit costs include the following components: service cost, interest cost, expected return on plan assets, gain (loss) on assets, prior service cost or credit, transition asset or obligation, and gain (loss) due to settlements or curtailments) and for (2) defined contribution plans (to the extent that a plan's defined contributions to an individual's account are to be made for periods in which that individual renders services, the net cost for a period is the contribution called for in that period; if a plan calls for contributions for periods after an individual retires or terminates, the estimated cost is accrued during the employee's service period).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 715<br><br><br><br> -SubTopic 70<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (j)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Financing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140104961478272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_RevenuesOtherThanCompanyShareInCollaborationAgreement', window );">REVENUES</a></td>
<td class="nump">$ 4,301<span></span>
</td>
<td class="nump">$ 2,396<span></span>
</td>
<td class="nump">$ 12,475<span></span>
</td>
<td class="nump">$ 11,517<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CompanyShareInCollaborationAgreement', window );">COMPANY'S SHARE IN COLLABORATION AGREEMENT</a></td>
<td class="nump">1,545<span></span>
</td>
<td class="nump">1,311<span></span>
</td>
<td class="nump">3,084<span></span>
</td>
<td class="nump">2,259<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">COST OF REVENUES</a></td>
<td class="num">(2,346)<span></span>
</td>
<td class="num">(1,798)<span></span>
</td>
<td class="num">(6,785)<span></span>
</td>
<td class="num">(7,476)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">GROSS PROFIT</a></td>
<td class="nump">3,500<span></span>
</td>
<td class="nump">1,909<span></span>
</td>
<td class="nump">8,774<span></span>
</td>
<td class="nump">6,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">RESEARCH AND DEVELOPMENT EXPENSES (1)</a></td>
<td class="num">(5,260)<span></span>
</td>
<td class="num">(8,052)<span></span>
</td>
<td class="num">(18,493)<span></span>
</td>
<td class="num">(23,280)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_GrantsAndReimbursementsReceivedOrReceivable', window );">Less - grants and reimbursements</a></td>
<td class="nump">1,207<span></span>
</td>
<td class="nump">1,947<span></span>
</td>
<td class="nump">3,856<span></span>
</td>
<td class="nump">6,146<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ResearchDevelopmentAndEngineeringExpenseNet', window );">RESEARCH AND DEVELOPMENT EXPENSES, NET</a></td>
<td class="num">(4,053)<span></span>
</td>
<td class="num">(6,105)<span></span>
</td>
<td class="num">(14,637)<span></span>
</td>
<td class="num">(17,134)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES (2)</a></td>
<td class="num">(2,254)<span></span>
</td>
<td class="num">(2,012)<span></span>
</td>
<td class="num">(6,259)<span></span>
</td>
<td class="num">(7,289)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">OPERATING LOSS</a></td>
<td class="num">(2,807)<span></span>
</td>
<td class="num">(6,208)<span></span>
</td>
<td class="num">(12,122)<span></span>
</td>
<td class="num">(18,123)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">FINANCIAL EXPENSES</a></td>
<td class="num">(1,030)<span></span>
</td>
<td class="num">(1,851)<span></span>
</td>
<td class="num">(2,805)<span></span>
</td>
<td class="num">(3,490)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">FINANCIAL INCOME</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">49<span></span>
</td>
<td class="nump">64<span></span>
</td>
<td class="nump">139<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">FINANCIAL EXPENSES - NET</a></td>
<td class="num">(1,013)<span></span>
</td>
<td class="num">(1,802)<span></span>
</td>
<td class="num">(2,741)<span></span>
</td>
<td class="num">(3,351)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS FOR THE PERIOD</a></td>
<td class="num">$ (3,820)<span></span>
</td>
<td class="num">$ (8,010)<span></span>
</td>
<td class="num">$ (14,863)<span></span>
</td>
<td class="num">$ (21,474)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>NET LOSS PER SHARE OF COMMON STOCK</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">NET LOSS PER SHARE OF COMMON STOCK - BASIC AND DILUTED:</a></td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="num">$ (0.09)<span></span>
</td>
<td class="num">$ (0.16)<span></span>
</td>
<td class="num">$ (0.23)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract', window );"><strong>WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE - BASIC AND DILUTED:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE - BASIC AND DILUTED:</a></td>
<td class="nump">93,943,772<span></span>
</td>
<td class="nump">92,971,572<span></span>
</td>
<td class="nump">93,599,414<span></span>
</td>
<td class="nump">92,828,851<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CompanyShareInCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Company''s share in collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_CompanyShareInCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_GrantsAndReimbursementsReceivedOrReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grants and reimbursements received or receivable from governmental institutions and collaboration partners for research and development expenses incurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_GrantsAndReimbursementsReceivedOrReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ResearchDevelopmentAndEngineeringExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development expenses, net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ResearchDevelopmentAndEngineeringExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_RevenuesOtherThanCompanyShareInCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Company's total revenues other than its share in collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_RevenuesOtherThanCompanyShareInCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.1,2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Net Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Other Comprehensive Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 9<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.7)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of other expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating expense recognized during the period. Such amounts may include: (a) unusual costs, (b) loss on foreign exchange transactions, (c) losses on securities (net of profits), and (d) miscellaneous other expense items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of other income amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) profits on securities (net of losses), and (d) miscellaneous other income items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.7)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 730<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 985<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 330<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 30<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51677171&amp;loc=d3e3636-108311<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140104975249008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>FAIR VALUE MEASUREMENT [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Fair value convertible notes</a></td>
<td class="nump">$ 45.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Convertible Security<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509036<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtFairValueDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140104962094080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Nov. 01, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PLX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PROTALIX BIOTHERAPEUTICS, INC.	<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001006281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,800,397<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation 12B<br><br><br><br> -Number 240<br><br><br><br> -Section 12b<br><br><br><br> -Subsection 1<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation 12B<br><br><br><br> -Number 240<br><br><br><br> -Section 12b<br><br><br><br> -Subsection 1<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140104965306640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK TRANSACTIONS (Details) - 2006 Employee Stock Incentive Plan [Member] - Option to purchase shares of common stock [Member]<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 23, 2015 </div>
<div>USD ($) </div>
<div>item </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Option granted (in shares) | shares</a></td>
<td class="nump">1,909,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Term of option</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.72<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue', window );">Fair value of option on the date of grant</a></td>
<td class="nump">$ 1.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">61.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">1.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life in years</a></td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=plx_EmployeeStockIncentivePlan2006Member', window );">Vest on the first anniversary of the grant date [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percentage of options vested</a></td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=plx_EmployeeStockIncentivePlan2006Member', window );">Vest over the subsequent quarterly period</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod', window );">Number of installments for vesting of stock | item</a></td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award number of installments for vesting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (f)(2)(iii)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (f)(2)(ii)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (f)(2)(iv)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(iv)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)(2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 14.D.2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (f)(2)(i)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 14<br><br><br><br> -Section D<br><br><br><br> -Subsection 2<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=plx_EmployeeStockIncentivePlan2006Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=plx_EmployeeStockIncentivePlan2006Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140104962082608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
<td class="nump">$ 258<span></span>
</td>
<td class="nump">$ 173<span></span>
</td>
<td class="nump">$ 667<span></span>
</td>
<td class="nump">$ 764<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
<td class="nump">$ 188<span></span>
</td>
<td class="num">$ (67)<span></span>
</td>
<td class="nump">$ 752<span></span>
</td>
<td class="num">$ (81)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 14.F)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (h)(1)(i)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 14<br><br><br><br> -Section F<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140105107605904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">
<p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px;"><b>NOTE 5 &#150; SUBSEQUENT EVENTS</b></p>
<p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px;">&#160;</p>
<p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0in; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 0.5in;">On October 12, 2015, the Company entered into the Amended Pfizer Agreement which amends and restates, in its entirety, the Pfizer Agreement. See Note 1. Pursuant to the Amended Pfizer Agreement, the Company sold its share in the collaboration with Pfizer on the commercialization of Elelyso to Pfizer in exchange for a cash payment equal to $<font>36.0</font> million. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer in exchange for full rights to Elelyso in Brazil. Under the Amended Pfizer Agreement, the Company will continue to manufacture drug substance for Pfizer, subject to certain terms and conditions. In addition, the Company issued to Pfizer a promissory note for approximately $<font>4.2</font> million, representing the Company's share of accumulated losses as of the date of the Amended Pfizer Agreement.&#160;The note is to be paid in October 2020, subject to certain terms and conditions. Under the Pfizer Agreement, Pfizer and the Company shared in revenues and expenses for the development and commercialization of Elelyso on a 60%/40% basis globally, excluding Israel and Brazil. Under the Amended Pfizer Agreement, Pfizer is responsible for 100% of expenses, and entitled to all of the revenues, globally for Elelyso, excluding Brazil, where the Company is responsible for all expenses and retains all revenues. The Amended Pfizer Agreement eliminates Pfizer's entitlement to annual payments of up to $12.5 million in relation to commercialization of Elelyso in Brazil.</p>
<p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0in; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 0.5in;"><br/></p>
<p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0in; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 0.5in;">On October 12, 2015, the Company also entered into a Stock Purchase Agreement with Pfizer, pursuant to which the Company issued <font>5,649,079</font> shares of the Company's common stock for an aggregate purchase price equal to $<font>10.0</font>&#160;million subject to certain other terms set forth in the Stock Purchase Agreement. As part of the Stock Purchase Agreement, Pfizer has agreed to a <font>180</font>-day lock-up with respect to the purchased shares and the Company's directors and executive officers have entered into <font>90</font>-day lock up agreements.</p>
</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140105106923088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCK TRANSACTIONS [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCK TRANSACTIONS</a></td>
<td class="text"><div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-family: 'times new roman', times; font-size: 10pt;"><b>NOTE 4 &#150; STOCK TRANSACTIONS</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0in;"><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0in;"><font style="font-family: 'times new roman', times; font-size: 10pt;">On March 23, 2015, the Company's compensation committee approved the grant of a <font>10</font>-year option to purchase <font>1,909,000</font> shares of Common Stock to its officers and other employees with an exercise price equal to $<font>1.72</font> per share under the Company's 2006 Employee Stock Incentive Plan, as amended (the &#147;Plan&#148;). The options vest over a <font>four</font>-year period; the first <font>25</font>% shares vest on the first anniversary of the grant date and the remaining shares vest in <font>12</font> equal quarterly increments over the subsequent <font>three</font>-year period. Vesting of the options granted to certain executive officers are subject to acceleration in full upon a Corporate Transaction or a Change in Control, as those terms are defined in the Plan. The Company estimated the fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately $<font>1.9</font> million based on the following weighted average assumptions: dividend yield of <font>0</font>% for all years; expected volatility of <font>61.7</font>%; risk-free interest rates of <font>1.6</font>%; and expected life of <font>six</font> years.</font></p> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(d),(e))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 4<br><br><br><br> -Subparagraph (SAB TOPIC 4.C)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Preferred Stock<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 11<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section C<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140104965258736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2015</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_PfizerAgreementMember', window );">Pfizer Agreement [Member] | Pfizer Incorporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage', window );">Agreement, future revenues and expenses sharing percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_PfizerAgreementMember', window );">Pfizer Agreement [Member] | Protalix Bio Therapeutics Incorporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage', window );">Agreement, future revenues and expenses sharing percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued</a></td>
<td class="nump">5,649,079<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issued, value</a></td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Directors and Executive Officers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_StockPurchaseAgreementLockUpPeriod', window );">Lock-up period with respect to the purchased shares of common stock</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Pfizer Incorporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_StockPurchaseAgreementLockUpPeriod', window );">Lock-up period with respect to the purchased shares of common stock</a></td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Amended Pfizer Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ProceedsFromSaleOfShareInCollaboration', window );">Proceeds from sale of share in the collaboration created under the initial Pfizer Agreement for the commercialization of Elelyso</a></td>
<td class="nump">$ 36.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Amended Pfizer Agreement [Member] | Pfizer Incorporation [Member] | Excluding Brazil [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage', window );">Agreement, future revenues and expenses sharing percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Amended Pfizer Agreement [Member] | Protalix Bio Therapeutics Incorporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfitsEliminationAmount', window );">License and supply agreement potential future payment, elimination amount</a></td>
<td class="nump">$ 12.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Amended Pfizer Agreement [Member] | Protalix Bio Therapeutics Incorporation [Member] | BRAZIL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage', window );">Agreement, future revenues and expenses sharing percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Amended Pfizer Agreement [Member] | October 2015 Promissory Note To Pfizer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Promissory note, amount</a></td>
<td class="nump">$ 4.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">Oct. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement revenues and expense sharing percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_CollaborativeArrangementRevenuesExpensesSharingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfitsEliminationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Amended Pfizer Agreement eliminates Pfizer's entitlement to annual payments in relation to commercialization of Elelyso in Brazil.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfitsEliminationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ProceedsFromSaleOfShareInCollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Pursuant to the Amended Pfizer Agreement, the Company sold to Pfizer its share in the collaboration created under the initial Pfizer Agreement for the commercialization of Elelyso in exchange for a cash payment amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ProceedsFromSaleOfShareInCollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockPurchaseAgreementLockUpPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>As part of the Stock Purchase Agreement, Pfizer has agreed to a lock-up period with respect to the purchased shares of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockPurchaseAgreementLockUpPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 835<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=34725769&amp;loc=d3e28878-108400<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 835<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28551-108399<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22(a)(2))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_PfizerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_PfizerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=plx_PfizerIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=plx_PfizerIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=plx_ProtalixBioTherapeuticsIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=plx_ProtalixBioTherapeuticsIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=us-gaap_ExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=us-gaap_ExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=plx_ExcludingBrazilMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=plx_ExcludingBrazilMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=country_BR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=country_BR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_October2015PromissoryNoteToPfizerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_October2015PromissoryNoteToPfizerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140104899303504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2015</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Jun. 18, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Options to purchase common stock not included in diluted LPS because the effect would be anti-dilutive</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,820,485<span></span>
</td>
<td class="nump">18,661,182<span></span>
</td>
<td class="nump">19,797,190<span></span>
</td>
<td class="nump">18,781,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_BrazilAgreementMember', window );">Brazil Agreement [Member] | Protalix Ltd. [Member] | Fiocruz [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights', window );">Supply commitment for entitled rights to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 280.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_PercentageOfAdultGaucherPatientsTreatedWithUplyso', window );">Percentage of adult Gaucher patients in Brazil currently treated with Uplyso</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_AgentFeePercentageOfNetProceeds', window );">Agent fee, percentage of net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_PfizerAgreementMember', window );">Pfizer Agreement [Member] | Pfizer Incorporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage', window );">Agreement, future revenues and expenses sharing percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_PfizerAgreementMember', window );">Pfizer Agreement [Member] | Protalix Bio Therapeutics Incorporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage', window );">Agreement, future revenues and expenses sharing percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Amended Pfizer Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ProceedsFromSaleOfShareInCollaboration', window );">Proceeds from sale of share in the collaboration created under the initial Pfizer Agreement for the commercialization of Elelyso</a></td>
<td class="nump">$ 36.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Amended Pfizer Agreement [Member] | Pfizer Incorporation [Member] | Excluding Brazil [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage', window );">Agreement, future revenues and expenses sharing percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Amended Pfizer Agreement [Member] | Protalix Bio Therapeutics Incorporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfitsEliminationAmount', window );">License and supply agreement potential future payment, elimination amount</a></td>
<td class="nump">$ 12.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Amended Pfizer Agreement [Member] | Protalix Bio Therapeutics Incorporation [Member] | BRAZIL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage', window );">Agreement, future revenues and expenses sharing percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AgentFeePercentageOfNetProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Company will pay a fee equal to percentage of the net proceeds generated in Brazil to its agent for services provided in assisting us complete the Brazil Agreement pursuant to an agency agreement between the agent and the Company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_AgentFeePercentageOfNetProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement revenues and expense sharing percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_CollaborativeArrangementRevenuesExpensesSharingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfitsEliminationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Amended Pfizer Agreement eliminates Pfizer's entitlement to annual payments in relation to commercialization of Elelyso in Brazil.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfitsEliminationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_PercentageOfAdultGaucherPatientsTreatedWithUplyso">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of adult Gaucher patients treated with Uplyso.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_PercentageOfAdultGaucherPatientsTreatedWithUplyso</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ProceedsFromSaleOfShareInCollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Pursuant to the Amended Pfizer Agreement, the Company sold to Pfizer its share in the collaboration created under the initial Pfizer Agreement for the commercialization of Elelyso in exchange for a cash payment amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ProceedsFromSaleOfShareInCollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The floor purchase amount that one or more customers of the entity must satisfy in order to be entitled to certain rights under the terms of disclosed arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Antidilution<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Diluted Earnings Per Share<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Contingent Stock Agreement<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_BrazilAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_BrazilAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=us-gaap_SubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=us-gaap_SubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=plx_FiocruzMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=plx_FiocruzMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_PfizerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_PfizerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=plx_PfizerIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=plx_PfizerIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=plx_ProtalixBioTherapeuticsIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=plx_ProtalixBioTherapeuticsIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=plx_ExcludingBrazilMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=plx_ExcludingBrazilMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=country_BR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=country_BR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140104961838928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Policy)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_NatureOfOperationsPolicyTextBlock', window );">General</a></td>
<td class="text"><div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">
<table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman', Times, serif; letter-spacing: normal; orphans: auto; text-indent: 0px; text-transform: none; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; margin-top: 0px; margin-bottom: 0px;">

<tr style="vertical-align: top; text-align: justify;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in; text-align: left;"><b>a.</b></td>
<td style="text-align: justify;"><b>General</b></td>
</tr>

</table>
<p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin-top: 0pt; margin-bottom: 0pt; font-stretch: normal;">&#160;</p>
<p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;"><font style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 13.3333px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: inline !important; float: none;">Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &#147;Company&#148;), and its wholly-owned subsidiary, Protalix Ltd., are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company's proprietary ProCellEx&#174; protein expression system (&#147;ProCellEx&#148;). Using the ProCellEx system, the Company is developing a pipeline of proprietary recombinant therapeutic proteins. The Company's initial commercial focus has been on complex therapeutic proteins, including proteins for the treatment of genetic disorders, such as Gaucher disease and Fabry disease. The Company's strategy is to develop proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications. To date, the Company has successfully developed a treatment for Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets, and the Company has number of product candidates in varying stages of the clinical development process. In September 2009, Protalix Ltd. formed another wholly-owned subsidiary under the laws of the Netherlands, Protalix B.V., in connection with the European Medicines Agency (&#147;EMA&#148;) application process in the European Union. The Company's two subsidiaries are referred to collectively herein as the &#147;Subsidiaries.&#148;</font></p>
<p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;">&#160;</p>
<p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;">On May 1, 2012, the U.S. Food and Drug Administration (&#147;FDA&#148;) approved for sale the Company's first commercial product, taliglucerase alfa for injection, an enzyme replacement therapy (&#147;ERT&#148;) for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. Subsequently, taliglucerase alfa was approved for marketing by the regulatory authorities of other countries. Taliglucerase alfa is being marketed under the name Uplyso<sup>TM</sup> in Brazil and certain other Latin American countries and&#160;Elelyso<sup>TM</sup> in the rest of the territories.</p>
<p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;">&#160;</p>
<p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;">Since its approval by the FDA, taliglucerase alfa has been marketed mainly in the United States by Pfizer Inc. (&#147;Pfizer&#148;), the Company's commercialization partner, as provided in the exclusive license and supply agreement by and between Protalix Ltd., the Company's wholly-owned subsidiary, and Pfizer, which is referred to herein as the Pfizer Agreement. In October 2015, the Company entered into an Amended and Restated Exclusive License and Supply Agreement (the &#147;Amended Pfizer Agreement&#148;) which amends and restates the Pfizer Agreement in its entirety. Pursuant to the Amended Pfizer Agreement, the Company sold to Pfizer its share in the collaboration created under the initial Pfizer Agreement for the commercialization of Elelyso in exchange for a cash payment equal to $<font>36.0</font> million. <font style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 13.3333px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: inline !important; float: none;">As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to Elelyso in Brazil. Under the initial Pfizer Agreement, Pfizer and the Company shared revenues and expenses for the development and commercialization of Elelyso on a&#160;</font><font>60</font>%/<font>40</font>% basis globally, excluding Israel and Brazil. Under the Amended Pfizer Agreement, Pfizer is responsible for <font>100</font>% of expenses, and entitled to all of the revenues, globally for Elelyso, excluding Brazil, where the Company is responsible for all expenses and retains all revenues. The Amended Pfizer Agreement eliminates Pfizer's entitlement to annual payments of up to $<font>12.5</font> million in relation to commercialization of Elelyso in Brazil.&#160;<font style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 13.3333px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: inline !important; float: none;">For further details please see Note 5.</font></p>
<p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;">&#160;</p>
<p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;">On June 18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#147;Brazil Agreement&#148;) with Funda&#231;&#227;o Oswaldo Cruz (&#147;Fiocruz&#148;), an arm of the Brazilian Ministry of Health for taliglucerase alfa. The agreement became effective in January 2014. The technology transfer is designed to be completed in <font>four</font> stages and is intended to transfer to Fiocruz the capacity and skills required for the Brazilian government to construct its own manufacturing facility, at its sole expense, and to produce a sustainable, high-quality, and cost-effective supply of taliglucerase alfa. The Company is not required to complete the final stage of the technology transfer until Fiocruz purchases at least approximately $<font>280</font> million worth of taliglucerase alfa.</p>
<p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;">&#160;</p>
<p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;"><font style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 13.3333px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: inline !important; float: none;">Fiocruz's purchases of Uplyso to date have been significantly below certain agreed upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the low purchase amounts, the Company is, at this time, continuing to supply Uplyso to Fiocruz under the Brazil Agreement, and patients continue to be treated with Uplyso in Brazil. Approximately</font>&#160;<font>10</font>% of adult Gaucher patients in Brazil are currently treated with Uplyso. The Company is discussing with Fiocruz potential actions that Fiocruz may take to comply with its purchase obligations and, based on such discussions, the Company will determine what it believes to be the course of action that is in the best interest of the Company.</p>
<p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px;">&#160;</p>
<p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;">The Company will pay a fee equal to <font>5</font>%&#160;<font style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 13.3333px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: inline !important; float: none;">of the net proceeds generated in Brazil to an agent for services provided in assisting the Company complete the Brazil Agreement pursuant to an agreement between the agent and the Company. The agreement will remain in effect with respect to the Brazil Agreement until the termination thereof.</font></p>
<p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;">&#160;</p>
<p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;">In addition to taliglucerase alfa, the Company is developing an innovative product pipeline using its ProCellEx protein expression system. The Company's product pipeline currently includes, among other candidates:</p>
<p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px;">&#160;</p>
<p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;">(1) PRX-102, or alpha-GAL-A, a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder in humans.</p>
<p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px;">&#160;</p>
<p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;">(2) PRX-106, the Company's oral antiTNF product candidate which is being developed as an orally-delivered anti inflammatory treatment using plant cells as a natural capsule for the expressed protein.</p>
<p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px;">&#160;</p>
<p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;">(3) PRX-110, a proprietary plant cell recombinant human Deoxyribonuclease 1, or DNase, under development for the treatment of cystic fibrosis, to be administered by inhalation.</p>
<p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px;">&#160;</p>
<p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;">(4) PRX-112, an orally administered glucocerebrosidase enzyme for the treatment of Gaucher patients utilizing oral delivery of the recombinant GCD enzyme produced and encapsulated within carrot cells.</p>
<p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;"><br/></p>
<p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;">Obtaining marketing approval with respect to any product candidate in any country is directly dependent on the Company's ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.</p>
<p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;">&#160;</p>
<p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;">Based on its current cash resources and commitments, the Company believes it will be able to maintain its current planned development activities and the corresponding level of expenditures for <font style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 13.3333px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: inline !important; float: none;">at least 12 months</font>, although <font>no</font> assurance can be given that it will not need additional funds prior to such time. If there are unexpected increases in general and administrative expenses or research and development expenses, the Company may need to seek additional financing.</p>
</div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">
<div class="CursorPointer">
<table cellpadding="0" cellspacing="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 0px; width: 100%;">

<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in; font-family: 'times new roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;"><b>b.</b></font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;"><b>Basis of Presentation</b></font></td>
</tr>

</table>
</div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt;"><font style="font-size: 10pt; font-family: 'times new roman', times;">The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (&#147;GAAP&#148;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt;"><font style="font-size: 10pt; font-family: 'times new roman', times;">These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December 31, 2014, filed by the Company with the U.S. Securities and Exchange Commission <font style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 13.3333330154419px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: inline !important; float: none;">(the &#147;Commission&#148;)</font>. The comparative balance sheet at December 31, 2014 has been derived from the audited financial statements at that date.</font></p>
</div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net loss per share</a></td>
<td class="text"><div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">
<div class="CursorPointer">
<table cellpadding="0" cellspacing="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 0px; width: 100%;">

<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in; font-family: 'times new roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;"><b>c.</b></font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;"><b>Net loss per share</b></font></td>
</tr>

</table>
</div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Basic and diluted loss per share (&#147;LPS&#148;) are computed by dividing net loss by the weighted average number of shares of the Company's common stock, par value $<font>0.001</font> per share (the &#147;Common Stock&#148;) outstanding for each period. Diluted LPS does not include <font>18,781,572</font>&#160;and <font>19,797,190</font> shares of Common Stock underlying outstanding options and restricted shares of Common Stock and shares issuable upon conversion of the convertible notes (issued in September 2013) for the nine months ended September 30, 2014 and 2015, respectively, and <font>18,661,182</font> and <font>19,820,485</font> shares of Common Stock for the three months ended September 30, 2014 and 2015, respectively, because the effect would be anti-dilutive.</font></p>
</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_NatureOfOperationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nature Of Operations Policy</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_NatureOfOperationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140104970820832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">
<div style="display: block; margin-left: 0.7in;">
<div class="CursorPointer">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 85%; /* margin-left: 0.7in;">

<tr style="vertical-align: bottom;">
<td style="text-align: center; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td>
<td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; border-bottom: Black 0.75pt solid;"><strong><font style="font-family: 'times new roman', times; font-size: 10pt;"> September 30, </font></strong></p>
</td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"><strong><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></strong></td>
<td style="text-align: center; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap" colspan="2">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; border-bottom: Black 0.75pt solid;"><strong><font style="font-family: 'times new roman', times; font-size: 10pt;"> December 31, </font></strong></p>
</td>
<td style="text-align: center; font-family: 'times new roman'; padding: 0px; width: 20px;" nowrap="nowrap" colspan="5">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center;"><br/></p>
</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: center; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td>
<td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; border-bottom: Black 0.75pt solid;"><strong><font style="font-family: 'times new roman', times; font-size: 10pt;"> 2015 </font></strong></p>
</td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"><strong><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></strong></td>
<td style="text-align: center; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap" colspan="2">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; border-bottom: Black 0.75pt solid;"><strong><font style="font-family: 'times new roman', times; font-size: 10pt;"> 2014 </font></strong></p>
</td>
<td style="text-align: center; font-family: 'times new roman'; padding: 0px; width: 20px;" nowrap="nowrap" colspan="5">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center;"><br/></p>
</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="font-family: 'Times New Roman';" nowrap="nowrap"></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"></td>
<td style="text-align: center; padding: 0px;" colspan="6" nowrap="nowrap"><font style="font-family: 'times new roman', times; font-size: 10pt;">(<i>U.S. dollars in thousands)</i></font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; width: 74%;"><font style="font-family: 'times new roman', times; font-size: 10pt;">Raw materials</font></td>
<td style="font-family: 'times new roman'; padding: 0px; width: 1%;"></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 1%;"><font style="font-family: 'times new roman', times; font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"><font><font style="font-size: 10pt;">1,502</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 1%;"><font style="font-family: 'times new roman', times; font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"><font style="font-family: 'times new roman', times; font-size: 10pt;"><font>1,616</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-family: 'times new roman', times; font-size: 10pt;">Work&#160;in&#160;progress</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><br/></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-family: 'times new roman', times; font-size: 10pt;"><font>132</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-family: 'times new roman', times; font-size: 10pt;">Finished goods</font></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt;">4,837</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-family: 'times new roman', times; font-size: 10pt;"><font>4,919</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-family: 'times new roman', times; font-size: 10pt;">Total inventory</font></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-family: 'times new roman', times; font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt;">6,339</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-family: 'times new roman', times; font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-family: 'times new roman', times; font-size: 10pt;"><font>6,667</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></td>
</tr>

</table>
</div>
</div>
</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 2<br><br><br><br> -Paragraph 6<br><br><br><br> -Subparagraph a,b,c<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140104902216544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 1,502<span></span>
</td>
<td class="nump">$ 1,616<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">4,837<span></span>
</td>
<td class="nump">4,919<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
<td class="nump">6,339<span></span>
</td>
<td class="nump">$ 6,667<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory write-down</a></td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.6(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 330<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 5.BB)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 5<br><br><br><br> -Section BB<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.6(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 330<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 35<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655945&amp;loc=d3e3927-108312<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 330<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 5.BB)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.6(a)(4))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 5<br><br><br><br> -Section BB<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.6(a)(3))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 330<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 5.BB)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 5<br><br><br><br> -Section BB<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Charge to cost of goods sold that represents the reduction of the carrying amount of inventory, generally attributable to obsolescence or market conditions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 330<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28360613&amp;loc=d3e4542-108314<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140104961222544">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN CAPITAL DEFICIENCY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (55,601)<span></span>
</td>
<td class="num">$ (26,946)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation related to stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">947<span></span>
</td>
<td class="nump">161<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures', window );">Share-based compensation related to restricted stock award, net of forfeitures</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">472<span></span>
</td>
<td class="nump">522<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options granted to employees (includes net exercise)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">534<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (3,820)<span></span>
</td>
<td class="num">$ (8,010)<span></span>
</td>
<td class="num">(14,863)<span></span>
</td>
<td class="num">(21,474)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(68,511)<span></span>
</td>
<td class="num">(47,694)<span></span>
</td>
<td class="num">(68,511)<span></span>
</td>
<td class="num">(47,694)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 94<span></span>
</td>
<td class="nump">$ 94<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,603,819<span></span>
</td>
<td class="nump">93,551,098<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation related to stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures', window );">Share-based compensation related to restricted stock award, net of forfeitures</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares', window );">Share-based compensation related to restricted stock award, net of forfeitures, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,501)<span></span>
</td>
<td class="num">(1,834)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options granted to employees (includes net exercise)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options granted to employees (includes net exercise), shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">550,000<span></span>
</td>
<td class="nump">113,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 94<span></span>
</td>
<td class="nump">$ 94<span></span>
</td>
<td class="nump">$ 94<span></span>
</td>
<td class="nump">$ 94<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">94,151,318<span></span>
</td>
<td class="nump">93,663,064<span></span>
</td>
<td class="nump">94,151,318<span></span>
</td>
<td class="nump">93,663,064<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-in Capital [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 185,633<span></span>
</td>
<td class="nump">$ 184,345<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation related to stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">947<span></span>
</td>
<td class="nump">161<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures', window );">Share-based compensation related to restricted stock award, net of forfeitures</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">472<span></span>
</td>
<td class="nump">522<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options granted to employees (includes net exercise)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 534<span></span>
</td>
<td class="nump">$ 43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 187,586<span></span>
</td>
<td class="nump">$ 185,071<span></span>
</td>
<td class="nump">$ 187,586<span></span>
</td>
<td class="nump">$ 185,071<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Accumulated Deficit [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (241,328)<span></span>
</td>
<td class="num">$ (211,385)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation related to stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures', window );">Share-based compensation related to restricted stock award, net of forfeitures</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options granted to employees (includes net exercise)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (14,863)<span></span>
</td>
<td class="num">$ (21,474)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (256,191)<span></span>
</td>
<td class="num">$ (232,859)<span></span>
</td>
<td class="num">$ (256,191)<span></span>
</td>
<td class="num">$ (232,859)<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Represents amount less than thousand</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of recognized equity-based compensation during the period for restricted stock awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of recognized equity-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "stock-based compensation".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 35<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415241&amp;loc=d3e4534-113899<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 12<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=32706628&amp;loc=d3e11149-113907<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 13<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=32706628&amp;loc=d3e11178-113907<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Net Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Other Comprehensive Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 9<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(iv)(2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28,29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140104974557088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>FAIR VALUE MEASUREMENT [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENT</a></td>
<td class="text"><div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><b>NOTE 3 &#150; FAIR VALUE MEASUREMENT</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt;"><font style="font-size: 10pt; font-family: 'times new roman', times;">The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt;"><font style="font-size: 10pt; font-family: 'times new roman', times;">The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt;"><font style="font-size: 10pt; font-family: 'times new roman', times;">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt;"><font style="font-size: 10pt; font-family: 'times new roman', times;">The fair value of the financial instruments included in the working capital of the Company is usually identical or close to their carrying value.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in;"><font style="font-size: 10pt; font-family: 'times new roman', times;">The fair value of the convertible notes as of September 30, 2015 is approximately $<font>45.5</font>&#160;million based on a level 2 measurement.</font></p>
</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 30<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14172-108612<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14064-108612<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 21<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13537-108611<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 16<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13504-108611<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 10<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13433-108611<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.3.0.814</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>52</ContextCount>
  <ElementCount>116</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>21</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="plx-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/plx-daei</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="plx-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/plx-ccbs</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="plx-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/plx-ccsoo</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="plx-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/plx-ccsoop</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="plx-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>005 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN CAPITAL DEFICIENCY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/plx-ccsocicd</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN CAPITAL DEFICIENCY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="plx-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>006 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN CAPITAL DEFICIENCY (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/plx-ccsocicdp</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN CAPITAL DEFICIENCY (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="plx-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/plx-ccsocf</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="plx-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/plx-sap</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="plx-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>102 - Disclosure - INVENTORIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/plx-i</Role>
      <ShortName>INVENTORIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="plx-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>103 - Disclosure - FAIR VALUE MEASUREMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/plx-fvm1</Role>
      <ShortName>FAIR VALUE MEASUREMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="plx-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>104 - Disclosure - STOCK TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/plx-st</Role>
      <ShortName>STOCK TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="plx-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>105 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/Disclosure-SUBSEQUENTEVENTS</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="plx-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>201 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policy)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/plx-sapp1</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Policy)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="plx-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>302 - Disclosure - INVENTORIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/plx-it</Role>
      <ShortName>INVENTORIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/plx-i</ParentRole>
      <Position>14</Position>
    </Report>
    <Report instance="plx-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/plx-sapd</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/plx-sapp1</ParentRole>
      <Position>15</Position>
    </Report>
    <Report instance="plx-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>40201 - Disclosure - INVENTORIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/plx-id</Role>
      <ShortName>INVENTORIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/plx-it</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="plx-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>40301 - Disclosure - FAIR VALUE MEASUREMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/plx-fvmd1</Role>
      <ShortName>FAIR VALUE MEASUREMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/plx-fvm1</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="plx-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>40401 - Disclosure - STOCK TRANSACTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/plx-std</Role>
      <ShortName>STOCK TRANSACTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/plx-st</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="plx-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>40501 - Disclosure - SUBSEQUENT EVENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/Disclosure-SUBSEQUENTEVENTSDetails</Role>
      <ShortName>SUBSEQUENT EVENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/Disclosure-SUBSEQUENTEVENTS</ParentRole>
      <Position>19</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">In ''CONDENSED CONSOLIDATED BALANCE SHEETS'', column(s) 3, 4 are contained in other reports, so were removed by flow through suppression.</Log>
    <Log type="Info">In ''CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS'', column(s) 1, 2 are contained in other reports, so were removed by flow through suppression.</Log>
  </Logs>
  <InputFiles>
    <File>plx-20150930.xml</File>
    <File>plx-20150930_cal.xml</File>
    <File>plx-20150930_def.xml</File>
    <File>plx-20150930_lab.xml</File>
    <File>plx-20150930_pre.xml</File>
    <File>plx-20150930.xsd</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies/>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>

</XBRL>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
